sent_id	token	entity_label
1	Identification	O
1	of	O
1	APC2	O
1	,	O
1	a	O
1	homologue	O
1	of	O
1	the	O
1	adenomatous	B-Disease
1	polyposis	I-Disease
1	coli	I-Disease
1	tumour	I-Disease
1	suppressor	O
1	.	O
2	The	O
2	adenomatous	B-Disease
2	polyposis	I-Disease
2	coli	I-Disease
2	(	I-Disease
2	APC	I-Disease
2	)	I-Disease
2	tumour	I-Disease
2	-	O
2	suppressor	O
2	protein	O
2	controls	O
2	the	O
2	Wnt	O
2	signalling	O
2	pathway	O
2	by	O
2	forming	O
2	a	O
2	complex	O
2	with	O
2	glycogen	O
2	synthase	O
2	kinase	O
2	3beta	O
2	(	O
2	GSK	O
2	-	O
2	3beta	O
2	)	O
2	,	O
2	axin	O
2	/	O
2	conductin	O
2	and	O
2	betacatenin	O
2	.	O
3	Complex	O
3	formation	O
3	induces	O
3	the	O
3	rapid	O
3	degradation	O
3	of	O
3	betacatenin	O
3	.	O
4	In	O
4	colon	B-Disease
4	carcinoma	I-Disease
4	cells	O
4	,	O
4	loss	O
4	of	O
4	APC	O
4	leads	O
4	to	O
4	the	O
4	accumulation	O
4	of	O
4	betacatenin	O
4	in	O
4	the	O
4	nucleus	O
4	,	O
4	where	O
4	it	O
4	binds	O
4	to	O
4	and	O
4	activates	O
4	the	O
4	Tcf	O
4	-	O
4	4	O
4	transcription	O
4	factor	O
4	(	O
4	reviewed	O
4	in	O
4	[	O
4	1	O
4	]	O
4	[	O
4	2	O
4	]	O
4	)	O
4	.	O
5	Here	O
5	,	O
5	we	O
5	report	O
5	the	O
5	identification	O
5	and	O
5	genomic	O
5	structure	O
5	of	O
5	APC	O
5	homologues	O
5	.	O
6	Mammalian	O
6	APC2	O
6	,	O
6	which	O
6	closely	O
6	resembles	O
6	APC	O
6	in	O
6	overall	O
6	domain	O
6	structure	O
6	,	O
6	was	O
6	functionally	O
6	analyzed	O
6	and	O
6	shown	O
6	to	O
6	contain	O
6	two	O
6	SAMP	O
6	domains	O
6	,	O
6	both	O
6	of	O
6	which	O
6	are	O
6	required	O
6	for	O
6	binding	O
6	to	O
6	conductin	O
6	.	O
7	Like	O
7	APC	O
7	,	O
7	APC2	O
7	regulates	O
7	the	O
7	formation	O
7	of	O
7	active	O
7	betacatenin	O
7	-	O
7	Tcf	O
7	complexes	O
7	,	O
7	as	O
7	demonstrated	O
7	using	O
7	transient	O
7	transcriptional	O
7	activation	O
7	assays	O
7	in	O
7	APC	O
7	-	O
7	/	O
7	-	O
7	colon	B-Disease
7	carcinoma	I-Disease
7	cells	O
7	.	O
8	Human	O
8	APC2	O
8	maps	O
8	to	O
8	chromosome	O
8	19p13	O
8	.	O
9	3	O
9	.	O
10	APC	O
10	and	O
10	APC2	O
10	may	O
10	therefore	O
10	have	O
10	comparable	O
10	functions	O
10	in	O
10	development	O
10	and	O
10	cancer	B-Disease
10	.	O
11	A	O
11	common	O
11	MSH2	O
11	mutation	O
11	in	O
11	English	O
11	and	O
11	North	O
11	American	O
11	HNPCC	B-Disease
11	families	O
11	:	O
11	origin	O
11	,	O
11	phenotypic	O
11	expression	O
11	,	O
11	and	O
11	sex	O
11	specific	O
11	differences	O
11	in	O
11	colorectal	B-Disease
11	cancer	I-Disease
11	.	O
12	The	O
12	frequency	O
12	,	O
12	origin	O
12	,	O
12	and	O
12	phenotypic	O
12	expression	O
12	of	O
12	a	O
12	germline	O
12	MSH2	O
12	gene	O
12	mutation	O
12	previously	O
12	identified	O
12	in	O
12	seven	O
12	kindreds	O
12	with	O
12	hereditary	B-Disease
12	non	I-Disease
12	-	I-Disease
12	polyposis	I-Disease
12	cancer	I-Disease
12	syndrome	I-Disease
12	(	O
12	HNPCC	B-Disease
12	)	O
12	was	O
12	investigated	O
12	.	O
13	The	O
13	mutation	O
13	(	O
13	A	O
13	-	O
13	-	O
13	>	O
13	T	O
13	at	O
13	nt943	O
13	+	O
13	3	O
13	)	O
13	disrupts	O
13	the	O
13	3	O
13	splice	O
13	site	O
13	of	O
13	exon	O
13	5	O
13	leading	O
13	to	O
13	the	O
13	deletion	O
13	of	O
13	this	O
13	exon	O
13	from	O
13	MSH2	O
13	mRNA	O
13	and	O
13	represents	O
13	the	O
13	only	O
13	frequent	O
13	MSH2	O
13	mutation	O
13	so	O
13	far	O
13	reported	O
13	.	O
14	Although	O
14	this	O
14	mutation	O
14	was	O
14	initially	O
14	detected	O
14	in	O
14	four	O
14	of	O
14	33	O
14	colorectal	B-Disease
14	cancer	I-Disease
14	families	O
14	analysed	O
14	from	O
14	eastern	O
14	England	O
14	,	O
14	more	O
14	extensive	O
14	analysis	O
14	has	O
14	reduced	O
14	the	O
14	frequency	O
14	to	O
14	four	O
14	of	O
14	52	O
14	(	O
14	8	O
14	%	O
14	)	O
14	English	O
14	HNPCC	B-Disease
14	kindreds	O
14	analysed	O
14	.	O
15	In	O
15	contrast	O
15	,	O
15	the	O
15	MSH2	O
15	mutation	O
15	was	O
15	identified	O
15	in	O
15	10	O
15	of	O
15	20	O
15	(	O
15	50	O
15	%	O
15	)	O
15	separately	O
15	identified	O
15	colorectal	B-Disease
15	families	O
15	from	O
15	Newfoundland	O
15	.	O
16	To	O
16	investigate	O
16	the	O
16	origin	O
16	of	O
16	this	O
16	mutation	O
16	in	O
16	colorectal	B-Disease
16	cancer	I-Disease
16	families	O
16	from	O
16	England	O
16	(	O
16	n	O
16	=	O
16	4	O
16	)	O
16	,	O
16	Newfoundland	O
16	(	O
16	n	O
16	=	O
16	10	O
16	)	O
16	,	O
16	and	O
16	the	O
16	United	O
16	States	O
16	(	O
16	n	O
16	=	O
16	3	O
16	)	O
16	,	O
16	haplotype	O
16	analysis	O
16	using	O
16	microsatellite	O
16	markers	O
16	linked	O
16	to	O
16	MSH2	O
16	was	O
16	performed	O
16	.	O
17	Within	O
17	the	O
17	English	O
17	and	O
17	US	O
17	families	O
17	there	O
17	was	O
17	little	O
17	evidence	O
17	for	O
17	a	O
17	recent	O
17	common	O
17	origin	O
17	of	O
17	the	O
17	MSH2	O
17	splice	O
17	site	O
17	mutation	O
17	in	O
17	most	O
17	families	O
17	.	O
18	In	O
18	contrast	O
18	,	O
18	a	O
18	common	O
18	haplotype	O
18	was	O
18	identified	O
18	at	O
18	the	O
18	two	O
18	flanking	O
18	markers	O
18	(	O
18	CA5	O
18	and	O
18	D2S288	O
18	)	O
18	in	O
18	eight	O
18	of	O
18	the	O
18	Newfoundland	O
18	families	O
18	.	O
19	These	O
19	findings	O
19	suggested	O
19	a	O
19	founder	O
19	effect	O
19	within	O
19	Newfoundland	O
19	similar	O
19	to	O
19	that	O
19	reported	O
19	by	O
19	others	O
19	for	O
19	two	O
19	MLH1	O
19	mutations	O
19	in	O
19	Finnish	O
19	HNPCC	B-Disease
19	families	O
19	.	O
20	We	O
20	calculated	O
20	age	O
20	related	O
20	risks	O
20	of	O
20	all	O
20	,	O
20	colorectal	B-Disease
20	,	I-Disease
20	endometrial	I-Disease
20	,	I-Disease
20	and	I-Disease
20	ovarian	I-Disease
20	cancers	I-Disease
20	in	O
20	nt943	O
20	+	O
20	3	O
20	A	O
20	-	O
20	-	O
20	>	O
20	T	O
20	MSH2	O
20	mutation	O
20	carriers	O
20	(	O
20	n	O
20	=	O
20	76	O
20	)	O
20	for	O
20	all	O
20	patients	O
20	and	O
20	for	O
20	men	O
20	and	O
20	women	O
20	separately	O
20	.	O
21	For	O
21	both	O
21	sexes	O
21	combined	O
21	,	O
21	the	O
21	penetrances	O
21	at	O
21	age	O
21	60	O
21	years	O
21	for	O
21	all	O
21	cancers	B-Disease
21	and	O
21	for	O
21	colorectal	B-Disease
21	cancer	I-Disease
21	were	O
21	0	O
21	.	O
22	86	O
22	and	O
22	0	O
22	.	O
23	57	O
23	,	O
23	respectively	O
23	.	O
24	The	O
24	risk	O
24	of	O
24	colorectal	B-Disease
24	cancer	I-Disease
24	was	O
24	significantly	O
24	higher	O
24	(	O
24	p	O
24	<	O
24	0	O
24	.	O
24	01	O
24	)	O
24	in	O
24	males	O
24	than	O
24	females	O
24	(	O
24	0	O
24	.	O
24	63	O
24	v	O
24	0	O
24	.	O
24	30	O
24	and	O
24	0	O
24	.	O
24	84	O
24	v	O
24	0	O
24	.	O
24	44	O
24	at	O
24	ages	O
24	50	O
24	and	O
24	60	O
24	years	O
24	,	O
24	respectively	O
24	)	O
24	.	O
25	For	O
25	females	O
25	there	O
25	was	O
25	a	O
25	high	O
25	risk	O
25	of	O
25	endometrial	B-Disease
25	cancer	I-Disease
25	(	O
25	0	O
25	.	O
25	5	O
25	at	O
25	age	O
25	60	O
25	years	O
25	)	O
25	and	O
25	premenopausal	B-Disease
25	ovarian	I-Disease
25	cancer	I-Disease
25	(	O
25	0	O
25	.	O
25	2	O
25	at	O
25	50	O
25	years	O
25	)	O
25	.	O
26	These	O
26	intersex	O
26	differences	O
26	in	O
26	colorectal	B-Disease
26	cancer	I-Disease
26	risks	O
26	have	O
26	implications	O
26	for	O
26	screening	O
26	programmes	O
26	and	O
26	for	O
26	attempts	O
26	to	O
26	identify	O
26	colorectal	B-Disease
26	cancer	I-Disease
26	susceptibility	O
26	modifiers	O
26	.	O
27	Age	O
27	of	O
27	onset	O
27	in	O
27	Huntington	B-Disease
27	disease	I-Disease
27	:	O
27	sex	O
27	specific	O
27	influence	O
27	of	O
27	apolipoprotein	O
27	E	O
27	genotype	O
27	and	O
27	normal	O
27	CAG	O
27	repeat	O
27	length	O
27	.	O
28	Age	O
28	of	O
28	onset	O
28	(	O
28	AO	O
28	)	O
28	of	O
28	Huntington	B-Disease
28	disease	I-Disease
28	(	O
28	HD	B-Disease
28	)	O
28	is	O
28	known	O
28	to	O
28	be	O
28	correlated	O
28	with	O
28	the	O
28	length	O
28	of	O
28	an	O
28	expanded	O
28	CAG	O
28	repeat	O
28	in	O
28	the	O
28	HD	B-Disease
28	gene	O
28	.	O
29	Apolipoprotein	O
29	E	O
29	(	O
29	APOE	O
29	)	O
29	genotype	O
29	,	O
29	in	O
29	turn	O
29	,	O
29	is	O
29	known	O
29	to	O
29	influence	O
29	AO	O
29	in	O
29	Alzheimer	B-Disease
29	disease	I-Disease
29	,	O
29	rendering	O
29	the	O
29	APOE	O
29	gene	O
29	a	O
29	likely	O
29	candidate	O
29	to	O
29	affect	O
29	AO	O
29	in	O
29	other	O
29	neurological	B-Disease
29	diseases	I-Disease
29	too	O
29	.	O
30	We	O
30	therefore	O
30	determined	O
30	APOE	O
30	genotype	O
30	and	O
30	normal	O
30	CAG	O
30	repeat	O
30	length	O
30	in	O
30	the	O
30	HD	B-Disease
30	gene	O
30	for	O
30	138	O
30	HD	B-Disease
30	patients	O
30	who	O
30	were	O
30	previously	O
30	analysed	O
30	with	O
30	respect	O
30	to	O
30	CAG	O
30	repeat	O
30	length	O
30	.	O
31	Genotyping	O
31	for	O
31	APOE	O
31	was	O
31	performed	O
31	blind	O
31	to	O
31	clinical	O
31	information	O
31	.	O
32	In	O
32	addition	O
32	to	O
32	highlighting	O
32	the	O
32	effect	O
32	of	O
32	the	O
32	normal	O
32	repeat	O
32	length	O
32	upon	O
32	AO	O
32	in	O
32	maternally	O
32	inherited	O
32	HD	B-Disease
32	and	O
32	in	O
32	male	O
32	patients	O
32	,	O
32	we	O
32	show	O
32	that	O
32	the	O
32	APOE	O
32	epsilon2epsilon3	O
32	genotype	O
32	is	O
32	associated	O
32	with	O
32	significantly	O
32	earlier	O
32	AO	O
32	in	O
32	males	O
32	than	O
32	in	O
32	females	O
32	.	O
33	Such	O
33	a	O
33	sex	O
33	difference	O
33	in	O
33	AO	O
33	was	O
33	not	O
33	apparent	O
33	for	O
33	any	O
33	of	O
33	the	O
33	other	O
33	APOE	O
33	genotypes	O
33	.	O
34	Our	O
34	findings	O
34	suggest	O
34	that	O
34	subtle	O
34	differences	O
34	in	O
34	the	O
34	course	O
34	of	O
34	the	O
34	neurodegeneration	B-Disease
34	in	O
34	HD	B-Disease
34	may	O
34	allow	O
34	interacting	O
34	genes	O
34	to	O
34	exert	O
34	gender	O
34	specific	O
34	effects	O
34	upon	O
34	AO	O
34	.	O
35	Familial	B-Disease
35	deficiency	I-Disease
35	of	I-Disease
35	the	I-Disease
35	seventh	I-Disease
35	component	I-Disease
35	of	I-Disease
35	complement	I-Disease
35	associated	O
35	with	O
35	recurrent	O
35	bacteremic	B-Disease
35	infections	I-Disease
35	due	I-Disease
35	to	I-Disease
35	Neisseria	I-Disease
35	.	O
36	The	O
36	serum	O
36	of	O
36	a	O
36	29	O
36	-	O
36	year	O
36	old	O
36	woman	O
36	with	O
36	a	O
36	recent	O
36	episode	O
36	of	O
36	disseminated	B-Disease
36	gonococcal	I-Disease
36	infection	I-Disease
36	and	O
36	a	O
36	history	O
36	of	O
36	meningococcal	B-Disease
36	meningitis	I-Disease
36	and	O
36	arthritis	B-Disease
36	as	O
36	a	O
36	child	O
36	was	O
36	found	O
36	to	O
36	lack	O
36	serum	O
36	hemolytic	O
36	complement	O
36	activity	O
36	.	O
37	The	O
37	seventh	O
37	component	O
37	of	O
37	complement	O
37	(	O
37	C7	O
37	)	O
37	was	O
37	not	O
37	detected	O
37	by	O
37	functional	O
37	or	O
37	immunochemical	O
37	assays	O
37	,	O
37	whereas	O
37	other	O
37	components	O
37	were	O
37	normal	O
37	by	O
37	hemolytic	O
37	and	O
37	immunochemical	O
37	assessment	O
37	.	O
38	Her	O
38	fresh	O
38	serum	O
38	lacked	O
38	complement	O
38	-	O
38	mediated	O
38	bactericidal	O
38	activity	O
38	against	O
38	Neisseria	O
38	gonorrhoeae	O
38	,	O
38	but	O
38	the	O
38	addition	O
38	of	O
38	fresh	O
38	normal	O
38	serum	O
38	or	O
38	purified	O
38	C7	O
38	restored	O
38	bactericidal	O
38	activity	O
38	as	O
38	well	O
38	as	O
38	hemolytic	O
38	activity	O
38	.	O
39	The	O
39	absence	B-Disease
39	of	I-Disease
39	functional	I-Disease
39	C7	I-Disease
39	activity	O
39	could	O
39	not	O
39	be	O
39	accounted	O
39	for	O
39	on	O
39	the	O
39	basis	O
39	of	O
39	an	O
39	inhibitor	O
39	.	O
40	Opsonization	O
40	and	O
40	generation	O
40	of	O
40	chemotactic	O
40	activity	O
40	functioned	O
40	normally	O
40	.	O
41	Complete	B-Disease
41	absence	I-Disease
41	of	I-Disease
41	C7	I-Disease
41	was	O
41	also	O
41	found	O
41	in	O
41	one	O
41	sibling	O
41	who	O
41	had	O
41	the	O
41	clinical	O
41	syndrome	O
41	of	O
41	meningococcal	B-Disease
41	meningitis	I-Disease
41	and	O
41	arthritis	B-Disease
41	as	O
41	a	O
41	child	O
41	and	O
41	in	O
41	this	O
41	siblings	O
41	clinically	O
41	well	O
41	eight	O
41	-	O
41	year	O
41	-	O
41	old	O
41	son	O
41	.	O
42	HLA	O
42	histocompatibility	O
42	typing	O
42	of	O
42	the	O
42	family	O
42	members	O
42	did	O
42	not	O
42	demonstrate	O
42	evidence	O
42	for	O
42	genetic	O
42	linkage	O
42	of	O
42	C7	B-Disease
42	deficiency	I-Disease
42	with	O
42	the	O
42	major	O
42	histocompatibility	O
42	loci	O
42	.	O
43	This	O
43	report	O
43	represents	O
43	the	O
43	first	O
43	cases	O
43	of	O
43	C7	B-Disease
43	deficiency	I-Disease
43	associated	O
43	with	O
43	infectious	O
43	complications	O
43	and	O
43	suggests	O
43	that	O
43	bactericidal	O
43	activity	O
43	may	O
43	be	O
43	important	O
43	in	O
43	host	O
43	defense	O
43	against	O
43	bacteremic	B-Disease
43	neisseria	I-Disease
43	infections	I-Disease
43	.	O
44	Increased	O
44	incidence	O
44	of	O
44	cancer	B-Disease
44	in	O
44	patients	O
44	with	O
44	cartilage	B-Disease
44	-	I-Disease
44	hair	I-Disease
44	hypoplasia	I-Disease
44	.	O
45	OBJECTIVE	O
45	Previous	O
45	reports	O
45	have	O
45	suggested	O
45	an	O
45	increased	O
45	risk	O
45	of	O
45	cancer	B-Disease
45	among	O
45	patients	O
45	with	O
45	cartilage	B-Disease
45	-	I-Disease
45	hair	I-Disease
45	hypoplasia	I-Disease
45	(	O
45	CHH	B-Disease
45	)	O
45	.	O
46	This	O
46	study	O
46	was	O
46	carried	O
46	out	O
46	to	O
46	further	O
46	evaluate	O
46	this	O
46	risk	O
46	among	O
46	patients	O
46	with	O
46	CHH	B-Disease
46	and	O
46	their	O
46	first	O
46	-	O
46	degree	O
46	relatives	O
46	.	O
47	STUDY	O
47	DESIGN	O
47	One	O
47	hundred	O
47	twenty	O
47	-	O
47	two	O
47	patients	O
47	with	O
47	CHH	B-Disease
47	were	O
47	identified	O
47	through	O
47	2	O
47	countrywide	O
47	epidemiologic	O
47	surveys	O
47	in	O
47	1974	O
47	and	O
47	in	O
47	1986	O
47	.	O
48	Their	O
48	parents	O
48	and	O
48	nonaffected	O
48	siblings	O
48	were	O
48	identified	O
48	through	O
48	the	O
48	Population	O
48	Register	O
48	Center	O
48	.	O
49	This	O
49	cohort	O
49	underwent	O
49	follow	O
49	-	O
49	up	O
49	for	O
49	cancer	B-Disease
49	incidence	O
49	through	O
49	the	O
49	Finnish	O
49	Cancer	O
49	Registry	O
49	to	O
49	the	O
49	end	O
49	of	O
49	1995	O
49	.	O
50	RESULTS	O
50	A	O
50	statistically	O
50	significant	O
50	excess	O
50	risk	O
50	of	O
50	cancer	B-Disease
50	was	O
50	seen	O
50	among	O
50	the	O
50	patients	O
50	with	O
50	CHH	B-Disease
50	(	O
50	standardized	O
50	incidence	O
50	ratio	O
50	6	O
50	.	O
50	9	O
50	,	O
50	95	O
50	%	O
50	confidence	O
50	interval	O
50	2	O
50	.	O
50	3	O
50	to	O
50	16	O
50	)	O
50	,	O
50	which	O
50	was	O
50	mainly	O
50	attributable	O
50	to	O
50	non	B-Disease
50	-	I-Disease
50	Hodgkins	I-Disease
50	lymphoma	I-Disease
50	(	O
50	standardized	O
50	incidence	O
50	ratio	O
50	90	O
50	,	O
50	95	O
50	%	O
50	confidence	O
50	interval	O
50	18	O
50	to	O
50	264	O
50	)	O
50	.	O
51	In	O
51	addition	O
51	,	O
51	a	O
51	significant	O
51	excess	O
51	risk	O
51	of	O
51	basal	B-Disease
51	cell	I-Disease
51	carcinoma	I-Disease
51	was	O
51	seen	O
51	(	O
51	standardized	O
51	incidence	O
51	ratio	O
51	35	O
51	,	O
51	95	O
51	%	O
51	confidence	O
51	interval	O
51	7	O
51	.	O
51	2	O
51	to	O
51	102	O
51	)	O
51	.	O
52	The	O
52	cancer	B-Disease
52	incidence	O
52	among	O
52	the	O
52	siblings	O
52	or	O
52	the	O
52	parents	O
52	did	O
52	not	O
52	differ	O
52	from	O
52	the	O
52	average	O
52	cancer	B-Disease
52	incidence	O
52	in	O
52	the	O
52	Finnish	O
52	population	O
52	.	O
53	CONCLUSIONS	O
53	This	O
53	study	O
53	confirms	O
53	an	O
53	increased	O
53	risk	O
53	of	O
53	cancer	B-Disease
53	,	O
53	especially	O
53	non	B-Disease
53	-	I-Disease
53	Hodgkins	I-Disease
53	lymphoma	I-Disease
53	,	O
53	probably	O
53	attributable	O
53	to	O
53	defective	O
53	immunity	O
53	,	O
53	among	O
53	patients	O
53	with	O
53	CHH	B-Disease
53	.	O
54	Genotype	O
54	and	O
54	phenotype	O
54	in	O
54	patients	O
54	with	O
54	dihydropyrimidine	B-Disease
54	dehydrogenase	I-Disease
54	deficiency	I-Disease
54	.	O
55	Dihydropyrimidine	B-Disease
55	dehydrogenase	I-Disease
55	(	I-Disease
55	DPD	I-Disease
55	)	I-Disease
55	deficiency	I-Disease
55	is	O
55	an	O
55	autosomal	B-Disease
55	recessive	I-Disease
55	disease	I-Disease
55	characterised	O
55	by	O
55	thymine	O
55	-	O
55	uraciluria	O
55	in	O
55	homozygous	O
55	deficient	O
55	patients	O
55	and	O
55	has	O
55	been	O
55	associated	O
55	with	O
55	a	O
55	variable	O
55	clinical	O
55	phenotype	O
55	.	O
56	In	O
56	order	O
56	to	O
56	understand	O
56	the	O
56	genetic	O
56	and	O
56	phenotypic	O
56	basis	O
56	for	O
56	DPD	B-Disease
56	deficiency	I-Disease
56	,	O
56	we	O
56	have	O
56	reviewed	O
56	17	O
56	families	O
56	presenting	O
56	22	O
56	patients	O
56	with	O
56	complete	O
56	deficiency	B-Disease
56	of	I-Disease
56	DPD	I-Disease
56	.	O
57	In	O
57	this	O
57	group	O
57	of	O
57	patients	O
57	,	O
57	7	O
57	different	O
57	mutations	O
57	have	O
57	been	O
57	identified	O
57	,	O
57	including	O
57	2	O
57	deletions	O
57	[	O
57	295	O
57	-	O
57	298delTCAT	O
57	,	O
57	1897delC	O
57	]	O
57	,	O
57	1	O
57	splice	O
57	-	O
57	site	O
57	mutation	O
57	[	O
57	IVS14	O
57	+	O
57	1G	O
57	>	O
57	A	O
57	)	O
57	]	O
57	and	O
57	4	O
57	missense	O
57	mutations	O
57	(	O
57	85T	O
57	>	O
57	C	O
57	,	O
57	703C	O
57	>	O
57	T	O
57	,	O
57	2658G	O
57	>	O
57	A	O
57	,	O
57	2983G	O
57	>	O
57	T	O
57	)	O
57	.	O
58	Analysis	O
58	of	O
58	the	O
58	prevalence	O
58	of	O
58	the	O
58	various	O
58	mutations	O
58	among	O
58	DPD	B-Disease
58	patients	O
58	has	O
58	shown	O
58	that	O
58	the	O
58	G	O
58	-	O
58	-	O
58	>	O
58	A	O
58	point	O
58	mutation	O
58	in	O
58	the	O
58	invariant	O
58	splice	O
58	donor	O
58	site	O
58	is	O
58	by	O
58	far	O
58	the	O
58	most	O
58	common	O
58	(	O
58	52	O
58	%	O
58	)	O
58	,	O
58	whereas	O
58	the	O
58	other	O
58	six	O
58	mutations	O
58	are	O
58	less	O
58	frequently	O
58	observed	O
58	.	O
59	A	O
59	large	O
59	phenotypic	O
59	variability	O
59	has	O
59	been	O
59	observed	O
59	,	O
59	with	O
59	convulsive	B-Disease
59	disorders	I-Disease
59	,	O
59	motor	B-Disease
59	retardation	I-Disease
59	and	O
59	mental	B-Disease
59	retardation	I-Disease
59	being	O
59	the	O
59	most	O
59	abundant	O
59	manifestations	O
59	.	O
60	A	O
60	clear	O
60	correlation	O
60	between	O
60	the	O
60	genotype	O
60	and	O
60	phenotype	O
60	has	O
60	not	O
60	been	O
60	established	O
60	.	O
61	An	O
61	altered	O
61	beta	O
61	-	O
61	alanine	O
61	,	O
61	uracil	O
61	and	O
61	thymine	O
61	homeostasis	O
61	might	O
61	underlie	O
61	the	O
61	various	O
61	clinical	B-Disease
61	abnormalities	I-Disease
61	encountered	O
61	in	O
61	patients	O
61	with	O
61	DPD	B-Disease
61	deficiency	I-Disease
61	.	O
62	Fibroblast	O
62	growth	O
62	factor	O
62	homologous	O
62	factor	O
62	2	O
62	(	O
62	FHF2	O
62	)	O
62	:	O
62	gene	O
62	structure	O
62	,	O
62	expression	O
62	and	O
62	mapping	O
62	to	O
62	the	O
62	Borjeson	B-Disease
62	-	I-Disease
62	Forssman	I-Disease
62	-	I-Disease
62	Lehmann	I-Disease
62	syndrome	I-Disease
62	region	O
62	in	O
62	Xq26	O
62	delineated	O
62	by	O
62	a	O
62	duplication	O
62	breakpoint	O
62	in	O
62	a	O
62	BFLS	B-Disease
62	-	O
62	like	O
62	patient	O
62	.	O
63	Borjeson	B-Disease
63	-	I-Disease
63	Forssman	I-Disease
63	-	I-Disease
63	Lehmann	I-Disease
63	syndrome	I-Disease
63	(	O
63	BFLS	B-Disease
63	)	O
63	is	O
63	a	O
63	syndromal	O
63	X	B-Disease
63	-	I-Disease
63	linked	I-Disease
63	mental	I-Disease
63	retardation	I-Disease
63	,	O
63	which	O
63	maps	O
63	by	O
63	linkage	O
63	to	O
63	the	O
63	q26	O
63	region	O
63	of	O
63	the	O
63	human	O
63	X	O
63	chromosome	O
63	.	O
64	We	O
64	have	O
64	identified	O
64	a	O
64	male	O
64	patient	O
64	with	O
64	BFLS	B-Disease
64	-	O
64	like	O
64	features	O
64	and	O
64	a	O
64	duplication	O
64	,	O
64	46	O
64	,	O
64	Y	O
64	,	O
64	dup	O
64	(	O
64	X	O
64	)	O
64	(	O
64	q26q28	O
64	)	O
64	,	O
64	inherited	O
64	from	O
64	his	O
64	phenotypically	O
64	normal	O
64	mother	O
64	.	O
65	Fluorescence	O
65	in	O
65	situ	O
65	hybridisation	O
65	using	O
65	yeast	O
65	artificial	O
65	chromosome	O
65	clones	O
65	from	O
65	Xq26	O
65	localised	O
65	the	O
65	duplication	O
65	breakpoint	O
65	to	O
65	an	O
65	approximately	O
65	400	O
65	-	O
65	kb	O
65	interval	O
65	in	O
65	the	O
65	Xq26	O
65	.	O
66	3	O
66	region	O
66	between	O
66	DXS155	O
66	and	O
66	DXS294	O
66	/	O
66	DXS730	O
66	.	O
67	Database	O
67	searches	O
67	and	O
67	analysis	O
67	of	O
67	available	O
67	genomic	O
67	DNA	O
67	sequence	O
67	from	O
67	the	O
67	region	O
67	revealed	O
67	the	O
67	presence	O
67	of	O
67	the	O
67	fibroblast	O
67	growth	O
67	factor	O
67	homologous	O
67	factor	O
67	gene	O
67	,	O
67	FHF2	O
67	,	O
67	within	O
67	the	O
67	duplication	O
67	breakpoint	O
67	interval	O
67	.	O
68	The	O
68	gene	O
68	structure	O
68	of	O
68	FHF2	O
68	was	O
68	determined	O
68	and	O
68	two	O
68	new	O
68	exons	O
68	were	O
68	identified	O
68	,	O
68	including	O
68	a	O
68	new	O
68	5	O
68	end	O
68	exon	O
68	,	O
68	1B	O
68	.	O
69	FHF2	O
69	is	O
69	a	O
69	large	O
69	gene	O
69	extending	O
69	over	O
69	approximately	O
69	200	O
69	kb	O
69	in	O
69	Xq26	O
69	.	O
70	3	O
70	and	O
70	is	O
70	composed	O
70	of	O
70	at	O
70	least	O
70	seven	O
70	exons	O
70	.	O
71	It	O
71	shows	O
71	tissue	O
71	-	O
71	specific	O
71	alternative	O
71	splicing	O
71	and	O
71	alternative	O
71	transcription	O
71	starts	O
71	.	O
72	Northern	O
72	blot	O
72	hybridisation	O
72	showed	O
72	highest	O
72	expression	O
72	in	O
72	brain	O
72	and	O
72	skeletal	O
72	muscle	O
72	.	O
73	The	O
73	FHF2	O
73	gene	O
73	localisation	O
73	and	O
73	tissue	O
73	-	O
73	specific	O
73	expression	O
73	pattern	O
73	suggest	O
73	it	O
73	to	O
73	be	O
73	a	O
73	candidate	O
73	gene	O
73	for	O
73	familial	O
73	cases	O
73	of	O
73	the	O
73	BFLS	B-Disease
73	syndrome	I-Disease
73	and	O
73	other	O
73	syndromal	O
73	and	O
73	non	O
73	-	O
73	specific	O
73	forms	O
73	of	O
73	X	B-Disease
73	-	I-Disease
73	linked	I-Disease
73	mental	I-Disease
73	retardation	I-Disease
73	mapping	O
73	to	O
73	the	O
73	region	O
73	.	O
74	Germline	O
74	E	O
74	-	O
74	cadherin	O
74	gene	O
74	(	O
74	CDH1	O
74	)	O
74	mutations	O
74	predispose	O
74	to	O
74	familial	B-Disease
74	gastric	I-Disease
74	cancer	I-Disease
74	and	O
74	colorectal	B-Disease
74	cancer	I-Disease
74	.	O
75	Inherited	O
75	mutations	O
75	in	O
75	the	O
75	E	O
75	-	O
75	cadherin	O
75	gene	O
75	(	O
75	CDH1	O
75	)	O
75	were	O
75	described	O
75	recently	O
75	in	O
75	three	O
75	Maori	O
75	kindreds	O
75	with	O
75	familial	B-Disease
75	gastric	I-Disease
75	cancer	I-Disease
75	.	O
76	Familial	B-Disease
76	gastric	I-Disease
76	cancer	I-Disease
76	is	O
76	genetically	O
76	heterogeneous	O
76	and	O
76	it	O
76	is	O
76	not	O
76	clear	O
76	what	O
76	proportion	O
76	of	O
76	gastric	B-Disease
76	cancer	I-Disease
76	susceptibility	O
76	in	O
76	non	O
76	-	O
76	Maori	O
76	populations	O
76	is	O
76	due	O
76	to	O
76	germline	O
76	CDH1	O
76	mutations	O
76	.	O
77	Therefore	O
77	,	O
77	we	O
77	screened	O
77	eight	O
77	familial	B-Disease
77	gastric	I-Disease
77	cancer	I-Disease
77	kindreds	O
77	of	O
77	British	O
77	and	O
77	Irish	O
77	origin	O
77	for	O
77	germline	O
77	CDH1	O
77	mutations	O
77	,	O
77	by	O
77	SSCP	O
77	analysis	O
77	of	O
77	all	O
77	16	O
77	exons	O
77	and	O
77	flanking	O
77	sequences	O
77	.	O
78	Each	O
78	family	O
78	contained	O
78	(	O
78	i	O
78	)	O
78	two	O
78	cases	O
78	of	O
78	gastric	B-Disease
78	cancer	I-Disease
78	in	O
78	first	O
78	degree	O
78	relatives	O
78	with	O
78	one	O
78	affected	O
78	before	O
78	age	O
78	50	O
78	years	O
78	;	O
78	or	O
78	(	O
78	ii	O
78	)	O
78	three	O
78	or	O
78	more	O
78	cases	O
78	of	O
78	gastric	B-Disease
78	cancer	I-Disease
78	.	O
79	Novel	O
79	germline	O
79	CDH1	O
79	mutations	O
79	(	O
79	a	O
79	nonsense	O
79	and	O
79	a	O
79	splice	O
79	site	O
79	)	O
79	were	O
79	detected	O
79	in	O
79	two	O
79	families	O
79	(	O
79	25	O
79	%	O
79	)	O
79	.	O
80	Both	O
80	mutations	O
80	were	O
80	predicted	O
80	to	O
80	truncate	O
80	the	O
80	E	O
80	-	O
80	cadherin	O
80	protein	O
80	in	O
80	the	O
80	signal	O
80	peptide	O
80	domain	O
80	.	O
81	In	O
81	one	O
81	family	O
81	there	O
81	was	O
81	evidence	O
81	of	O
81	non	O
81	-	O
81	penetrance	O
81	and	O
81	susceptibility	O
81	to	O
81	both	O
81	gastric	B-Disease
81	and	I-Disease
81	colorectal	I-Disease
81	cancer	I-Disease
81	;	O
81	thus	O
81	,	O
81	in	O
81	addition	O
81	to	O
81	six	O
81	cases	O
81	of	O
81	gastric	B-Disease
81	cancer	I-Disease
81	,	O
81	a	O
81	CDH1	O
81	mutation	O
81	carrier	O
81	developed	O
81	colorectal	B-Disease
81	cancer	I-Disease
81	at	O
81	age	O
81	30	O
81	years	O
81	.	O
82	We	O
82	have	O
82	confirmed	O
82	that	O
82	germline	O
82	mutations	O
82	in	O
82	the	O
82	CDH1	O
82	gene	O
82	cause	O
82	familial	B-Disease
82	gastric	I-Disease
82	cancer	I-Disease
82	in	O
82	non	O
82	-	O
82	Maori	O
82	populations	O
82	.	O
83	However	O
83	,	O
83	only	O
83	a	O
83	minority	O
83	of	O
83	familial	O
83	gastric	B-Disease
83	cancers	I-Disease
83	can	O
83	be	O
83	accounted	O
83	for	O
83	by	O
83	CDH1	O
83	mutations	O
83	.	O
84	Loss	O
84	of	O
84	E	O
84	-	O
84	cadherin	O
84	function	O
84	has	O
84	been	O
84	implicated	O
84	in	O
84	the	O
84	pathogenesis	O
84	of	O
84	sporadic	O
84	colorectal	B-Disease
84	and	I-Disease
84	other	I-Disease
84	cancers	I-Disease
84	,	O
84	and	O
84	our	O
84	findings	O
84	provide	O
84	evidence	O
84	that	O
84	germline	O
84	CDH1	O
84	mutations	O
84	predispose	O
84	to	O
84	early	O
84	onset	O
84	colorectal	B-Disease
84	cancer	I-Disease
84	.	O
85	Thus	O
85	,	O
85	CDH1	O
85	should	O
85	be	O
85	investigated	O
85	as	O
85	a	O
85	cause	O
85	of	O
85	inherited	O
85	susceptibility	O
85	to	O
85	both	O
85	gastric	B-Disease
85	and	I-Disease
85	colorectal	I-Disease
85	cancers	I-Disease
85	.	O
86	A	O
86	zinc	O
86	finger	O
86	truncation	O
86	of	O
86	murine	O
86	WT1	O
86	results	O
86	in	O
86	the	O
86	characteristic	O
86	urogenital	B-Disease
86	abnormalities	I-Disease
86	of	O
86	Denys	B-Disease
86	-	I-Disease
86	Drash	I-Disease
86	syndrome	I-Disease
86	.	O
87	The	O
87	Wilms	B-Disease
87	tumor	I-Disease
87	-	O
87	suppressor	O
87	gene	O
87	,	O
87	WT1	O
87	,	O
87	plays	O
87	a	O
87	key	O
87	role	O
87	in	O
87	urogenital	O
87	development	O
87	,	O
87	and	O
87	WT1	B-Disease
87	dysfunction	I-Disease
87	is	O
87	implicated	O
87	in	O
87	both	O
87	neoplastic	B-Disease
87	(	O
87	Wilms	B-Disease
87	tumor	I-Disease
87	,	O
87	mesothelioma	B-Disease
87	,	O
87	leukemias	B-Disease
87	,	O
87	and	O
87	breast	B-Disease
87	cancer	I-Disease
87	)	O
87	and	O
87	nonneoplastic	B-Disease
87	(	O
87	glomerulosclerosis	B-Disease
87	)	O
87	disease	O
87	.	O
88	The	O
88	analysis	O
88	of	O
88	diseases	O
88	linked	O
88	specifically	O
88	with	O
88	WT1	O
88	mutations	O
88	,	O
88	such	O
88	as	O
88	Denys	B-Disease
88	-	I-Disease
88	Drash	I-Disease
88	syndrome	I-Disease
88	(	O
88	DDS	B-Disease
88	)	O
88	,	O
88	can	O
88	provide	O
88	valuable	O
88	insight	O
88	concerning	O
88	the	O
88	role	O
88	of	O
88	WT1	O
88	in	O
88	development	O
88	and	O
88	disease	O
88	.	O
89	DDS	B-Disease
89	is	O
89	a	O
89	rare	O
89	childhood	O
89	disease	O
89	characterized	O
89	by	O
89	a	O
89	nephropathy	B-Disease
89	involving	O
89	mesangial	B-Disease
89	sclerosis	I-Disease
89	,	O
89	XY	O
89	pseudohermaphroditism	B-Disease
89	,	O
89	and	O
89	/	O
89	or	O
89	Wilms	B-Disease
89	tumor	I-Disease
89	(	O
89	WT	B-Disease
89	)	O
89	.	O
90	DDS	B-Disease
90	patients	O
90	are	O
90	constitutionally	O
90	heterozygous	O
90	for	O
90	exonic	O
90	point	O
90	mutations	O
90	in	O
90	WT1	O
90	,	O
90	which	O
90	include	O
90	mutations	O
90	predicted	O
90	to	O
90	truncate	O
90	the	O
90	protein	O
90	within	O
90	the	O
90	C	O
90	-	O
90	terminal	O
90	zinc	O
90	finger	O
90	(	O
90	ZF	O
90	)	O
90	region	O
90	.	O
91	We	O
91	report	O
91	that	O
91	heterozygosity	O
91	for	O
91	a	O
91	targeted	O
91	murine	O
91	Wt1	O
91	allele	O
91	,	O
91	Wt1	O
91	(	O
91	tmT396	O
91	)	O
91	,	O
91	which	O
91	truncates	O
91	ZF3	O
91	at	O
91	codon	O
91	396	O
91	,	O
91	induces	O
91	mesangial	B-Disease
91	sclerosis	I-Disease
91	characteristic	O
91	of	O
91	DDS	B-Disease
91	in	O
91	adult	O
91	heterozygous	O
91	and	O
91	chimeric	O
91	mice	O
91	.	O
92	Male	B-Disease
92	genital	I-Disease
92	defects	I-Disease
92	also	O
92	were	O
92	evident	O
92	and	O
92	there	O
92	was	O
92	a	O
92	single	O
92	case	O
92	of	O
92	Wilms	B-Disease
92	tumor	I-Disease
92	in	O
92	which	O
92	the	O
92	transcript	O
92	of	O
92	the	O
92	nontargeted	O
92	allele	O
92	showed	O
92	an	O
92	exon	O
92	9	O
92	skipping	O
92	event	O
92	,	O
92	implying	O
92	a	O
92	causal	O
92	link	O
92	between	O
92	Wt1	B-Disease
92	dysfunction	I-Disease
92	and	O
92	Wilms	B-Disease
92	tumorigenesis	I-Disease
92	in	O
92	mice	O
92	.	O
93	However	O
93	,	O
93	the	O
93	mutant	O
93	WT1	O
93	(	O
93	tmT396	O
93	)	O
93	protein	O
93	accounted	O
93	for	O
93	only	O
93	5	O
93	%	O
93	of	O
93	WT1	O
93	in	O
93	both	O
93	heterozygous	O
93	embryonic	O
93	stem	O
93	cells	O
93	and	O
93	the	O
93	WT	B-Disease
93	.	O
94	This	O
94	has	O
94	implications	O
94	regarding	O
94	the	O
94	mechanism	O
94	by	O
94	which	O
94	the	O
94	mutant	O
94	allele	O
94	exerts	O
94	its	O
94	effect	O
94	.	O
95	Mechanism	O
95	of	O
95	increased	O
95	iron	O
95	absorption	O
95	in	O
95	murine	O
95	model	O
95	of	O
95	hereditary	B-Disease
95	hemochromatosis	I-Disease
95	:	O
95	increased	O
95	duodenal	O
95	expression	O
95	of	O
95	the	O
95	iron	O
95	transporter	O
95	DMT1	O
95	.	O
96	Hereditary	B-Disease
96	hemochromatosis	I-Disease
96	(	O
96	HH	B-Disease
96	)	O
96	is	O
96	a	O
96	common	O
96	autosomal	B-Disease
96	recessive	I-Disease
96	disorder	I-Disease
96	characterized	O
96	by	O
96	tissue	O
96	iron	O
96	deposition	O
96	secondary	O
96	to	O
96	excessive	O
96	dietary	O
96	iron	O
96	absorption	O
96	.	O
97	We	O
97	recently	O
97	reported	O
97	that	O
97	HFE	O
97	,	O
97	the	O
97	protein	O
97	defective	O
97	in	O
97	HH	B-Disease
97	,	O
97	was	O
97	physically	O
97	associated	O
97	with	O
97	the	O
97	transferrin	O
97	receptor	O
97	(	O
97	TfR	O
97	)	O
97	in	O
97	duodenal	O
97	crypt	O
97	cells	O
97	and	O
97	proposed	O
97	that	O
97	mutations	O
97	in	O
97	HFE	O
97	attenuate	O
97	the	O
97	uptake	O
97	of	O
97	transferrin	O
97	-	O
97	bound	O
97	iron	O
97	from	O
97	plasma	O
97	by	O
97	duodenal	O
97	crypt	O
97	cells	O
97	,	O
97	leading	O
97	to	O
97	up	O
97	-	O
97	regulation	O
97	of	O
97	transporters	O
97	for	O
97	dietary	O
97	iron	O
97	.	O
98	Here	O
98	,	O
98	we	O
98	tested	O
98	the	O
98	hypothesis	O
98	that	O
98	HFE	O
98	-	O
98	/	O
98	-	O
98	mice	O
98	have	O
98	increased	O
98	duodenal	O
98	expression	O
98	of	O
98	the	O
98	divalent	O
98	metal	O
98	transporter	O
98	(	O
98	DMT1	O
98	)	O
98	.	O
99	By	O
99	4	O
99	weeks	O
99	of	O
99	age	O
99	,	O
99	the	O
99	HFE	O
99	-	O
99	/	O
99	-	O
99	mice	O
99	demonstrated	O
99	iron	O
99	loading	O
99	when	O
99	compared	O
99	with	O
99	HFE	O
99	+	O
99	/	O
99	+	O
99	littermates	O
99	,	O
99	with	O
99	elevated	O
99	transferrin	O
99	saturations	O
99	(	O
99	68	O
99	.	O
99	4	O
99	%	O
99	vs	O
99	.	O
99	49	O
99	.	O
99	8	O
99	%	O
99	)	O
99	and	O
99	elevated	O
99	liver	O
99	iron	O
99	concentrations	O
99	(	O
99	985	O
99	micrograms	O
99	vs	O
99	.	O
99	381	O
99	micrograms	O
99	)	O
99	.	O
100	By	O
100	using	O
100	Northern	O
100	blot	O
100	analyses	O
100	,	O
100	we	O
100	quantitated	O
100	duodenal	O
100	expression	O
100	of	O
100	both	O
100	classes	O
100	of	O
100	DMT1	O
100	transcripts	O
100	one	O
100	containing	O
100	an	O
100	iron	O
100	responsive	O
100	element	O
100	(	O
100	IRE	O
100	)	O
100	,	O
100	called	O
100	DMT1	O
100	(	O
100	IRE	O
100	)	O
100	,	O
100	and	O
100	one	O
100	containing	O
100	no	O
100	IRE	O
100	,	O
100	called	O
100	DMT1	O
100	(	O
100	non	O
100	-	O
100	IRE	O
100	)	O
100	.	O
101	The	O
101	positive	O
101	control	O
101	for	O
101	DMT1	O
101	up	O
101	-	O
101	regulation	O
101	was	O
101	a	O
101	murine	O
101	model	O
101	of	O
101	dietary	B-Disease
101	iron	I-Disease
101	deficiency	I-Disease
101	that	O
101	demonstrated	O
101	greatly	O
101	increased	O
101	levels	O
101	of	O
101	duodenal	O
101	DMT1	O
101	(	O
101	IRE	O
101	)	O
101	mRNA	O
101	.	O
102	HFE	O
102	-	O
102	/	O
102	-	O
102	mice	O
102	also	O
102	demonstrated	O
102	an	O
102	increase	O
102	in	O
102	duodenal	O
102	DMT1	O
102	(	O
102	IRE	O
102	)	O
102	mRNA	O
102	(	O
102	average	O
102	7	O
102	.	O
102	7	O
102	-	O
102	fold	O
102	)	O
102	,	O
102	despite	O
102	their	O
102	elevated	O
102	transferrin	O
102	saturation	O
102	and	O
102	hepatic	O
102	iron	O
102	content	O
102	.	O
103	Duodenal	O
103	expression	O
103	of	O
103	DMT1	O
103	(	O
103	non	O
103	-	O
103	IRE	O
103	)	O
103	was	O
103	not	O
103	increased	O
103	,	O
103	nor	O
103	was	O
103	hepatic	O
103	expression	O
103	of	O
103	DMT1	O
103	increased	O
103	.	O
104	These	O
104	data	O
104	support	O
104	the	O
104	model	O
104	for	O
104	HH	O
104	in	O
104	which	O
104	HFE	O
104	mutations	O
104	lead	O
104	to	O
104	inappropriately	O
104	low	O
104	crypt	O
104	cell	O
104	iron	O
104	,	O
104	with	O
104	resultant	O
104	stabilization	O
104	of	O
104	DMT1	O
104	(	O
104	IRE	O
104	)	O
104	mRNA	O
104	,	O
104	up	O
104	-	O
104	regulation	O
104	of	O
104	DMT1	O
104	,	O
104	and	O
104	increased	O
104	absorption	O
104	of	O
104	dietary	O
104	iron	O
104	.	O
105	Neurophysiologic	O
105	follow	O
105	-	O
105	up	O
105	of	O
105	long	O
105	-	O
105	term	O
105	dietary	O
105	treatment	O
105	in	O
105	adult	O
105	-	O
105	onset	O
105	adrenoleukodystrophy	B-Disease
105	.	O
106	OBJECTIVE	O
106	To	O
106	monitor	O
106	the	O
106	effects	O
106	of	O
106	dietary	O
106	treatment	O
106	in	O
106	adult	O
106	-	O
106	onset	O
106	adrenoleukodystrophy	B-Disease
106	(	O
106	ALD	B-Disease
106	)	O
106	by	O
106	means	O
106	of	O
106	somatosensory	O
106	evoked	O
106	potentials	O
106	(	O
106	SEPs	O
106	)	O
106	and	O
106	motor	O
106	evoked	O
106	potentials	O
106	(	O
106	MEPs	O
106	)	O
106	.	O
107	BACKGROUND	O
107	SEPs	O
107	and	O
107	MEPs	O
107	have	O
107	proved	O
107	useful	O
107	in	O
107	revealing	O
107	signs	O
107	of	O
107	progressively	O
107	severe	O
107	,	O
107	central	O
107	dying	B-Disease
107	-	I-Disease
107	back	I-Disease
107	axonopathy	I-Disease
107	in	O
107	early	O
107	stages	O
107	of	O
107	adult	O
107	-	O
107	onset	O
107	ALD	B-Disease
107	.	O
108	METHODS	O
108	Eight	O
108	patients	O
108	with	O
108	adult	O
108	-	O
108	onset	O
108	ALD	B-Disease
108	underwent	O
108	clinical	O
108	examination	O
108	,	O
108	brain	O
108	and	O
108	spine	O
108	MRI	O
108	,	O
108	and	O
108	SEP	O
108	and	O
108	MEP	O
108	studies	O
108	before	O
108	and	O
108	after	O
108	3	O
108	years	O
108	of	O
108	Lorenzos	O
108	oil	O
108	dietary	O
108	therapy	O
108	.	O
109	RESULTS	O
109	Before	O
109	treatment	O
109	,	O
109	brain	O
109	MRI	O
109	was	O
109	normal	O
109	in	O
109	five	O
109	patients	O
109	.	O
110	Three	O
110	of	O
110	these	O
110	patients	O
110	had	O
110	pure	O
110	spinal	B-Disease
110	SEP	I-Disease
110	abnormalities	I-Disease
110	and	O
110	in	O
110	the	O
110	remaining	O
110	two	O
110	patients	O
110	SEPs	O
110	showed	O
110	signs	O
110	of	O
110	involvement	O
110	of	O
110	both	O
110	the	O
110	spinal	O
110	and	O
110	cerebral	O
110	somatosensory	O
110	tracts	O
110	.	O
111	After	O
111	treatment	O
111	,	O
111	the	O
111	three	O
111	patients	O
111	with	O
111	pure	O
111	spinal	B-Disease
111	abnormalities	I-Disease
111	showed	O
111	clinical	O
111	and	O
111	neurophysiologic	O
111	worsening	O
111	,	O
111	whereas	O
111	the	O
111	two	O
111	patients	O
111	with	O
111	a	O
111	more	O
111	advanced	O
111	stage	O
111	of	O
111	disease	O
111	(	O
111	exhibited	O
111	by	O
111	SEPs	O
111	)	O
111	showed	O
111	substantially	O
111	unchanged	O
111	clinical	O
111	and	O
111	neurophysiologic	O
111	features	O
111	.	O
112	The	O
112	patients	O
112	with	O
112	abnormal	O
112	brain	O
112	MRI	O
112	at	O
112	the	O
112	onset	O
112	of	O
112	treatment	O
112	showed	O
112	clinical	O
112	and	O
112	neurophysiologic	O
112	worsening	O
112	.	O
113	CONCLUSIONS	O
113	Lorenzos	O
113	oil	O
113	therapy	O
113	had	O
113	no	O
113	effect	O
113	on	O
113	patients	O
113	with	O
113	evidence	O
113	of	O
113	inflammatory	B-Disease
113	brain	I-Disease
113	lesions	I-Disease
113	.	O
114	Moreover	O
114	,	O
114	in	O
114	patients	O
114	without	O
114	clear	O
114	signs	O
114	of	O
114	inflammatory	O
114	damage	O
114	,	O
114	this	O
114	treatment	O
114	does	O
114	not	O
114	modify	O
114	significantly	O
114	the	O
114	natural	O
114	course	O
114	of	O
114	the	O
114	disease	O
114	.	O
115	However	O
115	,	O
115	because	O
115	effective	O
115	treatments	O
115	should	O
115	begin	O
115	before	O
115	the	O
115	onset	O
115	of	O
115	severe	O
115	neurologic	O
115	symptoms	O
115	,	O
115	SEPs	O
115	and	O
115	MEPs	O
115	should	O
115	be	O
115	considered	O
115	to	O
115	evaluate	O
115	the	O
115	effectiveness	O
115	of	O
115	other	O
115	experimental	O
115	treatments	O
115	in	O
115	the	O
115	patient	O
115	with	O
115	a	O
115	negative	O
115	brain	O
115	MRI	O
115	.	O
116	GCH1	O
116	mutation	O
116	in	O
116	a	O
116	patient	O
116	with	O
116	adult	O
116	-	O
116	onset	O
116	oromandibular	B-Disease
116	dystonia	I-Disease
116	.	O
117	The	O
117	authors	O
117	report	O
117	a	O
117	mutation	O
117	in	O
117	exon	O
117	5	O
117	of	O
117	GCH1	O
117	in	O
117	a	O
117	patient	O
117	with	O
117	adult	O
117	-	O
117	onset	O
117	oromandibular	B-Disease
117	dystonia	I-Disease
117	and	O
117	no	O
117	obvious	O
117	family	O
117	history	O
117	of	O
117	dystonia	B-Disease
117	.	O
118	The	O
118	patient	O
118	responded	O
118	positively	O
118	to	O
118	treatment	O
118	with	O
118	L	O
118	-	O
118	dopa	O
118	.	O
119	These	O
119	findings	O
119	demonstrate	O
119	that	O
119	GCH1	O
119	mutations	O
119	must	O
119	be	O
119	considered	O
119	even	O
119	in	O
119	patients	O
119	with	O
119	dystonic	B-Disease
119	symptoms	O
119	not	O
119	typical	O
119	of	O
119	dopa	B-Disease
119	-	I-Disease
119	responsive	I-Disease
119	dystonia	I-Disease
119	.	O
120	Germline	O
120	mutations	O
120	of	O
120	the	O
120	APC	B-Disease
120	gene	O
120	in	O
120	Korean	O
120	familial	B-Disease
120	adenomatous	I-Disease
120	polyposis	I-Disease
120	patients	O
120	.	O
121	We	O
121	extensively	O
121	analyzed	O
121	genomic	O
121	DNA	O
121	and	O
121	messenger	O
121	RNA	O
121	(	O
121	mRNA	O
121	)	O
121	from	O
121	62	O
121	unrelated	O
121	Korean	O
121	patients	O
121	with	O
121	familial	B-Disease
121	adenomatous	I-Disease
121	polyposis	I-Disease
121	(	O
121	FAP	B-Disease
121	)	O
121	for	O
121	identification	O
121	of	O
121	germline	O
121	adenomatous	B-Disease
121	polyposis	I-Disease
121	coli	I-Disease
121	(	O
121	APC	B-Disease
121	)	O
121	gene	O
121	mutations	O
121	.	O
122	We	O
122	adopted	O
122	both	O
122	single	O
122	-	O
122	strand	O
122	conformation	O
122	polymorphism	O
122	(	O
122	SSCP	O
122	)	O
122	analysis	O
122	and	O
122	a	O
122	method	O
122	of	O
122	analysis	O
122	involving	O
122	the	O
122	reverse	O
122	transcription	O
122	-	O
122	polymerase	O
122	chain	O
122	reaction	O
122	(	O
122	RT	O
122	-	O
122	PCR	O
122	)	O
122	followed	O
122	by	O
122	a	O
122	protein	O
122	truncation	O
122	test	O
122	(	O
122	PTT	O
122	)	O
122	.	O
123	DNA	O
123	sequencing	O
123	confirmed	O
123	all	O
123	alterations	O
123	represented	O
123	by	O
123	aberrant	O
123	bands	O
123	.	O
124	Germline	O
124	mutations	O
124	were	O
124	identified	O
124	in	O
124	38	O
124	patients	O
124	(	O
124	61	O
124	%	O
124	)	O
124	.	O
125	Nineteen	O
125	of	O
125	the	O
125	detected	O
125	mutations	O
125	were	O
125	presumed	O
125	to	O
125	be	O
125	novel	O
125	,	O
125	thus	O
125	emphasizing	O
125	the	O
125	heterogeneity	O
125	of	O
125	the	O
125	mutational	O
125	spectrum	O
125	in	O
125	Korean	O
125	FAP	B-Disease
125	patients	O
125	.	O
126	In	O
126	the	O
126	initial	O
126	48	O
126	patients	O
126	,	O
126	SSCP	O
126	analysis	O
126	was	O
126	followed	O
126	by	O
126	PTT	O
126	for	O
126	those	O
126	patients	O
126	for	O
126	whom	O
126	no	O
126	detectable	O
126	mutations	O
126	were	O
126	found	O
126	by	O
126	SSCP	O
126	.	O
127	Using	O
127	this	O
127	combined	O
127	approach	O
127	,	O
127	we	O
127	identified	O
127	germline	O
127	APC	B-Disease
127	gene	O
127	mutations	O
127	in	O
127	29	O
127	of	O
127	the	O
127	48	O
127	FAP	B-Disease
127	patients	O
127	(	O
127	60	O
127	%	O
127	)	O
127	,	O
127	including	O
127	6	O
127	patients	O
127	in	O
127	whom	O
127	SSCP	O
127	analysis	O
127	failed	O
127	to	O
127	distinguish	O
127	the	O
127	mutant	O
127	allele	O
127	.	O
128	In	O
128	the	O
128	14	O
128	later	O
128	patients	O
128	,	O
128	we	O
128	identified	O
128	truncating	O
128	mutations	O
128	in	O
128	9	O
128	patients	O
128	(	O
128	64	O
128	%	O
128	)	O
128	using	O
128	PTT	O
128	only	O
128	.	O
129	Our	O
129	results	O
129	confirm	O
129	that	O
129	the	O
129	mutation	O
129	detection	O
129	rate	O
129	with	O
129	PTT	O
129	was	O
129	superior	O
129	to	O
129	that	O
129	with	O
129	SSCP	O
129	,	O
129	and	O
129	suggest	O
129	that	O
129	PTT	O
129	would	O
129	be	O
129	a	O
129	more	O
129	practical	O
129	screening	O
129	method	O
129	to	O
129	detect	O
129	germline	O
129	mutations	O
129	of	O
129	the	O
129	APC	B-Disease
129	gene	O
129	in	O
129	FAP	B-Disease
129	patients	O
129	.	O
130	Molecular	O
130	epidemiology	O
130	of	O
130	C9	B-Disease
130	deficiency	I-Disease
130	heterozygotes	O
130	with	O
130	an	O
130	Arg95Stop	O
130	mutation	O
130	of	O
130	the	O
130	C9	O
130	gene	O
130	in	O
130	Japan	O
130	.	O
131	Deficiency	B-Disease
131	of	I-Disease
131	the	I-Disease
131	ninth	I-Disease
131	component	I-Disease
131	of	I-Disease
131	human	I-Disease
131	complement	I-Disease
131	(	O
131	C9	O
131	)	O
131	is	O
131	the	O
131	most	O
131	common	O
131	complement	B-Disease
131	deficiency	I-Disease
131	in	O
131	Japan	O
131	,	O
131	with	O
131	an	O
131	incidence	O
131	of	O
131	approximately	O
131	one	O
131	homozygote	O
131	in	O
131	1000	O
131	,	O
131	but	O
131	is	O
131	very	O
131	rare	O
131	in	O
131	other	O
131	countries	O
131	.	O
132	Genetic	O
132	analyses	O
132	of	O
132	Japanese	O
132	C9	B-Disease
132	deficiency	I-Disease
132	have	O
132	shown	O
132	that	O
132	a	O
132	C	O
132	-	O
132	to	O
132	-	O
132	T	O
132	transition	O
132	leading	O
132	to	O
132	TGA	O
132	stop	O
132	codon	O
132	for	O
132	Arg95	O
132	in	O
132	exon	O
132	4	O
132	of	O
132	the	O
132	C9	O
132	gene	O
132	(	O
132	Arg95Stop	O
132	)	O
132	is	O
132	common	O
132	in	O
132	Japanese	O
132	C9	B-Disease
132	deficiency	I-Disease
132	.	O
133	To	O
133	determine	O
133	the	O
133	prevalence	O
133	of	O
133	heterozygous	O
133	carriers	O
133	of	O
133	the	O
133	Arg95Stop	O
133	mutation	O
133	in	O
133	a	O
133	Japanese	O
133	population	O
133	,	O
133	we	O
133	collected	O
133	DNA	O
133	samples	O
133	from	O
133	300	O
133	individuals	O
133	in	O
133	two	O
133	of	O
133	the	O
133	four	O
133	main	O
133	islands	O
133	of	O
133	Japan	O
133	.	O
134	Heterozygote	O
134	detection	O
134	was	O
134	performed	O
134	with	O
134	an	O
134	allele	O
134	-	O
134	specific	O
134	polymerase	O
134	chain	O
134	reaction	O
134	(	O
134	PCR	O
134	)	O
134	system	O
134	designed	O
134	to	O
134	detect	O
134	exclusively	O
134	only	O
134	one	O
134	of	O
134	the	O
134	normal	O
134	and	O
134	mutant	O
134	alleles	O
134	,	O
134	followed	O
134	by	O
134	confirmation	O
134	with	O
134	PCR	O
134	/	O
134	single	O
134	-	O
134	strand	O
134	conformation	O
134	polymorphism	O
134	(	O
134	SSCP	O
134	)	O
134	analysis	O
134	and	O
134	direct	O
134	sequencing	O
134	.	O
135	Twenty	O
135	individuals	O
135	were	O
135	heterozygous	O
135	for	O
135	the	O
135	Arg95Stop	O
135	mutation	O
135	.	O
136	None	O
136	was	O
136	homozygous	O
136	.	O
137	The	O
137	prevalence	O
137	of	O
137	carriers	O
137	of	O
137	the	O
137	Arg95Stop	O
137	mutation	O
137	was	O
137	6	O
137	.	O
138	7	O
138	%	O
138	(	O
138	20	O
138	/	O
138	300	O
138	)	O
138	.	O
139	An	O
139	estimated	O
139	frequency	O
139	(	O
139	0	O
139	.	O
139	12	O
139	%	O
139	)	O
139	of	O
139	complete	O
139	C9	B-Disease
139	deficiency	I-Disease
139	due	O
139	to	O
139	homozygous	O
139	Arg95Stop	O
139	mutation	O
139	was	O
139	consistent	O
139	with	O
139	frequencies	O
139	determined	O
139	by	O
139	serological	O
139	studies	O
140	The	O
140	hereditary	B-Disease
140	hemochromatosis	I-Disease
140	protein	O
140	,	O
140	HFE	O
140	,	O
140	specifically	O
140	regulates	O
140	transferrin	O
140	-	O
140	mediated	O
140	iron	O
140	uptake	O
140	in	O
140	HeLa	O
140	cells	O
140	.	O
141	HFE	O
141	is	O
141	the	O
141	protein	O
141	product	O
141	of	O
141	the	O
141	gene	O
141	mutated	O
141	in	O
141	the	O
141	autosomal	B-Disease
141	recessive	I-Disease
141	disease	I-Disease
141	hereditary	B-Disease
141	hemochromatosis	I-Disease
141	(	O
141	Feder	O
141	,	O
141	J	O
141	.	O
142	N	O
142	.	O
142	,	O
142	Gnirke	O
142	,	O
142	A	O
142	.	O
142	,	O
142	Thomas	O
142	,	O
142	W	O
142	.	O
142	,	O
142	Tsuchihashi	O
142	,	O
142	Z	O
142	.	O
142	,	O
142	Ruddy	O
142	,	O
142	D	O
142	.	O
143	A	O
143	.	O
143	,	O
143	Basava	O
143	,	O
143	A	O
143	.	O
143	,	O
143	Dormishian	O
143	,	O
143	F	O
143	.	O
143	,	O
143	Domingo	O
143	,	O
143	R	O
143	.	O
144	J	O
144	.	O
144	,	O
144	Ellis	O
144	,	O
144	M	O
144	.	O
145	C	O
145	.	O
145	,	O
145	Fullan	O
145	,	O
145	A	O
145	.	O
145	,	O
145	Hinton	O
145	,	O
145	L	O
145	.	O
146	M	O
146	.	O
146	,	O
146	Jones	O
146	,	O
146	N	O
146	.	O
147	L	O
147	.	O
147	,	O
147	Kimmel	O
147	,	O
147	B	O
147	.	O
148	E	O
148	.	O
148	,	O
148	Kronmal	O
148	,	O
148	G	O
148	.	O
149	S	O
149	.	O
149	,	O
149	Lauer	O
149	,	O
149	P	O
149	.	O
149	,	O
149	Lee	O
149	,	O
149	V	O
149	.	O
150	K	O
150	.	O
150	,	O
150	Loeb	O
150	,	O
150	D	O
150	.	O
151	B	O
151	.	O
151	,	O
151	Mapa	O
151	,	O
151	F	O
151	.	O
152	A	O
152	.	O
152	,	O
152	McClelland	O
152	,	O
152	E	O
152	.	O
152	,	O
152	Meyer	O
152	,	O
152	N	O
152	.	O
153	C	O
153	.	O
153	,	O
153	Mintier	O
153	,	O
153	G	O
153	.	O
154	A	O
154	.	O
154	,	O
154	Moeller	O
154	,	O
154	N	O
154	.	O
154	,	O
154	Moore	O
154	,	O
154	T	O
154	.	O
154	,	O
154	Morikang	O
154	,	O
154	E	O
154	.	O
154	,	O
154	Prasss	O
154	,	O
154	C	O
154	.	O
155	E	O
155	.	O
155	,	O
155	Quintana	O
155	,	O
155	L	O
155	.	O
155	,	O
155	Starnes	O
155	,	O
155	S	O
155	.	O
156	M	O
156	.	O
156	,	O
156	Schatzman	O
156	,	O
156	R	O
156	.	O
157	C	O
157	.	O
157	,	O
157	Brunke	O
157	,	O
157	K	O
157	.	O
158	J	O
158	.	O
158	,	O
158	Drayna	O
158	,	O
158	D	O
158	.	O
159	T	O
159	.	O
159	,	O
159	Risch	O
159	,	O
159	N	O
159	.	O
160	J	O
160	.	O
160	,	O
160	Bacon	O
160	,	O
160	B	O
160	.	O
161	R	O
161	.	O
161	,	O
161	and	O
161	Wolff	O
161	,	O
161	R	O
161	.	O
162	R	O
162	.	O
163	(	O
163	1996	O
163	)	O
163	Nat	O
163	.	O
164	Genet	O
164	.	O
165	13	O
165	,	O
165	399	O
165	-	O
165	408	O
165	)	O
165	.	O
166	At	O
166	the	O
166	cell	O
166	surface	O
166	,	O
166	HFE	O
166	complexes	O
166	with	O
166	transferrin	O
166	receptor	O
166	(	O
166	TfR	O
166	)	O
166	,	O
166	increasing	O
166	the	O
166	dissociation	O
166	constant	O
166	of	O
166	transferrin	O
166	(	O
166	Tf	O
166	)	O
166	for	O
166	its	O
166	receptor	O
166	10	O
166	-	O
166	fold	O
166	(	O
166	Gross	O
166	,	O
166	C	O
166	.	O
167	N	O
167	.	O
167	,	O
167	Irrinki	O
167	,	O
167	A	O
167	.	O
167	,	O
167	Feder	O
167	,	O
167	J	O
167	.	O
167	N	O
167	.	O
167	,	O
167	and	O
167	Enns	O
167	,	O
167	C	O
167	.	O
167	A	O
167	.	O
167	(	O
167	1998	O
167	)	O
167	J	O
167	.	O
167	Biol	O
167	.	O
167	Chem	O
167	.	O
167	273	O
167	,	O
167	22068	O
167	-	O
167	22074	O
167	;	O
167	Feder	O
167	,	O
167	J	O
167	.	O
167	N	O
167	.	O
167	,	O
167	Penny	O
167	,	O
167	D	O
167	.	O
167	M	O
167	.	O
167	,	O
167	Irrinki	O
167	,	O
167	A	O
167	.	O
167	,	O
167	Lee	O
167	,	O
167	V	O
167	.	O
167	K	O
167	.	O
167	,	O
167	Lebron	O
167	,	O
167	J	O
167	.	O
167	A	O
167	.	O
167	,	O
167	Watson	O
167	,	O
167	N	O
167	.	O
167	,	O
167	Tsuchihashi	O
167	,	O
167	Z	O
167	.	O
167	,	O
167	Sigal	O
167	,	O
167	E	O
167	.	O
167	,	O
167	Bjorkman	O
167	,	O
167	P	O
167	.	O
167	J	O
167	.	O
167	,	O
167	and	O
167	Schatzman	O
167	,	O
167	R	O
167	.	O
167	C	O
167	.	O
167	(	O
167	1998	O
167	)	O
167	Proc	O
167	.	O
167	Natl	O
167	.	O
168	Acad	O
168	.	O
169	Sci	O
169	.	O
170	U	O
170	S	O
170	A	O
170	95	O
170	,	O
170	1472	O
170	-	O
170	1477	O
170	)	O
170	.	O
171	HFE	O
171	does	O
171	not	O
171	remain	O
171	at	O
171	the	O
171	cell	O
171	surface	O
171	,	O
171	but	O
171	traffics	O
171	with	O
171	TfR	O
171	to	O
171	Tf	O
171	-	O
171	positive	O
171	internal	O
171	compartments	O
171	(	O
171	Gross	O
171	et	O
171	al	O
171	.	O
171	,	O
171	1998	O
171	)	O
171	.	O
172	Using	O
172	a	O
172	HeLa	O
172	cell	O
172	line	O
172	in	O
172	which	O
172	the	O
172	expression	O
172	of	O
172	HFE	O
172	is	O
172	controlled	O
172	by	O
172	tetracycline	O
172	,	O
172	we	O
172	show	O
172	that	O
172	the	O
172	expression	O
172	of	O
172	HFE	O
172	reduces	O
172	55Fe	O
172	uptake	O
172	from	O
172	Tf	O
172	by	O
172	33	O
172	%	O
172	but	O
172	does	O
172	not	O
172	affect	O
172	the	O
172	endocytic	O
172	or	O
172	exocytic	O
172	rates	O
172	of	O
172	TfR	O
172	cycling	O
172	.	O
173	Therefore	O
173	,	O
173	HFE	O
173	appears	O
173	to	O
173	reduce	O
173	cellular	O
173	acquisition	O
173	of	O
173	iron	O
173	from	O
173	Tf	O
173	within	O
173	endocytic	O
173	compartments	O
173	.	O
174	HFE	O
174	specifically	O
174	reduces	O
174	iron	O
174	uptake	O
174	from	O
174	Tf	O
174	,	O
174	as	O
174	non	O
174	-	O
174	Tf	O
174	-	O
174	mediated	O
174	iron	O
174	uptake	O
174	from	O
174	Fe	O
174	-	O
174	nitrilotriacetic	O
174	acid	O
174	is	O
174	not	O
174	altered	O
174	.	O
175	These	O
175	results	O
175	explain	O
175	the	O
175	decreased	O
175	ferritin	O
175	levels	O
175	seen	O
175	in	O
175	our	O
175	HeLa	O
175	cell	O
175	system	O
175	and	O
175	demonstrate	O
175	the	O
175	specific	O
175	control	O
175	of	O
175	HFE	O
175	over	O
175	the	O
175	Tf	O
175	-	O
175	mediated	O
175	pathway	O
175	of	O
175	iron	O
175	uptake	O
175	.	O
176	These	O
176	results	O
176	also	O
176	have	O
176	implications	O
176	for	O
176	the	O
176	understanding	O
176	of	O
176	cellular	O
176	iron	O
176	homeostasis	O
176	in	O
176	organs	O
176	such	O
176	as	O
176	the	O
176	liver	O
176	,	O
176	pancreas	O
176	,	O
176	heart	O
176	,	O
176	and	O
176	spleen	O
176	that	O
176	are	O
176	iron	O
176	loaded	O
176	in	O
176	hereditary	B-Disease
176	hemochromatotic	I-Disease
176	individuals	O
176	lacking	O
176	functional	O
176	HFE	O
176	.	O
177	Mutation	O
177	and	O
177	haplotype	O
177	studies	O
177	of	O
177	familial	B-Disease
177	Mediterranean	I-Disease
177	fever	I-Disease
177	reveal	O
177	new	O
177	ancestral	O
177	relationships	O
177	and	O
177	evidence	O
177	for	O
177	a	O
177	high	O
177	carrier	O
177	frequency	O
177	with	O
177	reduced	O
177	penetrance	O
177	in	O
177	the	O
177	Ashkenazi	O
177	Jewish	O
177	population	O
177	.	O
178	Familial	B-Disease
178	Mediterranean	I-Disease
178	fever	I-Disease
178	(	O
178	FMF	B-Disease
178	)	O
178	is	O
178	a	O
178	recessive	B-Disease
178	disorder	I-Disease
178	characterized	O
178	by	O
178	episodes	O
178	of	O
178	fever	O
178	with	O
178	serositis	B-Disease
178	or	O
178	synovitis	B-Disease
178	.	O
179	The	O
179	FMF	B-Disease
179	gene	O
179	(	O
179	MEFV	O
179	)	O
179	was	O
179	cloned	O
179	recently	O
179	,	O
179	and	O
179	four	O
179	missense	O
179	mutations	O
179	were	O
179	identified	O
179	.	O
180	Here	O
180	we	O
180	present	O
180	data	O
180	from	O
180	non	O
180	-	O
180	Ashkenazi	O
180	Jewish	O
180	and	O
180	Arab	O
180	patients	O
180	in	O
180	whom	O
180	we	O
180	had	O
180	not	O
180	originally	O
180	found	O
180	mutations	O
180	and	O
180	from	O
180	a	O
180	new	O
180	,	O
180	more	O
180	ethnically	O
180	diverse	O
180	panel	O
180	.	O
181	Among	O
181	90	O
181	symptomatic	O
181	mutation	O
181	-	O
181	positive	O
181	individuals	O
181	,	O
181	11	O
181	mutations	O
181	accounted	O
181	for	O
181	79	O
181	%	O
181	of	O
181	carrier	O
181	chromosomes	O
181	.	O
182	Of	O
182	the	O
182	two	O
182	mutations	O
182	that	O
182	are	O
182	novel	O
182	,	O
182	one	O
182	alters	O
182	the	O
182	same	O
182	residue	O
182	(	O
182	680	O
182	)	O
182	as	O
182	a	O
182	previously	O
182	known	O
182	mutation	O
182	,	O
182	and	O
182	the	O
182	other	O
182	(	O
182	P369S	O
182	)	O
182	is	O
182	located	O
182	in	O
182	exon	O
182	3	O
182	.	O
183	Consistent	O
183	with	O
183	another	O
183	recent	O
183	report	O
183	,	O
183	the	O
183	E148Q	O
183	mutation	O
183	was	O
183	observed	O
183	in	O
183	patients	O
183	of	O
183	several	O
183	ethnicities	O
183	and	O
183	on	O
183	multiple	O
183	microsatellite	O
183	haplotypes	O
183	,	O
183	but	O
183	haplotype	O
183	data	O
183	indicate	O
183	an	O
183	ancestral	O
183	relationships	O
183	between	O
183	non	O
183	-	O
183	Jewish	O
183	Italian	O
183	and	O
183	Ashkenazi	O
183	Jewish	O
183	patients	O
183	with	O
183	FMF	B-Disease
183	and	O
183	other	O
183	affected	O
183	populations	O
183	.	O
184	Among	O
184	approximately	O
184	200	O
184	anonymous	O
184	Ashkenazi	O
184	Jewish	O
184	DNA	O
184	samples	O
184	,	O
184	the	O
184	MEFV	O
184	carrier	O
184	frequency	O
184	was	O
184	21	O
184	%	O
184	,	O
184	with	O
184	E148Q	O
184	the	O
184	most	O
184	common	O
184	mutation	O
184	.	O
185	Several	O
185	lines	O
185	of	O
185	evidence	O
185	indicate	O
185	reduced	O
185	penetrance	O
185	among	O
185	Ashkenazi	O
185	Jews	O
185	,	O
185	especially	O
185	for	O
185	E148Q	O
185	,	O
185	P369S	O
185	,	O
185	and	O
185	K695R	O
185	.	O
186	Nevertheless	O
186	,	O
186	E148Q	O
186	helps	O
186	account	O
186	for	O
186	recessive	O
186	inheritance	O
186	in	O
186	an	O
186	Ashkenazi	O
186	family	O
186	previously	O
186	reported	O
186	as	O
186	an	O
186	unusual	O
186	case	O
186	of	O
186	dominantly	O
186	inherited	O
186	FMF	B-Disease
186	.	O
187	The	O
187	presence	O
187	of	O
187	three	O
187	frequent	O
187	MEFV	O
187	mutations	O
187	in	O
187	multiple	O
187	Mediterranean	O
187	populations	O
187	strongly	O
187	suggests	O
187	a	O
187	heterozygote	O
187	advantage	O
187	in	O
187	this	O
187	geographic	O
187	region	O
187	.	O
188	Autoimmune	B-Disease
188	lymphoproliferative	I-Disease
188	syndrome	I-Disease
188	with	O
188	defective	O
188	Fas	O
188	:	O
188	genotype	O
188	influences	O
188	penetrance	O
188	.	O
189	Autoimmune	B-Disease
189	lymphoproliferative	I-Disease
189	syndrome	I-Disease
189	(	O
189	ALPS	B-Disease
189	)	O
189	is	O
189	a	O
189	disorder	B-Disease
189	of	I-Disease
189	lymphocyte	I-Disease
189	homeostasis	I-Disease
189	and	I-Disease
189	immunological	I-Disease
189	tolerance	I-Disease
189	.	O
190	Most	O
190	patients	O
190	have	O
190	a	O
190	heterozygous	O
190	mutation	O
190	in	O
190	the	O
190	APT1	O
190	gene	O
190	,	O
190	which	O
190	encodes	O
190	Fas	O
190	(	O
190	CD95	O
190	,	O
190	APO	O
190	-	O
190	1	O
190	)	O
190	,	O
190	mediator	O
190	of	O
190	an	O
190	apoptotic	O
190	pathway	O
190	crucial	O
190	to	O
190	lymphocyte	O
190	homeostasis	O
190	.	O
191	Of	O
191	17	O
191	unique	O
191	APT1	O
191	mutations	O
191	in	O
191	unrelated	O
191	ALPS	B-Disease
191	probands	O
191	,	O
191	12	O
191	(	O
191	71	O
191	%	O
191	)	O
191	occurred	O
191	in	O
191	exons	O
191	7	O
191	-	O
191	9	O
191	,	O
191	which	O
191	encode	O
191	the	O
191	intracellular	O
191	portion	O
191	of	O
191	Fas	O
191	.	O
192	In	O
192	vitro	O
192	,	O
192	activated	O
192	lymphocytes	O
192	from	O
192	all	O
192	17	O
192	patients	O
192	showed	O
192	apoptotic	O
192	defects	O
192	when	O
192	exposed	O
192	to	O
192	an	O
192	anti	O
192	-	O
192	Fas	O
192	agonist	O
192	monoclonal	O
192	antibody	O
192	.	O
193	Similar	O
193	defects	O
193	were	O
193	found	O
193	in	O
193	a	O
193	Fas	O
193	-	O
193	negative	O
193	cell	O
193	line	O
193	transfected	O
193	with	O
193	cDNAs	O
193	bearing	O
193	each	O
193	of	O
193	the	O
193	mutations	O
193	.	O
194	In	O
194	cotransfection	O
194	experiments	O
194	,	O
194	Fas	O
194	constructs	O
194	with	O
194	either	O
194	intra	O
194	-	O
194	or	O
194	extracellular	O
194	mutations	O
194	caused	O
194	dominant	O
194	inhibition	O
194	of	O
194	apoptosis	O
194	mediated	O
194	by	O
194	wild	O
194	-	O
194	type	O
194	Fas	O
194	.	O
195	Two	O
195	missense	O
195	Fas	O
195	variants	O
195	,	O
195	not	O
195	restricted	O
195	to	O
195	patients	O
195	with	O
195	ALPS	B-Disease
195	,	O
195	were	O
195	identified	O
195	.	O
196	Variant	O
196	A	O
196	(	O
196	-	O
196	1	O
196	)	O
196	T	O
196	at	O
196	the	O
196	Fas	O
196	signal	O
196	-	O
196	sequence	O
196	cleavage	O
196	site	O
196	,	O
196	which	O
196	mediates	O
196	apoptosis	O
196	less	O
196	well	O
196	than	O
196	wild	O
196	-	O
196	type	O
196	Fas	O
196	and	O
196	is	O
196	partially	O
196	inhibitory	O
196	,	O
196	was	O
196	present	O
196	in	O
196	13	O
196	%	O
196	of	O
196	African	O
196	American	O
196	alleles	O
196	.	O
197	Among	O
197	the	O
197	ALPS	B-Disease
197	-	O
197	associated	O
197	Fas	O
197	mutants	O
197	,	O
197	dominant	O
197	inhibition	O
197	of	O
197	apoptosis	O
197	was	O
197	much	O
197	more	O
197	pronounced	O
197	in	O
197	mutants	O
197	affecting	O
197	the	O
197	intracellular	O
197	,	O
197	versus	O
197	extracellular	O
197	,	O
197	portion	O
197	of	O
197	the	O
197	Fas	O
197	receptor	O
197	.	O
198	Mutations	O
198	causing	O
198	disruption	O
198	of	O
198	the	O
198	intracellular	O
198	Fas	O
198	death	O
198	domain	O
198	also	O
198	showed	O
198	a	O
198	higher	O
198	penetrance	O
198	of	O
198	ALPS	B-Disease
198	phenotype	O
198	features	O
198	in	O
198	mutation	O
198	-	O
198	bearing	O
198	relatives	O
198	.	O
199	Significant	O
199	ALPS	B-Disease
199	-	O
199	related	O
199	morbidity	O
199	occurred	O
199	in	O
199	44	O
199	%	O
199	of	O
199	relatives	O
199	with	O
199	intracellular	O
199	mutations	O
199	,	O
199	versus	O
199	0	O
199	%	O
199	of	O
199	relatives	O
199	with	O
199	extracellular	O
199	mutations	O
199	.	O
200	Thus	O
200	,	O
200	the	O
200	location	O
200	of	O
200	mutations	O
200	within	O
200	APT1	O
200	strongly	O
200	influences	O
200	the	O
200	development	O
200	and	O
200	the	O
200	severity	O
200	of	O
200	ALPS	B-Disease
200	.	O
201	Multicentric	O
201	origin	O
201	of	O
201	hemochromatosis	B-Disease
201	gene	O
201	(	O
201	HFE	O
201	)	O
201	mutations	O
201	.	O
202	Genetic	B-Disease
202	hemochromatosis	I-Disease
202	(	O
202	GH	B-Disease
202	)	O
202	is	O
202	believed	O
202	to	O
202	be	O
202	a	O
202	disease	O
202	restricted	O
202	to	O
202	those	O
202	of	O
202	European	O
202	ancestry	O
202	.	O
203	In	O
203	northwestern	O
203	Europe	O
203	,	O
203	>	O
203	80	O
203	%	O
203	of	O
203	GH	B-Disease
203	patients	O
203	are	O
203	homozygous	O
203	for	O
203	one	O
203	mutation	O
203	,	O
203	the	O
203	substitution	O
203	of	O
203	tyrosine	O
203	for	O
203	cysteine	O
203	at	O
203	position	O
203	282	O
203	(	O
203	C282Y	O
203	)	O
203	in	O
203	the	O
203	unprocessed	O
203	protein	O
203	.	O
204	In	O
204	a	O
204	proportion	O
204	of	O
204	GH	B-Disease
204	patients	O
204	,	O
204	two	O
204	mutations	O
204	are	O
204	present	O
204	,	O
204	C282Y	O
204	and	O
204	H63D	O
204	.	O
205	The	O
205	clinical	O
205	significance	O
205	of	O
205	this	O
205	second	O
205	mutation	O
205	is	O
205	such	O
205	that	O
205	it	O
205	appears	O
205	to	O
205	predispose	O
205	1	O
205	%	O
205	-	O
205	2	O
205	%	O
205	of	O
205	compound	O
205	heterozygotes	O
205	to	O
205	expression	O
205	of	O
205	the	O
205	disease	O
205	.	O
206	The	O
206	distribution	O
206	of	O
206	the	O
206	two	O
206	mutations	O
206	differ	O
206	,	O
206	C282Y	O
206	being	O
206	limited	O
206	to	O
206	those	O
206	of	O
206	northwestern	O
206	European	O
206	ancestry	O
206	and	O
206	H63D	O
206	being	O
206	found	O
206	at	O
206	allele	O
206	frequencies	O
206	>	O
206	5	O
206	%	O
206	,	O
206	in	O
206	Europe	O
206	,	O
206	in	O
206	countries	O
206	bordering	O
206	the	O
206	Mediterranean	O
206	,	O
206	in	O
206	the	O
206	Middle	O
206	East	O
206	,	O
206	and	O
206	in	O
206	the	O
206	Indian	O
206	subcontinent	O
206	.	O
207	The	O
207	C282Y	O
207	mutation	O
207	occurs	O
207	on	O
207	a	O
207	haplotype	O
207	that	O
207	extends	O
207	<	O
207	/	O
207	=	O
207	6	O
207	Mb	O
207	,	O
207	suggesting	O
207	that	O
207	this	O
207	mutation	O
207	has	O
207	arisen	O
207	during	O
207	the	O
207	past	O
207	2	O
207	,	O
207	000	O
207	years	O
207	.	O
208	The	O
208	H63D	O
208	mutation	O
208	is	O
208	older	O
208	and	O
208	does	O
208	not	O
208	occur	O
208	on	O
208	such	O
208	a	O
208	large	O
208	extended	O
208	haplotype	O
208	,	O
208	the	O
208	haplotype	O
208	in	O
208	this	O
208	case	O
208	extending	O
208	<	O
208	/	O
208	=	O
208	700	O
208	kb	O
208	.	O
209	Here	O
209	we	O
209	report	O
209	the	O
209	finding	O
209	of	O
209	the	O
209	H63D	O
209	and	O
209	C282Y	O
209	mutations	O
209	on	O
209	new	O
209	haplotypes	O
209	.	O
210	In	O
210	Sri	O
210	Lanka	O
210	we	O
210	have	O
210	found	O
210	H63D	O
210	on	O
210	three	O
210	new	O
210	haplotypes	O
210	and	O
210	have	O
210	found	O
210	C282Y	O
210	on	O
210	one	O
210	new	O
210	haplotype	O
210	,	O
210	demonstrating	O
210	that	O
210	these	O
210	mutations	O
210	have	O
210	arisen	O
210	independently	O
210	on	O
210	this	O
210	island	O
210	.	O
211	These	O
211	results	O
211	suggest	O
211	that	O
211	the	O
211	HFE	O
211	gene	O
211	has	O
211	been	O
211	the	O
211	subject	O
211	of	O
211	selection	O
211	pressure	O
211	.	O
212	These	O
212	selection	O
212	pressures	O
212	could	O
212	be	O
212	due	O
212	to	O
212	infectious	B-Disease
212	diseases	I-Disease
212	,	O
212	environmental	O
212	conditions	O
212	,	O
212	or	O
212	other	O
212	genetic	B-Disease
212	disorders	I-Disease
212	such	O
212	as	O
212	anemia	B-Disease
212	.	O
213	A	O
213	retrospective	O
213	anonymous	O
213	pilot	O
213	study	O
213	in	O
213	screening	O
213	newborns	O
213	for	O
213	HFE	O
213	mutations	O
213	in	O
213	Scandinavian	O
213	populations	O
213	.	O
214	We	O
214	have	O
214	retrospectively	O
214	analyzed	O
214	837	O
214	random	O
214	anonymized	O
214	dried	O
214	blood	O
214	spot	O
214	(	O
214	DBS	O
214	)	O
214	samples	O
214	from	O
214	neonatal	O
214	screening	O
214	programs	O
214	in	O
214	Scandinavia	O
214	for	O
214	mutations	O
214	in	O
214	HFE	O
214	,	O
214	the	O
214	candidate	O
214	gene	O
214	for	O
214	hemochromatosis	B-Disease
214	.	O
215	We	O
215	have	O
215	found	O
215	C282Y	O
215	allele	O
215	frequencies	O
215	of	O
215	2	O
215	.	O
216	3	O
216	%	O
216	(	O
216	+	O
216	2	O
216	.	O
216	0	O
216	%	O
216	)	O
216	(	O
216	-	O
216	1	O
216	.	O
216	3	O
216	%	O
216	)	O
216	in	O
216	Greenland	O
216	,	O
216	4	O
216	.	O
217	5	O
217	%	O
217	+	O
217	/	O
217	-	O
217	1	O
217	.	O
218	9	O
218	%	O
218	in	O
218	Iceland	O
218	,	O
218	5	O
218	.	O
219	1	O
219	%	O
219	+	O
219	/	O
219	-	O
219	2	O
219	.	O
220	3	O
220	%	O
220	in	O
220	the	O
220	Faeroe	O
220	Islands	O
220	,	O
220	and	O
220	8	O
220	.	O
221	2	O
221	%	O
221	+	O
221	/	O
221	-	O
221	2	O
221	.	O
222	7	O
222	%	O
222	in	O
222	Denmark	O
222	.	O
223	The	O
223	high	O
223	prevalence	O
223	of	O
223	HFE	O
223	mutations	O
223	in	O
223	Denmark	O
223	suggests	O
223	that	O
223	population	O
223	screening	O
223	for	O
223	the	O
223	C282Y	O
223	mutation	O
223	could	O
223	be	O
223	highly	O
223	advantageous	O
223	in	O
223	terms	O
223	of	O
223	preventive	O
223	health	O
223	care	O
223	.	O
224	Long	O
224	-	O
224	term	O
224	follow	O
224	-	O
224	up	O
224	evaluation	O
224	of	O
224	C282Y	O
224	homozygotes	O
224	and	O
224	H63D	O
224	/	O
224	C282Y	O
224	compound	O
224	heterozygotes	O
224	will	O
224	give	O
224	an	O
224	indication	O
224	of	O
224	the	O
224	penetrance	O
224	of	O
224	the	O
224	mutations	O
224	.	O
225	Identification	O
225	of	O
225	the	O
225	mutation	O
225	in	O
225	the	O
225	alkaptonuria	B-Disease
225	mouse	O
225	model	O
225	.	O
226	Alkaptonuria	B-Disease
226	(	O
226	aku	B-Disease
226	)	O
226	,	O
226	an	O
226	inborn	B-Disease
226	error	I-Disease
226	of	I-Disease
226	metabolism	I-Disease
226	caused	O
226	by	O
226	the	O
226	loss	O
226	of	O
226	homogentisate	O
226	1	O
226	,	O
226	2	O
226	-	O
226	dioxygenase	O
226	(	O
226	HGD	O
226	)	O
226	,	O
226	has	O
226	been	O
226	described	O
226	in	O
226	a	O
226	mouse	O
226	model	O
226	created	O
226	by	O
226	ethylnitrosourea	O
226	mutagenesis	O
226	but	O
226	the	O
226	mutation	O
226	in	O
226	these	O
226	mice	O
226	has	O
226	not	O
226	previously	O
226	been	O
226	identified	O
226	.	O
227	We	O
227	used	O
227	RT	O
227	-	O
227	PCR	O
227	to	O
227	amplify	O
227	the	O
227	Hgd	O
227	cDNA	O
227	from	O
227	Hgd	O
227	(	O
227	aku	O
227	)	O
227	/	O
227	Hgd	O
227	(	O
227	aku	O
227	)	O
227	mice	O
227	.	O
228	Two	O
228	products	O
228	shorter	O
228	than	O
228	the	O
228	wild	O
228	-	O
228	type	O
228	product	O
228	were	O
228	amplified	O
228	.	O
229	Restriction	O
229	mapping	O
229	and	O
229	DNA	O
229	sequencing	O
229	were	O
229	then	O
229	used	O
229	to	O
229	identify	O
229	the	O
229	Hgd	O
229	(	O
229	aku	O
229	)	O
229	mouse	O
229	mutation	O
229	,	O
229	found	O
229	to	O
229	be	O
229	a	O
229	single	O
229	base	O
229	change	O
229	in	O
229	a	O
229	splice	O
229	donor	O
229	consensus	O
229	sequence	O
229	,	O
229	causing	O
229	exon	O
229	skipping	O
229	and	O
229	frame	O
229	-	O
229	shifted	O
229	products	O
229	.	O
230	This	O
230	base	O
230	change	O
230	allowed	O
230	us	O
230	to	O
230	create	O
230	a	O
230	non	O
230	-	O
230	radioactive	O
230	genotyping	O
230	assay	O
230	for	O
230	this	O
230	allele	O
230	.	O
231	Non	B-Disease
231	-	I-Disease
231	syndromic	I-Disease
231	hearing	I-Disease
231	loss	I-Disease
231	associated	O
231	with	O
231	enlarged	B-Disease
231	vestibular	I-Disease
231	aqueduct	I-Disease
231	is	O
231	caused	O
231	by	O
231	PDS	B-Disease
231	mutations	O
231	.	O
232	Enlarged	B-Disease
232	vestibular	I-Disease
232	aqueduct	I-Disease
232	(	O
232	EVA	B-Disease
232	)	O
232	,	O
232	known	O
232	as	O
232	the	O
232	most	O
232	common	O
232	form	O
232	of	O
232	inner	B-Disease
232	ear	I-Disease
232	abnormality	I-Disease
232	,	O
232	has	O
232	recently	O
232	been	O
232	of	O
232	particular	O
232	genetic	O
232	interest	O
232	because	O
232	this	O
232	anomaly	O
232	is	O
232	inherited	O
232	in	O
232	a	O
232	recessive	O
232	manner	O
232	.	O
233	The	O
233	locus	O
233	for	O
233	non	B-Disease
233	-	I-Disease
233	syndromic	I-Disease
233	sensorineural	I-Disease
233	hearing	I-Disease
233	loss	I-Disease
233	with	O
233	EVA	B-Disease
233	has	O
233	been	O
233	mapped	O
233	to	O
233	the	O
233	same	O
233	chromosomal	O
233	region	O
233	,	O
233	7q31	O
233	,	O
233	as	O
233	the	O
233	Pendred	B-Disease
233	syndrome	I-Disease
233	locus	O
233	.	O
234	In	O
234	the	O
234	present	O
234	study	O
234	,	O
234	seven	O
234	mutations	O
234	in	O
234	the	O
234	PDS	B-Disease
234	gene	O
234	(	O
234	PDS	O
234	)	O
234	,	O
234	the	O
234	gene	O
234	responsible	O
234	for	O
234	Pendred	B-Disease
234	syndrome	I-Disease
234	,	O
234	have	O
234	been	O
234	found	O
234	in	O
234	families	O
234	of	O
234	non	B-Disease
234	-	I-Disease
234	syndromic	I-Disease
234	sensorineural	I-Disease
234	hearing	I-Disease
234	loss	I-Disease
234	with	O
234	EVA	B-Disease
234	.	O
235	One	O
235	family	O
235	is	O
235	homozygous	O
235	,	O
235	three	O
235	families	O
235	are	O
235	compound	O
235	heterozygotes	O
235	,	O
235	and	O
235	two	O
235	families	O
235	are	O
235	heterozygous	O
235	but	O
235	with	O
235	no	O
235	other	O
235	mutation	O
235	detected	O
235	.	O
236	The	O
236	present	O
236	results	O
236	provide	O
236	evidence	O
236	that	O
236	mutations	O
236	in	O
236	PDS	O
236	cause	O
236	both	O
236	syndromic	B-Disease
236	and	I-Disease
236	non	I-Disease
236	-	I-Disease
236	syndromic	I-Disease
236	hearing	I-Disease
236	loss	I-Disease
236	.	O
236	.	O
237	Mutational	O
237	analysis	O
237	and	O
237	genotype	O
237	-	O
237	phenotype	O
237	correlation	O
237	of	O
237	29	O
237	unrelated	O
237	Japanese	O
237	patients	O
237	with	O
237	X	B-Disease
237	-	I-Disease
237	linked	I-Disease
237	adrenoleukodystrophy	I-Disease
237	.	O
238	BACKGROUND	O
238	X	B-Disease
238	-	I-Disease
238	linked	I-Disease
238	adrenoleukodystrophy	I-Disease
238	(	O
238	ALD	B-Disease
238	)	O
238	is	O
238	an	O
238	inherited	B-Disease
238	disease	I-Disease
238	characterized	O
238	by	O
238	progressive	O
238	neurologic	B-Disease
238	dysfunction	I-Disease
238	,	O
238	occasionally	O
238	associated	O
238	with	O
238	adrenal	B-Disease
238	insufficiency	I-Disease
238	.	O
239	The	O
239	classic	O
239	form	O
239	of	O
239	ALD	B-Disease
239	usually	O
239	has	O
239	onset	O
239	in	O
239	childhood	O
239	(	O
239	childhood	B-Disease
239	cerebral	I-Disease
239	ALD	I-Disease
239	)	O
239	,	O
239	with	O
239	rapid	O
239	neurologic	B-Disease
239	deterioration	I-Disease
239	leading	O
239	to	O
239	a	O
239	vegetative	O
239	state	O
239	.	O
240	Adult	O
240	-	O
240	onset	O
240	cerebral	B-Disease
240	ALD	I-Disease
240	also	O
240	presents	O
240	with	O
240	rapidly	O
240	progressive	O
240	neurologic	B-Disease
240	dysfunction	I-Disease
240	.	O
241	Milder	O
241	phenotypes	O
241	such	O
241	as	O
241	adrenomyeloneuropathy	B-Disease
241	and	O
241	Addison	B-Disease
241	disease	I-Disease
241	only	O
241	also	O
241	have	O
241	been	O
241	recognized	O
241	.	O
242	Despite	O
242	discovery	O
242	of	O
242	the	O
242	causative	O
242	gene	O
242	,	O
242	a	O
242	molecular	O
242	basis	O
242	for	O
242	the	O
242	diverse	O
242	clinical	O
242	presentations	O
242	remains	O
242	to	O
242	be	O
242	elucidated	O
242	.	O
243	OBJECTIVES	O
243	To	O
243	conduct	O
243	mutational	O
243	analyses	O
243	in	O
243	29	O
243	Japanese	O
243	patients	O
243	with	O
243	ALD	B-Disease
243	from	O
243	29	O
243	unrelated	O
243	families	O
243	,	O
243	to	O
243	obtain	O
243	knowledge	O
243	of	O
243	the	O
243	spectrum	O
243	of	O
243	mutations	O
243	in	O
243	this	O
243	gene	O
243	,	O
243	and	O
243	to	O
243	study	O
243	genotype	O
243	-	O
243	phenotype	O
243	correlations	O
243	in	O
243	Japanese	O
243	patients	O
243	.	O
244	METHODS	O
244	The	O
244	29	O
244	patients	O
244	comprised	O
244	13	O
244	patients	O
244	with	O
244	childhood	B-Disease
244	cerebral	I-Disease
244	ALD	I-Disease
244	,	O
244	11	O
244	patients	O
244	with	O
244	adult	O
244	-	O
244	onset	O
244	cerebral	B-Disease
244	ALD	I-Disease
244	,	O
244	and	O
244	5	O
244	patients	O
244	with	O
244	adrenomyeloneuropathy	B-Disease
244	.	O
245	We	O
245	conducted	O
245	detailed	O
245	mutational	O
245	analyses	O
245	of	O
245	29	O
245	unrelated	O
245	Japanese	O
245	patients	O
245	with	O
245	ALD	B-Disease
245	by	O
245	genomic	O
245	Southern	O
245	blot	O
245	analysis	O
245	and	O
245	direct	O
245	nucleotide	O
245	sequence	O
245	analysis	O
245	of	O
245	reverse	O
245	transcriptase	O
245	-	O
245	polymerase	O
245	chain	O
245	reaction	O
245	products	O
245	derived	O
245	from	O
245	total	O
245	RNA	O
245	that	O
245	was	O
245	extracted	O
245	from	O
245	cultured	O
245	skin	O
245	fibroblasts	O
245	,	O
245	lymphoblastoid	O
245	cells	O
245	,	O
245	or	O
245	peripheral	O
245	blood	O
245	leukocytes	O
245	.	O
246	RESULTS	O
246	Three	O
246	patients	O
246	with	O
246	adult	O
246	-	O
246	onset	O
246	cerebral	B-Disease
246	ALD	I-Disease
246	were	O
246	identified	O
246	as	O
246	having	O
246	large	O
246	genomic	O
246	rearrangements	O
246	.	O
247	The	O
247	remaining	O
247	26	O
247	patients	O
247	were	O
247	identified	O
247	as	O
247	having	O
247	21	O
247	independent	O
247	mutations	O
247	,	O
247	including	O
247	12	O
247	novel	O
247	mutations	O
247	resulting	O
247	in	O
247	small	O
247	nucleotide	O
247	alterations	O
247	in	O
247	the	O
247	ALD	B-Disease
247	gene	O
247	.	O
248	Eighteen	O
248	(	O
248	69	O
248	%	O
248	)	O
248	of	O
248	26	O
248	mutations	O
248	were	O
248	missense	O
248	mutations	O
248	.	O
249	Most	O
249	missense	O
249	mutations	O
249	involved	O
249	amino	O
249	acids	O
249	conserved	O
249	in	O
249	homologous	O
249	gene	O
249	products	O
249	,	O
249	including	O
249	PMP70	O
249	,	O
249	mALDRP	O
249	,	O
249	and	O
249	Pxa1p	O
249	.	O
250	The	O
250	AG	O
250	dinucleotide	O
250	deletion	O
250	at	O
250	position	O
250	1081	O
250	-	O
250	1082	O
250	,	O
250	which	O
250	has	O
250	been	O
250	reported	O
250	previously	O
250	to	O
250	be	O
250	the	O
250	most	O
250	common	O
250	mutation	O
250	in	O
250	white	O
250	patients	O
250	(	O
250	12	O
250	%	O
250	-	O
250	17	O
250	%	O
250	)	O
250	,	O
250	was	O
250	also	O
250	identified	O
250	as	O
250	the	O
250	most	O
250	common	O
250	mutation	O
250	in	O
250	Japanese	O
250	patients	O
250	(	O
250	12	O
250	%	O
250	)	O
250	.	O
251	All	O
251	phenotypes	O
251	were	O
251	associated	O
251	with	O
251	mutations	O
251	resulting	O
251	in	O
251	protein	O
251	truncation	O
251	or	O
251	subtle	O
251	amino	O
251	acid	O
251	changes	O
251	.	O
252	There	O
252	were	O
252	no	O
252	differences	O
252	in	O
252	phenotypic	O
252	expressions	O
252	between	O
252	missense	O
252	mutations	O
252	involving	O
252	conserved	O
252	amino	O
252	acids	O
252	and	O
252	those	O
252	involving	O
252	nonconserved	O
252	amino	O
252	acids	O
252	.	O
253	CONCLUSIONS	O
253	There	O
253	are	O
253	no	O
253	obvious	O
253	correlations	O
253	between	O
253	the	O
253	phenotypes	O
253	of	O
253	patients	O
253	with	O
253	ALD	B-Disease
253	and	O
253	their	O
253	genotypes	O
253	,	O
253	suggesting	O
253	that	O
253	other	O
253	genetic	O
253	or	O
253	environmental	O
253	factors	O
253	modify	O
253	the	O
253	phenotypic	O
253	expressions	O
253	of	O
253	ALD	B-Disease
253	.	O
253	.	O
254	A	O
254	common	O
254	human	O
254	skin	B-Disease
254	tumour	I-Disease
254	is	O
254	caused	O
254	by	O
254	activating	O
254	mutations	O
254	in	O
254	beta	O
254	-	O
254	catenin	O
254	.	O
255	WNT	O
255	signalling	O
255	orchestrates	O
255	a	O
255	number	O
255	of	O
255	developmental	O
255	programs	O
255	.	O
256	In	O
256	response	O
256	to	O
256	this	O
256	stimulus	O
256	,	O
256	cytoplasmic	O
256	beta	O
256	-	O
256	catenin	O
256	(	O
256	encoded	O
256	by	O
256	CTNNB1	O
256	)	O
256	is	O
256	stabilized	O
256	,	O
256	enabling	O
256	downstream	O
256	transcriptional	O
256	activation	O
256	by	O
256	members	O
256	of	O
256	the	O
256	LEF	O
256	/	O
256	TCF	O
256	family	O
256	.	O
257	One	O
257	of	O
257	the	O
257	target	O
257	genes	O
257	for	O
257	beta	O
257	-	O
257	catenin	O
257	/	O
257	TCF	O
257	encodes	O
257	c	O
257	-	O
257	MYC	O
257	,	O
257	explaining	O
257	why	O
257	constitutive	O
257	activation	O
257	of	O
257	the	O
257	WNT	O
257	pathway	O
257	can	O
257	lead	O
257	to	O
257	cancer	B-Disease
257	,	O
257	particularly	O
257	in	O
257	the	O
257	colon	O
257	.	O
258	Most	O
258	colon	B-Disease
258	cancers	I-Disease
258	arise	O
258	from	O
258	mutations	O
258	in	O
258	the	O
258	gene	O
258	encoding	O
258	adenomatous	B-Disease
258	polyposis	I-Disease
258	coli	I-Disease
258	(	O
258	APC	B-Disease
258	)	O
258	,	O
258	a	O
258	protein	O
258	required	O
258	for	O
258	ubiquitin	O
258	-	O
258	mediated	O
258	degradation	O
258	of	O
258	beta	O
258	-	O
258	catenin	O
258	,	O
258	but	O
258	a	O
258	small	O
258	percentage	O
258	of	O
258	colon	B-Disease
258	and	I-Disease
258	some	I-Disease
258	other	I-Disease
258	cancers	I-Disease
258	harbour	O
258	beta	O
258	-	O
258	catenin	O
258	-	O
258	stabilizing	O
258	mutations	O
258	.	O
259	Recently	O
259	,	O
259	we	O
259	discovered	O
259	that	O
259	transgenic	O
259	mice	O
259	expressing	O
259	an	O
259	activated	O
259	beta	O
259	-	O
259	catenin	O
259	are	O
259	predisposed	O
259	to	O
259	developing	O
259	skin	B-Disease
259	tumours	I-Disease
259	resembling	O
259	pilomatricomas	B-Disease
259	.	O
260	Given	O
260	that	O
260	the	O
260	skin	O
260	of	O
260	these	O
260	adult	O
260	mice	O
260	also	O
260	exhibits	O
260	signs	O
260	of	O
260	de	O
260	novo	O
260	hair	O
260	-	O
260	follicle	O
260	morphogenesis	O
260	,	O
260	we	O
260	wondered	O
260	whether	O
260	human	O
260	pilomatricomas	B-Disease
260	might	O
260	originate	O
260	from	O
260	hair	O
260	matrix	O
260	cells	O
260	and	O
260	whether	O
260	they	O
260	might	O
260	possess	O
260	beta	O
260	-	O
260	catenin	O
260	-	O
260	stabilizing	O
260	mutations	O
260	.	O
261	Here	O
261	,	O
261	we	O
261	explore	O
261	the	O
261	cell	O
261	origin	O
261	and	O
261	aetiology	O
261	of	O
261	this	O
261	common	O
261	human	O
261	skin	B-Disease
261	tumour	I-Disease
261	.	O
262	We	O
262	found	O
262	nuclear	O
262	LEF	O
262	-	O
262	1	O
262	in	O
262	the	O
262	dividing	O
262	tumour	B-Disease
262	cells	O
262	,	O
262	providing	O
262	biochemical	O
262	evidence	O
262	that	O
262	pilomatricomas	B-Disease
262	are	O
262	derived	O
262	from	O
262	hair	O
262	matrix	O
262	cells	O
262	.	O
263	At	O
263	least	O
263	75	O
263	%	O
263	of	O
263	these	O
263	tumours	B-Disease
263	possess	O
263	mutations	O
263	affecting	O
263	the	O
263	amino	O
263	-	O
263	terminal	O
263	segment	O
263	,	O
263	normally	O
263	involved	O
263	in	O
263	phosphorylation	O
263	-	O
263	dependent	O
263	,	O
263	ubiquitin	O
263	-	O
263	mediated	O
263	degradation	O
263	of	O
263	the	O
263	protein	O
263	.	O
264	This	O
264	percentage	O
264	of	O
264	CTNNB1	O
264	mutations	O
264	is	O
264	greater	O
264	than	O
264	in	O
264	all	O
264	other	O
264	human	O
264	tumours	B-Disease
264	examined	O
264	thus	O
264	far	O
264	,	O
264	and	O
264	directly	O
264	implicates	O
264	beta	O
264	-	O
264	catenin	O
264	/	O
264	LEF	O
264	misregulation	O
264	as	O
264	the	O
264	major	O
264	cause	O
264	of	O
264	hair	O
264	matrix	O
264	cell	O
264	tumorigenesis	O
264	in	O
264	humans	O
264	.	O
264	.	O
265	The	O
265	Pendred	B-Disease
265	syndrome	I-Disease
265	gene	O
265	encodes	O
265	a	O
265	chloride	O
265	-	O
265	iodide	O
265	transport	O
265	protein	O
265	.	O
266	Pendred	B-Disease
266	syndrome	I-Disease
266	is	O
266	the	O
266	most	O
266	common	O
266	form	O
266	of	O
266	syndromic	B-Disease
266	deafness	I-Disease
266	and	O
266	characterized	O
266	by	O
266	congenital	O
266	sensorineural	B-Disease
266	hearing	I-Disease
266	loss	I-Disease
266	and	O
266	goitre	B-Disease
266	.	O
267	This	O
267	disorder	O
267	was	O
267	mapped	O
267	to	O
267	chromosome	O
267	7	O
267	and	O
267	the	O
267	gene	O
267	causing	O
267	Pendred	B-Disease
267	syndrome	I-Disease
267	(	O
267	PDS	B-Disease
267	)	O
267	was	O
267	subsequently	O
267	identified	O
267	by	O
267	positional	O
267	cloning	O
267	.	O
268	PDS	O
268	encodes	O
268	a	O
268	putative	O
268	transmembrane	O
268	protein	O
268	designated	O
268	pendrin	O
268	.	O
269	Pendrin	O
269	is	O
269	closely	O
269	related	O
269	to	O
269	a	O
269	family	O
269	of	O
269	sulfate	O
269	transport	O
269	proteins	O
269	that	O
269	includes	O
269	the	O
269	rat	O
269	sulfate	O
269	-	O
269	anion	O
269	transporter	O
269	(	O
269	encoded	O
269	by	O
269	Sat	O
269	-	O
269	1	O
269	;	O
269	29	O
269	%	O
269	amino	O
269	acid	O
269	sequence	O
269	identity	O
269	)	O
269	,	O
269	the	O
269	human	O
269	diastrophic	B-Disease
269	dysplasia	I-Disease
269	sulfate	O
269	transporter	O
269	(	O
269	encoded	O
269	by	O
269	DTD	O
269	;	O
269	32	O
269	%	O
269	)	O
269	and	O
269	the	O
269	human	O
269	sulfate	O
269	transporter	O
269	downregulated	O
269	in	O
269	adenoma	B-Disease
269	(	O
269	encoded	O
269	by	O
269	DRA	O
269	;	O
269	45	O
269	%	O
269	)	O
269	.	O
270	On	O
270	the	O
270	basis	O
270	of	O
270	this	O
270	homology	O
270	and	O
270	the	O
270	presence	O
270	of	O
270	a	O
270	slightly	O
270	modified	O
270	sulfate	O
270	-	O
270	transporter	O
270	signature	O
270	sequence	O
270	comprising	O
270	its	O
270	putative	O
270	second	O
270	transmembrane	O
270	domain	O
270	,	O
270	pendrin	O
270	has	O
270	been	O
270	proposed	O
270	to	O
270	function	O
270	as	O
270	a	O
270	sulfate	O
270	transporter	O
270	.	O
271	We	O
271	were	O
271	unable	O
271	to	O
271	detect	O
271	evidence	O
271	of	O
271	sulfate	O
271	transport	O
271	following	O
271	the	O
271	expression	O
271	of	O
271	pendrin	O
271	in	O
271	Xenopus	O
271	laevis	O
271	oocytes	O
271	by	O
271	microinjection	O
271	of	O
271	PDS	O
271	cRNA	O
271	or	O
271	in	O
271	Sf9	O
271	cells	O
271	following	O
271	infection	O
271	with	O
271	PDS	O
271	-	O
271	recombinant	O
271	baculovirus	O
271	.	O
272	The	O
272	rates	O
272	of	O
272	transport	O
272	for	O
272	iodide	O
272	and	O
272	chloride	O
272	were	O
272	significantly	O
272	increased	O
272	following	O
272	the	O
272	expression	O
272	of	O
272	pendrin	O
272	in	O
272	both	O
272	cell	O
272	systems	O
272	.	O
273	Our	O
273	results	O
273	demonstrate	O
273	that	O
273	pendrin	O
273	functions	O
273	as	O
273	a	O
273	transporter	O
273	of	O
273	chloride	O
273	and	O
273	iodide	O
273	,	O
273	but	O
273	not	O
273	sulfate	O
273	,	O
273	and	O
273	may	O
273	provide	O
273	insight	O
273	into	O
273	thyroid	O
273	physiology	O
273	and	O
273	the	O
273	pathophysiology	O
273	of	O
273	Pendred	B-Disease
273	syndrome	I-Disease
273	.	O
273	.	O
274	HFE	O
274	mutations	O
274	analysis	O
274	in	O
274	711	O
274	hemochromatosis	B-Disease
274	probands	O
274	:	O
274	evidence	O
274	for	O
274	S65C	O
274	implication	O
274	in	O
274	mild	O
274	form	O
274	of	O
274	hemochromatosis	B-Disease
274	.	O
275	Hereditary	B-Disease
275	hemochromatosis	I-Disease
275	(	O
275	HH	B-Disease
275	)	O
275	is	O
275	a	O
275	common	O
275	autosomal	B-Disease
275	recessive	I-Disease
275	genetic	I-Disease
275	disorder	I-Disease
275	of	O
275	iron	O
275	metabolism	O
275	.	O
276	The	O
276	HFE	O
276	candidate	O
276	gene	O
276	encoding	O
276	an	O
276	HLA	O
276	class	O
276	I	O
276	-	O
276	like	O
276	protein	O
276	involved	O
276	in	O
276	HH	B-Disease
276	was	O
276	identified	O
276	in	O
276	1996	O
276	.	O
277	Two	O
277	missense	O
277	mutations	O
277	have	O
277	been	O
277	described	O
277	C282Y	O
277	,	O
277	accounting	O
277	for	O
277	80	O
277	%	O
277	to	O
277	90	O
277	%	O
277	of	O
277	HH	B-Disease
277	chromosomes	O
277	,	O
277	and	O
277	H63D	O
277	,	O
277	which	O
277	is	O
277	associated	O
277	with	O
277	a	O
277	milder	O
277	form	O
277	of	O
277	the	O
277	disease	O
277	representing	O
277	40	O
277	%	O
277	to	O
277	70	O
277	%	O
277	of	O
277	non	O
277	-	O
277	C282Y	O
277	HH	B-Disease
277	chromosomes	O
277	.	O
278	We	O
278	report	O
278	here	O
278	on	O
278	the	O
278	analysis	O
278	of	O
278	C282Y	O
278	,	O
278	H63D	O
278	,	O
278	and	O
278	the	O
278	193A	O
278	-	O
278	-	O
278	>	O
278	T	O
278	substitution	O
278	leading	O
278	to	O
278	the	O
278	S65C	O
278	missense	O
278	substitution	O
278	in	O
278	a	O
278	large	O
278	series	O
278	of	O
278	probands	O
278	and	O
278	controls	O
278	.	O
279	The	O
279	results	O
279	confirm	O
279	that	O
279	the	O
279	C282Y	O
279	substitution	O
279	was	O
279	the	O
279	main	O
279	mutation	O
279	involved	O
279	in	O
279	hemochromatosis	B-Disease
279	,	O
279	accounting	O
279	for	O
279	85	O
279	%	O
279	of	O
279	carrier	O
279	chromosomes	O
279	,	O
279	whereas	O
279	the	O
279	H63D	O
279	substitution	O
279	represented	O
279	39	O
279	%	O
279	of	O
279	the	O
279	HH	B-Disease
279	chromosomes	O
279	that	O
279	did	O
279	not	O
279	carry	O
279	the	O
279	C282Y	O
279	mutation	O
279	.	O
280	In	O
280	addition	O
280	,	O
280	our	O
280	screening	O
280	showed	O
280	that	O
280	the	O
280	S65C	O
280	substitution	O
280	was	O
280	significantly	O
280	enriched	O
280	in	O
280	probands	O
280	with	O
280	at	O
280	least	O
280	one	O
280	chromosome	O
280	without	O
280	an	O
280	assigned	O
280	mutation	O
280	.	O
281	This	O
281	substitution	O
281	accounted	O
281	for	O
281	7	O
281	.	O
282	8	O
282	%	O
282	of	O
282	HH	B-Disease
282	chromosomes	O
282	that	O
282	were	O
282	neither	O
282	C282Y	O
282	nor	O
282	H63D	O
282	.	O
283	This	O
283	enrichment	O
283	of	O
283	S65C	O
283	among	O
283	HH	B-Disease
283	chromosomes	O
283	suggests	O
283	that	O
283	the	O
283	S65C	O
283	substitution	O
283	is	O
283	associated	O
283	with	O
283	the	O
283	mild	O
283	form	O
283	of	O
283	hemochromatosis	B-Disease
283	.	O
284	Germline	O
284	BRCA1	O
284	alterations	O
284	in	O
284	a	O
284	population	O
284	-	O
284	based	O
284	series	O
284	of	O
284	ovarian	B-Disease
284	cancer	I-Disease
284	cases	O
284	.	O
285	The	O
285	objective	O
285	of	O
285	this	O
285	study	O
285	was	O
285	to	O
285	provide	O
285	more	O
285	accurate	O
285	frequency	O
285	estimates	O
285	of	O
285	breast	B-Disease
285	cancer	I-Disease
285	susceptibility	O
285	gene	O
285	1	O
285	(	O
285	BRCA1	O
285	)	O
285	germline	O
285	alterations	O
285	in	O
285	the	O
285	ovarian	B-Disease
285	cancer	I-Disease
285	population	O
285	.	O
286	To	O
286	achieve	O
286	this	O
286	,	O
286	we	O
286	determined	O
286	the	O
286	prevalence	O
286	of	O
286	BRCA1	O
286	alterations	O
286	in	O
286	a	O
286	population	O
286	-	O
286	based	O
286	series	O
286	of	O
286	consecutive	O
286	ovarian	B-Disease
286	cancer	I-Disease
286	cases	O
286	.	O
287	This	O
287	is	O
287	the	O
287	first	O
287	population	O
287	-	O
287	based	O
287	ovarian	B-Disease
287	cancer	I-Disease
287	study	O
287	reporting	O
287	BRCA1	O
287	alterations	O
287	derived	O
287	from	O
287	a	O
287	comprehensive	O
287	screen	O
287	of	O
287	the	O
287	entire	O
287	coding	O
287	region	O
287	.	O
288	One	O
288	hundred	O
288	and	O
288	seven	O
288	ovarian	B-Disease
288	cancer	I-Disease
288	cases	O
288	were	O
288	analyzed	O
288	for	O
288	BRCA1	O
288	alterations	O
288	using	O
288	the	O
288	RNase	O
288	mismatch	O
288	cleavage	O
288	assay	O
288	followed	O
288	by	O
288	direct	O
288	sequencing	O
288	.	O
289	Two	O
289	truncating	O
289	mutations	O
289	,	O
289	962del4	O
289	and	O
289	3600del11	O
289	,	O
289	were	O
289	identified	O
289	.	O
290	Both	O
290	patients	O
290	had	O
290	a	O
290	family	O
290	history	O
290	of	O
290	breast	B-Disease
290	or	I-Disease
290	ovarian	I-Disease
290	cancer	I-Disease
290	.	O
291	Several	O
291	novel	O
291	as	O
291	well	O
291	as	O
291	previously	O
291	reported	O
291	uncharacterized	O
291	variants	O
291	were	O
291	also	O
291	identified	O
291	,	O
291	some	O
291	of	O
291	which	O
291	were	O
291	associated	O
291	with	O
291	a	O
291	family	O
291	history	O
291	of	O
291	cancer	B-Disease
291	.	O
292	The	O
292	frequency	O
292	distribution	O
292	of	O
292	common	O
292	polymorphisms	O
292	was	O
292	determined	O
292	in	O
292	the	O
292	91	O
292	Caucasian	O
292	cancer	B-Disease
292	cases	O
292	in	O
292	this	O
292	series	O
292	and	O
292	24	O
292	sister	O
292	controls	O
292	using	O
292	allele	O
292	-	O
292	specific	O
292	amplification	O
292	.	O
293	The	O
293	rare	O
293	form	O
293	of	O
293	the	O
293	Q356R	O
293	polymorphism	O
293	was	O
293	significantly	O
293	(	O
293	P	O
293	=	O
293	0	O
293	.	O
293	03	O
293	)	O
293	associated	O
293	with	O
293	a	O
293	family	O
293	history	O
293	of	O
293	ovarian	B-Disease
293	cancer	I-Disease
293	,	O
293	suggesting	O
293	that	O
293	this	O
293	polymorphism	O
293	may	O
293	influence	O
293	ovarian	B-Disease
293	cancer	I-Disease
293	risk	O
293	.	O
294	In	O
294	summary	O
294	,	O
294	our	O
294	data	O
294	suggest	O
294	a	O
294	role	O
294	for	O
294	some	O
294	uncharacterized	O
294	variants	O
294	and	O
294	rare	O
294	forms	O
294	of	O
294	polymorphisms	O
294	in	O
294	determining	O
294	ovarian	B-Disease
294	cancer	I-Disease
294	risk	O
294	,	O
294	and	O
294	highlight	O
294	the	O
294	necessity	O
294	to	O
294	screen	O
294	for	O
294	missense	O
294	alterations	O
294	as	O
294	well	O
294	as	O
294	truncating	O
294	mutations	O
294	in	O
294	this	O
294	population	O
294	.	O
295	Adrenoleukodystrophy	O
295	-	O
295	related	O
295	protein	O
295	can	O
295	compensate	O
295	functionally	O
295	for	O
295	adrenoleukodystrophy	B-Disease
295	protein	I-Disease
295	deficiency	I-Disease
295	(	O
295	X	B-Disease
295	-	I-Disease
295	ALD	I-Disease
295	)	O
295	:	O
295	implications	O
295	for	O
295	therapy	O
295	.	O
296	Inherited	B-Disease
296	defects	I-Disease
296	in	O
296	the	O
296	peroxisomal	O
296	ATP	O
296	-	O
296	binding	O
296	cassette	O
296	(	O
296	ABC	O
296	)	O
296	transporter	O
296	adrenoleukodystrophy	B-Disease
296	protein	O
296	(	O
296	ALDP	O
296	)	O
296	lead	O
296	to	O
296	the	O
296	lethal	O
296	peroxisomal	B-Disease
296	disorder	I-Disease
296	X	B-Disease
296	-	I-Disease
296	linked	I-Disease
296	adrenoleukodystrophy	I-Disease
296	(	O
296	X	B-Disease
296	-	I-Disease
296	ALD	I-Disease
296	)	O
296	,	O
296	for	O
296	which	O
296	no	O
296	efficient	O
296	treatment	O
296	has	O
296	been	O
296	established	O
296	so	O
296	far	O
296	.	O
297	Three	O
297	other	O
297	peroxisomal	O
297	ABC	O
297	transporters	O
297	currently	O
297	are	O
297	known	O
297	adrenoleukodystrophy	O
297	-	O
297	related	O
297	protein	O
297	(	O
297	ALDRP	O
297	)	O
297	,	O
297	70	O
297	kDa	O
297	peroxisomal	O
297	membrane	O
297	protein	O
297	(	O
297	PMP70	O
297	)	O
297	and	O
297	PMP70	O
297	-	O
297	related	O
297	protein	O
297	.	O
298	By	O
298	using	O
298	transient	O
298	and	O
298	stable	O
298	overexpression	O
298	of	O
298	human	O
298	cDNAs	O
298	encoding	O
298	ALDP	O
298	and	O
298	its	O
298	closest	O
298	relative	O
298	ALDRP	O
298	,	O
298	we	O
298	could	O
298	restore	O
298	the	O
298	impaired	O
298	peroxisomal	O
298	beta	O
298	-	O
298	oxidation	O
298	in	O
298	fibroblasts	O
298	of	O
298	X	B-Disease
298	-	I-Disease
298	ALD	I-Disease
298	patients	O
298	.	O
299	The	O
299	pathognomonic	O
299	accumulation	O
299	of	O
299	very	O
299	long	O
299	chain	O
299	fatty	O
299	acids	O
299	could	O
299	also	O
299	be	O
299	prevented	O
299	by	O
299	overexpression	O
299	of	O
299	ALDRP	O
299	in	O
299	immortalized	O
299	X	O
299	-	O
299	ALD	O
299	cells	O
299	.	O
300	Immunofluorescence	O
300	analysis	O
300	demonstrated	O
300	that	O
300	the	O
300	functional	O
300	replacement	O
300	of	O
300	ALDP	O
300	by	O
300	ALDRP	O
300	was	O
300	not	O
300	due	O
300	to	O
300	stabilization	O
300	of	O
300	the	O
300	mutated	O
300	ALDP	O
300	itself	O
300	.	O
301	Moreover	O
301	,	O
301	we	O
301	were	O
301	able	O
301	to	O
301	restore	O
301	the	O
301	peroxisomal	O
301	beta	O
301	-	O
301	oxidation	O
301	defect	O
301	in	O
301	the	O
301	liver	O
301	of	O
301	ALDP	O
301	-	O
301	deficient	O
301	mice	O
301	by	O
301	stimulation	O
301	of	O
301	ALDRP	O
301	and	O
301	PMP70	O
301	gene	O
301	expression	O
301	through	O
301	a	O
301	dietary	O
301	treatment	O
301	with	O
301	the	O
301	peroxisome	O
301	proliferator	O
301	fenofibrate	O
301	.	O
302	These	O
302	results	O
302	suggest	O
302	that	O
302	a	O
302	correction	O
302	of	O
302	the	O
302	biochemical	O
302	defect	O
302	in	O
302	X	B-Disease
302	-	I-Disease
302	ALD	I-Disease
302	could	O
302	be	O
302	possible	O
302	by	O
302	drug	O
302	-	O
302	induced	O
302	overexpression	O
302	or	O
302	ectopic	O
302	expression	O
302	of	O
302	ALDRP	O
302	.	O
302	.	O
303	Centrosome	O
303	amplification	O
303	and	O
303	a	O
303	defective	O
303	G2	O
303	-	O
303	M	O
303	cell	O
303	cycle	O
303	checkpoint	O
303	induce	O
303	genetic	O
303	instability	O
303	in	O
303	BRCA1	O
303	exon	O
303	11	O
303	isoform	O
303	-	O
303	deficient	O
303	cells	O
303	.	O
304	Germline	O
304	mutations	O
304	of	O
304	the	O
304	Brca1	O
304	tumor	B-Disease
304	suppressor	O
304	gene	O
304	predispose	O
304	women	O
304	to	O
304	breast	B-Disease
304	and	I-Disease
304	ovarian	I-Disease
304	cancers	I-Disease
304	.	O
305	To	O
305	study	O
305	mechanisms	O
305	underlying	O
305	BRCA1	O
305	-	O
305	related	O
305	tumorigenesis	O
305	,	O
305	we	O
305	derived	O
305	mouse	O
305	embryonic	O
305	fibroblast	O
305	cells	O
305	carrying	O
305	a	O
305	targeted	O
305	deletion	O
305	of	O
305	exon	O
305	11	O
305	of	O
305	the	O
305	Brca1	O
305	gene	O
305	.	O
306	We	O
306	show	O
306	that	O
306	the	O
306	mutant	O
306	cells	O
306	maintain	O
306	an	O
306	intact	O
306	G1	O
306	-	O
306	S	O
306	cell	O
306	cycle	O
306	checkpoint	O
306	and	O
306	proliferate	O
306	poorly	O
306	.	O
307	However	O
307	,	O
307	a	O
307	defective	O
307	G2	O
307	-	O
307	M	O
307	checkpoint	O
307	in	O
307	these	O
307	cells	O
307	is	O
307	accompanied	O
307	by	O
307	extensive	O
307	chromosomal	B-Disease
307	abnormalities	I-Disease
307	.	O
308	Mutant	O
308	fibroblasts	O
308	contain	O
308	multiple	O
308	,	O
308	functional	O
308	centrosomes	O
308	,	O
308	which	O
308	lead	O
308	to	O
308	unequal	O
308	chromosome	O
308	segregation	O
308	,	O
308	abnormal	O
308	nuclear	O
308	division	O
308	,	O
308	and	O
308	aneuploidy	B-Disease
308	.	O
309	These	O
309	data	O
309	uncover	O
309	an	O
309	essential	O
309	role	O
309	of	O
309	BRCA1	O
309	in	O
309	maintaining	O
309	genetic	O
309	stability	O
309	through	O
309	the	O
309	regulation	O
309	of	O
309	centrosome	O
309	duplication	O
309	and	O
309	the	O
309	G2	O
309	-	O
309	M	O
309	checkpoint	O
309	and	O
309	provide	O
309	a	O
309	molecular	O
309	basis	O
309	for	O
309	the	O
309	role	O
309	of	O
309	BRCA1	O
309	in	O
309	tumorigenesis	O
309	.	O
309	.	O
310	Defective	O
310	CD95	O
310	/	O
310	APO	O
310	-	O
310	1	O
310	/	O
310	Fas	O
310	signal	O
310	complex	O
310	formation	O
310	in	O
310	the	O
310	human	O
310	autoimmune	B-Disease
310	lymphoproliferative	I-Disease
310	syndrome	I-Disease
310	,	I-Disease
310	type	I-Disease
310	Ia	I-Disease
310	.	O
311	Heterozygous	O
311	mutations	O
311	in	O
311	the	O
311	CD95	O
311	(	O
311	APO	O
311	-	O
311	1	O
311	/	O
311	Fas	O
311	)	O
311	receptor	O
311	occur	O
311	in	O
311	most	O
311	individuals	O
311	with	O
311	autoimmune	B-Disease
311	lymphoproliferative	I-Disease
311	syndrome	I-Disease
311	(	O
311	ALPS	B-Disease
311	)	O
311	and	O
311	dominantly	O
311	interfere	O
311	with	O
311	apoptosis	O
311	by	O
311	an	O
311	unknown	O
311	mechanism	O
311	.	O
312	We	O
312	show	O
312	that	O
312	local	O
312	or	O
312	global	O
312	alterations	O
312	in	O
312	the	O
312	structure	O
312	of	O
312	the	O
312	cytoplasmic	O
312	death	O
312	domain	O
312	from	O
312	nine	O
312	independent	O
312	ALPS	B-Disease
312	CD95	O
312	death	O
312	-	O
312	domain	O
312	mutations	O
312	result	O
312	in	O
312	a	O
312	failure	O
312	to	O
312	bind	O
312	the	O
312	FADD	O
312	/	O
312	MORT1	O
312	signaling	O
312	protein	O
312	.	O
313	Despite	O
313	heterozygosity	O
313	for	O
313	the	O
313	abnormal	O
313	allele	O
313	,	O
313	lymphocytes	O
313	from	O
313	ALPS	B-Disease
313	patients	O
313	showed	O
313	markedly	O
313	decreased	O
313	FADD	O
313	association	O
313	and	O
313	a	O
313	loss	O
313	of	O
313	caspase	O
313	recruitment	O
313	and	O
313	activation	O
313	after	O
313	CD95	O
313	crosslinking	O
313	.	O
314	These	O
314	data	O
314	suggest	O
314	that	O
314	intracytoplasmic	O
314	CD95	O
314	mutations	O
314	in	O
314	ALPS	B-Disease
314	impair	O
314	apoptosis	O
314	chiefly	O
314	by	O
314	disrupting	O
314	death	O
314	-	O
314	domain	O
314	interactions	O
314	with	O
314	the	O
314	signaling	O
314	protein	O
314	FADD	O
314	/	O
314	MORT1	O
314	.	O
314	.	O
315	Analysis	O
315	of	O
315	alkaptonuria	B-Disease
315	(	O
315	AKU	B-Disease
315	)	O
315	mutations	O
315	and	O
315	polymorphisms	O
315	reveals	O
315	that	O
315	the	O
315	CCC	O
315	sequence	O
315	motif	O
315	is	O
315	a	O
315	mutational	O
315	hot	O
315	spot	O
315	in	O
315	the	O
315	homogentisate	O
315	1	O
315	,	O
315	2	O
315	dioxygenase	O
315	gene	O
315	(	O
315	HGO	O
315	)	O
315	.	O
316	We	O
316	recently	O
316	showed	O
316	that	O
316	alkaptonuria	B-Disease
316	(	O
316	AKU	B-Disease
316	)	O
316	is	O
316	caused	O
316	by	O
316	loss	O
316	-	O
316	of	O
316	-	O
316	function	O
316	mutations	O
316	in	O
316	the	O
316	homogentisate	O
316	1	O
316	,	O
316	2	O
316	dioxygenase	O
316	gene	O
316	(	O
316	HGO	O
316	)	O
316	.	O
317	Herein	O
317	we	O
317	describe	O
317	haplotype	O
317	and	O
317	mutational	O
317	analyses	O
317	of	O
317	HGO	O
317	in	O
317	seven	O
317	new	O
317	AKU	B-Disease
317	pedigrees	O
317	.	O
318	These	O
318	analyses	O
318	identified	O
318	two	O
318	novel	O
318	single	O
318	-	O
318	nucleotide	O
318	polymorphisms	O
318	(	O
318	INV4	O
318	+	O
318	31A	O
318	-	O
318	-	O
318	>	O
318	G	O
318	and	O
318	INV11	O
318	+	O
318	18A	O
318	-	O
318	-	O
318	>	O
318	G	O
318	)	O
318	and	O
318	six	O
318	novel	O
318	AKU	B-Disease
318	mutations	O
318	(	O
318	INV1	O
318	-	O
318	1G	O
318	-	O
318	-	O
318	>	O
318	A	O
318	,	O
318	W60G	O
318	,	O
318	Y62C	O
318	,	O
318	A122D	O
318	,	O
318	P230T	O
318	,	O
318	and	O
318	D291E	O
318	)	O
318	,	O
318	which	O
318	further	O
318	illustrates	O
318	the	O
318	remarkable	O
318	allelic	O
318	heterogeneity	O
318	found	O
318	in	O
318	AKU	B-Disease
318	.	O
319	Reexamination	O
319	of	O
319	all	O
319	29	O
319	mutations	O
319	and	O
319	polymorphisms	O
319	thus	O
319	far	O
319	described	O
319	in	O
319	HGO	O
319	shows	O
319	that	O
319	these	O
319	nucleotide	O
319	changes	O
319	are	O
319	not	O
319	randomly	O
319	distributed	O
319	;	O
319	the	O
319	CCC	O
319	sequence	O
319	motif	O
319	and	O
319	its	O
319	inverted	O
319	complement	O
319	,	O
319	GGG	O
319	,	O
319	are	O
319	preferentially	O
319	mutated	O
319	.	O
320	These	O
320	analyses	O
320	also	O
320	demonstrated	O
320	that	O
320	the	O
320	nucleotide	O
320	substitutions	O
320	in	O
320	HGO	O
320	do	O
320	not	O
320	involve	O
320	CpG	O
320	dinucleotides	O
320	,	O
320	which	O
320	illustrates	O
320	important	O
320	differences	O
320	between	O
320	HGO	O
320	and	O
320	other	O
320	genes	O
320	for	O
320	the	O
320	occurrence	O
320	of	O
320	mutation	O
320	at	O
320	specific	O
320	short	O
320	-	O
320	sequence	O
320	motifs	O
320	.	O
321	Because	O
321	the	O
321	CCC	O
321	sequence	O
321	motifs	O
321	comprise	O
321	a	O
321	significant	O
321	proportion	O
321	(	O
321	34	O
321	.	O
321	5	O
321	%	O
321	)	O
321	of	O
321	all	O
321	mutated	O
321	bases	O
321	that	O
321	have	O
321	been	O
321	observed	O
321	in	O
321	HGO	O
321	,	O
321	we	O
321	conclude	O
321	that	O
321	the	O
321	CCC	O
321	triplet	O
321	is	O
321	a	O
321	mutational	O
321	hot	O
321	spot	O
321	in	O
321	HGO	O
321	.	O
322	Fabry	B-Disease
322	disease	I-Disease
322	:	O
322	identification	O
322	of	O
322	novel	O
322	alpha	O
322	-	O
322	galactosidase	O
322	A	O
322	mutations	O
322	and	O
322	molecular	O
322	carrier	O
322	detection	O
322	by	O
322	use	O
322	of	O
322	fluorescent	O
322	chemical	O
322	cleavage	O
322	of	O
322	mismatches	O
322	.	O
323	Fabry	B-Disease
323	disease	I-Disease
323	(	O
323	FD	B-Disease
323	)	O
323	(	O
323	angiokeratoma	B-Disease
323	corporis	I-Disease
323	diffusum	I-Disease
323	)	O
323	is	O
323	an	O
323	X	B-Disease
323	-	I-Disease
323	linked	I-Disease
323	inborn	I-Disease
323	error	I-Disease
323	of	I-Disease
323	glycosphingolipid	I-Disease
323	metabolism	I-Disease
323	caused	O
323	by	O
323	defects	O
323	in	O
323	the	O
323	lysosomal	O
323	alpha	O
323	-	O
323	galactosidase	O
323	A	O
323	gene	O
323	(	O
323	GLA	O
323	)	O
323	.	O
324	The	O
324	enzymatic	O
324	defect	O
324	leads	O
324	to	O
324	the	O
324	systemic	O
324	accumulation	O
324	of	O
324	neutral	O
324	glycosphingolipids	O
324	with	O
324	terminal	O
324	alpha	O
324	-	O
324	galactosyl	O
324	moieties	O
324	.	O
325	Clinically	O
325	,	O
325	affected	O
325	hemizygous	O
325	males	O
325	have	O
325	angiokeratoma	B-Disease
325	,	O
325	severe	B-Disease
325	acroparesthesia	I-Disease
325	,	O
325	renal	B-Disease
325	failure	I-Disease
325	,	O
325	and	O
325	vasculopathy	B-Disease
325	of	I-Disease
325	the	I-Disease
325	heart	I-Disease
325	and	I-Disease
325	brain	I-Disease
325	.	O
326	While	O
326	demonstration	O
326	of	O
326	alpha	B-Disease
326	-	I-Disease
326	galactosidase	I-Disease
326	deficiency	I-Disease
326	in	O
326	leukocytes	O
326	is	O
326	diagnostic	O
326	in	O
326	affected	O
326	males	O
326	,	O
326	enzymatic	O
326	detection	O
326	of	O
326	female	O
326	carriers	O
326	is	O
326	often	O
326	inconclusive	O
326	,	O
326	due	O
326	to	O
326	random	O
326	X	O
326	-	O
326	chromosomal	O
326	inactivation	O
326	,	O
326	underlining	O
326	the	O
326	need	O
326	of	O
326	molecular	O
326	investigations	O
326	for	O
326	accurate	O
326	genetic	O
326	counseling	O
326	.	O
327	By	O
327	use	O
327	of	O
327	chemical	O
327	cleavage	O
327	of	O
327	mismatches	O
327	adapted	O
327	to	O
327	fluorescence	O
327	-	O
327	based	O
327	detection	O
327	systems	O
327	,	O
327	we	O
327	have	O
327	characterized	O
327	the	O
327	mutations	O
327	underlying	O
327	alpha	B-Disease
327	-	I-Disease
327	Gal	I-Disease
327	A	I-Disease
327	deficiency	I-Disease
327	in	O
327	16	O
327	individuals	O
327	from	O
327	six	O
327	unrelated	O
327	families	O
327	with	O
327	FD	B-Disease
327	.	O
328	The	O
328	mutational	O
328	spectrum	O
328	included	O
328	five	O
328	missense	O
328	mutations	O
328	(	O
328	C202W	O
328	,	O
328	C223G	O
328	,	O
328	N224D	O
328	,	O
328	R301Q	O
328	,	O
328	and	O
328	Q327K	O
328	)	O
328	and	O
328	one	O
328	splice	O
328	-	O
328	site	O
328	mutation	O
328	[	O
328	IVS3	O
328	G	O
328	(	O
328	-	O
328	1	O
328	)	O
328	-	O
328	-	O
328	>	O
328	C	O
328	]	O
328	.	O
329	Studies	O
329	at	O
329	the	O
329	mRNA	O
329	level	O
329	showed	O
329	that	O
329	the	O
329	latter	O
329	led	O
329	to	O
329	altered	O
329	pre	O
329	-	O
329	mRNA	O
329	splicing	O
329	with	O
329	consequent	O
329	alteration	O
329	of	O
329	the	O
329	mRNA	O
329	translational	O
329	reading	O
329	frame	O
329	and	O
329	generation	O
329	of	O
329	a	O
329	premature	O
329	termination	O
329	codon	O
329	of	O
329	translation	O
329	.	O
330	By	O
330	use	O
330	of	O
330	this	O
330	strategy	O
330	,	O
330	carrier	O
330	status	O
330	was	O
330	accurately	O
330	assessed	O
330	in	O
330	all	O
330	seven	O
330	at	O
330	-	O
330	risk	O
330	females	O
330	tested	O
330	,	O
330	whereas	O
330	enzymatic	O
330	dosages	O
330	failed	O
330	to	O
330	diagnose	O
330	or	O
330	exclude	O
330	heterozygosity	O
330	.	O
330	.	O
331	Prenatal	O
331	diagnosis	O
331	by	O
331	FISH	O
331	in	O
331	a	O
331	family	O
331	with	O
331	Pelizaeus	B-Disease
331	-	I-Disease
331	Merzbacher	I-Disease
331	disease	I-Disease
331	caused	O
331	by	O
331	duplication	O
331	of	O
331	PLP	O
331	gene	O
331	.	O
332	A	O
332	diagnosis	O
332	of	O
332	Pelizaeus	B-Disease
332	-	I-Disease
332	Merzbacher	I-Disease
332	disease	I-Disease
332	(	O
332	MIM	O
332	312080	O
332	)	O
332	was	O
332	made	O
332	in	O
332	a	O
332	young	O
332	boy	O
332	.	O
333	No	O
333	mutation	O
333	in	O
333	the	O
333	coding	O
333	region	O
333	of	O
333	the	O
333	proteolipid	O
333	protein	O
333	(	O
333	PLP	O
333	)	O
333	gene	O
333	had	O
333	been	O
333	found	O
333	.	O
334	The	O
334	boys	O
334	maternal	O
334	aunt	O
334	came	O
334	for	O
334	prenatal	O
334	diagnosis	O
334	when	O
334	16	O
334	+	O
334	weeks	O
334	pregnant	O
334	and	O
334	carrying	O
334	a	O
334	male	O
334	fetus	O
334	.	O
335	Samples	O
335	were	O
335	tested	O
335	for	O
335	duplication	O
335	of	O
335	the	O
335	PLP	O
335	gene	O
335	,	O
335	by	O
335	interphase	O
335	FISH	O
335	,	O
335	in	O
335	lymphocyte	O
335	preparations	O
335	from	O
335	the	O
335	proband	O
335	,	O
335	his	O
335	aunt	O
335	and	O
335	an	O
335	amniotic	O
335	fluid	O
335	cell	O
335	preparation	O
335	from	O
335	the	O
335	fetus	O
335	.	O
336	The	O
336	proband	O
336	was	O
336	found	O
336	to	O
336	carry	O
336	the	O
336	duplication	O
336	,	O
336	thus	O
336	confirming	O
336	the	O
336	diagnosis	O
336	of	O
336	Pelizaeus	B-Disease
336	Merzbacher	I-Disease
336	disease	I-Disease
336	,	O
336	but	O
336	neither	O
336	the	O
336	aunt	O
336	nor	O
336	the	O
336	fetus	O
336	carried	O
336	a	O
336	duplication	O
336	.	O
336	.	O
337	Dominant	O
337	negative	O
337	effect	O
337	of	O
337	the	O
337	APC1309	O
337	mutation	O
337	:	O
337	a	O
337	possible	O
337	explanation	O
337	for	O
337	genotype	O
337	-	O
337	phenotype	O
337	correlations	O
337	in	O
337	familial	B-Disease
337	adenomatous	I-Disease
337	polyposis	I-Disease
337	.	O
338	Inactivation	O
338	of	O
338	the	O
338	adenomatous	B-Disease
338	polyposis	I-Disease
338	coli	I-Disease
338	(	O
338	APC	B-Disease
338	)	O
338	gene	O
338	product	O
338	initiates	O
338	colorectal	O
338	tumorigenesis	O
338	.	O
339	Patients	O
339	with	O
339	familial	B-Disease
339	APC	I-Disease
339	(	O
339	FAP	B-Disease
339	)	O
339	carry	O
339	germ	O
339	-	O
339	line	O
339	mutations	O
339	in	O
339	the	O
339	APC	B-Disease
339	gene	O
339	and	O
339	develop	O
339	multiple	O
339	colorectal	B-Disease
339	adenomas	I-Disease
339	and	O
339	subsequent	O
339	carcinomas	B-Disease
339	early	O
339	in	O
339	life	O
339	.	O
340	The	O
340	severity	O
340	of	O
340	the	O
340	disease	O
340	correlates	O
340	with	O
340	the	O
340	position	O
340	of	O
340	the	O
340	inherited	O
340	APC	B-Disease
340	mutation	O
340	(	O
340	genotype	O
340	-	O
340	phenotype	O
340	correlation	O
340	)	O
340	.	O
341	Together	O
341	with	O
341	the	O
341	fact	O
341	that	O
341	both	O
341	germ	O
341	-	O
341	line	O
341	and	O
341	sporadic	O
341	APC	B-Disease
341	mutations	O
341	cluster	O
341	in	O
341	the	O
341	central	O
341	region	O
341	of	O
341	the	O
341	APC	B-Disease
341	gene	O
341	,	O
341	this	O
341	points	O
341	to	O
341	a	O
341	dominant	O
341	negative	O
341	effect	O
341	of	O
341	certain	O
341	APC	B-Disease
341	mutants	O
341	.	O
342	Loss	O
342	of	O
342	APC	B-Disease
342	function	O
342	was	O
342	recently	O
342	shown	O
342	to	O
342	result	O
342	in	O
342	enhanced	O
342	beta	O
342	-	O
342	catenin	O
342	-	O
342	/	O
342	Tcf	O
342	-	O
342	mediated	O
342	transcription	O
342	in	O
342	colon	O
342	epithelial	O
342	cells	O
342	.	O
343	Here	O
343	,	O
343	we	O
343	provide	O
343	experimental	O
343	evidence	O
343	for	O
343	a	O
343	dominant	O
343	negative	O
343	effect	O
343	of	O
343	APC	B-Disease
343	gene	O
343	products	O
343	associated	O
343	with	O
343	severe	O
343	polyposis	B-Disease
343	.	O
344	Wild	O
344	-	O
344	type	O
344	APC	B-Disease
344	activity	O
344	in	O
344	beta	O
344	-	O
344	catenin	O
344	-	O
344	/	O
344	Tcf	O
344	-	O
344	mediated	O
344	transcription	O
344	was	O
344	strongly	O
344	inhibited	O
344	by	O
344	a	O
344	mutant	O
344	APC	B-Disease
344	that	O
344	is	O
344	truncated	O
344	at	O
344	codon	O
344	1309	O
344	.	O
345	In	O
345	contrast	O
345	,	O
345	mutant	O
345	APC	B-Disease
345	gene	O
345	products	O
345	that	O
345	are	O
345	associated	O
345	with	O
345	attenuated	B-Disease
345	polyposis	I-Disease
345	(	O
345	codon	O
345	386	O
345	or	O
345	1465	O
345	)	O
345	interfered	O
345	only	O
345	weakly	O
345	with	O
345	wild	O
345	-	O
345	type	O
345	APC	B-Disease
345	activity	O
345	.	O
346	These	O
346	results	O
346	suggest	O
346	a	O
346	molecular	O
346	explanation	O
346	for	O
346	the	O
346	genotype	O
346	-	O
346	phenotype	O
346	correlation	O
346	in	O
346	FAP	B-Disease
346	patients	O
346	and	O
346	support	O
346	the	O
346	idea	O
346	that	O
346	colorectal	B-Disease
346	tumor	I-Disease
346	growth	O
346	might	O
346	be	O
346	,	O
346	in	O
346	part	O
346	,	O
346	driven	O
346	by	O
346	selection	O
346	for	O
346	a	O
346	mutation	O
346	in	O
346	the	O
346	mutation	O
346	cluster	O
346	region	O
346	.	O
346	.	O
347	BRCA1	O
347	interacts	O
347	with	O
347	components	O
347	of	O
347	the	O
347	histone	O
347	deacetylase	O
347	complex	O
347	.	O
348	Germ	O
348	-	O
348	line	O
348	mutations	O
348	in	O
348	the	O
348	BRCA1	O
348	tumor	O
348	-	O
348	suppressor	O
348	gene	O
348	are	O
348	associated	O
348	with	O
348	an	O
348	increased	O
348	susceptibility	O
348	to	O
348	breast	B-Disease
348	and	I-Disease
348	ovarian	I-Disease
348	cancer	I-Disease
348	.	O
349	BRCA1	O
349	contains	O
349	a	O
349	carboxyl	O
349	-	O
349	terminal	O
349	domain	O
349	(	O
349	BRCT	O
349	)	O
349	that	O
349	is	O
349	shared	O
349	with	O
349	several	O
349	other	O
349	proteins	O
349	involved	O
349	in	O
349	maintaining	O
349	genome	O
349	integrity	O
349	.	O
350	In	O
350	an	O
350	effort	O
350	to	O
350	understand	O
350	the	O
350	function	O
350	of	O
350	BRCA1	O
350	,	O
350	we	O
350	sought	O
350	to	O
350	isolate	O
350	proteins	O
350	that	O
350	interact	O
350	with	O
350	the	O
350	BRCT	O
350	domain	O
350	.	O
351	Purified	O
351	BRCT	O
351	polypeptide	O
351	was	O
351	used	O
351	as	O
351	a	O
351	probe	O
351	to	O
351	screen	O
351	a	O
351	human	O
351	placenta	O
351	cDNA	O
351	expression	O
351	library	O
351	by	O
351	Far	O
351	Western	O
351	analysis	O
351	.	O
352	Here	O
352	we	O
352	report	O
352	that	O
352	BRCA1	O
352	interacts	O
352	in	O
352	vivo	O
352	and	O
352	in	O
352	vitro	O
352	with	O
352	the	O
352	Rb	O
352	-	O
352	binding	O
352	proteins	O
352	,	O
352	RbAp46	O
352	and	O
352	RbAp48	O
352	,	O
352	as	O
352	well	O
352	as	O
352	with	O
352	Rb	O
352	.	O
353	Moreover	O
353	,	O
353	the	O
353	BRCT	O
353	domain	O
353	associates	O
353	with	O
353	the	O
353	histone	O
353	deacetylases	O
353	HDAC1	O
353	and	O
353	HDAC2	O
353	.	O
354	These	O
354	results	O
354	demonstrate	O
354	that	O
354	BRCA1	O
354	interacts	O
354	with	O
354	components	O
354	of	O
354	the	O
354	histone	O
354	deacetylase	O
354	complex	O
354	,	O
354	and	O
354	therefore	O
354	may	O
354	explain	O
354	the	O
354	involvement	O
354	of	O
354	BRCA1	O
354	in	O
354	multiple	O
354	processes	O
354	such	O
354	as	O
354	transcription	O
354	,	O
354	DNA	O
354	repair	O
354	,	O
354	and	O
354	recombination	O
354	.	O
354	.	O
355	Combined	B-Disease
355	genetic	I-Disease
355	deficiency	I-Disease
355	of	I-Disease
355	C6	I-Disease
355	and	I-Disease
355	C7	I-Disease
355	in	O
355	man	O
355	.	O
356	By	O
356	routine	O
356	screening	O
356	of	O
356	sera	O
356	,	O
356	a	O
356	subject	O
356	was	O
356	discovered	O
356	who	O
356	showed	O
356	a	O
356	sub	B-Disease
356	-	I-Disease
356	total	I-Disease
356	deficiency	I-Disease
356	of	I-Disease
356	C6	I-Disease
356	and	I-Disease
356	C7	I-Disease
356	.	O
357	No	O
357	clinical	O
357	disease	O
357	was	O
357	associated	O
357	with	O
357	this	O
357	deficiency	O
357	which	O
357	was	O
357	transmitted	O
357	through	O
357	the	O
357	subjects	O
357	family	O
357	as	O
357	a	O
357	single	O
357	genetic	O
357	characteristic	O
357	,	O
357	the	O
357	C6	B-Disease
357	deficiency	I-Disease
357	being	O
357	associated	O
357	with	O
357	a	O
357	silent	O
357	allele	O
357	at	O
357	the	O
357	structural	O
357	locus	O
357	.	O
358	The	O
358	propositus	O
358	was	O
358	found	O
358	to	O
358	have	O
358	low	O
358	quantities	O
358	of	O
358	an	O
358	abnormal	O
358	C6	O
358	which	O
358	was	O
358	both	O
358	antigenically	O
358	deficient	O
358	and	O
358	smaller	O
358	in	O
358	size	O
358	than	O
358	normal	O
358	C6	O
358	(	O
358	110	O
358	,	O
358	000	O
358	daltons	O
358	compared	O
358	with	O
358	140	O
358	,	O
358	000	O
358	daltons	O
358	)	O
358	and	O
358	small	O
358	quantities	O
358	of	O
358	apparently	O
358	normal	O
358	C7	O
358	.	O
359	It	O
359	is	O
359	concluded	O
359	that	O
359	the	O
359	most	O
359	likely	O
359	explanation	O
359	for	O
359	this	O
359	defect	O
359	is	O
359	that	O
359	the	O
359	subject	O
359	has	O
359	a	O
359	structural	O
359	mutation	O
359	in	O
359	his	O
359	C6	O
359	gene	O
359	which	O
359	produces	O
359	hyopsynthesis	O
359	not	O
359	only	O
359	of	O
359	C6	O
359	but	O
359	also	O
359	of	O
359	the	O
359	closely	O
359	linked	O
359	gene	O
359	for	O
359	C7	O
359	.	O
360	These	O
360	findings	O
360	suggest	O
360	the	O
360	possibility	O
360	that	O
360	C6	O
360	and	O
360	C7	O
360	may	O
360	function	O
360	as	O
360	a	O
360	single	O
360	genetic	O
360	unit	O
360	and	O
360	that	O
360	the	O
360	primary	O
360	transcript	O
360	copied	O
360	from	O
360	the	O
360	genome	O
360	includes	O
360	information	O
360	for	O
360	both	O
360	proteins	O
360	.	O
360	.	O
361	Changes	O
361	at	O
361	P183	O
361	of	O
361	emerin	O
361	weaken	O
361	its	O
361	protein	O
361	-	O
361	protein	O
361	interactions	O
361	resulting	O
361	in	O
361	X	B-Disease
361	-	I-Disease
361	linked	I-Disease
361	Emery	I-Disease
361	-	I-Disease
361	Dreifuss	I-Disease
361	muscular	I-Disease
361	dystrophy	I-Disease
361	.	O
362	Emery	B-Disease
362	-	I-Disease
362	Dreifuss	I-Disease
362	muscular	I-Disease
362	dystrophy	I-Disease
362	(	O
362	EDMD	B-Disease
362	)	O
362	is	O
362	an	O
362	X	B-Disease
362	-	I-Disease
362	linked	I-Disease
362	recessive	I-Disease
362	muscular	I-Disease
362	dystrophy	I-Disease
362	characterized	O
362	by	O
362	early	O
362	contractures	B-Disease
362	of	I-Disease
362	the	I-Disease
362	elbows	I-Disease
362	,	I-Disease
362	Achilles	I-Disease
362	tendons	I-Disease
362	and	I-Disease
362	spine	I-Disease
362	,	O
362	slowly	O
362	progressive	O
362	muscle	B-Disease
362	wasting	I-Disease
362	and	O
362	weakness	B-Disease
362	,	O
362	and	O
362	cardiomyopathy	B-Disease
362	associated	O
362	with	O
362	cardiac	B-Disease
362	conduction	I-Disease
362	defects	I-Disease
362	.	O
363	The	O
363	emerin	O
363	gene	O
363	has	O
363	been	O
363	mapped	O
363	to	O
363	Xq28	O
363	and	O
363	encodes	O
363	a	O
363	34	O
363	-	O
363	kDa	O
363	serine	O
363	-	O
363	rich	O
363	protein	O
363	,	O
363	emerin	O
363	,	O
363	which	O
363	has	O
363	been	O
363	localized	O
363	to	O
363	the	O
363	nuclear	O
363	envelope	O
363	in	O
363	a	O
363	wide	O
363	variety	O
363	of	O
363	tissues	O
363	,	O
363	including	O
363	skeletal	O
363	and	O
363	cardiac	O
363	muscle	O
363	.	O
364	Mutations	O
364	spanning	O
364	the	O
364	emerin	O
364	gene	O
364	have	O
364	been	O
364	identified	O
364	in	O
364	patients	O
364	with	O
364	EDMD	B-Disease
364	.	O
365	We	O
365	present	O
365	here	O
365	the	O
365	effect	O
365	,	O
365	on	O
365	emerin	O
365	protein	O
365	expression	O
365	,	O
365	of	O
365	two	O
365	missense	O
365	mutations	O
365	identified	O
365	in	O
365	unrelated	O
365	EDMD	B-Disease
365	patients	O
365	.	O
366	These	O
366	alterations	O
366	predict	O
366	the	O
366	replacement	O
366	of	O
366	a	O
366	proline	O
366	residue	O
366	at	O
366	position	O
366	183	O
366	with	O
366	either	O
366	a	O
366	histidine	O
366	or	O
366	a	O
366	threonine	O
366	.	O
367	Biochemical	O
367	analysis	O
367	has	O
367	demonstrated	O
367	that	O
367	the	O
367	mobility	O
367	and	O
367	expression	O
367	levels	O
367	of	O
367	the	O
367	mutant	O
367	forms	O
367	of	O
367	emerin	O
367	are	O
367	indistinguishable	O
367	from	O
367	that	O
367	of	O
367	wild	O
367	-	O
367	type	O
367	emerin	O
367	,	O
367	but	O
367	that	O
367	they	O
367	have	O
367	weakened	O
367	interactions	O
367	with	O
367	nuclear	O
367	lamina	O
367	components	O
367	.	O
368	In	O
368	comparison	O
368	with	O
368	the	O
368	usual	O
368	EDMD	B-Disease
368	phenotype	O
368	,	O
368	patients	O
368	with	O
368	P183	O
368	missense	O
368	mutations	O
368	have	O
368	a	O
368	later	O
368	age	O
368	at	O
368	onset	O
368	of	O
368	first	O
368	symptoms	O
368	,	O
368	elbow	B-Disease
368	contractures	I-Disease
368	,	O
368	ankle	B-Disease
368	contractures	I-Disease
368	,	O
368	upper	B-Disease
368	limb	I-Disease
368	weakness	I-Disease
368	and	O
368	lower	B-Disease
368	limb	I-Disease
368	weakness	I-Disease
368	,	O
368	but	O
368	there	O
368	is	O
368	no	O
368	difference	O
368	for	O
368	the	O
368	age	O
368	at	O
368	onset	O
368	of	O
368	cardiac	B-Disease
368	involvement	I-Disease
368	.	O
369	This	O
369	is	O
369	the	O
369	first	O
369	report	O
369	of	O
369	protein	O
369	studies	O
369	on	O
369	patients	O
369	with	O
369	missense	O
369	mutations	O
369	resulting	O
369	in	O
369	the	O
369	clinical	O
369	features	O
369	of	O
369	EDMD	B-Disease
369	.	O
370	These	O
370	studies	O
370	demonstrate	O
370	the	O
370	importance	O
370	of	O
370	proline	O
370	183	O
370	for	O
370	the	O
370	proper	O
370	structure	O
370	/	O
370	function	O
370	of	O
370	emerin	O
370	.	O
370	.	O
371	Microdeletions	O
371	at	O
371	chromosome	O
371	bands	O
371	1q32	O
371	-	O
371	q41	O
371	as	O
371	a	O
371	cause	O
371	of	O
371	Van	B-Disease
371	der	I-Disease
371	Woude	I-Disease
371	syndrome	I-Disease
371	.	O
372	Van	B-Disease
372	der	I-Disease
372	Woude	I-Disease
372	syndrome	I-Disease
372	(	O
372	VWS	B-Disease
372	)	O
372	is	O
372	an	O
372	autosomal	B-Disease
372	dominant	I-Disease
372	disorder	I-Disease
372	comprising	O
372	cleft	B-Disease
372	lip	I-Disease
372	and	O
372	/	O
372	or	O
372	cleft	B-Disease
372	palate	I-Disease
372	and	O
372	lip	B-Disease
372	pits	I-Disease
372	.	O
373	We	O
373	reported	O
373	previously	O
373	a	O
373	family	O
373	whose	O
373	underlying	O
373	mutation	O
373	is	O
373	a	O
373	500	O
373	-	O
373	800	O
373	kb	O
373	deletion	O
373	localized	O
373	to	O
373	chromosome	O
373	bands	O
373	1q32	O
373	-	O
373	q41	O
373	[	O
373	Sander	O
373	et	O
373	al	O
373	.	O
373	,	O
373	1994	O
373	Hum	O
373	Mol	O
373	Genet	O
373	3	O
373	576	O
373	-	O
373	578	O
373	]	O
373	.	O
374	Along	O
374	with	O
374	cleft	B-Disease
374	lip	I-Disease
374	/	I-Disease
374	palate	I-Disease
374	and	O
374	lip	B-Disease
374	pits	I-Disease
374	,	O
374	affected	O
374	relatives	O
374	exhibit	O
374	developmental	B-Disease
374	delays	I-Disease
374	,	O
374	suggesting	O
374	that	O
374	the	O
374	function	O
374	of	O
374	a	O
374	gene	O
374	nearby	O
374	may	O
374	also	O
374	be	O
374	disrupted	O
374	.	O
375	To	O
375	further	O
375	localize	O
375	the	O
375	VWS	B-Disease
375	gene	O
375	we	O
375	searched	O
375	for	O
375	other	O
375	deletions	O
375	that	O
375	cause	O
375	VWS	B-Disease
375	.	O
376	An	O
376	allele	O
376	loss	O
376	assay	O
376	was	O
376	performed	O
376	using	O
376	a	O
376	novel	O
376	highly	O
376	polymorphic	O
376	marker	O
376	,	O
376	D1S3753	O
376	.	O
377	From	O
377	a	O
377	panel	O
377	of	O
377	37	O
377	unrelated	O
377	individuals	O
377	,	O
377	we	O
377	detected	O
377	an	O
377	allele	O
377	loss	O
377	in	O
377	one	O
377	family	O
377	,	O
377	indicating	O
377	the	O
377	presence	O
377	of	O
377	a	O
377	deletion	O
377	.	O
378	In	O
378	this	O
378	family	O
378	,	O
378	the	O
378	phenotype	O
378	in	O
378	three	O
378	generations	O
378	of	O
378	affected	O
378	individuals	O
378	was	O
378	confined	O
378	to	O
378	the	O
378	cardinal	O
378	signs	O
378	of	O
378	VWS	B-Disease
378	.	O
379	Surprisingly	O
379	,	O
379	mapping	O
379	of	O
379	the	O
379	new	O
379	deletion	O
379	showed	O
379	that	O
379	it	O
379	extended	O
379	0	O
379	.	O
380	2	O
380	-	O
380	1	O
380	Mb	O
380	beyond	O
380	the	O
380	proximal	O
380	breakpoint	O
380	for	O
380	the	O
380	deletion	O
380	described	O
380	previously	O
380	.	O
381	No	O
381	deletions	O
381	were	O
381	detected	O
381	in	O
381	seven	O
381	cases	O
381	of	O
381	popliteal	B-Disease
381	pterygia	I-Disease
381	syndrome	I-Disease
381	,	O
381	76	O
381	cases	O
381	of	O
381	mixed	O
381	syndromic	B-Disease
381	forms	I-Disease
381	of	I-Disease
381	cleft	I-Disease
381	lip	I-Disease
381	and	I-Disease
381	palate	I-Disease
381	,	O
381	and	O
381	178	O
381	cases	O
381	of	O
381	nonsyndromic	B-Disease
381	cleft	I-Disease
381	lip	I-Disease
381	and	I-Disease
381	palate	I-Disease
381	.	O
382	Splicing	O
382	defects	O
382	in	O
382	the	O
382	ataxia	B-Disease
382	-	I-Disease
382	telangiectasia	I-Disease
382	gene	O
382	,	O
382	ATM	O
382	:	O
382	underlying	O
382	mutations	O
382	and	O
382	consequences	O
382	.	O
383	Mutations	O
383	resulting	O
383	in	O
383	defective	O
383	splicing	O
383	constitute	O
383	a	O
383	significant	O
383	proportion	O
383	(	O
383	30	O
383	/	O
383	62	O
383	[	O
383	48	O
383	%	O
383	]	O
383	)	O
383	of	O
383	a	O
383	new	O
383	series	O
383	of	O
383	mutations	O
383	in	O
383	the	O
383	ATM	O
383	gene	O
383	in	O
383	patients	O
383	with	O
383	ataxia	B-Disease
383	-	I-Disease
383	telangiectasia	I-Disease
383	(	O
383	AT	B-Disease
383	)	O
383	that	O
383	were	O
383	detected	O
383	by	O
383	the	O
383	protein	O
383	-	O
383	truncation	O
383	assay	O
383	followed	O
383	by	O
383	sequence	O
383	analysis	O
383	of	O
383	genomic	O
383	DNA	O
383	.	O
384	Fewer	O
384	than	O
384	half	O
384	of	O
384	the	O
384	splicing	O
384	mutations	O
384	involved	O
384	the	O
384	canonical	O
384	AG	O
384	splice	O
384	-	O
384	acceptor	O
384	site	O
384	or	O
384	GT	O
384	splice	O
384	-	O
384	donor	O
384	site	O
384	.	O
385	A	O
385	higher	O
385	percentage	O
385	of	O
385	mutations	O
385	occurred	O
385	at	O
385	less	O
385	stringently	O
385	conserved	O
385	sites	O
385	,	O
385	including	O
385	silent	O
385	mutations	O
385	of	O
385	the	O
385	last	O
385	nucleotide	O
385	of	O
385	exons	O
385	,	O
385	mutations	O
385	in	O
385	nucleotides	O
385	other	O
385	than	O
385	the	O
385	conserved	O
385	AG	O
385	and	O
385	GT	O
385	in	O
385	the	O
385	consensus	O
385	splice	O
385	sites	O
385	,	O
385	and	O
385	creation	O
385	of	O
385	splice	O
385	-	O
385	acceptor	O
385	or	O
385	splice	O
385	-	O
385	donor	O
385	sites	O
385	in	O
385	either	O
385	introns	O
385	or	O
385	exons	O
385	.	O
386	These	O
386	splicing	O
386	mutations	O
386	led	O
386	to	O
386	a	O
386	variety	O
386	of	O
386	consequences	O
386	,	O
386	including	O
386	exon	O
386	skipping	O
386	and	O
386	,	O
386	to	O
386	a	O
386	lesser	O
386	degree	O
386	,	O
386	intron	O
386	retention	O
386	,	O
386	activation	O
386	of	O
386	cryptic	O
386	splice	O
386	sites	O
386	,	O
386	or	O
386	creation	O
386	of	O
386	new	O
386	splice	O
386	sites	O
386	.	O
387	In	O
387	addition	O
387	,	O
387	5	O
387	of	O
387	12	O
387	nonsense	O
387	mutations	O
387	and	O
387	1	O
387	missense	O
387	mutation	O
387	were	O
387	associated	O
387	with	O
387	deletion	O
387	in	O
387	the	O
387	cDNA	O
387	of	O
387	the	O
387	exons	O
387	in	O
387	which	O
387	the	O
387	mutations	O
387	occurred	O
387	.	O
388	No	O
388	ATM	O
388	protein	O
388	was	O
388	detected	O
388	by	O
388	western	O
388	blotting	O
388	in	O
388	any	O
388	AT	B-Disease
388	cell	O
388	line	O
388	in	O
388	which	O
388	splicing	O
388	mutations	O
388	were	O
388	identified	O
388	.	O
389	Several	O
389	cases	O
389	of	O
389	exon	O
389	skipping	O
389	in	O
389	both	O
389	normal	O
389	controls	O
389	and	O
389	patients	O
389	for	O
389	whom	O
389	no	O
389	underlying	O
389	defect	O
389	could	O
389	be	O
389	found	O
389	in	O
389	genomic	O
389	DNA	O
389	were	O
389	also	O
389	observed	O
389	,	O
389	suggesting	O
389	caution	O
389	in	O
389	the	O
389	interpretation	O
389	of	O
389	exon	O
389	deletions	O
389	observed	O
389	in	O
389	ATM	O
389	cDNA	O
389	when	O
389	there	O
389	is	O
389	no	O
389	accompanying	O
389	identification	O
389	of	O
389	genomic	O
389	mutations	O
389	.	O
389	.	O
390	Alpha	O
390	-	O
390	cardiac	O
390	actin	O
390	is	O
390	a	O
390	novel	O
390	disease	O
390	gene	O
390	in	O
390	familial	B-Disease
390	hypertrophic	I-Disease
390	cardiomyopathy	I-Disease
390	.	O
391	We	O
391	identified	O
391	the	O
391	alpha	O
391	-	O
391	cardiac	O
391	actin	O
391	gene	O
391	(	O
391	ACTC	O
391	)	O
391	as	O
391	a	O
391	novel	O
391	disease	O
391	gene	O
391	in	O
391	a	O
391	pedigree	O
391	suffering	O
391	from	O
391	familial	B-Disease
391	hypertrophic	I-Disease
391	cardiomyopathy	I-Disease
391	(	O
391	FHC	B-Disease
391	)	O
391	.	O
392	Linkage	O
392	analyses	O
392	excluded	O
392	all	O
392	the	O
392	previously	O
392	reported	O
392	FHC	B-Disease
392	loci	O
392	as	O
392	possible	O
392	disease	O
392	loci	O
392	in	O
392	the	O
392	family	O
392	studied	O
392	,	O
392	with	O
392	lod	O
392	scores	O
392	varying	O
392	between	O
392	-	O
392	2	O
392	.	O
393	5	O
393	and	O
393	-	O
393	6	O
393	.	O
394	0	O
394	0	O
394	.	O
395	Further	O
395	linkage	O
395	analyses	O
395	of	O
395	plausible	O
395	candidate	O
395	genes	O
395	highly	O
395	expressed	O
395	in	O
395	the	O
395	adult	O
395	human	O
395	heart	O
395	identified	O
395	ACTC	O
395	as	O
395	the	O
395	most	O
395	likely	O
395	disease	O
395	gene	O
395	,	O
395	showing	O
395	a	O
395	maximal	O
395	lod	O
395	score	O
395	of	O
395	3	O
395	.	O
396	6	O
396	6	O
396	.	O
397	Mutation	O
397	analysis	O
397	of	O
397	ACTC	O
397	revealed	O
397	an	O
397	Ala295Ser	O
397	mutation	O
397	in	O
397	exon	O
397	5	O
397	close	O
397	to	O
397	2	O
397	missense	O
397	mutations	O
397	recently	O
397	described	O
397	to	O
397	cause	O
397	the	O
397	inherited	O
397	form	O
397	of	O
397	idiopathic	B-Disease
397	dilated	I-Disease
397	cardiomyopathy	I-Disease
397	(	O
397	IDC	B-Disease
397	)	O
397	.	O
398	Overgrowth	B-Disease
398	of	I-Disease
398	oral	I-Disease
398	mucosa	I-Disease
398	and	I-Disease
398	facial	I-Disease
398	skin	I-Disease
398	,	O
398	a	O
398	novel	O
398	feature	O
398	of	O
398	aspartylglucosaminuria	B-Disease
398	.	O
399	Aspartylglucosaminuria	B-Disease
399	(	O
399	AGU	B-Disease
399	)	O
399	is	O
399	a	O
399	lysosomal	B-Disease
399	storage	I-Disease
399	disorder	I-Disease
399	caused	O
399	by	O
399	deficiency	B-Disease
399	of	I-Disease
399	aspartylglucosaminidase	I-Disease
399	(	O
399	AGA	O
399	)	O
399	.	O
400	The	O
400	main	O
400	symptom	O
400	is	O
400	progressive	O
400	mental	B-Disease
400	retardation	I-Disease
400	.	O
401	A	O
401	spectrum	O
401	of	O
401	different	O
401	mutations	O
401	has	O
401	been	O
401	reported	O
401	in	O
401	this	O
401	disease	O
401	,	O
401	one	O
401	missense	O
401	mutation	O
401	(	O
401	Cys163Ser	O
401	)	O
401	being	O
401	responsible	O
401	for	O
401	the	O
401	majority	O
401	of	O
401	Finnish	O
401	cases	O
401	.	O
402	We	O
402	were	O
402	able	O
402	to	O
402	examine	O
402	66	O
402	Finnish	O
402	AGU	B-Disease
402	patients	O
402	for	O
402	changes	O
402	in	O
402	the	O
402	oral	O
402	mucosa	O
402	and	O
402	44	O
402	of	O
402	these	O
402	for	O
402	changes	O
402	in	O
402	facial	O
402	skin	O
402	.	O
403	Biopsy	O
403	specimens	O
403	of	O
403	16	O
403	oral	O
403	lesions	O
403	,	O
403	12	O
403	of	O
403	them	O
403	associated	O
403	with	O
403	the	O
403	teeth	O
403	,	O
403	plus	O
403	two	O
403	facial	B-Disease
403	lesions	I-Disease
403	were	O
403	studied	O
403	histologically	O
403	.	O
404	Immunohistochemical	O
404	staining	O
404	for	O
404	AGA	O
404	was	O
404	performed	O
404	on	O
404	15	O
404	oral	O
404	specimens	O
404	.	O
405	Skin	O
405	was	O
405	seborrhoeic	O
405	in	O
405	adolescent	O
405	and	O
405	adult	O
405	patients	O
405	,	O
405	with	O
405	erythema	B-Disease
405	of	I-Disease
405	the	I-Disease
405	facial	I-Disease
405	skin	I-Disease
405	already	O
405	common	O
405	in	O
405	childhood	O
405	.	O
406	Of	O
406	44	O
406	patients	O
406	,	O
406	nine	O
406	(	O
406	20	O
406	%	O
406	)	O
406	had	O
406	facial	B-Disease
406	angiofibromas	I-Disease
406	,	O
406	tumours	B-Disease
406	primarily	O
406	occurring	O
406	in	O
406	association	O
406	with	O
406	tuberous	B-Disease
406	sclerosis	I-Disease
406	.	O
407	Oedemic	B-Disease
407	buccal	I-Disease
407	mucosa	I-Disease
407	(	O
407	leucoedema	B-Disease
407	)	O
407	and	O
407	gingival	B-Disease
407	overgrowths	I-Disease
407	were	O
407	more	O
407	frequent	O
407	in	O
407	AGU	B-Disease
407	patients	O
407	than	O
407	in	O
407	controls	O
407	(	O
407	p	O
407	<	O
407	0	O
407	.	O
407	001	O
407	)	O
407	.	O
408	Of	O
408	16	O
408	oral	B-Disease
408	mucosal	I-Disease
408	lesions	I-Disease
408	studied	O
408	histologically	O
408	,	O
408	15	O
408	represented	O
408	fibroepithelial	B-Disease
408	or	I-Disease
408	epithelial	I-Disease
408	hyperplasias	I-Disease
408	and	O
408	were	O
408	reactive	O
408	in	O
408	nature	O
408	.	O
409	Cytoplasmic	O
409	vacuolisation	O
409	was	O
409	evident	O
409	in	O
409	four	O
409	.	O
410	Immunohistochemically	O
410	,	O
410	expression	O
410	of	O
410	AGA	O
410	in	O
410	AGU	B-Disease
410	patients	O
410	mucosal	B-Disease
410	lesions	I-Disease
410	did	O
410	not	O
410	differ	O
410	from	O
410	that	O
410	seen	O
410	in	O
410	corresponding	O
410	lesions	O
410	of	O
410	normal	O
410	subjects	O
410	.	O
411	Thus	O
411	,	O
411	the	O
411	high	O
411	frequency	O
411	of	O
411	mucosal	B-Disease
411	overgrowth	I-Disease
411	in	O
411	AGU	B-Disease
411	patients	O
411	does	O
411	not	O
411	appear	O
411	to	O
411	be	O
411	directly	O
411	associated	O
411	with	O
411	lysosomal	O
411	storage	O
411	or	O
411	with	O
411	alterations	O
411	in	O
411	the	O
411	level	O
411	of	O
411	AGA	O
411	expression	O
411	.	O
412	Characterization	O
412	of	O
412	a	O
412	germline	O
412	mosaicism	O
412	in	O
412	families	O
412	with	O
412	Lowe	B-Disease
412	syndrome	I-Disease
412	,	O
412	and	O
412	identification	O
412	of	O
412	seven	O
412	novel	O
412	mutations	O
412	in	O
412	the	O
412	OCRL1	O
412	gene	O
412	.	O
413	The	O
413	oculocerebrorenal	B-Disease
413	syndrome	I-Disease
413	of	I-Disease
413	Lowe	I-Disease
413	(	O
413	OCRL	B-Disease
413	)	O
413	is	O
413	an	O
413	X	B-Disease
413	-	I-Disease
413	linked	I-Disease
413	disorder	I-Disease
413	characterized	O
413	by	O
413	major	O
413	abnormalities	B-Disease
413	of	I-Disease
413	eyes	I-Disease
413	,	I-Disease
413	nervous	I-Disease
413	system	I-Disease
413	,	I-Disease
413	and	I-Disease
413	kidneys	I-Disease
413	.	O
414	Mutations	O
414	in	O
414	the	O
414	OCRL1	O
414	gene	O
414	have	O
414	been	O
414	associated	O
414	with	O
414	the	O
414	disease	O
414	.	O
415	OCRL1	O
415	encodes	O
415	a	O
415	phosphatidylinositol	O
415	4	O
415	,	O
415	5	O
415	-	O
415	biphosphate	O
415	(	O
415	PtdIns	O
415	[	O
415	4	O
415	,	O
415	5	O
415	]	O
415	P2	O
415	)	O
415	5	O
415	-	O
415	phosphatase	O
415	.	O
416	We	O
416	have	O
416	examined	O
416	the	O
416	OCRL1	O
416	gene	O
416	in	O
416	eight	O
416	unrelated	O
416	patients	O
416	with	O
416	OCRL	B-Disease
416	and	O
416	have	O
416	found	O
416	seven	O
416	new	O
416	mutations	O
416	and	O
416	one	O
416	recurrent	O
416	in	O
416	-	O
416	frame	O
416	deletion	O
416	.	O
417	Among	O
417	the	O
417	new	O
417	mutations	O
417	,	O
417	two	O
417	nonsense	O
417	mutations	O
417	(	O
417	R317X	O
417	and	O
417	E558X	O
417	)	O
417	and	O
417	three	O
417	other	O
417	frameshift	O
417	mutations	O
417	caused	O
417	premature	O
417	termination	O
417	of	O
417	the	O
417	protein	O
417	.	O
418	A	O
418	missense	O
418	mutation	O
418	,	O
418	R483G	O
418	,	O
418	was	O
418	located	O
418	in	O
418	the	O
418	highly	O
418	conserved	O
418	PtdIns	O
418	(	O
418	4	O
418	,	O
418	5	O
418	)	O
418	P2	O
418	5	O
418	-	O
418	phosphatase	O
418	domain	O
418	.	O
419	Finally	O
419	,	O
419	one	O
419	frameshift	O
419	mutation	O
419	,	O
419	2799delC	O
419	,	O
419	modifies	O
419	the	O
419	C	O
419	-	O
419	terminal	O
419	part	O
419	of	O
419	OCRL1	O
419	,	O
419	with	O
419	an	O
419	extension	O
419	of	O
419	six	O
419	amino	O
419	acids	O
419	.	O
420	Altogether	O
420	,	O
420	70	O
420	%	O
420	of	O
420	missense	O
420	mutations	O
420	are	O
420	located	O
420	in	O
420	exon	O
420	15	O
420	,	O
420	and	O
420	52	O
420	%	O
420	of	O
420	all	O
420	mutations	O
420	cluster	O
420	in	O
420	exons	O
420	11	O
420	-	O
420	15	O
420	.	O
421	We	O
421	also	O
421	identified	O
421	two	O
421	new	O
421	microsatellite	O
421	markers	O
421	for	O
421	the	O
421	OCRL1	O
421	locus	O
421	,	O
421	and	O
421	we	O
421	detected	O
421	a	O
421	germline	O
421	mosaicism	O
421	in	O
421	one	O
421	family	O
421	.	O
422	This	O
422	observation	O
422	has	O
422	direct	O
422	implications	O
422	for	O
422	genetic	O
422	counseling	O
422	of	O
422	Lowe	B-Disease
422	syndrome	I-Disease
422	families	O
422	.	O
422	.	O
423	MEFV	O
423	-	O
423	Gene	O
423	analysis	O
423	in	O
423	armenian	O
423	patients	O
423	with	O
423	Familial	B-Disease
423	Mediterranean	I-Disease
423	fever	I-Disease
423	:	O
423	diagnostic	O
423	value	O
423	and	O
423	unfavorable	O
423	renal	O
423	prognosis	O
423	of	O
423	the	O
423	M694V	O
423	homozygous	O
423	genotype	O
423	-	O
423	genetic	O
423	and	O
423	therapeutic	O
423	implications	O
423	.	O
424	Familial	B-Disease
424	Mediterranean	I-Disease
424	fever	I-Disease
424	(	O
424	FMF	B-Disease
424	)	O
424	is	O
424	a	O
424	recessively	B-Disease
424	inherited	I-Disease
424	disorder	I-Disease
424	that	O
424	is	O
424	common	O
424	in	O
424	patients	O
424	of	O
424	Armenian	O
424	ancestry	O
424	.	O
425	To	O
425	date	O
425	,	O
425	its	O
425	diagnosis	O
425	,	O
425	which	O
425	can	O
425	be	O
425	made	O
425	only	O
425	retrospectively	O
425	,	O
425	is	O
425	one	O
425	of	O
425	exclusion	O
425	,	O
425	based	O
425	entirely	O
425	on	O
425	nonspecific	O
425	clinical	O
425	signs	O
425	that	O
425	result	O
425	from	O
425	serosal	B-Disease
425	inflammation	I-Disease
425	and	O
425	that	O
425	may	O
425	lead	O
425	to	O
425	unnecessary	O
425	surgery	O
425	.	O
426	Renal	B-Disease
426	amyloidosis	I-Disease
426	,	O
426	prevented	O
426	by	O
426	colchicine	O
426	,	O
426	is	O
426	the	O
426	most	O
426	severe	O
426	complication	O
426	of	O
426	FMF	B-Disease
426	,	O
426	a	O
426	disorder	O
426	associated	O
426	with	O
426	mutations	O
426	in	O
426	the	O
426	MEFV	O
426	gene	O
426	.	O
427	To	O
427	evaluate	O
427	the	O
427	diagnostic	O
427	and	O
427	prognostic	O
427	value	O
427	of	O
427	MEFV	O
427	-	O
427	gene	O
427	analysis	O
427	,	O
427	we	O
427	investigated	O
427	90	O
427	Armenian	O
427	FMF	B-Disease
427	patients	O
427	from	O
427	77	O
427	unrelated	O
427	families	O
427	that	O
427	were	O
427	not	O
427	selected	O
427	through	O
427	genetic	O
427	-	O
427	linkage	O
427	analysis	O
427	.	O
428	Eight	O
428	mutations	O
428	,	O
428	one	O
428	of	O
428	which	O
428	(	O
428	R408Q	O
428	)	O
428	is	O
428	new	O
428	,	O
428	were	O
428	found	O
428	to	O
428	account	O
428	for	O
428	93	O
428	%	O
428	of	O
428	the	O
428	163	O
428	independent	O
428	FMF	B-Disease
428	alleles	O
428	,	O
428	with	O
428	both	O
428	FMF	B-Disease
428	alleles	O
428	identified	O
428	in	O
428	89	O
428	%	O
428	of	O
428	the	O
428	patients	O
428	.	O
429	In	O
429	several	O
429	instances	O
429	,	O
429	family	O
429	studies	O
429	provided	O
429	molecular	O
429	evidence	O
429	for	O
429	pseudodominant	O
429	transmission	O
429	and	O
429	incomplete	O
429	penetrance	O
429	of	O
429	the	O
429	disease	O
429	phenotype	O
429	.	O
430	The	O
430	M694V	O
430	homozygous	O
430	genotype	O
430	was	O
430	found	O
430	to	O
430	be	O
430	associated	O
430	with	O
430	a	O
430	higher	O
430	prevalence	O
430	of	O
430	renal	B-Disease
430	amyloidosis	I-Disease
430	and	O
430	arthritis	B-Disease
430	,	O
430	compared	O
430	with	O
430	other	O
430	genotypes	O
430	(	O
430	P	O
430	=	O
430	.	O
430	0002	O
430	and	O
430	P	O
430	=	O
430	.	O
430	006	O
430	,	O
430	respectively	O
430	)	O
430	.	O
431	The	O
431	demonstration	O
431	of	O
431	both	O
431	the	O
431	diagnostic	O
431	and	O
431	prognostic	O
431	value	O
431	of	O
431	MEFV	O
431	analysis	O
431	and	O
431	particular	O
431	modes	O
431	of	O
431	inheritance	O
431	should	O
431	lead	O
431	to	O
431	new	O
431	ways	O
431	for	O
431	management	O
431	of	O
431	FMF	O
431	-	O
431	including	O
431	genetic	O
431	counseling	O
431	and	O
431	therapeutic	O
431	decisions	O
431	in	O
431	affected	O
431	families	O
431	.	O
432	Noninvasive	O
432	test	O
432	for	O
432	fragile	B-Disease
432	X	I-Disease
432	syndrome	I-Disease
432	,	O
432	using	O
432	hair	O
432	root	O
432	analysis	O
432	.	O
433	Identification	O
433	of	O
433	the	O
433	FMR1	O
433	gene	O
433	and	O
433	the	O
433	repeat	O
433	-	O
433	amplification	O
433	mechanism	O
433	causing	O
433	fragile	B-Disease
433	X	I-Disease
433	syndrome	I-Disease
433	led	O
433	to	O
433	development	O
433	of	O
433	reliable	O
433	DNA	O
433	-	O
433	based	O
433	diagnostic	O
433	methods	O
433	,	O
433	including	O
433	Southern	O
433	blot	O
433	hybridization	O
433	and	O
433	PCR	O
433	.	O
434	Both	O
434	methods	O
434	are	O
434	performed	O
434	on	O
434	DNA	O
434	isolated	O
434	from	O
434	peripheral	O
434	blood	O
434	cells	O
434	and	O
434	measure	O
434	the	O
434	repeat	O
434	size	O
434	in	O
434	FMR1	O
434	.	O
435	Using	O
435	an	O
435	immunocytochemical	O
435	technique	O
435	on	O
435	blood	O
435	smears	O
435	,	O
435	we	O
435	recently	O
435	developed	O
435	a	O
435	novel	O
435	test	O
435	for	O
435	identification	O
435	of	O
435	patients	O
435	with	O
435	fragile	B-Disease
435	X	I-Disease
435	syndrome	I-Disease
435	.	O
436	This	O
436	method	O
436	,	O
436	also	O
436	called	O
436	"	NN	O	O
436	antibody	NN	O	O
436	test	NN	O	O
436	,	NN	O	O
436	"	O
436	uses	O
436	monoclonal	O
436	antibodies	O
436	against	O
436	the	O
436	FMR1	O
436	gene	O
436	product	O
436	(	O
436	FMRP	O
436	)	O
436	and	O
436	is	O
436	based	O
436	on	O
436	absence	O
436	of	O
436	FMRP	O
436	in	O
436	patients	O
436	cells	O
436	.	O
437	Here	O
437	we	O
437	describe	O
437	a	O
437	new	O
437	diagnostic	O
437	test	O
437	to	O
437	identify	O
437	male	O
437	patients	O
437	with	O
437	fragile	B-Disease
437	X	I-Disease
437	syndrome	I-Disease
437	,	O
437	on	O
437	the	O
437	basis	O
437	of	O
437	lack	O
437	of	O
437	FMRP	O
437	in	O
437	their	O
437	hair	O
437	roots	O
437	.	O
438	Expression	O
438	of	O
438	FMRP	O
438	in	O
438	hair	O
438	roots	O
438	was	O
438	studied	O
438	by	O
438	use	O
438	of	O
438	an	O
438	FMRP	O
438	-	O
438	specific	O
438	antibody	O
438	test	O
438	,	O
438	and	O
438	the	O
438	percentage	O
438	of	O
438	FMRP	O
438	-	O
438	expressing	O
438	hair	O
438	roots	O
438	in	O
438	controls	O
438	and	O
438	in	O
438	male	O
438	fragile	B-Disease
438	X	I-Disease
438	patients	O
438	was	O
438	determined	O
438	.	O
439	Control	O
439	individuals	O
439	showed	O
439	clear	O
439	expression	O
439	of	O
439	FMRP	O
439	in	O
439	nearly	O
439	every	O
439	hair	O
439	root	O
439	,	O
439	whereas	O
439	male	O
439	fragile	B-Disease
439	X	I-Disease
439	patients	O
439	lacked	O
439	expression	O
439	of	O
439	FMRP	O
439	in	O
439	almost	O
439	all	O
439	their	O
439	hair	O
439	roots	O
439	.	O
440	Mentally	B-Disease
440	retarded	I-Disease
440	female	O
440	patients	O
440	with	O
440	a	O
440	full	O
440	mutation	O
440	showed	O
440	FMRP	O
440	expression	O
440	in	O
440	only	O
440	some	O
440	of	O
440	their	O
440	hair	O
440	roots	O
440	(	O
440	<	O
440	55	O
440	%	O
440	)	O
440	,	O
440	and	O
440	no	O
440	overlap	O
440	with	O
440	normal	O
440	female	O
440	controls	O
440	was	O
440	observed	O
440	.	O
441	The	O
441	advantages	O
441	of	O
441	this	O
441	test	O
441	are	O
441	(	O
441	1	O
441	)	O
441	plucking	O
441	of	O
441	hair	O
441	follicles	O
441	does	O
441	no	O
441	appreciable	O
441	harm	O
441	to	O
441	the	O
441	mentally	B-Disease
441	retarded	I-Disease
441	patient	O
441	,	O
441	(	O
441	2	O
441	)	O
441	hairs	O
441	can	O
441	be	O
441	sent	O
441	in	O
441	a	O
441	simple	O
441	envelope	O
441	to	O
441	a	O
441	diagnostic	O
441	center	O
441	,	O
441	and	O
441	(	O
441	3	O
441	)	O
441	the	O
441	result	O
441	of	O
441	the	O
441	test	O
441	is	O
441	available	O
441	within	O
441	5	O
441	h	O
441	of	O
441	plucking	O
441	.	O
442	In	O
442	addition	O
442	,	O
442	this	O
442	test	O
442	enabled	O
442	us	O
442	to	O
442	identify	O
442	two	O
442	fragile	B-Disease
442	X	I-Disease
442	patients	O
442	who	O
442	did	O
442	not	O
442	show	O
442	the	O
442	full	O
442	mutation	O
442	by	O
442	analysis	O
442	of	O
442	DNA	O
442	isolated	O
442	from	O
442	blood	O
442	cells	O
442	.	O
442	.	O
443	In	O
443	Swedish	O
443	families	O
443	with	O
443	hereditary	B-Disease
443	prostate	I-Disease
443	cancer	I-Disease
443	,	O
443	linkage	O
443	to	O
443	the	O
443	HPC1	O
443	locus	O
443	on	O
443	chromosome	O
443	1q24	O
443	-	O
443	25	O
443	is	O
443	restricted	O
443	to	O
443	families	O
443	with	O
443	early	O
443	-	O
443	onset	O
443	prostate	B-Disease
443	cancer	I-Disease
443	.	O
444	Prostate	B-Disease
444	cancer	I-Disease
444	clusters	O
444	in	O
444	some	O
444	families	O
444	,	O
444	and	O
444	an	O
444	estimated	O
444	5	O
444	%	O
444	-	O
444	10	O
444	%	O
444	of	O
444	all	O
444	cases	O
444	are	O
444	estimated	O
444	to	O
444	result	O
444	from	O
444	inheritance	O
444	of	O
444	prostate	O
444	cancer	O
444	-	O
444	susceptibility	O
444	genes	O
444	.	O
445	We	O
445	previously	O
445	reported	O
445	evidence	O
445	of	O
445	linkage	O
445	to	O
445	the	O
445	1q24	O
445	-	O
445	25	O
445	region	O
445	(	O
445	HPC1	O
445	)	O
445	in	O
445	91	O
445	North	O
445	American	O
445	and	O
445	Swedish	O
445	families	O
445	each	O
445	with	O
445	multiple	O
445	cases	O
445	of	O
445	prostate	B-Disease
445	cancer	I-Disease
445	(	O
445	Smith	O
445	et	O
445	al	O
445	.	O
445	1996	O
445	)	O
445	.	O
446	In	O
446	the	O
446	present	O
446	report	O
446	we	O
446	analyze	O
446	40	O
446	(	O
446	12	O
446	original	O
446	and	O
446	28	O
446	newly	O
446	identified	O
446	)	O
446	Swedish	O
446	families	O
446	with	O
446	hereditary	B-Disease
446	prostate	I-Disease
446	cancer	I-Disease
446	(	O
446	HPC	B-Disease
446	)	O
446	that	O
446	,	O
446	on	O
446	the	O
446	basis	O
446	of	O
446	40	O
446	markers	O
446	spanning	O
446	a	O
446	25	O
446	-	O
446	cM	O
446	interval	O
446	within	O
446	1q24	O
446	-	O
446	25	O
446	,	O
446	have	O
446	evidence	O
446	of	O
446	linkage	O
446	.	O
447	In	O
447	the	O
447	complete	O
447	set	O
447	of	O
447	families	O
447	,	O
447	a	O
447	maximum	O
447	two	O
447	-	O
447	point	O
447	LOD	O
447	score	O
447	of	O
447	1	O
447	.	O
448	10	O
448	was	O
448	observed	O
448	at	O
448	D1S413	O
448	(	O
448	at	O
448	a	O
448	recombination	O
448	fraction	O
448	[	O
448	theta	O
448	]	O
448	of	O
448	.	O
448	1	O
448	)	O
448	,	O
448	with	O
448	a	O
448	maximum	O
448	NPL	O
448	(	O
448	nonparametric	O
448	linkage	O
448	)	O
448	Z	O
448	score	O
448	of	O
448	1	O
448	.	O
449	64	O
449	at	O
449	D1S202	O
449	(	O
449	P	O
449	=	O
449	.	O
449	05	O
449	)	O
449	.	O
450	The	O
450	evidence	O
450	of	O
450	linkage	O
450	to	O
450	this	O
450	region	O
450	originated	O
450	almost	O
450	exclusively	O
450	from	O
450	the	O
450	subset	O
450	of	O
450	12	O
450	early	O
450	-	O
450	onset	O
450	(	O
450	age	O
450	<	O
450	65	O
450	years	O
450	)	O
450	families	O
450	,	O
450	which	O
450	yielded	O
450	a	O
450	maximum	O
450	LOD	O
450	score	O
450	of	O
450	2	O
450	.	O
451	38	O
451	at	O
451	D1S413	O
451	(	O
451	straight	O
451	theta	O
451	=	O
451	0	O
451	)	O
451	and	O
451	an	O
451	NPL	O
451	Z	O
451	score	O
451	of	O
451	1	O
451	.	O
452	95	O
452	at	O
452	D1S422	O
452	(	O
452	P	O
452	=	O
452	.	O
452	03	O
452	)	O
452	.	O
453	Estimates	O
453	from	O
453	heterogeneity	O
453	tests	O
453	suggest	O
453	that	O
453	,	O
453	within	O
453	Sweden	O
453	,	O
453	as	O
453	many	O
453	as	O
453	50	O
453	%	O
453	of	O
453	early	O
453	-	O
453	onset	O
453	families	O
453	had	O
453	evidence	O
453	of	O
453	linkage	O
453	to	O
453	the	O
453	HPC1	O
453	region	O
453	.	O
454	These	O
454	results	O
454	are	O
454	consistent	O
454	with	O
454	the	O
454	hypothesis	O
454	of	O
454	linkage	O
454	to	O
454	HPC1	O
454	in	O
454	a	O
454	subset	O
454	of	O
454	families	O
454	with	O
454	prostate	B-Disease
454	cancer	I-Disease
454	,	O
454	particularly	O
454	those	O
454	with	O
454	an	O
454	early	O
454	age	O
454	at	O
454	diagnosis	O
454	.	O
455	Molecular	O
455	basis	O
455	of	O
455	feline	O
455	beta	B-Disease
455	-	I-Disease
455	glucuronidase	I-Disease
455	deficiency	I-Disease
455	:	O
455	an	O
455	animal	O
455	model	O
455	of	O
455	mucopolysaccharidosis	B-Disease
455	VII	I-Disease
455	.	O
456	A	O
456	family	O
456	of	O
456	domestic	O
456	cats	O
456	was	O
456	found	O
456	that	O
456	exhibited	O
456	clinical	O
456	and	O
456	biochemical	O
456	abnormalities	O
456	consistent	O
456	with	O
456	mucopolysaccharidosis	B-Disease
456	VII	I-Disease
456	,	O
456	an	O
456	autosomal	B-Disease
456	recessive	I-Disease
456	lysosomal	I-Disease
456	storage	I-Disease
456	disorder	I-Disease
456	caused	O
456	by	O
456	beta	B-Disease
456	-	I-Disease
456	glucuronidase	I-Disease
456	deficiency	I-Disease
456	.	O
457	beta	O
457	-	O
457	Glucuronidase	O
457	activity	O
457	was	O
457	undetectable	O
457	in	O
457	affected	O
457	cat	O
457	fibroblasts	O
457	and	O
457	restored	O
457	by	O
457	retroviral	O
457	gene	O
457	transfer	O
457	of	O
457	rat	O
457	beta	O
457	-	O
457	glucuronidase	O
457	cDNA	O
457	.	O
458	beta	O
458	-	O
458	Glucuronidase	O
458	mRNA	O
458	was	O
458	normal	O
458	in	O
458	affected	O
458	cat	O
458	testis	O
458	by	O
458	Northern	O
458	blot	O
458	analysis	O
458	.	O
459	Normal	O
459	feline	O
459	beta	O
459	-	O
459	glucuronidase	O
459	cDNA	O
459	was	O
459	cloned	O
459	and	O
459	characterized	O
459	,	O
459	and	O
459	amplified	O
459	from	O
459	affected	O
459	cat	O
459	fibroblasts	O
459	by	O
459	reverse	O
459	transcription	O
459	coupled	O
459	polymerase	O
459	chain	O
459	reaction	O
459	.	O
460	There	O
460	was	O
460	a	O
460	G	O
460	-	O
460	to	O
460	-	O
460	A	O
460	transition	O
460	in	O
460	the	O
460	affected	O
460	cat	O
460	cDNA	O
460	that	O
460	predicted	O
460	an	O
460	E351K	O
460	substitution	O
460	,	O
460	destroyed	O
460	a	O
460	BssSI	O
460	site	O
460	,	O
460	and	O
460	eliminated	O
460	GUSB	O
460	enzymatic	O
460	activity	O
460	in	O
460	expression	O
460	studies	O
460	.	O
461	Multiple	O
461	species	O
461	comparison	O
461	and	O
461	the	O
461	crystal	O
461	structure	O
461	of	O
461	human	O
461	beta	O
461	-	O
461	glucuronidase	O
461	indicated	O
461	that	O
461	E351	O
461	is	O
461	a	O
461	highly	O
461	conserved	O
461	residue	O
461	most	O
461	likely	O
461	essential	O
461	in	O
461	maintenance	O
461	of	O
461	the	O
461	enzymes	O
461	conformation	O
461	.	O
462	BssSI	O
462	digestion	O
462	of	O
462	polymerase	O
462	chain	O
462	reaction	O
462	products	O
462	amplified	O
462	from	O
462	genomic	O
462	DNA	O
462	indicated	O
462	that	O
462	affected	O
462	cats	O
462	were	O
462	homozygous	O
462	and	O
462	cats	O
462	with	O
462	half	O
462	-	O
462	normal	O
462	beta	O
462	-	O
462	glucuronidase	O
462	activity	O
462	were	O
462	heterozygous	O
462	for	O
462	the	O
462	missense	O
462	mutation	O
462	.	O
463	Carriers	O
463	identified	O
463	in	O
463	this	O
463	manner	O
463	produced	O
463	affected	O
463	kittens	O
463	in	O
463	prospective	O
463	breedings	O
463	,	O
463	and	O
463	a	O
463	feline	O
463	MPS	B-Disease
463	VII	I-Disease
463	breeding	O
463	colony	O
463	has	O
463	been	O
463	established	O
463	.	O
463	.	O
464	A	O
464	common	O
464	molecular	O
464	basis	O
464	for	O
464	rearrangement	B-Disease
464	disorders	I-Disease
464	on	O
464	chromosome	O
464	22q11	O
464	.	O
465	The	O
465	chromosome	O
465	22q11	O
465	region	O
465	is	O
465	susceptible	O
465	to	O
465	rearrangements	O
465	that	O
465	are	O
465	associated	O
465	with	O
465	congenital	B-Disease
465	anomaly	I-Disease
465	disorders	I-Disease
465	and	O
465	malignant	B-Disease
465	tumors	I-Disease
465	.	O
466	Three	O
466	congenital	B-Disease
466	anomaly	I-Disease
466	disorders	I-Disease
466	,	O
466	cat	B-Disease
466	-	I-Disease
466	eye	I-Disease
466	syndrome	I-Disease
466	,	O
466	der	B-Disease
466	(	I-Disease
466	)	I-Disease
466	syndrome	I-Disease
466	and	O
466	velo	B-Disease
466	-	I-Disease
466	cardio	I-Disease
466	-	I-Disease
466	facial	I-Disease
466	syndrome	I-Disease
466	/	O
466	DiGeorge	B-Disease
466	syndrome	I-Disease
466	(	O
466	VCFS	B-Disease
466	/	O
466	DGS	B-Disease
466	)	O
466	are	O
466	associated	O
466	with	O
466	tetrasomy	O
466	,	O
466	trisomy	O
466	or	O
466	monosomy	O
466	,	O
466	respectively	O
466	,	O
466	for	O
466	part	O
466	of	O
466	chromosome	O
466	22q11	O
466	.	O
467	VCFS	B-Disease
467	/	O
467	DGS	B-Disease
467	is	O
467	the	O
467	most	O
467	common	O
467	syndrome	O
467	associated	O
467	with	O
467	22q11	O
467	rearrangements	O
467	.	O
468	In	O
468	order	O
468	to	O
468	determine	O
468	whether	O
468	there	O
468	are	O
468	particular	O
468	regions	O
468	on	O
468	22q11	O
468	that	O
468	are	O
468	prone	O
468	to	O
468	rearrangements	O
468	,	O
468	the	O
468	deletion	O
468	end	O
468	-	O
468	points	O
468	in	O
468	a	O
468	large	O
468	number	O
468	of	O
468	VCFS	B-Disease
468	/	O
468	DGS	B-Disease
468	patients	O
468	were	O
468	defined	O
468	by	O
468	haplotype	O
468	analysis	O
468	.	O
469	Most	O
469	VCFS	B-Disease
469	/	O
469	DGS	B-Disease
469	patients	O
469	have	O
469	a	O
469	similar	O
469	3	O
469	Mb	O
469	deletion	O
469	,	O
469	some	O
469	have	O
469	a	O
469	nested	O
469	distal	O
469	deletion	O
469	breakpoint	O
469	resulting	O
469	in	O
469	a	O
469	1	O
469	.	O
470	5	O
470	Mb	O
470	deletion	O
470	and	O
470	a	O
470	few	O
470	rare	O
470	patients	O
470	have	O
470	unique	O
470	deletions	O
470	or	O
470	translocations	O
470	.	O
471	The	O
471	high	O
471	prevalence	O
471	of	O
471	the	O
471	disorder	O
471	in	O
471	the	O
471	population	O
471	and	O
471	the	O
471	fact	O
471	that	O
471	most	O
471	cases	O
471	occur	O
471	sporadically	O
471	suggest	O
471	that	O
471	sequences	O
471	at	O
471	or	O
471	near	O
471	the	O
471	breakpoints	O
471	confer	O
471	susceptibility	O
471	to	O
471	chromosome	O
471	rearrangements	O
471	.	O
472	To	O
472	investigate	O
472	this	O
472	hypothesis	O
472	,	O
472	we	O
472	developed	O
472	hamster	O
472	-	O
472	human	O
472	somatic	O
472	hybrid	O
472	cell	O
472	lines	O
472	from	O
472	VCFS	B-Disease
472	/	O
472	DGS	B-Disease
472	patients	O
472	with	O
472	all	O
472	three	O
472	classes	O
472	of	O
472	deletions	O
472	and	O
472	we	O
472	now	O
472	show	O
472	that	O
472	the	O
472	breakpoints	O
472	occur	O
472	within	O
472	similar	O
472	low	O
472	copy	O
472	repeats	O
472	,	O
472	termed	O
472	LCR22s	O
472	.	O
473	To	O
473	support	O
473	this	O
473	idea	O
473	further	O
473	,	O
473	we	O
473	identified	O
473	a	O
473	family	O
473	that	O
473	carries	O
473	an	O
473	interstitial	O
473	duplication	O
473	of	O
473	the	O
473	same	O
473	3	O
473	Mb	O
473	region	O
473	that	O
473	is	O
473	deleted	O
473	in	O
473	VCFS	B-Disease
473	/	O
473	DGS	B-Disease
473	patients	O
473	.	O
474	We	O
474	present	O
474	models	O
474	to	O
474	explain	O
474	how	O
474	the	O
474	LCR22s	O
474	can	O
474	mediate	O
474	different	O
474	homologous	O
474	recombination	O
474	events	O
474	,	O
474	thereby	O
474	generating	O
474	a	O
474	number	O
474	of	O
474	rearrangements	O
474	that	O
474	are	O
474	associated	O
474	with	O
474	congenital	B-Disease
474	anomaly	I-Disease
474	disorders	I-Disease
474	.	O
475	We	O
475	identified	O
475	five	O
475	additional	O
475	copies	O
475	of	O
475	the	O
475	LCR22	O
475	on	O
475	22q11	O
475	that	O
475	may	O
475	mediate	O
475	other	O
475	rearrangements	O
475	leading	O
475	to	O
475	disease	O
475	.	O
476	Functional	O
476	consequences	O
476	of	O
476	mutations	O
476	in	O
476	the	O
476	early	O
476	growth	O
476	response	O
476	2	O
476	gene	O
476	(	O
476	EGR2	O
476	)	O
476	correlate	O
476	with	O
476	severity	O
476	of	O
476	human	O
476	myelinopathies	B-Disease
476	.	O
477	The	O
477	early	O
477	growth	O
477	response	O
477	2	O
477	gene	O
477	(	O
477	EGR2	O
477	)	O
477	is	O
477	a	O
477	Cys2His2zinc	O
477	finger	O
477	transcription	O
477	factor	O
477	which	O
477	is	O
477	thought	O
477	to	O
477	play	O
477	a	O
477	role	O
477	in	O
477	the	O
477	regulation	O
477	of	O
477	peripheral	O
477	nervous	O
477	system	O
477	myelination	O
477	.	O
478	This	O
478	idea	O
478	is	O
478	based	O
478	partly	O
478	on	O
478	the	O
478	phenotype	O
478	of	O
478	homozygous	O
478	Krox20	O
478	(	O
478	Egr2	O
478	)	O
478	knockout	O
478	mice	O
478	,	O
478	which	O
478	display	O
478	hypomyelination	B-Disease
478	of	I-Disease
478	the	I-Disease
478	PNS	I-Disease
478	and	O
478	a	O
478	block	O
478	of	O
478	Schwann	O
478	cells	O
478	at	O
478	an	O
478	early	O
478	stage	O
478	of	O
478	differentiation	O
478	.	O
479	Mutations	O
479	in	O
479	the	O
479	human	O
479	EGR2	O
479	gene	O
479	have	O
479	recently	O
479	been	O
479	associated	O
479	with	O
479	the	O
479	inherited	B-Disease
479	peripheral	I-Disease
479	neuropathies	I-Disease
479	Charcot	B-Disease
479	-	I-Disease
479	Marie	I-Disease
479	-	I-Disease
479	Tooth	I-Disease
479	type	I-Disease
479	1	I-Disease
479	,	O
479	Dejerine	B-Disease
479	-	I-Disease
479	Sottas	I-Disease
479	syndrome	I-Disease
479	and	O
479	congenital	B-Disease
479	hypomyelinating	I-Disease
479	neuropathy	I-Disease
479	.	O
480	Three	O
480	of	O
480	the	O
480	four	O
480	EGR2	O
480	mutations	O
480	are	O
480	dominant	O
480	and	O
480	occur	O
480	within	O
480	the	O
480	zinc	O
480	finger	O
480	DNA	O
480	-	O
480	binding	O
480	domain	O
480	.	O
481	The	O
481	fourth	O
481	mutation	O
481	is	O
481	recessive	O
481	and	O
481	affects	O
481	the	O
481	inhibitory	O
481	domain	O
481	(	O
481	R1	O
481	)	O
481	that	O
481	binds	O
481	the	O
481	NAB	O
481	transcriptional	O
481	co	O
481	-	O
481	repressors	O
481	.	O
482	A	O
482	combination	O
482	of	O
482	DNA	O
482	-	O
482	binding	O
482	assays	O
482	and	O
482	transcriptional	O
482	analysis	O
482	was	O
482	used	O
482	to	O
482	determine	O
482	the	O
482	functional	O
482	consequences	O
482	of	O
482	these	O
482	mutations	O
482	.	O
483	The	O
483	zinc	O
483	finger	O
483	mutations	O
483	affect	O
483	DNA	O
483	binding	O
483	and	O
483	the	O
483	amount	O
483	of	O
483	residual	O
483	binding	O
483	directly	O
483	correlates	O
483	with	O
483	disease	O
483	severity	O
483	.	O
484	The	O
484	R1	O
484	domain	O
484	mutation	O
484	prevents	O
484	interaction	O
484	of	O
484	EGR2	O
484	with	O
484	the	O
484	NAB	O
484	co	O
484	-	O
484	repressors	O
484	and	O
484	thereby	O
484	increases	O
484	transcriptional	O
484	activity	O
484	.	O
485	These	O
485	data	O
485	provide	O
485	insight	O
485	into	O
485	the	O
485	possible	O
485	disease	O
485	mechanisms	O
485	underlying	O
485	EGR2	O
485	mutations	O
485	and	O
485	the	O
485	reason	O
485	for	O
485	varying	O
485	severity	O
485	and	O
485	differences	O
485	in	O
485	inheritance	O
485	patterns	O
485	.	O
485	.	O
486	Autosomal	B-Disease
486	recessive	I-Disease
486	familial	I-Disease
486	neurohypophyseal	I-Disease
486	diabetes	I-Disease
486	insipidus	I-Disease
486	with	O
486	continued	O
486	secretion	O
486	of	O
486	mutant	O
486	weakly	O
486	active	O
486	vasopressin	O
486	.	O
487	Familial	B-Disease
487	neurohypophyseal	I-Disease
487	diabetes	I-Disease
487	insipidus	I-Disease
487	is	O
487	an	O
487	autosomal	B-Disease
487	dominant	I-Disease
487	disorder	I-Disease
487	characterized	O
487	by	O
487	post	O
487	-	O
487	natal	O
487	development	O
487	of	O
487	arginine	B-Disease
487	vasopressin	I-Disease
487	(	I-Disease
487	AVP	I-Disease
487	)	I-Disease
487	deficiency	I-Disease
487	due	O
487	to	O
487	mutations	O
487	in	O
487	the	O
487	AVP	O
487	gene	O
487	.	O
488	All	O
488	published	O
488	mutations	O
488	affect	O
488	the	O
488	signal	O
488	peptide	O
488	or	O
488	the	O
488	neurophysin	O
488	-	O
488	II	O
488	carrier	O
488	protein	O
488	and	O
488	are	O
488	presumed	O
488	to	O
488	interfere	O
488	with	O
488	processing	O
488	of	O
488	the	O
488	preprohormone	O
488	,	O
488	leading	O
488	to	O
488	neuronal	B-Disease
488	damage	I-Disease
488	.	O
489	We	O
489	studied	O
489	an	O
489	unusual	O
489	Palestinian	O
489	family	O
489	consisting	O
489	of	O
489	asymptomatic	O
489	first	O
489	cousin	O
489	parents	O
489	and	O
489	three	O
489	children	O
489	affected	O
489	with	O
489	neurohypophyseal	B-Disease
489	diabetes	I-Disease
489	insipidus	I-Disease
489	,	O
489	suggesting	O
489	autosomal	O
489	recessive	O
489	inheritance	O
489	.	O
490	All	O
490	three	O
490	affected	O
490	children	O
490	were	O
490	homozygous	O
490	and	O
490	the	O
490	parents	O
490	heterozygous	O
490	for	O
490	a	O
490	single	O
490	novel	O
490	mutation	O
490	(	O
490	C301	O
490	-	O
490	>	O
490	T	O
490	)	O
490	in	O
490	exon	O
490	1	O
490	,	O
490	replacing	O
490	Pro7	O
490	of	O
490	mature	O
490	AVP	O
490	with	O
490	Leu	O
490	(	O
490	Leu	O
490	-	O
490	AVP	O
490	)	O
490	.	O
491	Leu	O
491	-	O
491	AVP	O
491	was	O
491	a	O
491	weak	O
491	agonist	O
491	with	O
491	approximately	O
491	30	O
491	-	O
491	fold	O
491	reduced	O
491	binding	O
491	to	O
491	the	O
491	human	O
491	V2	O
491	receptor	O
491	.	O
492	Measured	O
492	by	O
492	radioimmunoassay	O
492	with	O
492	a	O
492	synthetic	O
492	Leu	O
492	-	O
492	AVP	O
492	standard	O
492	,	O
492	serum	O
492	Leu	O
492	-	O
492	AVP	O
492	levels	O
492	were	O
492	elevated	O
492	in	O
492	all	O
492	three	O
492	children	O
492	and	O
492	further	O
492	increased	O
492	during	O
492	water	O
492	deprivation	O
492	to	O
492	as	O
492	high	O
492	as	O
492	30	O
492	times	O
492	normal	O
492	.	O
493	The	O
493	youngest	O
493	child	O
493	(	O
493	2	O
493	years	O
493	old	O
493	)	O
493	was	O
493	only	O
493	mildly	O
493	affected	O
493	but	O
493	had	O
493	Leu	O
493	-	O
493	AVP	O
493	levels	O
493	similar	O
493	to	O
493	her	O
493	severely	O
493	affected	O
493	8	O
493	-	O
493	year	O
493	-	O
493	old	O
493	brother	O
493	,	O
493	suggesting	O
493	that	O
493	unknown	O
493	mechanisms	O
493	may	O
493	partially	O
493	compensate	O
493	for	O
493	a	O
493	deficiency	B-Disease
493	of	I-Disease
493	active	I-Disease
493	AVP	I-Disease
493	in	O
493	very	O
493	young	O
493	children	O
493	.	O
493	.	O
494	X	O
494	inactivation	O
494	and	O
494	somatic	O
494	cell	O
494	selection	O
494	rescue	O
494	female	O
494	mice	O
494	carrying	O
494	a	O
494	Piga	O
494	-	O
494	mutation	O
494	.	O
495	A	O
495	somatic	O
495	mutation	O
495	in	O
495	the	O
495	X	O
495	linked	O
495	PIGA	O
495	gene	O
495	is	O
495	responsible	O
495	for	O
495	the	O
495	deficiency	B-Disease
495	of	I-Disease
495	glycosyl	I-Disease
495	phosphatidylinositol	I-Disease
495	(	I-Disease
495	GPI	I-Disease
495	)	I-Disease
495	-	I-Disease
495	anchored	I-Disease
495	proteins	I-Disease
495	on	O
495	blood	O
495	cells	O
495	from	O
495	patients	O
495	with	O
495	paroxysmal	B-Disease
495	nocturnal	I-Disease
495	hemoglobinuria	I-Disease
495	.	O
496	No	O
496	inherited	O
496	form	O
496	of	O
496	GPI	B-Disease
496	-	I-Disease
496	anchor	I-Disease
496	deficiency	I-Disease
496	has	O
496	been	O
496	described	O
496	.	O
497	Because	O
497	conventional	O
497	Piga	O
497	gene	O
497	knockout	O
497	is	O
497	associated	O
497	with	O
497	high	O
497	embryonic	B-Disease
497	lethality	I-Disease
497	in	O
497	chimeric	O
497	mice	O
497	,	O
497	we	O
497	used	O
497	the	O
497	Cre	O
497	/	O
497	loxP	O
497	system	O
497	.	O
498	We	O
498	generated	O
498	mice	O
498	in	O
498	which	O
498	two	O
498	loxP	O
498	sites	O
498	flank	O
498	part	O
498	of	O
498	Piga	O
498	exon	O
498	2	O
498	.	O
499	After	O
499	crossbreeding	O
499	with	O
499	female	O
499	mice	O
499	of	O
499	the	O
499	EIIa	O
499	-	O
499	cre	O
499	strain	O
499	,	O
499	the	O
499	floxed	O
499	allele	O
499	undergoes	O
499	Cre	O
499	-	O
499	mediated	O
499	recombination	O
499	with	O
499	high	O
499	efficiency	O
499	during	O
499	early	O
499	embryonic	O
499	development	O
499	.	O
500	Because	O
500	of	O
500	X	O
500	chromosome	O
500	inactivation	O
500	,	O
500	female	O
500	offspring	O
500	are	O
500	mosaic	O
500	for	O
500	cells	O
500	that	O
500	express	O
500	or	O
500	lack	O
500	GPI	O
500	-	O
500	linked	O
500	proteins	O
500	.	O
501	Analysis	O
501	of	O
501	mosaic	O
501	mice	O
501	showed	O
501	that	O
501	in	O
501	heart	O
501	,	O
501	lung	O
501	,	O
501	kidney	O
501	,	O
501	brain	O
501	,	O
501	and	O
501	liver	O
501	,	O
501	mainly	O
501	wild	O
501	-	O
501	type	O
501	Piga	O
501	is	O
501	active	O
501	,	O
501	suggesting	O
501	that	O
501	these	O
501	tissues	O
501	require	O
501	GPI	O
501	-	O
501	linked	O
501	proteins	O
501	.	O
502	The	O
502	salient	O
502	exceptions	O
502	were	O
502	spleen	O
502	,	O
502	thymus	O
502	,	O
502	and	O
502	red	O
502	blood	O
502	cells	O
502	,	O
502	which	O
502	had	O
502	almost	O
502	equal	O
502	numbers	O
502	of	O
502	cells	O
502	expressing	O
502	the	O
502	wild	O
502	-	O
502	type	O
502	or	O
502	the	O
502	recombined	O
502	allele	O
502	,	O
502	implying	O
502	that	O
502	GPI	O
502	-	O
502	linked	O
502	proteins	O
502	are	O
502	not	O
502	essential	O
502	for	O
502	the	O
502	derivation	O
502	of	O
502	these	O
502	tissues	O
502	.	O
503	PIGA	O
503	(	O
503	-	O
503	)	O
503	cells	O
503	had	O
503	no	O
503	growth	O
503	advantage	O
503	,	O
503	suggesting	O
503	that	O
503	other	O
503	factors	O
503	are	O
503	needed	O
503	for	O
503	their	O
503	clonal	O
503	dominance	O
503	in	O
503	patients	O
503	with	O
503	paroxysmal	B-Disease
503	nocturnal	I-Disease
503	hemoglobinuria	I-Disease
503	.	O
503	.	O
504	The	O
504	C282Y	O
504	mutation	O
504	causing	O
504	hereditary	B-Disease
504	hemochromatosis	I-Disease
504	does	O
504	not	O
504	produce	O
504	a	O
504	allele	O
504	.	O
505	Targeted	O
505	mutagenesis	O
505	was	O
505	used	O
505	to	O
505	produce	O
505	two	O
505	mutations	O
505	in	O
505	the	O
505	murine	O
505	hemochromatosis	B-Disease
505	gene	O
505	(	O
505	Hfe	O
505	)	O
505	locus	O
505	.	O
506	The	O
506	first	O
506	mutation	O
506	deletes	O
506	a	O
506	large	O
506	portion	O
506	of	O
506	the	O
506	coding	O
506	sequence	O
506	,	O
506	generating	O
506	a	O
506	allele	O
506	.	O
507	The	O
507	second	O
507	mutation	O
507	introduces	O
507	a	O
507	missense	O
507	mutation	O
507	(	O
507	C282Y	O
507	)	O
507	into	O
507	the	O
507	Hfe	O
507	locus	O
507	,	O
507	but	O
507	otherwise	O
507	leaves	O
507	the	O
507	gene	O
507	intact	O
507	.	O
508	This	O
508	mutation	O
508	is	O
508	identical	O
508	to	O
508	the	O
508	disease	O
508	-	O
508	causing	O
508	mutation	O
508	in	O
508	patients	O
508	with	O
508	hereditary	B-Disease
508	hemochromatosis	I-Disease
508	.	O
509	Mice	O
509	carrying	O
509	each	O
509	of	O
509	the	O
509	two	O
509	mutations	O
509	were	O
509	bred	O
509	and	O
509	analyzed	O
509	.	O
510	Homozygosity	O
510	for	O
510	either	O
510	mutation	O
510	results	O
510	in	O
510	postnatal	O
510	iron	O
510	loading	O
510	.	O
511	The	O
511	effects	O
511	of	O
511	the	O
511	mutation	O
511	are	O
511	more	O
511	severe	O
511	than	O
511	the	O
511	effects	O
511	of	O
511	the	O
511	C282Y	O
511	mutation	O
511	.	O
512	Mice	O
512	heterozygous	O
512	for	O
512	either	O
512	mutation	O
512	accumulate	O
512	more	O
512	iron	O
512	than	O
512	normal	O
512	controls	O
512	.	O
513	Interestingly	O
513	,	O
513	although	O
513	liver	O
513	iron	O
513	stores	O
513	are	O
513	greatly	O
513	increased	O
513	,	O
513	splenic	O
513	iron	O
513	is	O
513	decreased	O
513	.	O
514	We	O
514	conclude	O
514	that	O
514	the	O
514	C282Y	O
514	mutation	O
514	does	O
514	not	O
514	result	O
514	in	O
514	a	O
514	allele	O
514	.	O
514	.	O
515	Genotype	O
515	-	O
515	phenotype	O
515	analysis	O
515	in	O
515	X	B-Disease
515	-	I-Disease
515	linked	I-Disease
515	Emery	I-Disease
515	-	I-Disease
515	Dreifuss	I-Disease
515	muscular	I-Disease
515	dystrophy	I-Disease
515	and	O
515	identification	O
515	of	O
515	a	O
515	missense	O
515	mutation	O
515	associated	O
515	with	O
515	a	O
515	milder	O
515	phenotype	O
515	.	O
516	Direct	O
516	sequencing	O
516	of	O
516	the	O
516	emerin	O
516	gene	O
516	in	O
516	22	O
516	families	O
516	with	O
516	Emery	B-Disease
516	-	I-Disease
516	Dreifuss	I-Disease
516	muscular	I-Disease
516	dystrophy	I-Disease
516	(	O
516	EMD	B-Disease
516	)	O
516	revealed	O
516	mutations	O
516	in	O
516	21	O
516	(	O
516	95	O
516	%	O
516	)	O
516	,	O
516	confirming	O
516	that	O
516	emerin	O
516	mutations	O
516	can	O
516	be	O
516	identified	O
516	in	O
516	the	O
516	majority	O
516	of	O
516	families	O
516	with	O
516	X	B-Disease
516	-	I-Disease
516	linked	I-Disease
516	EMD	I-Disease
516	.	O
517	Most	O
517	emerin	O
517	mutations	O
517	result	O
517	in	O
517	absence	O
517	of	O
517	the	O
517	protein	O
517	.	O
518	In	O
518	this	O
518	study	O
518	three	O
518	mutations	O
518	(	O
518	a	O
518	missense	O
518	mutation	O
518	Pro183Thr	O
518	and	O
518	two	O
518	in	O
518	-	O
518	frame	O
518	deletions	O
518	removing	O
518	residues	O
518	95	O
518	-	O
518	99	O
518	and	O
518	236	O
518	-	O
518	241	O
518	,	O
518	respectively	O
518	)	O
518	were	O
518	unusual	O
518	in	O
518	being	O
518	associated	O
518	with	O
518	expression	O
518	of	O
518	mutant	O
518	protein	O
518	.	O
519	The	O
519	phenotype	O
519	in	O
519	these	O
519	families	O
519	was	O
519	compared	O
519	in	O
519	detail	O
519	with	O
519	the	O
519	clinical	O
519	features	O
519	in	O
519	cases	O
519	with	O
519	typical	O
519	mutations	O
519	.	O
520	For	O
520	the	O
520	in	O
520	-	O
520	frame	O
520	deletions	O
520	there	O
520	were	O
520	no	O
520	significant	O
520	differences	O
520	.	O
521	In	O
521	the	O
521	family	O
521	with	O
521	the	O
521	missense	O
521	mutation	O
521	the	O
521	phenotype	O
521	was	O
521	milder	O
521	.	O
522	Age	O
522	at	O
522	onset	O
522	was	O
522	later	O
522	for	O
522	first	O
522	symptoms	O
522	and	O
522	for	O
522	development	O
522	of	O
522	ankle	B-Disease
522	contractures	I-Disease
522	and	O
522	muscle	B-Disease
522	weakness	I-Disease
522	.	O
523	These	O
523	findings	O
523	have	O
523	diagnostic	O
523	implications	O
523	as	O
523	well	O
523	as	O
523	pointing	O
523	to	O
523	functionally	O
523	important	O
523	regions	O
523	of	O
523	the	O
523	emerin	O
523	protein	O
523	.	O
523	.	O
524	Severe	O
524	clinical	O
524	expression	O
524	in	O
524	X	B-Disease
524	-	I-Disease
524	linked	I-Disease
524	Emery	I-Disease
524	-	I-Disease
524	Dreifuss	I-Disease
524	muscular	I-Disease
524	dystrophy	I-Disease
524	.	O
525	X	B-Disease
525	-	I-Disease
525	linked	I-Disease
525	Emery	I-Disease
525	-	I-Disease
525	Dreifuss	I-Disease
525	muscular	I-Disease
525	dystrophy	I-Disease
525	(	O
525	EDMD	B-Disease
525	)	O
525	is	O
525	a	O
525	relatively	O
525	rare	O
525	benign	B-Disease
525	neuromuscular	I-Disease
525	disorder	I-Disease
525	which	O
525	can	O
525	vary	O
525	remarkably	O
525	in	O
525	onset	O
525	,	O
525	course	O
525	and	O
525	severity	O
525	.	O
526	In	O
526	the	O
526	present	O
526	study	O
526	,	O
526	a	O
526	TCTAC	O
526	deletion	O
526	spanning	O
526	the	O
526	nucleotides	O
526	631	O
526	-	O
526	635	O
526	of	O
526	the	O
526	emerin	O
526	gene	O
526	caused	O
526	an	O
526	unusually	O
526	severe	O
526	disease	O
526	phenotype	O
526	including	O
526	loss	B-Disease
526	of	I-Disease
526	ambulation	I-Disease
526	and	O
526	severe	O
526	muscle	B-Disease
526	wasting	I-Disease
526	in	O
526	two	O
526	affected	O
526	brothers	O
526	.	O
527	The	O
527	same	O
527	mutation	O
527	has	O
527	been	O
527	reported	O
527	previously	O
527	in	O
527	an	O
527	unrelated	O
527	family	O
527	showing	O
527	a	O
527	significantly	O
527	milder	O
527	phenotype	O
527	.	O
528	The	O
528	interfamilial	O
528	heterogeneity	O
528	in	O
528	distribution	O
528	and	O
528	in	O
528	severity	O
528	of	O
528	the	O
528	features	O
528	in	O
528	the	O
528	two	O
528	families	O
528	point	O
528	to	O
528	environmental	O
528	or	O
528	genetic	O
528	modification	O
528	as	O
528	the	O
528	cause	O
528	of	O
528	clinical	O
528	variability	O
528	in	O
528	Emery	B-Disease
528	-	I-Disease
528	Dreifuss	I-Disease
528	muscular	I-Disease
528	dystrophy	I-Disease
528	.	O
528	.	O
529	Common	O
529	mutations	O
529	in	O
529	BRCA1	O
529	and	O
529	BRCA2	O
529	do	O
529	not	O
529	contribute	O
529	to	O
529	early	O
529	prostate	B-Disease
529	cancer	I-Disease
529	in	O
529	Jewish	O
529	men	O
529	.	O
530	BACKGROUND	O
530	Families	O
530	with	O
530	a	O
530	high	O
530	incidence	O
530	of	O
530	hereditary	B-Disease
530	breast	I-Disease
530	cancer	I-Disease
530	,	O
530	and	O
530	subsequently	O
530	shown	O
530	to	O
530	have	O
530	terminating	O
530	mutations	O
530	in	O
530	BRCA1	O
530	or	O
530	BRCA2	O
530	,	O
530	appear	O
530	to	O
530	have	O
530	a	O
530	higher	O
530	incidence	O
530	of	O
530	prostate	B-Disease
530	cancer	I-Disease
530	among	O
530	male	O
530	relatives	O
530	.	O
531	We	O
531	aimed	O
531	to	O
531	determine	O
531	whether	O
531	the	O
531	common	O
531	germline	O
531	mutations	O
531	of	O
531	BRCA1	O
531	or	O
531	BRCA2	O
531	in	O
531	Ashkenazi	O
531	Jewish	O
531	men	O
531	predisposed	O
531	them	O
531	to	O
531	prostate	B-Disease
531	cancer	I-Disease
531	.	O
532	METHODS	O
532	We	O
532	examined	O
532	genomic	O
532	DNA	O
532	from	O
532	83	O
532	(	O
532	for	O
532	BRCA1	O
532	185delAG	O
532	)	O
532	or	O
532	82	O
532	(	O
532	for	O
532	BRCA2	O
532	6174delT	O
532	)	O
532	Ashkenazi	O
532	Jewish	O
532	prostate	B-Disease
532	cancer	I-Disease
532	patients	O
532	,	O
532	most	O
532	of	O
532	whom	O
532	were	O
532	treated	O
532	at	O
532	a	O
532	relatively	O
532	young	O
532	age	O
532	,	O
532	for	O
532	the	O
532	most	O
532	common	O
532	germline	O
532	mutation	O
532	in	O
532	each	O
532	gene	O
532	seen	O
532	in	O
532	the	O
532	Ashkenazi	O
532	population	O
532	.	O
533	RESULTS	O
533	Our	O
533	study	O
533	should	O
533	have	O
533	been	O
533	able	O
533	to	O
533	detect	O
533	a	O
533	4	O
533	-	O
533	5	O
533	-	O
533	fold	O
533	increase	O
533	in	O
533	the	O
533	risk	O
533	of	O
533	prostate	B-Disease
533	cancer	I-Disease
533	due	O
533	to	O
533	mutation	O
533	of	O
533	BRCA1	O
533	or	O
533	BRCA2	O
533	.	O
534	However	O
534	,	O
534	only	O
534	one	O
534	(	O
534	1	O
534	.	O
534	15	O
534	%	O
534	;	O
534	95	O
534	%	O
534	confidence	O
534	interval	O
534	,	O
534	0	O
534	-	O
534	3	O
534	.	O
534	6	O
534	%	O
534	)	O
534	of	O
534	the	O
534	patients	O
534	was	O
534	heterozygous	O
534	for	O
534	the	O
534	BRCA1	O
534	mutant	O
534	allele	O
534	,	O
534	and	O
534	only	O
534	two	O
534	were	O
534	heterozygous	O
534	for	O
534	the	O
534	BRCA2	O
534	mutation	O
534	(	O
534	2	O
534	.	O
534	4	O
534	%	O
534	;	O
534	95	O
534	%	O
534	confidence	O
534	interval	O
534	,	O
534	0	O
534	-	O
534	6	O
534	.	O
534	2	O
534	%	O
534	)	O
534	.	O
535	CONCLUSIONS	O
535	The	O
535	incidence	O
535	of	O
535	each	O
535	of	O
535	the	O
535	germline	O
535	mutations	O
535	in	O
535	these	O
535	prostate	B-Disease
535	cancer	I-Disease
535	patients	O
535	closely	O
535	matched	O
535	their	O
535	incidence	O
535	(	O
535	about	O
535	1	O
535	%	O
535	)	O
535	in	O
535	the	O
535	general	O
535	Ashkenazi	O
535	Jewish	O
535	population	O
535	.	O
536	This	O
536	suggests	O
536	that	O
536	unlike	O
536	cases	O
536	of	O
536	breast	B-Disease
536	and	I-Disease
536	ovarian	I-Disease
536	cancers	I-Disease
536	,	O
536	mutations	O
536	in	O
536	BRCA1	O
536	or	O
536	BRCA2	O
536	do	O
536	not	O
536	significantly	O
536	predispose	O
536	men	O
536	to	O
536	prostate	B-Disease
536	cancer	I-Disease
537	Beta	O
537	-	O
537	catenin	O
537	accumulation	O
537	and	O
537	mutation	O
537	of	O
537	the	O
537	CTNNB1	O
537	gene	O
537	in	O
537	hepatoblastoma	B-Disease
537	.	O
538	Hepatoblastoma	B-Disease
538	is	O
538	a	O
538	rare	O
538	malignant	B-Disease
538	tumor	I-Disease
538	of	I-Disease
538	the	I-Disease
538	liver	I-Disease
538	that	O
538	occurs	O
538	in	O
538	children	O
538	at	O
538	an	O
538	average	O
538	age	O
538	of	O
538	2	O
538	to	O
538	3	O
538	years	O
538	.	O
539	Epidemiologic	O
539	studies	O
539	have	O
539	shown	O
539	an	O
539	increased	O
539	frequency	O
539	of	O
539	this	O
539	tumor	B-Disease
539	type	O
539	in	O
539	families	O
539	affected	O
539	by	O
539	adenomatous	B-Disease
539	polyposis	I-Disease
539	coli	I-Disease
539	.	O
540	In	O
540	addition	O
540	to	O
540	the	O
540	epidemiologic	O
540	data	O
540	,	O
540	molecular	O
540	genetic	O
540	studies	O
540	suggest	O
540	that	O
540	inactivation	O
540	of	O
540	the	O
540	APC	B-Disease
540	tumor	I-Disease
540	suppressor	O
540	may	O
540	be	O
540	involved	O
540	in	O
540	hepatoblastoma	B-Disease
540	tumorigenesis	O
540	.	O
541	A	O
541	major	O
541	function	O
541	of	O
541	APC	O
541	is	O
541	the	O
541	downregulation	O
541	of	O
541	beta	O
541	-	O
541	catenin	O
541	,	O
541	a	O
541	transcription	O
541	-	O
541	activating	O
541	protein	O
541	with	O
541	oncogenic	O
541	potential	O
541	.	O
542	In	O
542	an	O
542	ongoing	O
542	immunohistochemical	O
542	study	O
542	of	O
542	beta	O
542	-	O
542	catenin	O
542	expression	O
542	in	O
542	sporadic	O
542	cases	O
542	of	O
542	tumor	B-Disease
542	types	O
542	that	O
542	are	O
542	associated	O
542	with	O
542	adenomatous	B-Disease
542	polyposis	I-Disease
542	coli	I-Disease
542	,	O
542	we	O
542	observed	O
542	increased	O
542	beta	O
542	-	O
542	catenin	O
542	levels	O
542	in	O
542	the	O
542	cytoplasm	O
542	and	O
542	in	O
542	the	O
542	nuclei	O
542	of	O
542	three	O
542	investigated	O
542	hepatoblastomas	B-Disease
542	.	O
543	Sequencing	O
543	of	O
543	exon	O
543	3	O
543	of	O
543	the	O
543	beta	O
543	-	O
543	catenin	O
543	gene	O
543	(	O
543	CTNNB1	O
543	)	O
543	revealed	O
543	an	O
543	activating	O
543	mutation	O
543	in	O
543	one	O
543	of	O
543	the	O
543	tumor	B-Disease
543	samples	O
543	.	O
544	Our	O
544	data	O
544	indicate	O
544	for	O
544	the	O
544	first	O
544	time	O
544	that	O
544	beta	O
544	-	O
544	catenin	O
544	accumulation	O
544	may	O
544	play	O
544	a	O
544	role	O
544	in	O
544	the	O
544	development	O
544	of	O
544	hepatoblastoma	B-Disease
544	and	O
544	that	O
544	activating	O
544	mutations	O
544	of	O
544	the	O
544	beta	O
544	-	O
544	catenin	O
544	gene	O
544	may	O
544	substitute	O
544	biallelic	O
544	APC	O
544	inactivation	O
544	in	O
544	this	O
544	tumor	B-Disease
544	type	O
544	.	O
545	Genes	O
545	Chromosomes	O
545	Cancer	O
545	25	O
545	399	O
545	-	O
545	402	O
545	,	O
545	1999	O
545	.	O
545	.	O
546	Decrease	O
546	in	O
546	GTP	O
546	cyclohydrolase	O
546	I	O
546	gene	O
546	expression	O
546	caused	O
546	by	O
546	inactivation	O
546	of	O
546	one	O
546	allele	O
546	in	O
546	hereditary	B-Disease
546	progressive	I-Disease
546	dystonia	I-Disease
546	with	O
546	marked	O
546	diurnal	O
546	fluctuation	O
546	.	O
547	Hereditary	B-Disease
547	progressive	I-Disease
547	dystonia	I-Disease
547	with	O
547	marked	O
547	diurnal	O
547	fluctuation	O
547	(	O
547	HPD	B-Disease
547	;	O
547	dopa	B-Disease
547	-	I-Disease
547	responsive	I-Disease
547	dystonia	I-Disease
547	,	O
547	DRD	B-Disease
547	)	O
547	have	O
547	been	O
547	recently	O
547	found	O
547	to	O
547	be	O
547	caused	O
547	by	O
547	a	O
547	genetic	B-Disease
547	defect	I-Disease
547	in	O
547	the	O
547	GTP	O
547	cyclohydrolase	O
547	I	O
547	(	O
547	GCH1	O
547	)	O
547	gene	O
547	.	O
548	In	O
548	this	O
548	study	O
548	,	O
548	we	O
548	quantified	O
548	the	O
548	mRNA	O
548	level	O
548	of	O
548	GCH1	O
548	in	O
548	phytohemagglutinin	O
548	(	O
548	PHA	O
548	)	O
548	-	O
548	stimulated	O
548	mononuclear	O
548	blood	O
548	cells	O
548	from	O
548	one	O
548	Japanese	O
548	family	O
548	that	O
548	do	O
548	not	O
548	have	O
548	a	O
548	mutation	O
548	in	O
548	the	O
548	coding	O
548	region	O
548	or	O
548	splice	O
548	junctions	O
548	of	O
548	the	O
548	gene	O
548	.	O
549	The	O
549	results	O
549	showed	O
549	that	O
549	the	O
549	amounts	O
549	of	O
549	the	O
549	GCH1	O
549	mRNA	O
549	were	O
549	decreased	O
549	to	O
549	about	O
549	40	O
549	%	O
549	of	O
549	the	O
549	normal	O
549	level	O
549	in	O
549	both	O
549	patients	O
549	and	O
549	carriers	O
549	.	O
550	In	O
550	addition	O
550	,	O
550	we	O
550	found	O
550	that	O
550	the	O
550	GCH1	O
550	mRNA	O
550	was	O
550	transcribed	O
550	from	O
550	only	O
550	one	O
550	allele	O
550	,	O
550	indicating	O
550	that	O
550	the	O
550	other	O
550	allele	O
550	was	O
550	in	O
550	an	O
550	inactive	O
550	state	O
550	.	O
551	These	O
551	results	O
551	suggest	O
551	that	O
551	some	O
551	novel	O
551	mutations	O
551	should	O
551	exist	O
551	on	O
551	one	O
551	of	O
551	the	O
551	alleles	O
551	in	O
551	some	O
551	unknown	O
551	region	O
551	of	O
551	the	O
551	GCH1	O
551	gene	O
551	,	O
551	and	O
551	may	O
551	decrease	O
551	the	O
551	GCH1	O
551	mRNA	O
551	causing	O
551	the	O
551	HPD	B-Disease
551	/	O
551	DRD	B-Disease
551	symptoms	O
551	.	O
551	.	O
552	Sulfate	O
552	transport	O
552	is	O
552	not	O
552	impaired	O
552	in	O
552	pendred	B-Disease
552	syndrome	I-Disease
552	thyrocytes	O
552	.	O
553	Pendred	B-Disease
553	syndrome	I-Disease
553	is	O
553	the	O
553	most	O
553	common	O
553	form	O
553	of	O
553	syndromic	B-Disease
553	deafness	I-Disease
553	,	O
553	characterized	O
553	by	O
553	dyshormonogenic	B-Disease
553	goiter	I-Disease
553	associated	O
553	with	O
553	sensory	B-Disease
553	-	I-Disease
553	neural	I-Disease
553	deafness	I-Disease
553	.	O
554	The	O
554	gene	O
554	responsible	O
554	for	O
554	the	O
554	disease	O
554	(	O
554	PDS	B-Disease
554	)	O
554	has	O
554	been	O
554	cloned	O
554	,	O
554	but	O
554	its	O
554	function	O
554	is	O
554	as	O
554	yet	O
554	unknown	O
554	and	O
554	the	O
554	connection	O
554	between	O
554	thyroid	B-Disease
554	goiter	I-Disease
554	and	O
554	sensory	B-Disease
554	-	I-Disease
554	neural	I-Disease
554	deafness	I-Disease
554	remains	O
554	an	O
554	enigma	O
554	.	O
555	PDS	O
555	codes	O
555	for	O
555	a	O
555	novel	O
555	protein	O
555	,	O
555	pendrin	O
555	,	O
555	which	O
555	is	O
555	closely	O
555	related	O
555	to	O
555	a	O
555	number	O
555	of	O
555	sufate	O
555	transporters	O
555	.	O
556	Mechanisms	O
556	by	O
556	which	O
556	abnormal	O
556	sulfate	O
556	transport	O
556	could	O
556	deleteriously	O
556	affect	O
556	iodide	O
556	organification	O
556	have	O
556	been	O
556	proposed	O
556	.	O
557	We	O
557	tested	O
557	sulfate	O
557	transport	O
557	in	O
557	thyrocytes	O
557	obtained	O
557	from	O
557	Pendred	B-Disease
557	syndrome	I-Disease
557	patients	O
557	and	O
557	found	O
557	that	O
557	it	O
557	was	O
557	not	O
557	defective	O
557	.	O
558	This	O
558	suggests	O
558	that	O
558	pendrin	O
558	in	O
558	fact	O
558	may	O
558	not	O
558	be	O
558	a	O
558	sulfate	O
558	transporter	O
558	,	O
558	and	O
558	emphasizes	O
558	the	O
558	importance	O
558	of	O
558	functional	O
558	studies	O
558	on	O
558	this	O
558	novel	O
558	protein	O
558	.	O
558	.	O
559	Small	O
559	deletions	O
559	in	O
559	the	O
559	type	O
559	II	O
559	collagen	O
559	triple	O
559	helix	O
559	produce	O
559	kniest	B-Disease
559	dysplasia	I-Disease
559	.	O
560	Kniest	B-Disease
560	dysplasia	I-Disease
560	is	O
560	a	O
560	moderately	O
560	severe	O
560	type	B-Disease
560	II	I-Disease
560	collagenopathy	I-Disease
560	,	O
560	characterized	O
560	by	O
560	short	O
560	trunk	O
560	and	O
560	limbs	O
560	,	O
560	kyphoscoliosis	B-Disease
560	,	O
560	midface	B-Disease
560	hypoplasia	I-Disease
560	,	O
560	severe	O
560	myopia	B-Disease
560	,	O
560	and	O
560	hearing	B-Disease
560	loss	I-Disease
560	.	O
561	Mutations	O
561	in	O
561	the	O
561	gene	O
561	that	O
561	encodes	O
561	type	O
561	II	O
561	collagen	O
561	(	O
561	COL2A1	O
561	)	O
561	,	O
561	the	O
561	predominant	O
561	protein	O
561	of	O
561	cartilage	O
561	,	O
561	have	O
561	been	O
561	identified	O
561	in	O
561	a	O
561	number	O
561	of	O
561	individuals	O
561	with	O
561	Kniest	B-Disease
561	dysplasia	I-Disease
561	.	O
562	All	O
562	but	O
562	two	O
562	of	O
562	these	O
562	previously	O
562	described	O
562	mutations	O
562	cause	O
562	in	O
562	-	O
562	frame	O
562	deletions	O
562	in	O
562	type	O
562	II	O
562	collagen	O
562	,	O
562	either	O
562	by	O
562	small	O
562	deletions	O
562	in	O
562	the	O
562	gene	O
562	or	O
562	splice	O
562	site	O
562	alterations	O
562	.	O
563	Furthermore	O
563	,	O
563	all	O
563	but	O
563	one	O
563	of	O
563	these	O
563	mutations	O
563	is	O
563	located	O
563	between	O
563	exons	O
563	12	O
563	and	O
563	24	O
563	in	O
563	the	O
563	COL2A1	O
563	gene	O
563	.	O
564	We	O
564	used	O
564	heteroduplex	O
564	analysis	O
564	to	O
564	identify	O
564	sequence	O
564	anomalies	O
564	in	O
564	five	O
564	individuals	O
564	with	O
564	Kniest	B-Disease
564	dysplasia	I-Disease
564	.	O
565	Sequencing	O
565	of	O
565	the	O
565	index	O
565	patients	O
565	genomic	O
565	DNA	O
565	identified	O
565	four	O
565	new	O
565	dominant	O
565	mutations	O
565	in	O
565	COL2A1	O
565	that	O
565	result	O
565	in	O
565	Kniest	B-Disease
565	dysplasia	I-Disease
565	a	O
565	21	O
565	-	O
565	bp	O
565	deletion	O
565	in	O
565	exon	O
565	16	O
565	,	O
565	an	O
565	18	O
565	-	O
565	bp	O
565	deletion	O
565	in	O
565	exon	O
565	19	O
565	,	O
565	and	O
565	4	O
565	-	O
565	bp	O
565	deletions	O
565	in	O
565	the	O
565	splice	O
565	donor	O
565	sites	O
565	of	O
565	introns	O
565	14	O
565	and	O
565	20	O
565	.	O
566	A	O
566	previously	O
566	described	O
566	28	O
566	-	O
566	bp	O
566	deletion	O
566	at	O
566	the	O
566	COL2A1	O
566	exon	O
566	12	O
566	-	O
566	intron	O
566	12	O
566	junction	O
566	,	O
566	deleting	O
566	the	O
566	splice	O
566	donor	O
566	site	O
566	,	O
566	was	O
566	identified	O
566	in	O
566	the	O
566	fifth	O
566	case	O
566	.	O
567	The	O
567	latter	O
567	three	O
567	mutations	O
567	are	O
567	predicted	O
567	to	O
567	result	O
567	in	O
567	exon	O
567	skipping	O
567	in	O
567	the	O
567	mRNA	O
567	encoded	O
567	from	O
567	the	O
567	mutant	O
567	allele	O
567	.	O
568	These	O
568	data	O
568	suggest	O
568	that	O
568	Kniest	B-Disease
568	dysplasia	I-Disease
568	results	O
568	from	O
568	shorter	O
568	type	O
568	II	O
568	collagen	O
568	monomers	O
568	,	O
568	and	O
568	support	O
568	the	O
568	hypothesis	O
568	that	O
568	alteration	O
568	of	O
568	a	O
568	specific	O
568	COL2A1	O
568	domain	O
568	,	O
568	which	O
568	may	O
568	span	O
568	from	O
568	exons	O
568	12	O
568	to	O
568	24	O
568	,	O
568	leads	O
568	to	O
568	the	O
568	Kniest	B-Disease
568	dysplasia	I-Disease
568	phenotype	O
568	.	O
568	.	O
569	Classical	B-Disease
569	galactosemia	I-Disease
569	and	O
569	mutations	O
569	at	O
569	the	O
569	galactose	O
569	-	O
569	1	O
569	-	O
569	phosphate	O
569	uridyl	O
569	transferase	O
569	(	O
569	GALT	O
569	)	O
569	gene	O
569	.	O
570	Classical	B-Disease
570	galactosemia	I-Disease
570	is	O
570	caused	O
570	by	O
570	a	O
570	deficiency	O
570	in	O
570	activity	O
570	of	O
570	the	O
570	enzyme	O
570	galactose	O
570	-	O
570	1	O
570	-	O
570	phosphate	O
570	uridyl	O
570	transferase	O
570	(	O
570	GALT	O
570	)	O
570	,	O
570	which	O
570	,	O
570	in	O
570	turn	O
570	,	O
570	is	O
570	caused	O
570	by	O
570	mutations	O
570	at	O
570	the	O
570	GALT	O
570	gene	O
570	.	O
571	The	O
571	disorder	O
571	exhibits	O
571	considerable	O
571	allelic	O
571	heterogeneity	O
571	and	O
571	,	O
571	at	O
571	the	O
571	end	O
571	of	O
571	1998	O
571	,	O
571	more	O
571	than	O
571	150	O
571	different	O
571	base	O
571	changes	O
571	were	O
571	recorded	O
571	in	O
571	24	O
571	different	O
571	populations	O
571	and	O
571	ethnic	O
571	groups	O
571	in	O
571	15	O
571	countries	O
571	worldwide	O
571	.	O
572	The	O
572	mutations	O
572	most	O
572	frequently	O
572	cited	O
572	are	O
572	Q188R	O
572	,	O
572	K285N	O
572	,	O
572	S135L	O
572	,	O
572	and	O
572	N314D	O
572	.	O
573	Q188R	O
573	is	O
573	the	O
573	most	O
573	common	O
573	mutation	O
573	in	O
573	European	O
573	populations	O
573	or	O
573	in	O
573	those	O
573	predominantly	O
573	of	O
573	European	O
573	descent	O
573	.	O
574	Overall	O
574	,	O
574	it	O
574	accounts	O
574	for	O
574	60	O
574	-	O
574	70	O
574	%	O
574	of	O
574	mutant	O
574	chromosomes	O
574	,	O
574	but	O
574	there	O
574	are	O
574	significant	O
574	differences	O
574	in	O
574	its	O
574	relative	O
574	frequency	O
574	in	O
574	individual	O
574	populations	O
574	.	O
575	Individuals	O
575	homoallelic	O
575	for	O
575	Q188R	O
575	tend	O
575	to	O
575	have	O
575	a	O
575	severe	O
575	phenotype	O
575	and	O
575	this	O
575	is	O
575	in	O
575	keeping	O
575	with	O
575	the	O
575	virtually	O
575	complete	O
575	loss	O
575	of	O
575	enzyme	O
575	activity	O
575	observed	O
575	in	O
575	in	O
575	vitro	O
575	expression	O
575	systems	O
575	.	O
576	Globally	O
576	,	O
576	K285N	O
576	is	O
576	rarer	O
576	,	O
576	but	O
576	in	O
576	many	O
576	European	O
576	populations	O
576	it	O
576	can	O
576	be	O
576	found	O
576	on	O
576	25	O
576	-	O
576	40	O
576	%	O
576	of	O
576	mutant	O
576	chromosomes	O
576	.	O
577	It	O
577	is	O
577	invariably	O
577	associated	O
577	with	O
577	a	O
577	severe	O
577	phenotype	O
577	.	O
578	S135L	O
578	is	O
578	found	O
578	almost	O
578	exclusively	O
578	in	O
578	African	O
578	Americans	O
578	.	O
579	In	O
579	vitro	O
579	expression	O
579	results	O
579	are	O
579	discrepant	O
579	,	O
579	but	O
579	some	O
579	individuals	O
579	carrying	O
579	S135L	O
579	appear	O
579	to	O
579	exhibit	O
579	GALT	O
579	activity	O
579	in	O
579	some	O
579	tissues	O
579	.	O
580	Duarte	O
580	1	O
580	(	O
580	or	O
580	Los	O
580	Angeles	O
580	)	O
580	and	O
580	Duarte	O
580	2	O
580	(	O
580	or	O
580	Duarte	O
580	)	O
580	variants	O
580	carry	O
580	the	O
580	same	O
580	amino	O
580	acid	O
580	substitution	O
580	,	O
580	N314D	O
580	,	O
580	even	O
580	though	O
580	D1	O
580	is	O
580	associated	O
580	with	O
580	increased	O
580	erythrocyte	O
580	GALT	O
580	activity	O
580	and	O
580	D2	O
580	with	O
580	reduced	O
580	activity	O
580	.	O
581	N314D	O
581	is	O
581	in	O
581	linkage	O
581	disequilibrium	O
581	with	O
581	other	O
581	base	O
581	changes	O
581	that	O
581	differ	O
581	on	O
581	the	O
581	D1	O
581	and	O
581	D2	O
581	alleles	O
581	.	O
582	N314D	O
582	does	O
582	not	O
582	impair	O
582	GALT	O
582	activity	O
582	in	O
582	in	O
582	vitro	O
582	expression	O
582	systems	O
582	.	O
583	However	O
583	,	O
583	there	O
583	are	O
583	differences	O
583	in	O
583	the	O
583	abundance	O
583	of	O
583	GALT	O
583	protein	O
583	in	O
583	lymphoblastoid	O
583	cells	O
583	lines	O
583	from	O
583	D2	O
583	and	O
583	D1	O
583	individuals	O
583	.	O
584	It	O
584	is	O
584	unclear	O
584	whether	O
584	the	O
584	specific	O
584	molecular	O
584	changes	O
584	that	O
584	distinguish	O
584	the	O
584	D1	O
584	and	O
584	D2	O
584	alleles	O
584	account	O
584	for	O
584	the	O
584	different	O
584	activities	O
584	.	O
585	The	O
585	considerable	O
585	genetic	O
585	heterogeneity	O
585	documented	O
585	to	O
585	date	O
585	undoubtedly	O
585	contributes	O
585	to	O
585	the	O
585	phenotypic	O
585	heterogeneity	O
585	that	O
585	is	O
585	observed	O
585	in	O
585	galactosemia	B-Disease
585	.	O
586	The	O
586	additional	O
586	effects	O
586	of	O
586	nonallelic	O
586	variation	O
586	and	O
586	other	O
586	constitutional	O
586	factors	O
586	on	O
586	phenotypic	O
586	variability	O
586	remain	O
586	to	O
586	be	O
586	elucidated	O
586	.	O
586	.	O
587	Mutations	O
587	of	O
587	the	O
587	VHL	B-Disease
587	gene	O
587	in	O
587	sporadic	B-Disease
587	renal	I-Disease
587	cell	I-Disease
587	carcinoma	I-Disease
587	:	O
587	definition	O
587	of	O
587	a	O
587	risk	O
587	factor	O
587	for	O
587	VHL	B-Disease
587	patients	O
587	to	O
587	develop	O
587	an	O
587	RCC	B-Disease
587	.	O
588	To	O
588	investigate	O
588	the	O
588	nature	O
588	of	O
588	somatic	O
588	von	B-Disease
588	Hippel	I-Disease
588	-	I-Disease
588	Lindau	I-Disease
588	(	O
588	VHL	B-Disease
588	)	O
588	mutations	O
588	,	O
588	we	O
588	analyzed	O
588	173	O
588	primary	O
588	sporadic	O
588	human	O
588	renal	B-Disease
588	cell	I-Disease
588	carcinomas	I-Disease
588	for	O
588	mutations	O
588	of	O
588	the	O
588	VHL	B-Disease
588	tumor	I-Disease
588	suppressor	O
588	gene	O
588	,	O
588	using	O
588	polymerase	O
588	chain	O
588	reaction	O
588	(	O
588	PCR	O
588	)	O
588	and	O
588	single	O
588	-	O
588	strand	O
588	conformational	O
588	polymorphism	O
588	analysis	O
588	(	O
588	SSCP	O
588	)	O
588	of	O
588	DNA	O
588	.	O
589	We	O
589	detected	O
589	abnormal	O
589	SSCP	O
589	pattern	O
589	in	O
589	73	O
589	samples	O
589	.	O
590	After	O
590	sequencing	O
590	,	O
590	we	O
590	identified	O
590	microdeletions	O
590	in	O
590	58	O
590	%	O
590	of	O
590	cases	O
590	,	O
590	microinsertions	O
590	in	O
590	17	O
590	%	O
590	,	O
590	nonsense	O
590	mutations	O
590	in	O
590	8	O
590	%	O
590	,	O
590	and	O
590	missense	O
590	mutations	O
590	in	O
590	17	O
590	%	O
590	.	O
591	Among	O
591	these	O
591	mutations	O
591	,	O
591	50	O
591	%	O
591	correspond	O
591	to	O
591	new	O
591	mutations	O
591	.	O
592	VHL	B-Disease
592	mutations	O
592	were	O
592	found	O
592	only	O
592	in	O
592	the	O
592	nonpapillary	B-Disease
592	renal	I-Disease
592	cell	I-Disease
592	carcinoma	I-Disease
592	(	O
592	RCC	B-Disease
592	)	O
592	subtype	O
592	,	O
592	as	O
592	previously	O
592	reported	O
592	.	O
593	To	O
593	compare	O
593	somatic	O
593	and	O
593	germline	O
593	mutations	O
593	,	O
593	we	O
593	used	O
593	the	O
593	VHL	B-Disease
593	database	O
593	,	O
593	which	O
593	includes	O
593	507	O
593	mutations	O
593	.	O
594	The	O
594	study	O
594	of	O
594	mutational	O
594	events	O
594	revealed	O
594	a	O
594	significant	O
594	difference	O
594	between	O
594	somatic	O
594	and	O
594	germline	O
594	mutations	O
594	with	O
594	mutations	O
594	leading	O
594	to	O
594	truncated	O
594	proteins	O
594	observed	O
594	in	O
594	78	O
594	%	O
594	of	O
594	somatic	O
594	mutations	O
594	vs	O
594	only	O
594	37	O
594	%	O
594	in	O
594	germline	O
594	mutations	O
594	(	O
594	P	O
594	<	O
594	0	O
594	.	O
594	001	O
594	)	O
594	.	O
595	We	O
595	postulated	O
595	that	O
595	a	O
595	specific	O
595	pattern	O
595	of	O
595	VHL	B-Disease
595	mutations	O
595	is	O
595	associated	O
595	with	O
595	sporadic	B-Disease
595	RCC	I-Disease
595	.	O
596	This	O
596	pattern	O
596	corresponds	O
596	to	O
596	mutations	O
596	leading	O
596	mainly	O
596	to	O
596	truncated	O
596	proteins	O
596	with	O
596	few	O
596	specific	O
596	missense	O
596	mutations	O
596	.	O
597	We	O
597	then	O
597	analyzed	O
597	the	O
597	occurrence	O
597	of	O
597	RCC	B-Disease
597	in	O
597	VHL	B-Disease
597	families	O
597	,	O
597	based	O
597	on	O
597	the	O
597	nature	O
597	of	O
597	mutations	O
597	.	O
598	We	O
598	observed	O
598	RCC	B-Disease
598	in	O
598	at	O
598	least	O
598	one	O
598	member	O
598	of	O
598	the	O
598	VHL	B-Disease
598	families	O
598	in	O
598	77	O
598	%	O
598	of	O
598	cases	O
598	with	O
598	mutations	O
598	leading	O
598	to	O
598	truncated	O
598	proteins	O
598	versus	O
598	55	O
598	%	O
598	in	O
598	cases	O
598	with	O
598	missense	O
598	mutations	O
598	(	O
598	P	O
598	<	O
598	0	O
598	.	O
598	05	O
598	)	O
598	.	O
599	Thus	O
599	,	O
599	mutations	O
599	resulting	O
599	in	O
599	truncated	O
599	proteins	O
599	may	O
599	lead	O
599	to	O
599	a	O
599	higher	O
599	risk	O
599	of	O
599	RCC	B-Disease
599	in	O
599	VHL	B-Disease
599	patients	O
600	Defective	O
600	CTLA	O
600	-	O
600	4	O
600	cycling	O
600	pathway	O
600	in	O
600	Chediak	B-Disease
600	-	I-Disease
600	Higashi	I-Disease
600	syndrome	I-Disease
600	:	O
600	a	O
600	possible	O
600	mechanism	O
600	for	O
600	deregulation	O
600	of	O
600	T	O
600	lymphocyte	O
600	activation	O
600	.	O
601	Cytotoxic	O
601	T	O
601	lymphocyte	O
601	-	O
601	associated	O
601	antigen	O
601	4	O
601	(	O
601	CTLA	O
601	-	O
601	4	O
601	,	O
601	also	O
601	known	O
601	as	O
601	CD152	O
601	)	O
601	has	O
601	been	O
601	shown	O
601	to	O
601	play	O
601	a	O
601	major	O
601	role	O
601	in	O
601	the	O
601	regulation	O
601	of	O
601	T	O
601	cell	O
601	activation	O
601	.	O
602	Its	O
602	membrane	O
602	expression	O
602	is	O
602	highly	O
602	regulated	O
602	by	O
602	endocytosis	O
602	and	O
602	trafficking	O
602	through	O
602	the	O
602	secretory	O
602	lysosome	O
602	pathway	O
602	.	O
603	Chediak	B-Disease
603	-	I-Disease
603	Higashi	I-Disease
603	syndrome	I-Disease
603	(	O
603	CHS	B-Disease
603	)	O
603	is	O
603	an	O
603	inherited	B-Disease
603	disorder	I-Disease
603	caused	O
603	by	O
603	mutations	O
603	in	O
603	the	O
603	lysosomal	O
603	trafficking	O
603	regulator	O
603	gene	O
603	,	O
603	LYST	O
603	.	O
604	It	O
604	results	O
604	in	O
604	defective	O
604	membrane	O
604	targeting	O
604	of	O
604	the	O
604	proteins	O
604	present	O
604	in	O
604	secretory	O
604	lysosomes	O
604	,	O
604	and	O
604	it	O
604	is	O
604	associated	O
604	with	O
604	a	O
604	variety	O
604	of	O
604	features	O
604	,	O
604	including	O
604	a	O
604	lymphoproliferative	B-Disease
604	syndrome	I-Disease
604	with	O
604	hemophagocytosis	B-Disease
604	.	O
605	The	O
605	murine	O
605	equivalent	O
605	of	O
605	CHS	B-Disease
605	,	O
605	beige	O
605	mice	O
605	,	O
605	present	O
605	similar	O
605	characteristics	O
605	but	O
605	do	O
605	not	O
605	develop	O
605	the	O
605	lymphoproliferative	B-Disease
605	syndrome	I-Disease
605	.	O
606	We	O
606	show	O
606	herein	O
606	that	O
606	CTLA	O
606	-	O
606	4	O
606	is	O
606	present	O
606	in	O
606	enlarged	O
606	,	O
606	abnormal	O
606	vesicles	O
606	in	O
606	CHS	B-Disease
606	T	O
606	cells	O
606	and	O
606	is	O
606	not	O
606	properly	O
606	expressed	O
606	at	O
606	the	O
606	cell	O
606	surface	O
606	after	O
606	T	O
606	cell	O
606	activation	O
606	,	O
606	whereas	O
606	its	O
606	surface	O
606	expression	O
606	is	O
606	not	O
606	impaired	O
606	.	O
607	It	O
607	is	O
607	therefore	O
607	proposed	O
607	that	O
607	the	O
607	defective	O
607	surface	O
607	expression	O
607	of	O
607	CTLA	O
607	-	O
607	4	O
607	by	O
607	CHS	B-Disease
607	T	O
607	cells	O
607	is	O
607	involved	O
607	in	O
607	the	O
607	generation	O
607	of	O
607	lymphoproliferative	B-Disease
607	disease	I-Disease
607	.	O
608	This	O
608	observation	O
608	may	O
608	provide	O
608	insight	O
608	into	O
608	the	O
608	role	O
608	of	O
608	CTLA	O
608	-	O
608	4	O
608	in	O
608	humans	O
608	.	O
608	.	O
609	Proteolipoprotein	O
609	gene	O
609	analysis	O
609	in	O
609	82	O
609	patients	O
609	with	O
609	sporadic	O
609	Pelizaeus	B-Disease
609	-	I-Disease
609	Merzbacher	I-Disease
609	Disease	I-Disease
609	:	O
609	duplications	O
609	,	O
609	the	O
609	major	O
609	cause	O
609	of	O
609	the	O
609	disease	O
609	,	O
609	originate	O
609	more	O
609	frequently	O
609	in	O
609	male	O
609	germ	O
609	cells	O
609	,	O
609	but	O
609	point	O
609	mutations	O
609	do	O
609	not	O
609	.	O
610	The	O
610	Clinical	O
610	European	O
610	Network	O
610	on	O
610	Brain	B-Disease
610	Dysmyelinating	I-Disease
610	Disease	I-Disease
610	.	O
611	Pelizaeus	B-Disease
611	-	I-Disease
611	Merzbacher	I-Disease
611	Disease	I-Disease
611	(	O
611	PMD	B-Disease
611	)	O
611	is	O
611	an	O
611	X	B-Disease
611	-	I-Disease
611	linked	I-Disease
611	developmental	I-Disease
611	defect	I-Disease
611	of	I-Disease
611	myelination	I-Disease
611	affecting	O
611	the	O
611	central	O
611	nervous	O
611	system	O
611	and	O
611	segregating	O
611	with	O
611	the	O
611	proteolipoprotein	O
611	(	O
611	PLP	O
611	)	O
611	locus	O
611	.	O
612	Investigating	O
612	82	O
612	strictly	O
612	selected	O
612	sporadic	O
612	cases	O
612	of	O
612	PMD	B-Disease
612	,	O
612	we	O
612	found	O
612	PLP	O
612	mutations	O
612	in	O
612	77	O
612	%	O
612	;	O
612	complete	O
612	PLP	O
612	-	O
612	gene	O
612	duplications	O
612	were	O
612	the	O
612	most	O
612	frequent	O
612	abnormality	O
612	(	O
612	62	O
612	%	O
612	)	O
612	,	O
612	whereas	O
612	point	O
612	mutations	O
612	in	O
612	coding	O
612	or	O
612	splice	O
612	-	O
612	site	O
612	regions	O
612	of	O
612	the	O
612	gene	O
612	were	O
612	involved	O
612	less	O
612	frequently	O
612	(	O
612	38	O
612	%	O
612	)	O
612	.	O
613	We	O
613	analyzed	O
613	the	O
613	maternal	O
613	status	O
613	of	O
613	56	O
613	cases	O
613	to	O
613	determine	O
613	the	O
613	origin	O
613	of	O
613	both	O
613	types	O
613	of	O
613	PLP	O
613	mutation	O
613	,	O
613	since	O
613	this	O
613	is	O
613	relevant	O
613	to	O
613	genetic	O
613	counseling	O
613	.	O
614	In	O
614	the	O
614	22	O
614	point	O
614	mutations	O
614	,	O
614	68	O
614	%	O
614	of	O
614	mothers	O
614	were	O
614	heterozygous	O
614	for	O
614	the	O
614	mutation	O
614	,	O
614	a	O
614	value	O
614	identical	O
614	to	O
614	the	O
614	two	O
614	-	O
614	thirds	O
614	of	O
614	carrier	O
614	mothers	O
614	that	O
614	would	O
614	be	O
614	expected	O
614	if	O
614	there	O
614	were	O
614	an	O
614	equal	O
614	mutation	O
614	rate	O
614	in	O
614	male	O
614	and	O
614	female	O
614	germ	O
614	cells	O
614	.	O
615	In	O
615	sharp	O
615	contrast	O
615	,	O
615	among	O
615	the	O
615	34	O
615	duplicated	O
615	cases	O
615	,	O
615	91	O
615	%	O
615	of	O
615	mothers	O
615	were	O
615	carriers	O
615	,	O
615	a	O
615	value	O
615	significantly	O
615	(	O
615	chi2	O
615	=	O
615	9	O
615	.	O
615	20	O
615	,	O
615	P	O
615	<	O
615	.	O
615	01	O
615	)	O
615	in	O
615	favor	O
615	of	O
615	a	O
615	male	O
615	bias	O
615	,	O
615	with	O
615	an	O
615	estimation	O
615	of	O
615	the	O
615	male	O
615	/	O
615	female	O
615	mutation	O
615	frequency	O
615	(	O
615	k	O
615	)	O
615	of	O
615	9	O
615	.	O
616	3	O
616	3	O
616	.	O
617	Moreover	O
617	,	O
617	we	O
617	observed	O
617	the	O
617	occurrence	O
617	of	O
617	de	O
617	novo	O
617	mutations	O
617	between	O
617	parental	O
617	and	O
617	grandparental	O
617	generations	O
617	in	O
617	17	O
617	three	O
617	-	O
617	generation	O
617	families	O
617	,	O
617	which	O
617	allowed	O
617	a	O
617	direct	O
617	estimation	O
617	of	O
617	the	O
617	k	O
617	value	O
617	(	O
617	k	O
617	=	O
617	11	O
617	)	O
617	.	O
618	Again	O
618	,	O
618	a	O
618	significant	O
618	male	O
618	mutation	O
618	imbalance	O
618	was	O
618	observed	O
618	only	O
618	for	O
618	the	O
618	duplications	O
618	.	O
619	Chromosome	O
619	breakage	O
619	in	O
619	the	O
619	Prader	B-Disease
619	-	I-Disease
619	Willi	I-Disease
619	and	I-Disease
619	Angelman	I-Disease
619	syndromes	I-Disease
619	involves	O
619	recombination	O
619	between	O
619	large	O
619	,	O
619	transcribed	O
619	repeats	O
619	at	O
619	proximal	O
619	and	O
619	distal	O
619	breakpoints	O
619	.	O
620	Prader	B-Disease
620	-	I-Disease
620	Willi	I-Disease
620	syndrome	I-Disease
620	(	O
620	PWS	B-Disease
620	)	O
620	and	O
620	Angelman	B-Disease
620	syndrome	I-Disease
620	(	O
620	AS	B-Disease
620	)	O
620	are	O
620	distinct	O
620	neurobehavioral	B-Disease
620	disorders	I-Disease
620	that	O
620	most	O
620	often	O
620	arise	O
620	from	O
620	a	O
620	4	O
620	-	O
620	Mb	O
620	deletion	O
620	of	O
620	chromosome	O
620	15q11	O
620	-	O
620	q13	O
620	during	O
620	paternal	O
620	or	O
620	maternal	O
620	gametogenesis	O
620	,	O
620	respectively	O
620	.	O
621	At	O
621	a	O
621	de	O
621	novo	O
621	frequency	O
621	of	O
621	approximately	O
621	.	O
622	67	O
622	-	O
622	1	O
622	/	O
622	10	O
622	,	O
622	000	O
622	births	O
622	,	O
622	these	O
622	deletions	O
622	represent	O
622	a	O
622	common	O
622	structural	O
622	chromosome	O
622	change	O
622	in	O
622	the	O
622	human	O
622	genome	O
622	.	O
623	To	O
623	elucidate	O
623	the	O
623	mechanism	O
623	underlying	O
623	these	O
623	events	O
623	,	O
623	we	O
623	characterized	O
623	the	O
623	regions	O
623	that	O
623	contain	O
623	two	O
623	proximal	O
623	breakpoint	O
623	clusters	O
623	and	O
623	a	O
623	distal	O
623	cluster	O
623	.	O
624	Novel	O
624	DNA	O
624	sequences	O
624	potentially	O
624	associated	O
624	with	O
624	the	O
624	breakpoints	O
624	were	O
624	positionally	O
624	cloned	O
624	from	O
624	YACs	O
624	within	O
624	or	O
624	near	O
624	these	O
624	regions	O
624	.	O
625	Analyses	O
625	of	O
625	rodent	O
625	-	O
625	human	O
625	somatic	O
625	-	O
625	cell	O
625	hybrids	O
625	,	O
625	YAC	O
625	contigs	O
625	,	O
625	and	O
625	FISH	O
625	of	O
625	normal	O
625	or	O
625	rearranged	O
625	chromosomes	O
625	15	O
625	identified	O
625	duplicated	O
625	sequences	O
625	(	O
625	the	O
625	END	O
625	repeats	O
625	)	O
625	at	O
625	or	O
625	near	O
625	the	O
625	breakpoints	O
625	.	O
626	The	O
626	END	O
626	-	O
626	repeat	O
626	units	O
626	are	O
626	derived	O
626	from	O
626	large	O
626	genomic	O
626	duplications	O
626	of	O
626	a	O
626	novel	O
626	gene	O
626	(	O
626	HERC2	O
626	)	O
626	,	O
626	many	O
626	copies	O
626	of	O
626	which	O
626	are	O
626	transcriptionally	O
626	active	O
626	in	O
626	germline	O
626	tissues	O
626	.	O
627	One	O
627	of	O
627	five	O
627	PWS	B-Disease
627	/	O
627	AS	B-Disease
627	patients	O
627	analyzed	O
627	to	O
627	date	O
627	has	O
627	an	O
627	identifiable	O
627	,	O
627	rearranged	O
627	HERC2	O
627	transcript	O
627	derived	O
627	from	O
627	the	O
627	deletion	O
627	event	O
627	.	O
628	We	O
628	postulate	O
628	that	O
628	the	O
628	END	O
628	repeats	O
628	flanking	O
628	15q11	O
628	-	O
628	q13	O
628	mediate	O
628	homologous	O
628	recombination	O
628	resulting	O
628	in	O
628	deletion	O
628	.	O
629	Furthermore	O
629	,	O
629	we	O
629	propose	O
629	that	O
629	active	O
629	transcription	O
629	of	O
629	these	O
629	repeats	O
629	in	O
629	male	O
629	and	O
629	female	O
629	germ	O
629	cells	O
629	may	O
629	facilitate	O
629	the	O
629	homologous	O
629	recombination	O
629	process	O
629	.	O
630	Linkage	O
630	analysis	O
630	in	O
630	a	O
630	large	O
630	Brazilian	O
630	family	O
630	with	O
630	van	B-Disease
630	der	I-Disease
630	Woude	I-Disease
630	syndrome	I-Disease
630	suggests	O
630	the	O
630	existence	O
630	of	O
630	a	O
630	susceptibility	O
630	locus	O
630	for	O
630	cleft	B-Disease
630	palate	I-Disease
630	at	O
630	17p11	O
630	.	O
630	2	O
630	-	O
630	11	O
630	.	O
630	1	O
630	.	O
631	van	B-Disease
631	der	I-Disease
631	Woude	I-Disease
631	syndrome	I-Disease
631	(	O
631	VWS	B-Disease
631	)	O
631	,	O
631	which	O
631	has	O
631	been	O
631	mapped	O
631	to	O
631	1q32	O
631	-	O
631	41	O
631	,	O
631	is	O
631	characterized	O
631	by	O
631	pits	B-Disease
631	and	I-Disease
631	/	I-Disease
631	or	I-Disease
631	sinuses	I-Disease
631	of	I-Disease
631	the	I-Disease
631	lower	I-Disease
631	lip	I-Disease
631	,	O
631	cleft	B-Disease
631	lip	I-Disease
631	/	I-Disease
631	palate	I-Disease
631	(	O
631	CL	B-Disease
631	/	I-Disease
631	P	I-Disease
631	)	O
631	,	O
631	cleft	B-Disease
631	palate	I-Disease
631	(	O
631	CP	B-Disease
631	)	O
631	,	O
631	bifid	B-Disease
631	uvula	I-Disease
631	,	O
631	and	O
631	hypodontia	B-Disease
631	(	O
631	H	B-Disease
631	)	O
631	.	O
632	The	O
632	expression	O
632	of	O
632	VWS	B-Disease
632	,	O
632	which	O
632	has	O
632	incomplete	O
632	penetrance	O
632	,	O
632	is	O
632	highly	O
632	variable	O
632	.	O
633	Both	O
633	the	O
633	occurrence	O
633	of	O
633	CL	B-Disease
633	/	I-Disease
633	P	I-Disease
633	and	O
633	CP	B-Disease
633	within	O
633	the	O
633	same	O
633	genealogy	O
633	and	O
633	a	O
633	recurrence	O
633	risk	O
633	<	O
633	40	O
633	%	O
633	for	O
633	CP	B-Disease
633	among	O
633	descendants	O
633	with	O
633	VWS	B-Disease
633	have	O
633	suggested	O
633	that	O
633	the	O
633	development	O
633	of	O
633	clefts	B-Disease
633	in	O
633	this	O
633	syndrome	O
633	is	O
633	influenced	O
633	by	O
633	modifying	O
633	genes	O
633	at	O
633	other	O
633	loci	O
633	.	O
634	To	O
634	test	O
634	this	O
634	hypothesis	O
634	,	O
634	we	O
634	have	O
634	conducted	O
634	linkage	O
634	analysis	O
634	in	O
634	a	O
634	large	O
634	Brazilian	O
634	kindred	O
634	with	O
634	VWS	B-Disease
634	,	O
634	considering	O
634	as	O
634	affected	O
634	the	O
634	individuals	O
634	with	O
634	CP	B-Disease
634	,	O
634	regardless	O
634	of	O
634	whether	O
634	it	O
634	is	O
634	associated	O
634	with	O
634	other	O
634	clinical	O
634	signs	O
634	of	O
634	VWS	B-Disease
634	.	O
635	Our	O
635	results	O
635	suggest	O
635	that	O
635	a	O
635	gene	O
635	at	O
635	17p11	O
635	.	O
636	2	O
636	-	O
636	11	O
636	2	O
636	-	O
636	11	O
636	.	O
637	1	O
637	,	O
637	together	O
637	with	O
637	the	O
637	VWS	B-Disease
637	gene	O
637	at	O
637	1p32	O
637	-	O
637	41	O
637	,	O
637	enhances	O
637	the	O
637	probability	O
637	of	O
637	CP	B-Disease
637	in	O
637	an	O
637	individual	O
637	carrying	O
637	the	O
637	two	O
637	at	O
637	-	O
637	risk	O
637	genes	O
637	.	O
638	If	O
638	this	O
638	hypothesis	O
638	is	O
638	confirmed	O
638	in	O
638	other	O
638	VWS	B-Disease
638	pedigrees	O
638	,	O
638	it	O
638	will	O
638	represent	O
638	one	O
638	of	O
638	the	O
638	first	O
638	examples	O
638	of	O
638	a	O
638	gene	O
638	,	O
638	mapped	O
638	through	O
638	linkage	O
638	analysis	O
638	,	O
638	which	O
638	modifies	O
638	the	O
638	expression	O
638	of	O
638	a	O
638	major	O
638	gene	O
638	.	O
639	New	O
639	mutations	O
639	,	O
639	polymorphisms	O
639	,	O
639	and	O
639	rare	O
639	variants	O
639	in	O
639	the	O
639	ATM	O
639	gene	O
639	detected	O
639	by	O
639	a	O
639	novel	O
639	SSCP	O
639	strategy	O
639	.	O
640	The	O
640	gene	O
640	for	O
640	ataxia	B-Disease
640	-	I-Disease
640	telangiectasia	I-Disease
640	,	O
640	ATM	O
640	,	O
640	spans	O
640	about	O
640	150	O
640	kb	O
640	of	O
640	genomic	O
640	DNA	O
640	.	O
641	ATM	O
641	mutations	O
641	are	O
641	found	O
641	along	O
641	the	O
641	entire	O
641	gene	O
641	,	O
641	with	O
641	no	O
641	evidence	O
641	of	O
641	a	O
641	mutational	O
641	hot	O
641	spot	O
641	.	O
642	Using	O
642	DNA	O
642	as	O
642	the	O
642	starting	O
642	material	O
642	,	O
642	we	O
642	screened	O
642	the	O
642	ATM	O
642	gene	O
642	in	O
642	92	O
642	A	B-Disease
642	-	I-Disease
642	T	I-Disease
642	patients	O
642	,	O
642	using	O
642	an	O
642	optimized	O
642	single	O
642	-	O
642	strand	O
642	conformation	O
642	polymorphism	O
642	(	O
642	SSCP	O
642	)	O
642	technique	O
642	that	O
642	detected	O
642	all	O
642	previously	O
642	known	O
642	mutations	O
642	in	O
642	the	O
642	polymerase	O
642	chain	O
642	reaction	O
642	(	O
642	PCR	O
642	)	O
642	segments	O
642	being	O
642	analyzed	O
642	.	O
643	To	O
643	expedite	O
643	screening	O
643	,	O
643	we	O
643	sequentially	O
643	loaded	O
643	the	O
643	SSCP	O
643	gels	O
643	with	O
643	three	O
643	different	O
643	sets	O
643	of	O
643	PCR	O
643	products	O
643	that	O
643	were	O
643	pretested	O
643	to	O
643	avoid	O
643	overlapping	O
643	patterns	O
643	.	O
644	Many	O
644	of	O
644	the	O
644	DNA	O
644	changes	O
644	we	O
644	detected	O
644	were	O
644	intragenic	O
644	polymorphisms	O
644	.	O
645	Of	O
645	an	O
645	expected	O
645	177	O
645	unknown	O
645	mutations	O
645	,	O
645	we	O
645	detected	O
645	approximately	O
645	70	O
645	%	O
645	,	O
645	mostly	O
645	protein	O
645	truncating	O
645	mutations	O
645	(	O
645	that	O
645	would	O
645	have	O
645	been	O
645	detectable	O
645	by	O
645	protein	O
645	truncation	O
645	testing	O
645	if	O
645	RNA	O
645	starting	O
645	material	O
645	had	O
645	been	O
645	available	O
645	)	O
645	.	O
646	Mutations	O
646	have	O
646	now	O
646	been	O
646	defined	O
646	for	O
646	every	O
646	exon	O
646	of	O
646	the	O
646	ATM	O
646	gene	O
646	.	O
647	Herein	O
647	,	O
647	we	O
647	present	O
647	35	O
647	new	O
647	mutations	O
647	and	O
647	34	O
647	new	O
647	intragenic	O
647	polymorphisms	O
647	or	O
647	rare	O
647	variants	O
647	within	O
647	the	O
647	ATM	O
647	gene	O
647	.	O
648	This	O
648	is	O
648	the	O
648	most	O
648	comprehensive	O
648	compilation	O
648	of	O
648	ATM	O
648	polymorphisms	O
648	assembled	O
648	to	O
648	date	O
648	.	O
649	Defining	O
649	polymorphic	O
649	sites	O
649	as	O
649	well	O
649	as	O
649	mutations	O
649	in	O
649	the	O
649	ATM	O
649	gene	O
649	will	O
649	be	O
649	of	O
649	great	O
649	importance	O
649	in	O
649	designing	O
649	automated	O
649	methods	O
649	for	O
649	detecting	O
649	mutations	O
649	.	O
649	.	O
650	A	O
650	novel	O
650	frameshift	O
650	mutation	O
650	in	O
650	the	O
650	McLeod	B-Disease
650	syndrome	I-Disease
650	gene	O
650	in	O
650	a	O
650	Japanese	O
650	family	O
650	.	O
651	We	O
651	report	O
651	a	O
651	novel	O
651	mutation	O
651	in	O
651	the	O
651	XK	O
651	gene	O
651	(	O
651	XK	O
651	)	O
651	in	O
651	a	O
651	Japanese	O
651	patient	O
651	with	O
651	McLeod	B-Disease
651	syndrome	I-Disease
651	.	O
652	A	O
652	50	O
652	-	O
652	year	O
652	-	O
652	old	O
652	man	O
652	showed	O
652	progressive	O
652	muscular	B-Disease
652	atrophy	I-Disease
652	,	O
652	choreic	B-Disease
652	movement	I-Disease
652	,	O
652	elevated	O
652	level	O
652	of	O
652	serum	O
652	creatinine	O
652	kinase	O
652	,	O
652	and	O
652	acanthocytosis	B-Disease
652	.	O
653	The	O
653	expression	O
653	level	O
653	of	O
653	all	O
653	the	O
653	Kell	O
653	antigens	O
653	in	O
653	erythrocyte	O
653	was	O
653	decreased	O
653	and	O
653	molecular	O
653	analysis	O
653	revealed	O
653	a	O
653	single	O
653	-	O
653	base	O
653	(	O
653	T	O
653	)	O
653	deletion	O
653	at	O
653	the	O
653	nucleotide	O
653	position	O
653	1095	O
653	in	O
653	XK	O
653	.	O
654	This	O
654	deletion	O
654	caused	O
654	a	O
654	frameshift	O
654	in	O
654	translation	O
654	,	O
654	leading	O
654	to	O
654	a	O
654	premature	O
654	stop	O
654	codon	O
654	at	O
654	the	O
654	amino	O
654	acid	O
654	position	O
654	408	O
654	.	O
655	We	O
655	conclude	O
655	this	O
655	single	O
655	-	O
655	base	O
655	deletion	O
655	causes	O
655	defective	O
655	Kx	O
655	protein	O
655	,	O
655	which	O
655	is	O
655	responsible	O
655	for	O
655	the	O
655	McLeod	B-Disease
655	phenotype	O
655	in	O
655	this	O
655	patient	O
655	.	O
655	.	O
656	Association	O
656	of	O
656	BRCA1	O
656	with	O
656	the	O
656	hRad50	O
656	-	O
656	hMre11	O
656	-	O
656	p95	O
656	complex	O
656	and	O
656	the	O
656	DNA	O
656	damage	O
656	response	O
656	.	O
657	BRCA1	O
657	encodes	O
657	a	O
657	tumor	B-Disease
657	suppressor	O
657	that	O
657	is	O
657	mutated	O
657	in	O
657	familial	B-Disease
657	breast	I-Disease
657	and	I-Disease
657	ovarian	I-Disease
657	cancers	I-Disease
657	.	O
658	Here	O
658	,	O
658	it	O
658	is	O
658	shown	O
658	that	O
658	BRCA1	O
658	interacts	O
658	in	O
658	vitro	O
658	and	O
658	in	O
658	vivo	O
658	with	O
658	hRad50	O
658	,	O
658	which	O
658	forms	O
658	a	O
658	complex	O
658	with	O
658	hMre11	O
658	and	O
658	p95	O
658	/	O
658	nibrin	O
658	.	O
659	Upon	O
659	irradiation	O
659	,	O
659	BRCA1	O
659	was	O
659	detected	O
659	in	O
659	discrete	O
659	foci	O
659	in	O
659	the	O
659	nucleus	O
659	,	O
659	which	O
659	colocalize	O
659	with	O
659	hRad50	O
659	.	O
660	Formation	O
660	of	O
660	irradiation	O
660	-	O
660	induced	O
660	foci	O
660	positive	O
660	for	O
660	BRCA1	O
660	,	O
660	hRad50	O
660	,	O
660	hMre11	O
660	,	O
660	or	O
660	p95	O
660	was	O
660	dramatically	O
660	reduced	O
660	in	O
660	HCC	O
660	/	O
660	1937	O
660	breast	B-Disease
660	cancer	I-Disease
660	cells	O
660	carrying	O
660	a	O
660	homozygous	O
660	mutation	O
660	in	O
660	BRCA1	O
660	but	O
660	was	O
660	restored	O
660	by	O
660	transfection	O
660	of	O
660	wild	O
660	-	O
660	type	O
660	BRCA1	O
660	.	O
661	Ectopic	O
661	expression	O
661	of	O
661	wild	O
661	-	O
661	type	O
661	,	O
661	but	O
661	not	O
661	mutated	O
661	,	O
661	BRCA1	O
661	in	O
661	these	O
661	cells	O
661	rendered	O
661	them	O
661	less	O
661	sensitive	O
661	to	O
661	the	O
661	DNA	O
661	damage	O
661	agent	O
661	,	O
661	methyl	O
661	methanesulfonate	O
661	.	O
662	These	O
662	data	O
662	suggest	O
662	that	O
662	BRCA1	O
662	is	O
662	important	O
662	for	O
662	the	O
662	cellular	O
662	responses	O
662	to	O
662	DNA	O
662	damage	O
662	that	O
662	are	O
662	mediated	O
662	by	O
662	the	O
662	hRad50	O
662	-	O
662	hMre11	O
662	-	O
662	p95	O
662	complex	O
662	.	O
662	.	O
663	Relationship	O
663	among	O
663	genotype	O
663	,	O
663	biochemical	O
663	phenotype	O
663	,	O
663	and	O
663	cognitive	O
663	performance	O
663	in	O
663	females	O
663	with	O
663	phenylalanine	B-Disease
663	hydroxylase	I-Disease
663	deficiency	I-Disease
663	:	O
663	report	O
663	from	O
663	the	O
663	Maternal	B-Disease
663	Phenylketonuria	I-Disease
663	Collaborative	O
663	Study	O
663	.	O
664	OBJECTIVE	O
664	To	O
664	examine	O
664	the	O
664	relationship	O
664	of	O
664	phenylalanine	O
664	hydroxylase	O
664	(	O
664	PAH	O
664	)	O
664	genotypes	O
664	to	O
664	biochemical	O
664	phenotype	O
664	and	O
664	cognitive	O
664	development	O
664	in	O
664	maternal	B-Disease
664	phenylketonuria	I-Disease
664	(	O
664	PKU	B-Disease
664	)	O
664	.	O
665	METHODOLOGY	O
665	PAH	O
665	gene	O
665	mutations	O
665	were	O
665	examined	O
665	in	O
665	222	O
665	hyperphenylalaninemic	B-Disease
665	females	O
665	enrolled	O
665	in	O
665	the	O
665	Maternal	B-Disease
665	PKU	I-Disease
665	Collaborative	O
665	Study	O
665	(	O
665	MPKUCS	O
665	)	O
665	.	O
666	A	O
666	total	O
666	of	O
666	84	O
666	different	O
666	mutations	O
666	were	O
666	detected	O
666	,	O
666	and	O
666	complete	O
666	genotype	O
666	was	O
666	obtained	O
666	in	O
666	199	O
666	individuals	O
666	.	O
667	Based	O
667	on	O
667	previous	O
667	knowledge	O
667	about	O
667	mutation	O
667	-	O
667	phenotype	O
667	associations	O
667	,	O
667	78	O
667	of	O
667	the	O
667	mutations	O
667	could	O
667	be	O
667	assigned	O
667	to	O
667	one	O
667	of	O
667	four	O
667	classes	O
667	of	O
667	severity	O
667	(	O
667	severe	O
667	PKU	B-Disease
667	,	O
667	moderate	O
667	PKU	B-Disease
667	,	O
667	mild	O
667	PKU	B-Disease
667	,	O
667	and	O
667	mild	B-Disease
667	hyperphenylalaninemia	I-Disease
667	[	O
667	MHP	B-Disease
667	]	O
667	)	O
667	.	O
668	Then	O
668	,	O
668	189	O
668	MPKUCS	O
668	subjects	O
668	were	O
668	grouped	O
668	according	O
668	to	O
668	the	O
668	various	O
668	combinations	O
668	of	O
668	mutation	O
668	classifications	O
668	.	O
669	The	O
669	sample	O
669	sizes	O
669	were	O
669	large	O
669	enough	O
669	for	O
669	statistical	O
669	testing	O
669	in	O
669	four	O
669	groups	O
669	with	O
669	at	O
669	least	O
669	one	O
669	mutation	O
669	that	O
669	completely	O
669	abolishes	O
669	enzyme	O
669	activity	O
669	.	O
670	These	O
670	patients	O
670	are	O
670	considered	O
670	functionally	O
670	hemizygous	O
670	.	O
671	RESULTS	O
671	The	O
671	biochemical	O
671	phenotype	O
671	predicted	O
671	from	O
671	the	O
671	genotype	O
671	in	O
671	functionally	O
671	hemizygous	O
671	patients	O
671	was	O
671	related	O
671	significantly	O
671	to	O
671	the	O
671	assigned	O
671	phenylalanine	O
671	level	O
671	.	O
672	Cognitive	O
672	performance	O
672	(	O
672	IQ	O
672	)	O
672	was	O
672	also	O
672	significantly	O
672	related	O
672	to	O
672	genotype	O
672	.	O
673	The	O
673	IQ	O
673	of	O
673	PAH	B-Disease
673	-	I-Disease
673	deficient	I-Disease
673	mothers	O
673	with	O
673	a	O
673	severe	O
673	PKU	B-Disease
673	mutation	O
673	in	O
673	combination	O
673	with	O
673	a	O
673	MHP	B-Disease
673	mutation	O
673	or	O
673	a	O
673	mild	O
673	PKU	B-Disease
673	mutation	O
673	was	O
673	99	O
673	and	O
673	96	O
673	,	O
673	respectively	O
673	,	O
673	whereas	O
673	the	O
673	IQ	O
673	of	O
673	PKU	B-Disease
673	mothers	O
673	with	O
673	two	O
673	severe	O
673	PKU	B-Disease
673	mutations	O
673	or	O
673	with	O
673	one	O
673	severe	O
673	and	O
673	one	O
673	moderate	O
673	PKU	B-Disease
673	mutation	O
673	was	O
673	83	O
673	and	O
673	84	O
673	,	O
673	respectively	O
673	.	O
674	Of	O
674	the	O
674	patients	O
674	with	O
674	PKU	B-Disease
674	,	O
674	92	O
674	%	O
674	had	O
674	been	O
674	treated	O
674	during	O
674	childhood	O
674	.	O
675	Those	O
675	who	O
675	were	O
675	untreated	O
675	or	O
675	treated	O
675	late	O
675	had	O
675	lower	O
675	than	O
675	average	O
675	IQ	O
675	scores	O
675	for	O
675	their	O
675	group	O
675	of	O
675	mutation	O
675	combinations	O
675	.	O
676	Females	O
676	with	O
676	moderate	O
676	or	O
676	mild	O
676	PKU	B-Disease
676	who	O
676	were	O
676	treated	O
676	early	O
676	and	O
676	treated	O
676	for	O
676	>	O
676	6	O
676	years	O
676	showed	O
676	IQ	O
676	scores	O
676	10	O
676	points	O
676	above	O
676	average	O
676	for	O
676	their	O
676	group	O
676	.	O
677	CONCLUSIONS	O
677	The	O
677	reproductive	O
677	outcome	O
677	in	O
677	maternal	B-Disease
677	phenylketonuria	I-Disease
677	is	O
677	dependent	O
677	on	O
677	prenatal	O
677	metabolic	O
677	control	O
677	and	O
677	postnatal	O
677	environmental	O
677	circumstances	O
677	.	O
678	Both	O
678	factors	O
678	depend	O
678	on	O
678	the	O
678	intellectual	O
678	resources	O
678	of	O
678	the	O
678	mother	O
678	with	O
678	PKU	B-Disease
678	.	O
679	The	O
679	significant	O
679	relationship	O
679	among	O
679	genotype	O
679	,	O
679	biochemical	O
679	phenotype	O
679	,	O
679	and	O
679	cognitive	O
679	performance	O
679	observed	O
679	in	O
679	the	O
679	present	O
679	study	O
679	is	O
679	of	O
679	importance	O
679	for	O
679	the	O
679	development	O
679	of	O
679	an	O
679	optimal	O
679	strategy	O
679	for	O
679	future	O
679	treatment	O
679	of	O
679	females	O
679	with	O
679	PKU	B-Disease
679	who	O
679	plan	O
679	pregnancy	O
679	.	O
679	.	O
680	Spinal	B-Disease
680	xanthomatosis	I-Disease
680	:	O
680	a	O
680	variant	O
680	of	O
680	cerebrotendinous	B-Disease
680	xanthomatosis	I-Disease
680	.	O
681	We	O
681	describe	O
681	seven	O
681	Dutch	O
681	patients	O
681	from	O
681	six	O
681	families	O
681	with	O
681	a	O
681	slowly	O
681	progressive	O
681	,	O
681	mainly	O
681	spinal	B-Disease
681	cord	I-Disease
681	syndrome	I-Disease
681	that	O
681	remained	O
681	for	O
681	many	O
681	years	O
681	the	O
681	sole	O
681	expression	O
681	of	O
681	cerebrotendinous	B-Disease
681	xanthomatosis	I-Disease
681	(	O
681	CTX	B-Disease
681	)	O
681	.	O
682	MRI	O
682	demonstrated	O
682	white	B-Disease
682	matter	I-Disease
682	abnormalities	I-Disease
682	in	O
682	the	O
682	lateral	O
682	and	O
682	dorsal	O
682	columns	O
682	of	O
682	the	O
682	spinal	O
682	cord	O
682	.	O
683	Post	O
683	-	O
683	mortem	O
683	examination	O
683	of	O
683	one	O
683	of	O
683	the	O
683	patients	O
683	showed	O
683	extensive	O
683	myelin	O
683	loss	O
683	in	O
683	these	O
683	columns	O
683	.	O
684	An	O
684	array	O
684	of	O
684	genotypes	O
684	was	O
684	found	O
684	in	O
684	these	O
684	patients	O
684	.	O
685	We	O
685	conclude	O
685	that	O
685	spinal	B-Disease
685	xanthomatosis	I-Disease
685	is	O
685	a	O
685	clinical	O
685	and	O
685	radiological	O
685	separate	O
685	entity	O
685	of	O
685	CTX	B-Disease
685	that	O
685	should	O
685	be	O
685	included	O
685	in	O
685	the	O
685	differential	O
685	diagnosis	O
685	of	O
685	chronic	B-Disease
685	myelopathy	I-Disease
685	.	O
685	.	O
686	A	O
686	transgene	O
686	insertion	O
686	creating	O
686	a	O
686	heritable	O
686	chromosome	O
686	deletion	O
686	mouse	O
686	model	O
686	of	O
686	Prader	B-Disease
686	-	I-Disease
686	Willi	I-Disease
686	and	I-Disease
686	angelman	I-Disease
686	syndromes	I-Disease
686	.	O
687	Prader	B-Disease
687	-	I-Disease
687	Willi	I-Disease
687	syndrome	I-Disease
687	(	O
687	PWS	B-Disease
687	)	O
687	and	O
687	Angelman	B-Disease
687	syndrome	I-Disease
687	(	O
687	AS	B-Disease
687	)	O
687	result	O
687	from	O
687	the	O
687	loss	O
687	of	O
687	function	O
687	of	O
687	imprinted	O
687	genes	O
687	in	O
687	human	O
687	chromosome	O
687	15q11	O
687	-	O
687	q13	O
687	.	O
688	The	O
688	central	O
688	part	O
688	of	O
688	mouse	O
688	chromosome	O
688	7	O
688	is	O
688	homologous	O
688	to	O
688	human	O
688	15q11	O
688	-	O
688	q13	O
688	,	O
688	with	O
688	conservation	O
688	of	O
688	both	O
688	gene	O
688	order	O
688	and	O
688	imprinted	O
688	features	O
688	.	O
689	We	O
689	report	O
689	here	O
689	the	O
689	characterization	O
689	of	O
689	a	O
689	transgene	O
689	insertion	O
689	(	O
689	Epstein	O
689	-	O
689	Barr	O
689	virus	O
689	Latent	O
689	Membrane	O
689	Protein	O
689	2A	O
689	,	O
689	LMP2A	O
689	)	O
689	into	O
689	mouse	O
689	chromosome	O
689	7C	O
689	,	O
689	which	O
689	has	O
689	resulted	O
689	in	O
689	mouse	O
689	models	O
689	for	O
689	PWS	B-Disease
689	and	O
689	AS	B-Disease
689	dependent	O
689	on	O
689	the	O
689	sex	O
689	of	O
689	the	O
689	transmitting	O
689	parent	O
689	.	O
690	Epigenotype	O
690	(	O
690	allelic	O
690	expression	O
690	and	O
690	DNA	O
690	methylation	O
690	)	O
690	and	O
690	fluorescence	O
690	in	O
690	situ	O
690	hybridization	O
690	analyses	O
690	indicate	O
690	that	O
690	the	O
690	transgene	O
690	-	O
690	induced	O
690	mutation	O
690	has	O
690	generated	O
690	a	O
690	complete	O
690	deletion	O
690	of	O
690	the	O
690	PWS	B-Disease
690	/	O
690	AS	B-Disease
690	-	O
690	homologous	O
690	region	O
690	but	O
690	has	O
690	not	O
690	deleted	O
690	flanking	O
690	loci	O
690	.	O
691	Because	O
691	the	O
691	intact	O
691	chromosome	O
691	7	O
691	,	O
691	opposite	O
691	the	O
691	deleted	O
691	homolog	O
691	,	O
691	maintains	O
691	the	O
691	correct	O
691	imprint	O
691	in	O
691	somatic	O
691	cells	O
691	of	O
691	PWS	B-Disease
691	and	O
691	AS	B-Disease
691	mice	O
691	and	O
691	establishes	O
691	the	O
691	correct	O
691	imprint	O
691	in	O
691	male	O
691	and	O
691	female	O
691	germ	O
691	cells	O
691	of	O
691	AS	B-Disease
691	mice	O
691	,	O
691	homologous	O
691	association	O
691	and	O
691	replication	O
691	asynchrony	O
691	are	O
691	not	O
691	part	O
691	of	O
691	the	O
691	imprinting	O
691	mechanism	O
691	.	O
692	This	O
692	heritable	O
692	-	O
692	deletion	O
692	mouse	O
692	model	O
692	will	O
692	be	O
692	particularly	O
692	useful	O
692	for	O
692	the	O
692	identification	O
692	of	O
692	the	O
692	etiological	O
692	genes	O
692	and	O
692	mechanisms	O
692	,	O
692	phenotypic	O
692	basis	O
692	,	O
692	and	O
692	investigation	O
692	of	O
692	therapeutic	O
692	approaches	O
692	for	O
692	PWS	B-Disease
692	.	O
692	.	O
693	Linkage	O
693	analysis	O
693	of	O
693	5	O
693	novel	O
693	van	B-Disease
693	der	I-Disease
693	Woude	I-Disease
693	syndrome	I-Disease
693	kindreds	O
693	to	O
693	1q32	O
693	-	O
693	q41	O
693	markers	O
693	further	O
693	supports	O
693	locus	O
693	homogeneity	O
693	of	O
693	the	O
693	disease	O
693	trait	O
693	.	O
694	van	B-Disease
694	der	I-Disease
694	Woude	I-Disease
694	syndrome	I-Disease
694	(	O
694	vWS	B-Disease
694	,	O
694	MIM	O
694	119300	O
694	)	O
694	is	O
694	a	O
694	rare	O
694	autosomal	B-Disease
694	dominant	I-Disease
694	clefting	I-Disease
694	condition	I-Disease
694	with	O
694	cardinal	O
694	features	O
694	of	O
694	mucous	B-Disease
694	cysts	I-Disease
694	(	O
694	lower	B-Disease
694	-	I-Disease
694	lip	I-Disease
694	pits	I-Disease
694	)	O
694	and	O
694	clefts	B-Disease
694	to	I-Disease
694	the	I-Disease
694	lip	I-Disease
694	and	I-Disease
694	/	I-Disease
694	or	I-Disease
694	palate	I-Disease
694	.	O
695	The	O
695	vWS	B-Disease
695	gene	O
695	has	O
695	been	O
695	assigned	O
695	to	O
695	a	O
695	locus	O
695	in	O
695	1q32	O
695	-	O
695	q41	O
695	by	O
695	linkage	O
695	analysis	O
695	and	O
695	physical	O
695	mapping	O
695	.	O
696	We	O
696	have	O
696	investigated	O
696	5	O
696	novel	O
696	vWS	B-Disease
696	families	O
696	through	O
696	probands	O
696	attended	O
696	for	O
696	cleft	B-Disease
696	lip	I-Disease
696	and	I-Disease
696	/	I-Disease
696	or	I-Disease
696	palate	I-Disease
696	repair	O
696	at	O
696	the	O
696	Department	O
696	of	O
696	Maxillofacial	O
696	Surgery	O
696	of	O
696	Hopital	O
696	Trousseau	O
696	,	O
696	Paris	O
696	,	O
696	in	O
696	order	O
696	to	O
696	tentatively	O
696	refine	O
696	the	O
696	genetic	O
696	map	O
696	of	O
696	the	O
696	vWS	B-Disease
696	region	O
696	in	O
696	1q32	O
696	-	O
696	q41	O
696	and	O
696	possibly	O
696	identify	O
696	unlinked	O
696	pedigrees	O
696	.	O
697	Linkage	O
697	analysis	O
697	was	O
697	carried	O
697	out	O
697	to	O
697	6	O
697	microsatellite	O
697	markers	O
697	(	O
697	D1S249	O
697	,	O
697	D1S425	O
697	,	O
697	D1S491	O
697	,	O
697	D1S205	O
697	,	O
697	D1S414	O
697	,	O
697	D1S425	O
697	)	O
697	,	O
697	yielding	O
697	a	O
697	maximum	O
697	cumulative	O
697	LOD	O
697	score	O
697	of	O
697	Z	O
697	=	O
697	3	O
697	.	O
698	27	O
698	at	O
698	theta	O
698	=	O
698	0	O
698	.	O
699	00	O
699	for	O
699	D1S245	O
699	.	O
700	The	O
700	innermost	O
700	four	O
700	markers	O
700	were	O
700	found	O
700	to	O
700	be	O
700	tightly	O
700	linked	O
700	to	O
700	one	O
700	another	O
700	,	O
700	with	O
700	no	O
700	evidence	O
700	for	O
700	recombination	O
700	.	O
701	Our	O
701	results	O
701	support	O
701	linkage	O
701	of	O
701	vWS	B-Disease
701	within	O
701	a	O
701	region	O
701	of	O
701	tightly	O
701	linked	O
701	markers	O
701	and	O
701	do	O
701	not	O
701	favour	O
701	locus	O
701	heterogeneity	O
701	of	O
701	the	O
701	disease	O
701	trait	O
701	.	O
702	Null	O
702	mutation	O
702	of	O
702	the	O
702	murine	O
702	ATP7B	O
702	(	O
702	Wilson	B-Disease
702	disease	I-Disease
702	)	O
702	gene	O
702	results	O
702	in	O
702	intracellular	B-Disease
702	copper	I-Disease
702	accumulation	I-Disease
702	and	O
702	late	B-Disease
702	-	I-Disease
702	onset	I-Disease
702	hepatic	I-Disease
702	nodular	I-Disease
702	transformation	I-Disease
702	.	O
703	The	O
703	Atp7b	O
703	protein	O
703	is	O
703	a	O
703	copper	O
703	-	O
703	transporting	O
703	ATPase	O
703	expressed	O
703	predominantly	O
703	in	O
703	the	O
703	liver	O
703	and	O
703	to	O
703	a	O
703	lesser	O
703	extent	O
703	in	O
703	most	O
703	other	O
703	tissues	O
703	.	O
704	Mutations	O
704	in	O
704	the	O
704	ATP7B	O
704	gene	O
704	lead	O
704	to	O
704	Wilson	B-Disease
704	disease	I-Disease
704	,	O
704	a	O
704	copper	B-Disease
704	toxicity	I-Disease
704	disorder	I-Disease
704	characterized	O
704	by	O
704	dramatic	O
704	build	O
704	-	O
704	up	O
704	of	O
704	intracellular	O
704	hepatic	O
704	copper	O
704	with	O
704	subsequent	O
704	hepatic	B-Disease
704	and	I-Disease
704	neuro	I-Disease
704	-	I-Disease
704	logical	I-Disease
704	abnormalities	I-Disease
704	.	O
705	Using	O
705	homologous	O
705	recombination	O
705	to	O
705	disrupt	O
705	the	O
705	normal	O
705	translation	O
705	of	O
705	ATP7B	O
705	,	O
705	we	O
705	have	O
705	generated	O
705	a	O
705	strain	O
705	of	O
705	mice	O
705	that	O
705	are	O
705	homozygous	O
705	mutants	O
705	(	O
705	)	O
705	for	O
705	the	O
705	Wilson	B-Disease
705	disease	I-Disease
705	gene	O
705	.	O
706	The	O
706	ATP7B	O
706	mice	O
706	display	O
706	a	O
706	gradual	O
706	accumulation	O
706	of	O
706	hepatic	O
706	copper	O
706	that	O
706	increases	O
706	to	O
706	a	O
706	level	O
706	60	O
706	-	O
706	fold	O
706	greater	O
706	than	O
706	normal	O
706	by	O
706	5	O
706	months	O
706	of	O
706	age	O
706	.	O
707	An	O
707	increase	O
707	in	O
707	copper	O
707	concentration	O
707	was	O
707	also	O
707	observed	O
707	in	O
707	the	O
707	kidney	O
707	,	O
707	brain	O
707	,	O
707	placenta	O
707	and	O
707	lactating	O
707	mammary	O
707	glands	O
707	of	O
707	homo	O
707	-	O
707	zygous	O
707	mutants	O
707	,	O
707	although	O
707	milk	O
707	from	O
707	the	O
707	mutant	O
707	glands	O
707	was	O
707	copper	B-Disease
707	deficient	I-Disease
707	.	O
708	Morphological	B-Disease
708	abnormalities	I-Disease
708	resembling	O
708	cirrhosis	B-Disease
708	developed	O
708	in	O
708	the	O
708	majority	O
708	of	O
708	the	O
708	livers	O
708	from	O
708	homozygous	O
708	mutants	O
708	older	O
708	than	O
708	7	O
708	months	O
708	of	O
708	age	O
708	.	O
709	Progeny	O
709	of	O
709	the	O
709	homozygous	O
709	mutant	O
709	females	O
709	demonstrated	O
709	neurological	B-Disease
709	abnormalities	I-Disease
709	and	O
709	growth	B-Disease
709	retardation	I-Disease
709	characteristic	O
709	of	O
709	copper	B-Disease
709	deficiency	I-Disease
709	.	O
710	Copper	O
710	concentration	O
710	in	O
710	the	O
710	livers	O
710	of	O
710	the	O
710	newborn	O
710	homozygous	O
710	mutants	O
710	was	O
710	decreased	O
710	dramatically	O
710	.	O
711	In	O
711	summary	O
711	,	O
711	inactivation	O
711	of	O
711	the	O
711	murine	O
711	ATP7B	O
711	gene	O
711	produces	O
711	a	O
711	form	O
711	of	O
711	cirrhotic	B-Disease
711	liver	I-Disease
711	disease	I-Disease
711	that	O
711	resembles	O
711	Wilson	B-Disease
711	disease	I-Disease
711	in	O
711	humans	O
711	and	O
711	the	O
711	toxic	O
711	milk	O
711	phenotype	O
711	in	O
711	the	O
711	mouse	O
711	.	O
711	.	O
712	French	O
712	Machado	B-Disease
712	-	I-Disease
712	Joseph	I-Disease
712	disease	I-Disease
712	patients	O
712	do	O
712	not	O
712	exhibit	O
712	gametic	O
712	segregation	O
712	distortion	O
712	:	O
712	a	O
712	sperm	O
712	typing	O
712	analysis	O
712	.	O
713	Segregation	O
713	distortion	O
713	has	O
713	been	O
713	reported	O
713	to	O
713	occur	O
713	in	O
713	a	O
713	number	O
713	of	O
713	the	O
713	trinucleotide	B-Disease
713	repeat	I-Disease
713	disorders	I-Disease
713	.	O
714	On	O
714	the	O
714	basis	O
714	of	O
714	a	O
714	sperm	O
714	typing	O
714	study	O
714	performed	O
714	in	O
714	patients	O
714	of	O
714	Japanese	O
714	descent	O
714	with	O
714	Machado	B-Disease
714	-	I-Disease
714	Joseph	I-Disease
714	disease	I-Disease
714	(	O
714	MJD	B-Disease
714	)	O
714	,	O
714	it	O
714	was	O
714	reported	O
714	that	O
714	disease	O
714	alleles	O
714	are	O
714	preferentially	O
714	transmitted	O
714	during	O
714	meiosis	O
714	.	O
715	We	O
715	performed	O
715	a	O
715	sperm	O
715	typing	O
715	study	O
715	of	O
715	five	O
715	MJD	B-Disease
715	patients	O
715	of	O
715	French	O
715	descent	O
715	and	O
715	analysis	O
715	of	O
715	the	O
715	pooled	O
715	data	O
715	shows	O
715	a	O
715	ratio	O
715	of	O
715	mutant	O
715	to	O
715	normal	O
715	alleles	O
715	of	O
715	379	O
715	436	O
715	(	O
715	46	O
715	.	O
715	5	O
715	53	O
715	.	O
715	5	O
715	%	O
715	)	O
715	,	O
715	which	O
715	does	O
715	not	O
715	support	O
715	meiotic	O
715	segregation	O
715	distortion	O
715	.	O
716	To	O
716	confirm	O
716	these	O
716	results	O
716	,	O
716	sperm	O
716	typing	O
716	analysis	O
716	was	O
716	also	O
716	performed	O
716	using	O
716	a	O
716	polymorphic	O
716	marker	O
716	,	O
716	D14S1050	O
716	,	O
716	closely	O
716	linked	O
716	to	O
716	the	O
716	MJD1	O
716	gene	O
716	.	O
717	Among	O
717	910	O
717	sperm	O
717	analyzed	O
717	,	O
717	the	O
717	allele	O
717	linked	O
717	to	O
717	the	O
717	disease	O
717	chromosome	O
717	was	O
717	detected	O
717	in	O
717	50	O
717	.	O
718	3	O
718	%	O
718	of	O
718	the	O
718	samples	O
718	and	O
718	the	O
718	allele	O
718	linked	O
718	to	O
718	the	O
718	normal	O
718	chromosome	O
718	was	O
718	found	O
718	in	O
718	49	O
718	.	O
719	6	O
719	%	O
719	of	O
719	the	O
719	sperm	O
719	.	O
720	The	O
720	difference	O
720	in	O
720	frequency	O
720	of	O
720	these	O
720	two	O
720	alleles	O
720	is	O
720	not	O
720	significant	O
720	(	O
720	P	O
720	=	O
720	0	O
720	.	O
720	8423	O
720	)	O
720	.	O
721	Likelihood	O
721	-	O
721	based	O
721	analysis	O
721	of	O
721	segregation	O
721	distortion	O
721	in	O
721	the	O
721	single	O
721	sperm	O
721	data	O
721	using	O
721	the	O
721	SPERMSEG	O
721	program	O
721	also	O
721	showed	O
721	no	O
721	support	O
721	for	O
721	segregation	O
721	distortion	O
721	at	O
721	the	O
721	gamete	O
721	level	O
721	in	O
721	this	O
721	patient	O
721	population	O
721	.	O
722	The	O
722	previous	O
722	report	O
722	on	O
722	the	O
722	Japanese	O
722	patients	O
722	also	O
722	suggested	O
722	that	O
722	disease	O
722	allele	O
722	stability	O
722	may	O
722	be	O
722	influenced	O
722	by	O
722	a	O
722	trans	O
722	effect	O
722	of	O
722	an	O
722	intragenic	O
722	polymorphism	O
722	(	O
722	987	O
722	G	O
722	/	O
722	C	O
722	)	O
722	in	O
722	the	O
722	wild	O
722	-	O
722	type	O
722	allele	O
722	.	O
723	All	O
723	of	O
723	the	O
723	French	O
723	patients	O
723	were	O
723	heterozygous	O
723	for	O
723	this	O
723	polymorphism	O
723	.	O
724	However	O
724	,	O
724	analysis	O
724	of	O
724	the	O
724	variance	O
724	in	O
724	repeat	O
724	number	O
724	in	O
724	sperm	O
724	from	O
724	the	O
724	French	O
724	MJD	B-Disease
724	patients	O
724	overlapped	O
724	significantly	O
724	with	O
724	the	O
724	variance	O
724	in	O
724	repeat	O
724	number	O
724	observed	O
724	in	O
724	the	O
724	C	O
724	/	O
724	C	O
724	homozygous	O
724	Japanese	O
724	patients	O
724	.	O
725	Missense	O
725	mutation	O
725	in	O
725	the	O
725	alternative	O
725	splice	O
725	region	O
725	of	O
725	the	O
725	PAX6	O
725	gene	O
725	in	O
725	eye	B-Disease
725	anomalies	I-Disease
725	.	O
726	The	O
726	PAX6	O
726	gene	O
726	is	O
726	involved	O
726	in	O
726	ocular	O
726	morphogenesis	O
726	,	O
726	and	O
726	PAX6	O
726	mutations	O
726	have	O
726	been	O
726	detected	O
726	in	O
726	various	O
726	types	O
726	of	O
726	ocular	B-Disease
726	anomalies	I-Disease
726	,	O
726	including	O
726	aniridia	B-Disease
726	,	O
726	Peters	B-Disease
726	anomaly	I-Disease
726	,	O
726	corneal	B-Disease
726	dystrophy	I-Disease
726	,	O
726	congenital	B-Disease
726	cataract	I-Disease
726	,	O
726	and	O
726	foveal	B-Disease
726	hypoplasia	I-Disease
726	.	O
727	The	O
727	gene	O
727	encodes	O
727	a	O
727	transcriptional	O
727	regulator	O
727	that	O
727	recognizes	O
727	target	O
727	genes	O
727	through	O
727	its	O
727	paired	O
727	-	O
727	type	O
727	DNA	O
727	-	O
727	binding	O
727	domain	O
727	.	O
728	The	O
728	paired	O
728	domain	O
728	is	O
728	composed	O
728	of	O
728	two	O
728	distinct	O
728	DNA	O
728	-	O
728	binding	O
728	subdomains	O
728	,	O
728	the	O
728	N	O
728	-	O
728	terminal	O
728	subdomain	O
728	(	O
728	NTS	O
728	)	O
728	and	O
728	the	O
728	C	O
728	-	O
728	terminal	O
728	subdomain	O
728	(	O
728	CTS	O
728	)	O
728	,	O
728	which	O
728	bind	O
728	respective	O
728	consensus	O
728	DNA	O
728	sequences	O
728	.	O
729	The	O
729	human	O
729	PAX6	O
729	gene	O
729	produces	O
729	two	O
729	alternative	O
729	splice	O
729	isoforms	O
729	that	O
729	have	O
729	the	O
729	distinct	O
729	structure	O
729	of	O
729	the	O
729	paired	O
729	domain	O
729	.	O
730	The	O
730	insertion	O
730	,	O
730	into	O
730	the	O
730	NTS	O
730	,	O
730	of	O
730	14	O
730	additional	O
730	amino	O
730	acids	O
730	encoded	O
730	by	O
730	exon	O
730	5a	O
730	abolishes	O
730	the	O
730	DNA	O
730	-	O
730	binding	O
730	activity	O
730	of	O
730	the	O
730	NTS	O
730	and	O
730	unmasks	O
730	the	O
730	DNA	O
730	-	O
730	binding	O
730	ability	O
730	of	O
730	the	O
730	CTS	O
730	.	O
731	Thus	O
731	,	O
731	exon	O
731	5a	O
731	appears	O
731	to	O
731	function	O
731	as	O
731	a	O
731	molecular	O
731	switch	O
731	that	O
731	specifies	O
731	target	O
731	genes	O
731	.	O
732	We	O
732	ascertained	O
732	a	O
732	novel	O
732	missense	O
732	mutation	O
732	in	O
732	four	O
732	pedigrees	O
732	with	O
732	Peters	B-Disease
732	anomaly	I-Disease
732	,	O
732	congenital	B-Disease
732	cataract	I-Disease
732	,	O
732	Axenfeldt	B-Disease
732	anomaly	I-Disease
732	,	O
732	and	O
732	/	O
732	or	O
732	foveal	B-Disease
732	hypoplasia	I-Disease
732	,	O
732	which	O
732	,	O
732	to	O
732	our	O
732	knowledge	O
732	,	O
732	is	O
732	the	O
732	first	O
732	mutation	O
732	identified	O
732	in	O
732	the	O
732	splice	O
732	-	O
732	variant	O
732	region	O
732	.	O
733	A	O
733	T	O
733	-	O
733	-	O
733	>	O
733	A	O
733	transition	O
733	at	O
733	the	O
733	20th	O
733	nucleotide	O
733	position	O
733	of	O
733	exon	O
733	5a	O
733	results	O
733	in	O
733	a	O
733	Val	O
733	-	O
733	-	O
733	>	O
733	Asp	O
733	(	O
733	GTC	O
733	-	O
733	-	O
733	>	O
733	GAC	O
733	)	O
733	substitution	O
733	at	O
733	the	O
733	7th	O
733	codon	O
733	of	O
733	the	O
733	alternative	O
733	splice	O
733	region	O
733	.	O
734	Functional	O
734	analyses	O
734	demonstrated	O
734	that	O
734	the	O
734	V54D	O
734	mutation	O
734	slightly	O
734	increased	O
734	NTS	O
734	binding	O
734	and	O
734	decreased	O
734	CTS	O
734	transactivation	O
734	activity	O
734	to	O
734	almost	O
734	half	O
734	.	O
734	.	O
735	Penetrances	O
735	of	O
735	BRCA1	O
735	1675delA	O
735	and	O
735	1135insA	O
735	with	O
735	respect	O
735	to	O
735	breast	B-Disease
735	cancer	I-Disease
735	and	O
735	ovarian	B-Disease
735	cancer	I-Disease
735	.	O
736	For	O
736	genetic	O
736	counseling	O
736	and	O
736	predictive	O
736	testing	O
736	in	O
736	families	O
736	with	O
736	inherited	B-Disease
736	breast	I-Disease
736	-	I-Disease
736	ovarian	I-Disease
736	cancer	I-Disease
736	,	O
736	penetrances	O
736	and	O
736	expressions	O
736	of	O
736	the	O
736	underlying	O
736	mutations	O
736	should	O
736	be	O
736	known	O
736	.	O
737	We	O
737	have	O
737	previously	O
737	reported	O
737	two	O
737	BRCA1	O
737	founder	O
737	mutations	O
737	in	O
737	the	O
737	Norwegian	O
737	population	O
737	.	O
738	Index	O
738	cases	O
738	for	O
738	the	O
738	present	O
738	study	O
738	were	O
738	found	O
738	two	O
738	different	O
738	ways	O
738	through	O
738	a	O
738	series	O
738	of	O
738	consecutive	O
738	ovarian	B-Disease
738	cancers	I-Disease
738	(	O
738	n	O
738	=	O
738	16	O
738	)	O
738	and	O
738	through	O
738	our	O
738	family	O
738	cancer	B-Disease
738	clinic	O
738	(	O
738	n	O
738	=	O
738	14	O
738	)	O
738	.	O
739	Altogether	O
739	,	O
739	20	O
739	of	O
739	the	O
739	patients	O
739	had	O
739	BRCA1	O
739	1675delA	O
739	,	O
739	and	O
739	10	O
739	had	O
739	1135insA	O
739	.	O
740	Their	O
740	relatives	O
740	were	O
740	described	O
740	with	O
740	respect	O
740	to	O
740	absence	O
740	/	O
740	presence	O
740	of	O
740	breast	B-Disease
740	and	I-Disease
740	/	I-Disease
740	or	I-Disease
740	ovarian	I-Disease
740	cancer	I-Disease
740	.	O
741	Of	O
741	133	O
741	living	O
741	female	O
741	relatives	O
741	,	O
741	83	O
741	(	O
741	62	O
741	%	O
741	)	O
741	were	O
741	tested	O
741	for	O
741	the	O
741	presence	O
741	of	O
741	a	O
741	mutation	O
741	.	O
742	No	O
742	difference	O
742	,	O
742	in	O
742	penetrance	O
742	and	O
742	expression	O
742	,	O
742	between	O
742	the	O
742	two	O
742	mutations	O
742	were	O
742	found	O
742	,	O
742	whereas	O
742	differences	O
742	according	O
742	to	O
742	method	O
742	of	O
742	ascertainment	O
742	were	O
742	seen	O
742	.	O
743	The	O
743	overall	O
743	findings	O
743	were	O
743	that	O
743	disease	O
743	started	O
743	to	O
743	occur	O
743	at	O
743	age	O
743	30	O
743	years	O
743	and	O
743	that	O
743	by	O
743	age	O
743	50	O
743	years	O
743	48	O
743	%	O
743	of	O
743	the	O
743	mutation	O
743	-	O
743	carrying	O
743	women	O
743	had	O
743	experienced	O
743	breast	B-Disease
743	and	I-Disease
743	/	I-Disease
743	or	I-Disease
743	ovarian	I-Disease
743	cancer	I-Disease
743	.	O
744	More	O
744	ovarian	B-Disease
744	cancers	I-Disease
744	than	O
744	breast	B-Disease
744	cancers	I-Disease
744	were	O
744	recorded	O
744	.	O
745	Both	O
745	penetrance	O
745	and	O
745	expression	O
745	(	O
745	breast	B-Disease
745	cancer	I-Disease
745	vs	O
745	.	O
745	ovarian	B-Disease
745	cancer	I-Disease
745	)	O
745	were	O
745	different	O
745	from	O
745	those	O
745	in	O
745	reports	O
745	of	O
745	the	O
745	Ashkenazi	O
745	founder	O
745	mutations	O
745	.	O
746	Whether	O
746	the	O
746	reported	O
746	differences	O
746	reflect	O
746	true	O
746	differences	O
746	and	O
746	/	O
746	or	O
746	methodological	O
746	problems	O
746	is	O
746	discussed	O
746	.	O
747	An	O
747	observed	O
747	excess	O
747	of	O
747	mutation	O
747	carriers	O
747	could	O
747	not	O
747	be	O
747	accounted	O
747	for	O
747	by	O
747	methodological	O
747	problems	O
747	;	O
747	possible	O
747	explanations	O
747	were	O
747	a	O
747	"	NN	O	O
747	true	NN	O	O
747	"	O
747	low	O
747	penetrance	O
747	or	O
747	preferential	O
747	segregation	O
747	.	O
747	.	O
748	The	O
748	dermatofibrosarcoma	B-Disease
748	protuberans	I-Disease
748	-	O
748	associated	O
748	collagen	O
748	type	O
748	Ialpha1	O
748	/	O
748	platelet	O
748	-	O
748	derived	O
748	growth	O
748	factor	O
748	(	O
748	PDGF	O
748	)	O
748	B	O
748	-	O
748	chain	O
748	fusion	O
748	gene	O
748	generates	O
748	a	O
748	transforming	O
748	protein	O
748	that	O
748	is	O
748	processed	O
748	to	O
748	functional	O
748	PDGF	O
748	-	O
748	BB	O
748	.	O
749	Dermatofibrosarcoma	B-Disease
749	protuberans	I-Disease
749	(	O
749	DFSP	B-Disease
749	)	O
749	displays	O
749	chromosomal	O
749	rearrangements	O
749	involving	O
749	chromosome	O
749	17	O
749	and	O
749	22	O
749	,	O
749	which	O
749	fuse	O
749	the	O
749	collagen	O
749	type	O
749	Ialpha1	O
749	(	O
749	COLIA1	O
749	)	O
749	gene	O
749	to	O
749	the	O
749	platelet	O
749	-	O
749	derived	O
749	growth	O
749	factor	O
749	(	O
749	PDGF	O
749	)	O
749	B	O
749	-	O
749	chain	O
749	(	O
749	PDGFB	O
749	)	O
749	gene	O
749	.	O
750	To	O
750	characterize	O
750	the	O
750	functional	O
750	and	O
750	structural	O
750	properties	O
750	of	O
750	the	O
750	COLIA1	O
750	/	O
750	PDGFB	O
750	fusion	O
750	protein	O
750	,	O
750	we	O
750	generated	O
750	a	O
750	stable	O
750	NIH3T3	O
750	cell	O
750	line	O
750	that	O
750	contained	O
750	a	O
750	tumor	O
750	-	O
750	derived	O
750	chimeric	O
750	gene	O
750	resulting	O
750	from	O
750	a	O
750	COIA1	O
750	intron	O
750	7	O
750	-	O
750	PDGFB	O
750	intron	O
750	1	O
750	fusion	O
750	.	O
751	Expression	O
751	of	O
751	the	O
751	fusion	O
751	protein	O
751	led	O
751	to	O
751	morphological	O
751	transformation	O
751	and	O
751	increased	O
751	growth	O
751	rate	O
751	of	O
751	these	O
751	cells	O
751	.	O
752	The	O
752	PDGF	O
752	receptor	O
752	kinase	O
752	inhibitor	O
752	CGP57148B	O
752	reversed	O
752	the	O
752	transformed	O
752	phenotype	O
752	and	O
752	reduced	O
752	the	O
752	growth	O
752	rate	O
752	of	O
752	COLIA1	O
752	/	O
752	PDGFB	O
752	-	O
752	expressing	O
752	cells	O
752	but	O
752	had	O
752	no	O
752	effects	O
752	on	O
752	control	O
752	cells	O
752	.	O
753	The	O
753	presence	O
753	of	O
753	dimeric	O
753	COLIA1	O
753	/	O
753	PDGFB	O
753	precursors	O
753	was	O
753	demonstrated	O
753	through	O
753	PDGFB	O
753	immunoprecipitations	O
753	of	O
753	metabolically	O
753	labeled	O
753	cells	O
753	and	O
753	also	O
753	by	O
753	PDGFB	O
753	immunoprecipitations	O
753	followed	O
753	by	O
753	immunoblotting	O
753	with	O
753	COLIA1	O
753	antibodies	O
753	.	O
754	Pulse	O
754	-	O
754	chase	O
754	studies	O
754	demonstrated	O
754	that	O
754	the	O
754	COLIA1	O
754	/	O
754	PDGFB	O
754	precursor	O
754	was	O
754	processed	O
754	to	O
754	an	O
754	end	O
754	product	O
754	that	O
754	was	O
754	indistinguishable	O
754	from	O
754	wild	O
754	-	O
754	type	O
754	PDGF	O
754	-	O
754	BB	O
754	.	O
755	Finally	O
755	,	O
755	COLIA1	O
755	/	O
755	PDGFB	O
755	-	O
755	expressing	O
755	cells	O
755	generated	O
755	tumors	B-Disease
755	after	O
755	s	O
755	.	O
756	c	O
756	c	O
756	.	O
756	injection	O
756	into	O
756	nude	O
756	mice	O
756	,	O
756	and	O
756	tumor	B-Disease
756	growth	O
756	was	O
756	reduced	O
756	by	O
756	treatment	O
756	with	O
756	CGP57148B	O
756	.	O
757	We	O
757	conclude	O
757	that	O
757	the	O
757	COLIA1	O
757	/	O
757	PDGFB	O
757	fusion	O
757	associated	O
757	with	O
757	DFSP	B-Disease
757	contributes	O
757	to	O
757	tumor	B-Disease
757	development	O
757	through	O
757	ectopic	O
757	production	O
757	of	O
757	PDGF	O
757	-	O
757	BB	O
757	and	O
757	the	O
757	formation	O
757	of	O
757	an	O
757	autocrine	O
757	loop	O
757	.	O
758	Our	O
758	findings	O
758	,	O
758	thus	O
758	,	O
758	suggest	O
758	that	O
758	PDGF	O
758	receptors	O
758	could	O
758	be	O
758	a	O
758	target	O
758	for	O
758	pharmacological	O
758	treatment	O
758	of	O
758	DFSP	B-Disease
758	and	O
758	giant	B-Disease
758	cell	I-Disease
758	fibroblastoma	I-Disease
758	,	O
758	e	O
758	.	O
758	g	O
758	.	O
758	,	O
758	through	O
758	the	O
758	use	O
758	of	O
758	PDGF	O
758	receptor	O
758	kinase	O
758	inhibitors	O
758	such	O
758	as	O
758	CGP57148B	O
758	.	O
759	Identification	O
759	of	O
759	a	O
759	common	O
759	PEX1	O
759	mutation	O
759	in	O
759	Zellweger	B-Disease
759	syndrome	I-Disease
759	.	O
760	The	O
760	Zellweger	B-Disease
760	spectrum	I-Disease
760	of	I-Disease
760	disease	I-Disease
760	,	O
760	encompassing	O
760	Zellweger	B-Disease
760	syndrome	I-Disease
760	and	O
760	the	O
760	progressively	O
760	milder	O
760	phenotypes	O
760	of	O
760	neonatal	B-Disease
760	adrenoleukodystrophy	I-Disease
760	and	O
760	infantile	B-Disease
760	Refsum	I-Disease
760	disease	I-Disease
760	,	O
760	is	O
760	due	O
760	to	O
760	a	O
760	failure	O
760	to	O
760	form	O
760	functional	O
760	peroxisomes	O
760	.	O
761	Cell	O
761	fusion	O
761	complementation	O
761	studies	O
761	demonstrated	O
761	that	O
761	these	O
761	diseases	O
761	are	O
761	genetically	O
761	heterogeneous	O
761	,	O
761	with	O
761	two	O
761	-	O
761	thirds	O
761	of	O
761	all	O
761	patients	O
761	lying	O
761	within	O
761	a	O
761	single	O
761	complementation	O
761	group	O
761	,	O
761	CG1	O
761	.	O
762	Molecular	O
762	genetic	O
762	and	O
762	cell	O
762	biology	O
762	studies	O
762	have	O
762	shown	O
762	that	O
762	PEX1	O
762	is	O
762	deficient	O
762	in	O
762	many	O
762	CG1	O
762	patients	O
762	.	O
763	However	O
763	,	O
763	previous	O
763	studies	O
763	have	O
763	focused	O
763	on	O
763	mildly	O
763	affected	O
763	patients	O
763	and	O
763	there	O
763	is	O
763	still	O
763	no	O
763	report	O
763	of	O
763	two	O
763	mutant	O
763	PEX1	O
763	alleles	O
763	in	O
763	any	O
763	Zellweger	B-Disease
763	syndrome	I-Disease
763	patient	O
763	.	O
764	Furthermore	O
764	,	O
764	mutations	O
764	in	O
764	the	O
764	PMP70	O
764	gene	O
764	have	O
764	also	O
764	been	O
764	identified	O
764	in	O
764	two	O
764	Zellweger	B-Disease
764	syndrome	I-Disease
764	patients	O
764	from	O
764	CG1	O
764	,	O
764	raising	O
764	the	O
764	possibility	O
764	that	O
764	CG1	O
764	patients	O
764	may	O
764	represent	O
764	a	O
764	mixture	O
764	of	O
764	PEX1	O
764	-	O
764	deficient	O
764	and	O
764	PMP70	O
764	-	O
764	deficient	O
764	individuals	O
764	.	O
765	To	O
765	address	O
765	the	O
765	molecular	O
765	basis	O
765	of	O
765	disease	O
765	in	O
765	Zellweger	B-Disease
765	syndrome	I-Disease
765	patients	O
765	from	O
765	CG1	O
765	,	O
765	we	O
765	examined	O
765	all	O
765	24	O
765	PEX1	O
765	exons	O
765	in	O
765	four	O
765	patients	O
765	,	O
765	including	O
765	both	O
765	patients	O
765	that	O
765	have	O
765	mutations	O
765	in	O
765	PMP70	O
765	.	O
766	PEX1	O
766	mutations	O
766	were	O
766	detected	O
766	in	O
766	all	O
766	four	O
766	patients	O
766	,	O
766	including	O
766	a	O
766	1	O
766	-	O
766	bp	O
766	insertion	O
766	(	O
766	c	O
766	.	O
766	2097insT	O
766	)	O
766	in	O
766	exon	O
766	13	O
766	that	O
766	was	O
766	present	O
766	in	O
766	three	O
766	of	O
766	the	O
766	four	O
766	patients	O
766	.	O
767	Subsequent	O
767	studies	O
767	demonstrated	O
767	that	O
767	this	O
767	mutation	O
767	is	O
767	present	O
767	in	O
767	one	O
767	-	O
767	half	O
767	of	O
767	all	O
767	CG1	O
767	patients	O
767	and	O
767	correlates	O
767	with	O
767	the	O
767	Zellweger	B-Disease
767	syndrome	I-Disease
767	phenotype	O
767	.	O
768	As	O
768	this	O
768	mutation	O
768	leads	O
768	to	O
768	a	O
768	loss	O
768	of	O
768	protein	O
768	function	O
768	its	O
768	frequency	O
768	makes	O
768	it	O
768	the	O
768	most	O
768	common	O
768	cause	O
768	of	O
768	Zellweger	B-Disease
768	syndrome	I-Disease
768	,	O
768	helping	O
768	to	O
768	explain	O
768	the	O
768	high	O
768	percentage	O
768	of	O
768	patients	O
768	that	O
768	belong	O
768	to	O
768	CG1	O
768	.	O
769	Novel	O
769	mutations	O
769	in	O
769	the	O
769	Wiskott	B-Disease
769	-	I-Disease
769	Aldrich	I-Disease
769	syndrome	I-Disease
769	protein	O
769	gene	O
769	and	O
769	their	O
769	effects	O
769	on	O
769	transcriptional	O
769	,	O
769	translational	O
769	,	O
769	and	O
769	clinical	O
769	phenotypes	O
769	.	O
770	Wiskott	B-Disease
770	-	I-Disease
770	Aldrich	I-Disease
770	syndrome	I-Disease
770	(	O
770	WAS	B-Disease
770	)	O
770	is	O
770	an	O
770	X	B-Disease
770	-	I-Disease
770	linked	I-Disease
770	recessive	I-Disease
770	immunodeficiency	I-Disease
770	characterized	O
770	by	O
770	thrombocytopenia	B-Disease
770	,	O
770	eczema	B-Disease
770	,	O
770	and	O
770	recurrent	O
770	infections	O
770	,	O
770	and	O
770	caused	O
770	by	O
770	mutations	O
770	in	O
770	the	O
770	WAS	B-Disease
770	protein	O
770	(	O
770	WASP	O
770	)	O
770	gene	O
770	.	O
771	WASP	O
771	contains	O
771	several	O
771	functional	O
771	domains	O
771	through	O
771	which	O
771	it	O
771	interacts	O
771	with	O
771	proteins	O
771	involved	O
771	in	O
771	intracellular	O
771	signaling	O
771	and	O
771	regulation	O
771	of	O
771	the	O
771	actin	O
771	cytoskeleton	O
771	.	O
772	In	O
772	this	O
772	report	O
772	,	O
772	17	O
772	WASP	O
772	gene	O
772	mutations	O
772	were	O
772	identified	O
772	,	O
772	12	O
772	of	O
772	which	O
772	are	O
772	novel	O
772	.	O
773	DNA	O
773	of	O
773	affected	O
773	males	O
773	and	O
773	obligate	O
773	carriers	O
773	was	O
773	PCR	O
773	amplified	O
773	and	O
773	analyzed	O
773	by	O
773	SSCA	O
773	,	O
773	heteroduplex	O
773	analysis	O
773	,	O
773	and	O
773	direct	O
773	sequencing	O
773	.	O
774	The	O
774	effects	O
774	of	O
774	the	O
774	mutations	O
774	at	O
774	the	O
774	mRNA	O
774	and	O
774	protein	O
774	level	O
774	were	O
774	ascertained	O
774	by	O
774	RT	O
774	-	O
774	PCR	O
774	and	O
774	Western	O
774	blot	O
774	analyses	O
774	.	O
775	All	O
775	missense	O
775	mutations	O
775	were	O
775	located	O
775	in	O
775	exons	O
775	1	O
775	-	O
775	4	O
775	.	O
776	Most	O
776	of	O
776	the	O
776	nonsense	O
776	,	O
776	frameshift	O
776	and	O
776	splice	O
776	site	O
776	mutations	O
776	were	O
776	found	O
776	in	O
776	exons	O
776	6	O
776	-	O
776	11	O
776	.	O
777	Mutations	O
777	that	O
777	alter	O
777	splice	O
777	sites	O
777	led	O
777	to	O
777	the	O
777	synthesis	O
777	of	O
777	several	O
777	types	O
777	of	O
777	mRNAs	O
777	,	O
777	a	O
777	fraction	O
777	of	O
777	which	O
777	represented	O
777	the	O
777	normally	O
777	spliced	O
777	product	O
777	.	O
778	The	O
778	presence	O
778	of	O
778	normally	O
778	spliced	O
778	transcripts	O
778	was	O
778	correlated	O
778	with	O
778	a	O
778	milder	O
778	phenotype	O
778	.	O
779	When	O
779	one	O
779	such	O
779	case	O
779	was	O
779	studied	O
779	by	O
779	Western	O
779	blotting	O
779	,	O
779	reduced	O
779	amounts	O
779	of	O
779	normal	O
779	-	O
779	size	O
779	WASP	O
779	were	O
779	present	O
779	.	O
780	In	O
780	other	O
780	cases	O
780	as	O
780	well	O
780	,	O
780	a	O
780	correlation	O
780	was	O
780	found	O
780	between	O
780	the	O
780	amount	O
780	of	O
780	normal	O
780	or	O
780	mutant	O
780	WASP	O
780	present	O
780	and	O
780	the	O
780	phenotypes	O
780	of	O
780	the	O
780	affected	O
780	individuals	O
780	.	O
781	No	O
781	protein	O
781	was	O
781	detected	O
781	in	O
781	two	O
781	individuals	O
781	with	O
781	severe	O
781	WAS	B-Disease
781	.	O
782	Reduced	O
782	levels	O
782	of	O
782	a	O
782	normal	O
782	-	O
782	size	O
782	WASP	O
782	with	O
782	a	O
782	missense	O
782	mutation	O
782	were	O
782	seen	O
782	in	O
782	two	O
782	individuals	O
782	with	O
782	XLT	B-Disease
782	.	O
783	It	O
783	is	O
783	concluded	O
783	that	O
783	mutation	O
783	analysis	O
783	at	O
783	the	O
783	DNA	O
783	level	O
783	is	O
783	not	O
783	sufficient	O
783	for	O
783	predicting	O
783	clinical	O
783	course	O
783	.	O
784	Studies	O
784	at	O
784	the	O
784	transcript	O
784	and	O
784	protein	O
784	level	O
784	are	O
784	needed	O
784	for	O
784	a	O
784	better	O
784	assessment	O
784	.	O
784	.	O
785	Aminoglycoside	O
785	antibiotics	O
785	restore	O
785	dystrophin	O
785	function	O
785	to	O
785	skeletal	O
785	muscles	O
785	of	O
785	mdx	O
785	mice	O
785	.	O
786	Duchenne	B-Disease
786	muscular	I-Disease
786	dystrophy	I-Disease
786	(	O
786	DMD	B-Disease
786	)	O
786	is	O
786	caused	O
786	by	O
786	mutations	O
786	in	O
786	the	O
786	dystrophin	O
786	gene	O
786	,	O
786	leading	O
786	to	O
786	the	O
786	absence	O
786	of	O
786	the	O
786	dystrophin	O
786	protein	O
786	in	O
786	striated	O
786	muscle	O
786	.	O
787	A	O
787	significant	O
787	number	O
787	of	O
787	these	O
787	mutations	O
787	are	O
787	premature	O
787	stop	O
787	codons	O
787	.	O
788	On	O
788	the	O
788	basis	O
788	of	O
788	the	O
788	observation	O
788	that	O
788	aminoglycoside	O
788	treatment	O
788	can	O
788	suppress	O
788	stop	O
788	codons	O
788	in	O
788	cultured	O
788	cells	O
788	,	O
788	we	O
788	tested	O
788	the	O
788	effect	O
788	of	O
788	gentamicin	O
788	on	O
788	cultured	O
788	muscle	O
788	cells	O
788	from	O
788	the	O
788	mdx	O
788	mouse	O
788	-	O
788	an	O
788	animal	O
788	model	O
788	for	O
788	DMD	B-Disease
788	that	O
788	possesses	O
788	a	O
788	premature	O
788	stop	O
788	codon	O
788	in	O
788	the	O
788	dystrophin	O
788	gene	O
788	.	O
789	Exposure	O
789	of	O
789	mdx	O
789	myotubes	O
789	to	O
789	gentamicin	O
789	led	O
789	to	O
789	the	O
789	expression	O
789	and	O
789	localization	O
789	of	O
789	dystrophin	O
789	to	O
789	the	O
789	cell	O
789	membrane	O
789	.	O
790	We	O
790	then	O
790	evaluated	O
790	the	O
790	effects	O
790	of	O
790	differing	O
790	dosages	O
790	of	O
790	gentamicin	O
790	on	O
790	expression	O
790	and	O
790	functional	O
790	protection	O
790	of	O
790	the	O
790	muscles	O
790	of	O
790	mdx	O
790	mice	O
790	.	O
791	We	O
791	identified	O
791	a	O
791	treatment	O
791	regimen	O
791	that	O
791	resulted	O
791	in	O
791	the	O
791	presence	O
791	of	O
791	dystrophin	O
791	in	O
791	the	O
791	cell	O
791	membrane	O
791	in	O
791	all	O
791	striated	O
791	muscles	O
791	examined	O
791	and	O
791	that	O
791	provided	O
791	functional	O
791	protection	O
791	against	O
791	muscular	B-Disease
791	injury	I-Disease
791	.	O
792	To	O
792	our	O
792	knowledge	O
792	,	O
792	our	O
792	results	O
792	are	O
792	the	O
792	first	O
792	to	O
792	demonstrate	O
792	that	O
792	aminoglycosides	O
792	can	O
792	suppress	O
792	stop	O
792	codons	O
792	not	O
792	only	O
792	in	O
792	vitro	O
792	but	O
792	also	O
792	in	O
792	vivo	O
792	.	O
793	Furthermore	O
793	,	O
793	these	O
793	results	O
793	raise	O
793	the	O
793	possibility	O
793	of	O
793	a	O
793	novel	O
793	treatment	O
793	regimen	O
793	for	O
793	muscular	B-Disease
793	dystrophy	I-Disease
793	and	O
793	other	O
793	diseases	O
793	caused	O
793	by	O
793	premature	O
793	stop	O
793	codon	O
793	mutations	O
793	.	O
794	This	O
794	treatment	O
794	could	O
794	prove	O
794	effective	O
794	in	O
794	up	O
794	to	O
794	15	O
794	%	O
794	of	O
794	patients	O
794	with	O
794	DMD	B-Disease
794	.	O
794	.	O
795	Loss	O
795	of	O
795	the	O
795	ataxia	B-Disease
795	-	I-Disease
795	telangiectasia	I-Disease
795	gene	O
795	product	O
795	causes	O
795	oxidative	O
795	damage	O
795	in	O
795	target	O
795	organs	O
795	.	O
796	Ataxia	B-Disease
796	-	I-Disease
796	telangiectasia	I-Disease
796	(	O
796	A	B-Disease
796	-	I-Disease
796	T	I-Disease
796	)	O
796	is	O
796	characterized	O
796	by	O
796	a	O
796	markedly	O
796	increased	O
796	sensitivity	O
796	to	O
796	ionizing	O
796	radiation	O
796	,	O
796	increased	O
796	incidence	O
796	of	O
796	cancer	B-Disease
796	,	O
796	and	O
796	neurodegeneration	B-Disease
796	,	O
796	especially	O
796	of	O
796	the	O
796	cerebellar	O
796	Purkinje	O
796	cells	O
796	.	O
797	Ionizing	O
797	radiation	O
797	oxidizes	O
797	macromolecules	O
797	and	O
797	causes	O
797	tissue	O
797	damage	O
797	through	O
797	the	O
797	generation	O
797	of	O
797	reactive	O
797	oxygen	O
797	species	O
797	(	O
797	ROS	O
797	)	O
797	.	O
798	We	O
798	therefore	O
798	hypothesized	O
798	that	O
798	A	B-Disease
798	-	I-Disease
798	T	I-Disease
798	is	O
798	due	O
798	to	O
798	oxidative	O
798	damage	O
798	resulting	O
798	from	O
798	loss	O
798	of	O
798	function	O
798	of	O
798	the	O
798	A	B-Disease
798	-	I-Disease
798	T	I-Disease
798	gene	O
798	product	O
798	.	O
799	To	O
799	assess	O
799	this	O
799	hypothesis	O
799	,	O
799	we	O
799	employed	O
799	an	O
799	animal	O
799	model	O
799	of	O
799	A	B-Disease
799	-	I-Disease
799	T	I-Disease
799	,	O
799	the	O
799	mouse	O
799	with	O
799	a	O
799	disrupted	O
799	Atm	O
799	gene	O
799	.	O
800	We	O
800	show	O
800	that	O
800	organs	O
800	which	O
800	develop	O
800	pathologic	O
800	changes	O
800	in	O
800	the	O
800	Atm	O
800	-	O
800	deficient	O
800	mice	O
800	are	O
800	targets	O
800	of	O
800	oxidative	O
800	damage	O
800	,	O
800	and	O
800	that	O
800	cerebellar	O
800	Purkinje	O
800	cells	O
800	are	O
800	particularly	O
800	affected	O
800	.	O
801	These	O
801	observations	O
801	provide	O
801	a	O
801	mechanistic	O
801	basis	O
801	for	O
801	the	O
801	A	B-Disease
801	-	I-Disease
801	T	I-Disease
801	phenotype	O
801	and	O
801	lay	O
801	a	O
801	rational	O
801	foundation	O
801	for	O
801	therapeutic	O
801	intervention	O
801	.	O
801	.	O
802	Recessively	O
802	inherited	O
802	multiple	B-Disease
802	epiphyseal	I-Disease
802	dysplasia	I-Disease
802	with	O
802	normal	O
802	stature	O
802	,	O
802	club	B-Disease
802	foot	I-Disease
802	,	O
802	and	O
802	double	B-Disease
802	layered	I-Disease
802	patella	I-Disease
802	caused	O
802	by	O
802	a	O
802	DTDST	O
802	mutation	O
802	.	O
803	We	O
803	have	O
803	observed	O
803	over	O
803	25	O
803	different	O
803	mutations	O
803	in	O
803	the	O
803	diastrophic	B-Disease
803	dysplasia	I-Disease
803	sulphate	O
803	transporter	O
803	gene	O
803	(	O
803	DTDST	O
803	)	O
803	in	O
803	association	O
803	with	O
803	the	O
803	recessive	B-Disease
803	disorders	I-Disease
803	achondrogenesis	B-Disease
803	1B	I-Disease
803	,	O
803	atelosteogenesis	B-Disease
803	2	I-Disease
803	,	O
803	and	O
803	diastrophic	B-Disease
803	dysplasia	I-Disease
803	.	O
804	The	O
804	c862t	O
804	(	O
804	R279W	O
804	)	O
804	transition	O
804	is	O
804	the	O
804	most	O
804	common	O
804	mutation	O
804	in	O
804	non	O
804	-	O
804	Finnish	O
804	patients	O
804	,	O
804	but	O
804	in	O
804	these	O
804	disorders	O
804	it	O
804	is	O
804	usually	O
804	combined	O
804	with	O
804	other	O
804	DTDST	O
804	mutations	O
804	.	O
805	We	O
805	had	O
805	not	O
805	seen	O
805	a	O
805	case	O
805	of	O
805	homozygosity	O
805	for	O
805	c862t	O
805	(	O
805	R279W	O
805	)	O
805	until	O
805	we	O
805	analysed	O
805	DNA	O
805	from	O
805	a	O
805	36	O
805	year	O
805	old	O
805	male	O
805	with	O
805	tall	O
805	-	O
805	normal	O
805	stature	O
805	(	O
805	180	O
805	cm	O
805	)	O
805	who	O
805	asked	O
805	for	O
805	genetic	O
805	counselling	O
805	for	O
805	suspected	O
805	multiple	B-Disease
805	epiphyseal	I-Disease
805	dysplasia	I-Disease
805	.	O
806	He	O
806	was	O
806	treated	O
806	for	O
806	club	B-Disease
806	foot	I-Disease
806	and	O
806	hip	B-Disease
806	dysplasia	I-Disease
806	at	O
806	birth	O
806	.	O
807	Skeletal	O
807	changes	O
807	consistent	O
807	with	O
807	multiple	B-Disease
807	epiphyseal	I-Disease
807	dysplasia	I-Disease
807	,	O
807	with	O
807	the	O
807	peculiar	O
807	finding	O
807	of	O
807	a	O
807	double	B-Disease
807	layered	I-Disease
807	patella	I-Disease
807	,	O
807	were	O
807	recognised	O
807	during	O
807	childhood	O
807	.	O
808	Cleft	B-Disease
808	palate	I-Disease
808	,	O
808	swelling	B-Disease
808	of	I-Disease
808	the	I-Disease
808	ear	I-Disease
808	pinna	I-Disease
808	,	O
808	and	O
808	hitch	B-Disease
808	hiker	I-Disease
808	thumb	I-Disease
808	were	O
808	absent	O
808	.	O
809	He	O
809	was	O
809	found	O
809	to	O
809	be	O
809	homozygous	O
809	,	O
809	and	O
809	both	O
809	healthy	O
809	parents	O
809	heterozygous	O
809	,	O
809	for	O
809	the	O
809	R279W	O
809	mutation	O
809	in	O
809	DTDST	O
809	,	O
809	and	O
809	his	O
809	fibroblasts	O
809	showed	O
809	a	O
809	sulphate	O
809	incorporation	O
809	defect	O
809	typical	O
809	of	O
809	DTDST	B-Disease
809	disorders	I-Disease
809	.	O
810	Counselling	O
810	was	O
810	given	O
810	for	O
810	a	O
810	recessive	B-Disease
810	disorder	I-Disease
810	,	O
810	thereby	O
810	considerably	O
810	reducing	O
810	the	O
810	probability	O
810	of	O
810	affected	O
810	offspring	O
810	.	O
811	Multiple	B-Disease
811	epiphyseal	I-Disease
811	dysplasia	I-Disease
811	is	O
811	more	O
811	frequently	O
811	caused	O
811	by	O
811	dominant	O
811	mutations	O
811	in	O
811	the	O
811	COMP	O
811	(	O
811	EDM1	B-Disease
811	,	O
811	McKusick	O
811	132400	O
811	)	O
811	and	O
811	COL9A2	O
811	genes	O
811	(	O
811	EDM2	B-Disease
811	,	O
811	McKusick	O
811	600204	O
811	)	O
811	.	O
812	A	O
812	few	O
812	other	O
812	patients	O
812	and	O
812	families	O
812	with	O
812	features	O
812	similar	O
812	to	O
812	our	O
812	proband	O
812	have	O
812	been	O
812	described	O
812	previously	O
812	and	O
812	considered	O
812	to	O
812	have	O
812	autosomal	O
812	recessive	O
812	MED	B-Disease
812	(	O
812	EDM4	B-Disease
812	,	O
812	McKusick	O
812	226900	O
812	)	O
812	.	O
813	This	O
813	observation	O
813	confirms	O
813	the	O
813	existence	O
813	of	O
813	this	O
813	entity	O
813	and	O
813	assigns	O
813	it	O
813	to	O
813	the	O
813	phenotypic	O
813	spectrum	O
813	associated	O
813	with	O
813	mutations	O
813	at	O
813	the	O
813	DTDST	O
813	locus	O
813	.	O
813	.	O
814	Homozygosity	O
814	for	O
814	a	O
814	novel	O
814	DTDST	O
814	mutation	O
814	in	O
814	a	O
814	child	O
814	with	O
814	a	O
814	'	O
814	broad	O
814	bone	O
814	-	O
814	platyspondylic	O
814	'	O
814	variant	O
814	of	O
814	diastrophic	B-Disease
814	dysplasia	I-Disease
814	.	O
815	Atypical	O
815	or	O
815	variant	O
815	forms	O
815	of	O
815	well	O
815	-	O
815	known	O
815	chondrodysplasias	B-Disease
815	may	O
815	pose	O
815	diagnostic	O
815	problems	O
815	.	O
816	We	O
816	report	O
816	on	O
816	a	O
816	girl	O
816	with	O
816	clinical	O
816	features	O
816	suggesting	O
816	diastrophic	B-Disease
816	dysplasia	I-Disease
816	but	O
816	with	O
816	unusual	O
816	radiographic	O
816	features	O
816	including	O
816	severe	O
816	platyspondyly	B-Disease
816	,	O
816	wide	O
816	metaphyses	O
816	,	O
816	and	O
816	fibular	O
816	overgrowth	O
816	,	O
816	which	O
816	are	O
816	partially	O
816	reminiscent	O
816	of	O
816	metatropic	B-Disease
816	dysplasia	I-Disease
816	.	O
817	The	O
817	diagnosis	O
817	was	O
817	clarified	O
817	by	O
817	molecular	O
817	analysis	O
817	of	O
817	the	O
817	DTDST	O
817	gene	O
817	,	O
817	which	O
817	revealed	O
817	homozygosity	O
817	for	O
817	a	O
817	previously	O
817	undescribed	O
817	mutation	O
817	leading	O
817	to	O
817	a	O
817	Q454P	O
817	substitution	O
817	in	O
817	the	O
817	10th	O
817	transmembrane	O
817	domain	O
817	of	O
817	the	O
817	DTDST	O
817	sulfate	O
817	transporter	O
817	.	O
818	Molecular	O
818	analysis	O
818	may	O
818	be	O
818	of	O
818	particular	O
818	value	O
818	in	O
818	such	O
818	atypical	O
818	cases	O
818	.	O
818	.	O
819	The	O
819	type	O
819	of	O
819	somatic	O
819	mutation	O
819	at	O
819	APC	O
819	in	O
819	familial	B-Disease
819	adenomatous	I-Disease
819	polyposis	I-Disease
819	is	O
819	determined	O
819	by	O
819	the	O
819	site	O
819	of	O
819	the	O
819	germline	O
819	mutation	O
819	:	O
819	a	O
819	new	O
819	facet	O
819	to	O
819	Knudson	O
819	'	O
819	s	O
819	'	O
819	two	O
819	-	O
819	hit	O
819	'	O
819	hypothesis	O
819	.	O
820	APC	O
820	is	O
820	often	O
820	cited	O
820	as	O
820	a	O
820	prime	O
820	example	O
820	of	O
820	a	O
820	tumor	B-Disease
820	suppressor	O
820	gene	O
820	.	O
821	Truncating	O
821	germline	O
821	and	O
821	somatic	O
821	mutations	O
821	(	O
821	or	O
821	,	O
821	infrequently	O
821	,	O
821	allelic	O
821	loss	O
821	)	O
821	occur	O
821	in	O
821	tumors	B-Disease
821	in	O
821	FAP	B-Disease
821	(	O
821	familial	B-Disease
821	adenomatous	I-Disease
821	polyposis	I-Disease
821	)	O
821	.	O
822	Most	O
822	sporadic	B-Disease
822	colorectal	I-Disease
822	cancers	I-Disease
822	also	O
822	have	O
822	two	O
822	APC	B-Disease
822	mutations	O
822	.	O
823	Clues	O
823	from	O
823	attenuated	B-Disease
823	polyposis	I-Disease
823	,	O
823	missense	O
823	germline	O
823	variants	O
823	with	O
823	mild	O
823	disease	O
823	and	O
823	the	O
823	somatic	O
823	mutation	O
823	cluster	O
823	region	O
823	(	O
823	codons	O
823	1	O
823	,	O
823	250	O
823	-	O
823	1	O
823	,	O
823	450	O
823	)	O
823	indicate	O
823	,	O
823	however	O
823	,	O
823	that	O
823	APC	B-Disease
823	mutations	O
823	might	O
823	not	O
823	result	O
823	in	O
823	simple	O
823	loss	O
823	of	O
823	protein	O
823	function	O
823	.	O
824	We	O
824	have	O
824	found	O
824	that	O
824	FAP	B-Disease
824	patients	O
824	with	O
824	germline	O
824	APC	B-Disease
824	mutations	O
824	within	O
824	a	O
824	small	O
824	region	O
824	(	O
824	codons	O
824	1	O
824	,	O
824	194	O
824	-	O
824	1	O
824	,	O
824	392	O
824	at	O
824	most	O
824	)	O
824	mainly	O
824	show	O
824	allelic	O
824	loss	O
824	in	O
824	their	O
824	colorectal	B-Disease
824	adenomas	I-Disease
824	,	O
824	in	O
824	contrast	O
824	to	O
824	other	O
824	FAP	B-Disease
824	patients	O
824	,	O
824	whose	O
824	second	O
824	hits	O
824	tend	O
824	to	O
824	occur	O
824	by	O
824	truncating	O
824	mutations	O
824	in	O
824	the	O
824	mutation	O
824	cluster	O
824	region	O
824	.	O
825	Our	O
825	results	O
825	indicate	O
825	that	O
825	different	O
825	APC	B-Disease
825	mutations	O
825	provide	O
825	cells	O
825	with	O
825	different	O
825	selective	O
825	advantages	O
825	,	O
825	with	O
825	mutations	O
825	close	O
825	to	O
825	codon	O
825	1	O
825	,	O
825	300	O
825	providing	O
825	the	O
825	greatest	O
825	advantage	O
825	.	O
826	Allelic	O
826	loss	O
826	is	O
826	selected	O
826	strongly	O
826	in	O
826	cells	O
826	with	O
826	one	O
826	mutation	O
826	near	O
826	codon	O
826	1	O
826	,	O
826	300	O
826	.	O
827	A	O
827	different	O
827	germline	O
827	-	O
827	somatic	O
827	APC	B-Disease
827	mutation	O
827	association	O
827	exists	O
827	in	O
827	FAP	B-Disease
827	desmoids	I-Disease
827	.	O
828	APC	O
828	is	O
828	not	O
828	,	O
828	therefore	O
828	,	O
828	a	O
828	classical	O
828	tumor	B-Disease
828	suppressor	O
828	.	O
829	Our	O
829	findings	O
829	also	O
829	indicate	O
829	a	O
829	new	O
829	mechanism	O
829	for	O
829	disease	O
829	severity	O
829	if	O
829	a	O
829	broader	O
829	spectrum	O
829	of	O
829	mutations	O
829	is	O
829	selected	O
829	in	O
829	tumors	B-Disease
829	,	O
829	the	O
829	somatic	O
829	mutation	O
829	rate	O
829	is	O
829	effectively	O
829	higher	O
829	and	O
829	more	O
829	tumors	B-Disease
829	grow	O
829	.	O
829	.	O
830	Mxi1	O
830	mutations	O
830	in	O
830	human	O
830	neurofibrosarcomas	B-Disease
830	.	O
831	Mxi1	O
831	is	O
831	thought	O
831	to	O
831	negatively	O
831	regulate	O
831	Myc	O
831	function	O
831	and	O
831	may	O
831	therefore	O
831	be	O
831	a	O
831	potential	O
831	tumor	B-Disease
831	suppressor	O
831	gene	O
831	.	O
832	Little	O
832	effort	O
832	has	O
832	yet	O
832	been	O
832	made	O
832	to	O
832	find	O
832	alterations	O
832	involving	O
832	this	O
832	gene	O
832	in	O
832	human	O
832	solid	B-Disease
832	tumors	I-Disease
832	.	O
833	We	O
833	screened	O
833	31	O
833	human	O
833	gastric	B-Disease
833	cancers	I-Disease
833	,	O
833	7	O
833	esophageal	B-Disease
833	cancers	I-Disease
833	,	O
833	85	O
833	bone	B-Disease
833	and	I-Disease
833	soft	I-Disease
833	tissue	I-Disease
833	tumors	I-Disease
833	of	O
833	various	O
833	types	O
833	,	O
833	including	O
833	4	O
833	neurofibrosarcomas	B-Disease
833	.	O
834	We	O
834	also	O
834	examined	O
834	29	O
834	human	O
834	tumor	B-Disease
834	cell	O
834	lines	O
834	consisting	O
834	of	O
834	12	O
834	esophageal	B-Disease
834	cancers	I-Disease
834	,	O
834	7	O
834	glioma	B-Disease
834	/	O
834	glioblastomas	B-Disease
834	and	O
834	10	O
834	others	O
834	for	O
834	Mxi1	O
834	mutations	O
834	in	O
834	exons	O
834	1	O
834	,	O
834	2	O
834	,	O
834	4	O
834	(	O
834	HLH	O
834	domain	O
834	)	O
834	,	O
834	5	O
834	and	O
834	6	O
834	.	O
835	Polymerase	O
835	chain	O
835	reaction	O
835	-	O
835	single	O
835	-	O
835	strand	O
835	conformation	O
835	polymorphism	O
835	(	O
835	PCR	O
835	-	O
835	SSCP	O
835	)	O
835	and	O
835	subsequent	O
835	sequencing	O
835	revealed	O
835	three	O
835	distinct	O
835	polymorphisms	O
835	in	O
835	the	O
835	intron	O
835	-	O
835	exon	O
835	boundary	O
835	upstream	O
835	from	O
835	exon	O
835	6	O
835	.	O
836	We	O
836	discovered	O
836	a	O
836	missense	O
836	mutation	O
836	,	O
836	GCA	O
836	to	O
836	GTA	O
836	(	O
836	Ala	O
836	54	O
836	Val	O
836	)	O
836	,	O
836	in	O
836	exon	O
836	2	O
836	in	O
836	a	O
836	neurofibrosarcoma	B-Disease
836	patient	O
836	(	O
836	case	O
836	1	O
836	)	O
836	,	O
836	two	O
836	missense	O
836	mutations	O
836	,	O
836	AAA	O
836	to	O
836	CAA	O
836	(	O
836	Lys	O
836	118	O
836	Gln	O
836	)	O
836	and	O
836	GAA	O
836	to	O
836	GGA	O
836	(	O
836	Glu	O
836	154	O
836	Gly	O
836	)	O
836	in	O
836	exon	O
836	5	O
836	of	O
836	another	O
836	neurofibrosarcoma	B-Disease
836	patient	O
836	(	O
836	case	O
836	2	O
836	)	O
836	,	O
836	and	O
836	3	O
836	amino	O
836	acid	O
836	substitutions	O
836	,	O
836	GTG	O
836	to	O
836	GCG	O
836	(	O
836	Val	O
836	179	O
836	Ala	O
836	)	O
836	,	O
836	GTT	O
836	to	O
836	GCT	O
836	(	O
836	Val	O
836	181	O
836	Ala	O
836	)	O
836	and	O
836	TTC	O
836	to	O
836	CTC	O
836	(	O
836	Phe	O
836	186	O
836	Leu	O
836	)	O
836	,	O
836	in	O
836	a	O
836	third	O
836	neurofibrosarcoma	B-Disease
836	patient	O
836	(	O
836	case	O
836	3	O
836	)	O
836	.	O
837	In	O
837	case	O
837	3	O
837	,	O
837	loss	O
837	of	O
837	heterozygosity	O
837	was	O
837	also	O
837	demonstrated	O
837	by	O
837	informative	O
837	(	O
837	TTC	O
837	)	O
837	3	O
837	/	O
837	(	O
837	TTC	O
837	)	O
837	2	O
837	polymorphism	O
837	.	O
838	Our	O
838	data	O
838	demonstrate	O
838	that	O
838	mutations	O
838	occur	O
838	in	O
838	the	O
838	Mxi1	O
838	gene	O
838	in	O
838	neurofibrosarcoma	B-Disease
838	.	O
839	Missense	O
839	mutations	O
839	in	O
839	the	O
839	functional	O
839	domain	O
839	of	O
839	Mxi1	O
839	in	O
839	these	O
839	cases	O
839	may	O
839	be	O
839	involved	O
839	in	O
839	the	O
839	pathogenesis	O
839	of	O
839	neurofibrosarcoma	B-Disease
839	.	O
839	.	O
840	A	O
840	population	O
840	-	O
840	based	O
840	study	O
840	of	O
840	the	O
840	clinical	O
840	expression	O
840	of	O
840	the	O
840	hemochromatosis	B-Disease
840	gene	O
840	.	O
841	BACKGROUND	O
841	AND	O
841	METHODS	O
841	Hereditary	B-Disease
841	hemochromatosis	I-Disease
841	is	O
841	associated	O
841	with	O
841	homozygosity	O
841	for	O
841	the	O
841	C282Y	O
841	mutation	O
841	in	O
841	the	O
841	hemochromatosis	B-Disease
841	(	O
841	HFE	O
841	)	O
841	gene	O
841	on	O
841	chromosome	O
841	6	O
841	,	O
841	elevated	O
841	serum	O
841	transferrin	O
841	saturation	O
841	,	O
841	and	O
841	excess	B-Disease
841	iron	I-Disease
841	deposits	I-Disease
841	throughout	O
841	the	O
841	body	O
841	.	O
842	To	O
842	assess	O
842	the	O
842	prevalence	O
842	and	O
842	clinical	O
842	expression	O
842	of	O
842	the	O
842	HFE	O
842	gene	O
842	,	O
842	we	O
842	conducted	O
842	a	O
842	population	O
842	-	O
842	based	O
842	study	O
842	in	O
842	Busselton	O
842	,	O
842	Australia	O
842	.	O
843	In	O
843	1994	O
843	,	O
843	we	O
843	obtained	O
843	blood	O
843	samples	O
843	for	O
843	the	O
843	determination	O
843	of	O
843	serum	O
843	transferrin	O
843	saturation	O
843	and	O
843	ferritin	O
843	levels	O
843	and	O
843	the	O
843	presence	O
843	or	O
843	absence	O
843	of	O
843	the	O
843	C282Y	O
843	mutation	O
843	and	O
843	the	O
843	H63D	O
843	mutation	O
843	(	O
843	which	O
843	may	O
843	contribute	O
843	to	O
843	increased	O
843	hepatic	O
843	iron	O
843	levels	O
843	)	O
843	in	O
843	3011	O
843	unrelated	O
843	white	O
843	adults	O
843	.	O
844	We	O
844	evaluated	O
844	all	O
844	subjects	O
844	who	O
844	had	O
844	persistently	O
844	elevated	O
844	transferrin	O
844	-	O
844	saturation	O
844	values	O
844	(	O
844	45	O
844	percent	O
844	or	O
844	higher	O
844	)	O
844	or	O
844	were	O
844	homozygous	O
844	for	O
844	the	O
844	C282Y	O
844	mutation	O
844	.	O
845	We	O
845	recommended	O
845	liver	O
845	biopsy	O
845	for	O
845	subjects	O
845	with	O
845	serum	O
845	ferritin	O
845	levels	O
845	of	O
845	300	O
845	ng	O
845	per	O
845	milliliter	O
845	or	O
845	higher	O
845	.	O
846	The	O
846	subjects	O
846	were	O
846	followed	O
846	for	O
846	up	O
846	to	O
846	four	O
846	years	O
846	.	O
847	RESULTS	O
847	Sixteen	O
847	of	O
847	the	O
847	subjects	O
847	(	O
847	0	O
847	.	O
847	5	O
847	percent	O
847	)	O
847	were	O
847	homozygous	O
847	for	O
847	the	O
847	C282Y	O
847	mutation	O
847	,	O
847	and	O
847	424	O
847	(	O
847	14	O
847	.	O
847	1	O
847	percent	O
847	)	O
847	were	O
847	heterozygous	O
847	.	O
848	The	O
848	serum	O
848	transferrin	O
848	saturation	O
848	was	O
848	45	O
848	percent	O
848	or	O
848	higher	O
848	in	O
848	15	O
848	of	O
848	the	O
848	16	O
848	who	O
848	were	O
848	homozygous	O
848	;	O
848	in	O
848	1	O
848	subject	O
848	it	O
848	was	O
848	43	O
848	percent	O
848	.	O
849	Four	O
849	of	O
849	the	O
849	homozygous	O
849	subjects	O
849	had	O
849	previously	O
849	been	O
849	given	O
849	a	O
849	diagnosis	O
849	of	O
849	hemochromatosis	B-Disease
849	,	O
849	and	O
849	12	O
849	had	O
849	not	O
849	.	O
850	Seven	O
850	of	O
850	these	O
850	12	O
850	patients	O
850	had	O
850	elevated	O
850	serum	O
850	ferritin	O
850	levels	O
850	in	O
850	1994	O
850	;	O
850	6	O
850	of	O
850	the	O
850	7	O
850	had	O
850	further	O
850	increases	O
850	in	O
850	1998	O
850	,	O
850	and	O
850	1	O
850	had	O
850	a	O
850	decrease	O
850	,	O
850	although	O
850	the	O
850	value	O
850	remained	O
850	elevated	O
850	.	O
851	The	O
851	serum	O
851	ferritin	O
851	levels	O
851	in	O
851	the	O
851	four	O
851	other	O
851	homozygous	O
851	patients	O
851	remained	O
851	in	O
851	the	O
851	normal	O
851	range	O
851	.	O
852	Eleven	O
852	of	O
852	the	O
852	16	O
852	homozygous	O
852	subjects	O
852	underwent	O
852	liver	O
852	biopsy	O
852	;	O
852	3	O
852	had	O
852	hepatic	B-Disease
852	fibrosis	I-Disease
852	,	O
852	and	O
852	1	O
852	,	O
852	who	O
852	had	O
852	a	O
852	history	O
852	of	O
852	excessive	B-Disease
852	alcohol	I-Disease
852	consumption	I-Disease
852	,	O
852	had	O
852	cirrhosis	B-Disease
852	and	O
852	mild	O
852	microvesicular	B-Disease
852	steatosis	I-Disease
852	.	O
853	Eight	O
853	of	O
853	the	O
853	16	O
853	homozygous	O
853	subjects	O
853	had	O
853	clinical	O
853	findings	O
853	that	O
853	were	O
853	consistent	O
853	with	O
853	the	O
853	presence	O
853	of	O
853	hereditary	B-Disease
853	hemochromatosis	I-Disease
853	,	O
853	such	O
853	as	O
853	hepatomegaly	B-Disease
853	,	O
853	skin	B-Disease
853	pigmentation	I-Disease
853	,	O
853	and	O
853	arthritis	B-Disease
853	.	O
854	CONCLUSIONS	O
854	In	O
854	a	O
854	population	O
854	of	O
854	white	O
854	adults	O
854	of	O
854	northern	O
854	European	O
854	ancestry	O
854	,	O
854	0	O
854	.	O
855	5	O
855	percent	O
855	were	O
855	homozygous	O
855	for	O
855	the	O
855	C282Y	O
855	mutation	O
855	in	O
855	the	O
855	HFE	O
855	gene	O
855	.	O
856	However	O
856	,	O
856	only	O
856	half	O
856	of	O
856	those	O
856	who	O
856	were	O
856	homozygous	O
856	had	O
856	clinical	O
856	features	O
856	of	O
856	hemochromatosis	B-Disease
856	,	O
856	and	O
856	one	O
856	quarter	O
856	had	O
856	serum	O
856	ferritin	O
856	levels	O
856	that	O
856	remained	O
856	normal	O
856	over	O
856	a	O
856	four	O
856	-	O
856	year	O
856	period	O
856	.	O
857	Large	O
857	heterozygous	O
857	deletion	O
857	masquerading	O
857	as	O
857	homozygous	O
857	missense	O
857	mutation	O
857	:	O
857	a	O
857	pitfall	O
857	in	O
857	diagnostic	O
857	mutation	O
857	analysis	O
857	.	O
858	The	O
858	clinical	O
858	use	O
858	of	O
858	molecular	O
858	analyses	O
858	in	O
858	recessive	B-Disease
858	disorders	I-Disease
858	relies	O
858	on	O
858	the	O
858	exact	O
858	characterization	O
858	of	O
858	both	O
858	mutant	O
858	alleles	O
858	in	O
858	the	O
858	affected	O
858	patient	O
858	.	O
859	This	O
859	can	O
859	be	O
859	problematic	O
859	when	O
859	only	O
859	part	O
859	of	O
859	the	O
859	gene	O
859	is	O
859	examined	O
859	or	O
859	when	O
859	relevant	O
859	DNA	O
859	alterations	O
859	are	O
859	not	O
859	recognized	O
859	by	O
859	standard	O
859	methods	O
859	.	O
860	We	O
860	present	O
860	a	O
860	child	O
860	in	O
860	whom	O
860	phenylketonuria	B-Disease
860	was	O
860	apparently	O
860	caused	O
860	by	O
860	homozygosity	O
860	for	O
860	the	O
860	mutation	O
860	E390G	O
860	in	O
860	exon	O
860	11	O
860	of	O
860	the	O
860	phenylalanine	O
860	hydroxylase	O
860	(	O
860	PAH	O
860	)	O
860	gene	O
860	.	O
861	However	O
861	,	O
861	the	O
861	clinical	O
861	severity	O
861	of	O
861	the	O
861	disease	O
861	was	O
861	not	O
861	quite	O
861	as	O
861	mild	O
861	as	O
861	expected	O
861	,	O
861	the	O
861	mutation	O
861	was	O
861	not	O
861	identified	O
861	in	O
861	the	O
861	father	O
861	despite	O
861	confirmed	O
861	paternity	O
861	,	O
861	and	O
861	the	O
861	paternal	O
861	allele	O
861	showed	O
861	a	O
861	highly	O
861	unusual	O
861	pattern	O
861	of	O
861	polymorphic	O
861	markers	O
861	in	O
861	the	O
861	PAH	O
861	gene	O
861	.	O
862	Presence	O
862	of	O
862	a	O
862	large	O
862	deletion	O
862	involving	O
862	exons	O
862	9	O
862	,	O
862	10	O
862	and	O
862	11	O
862	of	O
862	the	O
862	phenylalanine	O
862	hydroxylase	O
862	gene	O
862	was	O
862	confirmed	O
862	by	O
862	long	O
862	-	O
862	range	O
862	PCR	O
862	.	O
863	Diagnostic	O
863	DNA	O
863	analyses	O
863	should	O
863	include	O
863	a	O
863	comprehensive	O
863	examination	O
863	of	O
863	the	O
863	whole	O
863	relevant	O
863	gene	O
863	in	O
863	the	O
863	patient	O
863	and	O
863	confirmation	O
863	of	O
863	carrier	O
863	status	O
863	in	O
863	both	O
863	parents	O
863	.	O
863	.	O
864	Early	O
864	onset	O
864	of	O
864	X	B-Disease
864	-	I-Disease
864	linked	I-Disease
864	Emery	I-Disease
864	-	I-Disease
864	Dreifuss	I-Disease
864	muscular	I-Disease
864	dystrophy	I-Disease
864	in	O
864	a	O
864	boy	O
864	with	O
864	emerin	O
864	gene	O
864	deletion	O
864	.	O
865	A	O
865	boy	O
865	developed	O
865	contractures	B-Disease
865	of	I-Disease
865	the	I-Disease
865	Achilles	I-Disease
865	tendons	I-Disease
865	at	O
865	3	O
865	years	O
865	and	O
865	of	O
865	the	O
865	postcervical	O
865	muscles	O
865	at	O
865	7	O
865	years	O
865	,	O
865	although	O
865	neither	O
865	contractures	B-Disease
865	of	I-Disease
865	the	I-Disease
865	elbows	I-Disease
865	nor	O
865	cardiac	B-Disease
865	abnormality	I-Disease
865	were	O
865	recognized	O
865	by	O
865	the	O
865	age	O
865	of	O
865	9	O
865	years	O
865	.	O
866	Muscle	O
866	computed	O
866	tomography	O
866	scanning	O
866	revealed	O
866	changes	O
866	characteristic	O
866	of	O
866	muscle	O
866	involvement	O
866	.	O
867	Emerin	O
867	was	O
867	not	O
867	detected	O
867	in	O
867	the	O
867	biopsied	O
867	muscle	O
867	,	O
867	and	O
867	RT	O
867	-	O
867	PCR	O
867	and	O
867	PCR	O
867	-	O
867	based	O
867	genomic	O
867	DNA	O
867	analyses	O
867	of	O
867	the	O
867	emerin	O
867	gene	O
867	demonstrated	O
867	no	O
867	amplification	O
867	product	O
867	in	O
867	the	O
867	patient	O
867	.	O
868	These	O
868	results	O
868	confirmed	O
868	the	O
868	diagnosis	O
868	of	O
868	X	B-Disease
868	-	I-Disease
868	linked	I-Disease
868	Emery	I-Disease
868	-	I-Disease
868	Dreifuss	I-Disease
868	muscular	I-Disease
868	dystrophy	I-Disease
868	(	O
868	EDMD	B-Disease
868	)	O
868	,	O
868	and	O
868	reinforce	O
868	the	O
868	necessity	O
868	of	O
868	molecular	O
868	genetic	O
868	diagnosis	O
868	of	O
868	the	O
868	membrane	O
868	protein	O
868	emerin	O
868	in	O
868	younger	O
868	patients	O
868	with	O
868	possible	O
868	EDMD	B-Disease
868	before	O
868	appearance	O
868	of	O
868	the	O
868	typical	O
868	symptoms	O
868	,	O
868	to	O
868	avoid	O
868	sudden	B-Disease
868	cardiac	I-Disease
868	death	I-Disease
868	.	O
868	.	O
869	Duchenne	B-Disease
869	/	I-Disease
869	Becker	I-Disease
869	muscular	I-Disease
869	dystrophy	I-Disease
869	:	O
869	correlation	O
869	of	O
869	phenotype	O
869	by	O
869	electroretinography	O
869	with	O
869	sites	O
869	of	O
869	dystrophin	O
869	mutations	O
869	.	O
870	The	O
870	dark	O
870	-	O
870	adapted	O
870	electroretinogram	O
870	(	O
870	ERG	O
870	)	O
870	of	O
870	patients	O
870	with	O
870	Duchenne	B-Disease
870	and	I-Disease
870	Becker	I-Disease
870	muscular	I-Disease
870	dystrophy	I-Disease
870	(	O
870	DMD	B-Disease
870	/	O
870	BMD	B-Disease
870	)	O
870	shows	O
870	a	O
870	marked	O
870	reduction	O
870	in	O
870	b	O
870	-	O
870	wave	O
870	amplitude	O
870	.	O
871	Genotype	O
871	-	O
871	phenotype	O
871	studies	O
871	of	O
871	mouse	O
871	models	O
871	for	O
871	DMD	B-Disease
871	show	O
871	position	O
871	-	O
871	specific	O
871	effects	O
871	of	O
871	the	O
871	mutations	O
871	upon	O
871	the	O
871	phenotype	O
871	mice	O
871	with	O
871	5	O
871	defects	O
871	of	O
871	dystrophin	O
871	have	O
871	normal	O
871	ERGs	O
871	,	O
871	those	O
871	with	O
871	defects	O
871	in	O
871	the	O
871	central	O
871	region	O
871	have	O
871	a	O
871	normal	O
871	b	O
871	-	O
871	wave	O
871	amplitude	O
871	associated	O
871	with	O
871	prolonged	O
871	implicit	O
871	times	O
871	for	O
871	both	O
871	the	O
871	b	O
871	-	O
871	wave	O
871	and	O
871	oscillatory	O
871	potentials	O
871	,	O
871	and	O
871	mice	O
871	with	O
871	3	O
871	defects	O
871	have	O
871	a	O
871	phenotype	O
871	similar	O
871	to	O
871	that	O
871	seen	O
871	in	O
871	DMD	B-Disease
871	/	O
871	BMD	B-Disease
871	patients	O
871	.	O
872	The	O
872	mouse	O
872	studies	O
872	suggest	O
872	a	O
872	key	O
872	role	O
872	for	O
872	the	O
872	carboxyl	O
872	terminal	O
872	dystrophin	O
872	isoform	O
872	,	O
872	Dp260	O
872	,	O
872	in	O
872	retinal	O
872	electrophysiology	O
872	.	O
873	We	O
873	have	O
873	undertaken	O
873	a	O
873	systematic	O
873	evaluation	O
873	of	O
873	DMD	B-Disease
873	/	O
873	BMD	B-Disease
873	patients	O
873	through	O
873	clinical	O
873	examination	O
873	and	O
873	review	O
873	of	O
873	the	O
873	literature	O
873	in	O
873	order	O
873	to	O
873	determine	O
873	whether	O
873	the	O
873	position	O
873	-	O
873	specific	O
873	effects	O
873	of	O
873	mutations	O
873	noted	O
873	in	O
873	the	O
873	mouse	O
873	are	O
873	present	O
873	in	O
873	man	O
873	.	O
874	We	O
874	have	O
874	found	O
874	that	O
874	,	O
874	in	O
874	man	O
874	,	O
874	a	O
874	wider	O
874	variation	O
874	of	O
874	DMD	B-Disease
874	defects	I-Disease
874	correlate	O
874	with	O
874	reductions	O
874	in	O
874	the	O
874	b	O
874	-	O
874	wave	O
874	amplitude	O
874	.	O
875	Individuals	O
875	with	O
875	normal	O
875	ERGs	O
875	have	O
875	mutations	O
875	predominantly	O
875	located	O
875	5	O
875	of	O
875	the	O
875	transcript	O
875	initiation	O
875	site	O
875	of	O
875	Dp260	O
875	.	O
876	Our	O
876	results	O
876	suggest	O
876	that	O
876	the	O
876	most	O
876	important	O
876	determinant	O
876	in	O
876	the	O
876	ERG	O
876	b	O
876	-	O
876	wave	O
876	phenotype	O
876	is	O
876	the	O
876	mutation	O
876	position	O
876	,	O
876	rather	O
876	than	O
876	muscle	B-Disease
876	disease	I-Disease
876	severity	O
876	.	O
877	Forty	O
877	-	O
877	six	O
877	per	O
877	cent	O
877	of	O
877	patients	O
877	with	O
877	mutations	O
877	5	O
877	of	O
877	the	O
877	Dp260	O
877	transcript	O
877	start	O
877	site	O
877	have	O
877	abnormal	O
877	ERGs	O
877	,	O
877	as	O
877	opposed	O
877	to	O
877	94	O
877	%	O
877	with	O
877	more	O
877	distal	O
877	mutations	O
877	.	O
878	The	O
878	human	O
878	genotype	O
878	-	O
878	phenotype	O
878	correlations	O
878	are	O
878	consistent	O
878	with	O
878	a	O
878	role	O
878	for	O
878	Dp260	O
878	in	O
878	normal	O
878	retinal	O
878	electrophysiology	O
878	and	O
878	may	O
878	also	O
878	reflect	O
878	the	O
878	expression	O
878	of	O
878	other	O
878	C	O
878	-	O
878	terminal	O
878	dystrophin	O
878	isoforms	O
878	and	O
878	their	O
878	contributions	O
878	to	O
878	retinal	O
878	signal	O
878	transmission	O
878	.	O
878	.	O
879	Cis	O
879	and	O
879	trans	O
879	effects	O
879	of	O
879	the	O
879	myotonic	B-Disease
879	dystrophy	I-Disease
879	(	O
879	DM	B-Disease
879	)	O
879	mutation	O
879	in	O
879	a	O
879	cell	O
879	culture	O
879	model	O
879	.	O
880	The	O
880	mutation	O
880	causing	O
880	myotonic	B-Disease
880	dystrophy	I-Disease
880	(	O
880	DM	B-Disease
880	)	O
880	has	O
880	been	O
880	identified	O
880	as	O
880	a	O
880	CTG	O
880	expansion	O
880	in	O
880	the	O
880	3	O
880	-	O
880	untranslated	O
880	region	O
880	(	O
880	3	O
880	-	O
880	UTR	O
880	)	O
880	of	O
880	the	O
880	DM	B-Disease
880	protein	O
880	kinase	O
880	gene	O
880	(	O
880	DMPK	O
880	)	O
880	,	O
880	but	O
880	the	O
880	mechanism	O
880	(	O
880	s	O
880	)	O
880	of	O
880	pathogenesis	O
880	remain	O
880	unknown	O
880	.	O
881	Studies	O
881	using	O
881	DM	B-Disease
881	patient	O
881	materials	O
881	have	O
881	often	O
881	produced	O
881	confusing	O
881	results	O
881	.	O
882	Therefore	O
882	,	O
882	to	O
882	study	O
882	the	O
882	effects	O
882	of	O
882	the	O
882	DM	B-Disease
882	mutation	O
882	in	O
882	a	O
882	controlled	O
882	environment	O
882	,	O
882	we	O
882	have	O
882	established	O
882	a	O
882	cell	O
882	culture	O
882	model	O
882	system	O
882	using	O
882	C2C12	O
882	mouse	O
882	myoblasts	O
882	.	O
883	By	O
883	expressing	O
883	chimeric	O
883	reporter	O
883	constructs	O
883	containing	O
883	a	O
883	reporter	O
883	gene	O
883	fused	O
883	to	O
883	a	O
883	human	O
883	DMPK	O
883	3	O
883	-	O
883	UTR	O
883	,	O
883	we	O
883	identified	O
883	both	O
883	cis	O
883	and	O
883	trans	O
883	effects	O
883	that	O
883	are	O
883	mediated	O
883	by	O
883	the	O
883	DM	B-Disease
883	mutation	O
883	.	O
884	Our	O
884	data	O
884	show	O
884	that	O
884	a	O
884	mutant	O
884	DMPK	O
884	3	O
884	-	O
884	UTR	O
884	,	O
884	with	O
884	as	O
884	few	O
884	as	O
884	57	O
884	CTGs	O
884	,	O
884	had	O
884	a	O
884	negative	O
884	cis	O
884	effect	O
884	on	O
884	protein	O
884	expression	O
884	and	O
884	resulted	O
884	in	O
884	the	O
884	aggregation	O
884	of	O
884	reporter	O
884	transcripts	O
884	into	O
884	discrete	O
884	nuclear	O
884	foci	O
884	.	O
885	We	O
885	determined	O
885	by	O
885	deletion	O
885	analysis	O
885	that	O
885	an	O
885	expanded	O
885	(	O
885	CTG	O
885	)	O
885	(	O
885	n	O
885	)	O
885	tract	O
885	alone	O
885	was	O
885	sufficient	O
885	to	O
885	mediate	O
885	these	O
885	cis	O
885	effects	O
885	.	O
886	Furthermore	O
886	,	O
886	in	O
886	contrast	O
886	to	O
886	the	O
886	normal	O
886	DMPK	O
886	3	O
886	-	O
886	UTR	O
886	mRNA	O
886	,	O
886	a	O
886	mutant	O
886	DMPK	O
886	3	O
886	-	O
886	UTR	O
886	mRNA	O
886	with	O
886	(	O
886	CUG	O
886	)	O
886	(	O
886	200	O
886	)	O
886	selectively	O
886	inhibited	O
886	myogenic	O
886	differentiation	O
886	of	O
886	C2C12	O
886	myoblasts	O
886	.	O
887	Genetic	O
887	analysis	O
887	and	O
887	the	O
887	Cre	O
887	-	O
887	loxP	O
887	system	O
887	were	O
887	used	O
887	to	O
887	clearly	O
887	demonstrate	O
887	that	O
887	the	O
887	myoblast	O
887	fusion	O
887	defect	O
887	could	O
887	be	O
887	rescued	O
887	by	O
887	eliminating	O
887	the	O
887	expression	O
887	of	O
887	the	O
887	mutant	O
887	DMPK	O
887	3	O
887	-	O
887	UTR	O
887	transcript	O
887	.	O
888	Characterization	O
888	of	O
888	spontaneous	O
888	deletion	O
888	events	O
888	mapped	O
888	the	O
888	inhibitory	O
888	effect	O
888	to	O
888	the	O
888	(	O
888	CTG	O
888	)	O
888	(	O
888	n	O
888	)	O
888	expansion	O
888	and	O
888	/	O
888	or	O
888	the	O
888	3	O
888	end	O
888	of	O
888	the	O
888	DMPK	O
888	3	O
888	-	O
888	UTR	O
888	.	O
889	These	O
889	results	O
889	provide	O
889	evidence	O
889	that	O
889	the	O
889	DM	B-Disease
889	mutation	O
889	acts	O
889	in	O
889	cis	O
889	to	O
889	reduce	O
889	protein	O
889	production	O
889	(	O
889	consistent	O
889	with	O
889	DMPK	B-Disease
889	haploinsufficiency	I-Disease
889	)	O
889	and	O
889	in	O
889	trans	O
889	as	O
889	a	O
889	riboregulator	O
889	to	O
889	inhibit	O
889	myogenesis	O
889	.	O
889	.	O
890	Coats	B-Disease
890	'	I-Disease
890	disease	I-Disease
890	of	O
890	the	O
890	retina	O
890	(	O
890	unilateral	B-Disease
890	retinal	I-Disease
890	telangiectasis	I-Disease
890	)	O
890	caused	O
890	by	O
890	somatic	O
890	mutation	O
890	in	O
890	the	O
890	NDP	O
890	gene	O
890	:	O
890	a	O
890	role	O
890	for	O
890	norrin	O
890	in	O
890	retinal	O
890	angiogenesis	O
890	.	O
891	Coats	B-Disease
891	disease	I-Disease
891	is	O
891	characterized	O
891	by	O
891	abnormal	B-Disease
891	retinal	I-Disease
891	vascular	I-Disease
891	development	I-Disease
891	(	O
891	so	O
891	-	O
891	called	O
891	retinal	B-Disease
891	telangiectasis	I-Disease
891	)	O
891	which	O
891	results	O
891	in	O
891	massive	O
891	intraretinal	B-Disease
891	and	I-Disease
891	subretinal	I-Disease
891	lipid	I-Disease
891	accumulation	I-Disease
891	(	O
891	exudative	B-Disease
891	retinal	I-Disease
891	detachment	I-Disease
891	)	O
891	.	O
892	The	O
892	classical	O
892	form	O
892	of	O
892	Coats	B-Disease
892	disease	I-Disease
892	is	O
892	almost	O
892	invariably	O
892	isolated	O
892	,	O
892	unilateral	O
892	and	O
892	seen	O
892	in	O
892	males	O
892	.	O
893	A	O
893	female	O
893	with	O
893	a	O
893	unilateral	O
893	variant	O
893	of	O
893	Coats	B-Disease
893	disease	I-Disease
893	gave	O
893	birth	O
893	to	O
893	a	O
893	son	O
893	affected	O
893	by	O
893	Norrie	B-Disease
893	disease	I-Disease
893	.	O
894	Both	O
894	carried	O
894	a	O
894	missense	O
894	mutation	O
894	within	O
894	the	O
894	NDP	O
894	gene	O
894	on	O
894	chromosome	O
894	Xp11	O
894	.	O
895	2	O
895	2	O
895	.	O
896	Subsequently	O
896	analysis	O
896	of	O
896	the	O
896	retinas	O
896	of	O
896	nine	O
896	enucleated	O
896	eyes	O
896	from	O
896	males	O
896	with	O
896	Coats	B-Disease
896	disease	I-Disease
896	demonstrated	O
896	in	O
896	one	O
896	a	O
896	somatic	O
896	mutation	O
896	in	O
896	the	O
896	NDP	O
896	gene	O
896	which	O
896	was	O
896	not	O
896	present	O
896	within	O
896	non	O
896	-	O
896	retinal	O
896	tissue	O
896	.	O
897	We	O
897	suggest	O
897	that	O
897	Coats	B-Disease
897	telangiectasis	I-Disease
897	is	O
897	secondary	O
897	to	O
897	somatic	O
897	mutation	O
897	in	O
897	the	O
897	NDP	O
897	gene	O
897	which	O
897	results	O
897	in	O
897	a	O
897	deficiency	B-Disease
897	of	I-Disease
897	norrin	I-Disease
897	(	O
897	the	O
897	protein	O
897	product	O
897	of	O
897	the	O
897	NDP	O
897	gene	O
897	)	O
897	within	O
897	the	O
897	developing	O
897	retina	O
897	.	O
898	This	O
898	supports	O
898	recent	O
898	observations	O
898	that	O
898	the	O
898	protein	O
898	is	O
898	critical	O
898	for	O
898	normal	O
898	retinal	O
898	vasculogenesis	O
898	.	O
899	Hereditary	O
899	TP53	O
899	codon	O
899	292	O
899	and	O
899	somatic	O
899	P16INK4A	O
899	codon	O
899	94	O
899	mutations	O
899	in	O
899	a	O
899	Li	B-Disease
899	-	I-Disease
899	Fraumeni	I-Disease
899	syndrome	I-Disease
899	family	O
899	.	O
900	Li	B-Disease
900	-	I-Disease
900	Fraumeni	I-Disease
900	syndrome	I-Disease
900	is	O
900	an	O
900	autosomal	B-Disease
900	dominant	I-Disease
900	disorder	I-Disease
900	that	O
900	is	O
900	characterized	O
900	by	O
900	various	O
900	types	O
900	of	O
900	cancer	B-Disease
900	in	O
900	childhood	O
900	and	O
900	adult	O
900	cases	O
900	.	O
901	Although	O
901	hereditary	O
901	TP53	O
901	mutation	O
901	is	O
901	very	O
901	rare	O
901	in	O
901	different	O
901	human	O
901	cancers	B-Disease
901	,	O
901	it	O
901	has	O
901	been	O
901	frequently	O
901	reported	O
901	in	O
901	Li	B-Disease
901	-	I-Disease
901	Fraumeni	I-Disease
901	syndrome	I-Disease
901	.	O
902	On	O
902	the	O
902	other	O
902	hand	O
902	,	O
902	hereditary	O
902	mutations	O
902	of	O
902	TP57KIP2	O
902	,	O
902	P15INK4B	O
902	,	O
902	and	O
902	P16INK4A	O
902	,	O
902	which	O
902	affect	O
902	the	O
902	cell	O
902	cycle	O
902	similar	O
902	to	O
902	TP53	O
902	,	O
902	were	O
902	observed	O
902	in	O
902	some	O
902	types	O
902	of	O
902	cancer	B-Disease
902	.	O
903	In	O
903	a	O
903	Turkish	O
903	family	O
903	with	O
903	the	O
903	diagnosis	O
903	of	O
903	Li	B-Disease
903	-	I-Disease
903	Fraumeni	I-Disease
903	syndrome	I-Disease
903	,	O
903	we	O
903	analyzed	O
903	the	O
903	mutation	O
903	pattern	O
903	of	O
903	TP53	O
903	,	O
903	P57KIP2	O
903	,	O
903	P15INK4B	O
903	,	O
903	and	O
903	P16INK4A	O
903	in	O
903	the	O
903	peripheral	O
903	blood	O
903	,	O
903	and	O
903	loss	O
903	of	O
903	heterozygosity	O
903	(	O
903	homo	O
903	/	O
903	hemizygous	O
903	deletion	O
903	)	O
903	pattern	O
903	of	O
903	TP53	O
903	and	O
903	P15INK4B	O
903	/	O
903	P16INK4A	O
903	in	O
903	two	O
903	tumor	B-Disease
903	tissues	O
903	.	O
904	The	O
904	propositus	O
904	had	O
904	a	O
904	seminoma	B-Disease
904	,	O
904	his	O
904	daughter	O
904	a	O
904	medulloblastoma	B-Disease
904	,	O
904	and	O
904	one	O
904	of	O
904	his	O
904	healthy	O
904	cousins	O
904	,	O
904	a	O
904	TP53	O
904	codon	O
904	292	O
904	missense	O
904	point	O
904	mutation	O
904	(	O
904	AAA	O
904	-	O
904	-	O
904	>	O
904	ATA	O
904	;	O
904	Lys	O
904	-	O
904	-	O
904	>	O
904	Ile	O
904	)	O
904	in	O
904	the	O
904	peripheral	O
904	blood	O
904	cells	O
904	.	O
905	Tumor	O
905	tissue	O
905	obtained	O
905	from	O
905	the	O
905	propositus	O
905	with	O
905	the	O
905	seminoma	B-Disease
905	revealed	O
905	loss	O
905	of	O
905	heterozygosity	O
905	in	O
905	the	O
905	TP53	O
905	gene	O
905	.	O
906	In	O
906	the	O
906	analyses	O
906	of	O
906	tumor	B-Disease
906	tissues	O
906	from	O
906	the	O
906	propositus	O
906	and	O
906	his	O
906	daughter	O
906	,	O
906	a	O
906	P16INK4A	O
906	codon	O
906	94	O
906	missense	O
906	point	O
906	mutation	O
906	(	O
906	GCG	O
906	-	O
906	-	O
906	>	O
906	GAG	O
906	;	O
906	Ala	O
906	-	O
906	-	O
906	>	O
906	Glu	O
906	)	O
906	was	O
906	observed	O
906	with	O
906	the	O
906	hereditary	O
906	TP53	O
906	mutation	O
906	.	O
907	P16INK4A	O
907	codon	O
907	94	O
907	mutation	O
907	observed	O
907	in	O
907	our	O
907	family	O
907	is	O
907	a	O
907	novel	O
907	mutation	O
907	in	O
907	Li	B-Disease
907	-	I-Disease
907	Fraumeni	I-Disease
907	syndrome	I-Disease
907	.	O
908	No	O
908	other	O
908	gene	O
908	alteration	O
908	in	O
908	TP53	O
908	,	O
908	P57KIP2	O
908	,	O
908	P15INK4B	O
908	,	O
908	and	O
908	P16INK4A	O
908	was	O
908	observed	O
908	.	O
909	Existence	O
909	of	O
909	the	O
909	P16INK4A	O
909	mutation	O
909	and	O
909	the	O
909	hereditary	O
909	TP53	O
909	mutation	O
909	with	O
909	or	O
909	without	O
909	loss	O
909	of	O
909	heterozygosity	O
909	in	O
909	the	O
909	TP53	O
909	gene	O
909	(	O
909	seminoma	B-Disease
909	/	O
909	medulloblastoma	B-Disease
909	)	O
909	may	O
909	be	O
909	evidence	O
909	for	O
909	a	O
909	common	O
909	mechanism	O
909	involved	O
909	in	O
909	tumorogenesis	B-Disease
909	.	O
910	The	O
910	gene	O
910	alterations	O
910	in	O
910	TP53	O
910	and	O
910	P16INK4A	O
910	genes	O
910	may	O
910	be	O
910	used	O
910	as	O
910	tumor	B-Disease
910	markers	O
910	in	O
910	our	O
910	family	O
910	.	O
910	.	O
911	A	O
911	novel	O
911	mutation	O
911	in	O
911	the	O
911	sodium	O
911	/	O
911	iodide	O
911	symporter	O
911	gene	O
911	in	O
911	the	O
911	largest	O
911	family	O
911	with	O
911	iodide	B-Disease
911	transport	I-Disease
911	defect	I-Disease
911	.	O
912	We	O
912	previously	O
912	reported	O
912	nine	O
912	children	O
912	with	O
912	an	O
912	autosomally	O
912	recessive	O
912	form	O
912	of	O
912	congenital	B-Disease
912	hypothyroidism	I-Disease
912	due	O
912	to	O
912	an	O
912	iodide	B-Disease
912	transport	I-Disease
912	defect	I-Disease
912	in	O
912	a	O
912	large	O
912	Hutterite	O
912	family	O
912	with	O
912	extensive	O
912	consanguinity	O
912	living	O
912	in	O
912	central	O
912	Canada	O
912	.	O
913	Since	O
913	the	O
913	original	O
913	report	O
913	,	O
913	we	O
913	have	O
913	diagnosed	O
913	congenital	B-Disease
913	hypothyroidism	I-Disease
913	by	O
913	newborn	O
913	TSH	O
913	screening	O
913	in	O
913	9	O
913	additional	O
913	children	O
913	from	O
913	the	O
913	family	O
913	.	O
914	We	O
914	performed	O
914	direct	O
914	sequencing	O
914	of	O
914	the	O
914	PCR	O
914	products	O
914	of	O
914	each	O
914	NIS	O
914	(	O
914	sodium	O
914	/	O
914	iodide	O
914	symporter	O
914	)	O
914	gene	O
914	exon	O
914	with	O
914	flanking	O
914	introns	O
914	amplified	O
914	from	O
914	genomic	O
914	DNA	O
914	extracted	O
914	from	O
914	peripheral	O
914	blood	O
914	cells	O
914	of	O
914	the	O
914	patients	O
914	.	O
915	We	O
915	identified	O
915	a	O
915	novel	O
915	NIS	O
915	gene	O
915	mutation	O
915	,	O
915	G395R	O
915	(	O
915	Gly395	O
915	-	O
915	-	O
915	>	O
915	Arg	O
915	;	O
915	GGA	O
915	-	O
915	-	O
915	>	O
915	AGA	O
915	)	O
915	,	O
915	in	O
915	10	O
915	patients	O
915	examined	O
915	in	O
915	the	O
915	present	O
915	study	O
915	.	O
916	All	O
916	of	O
916	the	O
916	parents	O
916	tested	O
916	were	O
916	heterozygous	O
916	for	O
916	the	O
916	mutation	O
916	,	O
916	suggesting	O
916	that	O
916	the	O
916	patients	O
916	were	O
916	homozygous	O
916	.	O
917	The	O
917	mutation	O
917	was	O
917	located	O
917	in	O
917	the	O
917	10th	O
917	transmembrane	O
917	helix	O
917	.	O
918	Expression	O
918	experiments	O
918	by	O
918	transfection	O
918	of	O
918	the	O
918	mutant	O
918	NIS	O
918	complimentary	O
918	DNA	O
918	into	O
918	COS	O
918	-	O
918	7	O
918	cells	O
918	showed	O
918	no	O
918	perchlorate	O
918	-	O
918	sensitive	O
918	iodide	O
918	uptake	O
918	,	O
918	confirming	O
918	that	O
918	the	O
918	mutation	O
918	is	O
918	the	O
918	direct	O
918	cause	O
918	of	O
918	the	O
918	iodide	B-Disease
918	transport	I-Disease
918	defect	I-Disease
918	in	O
918	these	O
918	patients	O
918	.	O
919	A	O
919	patient	O
919	who	O
919	showed	O
919	an	O
919	intermediate	O
919	saliva	O
919	/	O
919	serum	O
919	technetium	O
919	ratio	O
919	(	O
919	14	O
919	.	O
919	0	O
919	;	O
919	normal	O
919	,	O
919	>	O
919	or	O
919	=	O
919	20	O
919	)	O
919	and	O
919	was	O
919	considered	O
919	to	O
919	have	O
919	a	O
919	partial	O
919	or	O
919	less	O
919	severe	O
919	defect	O
919	in	O
919	the	O
919	previous	O
919	report	O
919	(	O
919	IX	O
919	-	O
919	24	O
919	)	O
919	did	O
919	not	O
919	have	O
919	a	O
919	NIS	O
919	gene	O
919	mutation	O
919	.	O
920	It	O
920	is	O
920	now	O
920	possible	O
920	to	O
920	use	O
920	gene	O
920	diagnostics	O
920	of	O
920	this	O
920	unique	O
920	NIS	O
920	mutation	O
920	to	O
920	identify	O
920	patients	O
920	with	O
920	congenital	B-Disease
920	hypothyroidism	I-Disease
920	due	O
920	to	O
920	an	O
920	iodide	B-Disease
920	transport	I-Disease
920	defect	I-Disease
920	in	O
920	this	O
920	family	O
920	and	O
920	to	O
920	determine	O
920	the	O
920	carrier	O
920	state	O
920	of	O
920	potential	O
920	parents	O
920	for	O
920	genetic	O
920	counseling	O
920	and	O
920	arranging	O
920	rapid	O
920	and	O
920	early	O
920	diagnosis	O
920	of	O
920	their	O
920	infants	O
920	.	O
921	Molecular	O
921	analysis	O
921	in	O
921	familial	B-Disease
921	neurohypophyseal	I-Disease
921	diabetes	I-Disease
921	insipidus	I-Disease
921	:	O
921	early	O
921	diagnosis	O
921	of	O
921	an	O
921	asymptomatic	O
921	carrier	O
921	.	O
922	Familial	B-Disease
922	neurohypophyseal	I-Disease
922	diabetes	I-Disease
922	insipidus	I-Disease
922	(	O
922	FNDI	B-Disease
922	)	O
922	is	O
922	an	O
922	inherited	O
922	deficiency	B-Disease
922	of	I-Disease
922	the	I-Disease
922	hormone	I-Disease
922	arginine	I-Disease
922	vasopressin	I-Disease
922	(	O
922	AVP	O
922	)	O
922	and	O
922	is	O
922	transmitted	O
922	as	O
922	an	O
922	autosomal	O
922	dominant	O
922	trait	O
922	.	O
923	In	O
923	the	O
923	present	O
923	study	O
923	we	O
923	have	O
923	analyzed	O
923	the	O
923	AVP	O
923	-	O
923	neurophysin	O
923	II	O
923	(	O
923	AVP	O
923	-	O
923	NPII	O
923	)	O
923	gene	O
923	in	O
923	a	O
923	Spanish	O
923	kindred	O
923	.	O
924	Studies	O
924	were	O
924	performed	O
924	on	O
924	seven	O
924	members	O
924	(	O
924	four	O
924	clinically	O
924	affected	O
924	)	O
924	of	O
924	the	O
924	family	O
924	.	O
925	Patients	O
925	were	O
925	diagnosed	O
925	at	O
925	the	O
925	Hospital	O
925	Universitario	O
925	Gregorio	O
925	Maranon	O
925	(	O
925	Madrid	O
925	,	O
925	Spain	O
925	)	O
925	.	O
926	The	O
926	entire	O
926	coding	O
926	region	O
926	of	O
926	the	O
926	AVP	O
926	-	O
926	NPII	O
926	gene	O
926	of	O
926	all	O
926	family	O
926	members	O
926	was	O
926	amplified	O
926	by	O
926	PCR	O
926	and	O
926	sequenced	O
926	.	O
927	All	O
927	affected	O
927	individuals	O
927	presented	O
927	a	O
927	missense	O
927	mutation	O
927	(	O
927	G1757	O
927	-	O
927	-	O
927	>	O
927	A	O
927	)	O
927	that	O
927	replaces	O
927	glycine	O
927	at	O
927	position	O
927	23	O
927	with	O
927	arginine	O
927	within	O
927	the	O
927	NPII	O
927	domain	O
927	.	O
928	The	O
928	substitution	O
928	was	O
928	confirmed	O
928	by	O
928	restriction	O
928	endonuclease	O
928	analysis	O
928	and	O
928	was	O
928	present	O
928	in	O
928	heterozygosis	O
928	.	O
929	Additionally	O
929	,	O
929	one	O
929	of	O
929	the	O
929	asymptomatic	O
929	relatives	O
929	(	O
929	a	O
929	girl	O
929	8	O
929	months	O
929	old	O
929	at	O
929	the	O
929	time	O
929	of	O
929	study	O
929	)	O
929	was	O
929	identified	O
929	as	O
929	carrier	O
929	of	O
929	the	O
929	same	O
929	mutation	O
929	and	O
929	developed	O
929	the	O
929	disease	O
929	3	O
929	months	O
929	later	O
929	.	O
930	The	O
930	alteration	O
930	found	O
930	in	O
930	the	O
930	second	O
930	exon	O
930	of	O
930	the	O
930	gene	O
930	in	O
930	this	O
930	family	O
930	seems	O
930	to	O
930	be	O
930	responsible	O
930	for	O
930	the	O
930	disease	O
930	,	O
930	as	O
930	all	O
930	individuals	O
930	harboring	O
930	the	O
930	mutation	O
930	had	O
930	been	O
930	previously	O
930	diagnosed	O
930	or	O
930	have	O
930	eventually	O
930	developed	O
930	FNDI	B-Disease
930	.	O
931	Identification	O
931	of	O
931	the	O
931	molecular	O
931	defect	O
931	underlying	O
931	FNDI	B-Disease
931	in	O
931	affected	O
931	families	O
931	is	O
931	a	O
931	powerful	O
931	tool	O
931	for	O
931	early	O
931	asymptomatic	O
931	diagnosis	O
931	in	O
931	infants	O
931	.	O
931	.	O
932	Deficit	O
932	of	O
932	in	O
932	vivo	O
932	mitochondrial	O
932	ATP	O
932	production	O
932	in	O
932	patients	O
932	with	O
932	Friedreich	B-Disease
932	ataxia	I-Disease
932	.	O
933	Friedreich	B-Disease
933	ataxia	I-Disease
933	(	O
933	FRDA	B-Disease
933	)	O
933	,	O
933	the	O
933	most	O
933	common	O
933	of	O
933	the	O
933	inherited	B-Disease
933	ataxias	I-Disease
933	,	O
933	is	O
933	an	O
933	autosomal	B-Disease
933	recessive	I-Disease
933	degenerative	I-Disease
933	disorder	I-Disease
933	,	O
933	characterized	O
933	clinically	O
933	by	O
933	onset	O
933	before	O
933	the	O
933	age	O
933	of	O
933	25	O
933	of	O
933	progressive	B-Disease
933	gait	I-Disease
933	and	I-Disease
933	limb	I-Disease
933	ataxia	I-Disease
933	,	O
933	absence	B-Disease
933	of	I-Disease
933	deep	I-Disease
933	tendon	I-Disease
933	reflexes	I-Disease
933	,	O
933	extensor	B-Disease
933	plantar	I-Disease
933	responses	I-Disease
933	,	O
933	and	O
933	loss	B-Disease
933	of	I-Disease
933	position	I-Disease
933	and	I-Disease
933	vibration	I-Disease
933	sense	I-Disease
933	in	O
933	the	O
933	lower	O
933	limbs	O
933	.	O
934	FRDA	B-Disease
934	is	O
934	caused	O
934	by	O
934	a	O
934	GAA	O
934	triplet	O
934	expansion	O
934	in	O
934	the	O
934	first	O
934	intron	O
934	of	O
934	the	O
934	FRDA	B-Disease
934	gene	O
934	on	O
934	chromosome	O
934	9q13	O
934	in	O
934	97	O
934	%	O
934	of	O
934	patients	O
934	.	O
935	The	O
935	FRDA	B-Disease
935	gene	O
935	encodes	O
935	a	O
935	widely	O
935	expressed	O
935	210	O
935	-	O
935	aa	O
935	protein	O
935	,	O
935	frataxin	O
935	,	O
935	which	O
935	is	O
935	located	O
935	in	O
935	mitochondria	O
935	and	O
935	is	O
935	severely	O
935	reduced	O
935	in	O
935	FRDA	B-Disease
935	patients	O
935	.	O
936	Frataxin	O
936	function	O
936	is	O
936	still	O
936	unknown	O
936	but	O
936	the	O
936	knockout	O
936	of	O
936	the	O
936	yeast	O
936	frataxin	O
936	homologue	O
936	gene	O
936	(	O
936	YFH1	O
936	)	O
936	showed	O
936	a	O
936	severe	O
936	defect	O
936	of	O
936	mitochondrial	O
936	respiration	O
936	and	O
936	loss	O
936	of	O
936	mtDNA	O
936	associated	O
936	with	O
936	elevated	O
936	intramitochondrial	O
936	iron	O
936	.	O
937	Here	O
937	we	O
937	report	O
937	in	O
937	vivo	O
937	evidence	O
937	of	O
937	impaired	O
937	mitochondrial	O
937	respiration	O
937	in	O
937	skeletal	O
937	muscle	O
937	of	O
937	FRDA	B-Disease
937	patients	O
937	.	O
938	Using	O
938	phosphorus	O
938	magnetic	O
938	resonance	O
938	spectroscopy	O
938	we	O
938	demonstrated	O
938	a	O
938	maximum	O
938	rate	O
938	of	O
938	muscle	O
938	mitochondrial	O
938	ATP	O
938	production	O
938	(	O
938	V	O
938	(	O
938	max	O
938	)	O
938	)	O
938	below	O
938	the	O
938	normal	O
938	range	O
938	in	O
938	all	O
938	12	O
938	FRDA	B-Disease
938	patients	O
938	and	O
938	a	O
938	strong	O
938	negative	O
938	correlation	O
938	between	O
938	mitochondrial	O
938	V	O
938	(	O
938	max	O
938	)	O
938	and	O
938	the	O
938	number	O
938	of	O
938	GAA	O
938	repeats	O
938	in	O
938	the	O
938	smaller	O
938	allele	O
938	.	O
939	Our	O
939	results	O
939	show	O
939	that	O
939	FRDA	B-Disease
939	is	O
939	a	O
939	nuclear	O
939	-	O
939	encoded	O
939	mitochondrial	B-Disease
939	disorder	I-Disease
939	affecting	O
939	oxidative	O
939	phosphorylation	O
939	and	O
939	give	O
939	a	O
939	rationale	O
939	for	O
939	treatments	O
939	aimed	O
939	to	O
939	improve	O
939	mitochondrial	O
939	function	O
939	in	O
939	this	O
939	condition	O
939	.	O
939	.	O
940	Identification	O
940	of	O
940	a	O
940	novel	O
940	R21X	O
940	mutation	O
940	in	O
940	the	O
940	liver	O
940	-	O
940	type	O
940	arginase	O
940	gene	O
940	(	O
940	ARG1	O
940	)	O
940	in	O
940	four	O
940	Portuguese	O
940	patients	O
940	with	O
940	argininemia	B-Disease
940	.	O
941	Argininemia	B-Disease
941	is	O
941	a	O
941	rare	O
941	autossomal	B-Disease
941	recessive	I-Disease
941	disorder	I-Disease
941	caused	O
941	by	O
941	deficiency	B-Disease
941	in	I-Disease
941	the	I-Disease
941	cytosolic	I-Disease
941	liver	I-Disease
941	-	I-Disease
941	type	I-Disease
941	arginase	I-Disease
941	enzyme	I-Disease
941	(	O
941	L	O
941	-	O
941	arginine	O
941	urea	O
941	-	O
941	hydrolase	O
941	;	O
941	E	O
941	.	O
941	C	O
941	.	O
941	3	O
941	.	O
941	5	O
941	.	O
941	3	O
941	.	O
941	1	O
941	)	O
941	.	O
942	In	O
942	order	O
942	to	O
942	investigate	O
942	the	O
942	molecular	O
942	basis	O
942	for	O
942	argininemia	B-Disease
942	in	O
942	four	O
942	unrelated	O
942	Portuguese	O
942	patients	O
942	(	O
942	two	O
942	from	O
942	northern	O
942	Portugal	O
942	and	O
942	two	O
942	from	O
942	Madeira	O
942	Island	O
942	)	O
942	we	O
942	performed	O
942	a	O
942	DNA	O
942	sequence	O
942	analysis	O
942	of	O
942	all	O
942	the	O
942	exons	O
942	and	O
942	exon	O
942	/	O
942	intron	O
942	boundaries	O
942	of	O
942	the	O
942	liver	O
942	-	O
942	type	O
942	arginase	O
942	gene	O
942	(	O
942	ARG1	O
942	)	O
942	.	O
943	All	O
943	patients	O
943	were	O
943	found	O
943	to	O
943	be	O
943	homozygous	O
943	for	O
943	a	O
943	newly	O
943	identified	O
943	C	O
943	-	O
943	>	O
943	T	O
943	transition	O
943	in	O
943	codon	O
943	21	O
943	(	O
943	exon	O
943	2	O
943	)	O
943	substituting	O
943	arginine	O
943	for	O
943	a	O
943	premature	O
943	stop	O
943	codon	O
943	(	O
943	R21X	O
943	CGA	O
943	to	O
943	TGA	O
943	)	O
943	and	O
943	generating	O
943	a	O
943	NlaIII	O
943	restriction	O
943	site	O
943	.	O
944	Restriction	O
944	digestion	O
944	following	O
944	PCR	O
944	amplification	O
944	of	O
944	ARG1	O
944	exon	O
944	2	O
944	confirmed	O
944	the	O
944	presence	O
944	of	O
944	the	O
944	mutation	O
944	.	O
945	Mutation	O
945	of	O
945	the	O
945	sterol	O
945	27	O
945	-	O
945	hydroxylase	O
945	gene	O
945	(	O
945	CYP27	O
945	)	O
945	results	O
945	in	O
945	truncation	O
945	of	O
945	mRNA	O
945	expressed	O
945	in	O
945	leucocytes	O
945	in	O
945	a	O
945	Japanese	O
945	family	O
945	with	O
945	cerebrotendinous	B-Disease
945	xanthomatosis	I-Disease
945	.	O
946	OBJECTIVES	O
946	A	O
946	Japanese	O
946	family	O
946	with	O
946	cerebrotendinous	B-Disease
946	xanthomatosis	I-Disease
946	(	O
946	CTX	B-Disease
946	)	O
946	was	O
946	investigated	O
946	for	O
946	a	O
946	sequence	O
946	alteration	O
946	in	O
946	the	O
946	sterol	O
946	27	O
946	-	O
946	hydroxylase	O
946	gene	O
946	(	O
946	CYP27	O
946	)	O
946	.	O
947	The	O
947	expression	O
947	of	O
947	CYP27	O
947	has	O
947	been	O
947	mostly	O
947	explored	O
947	using	O
947	cultured	O
947	fibroblasts	O
947	,	O
947	prompting	O
947	the	O
947	examination	O
947	of	O
947	the	O
947	transcripts	O
947	from	O
947	blood	O
947	leucocytes	O
947	as	O
947	a	O
947	simple	O
947	and	O
947	rapid	O
947	technique	O
947	.	O
948	METHODS	O
948	An	O
948	alteration	O
948	in	O
948	CYP27	O
948	of	O
948	the	O
948	proband	O
948	was	O
948	searched	O
948	for	O
948	by	O
948	polymerase	O
948	chain	O
948	reaction	O
948	-	O
948	single	O
948	strand	O
948	conformation	O
948	polymorphism	O
948	(	O
948	PCR	O
948	-	O
948	SSCP	O
948	)	O
948	analysis	O
948	and	O
948	subsequent	O
948	sequencing	O
948	.	O
949	Samples	O
949	of	O
949	RNA	O
949	were	O
949	subjected	O
949	to	O
949	reverse	O
949	transcription	O
949	PCR	O
949	(	O
949	RT	O
949	-	O
949	PCR	O
949	)	O
949	and	O
949	the	O
949	product	O
949	of	O
949	the	O
949	proband	O
949	was	O
949	amplified	O
949	with	O
949	nested	O
949	primers	O
949	and	O
949	sequenced	O
949	.	O
950	RESULTS	O
950	A	O
950	homozygous	O
950	G	O
950	to	O
950	A	O
950	transition	O
950	at	O
950	the	O
950	5	O
950	end	O
950	of	O
950	intron	O
950	7	O
950	was	O
950	detected	O
950	in	O
950	the	O
950	patient	O
950	.	O
951	In	O
951	RT	O
951	-	O
951	PCR	O
951	analysis	O
951	,	O
951	only	O
951	a	O
951	truncated	O
951	transcript	O
951	was	O
951	detected	O
951	in	O
951	the	O
951	patient	O
951	,	O
951	whereas	O
951	both	O
951	normal	O
951	and	O
951	truncated	O
951	transcripts	O
951	were	O
951	detected	O
951	in	O
951	the	O
951	siblings	O
951	.	O
952	The	O
952	sequencing	O
952	of	O
952	the	O
952	patients	O
952	cDNA	O
952	fragment	O
952	disclosed	O
952	a	O
952	direct	O
952	conjuction	O
952	of	O
952	exon	O
952	6	O
952	and	O
952	exon	O
952	8	O
952	.	O
953	CONCLUSION	O
953	The	O
953	mutation	O
953	at	O
953	splice	O
953	donor	O
953	site	O
953	and	O
953	the	O
953	truncation	O
953	of	O
953	mRNA	O
953	were	O
953	identical	O
953	with	O
953	those	O
953	of	O
953	a	O
953	recently	O
953	reported	O
953	Italian	O
953	patient	O
953	,	O
953	although	O
953	different	O
953	in	O
953	symptomatology	O
953	.	O
954	The	O
954	application	O
954	of	O
954	blood	O
954	leucocytes	O
954	can	O
954	be	O
954	a	O
954	simple	O
954	technique	O
954	on	O
954	analysing	O
954	a	O
954	constructive	O
954	abnormality	B-Disease
954	of	I-Disease
954	CYP27	I-Disease
954	mRNA	O
954	.	O
954	.	O
955	Clinical	O
955	and	O
955	molecular	O
955	genetic	O
955	analysis	O
955	of	O
955	19	O
955	Wolfram	B-Disease
955	syndrome	I-Disease
955	kindreds	O
955	demonstrating	O
955	a	O
955	wide	O
955	spectrum	O
955	of	O
955	mutations	O
955	in	O
955	WFS1	O
955	.	O
956	Wolfram	B-Disease
956	syndrome	I-Disease
956	is	O
956	an	O
956	autosomal	B-Disease
956	recessive	I-Disease
956	neurodegenerative	I-Disease
956	disorder	I-Disease
956	characterized	O
956	by	O
956	juvenile	B-Disease
956	-	I-Disease
956	onset	I-Disease
956	diabetes	I-Disease
956	mellitus	I-Disease
956	and	O
956	progressive	O
956	optic	B-Disease
956	atrophy	I-Disease
956	.	O
957	mtDNA	O
957	deletions	O
957	have	O
957	been	O
957	described	O
957	,	O
957	and	O
957	a	O
957	gene	O
957	(	O
957	WFS1	O
957	)	O
957	recently	O
957	has	O
957	been	O
957	identified	O
957	,	O
957	on	O
957	chromosome	O
957	4p16	O
957	,	O
957	encoding	O
957	a	O
957	predicted	O
957	890	O
957	amino	O
957	acid	O
957	transmembrane	O
957	protein	O
957	.	O
958	Direct	O
958	DNA	O
958	sequencing	O
958	was	O
958	done	O
958	to	O
958	screen	O
958	the	O
958	entire	O
958	coding	O
958	region	O
958	of	O
958	the	O
958	WFS1	O
958	gene	O
958	in	O
958	30	O
958	patients	O
958	from	O
958	19	O
958	British	O
958	kindreds	O
958	with	O
958	Wolfram	B-Disease
958	syndrome	I-Disease
958	.	O
959	DNA	O
959	was	O
959	also	O
959	screened	O
959	for	O
959	structural	O
959	rearrangements	O
959	(	O
959	deletions	O
959	and	O
959	duplications	O
959	)	O
959	and	O
959	point	O
959	mutations	O
959	in	O
959	mtDNA	O
959	.	O
960	No	O
960	pathogenic	O
960	mtDNA	O
960	mutations	O
960	were	O
960	found	O
960	in	O
960	our	O
960	cohort	O
960	.	O
961	We	O
961	identified	O
961	24	O
961	mutations	O
961	in	O
961	the	O
961	WFS1	O
961	gene	O
961	8	O
961	nonsense	O
961	mutations	O
961	,	O
961	8	O
961	missense	O
961	mutations	O
961	,	O
961	3	O
961	in	O
961	-	O
961	frame	O
961	deletions	O
961	,	O
961	1	O
961	in	O
961	-	O
961	frame	O
961	insertion	O
961	,	O
961	and	O
961	4	O
961	frameshift	O
961	mutations	O
961	.	O
962	Of	O
962	these	O
962	,	O
962	23	O
962	were	O
962	novel	O
962	mutations	O
962	,	O
962	and	O
962	most	O
962	occurred	O
962	in	O
962	exon	O
962	8	O
962	.	O
963	The	O
963	majority	O
963	of	O
963	patients	O
963	were	O
963	compound	O
963	heterozygotes	O
963	for	O
963	two	O
963	mutations	O
963	,	O
963	and	O
963	there	O
963	was	O
963	no	O
963	common	O
963	founder	O
963	mutation	O
963	.	O
964	The	O
964	data	O
964	were	O
964	also	O
964	analyzed	O
964	for	O
964	genotype	O
964	-	O
964	phenotype	O
964	relationships	O
964	.	O
965	Although	O
965	some	O
965	interesting	O
965	cases	O
965	were	O
965	noted	O
965	,	O
965	consideration	O
965	of	O
965	the	O
965	small	O
965	sample	O
965	size	O
965	and	O
965	frequency	O
965	of	O
965	each	O
965	mutation	O
965	indicated	O
965	no	O
965	clear	O
965	-	O
965	cut	O
965	correlations	O
965	between	O
965	any	O
965	of	O
965	the	O
965	observed	O
965	mutations	O
965	and	O
965	disease	O
965	severity	O
965	.	O
966	There	O
966	were	O
966	no	O
966	obvious	O
966	mutation	O
966	hot	O
966	spots	O
966	or	O
966	clusters	O
966	.	O
967	Hence	O
967	,	O
967	molecular	O
967	screening	O
967	for	O
967	Wolfram	B-Disease
967	syndrome	I-Disease
967	in	O
967	affected	O
967	families	O
967	and	O
967	for	O
967	Wolfram	B-Disease
967	syndrome	I-Disease
967	-	O
967	carrier	O
967	status	O
967	in	O
967	subjects	O
967	with	O
967	psychiatric	B-Disease
967	disorders	I-Disease
967	or	O
967	diabetes	B-Disease
967	mellitus	I-Disease
967	will	O
967	require	O
967	complete	O
967	analysis	O
967	of	O
967	exon	O
967	8	O
967	and	O
967	upstream	O
967	exons	O
967	.	O
967	.	O
968	Late	O
968	-	O
968	onset	O
968	familial	B-Disease
968	Mediterranean	I-Disease
968	fever	I-Disease
968	(	O
968	FMF	B-Disease
968	)	O
968	:	O
968	a	O
968	subset	O
968	with	O
968	distinct	O
968	clinical	O
968	,	O
968	demographic	O
968	,	O
968	and	O
968	molecular	O
968	genetic	O
968	characteristics	O
968	.	O
969	To	O
969	determine	O
969	the	O
969	prevalence	O
969	and	O
969	characterize	O
969	demographic	O
969	,	O
969	clinical	O
969	,	O
969	and	O
969	genetic	O
969	features	O
969	of	O
969	familial	B-Disease
969	Mediterranean	I-Disease
969	fever	I-Disease
969	(	O
969	FMF	B-Disease
969	)	O
969	of	O
969	late	O
969	onset	O
969	,	O
969	all	O
969	patients	O
969	experiencing	O
969	their	O
969	first	O
969	FMF	B-Disease
969	attack	O
969	at	O
969	age	O
969	40	O
969	years	O
969	or	O
969	more	O
969	were	O
969	identified	O
969	using	O
969	the	O
969	computerized	O
969	registry	O
969	of	O
969	our	O
969	FMF	B-Disease
969	clinic	O
969	,	O
969	and	O
969	then	O
969	thoroughly	O
969	interviewed	O
969	and	O
969	examined	O
969	.	O
970	The	O
970	control	O
970	group	O
970	consisted	O
970	of	O
970	40	O
970	consecutive	O
970	FMF	B-Disease
970	patients	O
970	,	O
970	who	O
970	arrived	O
970	at	O
970	the	O
970	FMF	B-Disease
970	clinic	O
970	for	O
970	their	O
970	regular	O
970	follow	O
970	-	O
970	up	O
970	visit	O
970	and	O
970	were	O
970	40	O
970	years	O
970	of	O
970	age	O
970	or	O
970	older	O
970	at	O
970	the	O
970	time	O
970	of	O
970	the	O
970	examination	O
970	.	O
971	The	O
971	severity	O
971	of	O
971	the	O
971	disease	O
971	in	O
971	patients	O
971	and	O
971	controls	O
971	was	O
971	determined	O
971	using	O
971	a	O
971	modified	O
971	score	O
971	,	O
971	developed	O
971	previously	O
971	.	O
972	Mutational	O
972	analysis	O
972	in	O
972	the	O
972	FMF	B-Disease
972	gene	O
972	was	O
972	performed	O
972	using	O
972	a	O
972	commercial	O
972	kit	O
972	.	O
973	Only	O
973	20	O
973	of	O
973	4000	O
973	(	O
973	0	O
973	.	O
973	5	O
973	%	O
973	)	O
973	patients	O
973	had	O
973	late	O
973	-	O
973	onset	O
973	FMF	B-Disease
973	.	O
974	These	O
974	patients	O
974	were	O
974	mostly	O
974	men	O
974	,	O
974	of	O
974	non	O
974	-	O
974	North	O
974	African	O
974	origin	O
974	,	O
974	P	O
974	<	O
974	0	O
974	.	O
975	05	O
975	compared	O
975	to	O
975	controls	O
975	.	O
976	All	O
976	had	O
976	abdominal	O
976	attacks	O
976	and	O
976	in	O
976	most	O
976	these	O
976	were	O
976	the	O
976	only	O
976	manifestation	O
976	of	O
976	their	O
976	disease	O
976	,	O
976	P	O
976	<	O
976	0	O
976	.	O
977	001	O
977	001	O
977	.	O
978	None	O
978	had	O
978	chronic	O
978	or	O
978	prolonged	O
978	manifestations	O
978	of	O
978	FMF	B-Disease
978	,	O
978	for	O
978	example	O
978	,	O
978	amyloidosis	B-Disease
978	,	O
978	chronic	B-Disease
978	arthritis	I-Disease
978	,	O
978	or	O
978	protracted	O
978	myalgia	B-Disease
978	,	O
978	P	O
978	<	O
978	0	O
978	.	O
979	001	O
979	.	O
980	The	O
980	response	O
980	to	O
980	treatment	O
980	was	O
980	good	O
980	despite	O
980	using	O
980	low	O
980	colchicine	O
980	dose	O
980	,	O
980	P	O
980	<	O
980	0	O
980	.	O
981	05	O
981	.	O
982	The	O
982	overall	O
982	severity	O
982	score	O
982	indicated	O
982	a	O
982	mild	O
982	disease	O
982	,	O
982	P	O
982	<	O
982	0	O
982	.	O
983	001	O
983	.	O
984	Mutational	O
984	analysis	O
984	revealed	O
984	absence	O
984	of	O
984	M694V	O
984	homozygosity	O
984	,	O
984	P	O
984	<	O
984	0	O
984	.	O
985	01	O
985	,	O
985	compared	O
985	to	O
985	our	O
985	regular	O
985	FMF	B-Disease
985	population	O
985	.	O
986	We	O
986	conclude	O
986	that	O
986	the	O
986	onset	O
986	of	O
986	FMF	B-Disease
986	in	O
986	a	O
986	late	O
986	age	O
986	defines	O
986	a	O
986	milder	O
986	form	O
986	of	O
986	disease	O
986	with	O
986	typical	O
986	clinical	O
986	,	O
986	demographic	O
986	,	O
986	and	O
986	molecular	O
986	genetic	O
986	characteristics	O
987	A	O
987	highly	O
987	accurate	O
987	,	O
987	low	O
987	cost	O
987	test	O
987	for	O
987	BRCA1	O
987	mutations	O
987	.	O
988	The	O
988	hereditary	B-Disease
988	breast	I-Disease
988	and	I-Disease
988	ovarian	I-Disease
988	cancer	I-Disease
988	syndrome	I-Disease
988	is	O
988	associated	O
988	with	O
988	a	O
988	high	O
988	frequency	O
988	of	O
988	BRCA1	O
988	mutations	O
988	.	O
989	However	O
989	,	O
989	the	O
989	widespread	O
989	use	O
989	of	O
989	BRCA1	O
989	testing	O
989	has	O
989	been	O
989	limited	O
989	to	O
989	date	O
989	by	O
989	three	O
989	principal	O
989	concerns	O
989	the	O
989	fear	O
989	of	O
989	loss	O
989	of	O
989	health	O
989	and	O
989	life	O
989	insurance	O
989	,	O
989	the	O
989	uncertain	O
989	clinical	O
989	value	O
989	of	O
989	a	O
989	positive	O
989	test	O
989	result	O
989	,	O
989	and	O
989	the	O
989	current	O
989	lack	O
989	of	O
989	an	O
989	inexpensive	O
989	and	O
989	sensitive	O
989	screening	O
989	test	O
989	for	O
989	BRCA1	O
989	mutations	O
989	.	O
990	We	O
990	have	O
990	developed	O
990	an	O
990	inexpensive	O
990	system	O
990	for	O
990	gene	O
990	mutational	O
990	scanning	O
990	,	O
990	based	O
990	on	O
990	a	O
990	combination	O
990	of	O
990	extensive	O
990	multiplex	O
990	PCR	O
990	amplification	O
990	and	O
990	two	O
990	dimensional	O
990	electrophoresis	O
990	.	O
991	The	O
991	efficiency	O
991	of	O
991	this	O
991	system	O
991	,	O
991	as	O
991	a	O
991	screening	O
991	test	O
991	for	O
991	BRCA1	O
991	mutations	O
991	,	O
991	was	O
991	evaluated	O
991	in	O
991	a	O
991	panel	O
991	of	O
991	60	O
991	samples	O
991	from	O
991	high	O
991	risk	O
991	women	O
991	,	O
991	14	O
991	of	O
991	which	O
991	contained	O
991	a	O
991	previously	O
991	identified	O
991	mutation	O
991	in	O
991	BRCA1	O
991	.	O
992	All	O
992	14	O
992	mutations	O
992	were	O
992	identified	O
992	,	O
992	as	O
992	well	O
992	as	O
992	an	O
992	additional	O
992	five	O
992	that	O
992	had	O
992	previously	O
992	escaped	O
992	detection	O
992	.	O
993	In	O
993	addition	O
993	to	O
993	the	O
993	19	O
993	mutations	O
993	,	O
993	a	O
993	total	O
993	of	O
993	15	O
993	different	O
993	polymorphic	O
993	variants	O
993	were	O
993	scored	O
993	,	O
993	most	O
993	of	O
993	which	O
993	were	O
993	recurring	O
993	.	O
994	All	O
994	were	O
994	confirmed	O
994	by	O
994	nucleotide	O
994	sequencing	O
994	.	O
995	The	O
995	cost	O
995	of	O
995	screening	O
995	per	O
995	sample	O
995	was	O
995	calculated	O
995	to	O
995	be	O
995	approximately	O
995	US	O
995	$	O
995	70	O
995	for	O
995	the	O
995	manual	O
995	technique	O
995	used	O
995	in	O
995	this	O
995	study	O
995	,	O
995	and	O
995	may	O
995	be	O
995	reduced	O
995	to	O
995	approximately	O
995	US	O
995	$	O
995	10	O
995	with	O
995	the	O
995	introduction	O
995	of	O
995	commercially	O
995	available	O
995	PCR	O
995	robotics	O
995	and	O
995	fluorescent	O
995	imaging	O
995	.	O
996	Implementation	O
996	of	O
996	this	O
996	method	O
996	of	O
996	mutation	O
996	screening	O
996	in	O
996	the	O
996	research	O
996	and	O
996	clinical	O
996	setting	O
996	should	O
996	permit	O
996	rapid	O
996	accrual	O
996	of	O
996	quantitative	O
996	data	O
996	on	O
996	genotype	O
996	-	O
996	phenotype	O
996	associations	O
996	for	O
996	the	O
996	evaluation	O
996	of	O
996	diagnostic	O
996	testing	O
996	.	O
996	.	O
997	Maternal	B-Disease
997	uniparental	I-Disease
997	disomy	I-Disease
997	for	I-Disease
997	chromosome	I-Disease
997	14	I-Disease
997	in	O
997	a	O
997	boy	O
997	with	O
997	a	O
997	normal	O
997	karyotype	O
997	.	O
998	We	O
998	report	O
998	on	O
998	a	O
998	boy	O
998	with	O
998	a	O
998	maternal	B-Disease
998	uniparental	I-Disease
998	disomy	I-Disease
998	for	I-Disease
998	chromosome	I-Disease
998	14	I-Disease
998	(	O
998	UPD	B-Disease
998	(	O
998	14	O
998	)	O
998	)	O
998	.	O
999	At	O
999	7	O
999	years	O
999	of	O
999	age	O
999	he	O
999	was	O
999	referred	O
999	to	O
999	us	O
999	by	O
999	the	O
999	paediatrician	O
999	because	O
999	of	O
999	symptoms	O
999	of	O
999	Prader	B-Disease
999	-	I-Disease
999	Willi	I-Disease
999	syndrome	I-Disease
999	(	O
999	PWS	B-Disease
999	)	O
999	.	O
1000	He	O
1000	showed	O
1000	short	B-Disease
1000	stature	I-Disease
1000	,	O
1000	obesity	B-Disease
1000	,	O
1000	mild	O
1000	developmental	B-Disease
1000	delay	I-Disease
1000	,	O
1000	cryptorchidism	B-Disease
1000	,	O
1000	and	O
1000	some	O
1000	mild	O
1000	dysmorphic	B-Disease
1000	features	I-Disease
1000	.	O
1001	The	O
1001	history	O
1001	further	O
1001	indicated	O
1001	intrauterine	B-Disease
1001	growth	I-Disease
1001	retardation	I-Disease
1001	at	O
1001	the	O
1001	end	O
1001	of	O
1001	the	O
1001	pregnancy	O
1001	.	O
1002	His	O
1002	mother	O
1002	was	O
1002	44	O
1002	years	O
1002	of	O
1002	age	O
1002	at	O
1002	the	O
1002	time	O
1002	of	O
1002	his	O
1002	birth	O
1002	.	O
1003	After	O
1003	birth	O
1003	he	O
1003	showed	O
1003	hypotonia	B-Disease
1003	with	O
1003	poor	O
1003	sucking	O
1003	,	O
1003	for	O
1003	which	O
1003	gavage	O
1003	feeding	O
1003	was	O
1003	needed	O
1003	.	O
1004	Motor	O
1004	development	O
1004	was	O
1004	delayed	O
1004	.	O
1005	After	O
1005	1	O
1005	year	O
1005	he	O
1005	became	O
1005	obese	B-Disease
1005	despite	O
1005	a	O
1005	normal	O
1005	appetite	O
1005	.	O
1006	Recurrent	O
1006	middle	B-Disease
1006	ear	I-Disease
1006	infections	I-Disease
1006	,	O
1006	a	O
1006	high	O
1006	pain	O
1006	threshold	O
1006	,	O
1006	and	O
1006	a	O
1006	great	O
1006	skill	O
1006	with	O
1006	jigsaw	O
1006	puzzles	O
1006	were	O
1006	reported	O
1006	.	O
1007	There	O
1007	were	O
1007	no	O
1007	behavioural	O
1007	problems	O
1007	or	O
1007	sleep	O
1007	disturbance	O
1007	.	O
1008	Chromosomal	O
1008	analysis	O
1008	was	O
1008	normal	O
1008	(	O
1008	46	O
1008	,	O
1008	XY	O
1008	)	O
1008	.	O
1009	DNA	O
1009	analysis	O
1009	for	O
1009	Prader	B-Disease
1009	-	I-Disease
1009	Willi	I-Disease
1009	syndrome	I-Disease
1009	showed	O
1009	no	O
1009	abnormalities	O
1009	.	O
1010	Two	O
1010	years	O
1010	later	O
1010	he	O
1010	was	O
1010	re	O
1010	-	O
1010	examined	O
1010	because	O
1010	we	O
1010	thought	O
1010	his	O
1010	features	O
1010	fitted	O
1010	the	O
1010	PWS	B-Disease
1010	-	O
1010	like	O
1010	phenotype	O
1010	associated	O
1010	with	O
1010	maternal	O
1010	UPD	B-Disease
1010	(	O
1010	14	O
1010	)	O
1010	.	O
1011	At	O
1011	that	O
1011	time	O
1011	precocious	O
1011	puberty	O
1011	was	O
1011	evident	O
1011	.	O
1012	DNA	O
1012	analysis	O
1012	showed	O
1012	maternal	B-Disease
1012	heterodisomy	I-Disease
1012	for	O
1012	chromosome	O
1012	14	O
1012	.	O
1013	In	O
1013	all	O
1013	the	O
1013	previously	O
1013	described	O
1013	11	O
1013	cases	O
1013	with	O
1013	maternal	O
1013	UPD	B-Disease
1013	(	O
1013	14	O
1013	)	O
1013	,	O
1013	a	O
1013	Robertsonian	O
1013	translocation	O
1013	involving	O
1013	chromosome	O
1013	14	O
1013	was	O
1013	detected	O
1013	cytogenetically	O
1013	before	O
1013	DNA	O
1013	analysis	O
1013	.	O
1014	This	O
1014	is	O
1014	the	O
1014	first	O
1014	report	O
1014	of	O
1014	diagnosis	O
1014	of	O
1014	maternal	O
1014	UPD	B-Disease
1014	(	O
1014	14	O
1014	)	O
1014	based	O
1014	on	O
1014	clinical	O
1014	features	O
1014	.	O
1015	This	O
1015	finding	O
1015	underlines	O
1015	the	O
1015	importance	O
1015	of	O
1015	DNA	O
1015	analysis	O
1015	for	O
1015	maternal	O
1015	UPD	O
1015	(	O
1015	14	O
1015	)	O
1015	in	O
1015	patients	O
1015	with	O
1015	a	O
1015	similar	O
1015	PWS	B-Disease
1015	-	O
1015	like	O
1015	phenotype	O
1015	even	O
1015	without	O
1015	previous	O
1015	identification	O
1015	of	O
1015	a	O
1015	Robertsonian	O
1015	translocation	O
1015	involving	O
1015	chromosome	O
1015	14	O
1015	.	O
1015	.	O
1016	Clinical	O
1016	and	O
1016	genetic	O
1016	study	O
1016	of	O
1016	Friedreich	B-Disease
1016	ataxia	I-Disease
1016	in	O
1016	an	O
1016	Australian	O
1016	population	O
1016	.	O
1017	Friedreich	B-Disease
1017	ataxia	I-Disease
1017	is	O
1017	an	O
1017	autosomal	B-Disease
1017	recessive	I-Disease
1017	disorder	I-Disease
1017	caused	O
1017	by	O
1017	mutations	O
1017	in	O
1017	the	O
1017	FRDA	B-Disease
1017	gene	O
1017	that	O
1017	encodes	O
1017	a	O
1017	210	O
1017	-	O
1017	amino	O
1017	acid	O
1017	protein	O
1017	called	O
1017	frataxin	O
1017	.	O
1018	An	O
1018	expansion	O
1018	of	O
1018	a	O
1018	GAA	O
1018	trinucleotide	O
1018	repeat	O
1018	in	O
1018	intron	O
1018	1	O
1018	of	O
1018	the	O
1018	gene	O
1018	is	O
1018	present	O
1018	in	O
1018	more	O
1018	than	O
1018	95	O
1018	%	O
1018	of	O
1018	mutant	O
1018	alleles	O
1018	.	O
1019	Of	O
1019	the	O
1019	83	O
1019	people	O
1019	we	O
1019	studied	O
1019	who	O
1019	have	O
1019	mutations	O
1019	in	O
1019	FRDA	O
1019	,	O
1019	78	O
1019	are	O
1019	homozygous	O
1019	for	O
1019	an	O
1019	expanded	O
1019	GAA	O
1019	repeat	O
1019	;	O
1019	the	O
1019	other	O
1019	five	O
1019	patients	O
1019	have	O
1019	an	O
1019	expansion	O
1019	in	O
1019	one	O
1019	allele	O
1019	and	O
1019	a	O
1019	point	O
1019	mutation	O
1019	in	O
1019	the	O
1019	other	O
1019	.	O
1020	Here	O
1020	we	O
1020	present	O
1020	a	O
1020	detailed	O
1020	clinical	O
1020	and	O
1020	genetic	O
1020	study	O
1020	of	O
1020	a	O
1020	subset	O
1020	of	O
1020	51	O
1020	patients	O
1020	homozygous	O
1020	for	O
1020	an	O
1020	expansion	O
1020	of	O
1020	the	O
1020	GAA	O
1020	repeat	O
1020	.	O
1021	We	O
1021	found	O
1021	a	O
1021	correlation	O
1021	between	O
1021	the	O
1021	size	O
1021	of	O
1021	the	O
1021	smaller	O
1021	of	O
1021	the	O
1021	two	O
1021	expanded	O
1021	alleles	O
1021	and	O
1021	age	O
1021	at	O
1021	onset	O
1021	,	O
1021	age	O
1021	into	O
1021	wheelchair	O
1021	,	O
1021	scoliosis	B-Disease
1021	,	O
1021	impaired	O
1021	vibration	O
1021	sense	O
1021	,	O
1021	and	O
1021	the	O
1021	presence	O
1021	of	O
1021	foot	B-Disease
1021	deformity	I-Disease
1021	.	O
1022	There	O
1022	was	O
1022	no	O
1022	significant	O
1022	correlation	O
1022	between	O
1022	the	O
1022	size	O
1022	of	O
1022	the	O
1022	smaller	O
1022	allele	O
1022	and	O
1022	cardiomyopathy	B-Disease
1022	,	O
1022	diabetes	B-Disease
1022	mellitus	I-Disease
1022	,	O
1022	loss	B-Disease
1022	of	I-Disease
1022	proprioception	I-Disease
1022	,	O
1022	or	O
1022	bladder	B-Disease
1022	symptoms	I-Disease
1022	.	O
1023	The	O
1023	larger	O
1023	allele	O
1023	size	O
1023	correlated	O
1023	with	O
1023	bladder	B-Disease
1023	symptoms	I-Disease
1023	and	O
1023	the	O
1023	presence	O
1023	of	O
1023	foot	B-Disease
1023	deformity	I-Disease
1023	.	O
1024	The	O
1024	duration	O
1024	of	O
1024	disease	O
1024	is	O
1024	correlated	O
1024	with	O
1024	wheelchair	O
1024	use	O
1024	and	O
1024	the	O
1024	presence	O
1024	of	O
1024	diabetes	B-Disease
1024	,	O
1024	scoliosis	B-Disease
1024	,	O
1024	bladder	B-Disease
1024	symptoms	I-Disease
1024	and	O
1024	impaired	B-Disease
1024	proprioception	I-Disease
1024	,	O
1024	and	O
1024	vibration	O
1024	sense	O
1024	but	O
1024	no	O
1024	other	O
1024	complications	O
1024	studied	O
1024	.	O
1024	.	O
1025	Novel	O
1025	mutations	O
1025	in	O
1025	XLRS1	O
1025	causing	O
1025	retinoschisis	B-Disease
1025	,	O
1025	including	O
1025	first	O
1025	evidence	O
1025	of	O
1025	putative	O
1025	leader	O
1025	sequence	O
1025	change	O
1025	.	O
1026	Juvenile	B-Disease
1026	retinoschisis	I-Disease
1026	is	O
1026	an	O
1026	X	B-Disease
1026	-	I-Disease
1026	linked	I-Disease
1026	recessive	I-Disease
1026	disease	I-Disease
1026	caused	O
1026	by	O
1026	mutations	O
1026	in	O
1026	the	O
1026	XLRS1	O
1026	gene	O
1026	.	O
1027	We	O
1027	screened	O
1027	31	O
1027	new	O
1027	unrelated	O
1027	patients	O
1027	and	O
1027	families	O
1027	for	O
1027	XLRS1	O
1027	mutations	O
1027	in	O
1027	addition	O
1027	to	O
1027	previously	O
1027	reported	O
1027	mutations	O
1027	for	O
1027	60	O
1027	of	O
1027	our	O
1027	families	O
1027	(	O
1027	Retinoschisis	B-Disease
1027	Consortium	O
1027	,	O
1027	Hum	O
1027	Mol	O
1027	Genet	O
1027	1998	O
1027	;	O
1027	7	O
1027	1185	O
1027	-	O
1027	1192	O
1027	)	O
1027	.	O
1028	Twenty	O
1028	-	O
1028	three	O
1028	different	O
1028	mutations	O
1028	including	O
1028	12	O
1028	novel	O
1028	ones	O
1028	were	O
1028	identified	O
1028	in	O
1028	28	O
1028	patients	O
1028	.	O
1029	Mutations	O
1029	identified	O
1029	in	O
1029	this	O
1029	study	O
1029	include	O
1029	19	O
1029	missense	O
1029	mutations	O
1029	,	O
1029	two	O
1029	nonsense	O
1029	mutations	O
1029	,	O
1029	one	O
1029	intragenic	O
1029	deletion	O
1029	,	O
1029	four	O
1029	microdeletions	O
1029	,	O
1029	one	O
1029	insertion	O
1029	,	O
1029	and	O
1029	one	O
1029	intronic	O
1029	sequence	O
1029	substitution	O
1029	that	O
1029	is	O
1029	likely	O
1029	to	O
1029	result	O
1029	in	O
1029	a	O
1029	splice	O
1029	site	O
1029	defect	O
1029	.	O
1030	Two	O
1030	novel	O
1030	mutations	O
1030	,	O
1030	c	O
1030	.	O
1031	38T	O
1031	-	O
1031	-	O
1031	>	O
1031	C	O
1031	(	O
1031	L13P	O
1031	)	O
1031	and	O
1031	c	O
1031	.	O
1032	667T	O
1032	-	O
1032	-	O
1032	>	O
1032	C	O
1032	(	O
1032	C223R	O
1032	)	O
1032	,	O
1032	respectively	O
1032	,	O
1032	present	O
1032	the	O
1032	first	O
1032	genetic	O
1032	evidence	O
1032	for	O
1032	the	O
1032	functional	O
1032	significance	O
1032	of	O
1032	the	O
1032	putative	O
1032	leader	O
1032	peptide	O
1032	sequence	O
1032	and	O
1032	for	O
1032	the	O
1032	functional	O
1032	significance	O
1032	at	O
1032	the	O
1032	carboxyl	O
1032	terminal	O
1032	of	O
1032	the	O
1032	XLRS1	O
1032	protein	O
1032	beyond	O
1032	the	O
1032	discoidin	O
1032	domain	O
1032	.	O
1033	Mutations	O
1033	in	O
1033	25	O
1033	of	O
1033	the	O
1033	families	O
1033	were	O
1033	localized	O
1033	to	O
1033	exons	O
1033	4	O
1033	-	O
1033	6	O
1033	,	O
1033	emphasizing	O
1033	the	O
1033	critical	O
1033	functional	O
1033	significance	O
1033	of	O
1033	the	O
1033	discoidin	O
1033	domain	O
1033	of	O
1033	the	O
1033	XLRS1	O
1033	protein	O
1034	Growth	O
1034	hormone	O
1034	treatment	O
1034	increases	O
1034	CO	O
1034	(	O
1034	2	O
1034	)	O
1034	response	O
1034	,	O
1034	ventilation	O
1034	and	O
1034	central	O
1034	inspiratory	O
1034	drive	O
1034	in	O
1034	children	O
1034	with	O
1034	Prader	B-Disease
1034	-	I-Disease
1034	Willi	I-Disease
1034	syndrome	I-Disease
1034	.	O
1035	We	O
1035	studied	O
1035	whether	O
1035	the	O
1035	beneficial	O
1035	effects	O
1035	of	O
1035	growth	O
1035	hormone	O
1035	(	O
1035	GH	O
1035	)	O
1035	treatment	O
1035	on	O
1035	growth	O
1035	and	O
1035	body	O
1035	composition	O
1035	in	O
1035	PWS	B-Disease
1035	are	O
1035	accompanied	O
1035	by	O
1035	an	O
1035	improvement	O
1035	in	O
1035	respiratory	O
1035	function	O
1035	.	O
1036	We	O
1036	measured	O
1036	resting	O
1036	ventilation	O
1036	,	O
1036	airway	O
1036	occlusion	O
1036	pressure	O
1036	(	O
1036	P	O
1036	(	O
1036	0	O
1036	.	O
1036	1	O
1036	)	O
1036	)	O
1036	and	O
1036	ventilatory	O
1036	response	O
1036	to	O
1036	CO	O
1036	(	O
1036	2	O
1036	)	O
1036	in	O
1036	nine	O
1036	children	O
1036	,	O
1036	aged	O
1036	7	O
1036	-	O
1036	14	O
1036	years	O
1036	,	O
1036	before	O
1036	and	O
1036	6	O
1036	-	O
1036	9	O
1036	months	O
1036	after	O
1036	the	O
1036	start	O
1036	of	O
1036	GH	O
1036	treatment	O
1036	.	O
1037	During	O
1037	GH	O
1037	treatment	O
1037	,	O
1037	resting	O
1037	ventilation	O
1037	increased	O
1037	by	O
1037	26	O
1037	%	O
1037	,	O
1037	P	O
1037	(	O
1037	0	O
1037	.	O
1037	1	O
1037	)	O
1037	by	O
1037	72	O
1037	%	O
1037	and	O
1037	the	O
1037	response	O
1037	to	O
1037	CO	O
1037	(	O
1037	2	O
1037	)	O
1037	by	O
1037	65	O
1037	%	O
1037	(	O
1037	P	O
1037	<	O
1037	0	O
1037	.	O
1037	002	O
1037	,	O
1037	<	O
1037	0	O
1037	.	O
1037	04	O
1037	and	O
1037	<	O
1037	0	O
1037	.	O
1037	02	O
1037	,	O
1037	respectively	O
1037	)	O
1037	.	O
1038	This	O
1038	observed	O
1038	increase	O
1038	in	O
1038	ventilatory	O
1038	output	O
1038	was	O
1038	not	O
1038	correlated	O
1038	to	O
1038	changes	O
1038	in	O
1038	body	O
1038	mass	O
1038	index	O
1038	.	O
1039	CONCLUSION	O
1039	Treatment	O
1039	of	O
1039	children	O
1039	with	O
1039	Prader	B-Disease
1039	-	I-Disease
1039	Willi	I-Disease
1039	syndrome	I-Disease
1039	(	O
1039	PWS	B-Disease
1039	)	O
1039	seems	O
1039	to	O
1039	have	O
1039	a	O
1039	stimulatory	O
1039	effect	O
1039	on	O
1039	central	O
1039	respiratory	O
1039	structures	O
1039	.	O
1040	The	O
1040	observed	O
1040	increase	O
1040	in	O
1040	ventilation	O
1040	and	O
1040	inspiratory	O
1040	drive	O
1040	may	O
1040	contribute	O
1040	to	O
1040	the	O
1040	improved	O
1040	activity	O
1040	level	O
1040	reported	O
1040	by	O
1040	parents	O
1040	of	O
1040	PWS	B-Disease
1040	children	O
1040	during	O
1040	growth	O
1040	hormone	O
1040	therapy	O
1041	G130V	O
1041	,	O
1041	a	O
1041	common	O
1041	FRDA	B-Disease
1041	point	O
1041	mutation	O
1041	,	O
1041	appears	O
1041	to	O
1041	have	O
1041	arisen	O
1041	from	O
1041	a	O
1041	common	O
1041	founder	O
1041	.	O
1042	Friedreich	B-Disease
1042	ataxia	I-Disease
1042	(	O
1042	FRDA	B-Disease
1042	)	O
1042	is	O
1042	the	O
1042	most	O
1042	common	O
1042	inherited	B-Disease
1042	ataxia	I-Disease
1042	.	O
1043	About	O
1043	98	O
1043	%	O
1043	of	O
1043	mutant	O
1043	alleles	O
1043	have	O
1043	an	O
1043	expansion	O
1043	of	O
1043	a	O
1043	GAA	O
1043	trinucleotide	O
1043	repeat	O
1043	in	O
1043	intron	O
1043	1	O
1043	of	O
1043	the	O
1043	affected	O
1043	gene	O
1043	,	O
1043	FRDA	O
1043	.	O
1044	The	O
1044	other	O
1044	2	O
1044	%	O
1044	are	O
1044	point	O
1044	mutations	O
1044	.	O
1045	Of	O
1045	the	O
1045	17	O
1045	point	O
1045	mutations	O
1045	so	O
1045	far	O
1045	described	O
1045	,	O
1045	three	O
1045	appear	O
1045	to	O
1045	be	O
1045	more	O
1045	common	O
1045	.	O
1046	One	O
1046	of	O
1046	these	O
1046	is	O
1046	the	O
1046	G130V	O
1046	mutation	O
1046	in	O
1046	exon	O
1046	4	O
1046	of	O
1046	FRDA	O
1046	.	O
1047	G130V	O
1047	,	O
1047	when	O
1047	present	O
1047	with	O
1047	an	O
1047	expanded	O
1047	GAA	O
1047	repeat	O
1047	on	O
1047	the	O
1047	other	O
1047	allele	O
1047	,	O
1047	is	O
1047	associated	O
1047	with	O
1047	an	O
1047	atypical	O
1047	FRDA	B-Disease
1047	phenotype	O
1047	.	O
1048	Haplotype	O
1048	analysis	O
1048	was	O
1048	undertaken	O
1048	on	O
1048	the	O
1048	four	O
1048	families	O
1048	who	O
1048	have	O
1048	been	O
1048	described	O
1048	with	O
1048	this	O
1048	mutation	O
1048	.	O
1049	The	O
1049	results	O
1049	suggest	O
1049	a	O
1049	common	O
1049	founder	O
1049	for	O
1049	this	O
1049	mutation	O
1049	.	O
1050	Although	O
1050	marked	O
1050	differences	O
1050	in	O
1050	extragenic	O
1050	marker	O
1050	haplotypes	O
1050	were	O
1050	seen	O
1050	in	O
1050	one	O
1050	family	O
1050	,	O
1050	similar	O
1050	intragenic	O
1050	haplotyping	O
1050	suggests	O
1050	the	O
1050	same	O
1050	mutation	O
1050	founder	O
1050	for	O
1050	this	O
1050	family	O
1050	with	O
1050	the	O
1050	differences	O
1050	explicable	O
1050	by	O
1050	two	O
1050	recombination	O
1050	events	O
1050	.	O
1050	.	O
1051	Synergistic	O
1051	effect	O
1051	of	O
1051	histone	O
1051	hyperacetylation	O
1051	and	O
1051	DNA	O
1051	demethylation	O
1051	in	O
1051	the	O
1051	reactivation	O
1051	of	O
1051	the	O
1051	FMR1	O
1051	gene	O
1051	.	O
1052	Most	O
1052	fragile	B-Disease
1052	X	I-Disease
1052	syndrome	I-Disease
1052	patients	O
1052	have	O
1052	expansion	O
1052	of	O
1052	a	O
1052	(	O
1052	CGG	O
1052	)	O
1052	(	O
1052	n	O
1052	)	O
1052	sequence	O
1052	with	O
1052	>	O
1052	200	O
1052	repeats	O
1052	(	O
1052	full	O
1052	mutation	O
1052	)	O
1052	in	O
1052	the	O
1052	FMR1	O
1052	gene	O
1052	responsible	O
1052	for	O
1052	this	O
1052	condition	O
1052	.	O
1053	Hypermethylation	O
1053	of	O
1053	the	O
1053	expanded	O
1053	repeat	O
1053	and	O
1053	of	O
1053	the	O
1053	FMR1	O
1053	promoter	O
1053	is	O
1053	almost	O
1053	always	O
1053	present	O
1053	and	O
1053	apparently	O
1053	suppresses	O
1053	transcription	O
1053	,	O
1053	resulting	O
1053	in	O
1053	absence	O
1053	of	O
1053	the	O
1053	FMR1	O
1053	protein	O
1053	.	O
1054	We	O
1054	recently	O
1054	showed	O
1054	that	O
1054	transcriptional	O
1054	reactivation	O
1054	of	O
1054	FMR1	O
1054	full	O
1054	mutations	O
1054	can	O
1054	be	O
1054	achieved	O
1054	by	O
1054	inducing	O
1054	DNA	O
1054	demethylation	O
1054	with	O
1054	5	O
1054	-	O
1054	azadeoxycytidine	O
1054	(	O
1054	5	O
1054	-	O
1054	azadC	O
1054	)	O
1054	.	O
1055	The	O
1055	level	O
1055	of	O
1055	histone	O
1055	acetylation	O
1055	is	O
1055	another	O
1055	important	O
1055	factor	O
1055	in	O
1055	regulating	O
1055	gene	O
1055	expression	O
1055	;	O
1055	therefore	O
1055	,	O
1055	we	O
1055	treated	O
1055	lymphoblastoid	O
1055	cell	O
1055	lines	O
1055	of	O
1055	non	O
1055	-	O
1055	mosaic	O
1055	full	O
1055	mutation	O
1055	patients	O
1055	with	O
1055	three	O
1055	drugs	O
1055	capable	O
1055	of	O
1055	inducing	O
1055	histone	O
1055	hyperacetylation	O
1055	.	O
1056	We	O
1056	observed	O
1056	a	O
1056	consistent	O
1056	,	O
1056	although	O
1056	modest	O
1056	,	O
1056	reactivation	O
1056	of	O
1056	the	O
1056	FMR1	O
1056	gene	O
1056	with	O
1056	4	O
1056	-	O
1056	phenylbutyrate	O
1056	,	O
1056	sodium	O
1056	butyrate	O
1056	and	O
1056	trichostatin	O
1056	A	O
1056	,	O
1056	as	O
1056	shown	O
1056	by	O
1056	RT	O
1056	-	O
1056	PCR	O
1056	.	O
1057	However	O
1057	,	O
1057	we	O
1057	report	O
1057	that	O
1057	combining	O
1057	these	O
1057	drugs	O
1057	with	O
1057	5	O
1057	-	O
1057	azadC	O
1057	results	O
1057	in	O
1057	a	O
1057	2	O
1057	-	O
1057	to	O
1057	5	O
1057	-	O
1057	fold	O
1057	increase	O
1057	in	O
1057	FMR1	O
1057	mRNA	O
1057	levels	O
1057	obtained	O
1057	with	O
1057	5	O
1057	-	O
1057	azadC	O
1057	alone	O
1057	,	O
1057	thus	O
1057	showing	O
1057	a	O
1057	marked	O
1057	synergistic	O
1057	effect	O
1057	of	O
1057	histone	O
1057	hyperacetylation	O
1057	and	O
1057	DNA	O
1057	demethylation	O
1057	in	O
1057	the	O
1057	reactivation	O
1057	of	O
1057	FMR1	O
1057	full	O
1057	mutations	O
1057	.	O
1057	.	O
1058	Constitutional	O
1058	von	B-Disease
1058	Hippel	I-Disease
1058	-	I-Disease
1058	Lindau	I-Disease
1058	(	O
1058	VHL	B-Disease
1058	)	O
1058	gene	O
1058	deletions	O
1058	detected	O
1058	in	O
1058	VHL	B-Disease
1058	families	O
1058	by	O
1058	fluorescence	O
1058	in	O
1058	situ	O
1058	hybridization	O
1058	.	O
1059	von	B-Disease
1059	Hippel	I-Disease
1059	-	I-Disease
1059	Lindau	I-Disease
1059	(	I-Disease
1059	VHL	I-Disease
1059	)	I-Disease
1059	disease	I-Disease
1059	is	O
1059	an	O
1059	autosomal	B-Disease
1059	dominantly	I-Disease
1059	inherited	I-Disease
1059	cancer	I-Disease
1059	syndrome	I-Disease
1059	predisposing	O
1059	to	O
1059	a	O
1059	variety	O
1059	of	O
1059	tumor	B-Disease
1059	types	O
1059	that	O
1059	include	O
1059	retinal	O
1059	hemangioblastomas	B-Disease
1059	,	O
1059	hemangioblastomas	B-Disease
1059	of	O
1059	the	O
1059	central	O
1059	nervous	O
1059	system	O
1059	,	O
1059	renal	B-Disease
1059	cell	I-Disease
1059	carcinomas	I-Disease
1059	,	O
1059	pancreatic	B-Disease
1059	cysts	I-Disease
1059	and	I-Disease
1059	tumors	I-Disease
1059	,	O
1059	pheochromocytomas	B-Disease
1059	,	O
1059	endolymphatic	B-Disease
1059	sac	I-Disease
1059	tumors	I-Disease
1059	,	O
1059	and	O
1059	epididymal	B-Disease
1059	cystadenomas	I-Disease
1059	[	O
1059	W	O
1059	.	O
1060	M	O
1060	.	O
1061	Linehan	O
1061	et	O
1061	al	O
1061	.	O
1061	,	O
1061	J	O
1061	.	O
1062	Am	O
1062	.	O
1062	Med	O
1062	.	O
1062	Assoc	O
1062	.	O
1062	,	O
1062	273	O
1062	564	O
1062	-	O
1062	570	O
1062	,	O
1062	1995	O
1062	;	O
1062	E	O
1062	.	O
1062	A	O
1062	.	O
1062	Maher	O
1062	and	O
1062	W	O
1062	.	O
1062	G	O
1062	.	O
1062	Kaelin	O
1062	,	O
1062	Jr	O
1062	.	O
1062	,	O
1062	Medicine	O
1062	(	O
1062	Baltimore	O
1062	)	O
1062	,	O
1062	76	O
1062	381	O
1062	-	O
1062	391	O
1062	,	O
1062	1997	O
1062	;	O
1062	W	O
1062	.	O
1062	M	O
1062	.	O
1062	Linehan	O
1062	and	O
1062	R	O
1062	.	O
1062	D	O
1062	.	O
1062	Klausner	O
1062	,	O
1062	In	O
1062	B	O
1062	.	O
1062	Vogelstein	O
1062	and	O
1062	K	O
1062	.	O
1062	Kinzler	O
1062	(	O
1062	eds	O
1062	.	O
1062	)	O
1062	,	O
1062	The	O
1062	Genetic	O
1062	Basis	O
1062	of	O
1062	Human	O
1062	Cancer	O
1062	,	O
1062	pp	O
1062	.	O
1063	455	O
1063	-	O
1063	473	O
1063	,	O
1063	McGraw	O
1063	-	O
1063	Hill	O
1063	,	O
1063	1998	O
1063	]	O
1063	.	O
1064	The	O
1064	VHL	B-Disease
1064	gene	O
1064	was	O
1064	localized	O
1064	to	O
1064	chromosome	O
1064	3p25	O
1064	-	O
1064	26	O
1064	and	O
1064	cloned	O
1064	[	O
1064	F	O
1064	.	O
1064	Latif	O
1064	et	O
1064	al	O
1064	.	O
1064	,	O
1064	Science	O
1064	(	O
1064	Washington	O
1064	DC	O
1064	)	O
1064	,	O
1064	260	O
1064	1317	O
1064	-	O
1064	1320	O
1064	,	O
1064	1993	O
1064	]	O
1064	.	O
1065	Germline	O
1065	mutations	O
1065	in	O
1065	the	O
1065	VHL	B-Disease
1065	gene	O
1065	have	O
1065	been	O
1065	detected	O
1065	in	O
1065	the	O
1065	majority	O
1065	of	O
1065	VHL	B-Disease
1065	kindreds	O
1065	.	O
1066	The	O
1066	reported	O
1066	frequency	O
1066	of	O
1066	detection	O
1066	of	O
1066	VHL	B-Disease
1066	germline	O
1066	mutations	O
1066	has	O
1066	varied	O
1066	from	O
1066	39	O
1066	to	O
1066	80	O
1066	%	O
1066	(	O
1066	J	O
1066	.	O
1066	M	O
1066	.	O
1066	Whaley	O
1066	et	O
1066	al	O
1066	.	O
1066	,	O
1066	Am	O
1066	.	O
1066	J	O
1066	.	O
1066	Hum	O
1066	.	O
1066	Genet	O
1066	.	O
1066	,	O
1066	55	O
1066	1092	O
1066	-	O
1066	1102	O
1066	,	O
1066	1994	O
1066	;	O
1066	Clinical	O
1066	Research	O
1066	Group	O
1066	for	O
1066	Japan	O
1066	,	O
1066	Hum	O
1066	.	O
1066	Mol	O
1066	.	O
1066	Genet	O
1066	.	O
1066	,	O
1066	4	O
1066	2233	O
1066	-	O
1066	2237	O
1066	,	O
1066	1995	O
1066	;	O
1066	F	O
1066	.	O
1066	Chen	O
1066	et	O
1066	al	O
1066	.	O
1066	,	O
1066	Hum	O
1066	.	O
1066	Mutat	O
1066	.	O
1066	,	O
1066	5	O
1066	66	O
1066	-	O
1066	75	O
1066	,	O
1066	1995	O
1066	;	O
1066	E	O
1066	.	O
1066	R	O
1066	.	O
1066	Maher	O
1066	et	O
1066	al	O
1066	.	O
1066	,	O
1066	J	O
1066	.	O
1066	Med	O
1066	.	O
1066	Genet	O
1066	.	O
1066	,	O
1066	33	O
1066	328	O
1066	-	O
1066	332	O
1066	,	O
1066	1996	O
1066	;	O
1066	B	O
1066	.	O
1066	Zbar	O
1066	,	O
1066	Cancer	O
1066	Surv	O
1066	.	O
1066	,	O
1066	25	O
1066	219	O
1066	-	O
1066	232	O
1066	,	O
1066	1995	O
1066	)	O
1066	.	O
1067	Recently	O
1067	a	O
1067	quantitative	O
1067	Southern	O
1067	blotting	O
1067	procedure	O
1067	was	O
1067	found	O
1067	to	O
1067	improve	O
1067	this	O
1067	frequency	O
1067	(	O
1067	C	O
1067	.	O
1067	Stolle	O
1067	et	O
1067	al	O
1067	.	O
1067	,	O
1067	Hum	O
1067	.	O
1067	Mutat	O
1067	.	O
1067	,	O
1067	12	O
1067	417	O
1067	-	O
1067	423	O
1067	,	O
1067	1998	O
1067	)	O
1067	.	O
1068	In	O
1068	the	O
1068	present	O
1068	study	O
1068	,	O
1068	we	O
1068	report	O
1068	the	O
1068	use	O
1068	of	O
1068	fluorescence	O
1068	in	O
1068	situ	O
1068	hybridization	O
1068	(	O
1068	FISH	O
1068	)	O
1068	as	O
1068	a	O
1068	method	O
1068	to	O
1068	detect	O
1068	and	O
1068	characterize	O
1068	VHL	B-Disease
1068	germline	O
1068	deletions	O
1068	.	O
1069	We	O
1069	reexamined	O
1069	a	O
1069	group	O
1069	of	O
1069	VHL	B-Disease
1069	patients	O
1069	shown	O
1069	previously	O
1069	by	O
1069	single	O
1069	-	O
1069	strand	O
1069	conformation	O
1069	and	O
1069	sequencing	O
1069	analysis	O
1069	not	O
1069	to	O
1069	harbor	O
1069	point	O
1069	mutations	O
1069	in	O
1069	the	O
1069	VHL	B-Disease
1069	locus	O
1069	.	O
1070	We	O
1070	found	O
1070	constitutional	O
1070	deletions	O
1070	in	O
1070	29	O
1070	of	O
1070	30	O
1070	VHL	B-Disease
1070	patients	O
1070	in	O
1070	this	O
1070	group	O
1070	using	O
1070	cosmid	O
1070	and	O
1070	P1	O
1070	probes	O
1070	that	O
1070	cover	O
1070	the	O
1070	VHL	B-Disease
1070	locus	O
1070	.	O
1071	We	O
1071	then	O
1071	tested	O
1071	six	O
1071	phenotypically	O
1071	normal	O
1071	offspring	O
1071	from	O
1071	four	O
1071	of	O
1071	these	O
1071	VHL	B-Disease
1071	families	O
1071	two	O
1071	were	O
1071	found	O
1071	to	O
1071	carry	O
1071	the	O
1071	deletion	O
1071	and	O
1071	the	O
1071	other	O
1071	four	O
1071	were	O
1071	deletion	O
1071	-	O
1071	free	O
1071	.	O
1072	In	O
1072	addition	O
1072	,	O
1072	germline	O
1072	mosaicism	O
1072	of	O
1072	the	O
1072	VHL	B-Disease
1072	gene	O
1072	was	O
1072	identified	O
1072	in	O
1072	one	O
1072	family	O
1072	.	O
1073	In	O
1073	sum	O
1073	,	O
1073	FISH	O
1073	was	O
1073	found	O
1073	to	O
1073	be	O
1073	a	O
1073	simple	O
1073	and	O
1073	reliable	O
1073	method	O
1073	to	O
1073	detect	O
1073	VHL	B-Disease
1073	germline	O
1073	deletions	O
1073	and	O
1073	practically	O
1073	useful	O
1073	in	O
1073	cases	O
1073	where	O
1073	other	O
1073	methods	O
1073	of	O
1073	screening	O
1073	have	O
1073	failed	O
1073	to	O
1073	detect	O
1073	a	O
1073	VHL	B-Disease
1073	gene	I-Disease
1073	abnormality	I-Disease
1074	Spectrum	O
1074	of	O
1074	hSNF5	O
1074	/	O
1074	INI1	O
1074	somatic	O
1074	mutations	O
1074	in	O
1074	human	O
1074	cancer	B-Disease
1074	and	O
1074	genotype	O
1074	-	O
1074	phenotype	O
1074	correlations	O
1074	.	O
1075	The	O
1075	hSNF5	O
1075	/	O
1075	INI1	O
1075	gene	O
1075	which	O
1075	encodes	O
1075	a	O
1075	member	O
1075	of	O
1075	the	O
1075	SWI	O
1075	/	O
1075	SNF	O
1075	chromatin	O
1075	ATP	O
1075	-	O
1075	dependent	O
1075	remodeling	O
1075	complex	O
1075	,	O
1075	is	O
1075	a	O
1075	new	O
1075	tumor	B-Disease
1075	suppressor	O
1075	gene	O
1075	localized	O
1075	on	O
1075	chromosome	O
1075	22q11	O
1075	.	O
1076	2	O
1076	and	O
1076	recently	O
1076	shown	O
1076	to	O
1076	be	O
1076	mutated	O
1076	in	O
1076	malignant	B-Disease
1076	rhabdoid	I-Disease
1076	tumors	I-Disease
1076	.	O
1077	We	O
1077	have	O
1077	searched	O
1077	for	O
1077	hSNF5	O
1077	/	O
1077	INI1	O
1077	mutations	O
1077	in	O
1077	229	O
1077	tumors	B-Disease
1077	of	O
1077	various	O
1077	origins	O
1077	using	O
1077	a	O
1077	screening	O
1077	method	O
1077	based	O
1077	on	O
1077	denaturing	O
1077	high	O
1077	-	O
1077	performance	O
1077	liquid	O
1077	chromatography	O
1077	.	O
1078	A	O
1078	total	O
1078	of	O
1078	31	O
1078	homozygous	O
1078	deletions	O
1078	and	O
1078	36	O
1078	point	O
1078	alterations	O
1078	were	O
1078	identified	O
1078	.	O
1079	Point	O
1079	mutations	O
1079	were	O
1079	scattered	O
1079	along	O
1079	the	O
1079	coding	O
1079	sequence	O
1079	and	O
1079	included	O
1079	15	O
1079	nonsense	O
1079	,	O
1079	15	O
1079	frameshift	O
1079	,	O
1079	three	O
1079	splice	O
1079	site	O
1079	,	O
1079	two	O
1079	missense	O
1079	and	O
1079	one	O
1079	editing	O
1079	mutations	O
1079	.	O
1080	Mutations	O
1080	were	O
1080	retrieved	O
1080	in	O
1080	most	O
1080	rhabdoid	B-Disease
1080	tumors	I-Disease
1080	,	O
1080	whatever	O
1080	their	O
1080	sites	O
1080	of	O
1080	occurrence	O
1080	,	O
1080	indicating	O
1080	the	O
1080	common	O
1080	pathogenetic	O
1080	origin	O
1080	of	O
1080	these	O
1080	tumors	B-Disease
1080	.	O
1081	Recurrent	O
1081	hSNF5	O
1081	/	O
1081	INI1	O
1081	alterations	O
1081	were	O
1081	also	O
1081	observed	O
1081	in	O
1081	choroid	B-Disease
1081	plexus	I-Disease
1081	carcinomas	I-Disease
1081	and	O
1081	in	O
1081	a	O
1081	subset	O
1081	of	O
1081	central	O
1081	primitive	O
1081	neuroectodermal	B-Disease
1081	tumors	I-Disease
1081	(	O
1081	cPNETs	O
1081	)	O
1081	and	O
1081	medulloblastomas	B-Disease
1081	.	O
1082	In	O
1082	contrast	O
1082	,	O
1082	hSNF5	O
1082	/	O
1082	INI1	O
1082	point	O
1082	mutations	O
1082	were	O
1082	not	O
1082	detected	O
1082	in	O
1082	breast	B-Disease
1082	cancers	I-Disease
1082	,	O
1082	Wilms	B-Disease
1082	tumors	I-Disease
1082	,	O
1082	gliomas	B-Disease
1082	,	O
1082	ependymomas	B-Disease
1082	,	O
1082	sarcomas	B-Disease
1082	and	O
1082	other	O
1082	tumor	B-Disease
1082	types	O
1082	,	O
1082	even	O
1082	though	O
1082	most	O
1082	analyzed	O
1082	cases	O
1082	harbored	O
1082	loss	O
1082	of	O
1082	heterozygosity	O
1082	at	O
1082	22q11	O
1082	.	O
1083	2	O
1083	loci	O
1083	.	O
1084	These	O
1084	results	O
1084	suggest	O
1084	that	O
1084	rhabdoid	B-Disease
1084	tumors	I-Disease
1084	,	O
1084	choroid	B-Disease
1084	plexus	I-Disease
1084	carcinomas	I-Disease
1084	and	O
1084	a	O
1084	subset	O
1084	of	O
1084	medulloblastomas	B-Disease
1084	and	O
1084	cPNETs	O
1084	share	O
1084	common	O
1084	pathways	O
1084	of	O
1084	oncogenesis	O
1084	related	O
1084	to	O
1084	hSNF5	O
1084	/	O
1084	INI1	O
1084	alteration	O
1084	and	O
1084	that	O
1084	hSNF5	O
1084	/	O
1084	INI1	O
1084	mutations	O
1084	define	O
1084	a	O
1084	genetically	O
1084	homogeneous	O
1084	family	O
1084	of	O
1084	highly	O
1084	aggressive	O
1084	cancers	B-Disease
1084	mainly	O
1084	occurring	O
1084	in	O
1084	young	O
1084	children	O
1084	and	O
1084	frequently	O
1084	,	O
1084	but	O
1084	not	O
1084	always	O
1084	,	O
1084	exhibiting	O
1084	a	O
1084	rhabdoid	B-Disease
1084	phenotype	O
1085	Ataxin	O
1085	-	O
1085	3	O
1085	with	O
1085	an	O
1085	altered	O
1085	conformation	O
1085	that	O
1085	exposes	O
1085	the	O
1085	polyglutamine	O
1085	domain	O
1085	is	O
1085	associated	O
1085	with	O
1085	the	O
1085	nuclear	O
1085	matrix	O
1085	.	O
1086	Spinocerebellar	B-Disease
1086	ataxia	I-Disease
1086	type	I-Disease
1086	-	I-Disease
1086	3	I-Disease
1086	or	O
1086	Machado	B-Disease
1086	-	I-Disease
1086	Joseph	I-Disease
1086	disease	I-Disease
1086	(	O
1086	SCA3	B-Disease
1086	/	O
1086	MJD	B-Disease
1086	)	O
1086	is	O
1086	a	O
1086	member	O
1086	of	O
1086	the	O
1086	CAG	B-Disease
1086	/	I-Disease
1086	polyglutamine	I-Disease
1086	repeat	I-Disease
1086	disease	I-Disease
1086	family	O
1086	.	O
1087	In	O
1087	this	O
1087	family	O
1087	of	O
1087	disorders	O
1087	,	O
1087	a	O
1087	normally	O
1087	polymorphic	O
1087	CAG	O
1087	repeat	O
1087	becomes	O
1087	expanded	O
1087	,	O
1087	resulting	O
1087	in	O
1087	expression	O
1087	of	O
1087	an	O
1087	expanded	O
1087	polyglutamine	O
1087	domain	O
1087	in	O
1087	the	O
1087	disease	O
1087	gene	O
1087	product	O
1087	.	O
1088	Experimental	O
1088	models	O
1088	of	O
1088	polyglutamine	B-Disease
1088	disease	I-Disease
1088	implicate	O
1088	the	O
1088	nucleus	O
1088	in	O
1088	pathogenesis	O
1088	;	O
1088	however	O
1088	,	O
1088	the	O
1088	link	O
1088	between	O
1088	intranuclear	O
1088	expression	O
1088	of	O
1088	expanded	O
1088	polyglutamine	O
1088	and	O
1088	neuronal	B-Disease
1088	dysfunction	I-Disease
1088	remains	O
1088	unclear	O
1088	.	O
1089	Here	O
1089	we	O
1089	demonstrate	O
1089	that	O
1089	ataxin	O
1089	-	O
1089	3	O
1089	,	O
1089	the	O
1089	disease	O
1089	protein	O
1089	in	O
1089	SCA3	B-Disease
1089	/	O
1089	MJD	B-Disease
1089	,	O
1089	adopts	O
1089	a	O
1089	unique	O
1089	conformation	O
1089	when	O
1089	expressed	O
1089	within	O
1089	the	O
1089	nucleus	O
1089	of	O
1089	transfected	O
1089	cells	O
1089	.	O
1090	The	O
1090	monoclonal	O
1090	antibody	O
1090	1C2	O
1090	is	O
1090	known	O
1090	preferentially	O
1090	to	O
1090	bind	O
1090	expanded	O
1090	polyglutamine	O
1090	,	O
1090	but	O
1090	we	O
1090	find	O
1090	that	O
1090	it	O
1090	also	O
1090	binds	O
1090	a	O
1090	fragment	O
1090	of	O
1090	ataxin	O
1090	-	O
1090	3	O
1090	containing	O
1090	a	O
1090	normal	O
1090	glutamine	O
1090	repeat	O
1090	.	O
1091	In	O
1091	addition	O
1091	,	O
1091	expression	O
1091	of	O
1091	ataxin	O
1091	-	O
1091	3	O
1091	within	O
1091	the	O
1091	nucleus	O
1091	exposes	O
1091	the	O
1091	glutamine	O
1091	domain	O
1091	of	O
1091	the	O
1091	full	O
1091	-	O
1091	length	O
1091	non	O
1091	-	O
1091	pathological	O
1091	protein	O
1091	,	O
1091	allowing	O
1091	it	O
1091	to	O
1091	bind	O
1091	the	O
1091	monoclonal	O
1091	antibody	O
1091	1C2	O
1091	.	O
1092	Fractionation	O
1092	and	O
1092	immunochemical	O
1092	experiments	O
1092	indicate	O
1092	that	O
1092	this	O
1092	novel	O
1092	conformation	O
1092	of	O
1092	intranuclear	O
1092	ataxin	O
1092	-	O
1092	3	O
1092	is	O
1092	not	O
1092	due	O
1092	to	O
1092	proteolysis	O
1092	,	O
1092	suggesting	O
1092	instead	O
1092	that	O
1092	association	O
1092	with	O
1092	nuclear	O
1092	protein	O
1092	(	O
1092	s	O
1092	)	O
1092	alters	O
1092	the	O
1092	structure	O
1092	of	O
1092	full	O
1092	-	O
1092	length	O
1092	ataxin	O
1092	-	O
1092	3	O
1092	which	O
1092	exposes	O
1092	the	O
1092	polyglutamine	O
1092	domain	O
1092	.	O
1093	This	O
1093	conformationally	O
1093	altered	O
1093	ataxin	O
1093	-	O
1093	3	O
1093	is	O
1093	bound	O
1093	to	O
1093	the	O
1093	nuclear	O
1093	matrix	O
1093	.	O
1094	The	O
1094	pathological	O
1094	form	O
1094	of	O
1094	ataxin	O
1094	-	O
1094	3	O
1094	with	O
1094	an	O
1094	expanded	O
1094	polyglutamine	O
1094	domain	O
1094	also	O
1094	associates	O
1094	with	O
1094	the	O
1094	nuclear	O
1094	matrix	O
1094	.	O
1095	These	O
1095	data	O
1095	suggest	O
1095	that	O
1095	an	O
1095	early	O
1095	event	O
1095	in	O
1095	the	O
1095	pathogenesis	O
1095	of	O
1095	SCA3	B-Disease
1095	/	O
1095	MJD	B-Disease
1095	may	O
1095	be	O
1095	an	O
1095	altered	O
1095	conformation	O
1095	of	O
1095	ataxin	O
1095	-	O
1095	3	O
1095	within	O
1095	the	O
1095	nucleus	O
1095	that	O
1095	exposes	O
1095	the	O
1095	polyglutamine	O
1095	domain	O
1095	.	O
1095	.	O
1096	The	O
1096	human	O
1096	MAGEL2	O
1096	gene	O
1096	and	O
1096	its	O
1096	mouse	O
1096	homologue	O
1096	are	O
1096	paternally	O
1096	expressed	O
1096	and	O
1096	mapped	O
1096	to	O
1096	the	O
1096	Prader	B-Disease
1096	-	I-Disease
1096	Willi	I-Disease
1096	region	O
1096	.	O
1097	Prader	B-Disease
1097	-	I-Disease
1097	Willi	I-Disease
1097	syndrome	I-Disease
1097	(	O
1097	PWS	B-Disease
1097	)	O
1097	is	O
1097	a	O
1097	complex	O
1097	neurogenetic	B-Disease
1097	disorder	I-Disease
1097	.	O
1098	The	O
1098	phenotype	O
1098	is	O
1098	likely	O
1098	to	O
1098	be	O
1098	a	O
1098	contiguous	B-Disease
1098	gene	I-Disease
1098	syndrome	I-Disease
1098	involving	O
1098	genes	O
1098	which	O
1098	are	O
1098	paternally	O
1098	expressed	O
1098	only	O
1098	,	O
1098	located	O
1098	in	O
1098	the	O
1098	human	O
1098	15q11	O
1098	-	O
1098	q13	O
1098	region	O
1098	.	O
1099	Four	O
1099	mouse	O
1099	models	O
1099	of	O
1099	PWS	B-Disease
1099	have	O
1099	been	O
1099	reported	O
1099	but	O
1099	these	O
1099	do	O
1099	not	O
1099	definitively	O
1099	allow	O
1099	the	O
1099	delineation	O
1099	of	O
1099	the	O
1099	critical	O
1099	region	O
1099	and	O
1099	the	O
1099	associated	O
1099	genes	O
1099	involved	O
1099	in	O
1099	the	O
1099	aetiology	O
1099	of	O
1099	PWS	B-Disease
1099	.	O
1100	Moreover	O
1100	,	O
1100	targeted	O
1100	mutagenesis	O
1100	of	O
1100	mouse	O
1100	homologues	O
1100	of	O
1100	the	O
1100	human	O
1100	candidate	O
1100	PWS	B-Disease
1100	genes	O
1100	does	O
1100	not	O
1100	appear	O
1100	to	O
1100	result	O
1100	in	O
1100	any	O
1100	of	O
1100	the	O
1100	features	O
1100	of	O
1100	PWS	B-Disease
1100	.	O
1101	Therefore	O
1101	,	O
1101	the	O
1101	isolation	O
1101	of	O
1101	new	O
1101	genes	O
1101	in	O
1101	this	O
1101	region	O
1101	remains	O
1101	crucial	O
1101	for	O
1101	a	O
1101	better	O
1101	understanding	O
1101	of	O
1101	the	O
1101	molecular	O
1101	basis	O
1101	of	O
1101	PWS	B-Disease
1101	.	O
1102	In	O
1102	this	O
1102	manuscript	O
1102	,	O
1102	we	O
1102	report	O
1102	the	O
1102	characterization	O
1102	of	O
1102	MAGEL2	O
1102	and	O
1102	its	O
1102	mouse	O
1102	homologue	O
1102	Magel2	O
1102	.	O
1103	These	O
1103	are	O
1103	located	O
1103	in	O
1103	the	O
1103	human	O
1103	15q11	O
1103	-	O
1103	q13	O
1103	and	O
1103	mouse	O
1103	7C	O
1103	regions	O
1103	,	O
1103	in	O
1103	close	O
1103	proximity	O
1103	to	O
1103	NDN	O
1103	/	O
1103	Ndn	O
1103	.	O
1104	By	O
1104	northern	O
1104	blot	O
1104	analysis	O
1104	we	O
1104	did	O
1104	not	O
1104	detect	O
1104	any	O
1104	expression	O
1104	of	O
1104	MAGEL2	O
1104	/	O
1104	Magel2	O
1104	but	O
1104	by	O
1104	RT	O
1104	-	O
1104	PCR	O
1104	analysis	O
1104	,	O
1104	specific	O
1104	expression	O
1104	was	O
1104	detected	O
1104	in	O
1104	fetal	O
1104	and	O
1104	adult	O
1104	brain	O
1104	and	O
1104	in	O
1104	placenta	O
1104	.	O
1105	Both	O
1105	genes	O
1105	are	O
1105	intronless	O
1105	with	O
1105	tandem	O
1105	direct	O
1105	repeat	O
1105	sequences	O
1105	contained	O
1105	within	O
1105	a	O
1105	CpG	O
1105	island	O
1105	in	O
1105	the	O
1105	5	O
1105	-	O
1105	untranscribed	O
1105	region	O
1105	.	O
1106	The	O
1106	transcripts	O
1106	encode	O
1106	putative	O
1106	proteins	O
1106	that	O
1106	are	O
1106	homologous	O
1106	to	O
1106	the	O
1106	MAGE	O
1106	proteins	O
1106	and	O
1106	NDN	O
1106	.	O
1107	Moreover	O
1107	,	O
1107	MAGEL2	O
1107	/	O
1107	Magel2	O
1107	are	O
1107	expressed	O
1107	only	O
1107	from	O
1107	the	O
1107	paternal	O
1107	allele	O
1107	in	O
1107	brain	O
1107	,	O
1107	suggesting	O
1107	a	O
1107	potential	O
1107	role	O
1107	in	O
1107	the	O
1107	aetiology	O
1107	of	O
1107	PWS	B-Disease
1107	and	O
1107	its	O
1107	mouse	O
1107	model	O
1107	,	O
1107	respectively	O
1107	.	O
1107	.	O
1108	cDNA	O
1108	microarrays	O
1108	detect	O
1108	activation	O
1108	of	O
1108	a	O
1108	myogenic	O
1108	transcription	O
1108	program	O
1108	by	O
1108	the	O
1108	PAX3	O
1108	-	O
1108	FKHR	O
1108	fusion	O
1108	oncogene	O
1108	.	O
1109	Alveolar	B-Disease
1109	rhabdomyosarcoma	I-Disease
1109	is	O
1109	an	O
1109	aggressive	O
1109	pediatric	B-Disease
1109	cancer	I-Disease
1109	of	I-Disease
1109	striated	I-Disease
1109	muscle	I-Disease
1109	characterized	O
1109	in	O
1109	60	O
1109	%	O
1109	of	O
1109	cases	O
1109	by	O
1109	a	O
1109	t	O
1109	(	O
1109	2	O
1109	;	O
1109	13	O
1109	)	O
1109	(	O
1109	q35	O
1109	;	O
1109	q14	O
1109	)	O
1109	.	O
1110	This	O
1110	results	O
1110	in	O
1110	the	O
1110	fusion	O
1110	of	O
1110	PAX3	O
1110	,	O
1110	a	O
1110	developmental	O
1110	transcription	O
1110	factor	O
1110	required	O
1110	for	O
1110	limb	O
1110	myogenesis	O
1110	,	O
1110	with	O
1110	FKHR	O
1110	,	O
1110	a	O
1110	member	O
1110	of	O
1110	the	O
1110	forkhead	O
1110	family	O
1110	of	O
1110	transcription	O
1110	factors	O
1110	.	O
1111	The	O
1111	resultant	O
1111	PAX3	O
1111	-	O
1111	FKHR	O
1111	gene	O
1111	possesses	O
1111	transforming	O
1111	properties	O
1111	;	O
1111	however	O
1111	,	O
1111	the	O
1111	effects	O
1111	of	O
1111	this	O
1111	chimeric	O
1111	oncogene	O
1111	on	O
1111	gene	O
1111	expression	O
1111	are	O
1111	largely	O
1111	unknown	O
1111	.	O
1112	To	O
1112	investigate	O
1112	the	O
1112	actions	O
1112	of	O
1112	these	O
1112	transcription	O
1112	factors	O
1112	,	O
1112	both	O
1112	Pax3	O
1112	and	O
1112	PAX3	O
1112	-	O
1112	FKHR	O
1112	were	O
1112	introduced	O
1112	into	O
1112	NIH	O
1112	3T3	O
1112	cells	O
1112	,	O
1112	and	O
1112	the	O
1112	resultant	O
1112	gene	O
1112	expression	O
1112	changes	O
1112	were	O
1112	analyzed	O
1112	with	O
1112	a	O
1112	murine	O
1112	cDNA	O
1112	microarray	O
1112	containing	O
1112	2	O
1112	,	O
1112	225	O
1112	elements	O
1112	.	O
1113	We	O
1113	found	O
1113	that	O
1113	PAX3	O
1113	-	O
1113	FKHR	O
1113	but	O
1113	not	O
1113	PAX3	O
1113	activated	O
1113	a	O
1113	myogenic	O
1113	transcription	O
1113	program	O
1113	including	O
1113	the	O
1113	induction	O
1113	of	O
1113	transcription	O
1113	factors	O
1113	MyoD	O
1113	,	O
1113	Myogenin	O
1113	,	O
1113	Six1	O
1113	,	O
1113	and	O
1113	Slug	O
1113	as	O
1113	well	O
1113	as	O
1113	a	O
1113	battery	O
1113	of	O
1113	genes	O
1113	involved	O
1113	in	O
1113	several	O
1113	aspects	O
1113	of	O
1113	muscle	O
1113	function	O
1113	.	O
1114	Notable	O
1114	among	O
1114	this	O
1114	group	O
1114	were	O
1114	the	O
1114	growth	O
1114	factor	O
1114	gene	O
1114	Igf2	O
1114	and	O
1114	its	O
1114	binding	O
1114	protein	O
1114	Igfbp5	O
1114	.	O
1115	Relevance	O
1115	of	O
1115	this	O
1115	model	O
1115	was	O
1115	suggested	O
1115	by	O
1115	verification	O
1115	that	O
1115	three	O
1115	of	O
1115	these	O
1115	genes	O
1115	(	O
1115	IGFBP5	O
1115	,	O
1115	HSIX1	O
1115	,	O
1115	and	O
1115	Slug	O
1115	)	O
1115	were	O
1115	also	O
1115	expressed	O
1115	in	O
1115	alveolar	B-Disease
1115	rhabdomyosarcoma	I-Disease
1115	cell	O
1115	lines	O
1115	.	O
1116	This	O
1116	study	O
1116	utilizes	O
1116	cDNA	O
1116	microarrays	O
1116	to	O
1116	elucidate	O
1116	the	O
1116	pattern	O
1116	of	O
1116	gene	O
1116	expression	O
1116	induced	O
1116	by	O
1116	an	O
1116	oncogenic	O
1116	transcription	O
1116	factor	O
1116	and	O
1116	demonstrates	O
1116	the	O
1116	profound	O
1116	myogenic	O
1116	properties	O
1116	of	O
1116	PAX3	O
1116	-	O
1116	FKHR	O
1116	in	O
1116	NIH	O
1116	3T3	O
1116	cells	O
1116	.	O
1116	.	O
1117	Experimental	O
1117	hemochromatosis	B-Disease
1117	due	O
1117	to	O
1117	MHC	O
1117	class	O
1117	I	O
1117	HFE	B-Disease
1117	deficiency	I-Disease
1117	:	O
1117	immune	O
1117	status	O
1117	and	O
1117	iron	O
1117	metabolism	O
1117	.	O
1118	The	O
1118	puzzling	O
1118	linkage	O
1118	between	O
1118	genetic	O
1118	hemochromatosis	B-Disease
1118	and	O
1118	histocompatibility	O
1118	loci	O
1118	became	O
1118	even	O
1118	more	O
1118	so	O
1118	when	O
1118	the	O
1118	gene	O
1118	involved	O
1118	,	O
1118	HFE	O
1118	,	O
1118	was	O
1118	identified	O
1118	.	O
1119	Indeed	O
1119	,	O
1119	within	O
1119	the	O
1119	well	O
1119	defined	O
1119	,	O
1119	mainly	O
1119	peptide	O
1119	-	O
1119	binding	O
1119	,	O
1119	MHC	O
1119	class	O
1119	I	O
1119	family	O
1119	of	O
1119	molecules	O
1119	,	O
1119	HFE	O
1119	seems	O
1119	to	O
1119	perform	O
1119	an	O
1119	unusual	O
1119	yet	O
1119	essential	O
1119	function	O
1119	.	O
1120	As	O
1120	yet	O
1120	,	O
1120	our	O
1120	understanding	O
1120	of	O
1120	HFE	O
1120	function	O
1120	in	O
1120	iron	O
1120	homeostasis	O
1120	is	O
1120	only	O
1120	partial	O
1120	;	O
1120	an	O
1120	even	O
1120	more	O
1120	open	O
1120	question	O
1120	is	O
1120	its	O
1120	possible	O
1120	role	O
1120	in	O
1120	the	O
1120	immune	O
1120	system	O
1120	.	O
1121	To	O
1121	advance	O
1121	on	O
1121	both	O
1121	of	O
1121	these	O
1121	avenues	O
1121	,	O
1121	we	O
1121	report	O
1121	the	O
1121	deletion	O
1121	of	O
1121	HFE	O
1121	alpha1	O
1121	and	O
1121	alpha2	O
1121	putative	O
1121	ligand	O
1121	binding	O
1121	domains	O
1121	in	O
1121	vivo	O
1121	.	O
1122	HFE	B-Disease
1122	-	I-Disease
1122	deficient	I-Disease
1122	animals	O
1122	were	O
1122	analyzed	O
1122	for	O
1122	a	O
1122	comprehensive	O
1122	set	O
1122	of	O
1122	metabolic	O
1122	and	O
1122	immune	O
1122	parameters	O
1122	.	O
1123	Faithfully	O
1123	mimicking	O
1123	human	O
1123	hemochromatosis	B-Disease
1123	,	O
1123	mice	O
1123	homozygous	O
1123	for	O
1123	this	O
1123	deletion	O
1123	develop	O
1123	iron	O
1123	overload	O
1123	,	O
1123	characterized	O
1123	by	O
1123	a	O
1123	higher	O
1123	plasma	O
1123	iron	O
1123	content	O
1123	and	O
1123	a	O
1123	raised	O
1123	transferrin	O
1123	saturation	O
1123	as	O
1123	well	O
1123	as	O
1123	an	O
1123	elevated	O
1123	hepatic	O
1123	iron	O
1123	load	O
1123	.	O
1124	The	O
1124	primary	O
1124	defect	O
1124	could	O
1124	,	O
1124	indeed	O
1124	,	O
1124	be	O
1124	traced	O
1124	to	O
1124	an	O
1124	augmented	O
1124	duodenal	O
1124	iron	O
1124	absorption	O
1124	.	O
1125	In	O
1125	parallel	O
1125	,	O
1125	measurement	O
1125	of	O
1125	the	O
1125	gut	O
1125	mucosal	O
1125	iron	O
1125	content	O
1125	as	O
1125	well	O
1125	as	O
1125	iron	O
1125	regulatory	O
1125	proteins	O
1125	allows	O
1125	a	O
1125	more	O
1125	informed	O
1125	evaluation	O
1125	of	O
1125	various	O
1125	hypotheses	O
1125	regarding	O
1125	the	O
1125	precise	O
1125	role	O
1125	of	O
1125	HFE	O
1125	in	O
1125	iron	O
1125	homeostasis	O
1125	.	O
1126	Finally	O
1126	,	O
1126	an	O
1126	extensive	O
1126	phenotyping	O
1126	of	O
1126	primary	O
1126	and	O
1126	secondary	O
1126	lymphoid	O
1126	organs	O
1126	including	O
1126	the	O
1126	gut	O
1126	provides	O
1126	no	O
1126	compelling	O
1126	evidence	O
1126	for	O
1126	an	O
1126	obvious	O
1126	immune	O
1126	-	O
1126	linked	O
1126	function	O
1126	for	O
1126	HFE	O
1126	.	O
1126	.	O
1127	Somatic	O
1127	rearrangement	O
1127	of	O
1127	chromosome	O
1127	14	O
1127	in	O
1127	human	O
1127	lymphocytes	O
1127	.	O
1128	Ataxia	B-Disease
1128	-	I-Disease
1128	telangiectasia	I-Disease
1128	is	O
1128	a	O
1128	rare	O
1128	genetic	B-Disease
1128	disorder	I-Disease
1128	associated	O
1128	with	O
1128	immune	B-Disease
1128	deficiency	I-Disease
1128	,	O
1128	chromosome	B-Disease
1128	instability	I-Disease
1128	,	O
1128	and	O
1128	a	O
1128	predisposition	O
1128	to	O
1128	lymphoid	B-Disease
1128	malignancy	I-Disease
1128	.	O
1129	We	O
1129	have	O
1129	detected	O
1129	chromosomally	O
1129	anomalous	O
1129	clones	O
1129	of	O
1129	lymphocytes	O
1129	in	O
1129	eight	O
1129	patients	O
1129	with	O
1129	this	O
1129	disorder	O
1129	.	O
1130	Chromosome	O
1130	banding	O
1130	disclosed	O
1130	that	O
1130	the	O
1130	clones	O
1130	are	O
1130	consistently	O
1130	marked	O
1130	by	O
1130	structural	O
1130	rearrangement	O
1130	of	O
1130	the	O
1130	long	O
1130	arm	O
1130	(	O
1130	q	O
1130	)	O
1130	of	O
1130	chromosome	O
1130	14	O
1130	.	O
1131	A	O
1131	translocation	O
1131	involving	O
1131	14q	O
1131	was	O
1131	found	O
1131	in	O
1131	clones	O
1131	obtained	O
1131	from	O
1131	seven	O
1131	of	O
1131	the	O
1131	eight	O
1131	patients	O
1131	whereas	O
1131	a	O
1131	ring	O
1131	14	O
1131	chromosome	O
1131	was	O
1131	found	O
1131	in	O
1131	a	O
1131	clone	O
1131	obtained	O
1131	from	O
1131	the	O
1131	other	O
1131	.	O
1132	These	O
1132	findings	O
1132	as	O
1132	well	O
1132	as	O
1132	data	O
1132	obtained	O
1132	by	O
1132	others	O
1132	for	O
1132	patients	O
1132	with	O
1132	ataxia	B-Disease
1132	-	I-Disease
1132	telangiectasia	I-Disease
1132	suggest	O
1132	that	O
1132	structural	O
1132	rearrangement	O
1132	of	O
1132	14q	O
1132	is	O
1132	the	O
1132	initial	O
1132	chromosomal	O
1132	change	O
1132	in	O
1132	lymphocyte	O
1132	clones	O
1132	of	O
1132	patients	O
1132	with	O
1132	this	O
1132	disorder	O
1132	.	O
1133	Chromosomes	O
1133	of	O
1133	lymphocytes	O
1133	from	O
1133	one	O
1133	of	O
1133	the	O
1133	patients	O
1133	were	O
1133	studied	O
1133	before	O
1133	and	O
1133	after	O
1133	the	O
1133	onset	O
1133	of	O
1133	chronic	B-Disease
1133	lymphocytic	I-Disease
1133	leukemia	I-Disease
1133	.	O
1134	Before	O
1134	leukemia	B-Disease
1134	was	O
1134	diagnosed	O
1134	,	O
1134	the	O
1134	patient	O
1134	had	O
1134	a	O
1134	lymphocyte	O
1134	clone	O
1134	with	O
1134	a	O
1134	14q	O
1134	translocation	O
1134	.	O
1135	This	O
1135	clone	O
1135	appears	O
1135	to	O
1135	have	O
1135	given	O
1135	rise	O
1135	to	O
1135	the	O
1135	leukemic	B-Disease
1135	cells	O
1135	.	O
1136	We	O
1136	hypothesize	O
1136	that	O
1136	structural	O
1136	rearrangement	O
1136	of	O
1136	14q	O
1136	is	O
1136	directly	O
1136	related	O
1136	to	O
1136	abnormal	O
1136	growth	O
1136	of	O
1136	lymphocytes	O
1136	and	O
1136	that	O
1136	it	O
1136	may	O
1136	be	O
1136	a	O
1136	step	O
1136	toward	O
1136	the	O
1136	development	O
1136	of	O
1136	lymphoid	B-Disease
1136	malignancies	I-Disease
1136	.	O
1137	Increasing	O
1137	evidence	O
1137	,	O
1137	provided	O
1137	by	O
1137	others	O
1137	,	O
1137	for	O
1137	the	O
1137	nonrandom	O
1137	involvement	O
1137	of	O
1137	14q	O
1137	in	O
1137	African	O
1137	-	O
1137	type	O
1137	Burkitts	B-Disease
1137	lymphoma	I-Disease
1137	and	O
1137	other	O
1137	lymphoid	B-Disease
1137	neoplasms	I-Disease
1137	further	O
1137	strengthens	O
1137	this	O
1137	hypothesis	O
1137	.	O
1137	.	O
1138	Exon	O
1138	9	O
1138	mutations	O
1138	in	O
1138	the	O
1138	WT1	O
1138	gene	O
1138	,	O
1138	without	O
1138	influencing	O
1138	KTS	O
1138	splice	O
1138	isoforms	O
1138	,	O
1138	are	O
1138	also	O
1138	responsible	O
1138	for	O
1138	Frasier	B-Disease
1138	syndrome	I-Disease
1138	.	O
1139	We	O
1139	report	O
1139	new	O
1139	mutations	O
1139	in	O
1139	exon	O
1139	9	O
1139	of	O
1139	the	O
1139	WT1	O
1139	gene	O
1139	that	O
1139	did	O
1139	not	O
1139	alter	O
1139	the	O
1139	ratio	O
1139	of	O
1139	+	O
1139	/	O
1139	-	O
1139	KTS	O
1139	splice	O
1139	isoforms	O
1139	in	O
1139	two	O
1139	unrelated	O
1139	patients	O
1139	with	O
1139	Frasier	B-Disease
1139	syndrome	I-Disease
1139	(	O
1139	FS	B-Disease
1139	)	O
1139	.	O
1140	The	O
1140	mutation	O
1140	of	O
1140	intron	O
1140	9	O
1140	inducing	O
1140	defective	O
1140	alternative	O
1140	splicing	O
1140	was	O
1140	reported	O
1140	to	O
1140	be	O
1140	responsible	O
1140	for	O
1140	this	O
1140	syndrome	O
1140	.	O
1141	The	O
1141	mutations	O
1141	found	O
1141	in	O
1141	our	O
1141	cases	O
1141	occurred	O
1141	in	O
1141	the	O
1141	same	O
1141	exon	O
1141	of	O
1141	the	O
1141	WT1	O
1141	gene	O
1141	as	O
1141	detected	O
1141	in	O
1141	Denys	B-Disease
1141	-	I-Disease
1141	Drash	I-Disease
1141	syndrome	I-Disease
1141	(	O
1141	DDS	B-Disease
1141	)	O
1141	and	O
1141	could	O
1141	not	O
1141	be	O
1141	explained	O
1141	by	O
1141	the	O
1141	previously	O
1141	proposed	O
1141	mechanism	O
1141	.	O
1142	The	O
1142	results	O
1142	suggest	O
1142	that	O
1142	the	O
1142	two	O
1142	syndromes	O
1142	originate	O
1142	from	O
1142	the	O
1142	same	O
1142	WT1	B-Disease
1142	gene	I-Disease
1142	abnormality	I-Disease
1142	.	O
1143	From	O
1143	a	O
1143	molecular	O
1143	biological	O
1143	point	O
1143	of	O
1143	view	O
1143	,	O
1143	we	O
1143	concluded	O
1143	that	O
1143	the	O
1143	two	O
1143	diseases	O
1143	were	O
1143	not	O
1143	separable	O
1143	,	O
1143	and	O
1143	that	O
1143	FS	B-Disease
1143	should	O
1143	be	O
1143	included	O
1143	as	O
1143	an	O
1143	atypical	O
1143	form	O
1143	of	O
1143	DDS	B-Disease
1143	.	O
1143	.	O
1144	Splice	O
1144	-	O
1144	site	O
1144	mutation	O
1144	in	O
1144	the	O
1144	PDS	B-Disease
1144	gene	O
1144	may	O
1144	result	O
1144	in	O
1144	intrafamilial	O
1144	variability	O
1144	for	O
1144	deafness	B-Disease
1144	in	O
1144	Pendred	B-Disease
1144	syndrome	I-Disease
1144	.	O
1145	Pendred	B-Disease
1145	syndrome	I-Disease
1145	is	O
1145	a	O
1145	recessive	B-Disease
1145	inherited	I-Disease
1145	disorder	I-Disease
1145	that	O
1145	consists	O
1145	of	O
1145	developmental	B-Disease
1145	abnormalities	I-Disease
1145	of	I-Disease
1145	the	I-Disease
1145	cochlea	I-Disease
1145	,	O
1145	sensorineural	B-Disease
1145	hearing	I-Disease
1145	loss	I-Disease
1145	,	O
1145	and	O
1145	diffuse	B-Disease
1145	thyroid	I-Disease
1145	enlargement	I-Disease
1145	(	O
1145	goiter	B-Disease
1145	)	O
1145	.	O
1146	This	O
1146	disorder	O
1146	may	O
1146	account	O
1146	for	O
1146	up	O
1146	to	O
1146	10	O
1146	%	O
1146	of	O
1146	cases	O
1146	of	O
1146	hereditary	B-Disease
1146	deafness	I-Disease
1146	.	O
1147	The	O
1147	disease	O
1147	gene	O
1147	(	O
1147	PDS	B-Disease
1147	)	O
1147	has	O
1147	been	O
1147	mapped	O
1147	to	O
1147	chromosome	O
1147	7q22	O
1147	-	O
1147	q31	O
1147	,	O
1147	and	O
1147	encodes	O
1147	a	O
1147	chloride	O
1147	-	O
1147	iodide	O
1147	transport	O
1147	protein	O
1147	.	O
1148	We	O
1148	performed	O
1148	mutation	O
1148	analysis	O
1148	of	O
1148	individual	O
1148	exons	O
1148	of	O
1148	the	O
1148	PDS	B-Disease
1148	gene	O
1148	in	O
1148	one	O
1148	Spanish	O
1148	family	O
1148	that	O
1148	shows	O
1148	intrafamilial	O
1148	variability	O
1148	of	O
1148	the	O
1148	deafness	B-Disease
1148	phenotype	O
1148	(	O
1148	two	O
1148	patients	O
1148	with	O
1148	profound	O
1148	and	O
1148	one	O
1148	with	O
1148	moderate	O
1148	-	O
1148	severe	O
1148	deafness	B-Disease
1148	)	O
1148	.	O
1149	We	O
1149	identified	O
1149	a	O
1149	new	O
1149	splice	O
1149	-	O
1149	site	O
1149	mutation	O
1149	affecting	O
1149	intron	O
1149	4	O
1149	of	O
1149	the	O
1149	PDS	B-Disease
1149	gene	O
1149	,	O
1149	at	O
1149	nucleotide	O
1149	position	O
1149	639	O
1149	+	O
1149	7	O
1149	.	O
1150	RNA	O
1150	analysis	O
1150	from	O
1150	lymphocytes	O
1150	of	O
1150	the	O
1150	affected	O
1150	patients	O
1150	showed	O
1150	that	O
1150	mutation	O
1150	639	O
1150	+	O
1150	7A	O
1150	-	O
1150	-	O
1150	>	O
1150	G	O
1150	generates	O
1150	a	O
1150	new	O
1150	donor	O
1150	splice	O
1150	site	O
1150	,	O
1150	leading	O
1150	to	O
1150	an	O
1150	mRNA	O
1150	with	O
1150	an	O
1150	insertion	O
1150	of	O
1150	six	O
1150	nucleotides	O
1150	from	O
1150	intron	O
1150	4	O
1150	of	O
1150	PDS	O
1150	.	O
1151	Since	O
1151	the	O
1151	newly	O
1151	created	O
1151	donor	O
1151	splice	O
1151	site	O
1151	is	O
1151	likely	O
1151	to	O
1151	compete	O
1151	with	O
1151	the	O
1151	normal	O
1151	one	O
1151	,	O
1151	variations	O
1151	of	O
1151	the	O
1151	levels	O
1151	of	O
1151	normal	O
1151	and	O
1151	aberrant	O
1151	transcripts	O
1151	of	O
1151	the	O
1151	PDS	B-Disease
1151	gene	O
1151	in	O
1151	the	O
1151	cochlea	O
1151	may	O
1151	explain	O
1151	the	O
1151	variability	O
1151	in	O
1151	the	O
1151	deafness	B-Disease
1151	presentation	O
1151	.	O
1151	.	O
1152	The	O
1152	molecular	O
1152	basis	O
1152	of	O
1152	Sjogren	B-Disease
1152	-	I-Disease
1152	Larsson	I-Disease
1152	syndrome	I-Disease
1152	:	O
1152	mutation	O
1152	analysis	O
1152	of	O
1152	the	O
1152	fatty	O
1152	aldehyde	O
1152	dehydrogenase	O
1152	gene	O
1152	.	O
1153	Sjogren	B-Disease
1153	-	I-Disease
1153	Larsson	I-Disease
1153	syndrome	I-Disease
1153	(	O
1153	SLS	B-Disease
1153	)	O
1153	is	O
1153	an	O
1153	autosomal	B-Disease
1153	recessive	I-Disease
1153	disorder	I-Disease
1153	characterized	O
1153	by	O
1153	ichthyosis	B-Disease
1153	,	O
1153	mental	B-Disease
1153	retardation	I-Disease
1153	,	O
1153	spasticity	B-Disease
1153	,	O
1153	and	O
1153	deficient	B-Disease
1153	activity	I-Disease
1153	of	I-Disease
1153	fatty	I-Disease
1153	aldehyde	I-Disease
1153	dehydrogenase	I-Disease
1153	(	O
1153	FALDH	O
1153	)	O
1153	.	O
1154	To	O
1154	define	O
1154	the	O
1154	molecular	O
1154	defects	O
1154	causing	O
1154	SLS	B-Disease
1154	,	O
1154	we	O
1154	performed	O
1154	mutation	O
1154	analysis	O
1154	of	O
1154	the	O
1154	FALDH	O
1154	gene	O
1154	in	O
1154	probands	O
1154	from	O
1154	63	O
1154	kindreds	O
1154	with	O
1154	SLS	B-Disease
1154	.	O
1155	Among	O
1155	these	O
1155	patients	O
1155	,	O
1155	49	O
1155	different	O
1155	mutations	O
1155	-	O
1155	including	O
1155	10	O
1155	deletions	O
1155	,	O
1155	2	O
1155	insertions	O
1155	,	O
1155	22	O
1155	amino	O
1155	acid	O
1155	substitutions	O
1155	,	O
1155	3	O
1155	nonsense	O
1155	mutations	O
1155	,	O
1155	9	O
1155	splice	O
1155	-	O
1155	site	O
1155	defects	O
1155	,	O
1155	and	O
1155	3	O
1155	complex	O
1155	mutations	O
1155	-	O
1155	were	O
1155	found	O
1155	.	O
1156	All	O
1156	of	O
1156	the	O
1156	patients	O
1156	with	O
1156	SLS	B-Disease
1156	were	O
1156	found	O
1156	to	O
1156	carry	O
1156	mutations	O
1156	.	O
1157	Nineteen	O
1157	of	O
1157	the	O
1157	missense	O
1157	mutations	O
1157	resulted	O
1157	in	O
1157	a	O
1157	severe	O
1157	reduction	O
1157	of	O
1157	FALDH	O
1157	enzyme	O
1157	catalytic	O
1157	activity	O
1157	when	O
1157	expressed	O
1157	in	O
1157	mammalian	O
1157	cells	O
1157	,	O
1157	but	O
1157	one	O
1157	mutation	O
1157	(	O
1157	798G	O
1157	-	O
1157	-	O
1157	>	O
1157	C	O
1157	[	O
1157	K266N	O
1157	]	O
1157	)	O
1157	seemed	O
1157	to	O
1157	have	O
1157	a	O
1157	greater	O
1157	effect	O
1157	on	O
1157	mRNA	O
1157	stability	O
1157	.	O
1158	The	O
1158	splice	O
1158	-	O
1158	site	O
1158	mutations	O
1158	led	O
1158	to	O
1158	exon	O
1158	skipping	O
1158	or	O
1158	utilization	O
1158	of	O
1158	cryptic	O
1158	acceptor	O
1158	-	O
1158	splice	O
1158	sites	O
1158	.	O
1159	Thirty	O
1159	-	O
1159	seven	O
1159	mutations	O
1159	were	O
1159	private	O
1159	,	O
1159	and	O
1159	12	O
1159	mutations	O
1159	were	O
1159	seen	O
1159	in	O
1159	two	O
1159	or	O
1159	more	O
1159	probands	O
1159	of	O
1159	European	O
1159	or	O
1159	Middle	O
1159	Eastern	O
1159	descent	O
1159	.	O
1160	Four	O
1160	single	O
1160	-	O
1160	nucleotide	O
1160	polymorphisms	O
1160	(	O
1160	SNPs	O
1160	)	O
1160	were	O
1160	found	O
1160	in	O
1160	the	O
1160	FALDH	O
1160	gene	O
1160	.	O
1161	At	O
1161	least	O
1161	four	O
1161	of	O
1161	the	O
1161	common	O
1161	mutations	O
1161	(	O
1161	551C	O
1161	-	O
1161	-	O
1161	>	O
1161	T	O
1161	,	O
1161	682C	O
1161	-	O
1161	-	O
1161	>	O
1161	T	O
1161	,	O
1161	733G	O
1161	-	O
1161	-	O
1161	>	O
1161	A	O
1161	,	O
1161	and	O
1161	798	O
1161	+	O
1161	1delG	O
1161	)	O
1161	were	O
1161	associated	O
1161	with	O
1161	multiple	O
1161	SNP	O
1161	haplotypes	O
1161	,	O
1161	suggesting	O
1161	that	O
1161	these	O
1161	mutations	O
1161	originated	O
1161	independently	O
1161	on	O
1161	more	O
1161	than	O
1161	one	O
1161	occasion	O
1161	or	O
1161	were	O
1161	ancient	O
1161	SLS	B-Disease
1161	genes	O
1161	that	O
1161	had	O
1161	undergone	O
1161	intragenic	O
1161	recombination	O
1161	.	O
1162	Our	O
1162	results	O
1162	demonstrate	O
1162	that	O
1162	SLS	B-Disease
1162	is	O
1162	caused	O
1162	by	O
1162	a	O
1162	strikingly	O
1162	heterogeneous	O
1162	group	O
1162	of	O
1162	mutations	O
1162	in	O
1162	the	O
1162	FALDH	O
1162	gene	O
1162	and	O
1162	provide	O
1162	a	O
1162	framework	O
1162	for	O
1162	understanding	O
1162	the	O
1162	genetic	O
1162	basis	O
1162	of	O
1162	SLS	B-Disease
1162	and	O
1162	the	O
1162	development	O
1162	of	O
1162	DNA	O
1162	-	O
1162	based	O
1162	diagnostic	O
1162	tests	O
1162	.	O
1162	.	O
1163	Loss	O
1163	-	O
1163	of	O
1163	-	O
1163	function	O
1163	mutations	O
1163	in	O
1163	the	O
1163	cathepsin	O
1163	C	O
1163	gene	O
1163	result	O
1163	in	O
1163	periodontal	B-Disease
1163	disease	I-Disease
1163	and	O
1163	palmoplantar	B-Disease
1163	keratosis	I-Disease
1163	.	O
1164	Papillon	B-Disease
1164	-	I-Disease
1164	Lefevre	I-Disease
1164	syndrome	I-Disease
1164	,	O
1164	or	O
1164	keratosis	B-Disease
1164	palmoplantaris	I-Disease
1164	with	O
1164	periodontopathia	B-Disease
1164	(	O
1164	PLS	B-Disease
1164	,	O
1164	MIM	O
1164	245000	O
1164	)	O
1164	,	O
1164	is	O
1164	an	O
1164	autosomal	B-Disease
1164	recessive	I-Disease
1164	disorder	I-Disease
1164	that	O
1164	is	O
1164	mainly	O
1164	ascertained	O
1164	by	O
1164	dentists	O
1164	because	O
1164	of	O
1164	the	O
1164	severe	O
1164	periodontitis	B-Disease
1164	that	O
1164	afflicts	O
1164	patients	O
1164	.	O
1165	Both	O
1165	the	O
1165	deciduous	O
1165	and	O
1165	permanent	O
1165	dentitions	O
1165	are	O
1165	affected	O
1165	,	O
1165	resulting	O
1165	in	O
1165	premature	O
1165	tooth	B-Disease
1165	loss	I-Disease
1165	.	O
1166	Palmoplantar	B-Disease
1166	keratosis	I-Disease
1166	,	O
1166	varying	O
1166	from	O
1166	mild	O
1166	psoriasiform	O
1166	scaly	O
1166	skin	O
1166	to	O
1166	overt	O
1166	hyperkeratosis	B-Disease
1166	,	O
1166	typically	O
1166	develops	O
1166	within	O
1166	the	O
1166	first	O
1166	three	O
1166	years	O
1166	of	O
1166	life	O
1166	.	O
1167	Keratosis	B-Disease
1167	also	O
1167	affects	O
1167	other	O
1167	sites	O
1167	such	O
1167	as	O
1167	elbows	O
1167	and	O
1167	knees	O
1167	.	O
1168	Most	O
1168	PLS	B-Disease
1168	patients	O
1168	display	O
1168	both	O
1168	periodontitis	B-Disease
1168	and	O
1168	hyperkeratosis	B-Disease
1168	.	O
1169	Some	O
1169	patients	O
1169	have	O
1169	only	O
1169	palmoplantar	B-Disease
1169	keratosis	I-Disease
1169	or	O
1169	periodontitis	B-Disease
1169	,	O
1169	and	O
1169	in	O
1169	rare	O
1169	individuals	O
1169	the	O
1169	periodontitis	B-Disease
1169	is	O
1169	mild	O
1169	and	O
1169	of	O
1169	late	O
1169	onset	O
1169	.	O
1170	The	O
1170	PLS	O
1170	locus	O
1170	has	O
1170	been	O
1170	mapped	O
1170	to	O
1170	chromosome	O
1170	11q14	O
1170	-	O
1170	q21	O
1170	(	O
1170	refs	O
1170	7	O
1170	,	O
1170	8	O
1170	,	O
1170	9	O
1170	)	O
1170	.	O
1171	Using	O
1171	homozygosity	O
1171	mapping	O
1171	in	O
1171	eight	O
1171	small	O
1171	consanguineous	O
1171	families	O
1171	,	O
1171	we	O
1171	have	O
1171	narrowed	O
1171	the	O
1171	candidate	O
1171	region	O
1171	to	O
1171	a	O
1171	1	O
1171	.	O
1172	2	O
1172	-	O
1172	cM	O
1172	interval	O
1172	between	O
1172	D11S4082	O
1172	and	O
1172	D11S931	O
1172	.	O
1173	The	O
1173	gene	O
1173	(	O
1173	CTSC	O
1173	)	O
1173	encoding	O
1173	the	O
1173	lysosomal	O
1173	protease	O
1173	cathepsin	O
1173	C	O
1173	(	O
1173	or	O
1173	dipeptidyl	O
1173	aminopeptidase	O
1173	I	O
1173	)	O
1173	lies	O
1173	within	O
1173	this	O
1173	interval	O
1173	.	O
1174	We	O
1174	defined	O
1174	the	O
1174	genomic	O
1174	structure	O
1174	of	O
1174	CTSC	O
1174	and	O
1174	found	O
1174	mutations	O
1174	in	O
1174	all	O
1174	eight	O
1174	families	O
1174	.	O
1175	In	O
1175	two	O
1175	of	O
1175	these	O
1175	families	O
1175	we	O
1175	used	O
1175	a	O
1175	functional	O
1175	assay	O
1175	to	O
1175	demonstrate	O
1175	an	O
1175	almost	O
1175	total	O
1175	loss	O
1175	of	O
1175	cathepsin	O
1175	C	O
1175	activity	O
1175	in	O
1175	PLS	B-Disease
1175	patients	O
1175	and	O
1175	reduced	O
1175	activity	O
1175	in	O
1175	obligate	O
1175	carriers	O
1175	.	O
1176	Confirmation	O
1176	of	O
1176	linkage	O
1176	of	O
1176	Van	B-Disease
1176	der	I-Disease
1176	Woude	I-Disease
1176	syndrome	I-Disease
1176	to	O
1176	chromosome	O
1176	1q32	O
1176	:	O
1176	evidence	O
1176	of	O
1176	association	O
1176	with	O
1176	STR	O
1176	alleles	O
1176	suggests	O
1176	possible	O
1176	unique	O
1176	origin	O
1176	of	O
1176	the	O
1176	disease	O
1176	mutation	O
1176	.	O
1177	Van	B-Disease
1177	der	I-Disease
1177	Woude	I-Disease
1177	syndrome	I-Disease
1177	(	O
1177	VWS	B-Disease
1177	)	O
1177	is	O
1177	an	O
1177	autosomal	B-Disease
1177	dominant	I-Disease
1177	craniofacial	I-Disease
1177	disorder	I-Disease
1177	with	O
1177	high	O
1177	penetrance	O
1177	and	O
1177	variable	O
1177	expression	O
1177	.	O
1178	Its	O
1178	clinical	O
1178	features	O
1178	are	O
1178	variably	O
1178	expressed	O
1178	,	O
1178	but	O
1178	include	O
1178	cleft	B-Disease
1178	lip	I-Disease
1178	and	O
1178	/	O
1178	or	O
1178	cleft	B-Disease
1178	palate	I-Disease
1178	,	O
1178	lip	B-Disease
1178	pits	I-Disease
1178	and	O
1178	hypodontia	B-Disease
1178	.	O
1179	All	O
1179	VWS	B-Disease
1179	families	O
1179	studied	O
1179	to	O
1179	date	O
1179	map	O
1179	the	O
1179	disease	O
1179	gene	O
1179	to	O
1179	a	O
1179	<	O
1179	2	O
1179	cM	O
1179	region	O
1179	of	O
1179	chromosome	O
1179	1q32	O
1179	,	O
1179	with	O
1179	no	O
1179	evidence	O
1179	of	O
1179	locus	O
1179	heterogeneity	O
1179	.	O
1180	The	O
1180	aim	O
1180	of	O
1180	this	O
1180	study	O
1180	is	O
1180	to	O
1180	refine	O
1180	the	O
1180	localization	O
1180	of	O
1180	the	O
1180	VWS	B-Disease
1180	gene	O
1180	and	O
1180	to	O
1180	further	O
1180	assess	O
1180	possible	O
1180	heterogeneity	O
1180	.	O
1181	We	O
1181	analyzed	O
1181	four	O
1181	multiplex	O
1181	VWS	B-Disease
1181	families	O
1181	.	O
1182	All	O
1182	available	O
1182	members	O
1182	were	O
1182	clinically	O
1182	assessed	O
1182	and	O
1182	genotyped	O
1182	for	O
1182	19	O
1182	short	O
1182	tandem	O
1182	repeat	O
1182	markers	O
1182	on	O
1182	chromosome	O
1182	1	O
1182	in	O
1182	the	O
1182	VWS	B-Disease
1182	candidate	O
1182	gene	O
1182	region	O
1182	.	O
1183	We	O
1183	performed	O
1183	two	O
1183	-	O
1183	point	O
1183	and	O
1183	multipoint	O
1183	limit	O
1183	of	O
1183	detection	O
1183	(	O
1183	LOD	O
1183	)	O
1183	score	O
1183	analyses	O
1183	using	O
1183	a	O
1183	high	O
1183	penetrance	O
1183	autosomal	O
1183	dominant	O
1183	model	O
1183	.	O
1184	All	O
1184	families	O
1184	showed	O
1184	positive	O
1184	LOD	O
1184	scores	O
1184	without	O
1184	any	O
1184	recombination	O
1184	in	O
1184	the	O
1184	candidate	O
1184	region	O
1184	.	O
1185	The	O
1185	largest	O
1185	two	O
1185	-	O
1185	point	O
1185	LOD	O
1185	score	O
1185	was	O
1185	5	O
1185	.	O
1186	87	O
1186	87	O
1186	.	O
1187	Our	O
1187	assay	O
1187	method	O
1187	for	O
1187	short	O
1187	tandem	O
1187	repeat	O
1187	(	O
1187	STR	O
1187	)	O
1187	markers	O
1187	provided	O
1187	highly	O
1187	accurate	O
1187	size	O
1187	estimation	O
1187	of	O
1187	marker	O
1187	allele	O
1187	fragment	O
1187	sizes	O
1187	,	O
1187	and	O
1187	therefore	O
1187	enabled	O
1187	us	O
1187	to	O
1187	determine	O
1187	the	O
1187	specific	O
1187	alleles	O
1187	segregating	O
1187	with	O
1187	the	O
1187	VWS	B-Disease
1187	gene	O
1187	in	O
1187	each	O
1187	of	O
1187	our	O
1187	four	O
1187	families	O
1187	.	O
1188	We	O
1188	observed	O
1188	a	O
1188	striking	O
1188	pattern	O
1188	of	O
1188	STR	O
1188	allele	O
1188	sharing	O
1188	at	O
1188	several	O
1188	closely	O
1188	linked	O
1188	loci	O
1188	among	O
1188	our	O
1188	four	O
1188	Caucasian	O
1188	VWS	B-Disease
1188	families	O
1188	recruited	O
1188	at	O
1188	three	O
1188	different	O
1188	locations	O
1188	in	O
1188	the	O
1188	US	O
1188	.	O
1189	These	O
1189	results	O
1189	suggest	O
1189	the	O
1189	possibility	O
1189	of	O
1189	a	O
1189	unique	O
1189	origin	O
1189	for	O
1189	a	O
1189	mutation	O
1189	responsible	O
1189	for	O
1189	many	O
1189	or	O
1189	most	O
1189	cases	O
1189	of	O
1189	VWS	B-Disease
1189	.	O
1190	A	O
1190	point	O
1190	mutation	O
1190	Thr	O
1190	(	O
1190	799	O
1190	)	O
1190	Met	O
1190	on	O
1190	the	O
1190	alpha	O
1190	(	O
1190	2	O
1190	)	O
1190	integrin	O
1190	leads	O
1190	to	O
1190	the	O
1190	formation	O
1190	of	O
1190	new	O
1190	human	O
1190	platelet	O
1190	alloantigen	O
1190	Sit	O
1190	(	O
1190	a	O
1190	)	O
1190	and	O
1190	affects	O
1190	collagen	O
1190	-	O
1190	induced	O
1190	aggregation	O
1190	.	O
1191	A	O
1191	new	O
1191	platelet	O
1191	-	O
1191	specific	O
1191	alloantigen	O
1191	,	O
1191	termed	O
1191	Sit	O
1191	(	O
1191	a	O
1191	)	O
1191	,	O
1191	was	O
1191	identified	O
1191	in	O
1191	a	O
1191	severe	O
1191	case	O
1191	of	O
1191	neonatal	B-Disease
1191	alloimmune	I-Disease
1191	thrombocytopenia	I-Disease
1191	.	O
1192	The	O
1192	Sit	O
1192	(	O
1192	a	O
1192	)	O
1192	alloantigen	O
1192	is	O
1192	of	O
1192	low	O
1192	frequency	O
1192	(	O
1192	1	O
1192	/	O
1192	400	O
1192	)	O
1192	in	O
1192	the	O
1192	German	O
1192	population	O
1192	.	O
1193	Immunochemical	O
1193	studies	O
1193	demonstrated	O
1193	that	O
1193	the	O
1193	Sit	O
1193	(	O
1193	a	O
1193	)	O
1193	epitopes	O
1193	reside	O
1193	on	O
1193	platelet	O
1193	glycoprotein	O
1193	(	O
1193	GP	O
1193	)	O
1193	Ia	O
1193	.	O
1194	Nucleotide	O
1194	sequence	O
1194	analysis	O
1194	of	O
1194	GPIa	O
1194	cDNA	O
1194	derived	O
1194	from	O
1194	Sit	O
1194	(	O
1194	a	O
1194	)	O
1194	-	O
1194	positive	O
1194	platelets	O
1194	showed	O
1194	C	O
1194	(	O
1194	2531	O
1194	)	O
1194	-	O
1194	-	O
1194	>	O
1194	T	O
1194	(	O
1194	2531	O
1194	)	O
1194	point	O
1194	mutation	O
1194	,	O
1194	resulting	O
1194	in	O
1194	Thr	O
1194	(	O
1194	799	O
1194	)	O
1194	Met	O
1194	dimorphism	O
1194	.	O
1195	Analysis	O
1195	of	O
1195	genomic	O
1195	DNA	O
1195	from	O
1195	22	O
1195	Sit	O
1195	(	O
1195	a	O
1195	)	O
1195	-	O
1195	negative	O
1195	normal	O
1195	individuals	O
1195	showed	O
1195	that	O
1195	the	O
1195	Thr	O
1195	(	O
1195	799	O
1195	)	O
1195	is	O
1195	encoded	O
1195	by	O
1195	ACG	O
1195	(	O
1195	2532	O
1195	)	O
1195	(	O
1195	90	O
1195	.	O
1195	9	O
1195	%	O
1195	)	O
1195	or	O
1195	ACA	O
1195	(	O
1195	2532	O
1195	)	O
1195	(	O
1195	9	O
1195	.	O
1195	1	O
1195	%	O
1195	)	O
1195	.	O
1196	To	O
1196	establish	O
1196	a	O
1196	DNA	O
1196	typing	O
1196	technique	O
1196	,	O
1196	we	O
1196	elucidated	O
1196	the	O
1196	organization	O
1196	of	O
1196	the	O
1196	GPIa	O
1196	gene	O
1196	adjacent	O
1196	to	O
1196	the	O
1196	polymorphic	O
1196	bases	O
1196	.	O
1197	The	O
1197	introns	O
1197	(	O
1197	421	O
1197	bp	O
1197	and	O
1197	1	O
1197	.	O
1197	2	O
1197	kb	O
1197	)	O
1197	encompass	O
1197	a	O
1197	142	O
1197	-	O
1197	bp	O
1197	exon	O
1197	with	O
1197	the	O
1197	2	O
1197	polymorphic	O
1197	bases	O
1197	2531	O
1197	and	O
1197	2532	O
1197	.	O
1198	Polymerase	O
1198	chain	O
1198	reaction	O
1198	-	O
1198	restriction	O
1198	fragment	O
1198	length	O
1198	polymorphism	O
1198	analysis	O
1198	on	O
1198	DNA	O
1198	derived	O
1198	from	O
1198	100	O
1198	donors	O
1198	using	O
1198	the	O
1198	restriction	O
1198	enzyme	O
1198	Mae	O
1198	III	O
1198	showed	O
1198	that	O
1198	the	O
1198	Met	O
1198	(	O
1198	799	O
1198	)	O
1198	form	O
1198	of	O
1198	GPIa	O
1198	is	O
1198	restricted	O
1198	to	O
1198	Sit	O
1198	(	O
1198	a	O
1198	)	O
1198	(	O
1198	+	O
1198	)	O
1198	phenotype	O
1198	.	O
1199	Analysis	O
1199	of	O
1199	stable	O
1199	Chinese	O
1199	hamster	O
1199	ovary	O
1199	transfectants	O
1199	expressing	O
1199	allele	O
1199	-	O
1199	specific	O
1199	recombinant	O
1199	forms	O
1199	of	O
1199	GPIa	O
1199	showed	O
1199	that	O
1199	anti	O
1199	-	O
1199	Sit	O
1199	(	O
1199	a	O
1199	)	O
1199	exclusively	O
1199	reacted	O
1199	with	O
1199	the	O
1199	Glu	O
1199	(	O
1199	505	O
1199	)	O
1199	Met	O
1199	(	O
1199	799	O
1199	)	O
1199	,	O
1199	but	O
1199	not	O
1199	with	O
1199	the	O
1199	Glu	O
1199	(	O
1199	505	O
1199	)	O
1199	Thr	O
1199	(	O
1199	799	O
1199	)	O
1199	and	O
1199	the	O
1199	Lys	O
1199	(	O
1199	505	O
1199	)	O
1199	Thr	O
1199	(	O
1199	799	O
1199	)	O
1199	isoforms	O
1199	.	O
1200	In	O
1200	contrast	O
1200	,	O
1200	anti	O
1200	-	O
1200	Br	O
1200	(	O
1200	a	O
1200	)	O
1200	(	O
1200	HPA	O
1200	-	O
1200	5b	O
1200	)	O
1200	only	O
1200	recognized	O
1200	the	O
1200	Lys	O
1200	(	O
1200	505	O
1200	)	O
1200	Thr	O
1200	(	O
1200	799	O
1200	)	O
1200	form	O
1200	,	O
1200	whereas	O
1200	anti	O
1200	-	O
1200	Br	O
1200	(	O
1200	b	O
1200	)	O
1200	(	O
1200	HPA	O
1200	-	O
1200	5a	O
1200	)	O
1200	reacted	O
1200	with	O
1200	both	O
1200	Glu	O
1200	(	O
1200	505	O
1200	)	O
1200	Thr	O
1200	(	O
1200	799	O
1200	)	O
1200	and	O
1200	Glu	O
1200	(	O
1200	505	O
1200	)	O
1200	Met	O
1200	(	O
1200	799	O
1200	)	O
1200	isoforms	O
1200	.	O
1201	These	O
1201	results	O
1201	demonstrated	O
1201	that	O
1201	the	O
1201	Met	O
1201	(	O
1201	799	O
1201	)	O
1201	is	O
1201	responsible	O
1201	for	O
1201	formation	O
1201	of	O
1201	the	O
1201	Sit	O
1201	(	O
1201	a	O
1201	)	O
1201	alloantigenic	O
1201	determinants	O
1201	,	O
1201	whereas	O
1201	amino	O
1201	acid	O
1201	505	O
1201	(	O
1201	Lys	O
1201	or	O
1201	Glu	O
1201	)	O
1201	specifically	O
1201	controls	O
1201	the	O
1201	expression	O
1201	of	O
1201	Br	O
1201	(	O
1201	a	O
1201	)	O
1201	and	O
1201	Br	O
1201	(	O
1201	b	O
1201	)	O
1201	epitopes	O
1201	,	O
1201	respectively	O
1201	.	O
1202	Platelet	O
1202	aggregation	O
1202	responses	O
1202	of	O
1202	Sit	O
1202	(	O
1202	a	O
1202	)	O
1202	(	O
1202	+	O
1202	)	O
1202	individuals	O
1202	were	O
1202	diminished	O
1202	in	O
1202	response	O
1202	to	O
1202	collagen	O
1202	,	O
1202	indicating	O
1202	that	O
1202	the	O
1202	Thr	O
1202	(	O
1202	799	O
1202	)	O
1202	Met	O
1202	mutation	O
1202	affects	O
1202	the	O
1202	function	O
1202	of	O
1202	the	O
1202	GPIa	O
1202	/	O
1202	IIa	O
1202	complex	O
1203	Mutations	O
1203	of	O
1203	the	O
1203	cathepsin	O
1203	C	O
1203	gene	O
1203	are	O
1203	responsible	O
1203	for	O
1203	Papillon	B-Disease
1203	-	I-Disease
1203	Lefevre	I-Disease
1203	syndrome	I-Disease
1203	.	O
1204	Papillon	B-Disease
1204	-	I-Disease
1204	Lefevre	I-Disease
1204	syndrome	I-Disease
1204	(	O
1204	PLS	B-Disease
1204	)	O
1204	is	O
1204	an	O
1204	autosomal	B-Disease
1204	recessive	I-Disease
1204	disorder	I-Disease
1204	characterised	O
1204	by	O
1204	palmoplantar	B-Disease
1204	hyperkeratosis	I-Disease
1204	and	O
1204	severe	O
1204	early	O
1204	onset	O
1204	periodontitis	B-Disease
1204	that	O
1204	results	O
1204	in	O
1204	the	O
1204	premature	O
1204	loss	O
1204	of	O
1204	the	O
1204	primary	O
1204	and	O
1204	secondary	O
1204	dentitions	O
1204	.	O
1205	A	O
1205	major	O
1205	gene	O
1205	locus	O
1205	for	O
1205	PLS	B-Disease
1205	has	O
1205	been	O
1205	mapped	O
1205	to	O
1205	a	O
1205	2	O
1205	.	O
1206	8	O
1206	cM	O
1206	interval	O
1206	on	O
1206	chromosome	O
1206	11q14	O
1206	.	O
1207	Correlation	O
1207	of	O
1207	physical	O
1207	and	O
1207	genetic	O
1207	maps	O
1207	of	O
1207	this	O
1207	interval	O
1207	indicate	O
1207	it	O
1207	includes	O
1207	at	O
1207	least	O
1207	40	O
1207	ESTs	O
1207	and	O
1207	six	O
1207	known	O
1207	genes	O
1207	including	O
1207	the	O
1207	lysosomal	O
1207	protease	O
1207	cathepsin	O
1207	C	O
1207	gene	O
1207	(	O
1207	CTSC	O
1207	)	O
1207	.	O
1208	The	O
1208	CTSC	O
1208	message	O
1208	is	O
1208	expressed	O
1208	at	O
1208	high	O
1208	levels	O
1208	in	O
1208	a	O
1208	variety	O
1208	of	O
1208	immune	O
1208	cells	O
1208	including	O
1208	polymorphonuclear	O
1208	leucocytes	O
1208	,	O
1208	macrophages	O
1208	,	O
1208	and	O
1208	their	O
1208	precursors	O
1208	.	O
1209	By	O
1209	RT	O
1209	-	O
1209	PCR	O
1209	,	O
1209	we	O
1209	found	O
1209	CTSC	O
1209	is	O
1209	also	O
1209	expressed	O
1209	in	O
1209	epithelial	O
1209	regions	O
1209	commonly	O
1209	affected	O
1209	by	O
1209	PLS	B-Disease
1209	,	O
1209	including	O
1209	the	O
1209	palms	O
1209	,	O
1209	soles	O
1209	,	O
1209	knees	O
1209	,	O
1209	and	O
1209	oral	O
1209	keratinised	O
1209	gingiva	O
1209	.	O
1210	The	O
1210	4	O
1210	.	O
1211	7	O
1211	kb	O
1211	CTSC	O
1211	gene	O
1211	consists	O
1211	of	O
1211	two	O
1211	exons	O
1211	.	O
1212	Sequence	O
1212	analysis	O
1212	of	O
1212	CTSC	O
1212	from	O
1212	subjects	O
1212	affected	O
1212	with	O
1212	PLS	B-Disease
1212	from	O
1212	five	O
1212	consanguineous	O
1212	Turkish	O
1212	families	O
1212	identified	O
1212	four	O
1212	different	O
1212	mutations	O
1212	.	O
1213	An	O
1213	exon	O
1213	1	O
1213	nonsense	O
1213	mutation	O
1213	(	O
1213	856C	O
1213	-	O
1213	-	O
1213	>	O
1213	T	O
1213	)	O
1213	introduces	O
1213	a	O
1213	premature	O
1213	stop	O
1213	codon	O
1213	at	O
1213	amino	O
1213	acid	O
1213	286	O
1213	.	O
1214	Three	O
1214	exon	O
1214	2	O
1214	mutations	O
1214	were	O
1214	identified	O
1214	,	O
1214	including	O
1214	a	O
1214	single	O
1214	nucleotide	O
1214	deletion	O
1214	(	O
1214	2692delA	O
1214	)	O
1214	of	O
1214	codon	O
1214	349	O
1214	introducing	O
1214	a	O
1214	frameshift	O
1214	and	O
1214	premature	O
1214	termination	O
1214	codon	O
1214	,	O
1214	a	O
1214	2	O
1214	bp	O
1214	deletion	O
1214	(	O
1214	2673	O
1214	-	O
1214	2674delCT	O
1214	)	O
1214	that	O
1214	results	O
1214	in	O
1214	introduction	O
1214	of	O
1214	a	O
1214	stop	O
1214	codon	O
1214	at	O
1214	amino	O
1214	acid	O
1214	343	O
1214	,	O
1214	and	O
1214	a	O
1214	G	O
1214	-	O
1214	-	O
1214	>	O
1214	A	O
1214	substitution	O
1214	in	O
1214	codon	O
1214	429	O
1214	(	O
1214	2931G	O
1214	-	O
1214	-	O
1214	>	O
1214	A	O
1214	)	O
1214	introducing	O
1214	a	O
1214	premature	O
1214	termination	O
1214	codon	O
1214	.	O
1215	All	O
1215	PLS	B-Disease
1215	patients	O
1215	were	O
1215	homozygous	O
1215	for	O
1215	cathepsin	O
1215	C	O
1215	mutations	O
1215	inherited	O
1215	from	O
1215	a	O
1215	common	O
1215	ancestor	O
1215	.	O
1216	Parents	O
1216	and	O
1216	sibs	O
1216	heterozygous	O
1216	for	O
1216	cathepsin	O
1216	C	O
1216	mutations	O
1216	do	O
1216	not	O
1216	show	O
1216	either	O
1216	the	O
1216	palmoplantar	B-Disease
1216	hyperkeratosis	I-Disease
1216	or	O
1216	severe	O
1216	early	O
1216	onset	O
1216	periodontitis	B-Disease
1216	characteristic	O
1216	of	O
1216	PLS	B-Disease
1216	.	O
1217	A	O
1217	more	O
1217	complete	O
1217	understanding	O
1217	of	O
1217	the	O
1217	functional	O
1217	physiology	O
1217	of	O
1217	cathepsin	O
1217	C	O
1217	carries	O
1217	significant	O
1217	implications	O
1217	for	O
1217	understanding	O
1217	normal	O
1217	and	O
1217	abnormal	O
1217	skin	O
1217	development	O
1217	and	O
1217	periodontal	B-Disease
1217	disease	I-Disease
1217	susceptibility	O
1218	Mutational	O
1218	analysis	O
1218	of	O
1218	the	O
1218	HGO	O
1218	gene	O
1218	in	O
1218	Finnish	O
1218	alkaptonuria	B-Disease
1218	patients	O
1218	.	O
1219	Alkaptonuria	B-Disease
1219	(	O
1219	AKU	B-Disease
1219	)	O
1219	,	O
1219	the	O
1219	prototypic	O
1219	inborn	B-Disease
1219	error	I-Disease
1219	of	I-Disease
1219	metabolism	I-Disease
1219	,	O
1219	has	O
1219	recently	O
1219	been	O
1219	shown	O
1219	to	O
1219	be	O
1219	caused	O
1219	by	O
1219	loss	O
1219	of	O
1219	function	O
1219	mutations	O
1219	in	O
1219	the	O
1219	homogentisate	O
1219	-	O
1219	1	O
1219	,	O
1219	2	O
1219	-	O
1219	dioxygenase	O
1219	gene	O
1219	(	O
1219	HGO	O
1219	)	O
1219	.	O
1220	So	O
1220	far	O
1220	17	O
1220	mutations	O
1220	have	O
1220	been	O
1220	characterised	O
1220	in	O
1220	AKU	B-Disease
1220	patients	O
1220	of	O
1220	different	O
1220	ethnic	O
1220	origin	O
1220	.	O
1221	We	O
1221	describe	O
1221	three	O
1221	novel	O
1221	mutations	O
1221	(	O
1221	R58fs	O
1221	,	O
1221	R330S	O
1221	,	O
1221	and	O
1221	H371R	O
1221	)	O
1221	and	O
1221	one	O
1221	common	O
1221	AKU	B-Disease
1221	mutation	O
1221	(	O
1221	M368V	O
1221	)	O
1221	,	O
1221	detected	O
1221	by	O
1221	mutational	O
1221	and	O
1221	polymorphism	O
1221	analysis	O
1221	of	O
1221	the	O
1221	HGO	O
1221	gene	O
1221	in	O
1221	five	O
1221	Finnish	O
1221	AKU	B-Disease
1221	pedigrees	O
1221	.	O
1222	The	O
1222	three	O
1222	novel	O
1222	AKU	B-Disease
1222	mutations	O
1222	are	O
1222	most	O
1222	likely	O
1222	specific	O
1222	for	O
1222	the	O
1222	Finnish	O
1222	population	O
1222	and	O
1222	have	O
1222	originated	O
1222	recently	O
1222	.	O
1222	.	O
1223	The	O
1223	identical	O
1223	5	O
1223	'	O
1223	splice	O
1223	-	O
1223	site	O
1223	acceptor	O
1223	mutation	O
1223	in	O
1223	five	O
1223	attenuated	B-Disease
1223	APC	I-Disease
1223	families	O
1223	from	O
1223	Newfoundland	O
1223	demonstrates	O
1223	a	O
1223	founder	O
1223	effect	O
1223	.	O
1224	Inherited	O
1224	mutations	O
1224	of	O
1224	the	O
1224	APC	B-Disease
1224	gene	O
1224	predispose	O
1224	carriers	O
1224	to	O
1224	multiple	O
1224	adenomatous	B-Disease
1224	polyps	I-Disease
1224	of	I-Disease
1224	the	I-Disease
1224	colon	I-Disease
1224	and	I-Disease
1224	rectum	I-Disease
1224	and	O
1224	to	O
1224	colorectal	B-Disease
1224	cancer	I-Disease
1224	.	O
1225	Mutations	O
1225	located	O
1225	at	O
1225	the	O
1225	extreme	O
1225	5	O
1225	end	O
1225	of	O
1225	the	O
1225	APC	B-Disease
1225	gene	O
1225	,	O
1225	however	O
1225	,	O
1225	are	O
1225	associated	O
1225	with	O
1225	a	O
1225	less	O
1225	severe	O
1225	disease	O
1225	known	O
1225	as	O
1225	attenuated	B-Disease
1225	adenomatous	I-Disease
1225	polyposis	I-Disease
1225	coli	I-Disease
1225	(	O
1225	AAPC	B-Disease
1225	)	O
1225	.	O
1226	Many	O
1226	individuals	O
1226	with	O
1226	AAPC	B-Disease
1226	develop	O
1226	relatively	O
1226	few	O
1226	colorectal	B-Disease
1226	polyps	I-Disease
1226	but	O
1226	are	O
1226	still	O
1226	at	O
1226	high	O
1226	risk	O
1226	for	O
1226	colorectal	B-Disease
1226	cancer	I-Disease
1226	.	O
1227	We	O
1227	report	O
1227	here	O
1227	the	O
1227	identification	O
1227	of	O
1227	a	O
1227	5	O
1227	APC	B-Disease
1227	germline	O
1227	mutation	O
1227	in	O
1227	five	O
1227	separately	O
1227	ascertained	O
1227	AAPC	B-Disease
1227	families	O
1227	from	O
1227	Newfoundland	O
1227	,	O
1227	Canada	O
1227	.	O
1228	This	O
1228	disease	O
1228	-	O
1228	causing	O
1228	mutation	O
1228	is	O
1228	a	O
1228	single	O
1228	basepair	O
1228	change	O
1228	(	O
1228	G	O
1228	to	O
1228	A	O
1228	)	O
1228	in	O
1228	the	O
1228	splice	O
1228	-	O
1228	acceptor	O
1228	region	O
1228	of	O
1228	APC	B-Disease
1228	intron	O
1228	3	O
1228	that	O
1228	creates	O
1228	a	O
1228	mutant	O
1228	RNA	O
1228	without	O
1228	exon	O
1228	4	O
1228	of	O
1228	APC	O
1228	.	O
1229	The	O
1229	observation	O
1229	of	O
1229	the	O
1229	same	O
1229	APC	B-Disease
1229	mutation	O
1229	in	O
1229	five	O
1229	families	O
1229	from	O
1229	the	O
1229	same	O
1229	geographic	O
1229	area	O
1229	demonstrates	O
1229	a	O
1229	founder	O
1229	effect	O
1229	.	O
1230	Furthermore	O
1230	,	O
1230	the	O
1230	identification	O
1230	of	O
1230	this	O
1230	germline	O
1230	mutation	O
1230	strengthens	O
1230	the	O
1230	correlation	O
1230	between	O
1230	the	O
1230	5	O
1230	location	O
1230	of	O
1230	an	O
1230	APC	B-Disease
1230	disease	O
1230	-	O
1230	causing	O
1230	mutation	O
1230	and	O
1230	the	O
1230	attenuated	B-Disease
1230	polyposis	I-Disease
1230	phenotype	O
1230	.	O
1230	.	O
1231	Alstrom	B-Disease
1231	syndrome	I-Disease
1231	:	O
1231	further	O
1231	evidence	O
1231	for	O
1231	linkage	O
1231	to	O
1231	human	O
1231	chromosome	O
1231	2p13	O
1231	.	O
1232	Alstrom	B-Disease
1232	syndrome	I-Disease
1232	is	O
1232	a	O
1232	rare	O
1232	autosomal	B-Disease
1232	recessive	I-Disease
1232	disorder	I-Disease
1232	characterized	O
1232	by	O
1232	retinal	B-Disease
1232	degeneration	I-Disease
1232	,	O
1232	sensorineural	B-Disease
1232	hearing	I-Disease
1232	loss	I-Disease
1232	,	O
1232	early	O
1232	-	O
1232	onset	O
1232	obesity	B-Disease
1232	,	O
1232	and	O
1232	non	B-Disease
1232	-	I-Disease
1232	insulin	I-Disease
1232	-	I-Disease
1232	dependent	I-Disease
1232	diabetes	I-Disease
1232	mellitus	I-Disease
1232	.	O
1233	The	O
1233	gene	O
1233	for	O
1233	Alstrom	B-Disease
1233	syndrome	I-Disease
1233	(	O
1233	ALMS1	O
1233	)	O
1233	has	O
1233	been	O
1233	previously	O
1233	localized	O
1233	to	O
1233	human	O
1233	chromosome	O
1233	2p13	O
1233	by	O
1233	homozygosity	O
1233	mapping	O
1233	in	O
1233	two	O
1233	distinct	O
1233	isolated	O
1233	populations	O
1233	-	O
1233	French	O
1233	Acadian	O
1233	and	O
1233	North	O
1233	African	O
1233	.	O
1234	Pair	O
1234	-	O
1234	wise	O
1234	analyses	O
1234	resulted	O
1234	in	O
1234	maximum	O
1234	lod	O
1234	(	O
1234	logarithm	O
1234	of	O
1234	the	O
1234	odds	O
1234	ratio	O
1234	)	O
1234	scores	O
1234	of	O
1234	3	O
1234	.	O
1235	84	O
1235	and	O
1235	2	O
1235	.	O
1236	9	O
1236	,	O
1236	respectively	O
1236	.	O
1237	To	O
1237	confirm	O
1237	these	O
1237	findings	O
1237	,	O
1237	a	O
1237	large	O
1237	linkage	O
1237	study	O
1237	was	O
1237	performed	O
1237	in	O
1237	twelve	O
1237	additional	O
1237	families	O
1237	segregating	O
1237	for	O
1237	Alstrom	B-Disease
1237	syndrome	I-Disease
1237	.	O
1238	A	O
1238	maximum	O
1238	two	O
1238	-	O
1238	point	O
1238	lod	O
1238	score	O
1238	of	O
1238	7	O
1238	.	O
1239	13	O
1239	(	O
1239	theta	O
1239	=	O
1239	0	O
1239	.	O
1239	00	O
1239	)	O
1239	for	O
1239	marker	O
1239	D2S2110	O
1239	and	O
1239	a	O
1239	maximum	O
1239	cumulative	O
1239	multipoint	O
1239	lod	O
1239	score	O
1239	of	O
1239	9	O
1239	.	O
1240	16	O
1240	for	O
1240	marker	O
1240	D2S2110	O
1240	were	O
1240	observed	O
1240	,	O
1240	further	O
1240	supporting	O
1240	linkage	O
1240	to	O
1240	chromosome	O
1240	2p13	O
1240	.	O
1241	No	O
1241	evidence	O
1241	of	O
1241	genetic	O
1241	heterogeneity	O
1241	was	O
1241	observed	O
1241	in	O
1241	these	O
1241	families	O
1241	.	O
1242	Meiotic	O
1242	recombination	O
1242	events	O
1242	have	O
1242	localized	O
1242	the	O
1242	critical	O
1242	region	O
1242	containing	O
1242	ALMS1	O
1242	to	O
1242	a	O
1242	6	O
1242	.	O
1243	1	O
1243	-	O
1243	cM	O
1243	interval	O
1243	flanked	O
1243	by	O
1243	markers	O
1243	D2S327	O
1243	and	O
1243	D2S286	O
1243	.	O
1244	A	O
1244	fine	O
1244	resolution	O
1244	radiation	O
1244	hybrid	O
1244	map	O
1244	of	O
1244	31	O
1244	genes	O
1244	and	O
1244	markers	O
1244	has	O
1244	been	O
1244	constructed	O
1244	.	O
1245	Pendred	B-Disease
1245	syndrome	I-Disease
1245	:	O
1245	phenotypic	O
1245	variability	O
1245	in	O
1245	two	O
1245	families	O
1245	carrying	O
1245	the	O
1245	same	O
1245	PDS	B-Disease
1245	missense	O
1245	mutation	O
1245	.	O
1246	Pendred	B-Disease
1246	syndrome	I-Disease
1246	comprises	O
1246	congenital	B-Disease
1246	sensorineural	I-Disease
1246	hearing	I-Disease
1246	loss	I-Disease
1246	,	O
1246	thyroid	B-Disease
1246	goiter	I-Disease
1246	,	O
1246	and	O
1246	positive	O
1246	perchlorate	O
1246	discharge	O
1246	test	O
1246	.	O
1247	Recently	O
1247	,	O
1247	this	O
1247	autosomal	B-Disease
1247	recessive	I-Disease
1247	disorder	I-Disease
1247	was	O
1247	shown	O
1247	to	O
1247	be	O
1247	caused	O
1247	by	O
1247	mutations	O
1247	in	O
1247	the	O
1247	PDS	B-Disease
1247	gene	O
1247	,	O
1247	which	O
1247	encodes	O
1247	an	O
1247	anion	O
1247	transporter	O
1247	called	O
1247	pendrin	O
1247	.	O
1248	Molecular	O
1248	analysis	O
1248	of	O
1248	the	O
1248	PDS	B-Disease
1248	gene	O
1248	was	O
1248	performed	O
1248	in	O
1248	two	O
1248	consanguineous	O
1248	large	O
1248	families	O
1248	from	O
1248	Southern	O
1248	Tunisia	O
1248	comprising	O
1248	a	O
1248	total	O
1248	of	O
1248	23	O
1248	individuals	O
1248	affected	O
1248	with	O
1248	profound	O
1248	congenital	B-Disease
1248	deafness	I-Disease
1248	;	O
1248	the	O
1248	same	O
1248	missense	O
1248	mutation	O
1248	,	O
1248	L445W	O
1248	,	O
1248	was	O
1248	identified	O
1248	in	O
1248	all	O
1248	affected	O
1248	individuals	O
1248	.	O
1249	A	O
1249	widened	B-Disease
1249	vestibular	I-Disease
1249	aqueduct	I-Disease
1249	was	O
1249	found	O
1249	in	O
1249	all	O
1249	patients	O
1249	who	O
1249	underwent	O
1249	computed	O
1249	tomography	O
1249	(	O
1249	CT	O
1249	)	O
1249	scan	O
1249	exploration	O
1249	of	O
1249	the	O
1249	inner	O
1249	ear	O
1249	.	O
1250	In	O
1250	contrast	O
1250	,	O
1250	goiter	B-Disease
1250	was	O
1250	present	O
1250	in	O
1250	only	O
1250	11	O
1250	affected	O
1250	individuals	O
1250	,	O
1250	who	O
1250	interestingly	O
1250	had	O
1250	a	O
1250	normal	O
1250	result	O
1250	of	O
1250	the	O
1250	perchlorate	O
1250	discharge	O
1250	test	O
1250	whenever	O
1250	performed	O
1250	.	O
1251	The	O
1251	present	O
1251	results	O
1251	question	O
1251	the	O
1251	sensitivity	O
1251	of	O
1251	the	O
1251	perchlorate	O
1251	test	O
1251	for	O
1251	the	O
1251	diagnosis	O
1251	of	O
1251	Pendred	B-Disease
1251	syndrome	I-Disease
1251	and	O
1251	support	O
1251	the	O
1251	use	O
1251	of	O
1251	a	O
1251	molecular	O
1251	analysis	O
1251	of	O
1251	the	O
1251	PDS	B-Disease
1251	gene	O
1251	in	O
1251	the	O
1251	assessment	O
1251	of	O
1251	individuals	O
1251	with	O
1251	severe	O
1251	to	O
1251	profound	O
1251	congenital	B-Disease
1251	hearing	I-Disease
1251	loss	I-Disease
1251	associated	O
1251	with	O
1251	inner	B-Disease
1251	ear	I-Disease
1251	morphological	I-Disease
1251	anomaly	I-Disease
1251	even	O
1251	in	O
1251	the	O
1251	absence	O
1251	of	O
1251	a	O
1251	thyroid	B-Disease
1251	goiter	I-Disease
1251	.	O
1251	.	O
1252	Knobloch	B-Disease
1252	syndrome	I-Disease
1252	involving	O
1252	midline	B-Disease
1252	scalp	I-Disease
1252	defect	I-Disease
1252	of	I-Disease
1252	the	I-Disease
1252	frontal	I-Disease
1252	region	I-Disease
1252	.	O
1253	We	O
1253	report	O
1253	on	O
1253	a	O
1253	4	O
1253	-	O
1253	year	O
1253	-	O
1253	old	O
1253	boy	O
1253	with	O
1253	Knobloch	B-Disease
1253	syndrome	I-Disease
1253	.	O
1254	He	O
1254	has	O
1254	vitreoretinal	B-Disease
1254	degeneration	I-Disease
1254	,	O
1254	high	B-Disease
1254	myopia	I-Disease
1254	,	O
1254	cataract	B-Disease
1254	,	O
1254	telecanthus	B-Disease
1254	,	O
1254	hypertelorism	B-Disease
1254	,	O
1254	and	O
1254	a	O
1254	high	B-Disease
1254	-	I-Disease
1254	arched	I-Disease
1254	palate	I-Disease
1254	.	O
1255	He	O
1255	also	O
1255	has	O
1255	a	O
1255	defect	B-Disease
1255	of	I-Disease
1255	the	I-Disease
1255	anterior	I-Disease
1255	midline	I-Disease
1255	scalp	I-Disease
1255	with	O
1255	involvement	O
1255	of	O
1255	the	O
1255	frontal	O
1255	bone	O
1255	as	O
1255	documented	O
1255	by	O
1255	a	O
1255	computed	O
1255	tomography	O
1255	(	O
1255	CT	O
1255	)	O
1255	scan	O
1255	.	O
1256	The	O
1256	brain	O
1256	was	O
1256	normal	O
1256	on	O
1256	CT	O
1256	scan	O
1256	and	O
1256	magnetic	O
1256	resonance	O
1256	imaging	O
1256	.	O
1257	We	O
1257	present	O
1257	a	O
1257	review	O
1257	of	O
1257	the	O
1257	23	O
1257	published	O
1257	cases	O
1257	with	O
1257	this	O
1257	syndrome	O
1257	.	O
1258	Our	O
1258	patient	O
1258	illustrates	O
1258	the	O
1258	importance	O
1258	of	O
1258	investigating	O
1258	for	O
1258	underlying	O
1258	ocular	O
1258	and	O
1258	central	O
1258	nervous	O
1258	system	O
1258	pathology	O
1258	whenever	O
1258	midline	B-Disease
1258	scalp	I-Disease
1258	defects	I-Disease
1258	are	O
1258	present	O
1258	.	O
1258	.	O
1259	The	O
1259	DNA	O
1259	double	O
1259	-	O
1259	strand	O
1259	break	O
1259	repair	O
1259	gene	O
1259	hMRE11	O
1259	is	O
1259	mutated	O
1259	in	O
1259	individuals	O
1259	with	O
1259	an	O
1259	ataxia	B-Disease
1259	-	I-Disease
1259	telangiectasia	I-Disease
1259	-	I-Disease
1259	like	I-Disease
1259	disorder	I-Disease
1259	.	O
1260	We	O
1260	show	O
1260	that	O
1260	hypomorphic	O
1260	mutations	O
1260	in	O
1260	hMRE11	O
1260	,	O
1260	but	O
1260	not	O
1260	in	O
1260	ATM	O
1260	,	O
1260	are	O
1260	present	O
1260	in	O
1260	certain	O
1260	individuals	O
1260	with	O
1260	an	O
1260	ataxia	B-Disease
1260	-	I-Disease
1260	telangiectasia	I-Disease
1260	-	I-Disease
1260	like	I-Disease
1260	disorder	I-Disease
1260	(	O
1260	ATLD	B-Disease
1260	)	O
1260	.	O
1261	The	O
1261	cellular	O
1261	features	O
1261	resulting	O
1261	from	O
1261	these	O
1261	hMRE11	O
1261	mutations	O
1261	are	O
1261	similar	O
1261	to	O
1261	those	O
1261	seen	O
1261	in	O
1261	A	B-Disease
1261	-	I-Disease
1261	T	I-Disease
1261	as	O
1261	well	O
1261	as	O
1261	NBS	B-Disease
1261	and	O
1261	include	O
1261	hypersensitivity	B-Disease
1261	to	I-Disease
1261	ionizing	I-Disease
1261	radiation	I-Disease
1261	,	O
1261	radioresistant	O
1261	DNA	O
1261	synthesis	O
1261	,	O
1261	and	O
1261	abrogation	O
1261	of	O
1261	ATM	O
1261	-	O
1261	dependent	O
1261	events	O
1261	,	O
1261	such	O
1261	as	O
1261	the	O
1261	activation	O
1261	of	O
1261	Jun	O
1261	kinase	O
1261	following	O
1261	exposure	O
1261	to	O
1261	gamma	O
1261	irradiation	O
1261	.	O
1262	Although	O
1262	the	O
1262	mutant	O
1262	hMre11	O
1262	proteins	O
1262	retain	O
1262	some	O
1262	ability	O
1262	to	O
1262	interact	O
1262	with	O
1262	hRad50	O
1262	and	O
1262	Nbs1	O
1262	,	O
1262	formation	O
1262	of	O
1262	ionizing	O
1262	radiation	O
1262	-	O
1262	induced	O
1262	hMre11	O
1262	and	O
1262	Nbs1	O
1262	foci	O
1262	was	O
1262	absent	O
1262	in	O
1262	hMRE11	O
1262	mutant	O
1262	cells	O
1262	.	O
1263	These	O
1263	data	O
1263	demonstrate	O
1263	that	O
1263	ATM	O
1263	and	O
1263	the	O
1263	hMre11	O
1263	/	O
1263	hRad50	O
1263	/	O
1263	Nbs1	O
1263	protein	O
1263	complex	O
1263	act	O
1263	in	O
1263	the	O
1263	same	O
1263	DNA	O
1263	damage	O
1263	response	O
1263	pathway	O
1263	and	O
1263	link	O
1263	hMre11	O
1263	to	O
1263	the	O
1263	complex	O
1263	pathology	O
1263	of	O
1263	A	B-Disease
1263	-	I-Disease
1263	T	I-Disease
1263	.	O
1263	.	O
1264	Mutations	O
1264	in	O
1264	TNFRSF11A	O
1264	,	O
1264	affecting	O
1264	the	O
1264	signal	O
1264	peptide	O
1264	of	O
1264	RANK	O
1264	,	O
1264	cause	O
1264	familial	B-Disease
1264	expansile	I-Disease
1264	osteolysis	I-Disease
1264	.	O
1265	Familial	B-Disease
1265	expansile	I-Disease
1265	osteolysis	I-Disease
1265	(	O
1265	FEO	B-Disease
1265	,	O
1265	MIM	O
1265	174810	O
1265	)	O
1265	is	O
1265	a	O
1265	rare	O
1265	,	O
1265	autosomal	B-Disease
1265	dominant	I-Disease
1265	bone	I-Disease
1265	disorder	I-Disease
1265	characterized	O
1265	by	O
1265	focal	O
1265	areas	O
1265	of	O
1265	increased	B-Disease
1265	bone	I-Disease
1265	remodelling	I-Disease
1265	.	O
1266	The	O
1266	osteolytic	B-Disease
1266	lesions	I-Disease
1266	,	O
1266	which	O
1266	develop	O
1266	usually	O
1266	in	O
1266	the	O
1266	long	O
1266	bones	O
1266	during	O
1266	early	O
1266	adulthood	O
1266	,	O
1266	show	O
1266	increased	O
1266	osteoblast	O
1266	and	O
1266	osteoclast	O
1266	activity	O
1266	.	O
1267	Our	O
1267	previous	O
1267	linkage	O
1267	studies	O
1267	mapped	O
1267	the	O
1267	gene	O
1267	responsible	O
1267	for	O
1267	FEO	B-Disease
1267	to	O
1267	an	O
1267	interval	O
1267	of	O
1267	less	O
1267	than	O
1267	5	O
1267	cM	O
1267	between	O
1267	D18S64	O
1267	and	O
1267	D18S51	O
1267	on	O
1267	chromosome	O
1267	18q21	O
1267	.	O
1268	2	O
1268	-	O
1268	21	O
1268	2	O
1268	-	O
1268	21	O
1268	.	O
1269	3	O
1269	in	O
1269	a	O
1269	large	O
1269	Northern	O
1269	Irish	O
1269	family	O
1269	.	O
1270	The	O
1270	gene	O
1270	encoding	O
1270	receptor	O
1270	activator	O
1270	of	O
1270	nuclear	O
1270	factor	O
1270	-	O
1270	kappa	O
1270	B	O
1270	(	O
1270	RANK	O
1270	;	O
1270	ref	O
1270	.	O
1270	5	O
1270	)	O
1270	,	O
1270	TNFRSF11A	O
1270	,	O
1270	maps	O
1270	to	O
1270	this	O
1270	region	O
1270	.	O
1271	RANK	O
1271	is	O
1271	essential	O
1271	in	O
1271	osteoclast	O
1271	formation	O
1271	.	O
1272	We	O
1272	identified	O
1272	two	O
1272	heterozygous	O
1272	insertion	O
1272	mutations	O
1272	in	O
1272	exon	O
1272	1	O
1272	of	O
1272	TNFRSF11A	O
1272	in	O
1272	affected	O
1272	members	O
1272	of	O
1272	four	O
1272	families	O
1272	with	O
1272	FEO	B-Disease
1272	or	O
1272	familial	B-Disease
1272	Paget	I-Disease
1272	disease	I-Disease
1272	of	I-Disease
1272	bone	I-Disease
1272	(	O
1272	PDB	B-Disease
1272	)	O
1272	.	O
1273	One	O
1273	was	O
1273	a	O
1273	duplication	O
1273	of	O
1273	18	O
1273	bases	O
1273	and	O
1273	the	O
1273	other	O
1273	a	O
1273	duplication	O
1273	of	O
1273	27	O
1273	bases	O
1273	,	O
1273	both	O
1273	of	O
1273	which	O
1273	affected	O
1273	the	O
1273	signal	O
1273	peptide	O
1273	region	O
1273	of	O
1273	the	O
1273	RANK	O
1273	molecule	O
1273	.	O
1274	Expression	O
1274	of	O
1274	recombinant	O
1274	forms	O
1274	of	O
1274	the	O
1274	mutant	O
1274	RANK	O
1274	proteins	O
1274	revealed	O
1274	perturbations	O
1274	in	O
1274	expression	O
1274	levels	O
1274	and	O
1274	lack	O
1274	of	O
1274	normal	O
1274	cleavage	O
1274	of	O
1274	the	O
1274	signal	O
1274	peptide	O
1274	.	O
1275	Both	O
1275	mutations	O
1275	caused	O
1275	an	O
1275	increase	O
1275	in	O
1275	RANK	O
1275	-	O
1275	mediated	O
1275	nuclear	O
1275	factor	O
1275	-	O
1275	kappaB	O
1275	(	O
1275	NF	O
1275	-	O
1275	kappaB	O
1275	)	O
1275	signalling	O
1275	in	O
1275	vitro	O
1275	,	O
1275	consistent	O
1275	with	O
1275	the	O
1275	presence	O
1275	of	O
1275	an	O
1275	activating	O
1275	mutation	O
1275	.	O
1276	Cardiac	O
1276	Na	O
1276	(	O
1276	+	O
1276	)	O
1276	channel	O
1276	dysfunction	O
1276	in	O
1276	Brugada	B-Disease
1276	syndrome	I-Disease
1276	is	O
1276	aggravated	O
1276	by	O
1276	beta	O
1276	(	O
1276	1	O
1276	)	O
1276	-	O
1276	subunit	O
1276	.	O
1277	BACKGROUND	O
1277	Mutations	O
1277	in	O
1277	the	O
1277	gene	O
1277	encoding	O
1277	the	O
1277	human	O
1277	cardiac	O
1277	Na	O
1277	(	O
1277	+	O
1277	)	O
1277	channel	O
1277	alpha	O
1277	-	O
1277	subunit	O
1277	(	O
1277	hH1	O
1277	)	O
1277	are	O
1277	responsible	O
1277	for	O
1277	chromosome	O
1277	3	O
1277	-	O
1277	linked	O
1277	congenital	B-Disease
1277	long	I-Disease
1277	-	I-Disease
1277	QT	I-Disease
1277	syndrome	I-Disease
1277	(	O
1277	LQT3	B-Disease
1277	)	O
1277	and	O
1277	idiopathic	B-Disease
1277	ventricular	I-Disease
1277	fibrillation	I-Disease
1277	(	O
1277	IVF	B-Disease
1277	)	O
1277	.	O
1278	An	O
1278	auxiliary	O
1278	beta	O
1278	(	O
1278	1	O
1278	)	O
1278	-	O
1278	subunit	O
1278	,	O
1278	widely	O
1278	expressed	O
1278	in	O
1278	excitable	O
1278	tissues	O
1278	,	O
1278	shifts	O
1278	the	O
1278	voltage	O
1278	dependence	O
1278	of	O
1278	steady	O
1278	-	O
1278	state	O
1278	inactivation	O
1278	toward	O
1278	more	O
1278	negative	O
1278	potentials	O
1278	and	O
1278	restores	O
1278	normal	O
1278	gating	O
1278	kinetics	O
1278	of	O
1278	brain	O
1278	and	O
1278	skeletal	O
1278	muscle	O
1278	Na	O
1278	(	O
1278	+	O
1278	)	O
1278	channels	O
1278	expressed	O
1278	in	O
1278	Xenopus	O
1278	oocytes	O
1278	but	O
1278	has	O
1278	little	O
1278	if	O
1278	any	O
1278	functional	O
1278	effect	O
1278	on	O
1278	the	O
1278	cardiac	O
1278	isoform	O
1278	.	O
1279	Here	O
1279	,	O
1279	we	O
1279	characterize	O
1279	the	O
1279	altered	O
1279	effects	O
1279	of	O
1279	a	O
1279	human	O
1279	beta	O
1279	(	O
1279	1	O
1279	)	O
1279	-	O
1279	subunit	O
1279	(	O
1279	hbeta	O
1279	(	O
1279	1	O
1279	)	O
1279	)	O
1279	on	O
1279	the	O
1279	heterologously	O
1279	expressed	O
1279	hH1	O
1279	mutation	O
1279	(	O
1279	T1620M	O
1279	)	O
1279	previously	O
1279	associated	O
1279	with	O
1279	IVF	B-Disease
1279	.	O
1280	METHODS	O
1280	AND	O
1280	RESULTS	O
1280	When	O
1280	expressed	O
1280	alone	O
1280	in	O
1280	Xenopus	O
1280	oocytes	O
1280	,	O
1280	T1620M	O
1280	exhibited	O
1280	no	O
1280	persistent	O
1280	currents	O
1280	,	O
1280	in	O
1280	contrast	O
1280	to	O
1280	the	O
1280	LQT3	B-Disease
1280	mutant	O
1280	channels	O
1280	,	O
1280	but	O
1280	the	O
1280	midpoint	O
1280	of	O
1280	steady	O
1280	-	O
1280	state	O
1280	inactivation	O
1280	(	O
1280	V	O
1280	(	O
1280	1	O
1280	/	O
1280	2	O
1280	)	O
1280	)	O
1280	was	O
1280	significantly	O
1280	shifted	O
1280	toward	O
1280	more	O
1280	positive	O
1280	potentials	O
1280	than	O
1280	for	O
1280	wild	O
1280	-	O
1280	type	O
1280	hH1	O
1280	.	O
1281	Coexpression	O
1281	of	O
1281	hbeta	O
1281	(	O
1281	1	O
1281	)	O
1281	did	O
1281	not	O
1281	significantly	O
1281	alter	O
1281	current	O
1281	decay	O
1281	or	O
1281	recovery	O
1281	from	O
1281	inactivation	O
1281	of	O
1281	wild	O
1281	-	O
1281	type	O
1281	hH1	O
1281	;	O
1281	however	O
1281	,	O
1281	it	O
1281	further	O
1281	shifted	O
1281	the	O
1281	V	O
1281	(	O
1281	1	O
1281	/	O
1281	2	O
1281	)	O
1281	and	O
1281	accelerated	O
1281	the	O
1281	recovery	O
1281	from	O
1281	inactivation	O
1281	of	O
1281	T1620M	O
1281	.	O
1282	Oocyte	O
1282	macropatch	O
1282	analysis	O
1282	revealed	O
1282	that	O
1282	the	O
1282	activation	O
1282	kinetics	O
1282	of	O
1282	T1620M	O
1282	were	O
1282	normal	O
1282	.	O
1283	CONCLUSIONS	O
1283	It	O
1283	is	O
1283	suggested	O
1283	that	O
1283	coexpression	O
1283	of	O
1283	hbeta	O
1283	(	O
1283	1	O
1283	)	O
1283	exposes	O
1283	a	O
1283	more	O
1283	severe	O
1283	functional	O
1283	defect	O
1283	that	O
1283	results	O
1283	in	O
1283	a	O
1283	greater	O
1283	overlap	O
1283	in	O
1283	the	O
1283	relationship	O
1283	between	O
1283	channel	O
1283	inactivation	O
1283	and	O
1283	activation	O
1283	(	O
1283	window	O
1283	current	O
1283	)	O
1283	in	O
1283	T1620M	O
1283	,	O
1283	which	O
1283	is	O
1283	proposed	O
1283	to	O
1283	be	O
1283	a	O
1283	potential	O
1283	pathophysiological	O
1283	mechanism	O
1283	of	O
1283	IVF	B-Disease
1283	in	O
1283	vivo	O
1283	.	O
1284	One	O
1284	possible	O
1284	explanation	O
1284	for	O
1284	our	O
1284	finding	O
1284	is	O
1284	an	O
1284	altered	O
1284	alpha	O
1284	-	O
1284	/	O
1284	beta	O
1284	(	O
1284	1	O
1284	)	O
1284	-	O
1284	subunit	O
1284	association	O
1284	in	O
1284	the	O
1284	mutant	O
1284	.	O
1284	.	O
1285	Meiotic	O
1285	segregation	O
1285	analysis	O
1285	of	O
1285	RB1	O
1285	alleles	O
1285	in	O
1285	retinoblastoma	B-Disease
1285	pedigrees	O
1285	by	O
1285	use	O
1285	of	O
1285	single	O
1285	-	O
1285	sperm	O
1285	typing	O
1285	.	O
1286	In	O
1286	hereditary	B-Disease
1286	retinoblastoma	I-Disease
1286	,	O
1286	different	O
1286	epidemiological	O
1286	studies	O
1286	have	O
1286	indicated	O
1286	a	O
1286	preferential	O
1286	paternal	O
1286	transmission	O
1286	of	O
1286	mutant	O
1286	retinoblastoma	B-Disease
1286	alleles	O
1286	to	O
1286	offspring	O
1286	,	O
1286	suggesting	O
1286	the	O
1286	occurrence	O
1286	of	O
1286	a	O
1286	meiotic	O
1286	drive	O
1286	.	O
1287	To	O
1287	investigate	O
1287	this	O
1287	mechanism	O
1287	,	O
1287	we	O
1287	analyzed	O
1287	sperm	O
1287	samples	O
1287	from	O
1287	six	O
1287	individuals	O
1287	from	O
1287	five	O
1287	unrelated	O
1287	families	O
1287	affected	O
1287	with	O
1287	hereditary	B-Disease
1287	retinoblastoma	I-Disease
1287	.	O
1288	Single	O
1288	-	O
1288	sperm	O
1288	typing	O
1288	techniques	O
1288	were	O
1288	performed	O
1288	for	O
1288	each	O
1288	sample	O
1288	by	O
1288	study	O
1288	of	O
1288	two	O
1288	informative	O
1288	short	O
1288	tandem	O
1288	repeats	O
1288	located	O
1288	either	O
1288	in	O
1288	or	O
1288	close	O
1288	to	O
1288	the	O
1288	retinoblastoma	B-Disease
1288	gene	O
1288	(	O
1288	RB1	O
1288	)	O
1288	.	O
1289	The	O
1289	segregation	O
1289	probability	O
1289	of	O
1289	mutant	O
1289	RB1	O
1289	alleles	O
1289	in	O
1289	sperm	O
1289	samples	O
1289	was	O
1289	assessed	O
1289	by	O
1289	use	O
1289	of	O
1289	the	O
1289	SPERMSEG	O
1289	program	O
1289	,	O
1289	which	O
1289	includes	O
1289	experimental	O
1289	parameters	O
1289	,	O
1289	recombination	O
1289	fractions	O
1289	between	O
1289	the	O
1289	markers	O
1289	,	O
1289	and	O
1289	segregation	O
1289	parameters	O
1289	.	O
1290	A	O
1290	total	O
1290	of	O
1290	2	O
1290	,	O
1290	952	O
1290	single	O
1290	sperm	O
1290	from	O
1290	the	O
1290	six	O
1290	donors	O
1290	were	O
1290	analyzed	O
1290	.	O
1291	We	O
1291	detected	O
1291	a	O
1291	significant	O
1291	segregation	O
1291	distortion	O
1291	in	O
1291	the	O
1291	data	O
1291	as	O
1291	a	O
1291	whole	O
1291	(	O
1291	P	O
1291	=	O
1291	.	O
1291	0099	O
1291	)	O
1291	and	O
1291	a	O
1291	significant	O
1291	heterogeneity	O
1291	in	O
1291	the	O
1291	segregation	O
1291	rate	O
1291	across	O
1291	donors	O
1291	(	O
1291	.	O
1291	0092	O
1291	)	O
1291	.	O
1292	Further	O
1292	analysis	O
1292	shows	O
1292	that	O
1292	this	O
1292	result	O
1292	can	O
1292	be	O
1292	explained	O
1292	by	O
1292	segregation	O
1292	distortion	O
1292	in	O
1292	favor	O
1292	of	O
1292	the	O
1292	normal	O
1292	allele	O
1292	in	O
1292	one	O
1292	donor	O
1292	only	O
1292	and	O
1292	that	O
1292	it	O
1292	does	O
1292	not	O
1292	provide	O
1292	evidence	O
1292	of	O
1292	a	O
1292	significant	O
1292	segregation	O
1292	distortion	O
1292	in	O
1292	the	O
1292	other	O
1292	donors	O
1292	.	O
1293	The	O
1293	segregation	O
1293	distortion	O
1293	favoring	O
1293	the	O
1293	mutant	O
1293	RB1	O
1293	allele	O
1293	does	O
1293	not	O
1293	seem	O
1293	to	O
1293	occur	O
1293	during	O
1293	spermatogenesis	O
1293	,	O
1293	and	O
1293	,	O
1293	thus	O
1293	,	O
1293	meiotic	O
1293	drive	O
1293	may	O
1293	result	O
1293	either	O
1293	from	O
1293	various	O
1293	mechanisms	O
1293	,	O
1293	including	O
1293	a	O
1293	fertilization	O
1293	advantage	O
1293	or	O
1293	a	O
1293	better	O
1293	mobility	O
1293	in	O
1293	sperm	O
1293	bearing	O
1293	a	O
1293	mutant	O
1293	RB1	O
1293	gene	O
1293	,	O
1293	or	O
1293	from	O
1293	the	O
1293	existence	O
1293	of	O
1293	a	O
1293	defectively	O
1293	imprinted	O
1293	gene	O
1293	located	O
1293	on	O
1293	the	O
1293	human	O
1293	X	O
1293	chromosome	O
1293	.	O
1294	Friedreich	B-Disease
1294	ataxia	I-Disease
1294	:	O
1294	an	O
1294	overview	O
1294	.	O
1295	Friedreich	B-Disease
1295	ataxia	I-Disease
1295	,	O
1295	an	O
1295	autosomal	B-Disease
1295	recessive	I-Disease
1295	neurodegenerative	I-Disease
1295	disease	I-Disease
1295	,	O
1295	is	O
1295	the	O
1295	most	O
1295	common	O
1295	of	O
1295	the	O
1295	inherited	B-Disease
1295	ataxias	I-Disease
1295	.	O
1296	The	O
1296	recent	O
1296	discovery	O
1296	of	O
1296	the	O
1296	gene	O
1296	that	O
1296	is	O
1296	mutated	O
1296	in	O
1296	this	O
1296	condition	O
1296	,	O
1296	FRDA	O
1296	,	O
1296	has	O
1296	led	O
1296	to	O
1296	rapid	O
1296	advances	O
1296	in	O
1296	the	O
1296	understanding	O
1296	of	O
1296	the	O
1296	pathogenesis	O
1296	of	O
1296	Friedreich	B-Disease
1296	ataxia	I-Disease
1296	.	O
1297	About	O
1297	98	O
1297	%	O
1297	of	O
1297	mutant	O
1297	alleles	O
1297	have	O
1297	an	O
1297	expansion	O
1297	of	O
1297	a	O
1297	GAA	O
1297	trinucleotide	O
1297	repeat	O
1297	in	O
1297	intron	O
1297	1	O
1297	of	O
1297	the	O
1297	gene	O
1297	.	O
1298	This	O
1298	leads	O
1298	to	O
1298	reduced	O
1298	levels	O
1298	of	O
1298	the	O
1298	protein	O
1298	,	O
1298	frataxin	O
1298	.	O
1299	There	O
1299	is	O
1299	mounting	O
1299	evidence	O
1299	to	O
1299	suggest	O
1299	that	O
1299	Friedreich	B-Disease
1299	ataxia	I-Disease
1299	is	O
1299	the	O
1299	result	O
1299	of	O
1299	accumulation	O
1299	of	O
1299	iron	O
1299	in	O
1299	mitochondria	O
1299	leading	O
1299	to	O
1299	excess	O
1299	production	O
1299	of	O
1299	free	O
1299	radicals	O
1299	,	O
1299	which	O
1299	then	O
1299	results	O
1299	in	O
1299	cellular	O
1299	damage	O
1299	and	O
1299	death	O
1299	.	O
1300	Currently	O
1300	there	O
1300	is	O
1300	no	O
1300	known	O
1300	treatment	O
1300	that	O
1300	alters	O
1300	the	O
1300	natural	O
1300	course	O
1300	of	O
1300	the	O
1300	disease	O
1300	.	O
1301	The	O
1301	discovery	O
1301	of	O
1301	the	O
1301	FRDA	B-Disease
1301	gene	O
1301	and	O
1301	its	O
1301	possible	O
1301	function	O
1301	has	O
1301	raised	O
1301	hope	O
1301	that	O
1301	rational	O
1301	therapeutic	O
1301	strategies	O
1301	will	O
1301	be	O
1301	developed	O
1301	.	O
1301	.	O
1302	X	B-Disease
1302	-	I-Disease
1302	linked	I-Disease
1302	retinoschisis	I-Disease
1302	with	O
1302	point	O
1302	mutations	O
1302	in	O
1302	the	O
1302	XLRS1	O
1302	gene	O
1302	.	O
1303	BACKGROUND	O
1303	X	B-Disease
1303	-	I-Disease
1303	linked	I-Disease
1303	retinoschisis	I-Disease
1303	(	O
1303	XLRS	B-Disease
1303	)	O
1303	is	O
1303	a	O
1303	relatively	O
1303	rare	O
1303	vitreoretinal	B-Disease
1303	dystrophy	I-Disease
1303	that	O
1303	causes	O
1303	visual	B-Disease
1303	loss	I-Disease
1303	in	O
1303	young	O
1303	men	O
1303	.	O
1304	Recently	O
1304	,	O
1304	a	O
1304	gene	O
1304	responsible	O
1304	for	O
1304	this	O
1304	disease	O
1304	,	O
1304	designated	O
1304	XLRS1	O
1304	,	O
1304	was	O
1304	identified	O
1304	,	O
1304	and	O
1304	several	O
1304	deleterious	O
1304	gene	O
1304	mutations	O
1304	were	O
1304	reported	O
1304	.	O
1305	OBJECTIVE	O
1305	To	O
1305	analyze	O
1305	Japanese	O
1305	patients	O
1305	clinically	O
1305	diagnosed	O
1305	as	O
1305	having	O
1305	XLRS	B-Disease
1305	formutational	O
1305	changes	O
1305	in	O
1305	the	O
1305	XLRS1	O
1305	gene	O
1305	.	O
1306	METHODS	O
1306	Ten	O
1306	patients	O
1306	with	O
1306	XLRS	B-Disease
1306	underwent	O
1306	full	O
1306	ophthalmologic	O
1306	examination	O
1306	,	O
1306	including	O
1306	slitlamp	O
1306	biomicroscopy	O
1306	and	O
1306	dilated	O
1306	funduscopy	O
1306	.	O
1307	Genomic	O
1307	DNA	O
1307	was	O
1307	isolated	O
1307	from	O
1307	leukocytes	O
1307	,	O
1307	and	O
1307	all	O
1307	exons	O
1307	of	O
1307	the	O
1307	XLRS1	O
1307	gene	O
1307	were	O
1307	amplified	O
1307	by	O
1307	polymerase	O
1307	chain	O
1307	reaction	O
1307	and	O
1307	analyzed	O
1307	using	O
1307	a	O
1307	direct	O
1307	sequencing	O
1307	method	O
1307	.	O
1308	RESULTS	O
1308	Point	O
1308	mutations	O
1308	in	O
1308	the	O
1308	XLRS1	O
1308	gene	O
1308	were	O
1308	identified	O
1308	in	O
1308	all	O
1308	10	O
1308	patients	O
1308	.	O
1309	The	O
1309	mutations	O
1309	were	O
1309	identical	O
1309	in	O
1309	each	O
1309	of	O
1309	2	O
1309	pairs	O
1309	of	O
1309	brothers	O
1309	.	O
1310	Six	O
1310	of	O
1310	the	O
1310	point	O
1310	mutations	O
1310	represented	O
1310	missense	O
1310	mutations	O
1310	,	O
1310	1	O
1310	was	O
1310	a	O
1310	nonsense	O
1310	mutation	O
1310	,	O
1310	and	O
1310	1	O
1310	was	O
1310	a	O
1310	frameshift	O
1310	mutation	O
1310	.	O
1311	Five	O
1311	of	O
1311	the	O
1311	mutations	O
1311	are	O
1311	newly	O
1311	reported	O
1311	herein	O
1311	.	O
1312	CONCLUSIONS	O
1312	The	O
1312	discovery	O
1312	of	O
1312	new	O
1312	point	O
1312	mutations	O
1312	in	O
1312	this	O
1312	study	O
1312	increases	O
1312	the	O
1312	available	O
1312	information	O
1312	regarding	O
1312	the	O
1312	spectrum	O
1312	of	O
1312	genetic	B-Disease
1312	abnormalities	I-Disease
1312	and	O
1312	clinical	O
1312	manifestations	O
1312	of	O
1312	XLRS	B-Disease
1312	.	O
1313	However	O
1313	,	O
1313	the	O
1313	limited	O
1313	data	O
1313	failed	O
1313	to	O
1313	reveal	O
1313	a	O
1313	correlation	O
1313	between	O
1313	mutation	O
1313	and	O
1313	disease	O
1313	phenotype	O
1313	.	O
1314	CLINICAL	O
1314	RELEVANCE	O
1314	Identification	O
1314	of	O
1314	mutations	O
1314	in	O
1314	the	O
1314	XLRS1	O
1314	gene	O
1314	and	O
1314	expanded	O
1314	information	O
1314	on	O
1314	clinical	O
1314	manifestations	O
1314	will	O
1314	facilitate	O
1314	early	O
1314	diagnosis	O
1314	,	O
1314	appropriate	O
1314	early	O
1314	therapy	O
1314	,	O
1314	and	O
1314	genetic	O
1314	counseling	O
1314	regarding	O
1314	the	O
1314	prognosis	O
1314	of	O
1314	XLRS	B-Disease
1314	.	O
1314	.	O
1315	Atm	O
1315	and	O
1315	Bax	O
1315	cooperate	O
1315	in	O
1315	ionizing	O
1315	radiation	O
1315	-	O
1315	induced	O
1315	apoptosis	O
1315	in	O
1315	the	O
1315	central	O
1315	nervous	O
1315	system	O
1315	.	O
1316	Ataxia	B-Disease
1316	-	I-Disease
1316	telangiectasia	I-Disease
1316	is	O
1316	a	O
1316	hereditary	B-Disease
1316	multisystemic	I-Disease
1316	disease	I-Disease
1316	resulting	O
1316	from	O
1316	mutations	O
1316	of	O
1316	ataxia	B-Disease
1316	telangiectasia	I-Disease
1316	,	O
1316	mutated	O
1316	(	O
1316	ATM	O
1316	)	O
1316	and	O
1316	is	O
1316	characterized	O
1316	by	O
1316	neurodegeneration	B-Disease
1316	,	O
1316	cancer	B-Disease
1316	,	O
1316	immune	B-Disease
1316	defects	I-Disease
1316	,	O
1316	and	O
1316	hypersensitivity	B-Disease
1316	to	I-Disease
1316	ionizing	I-Disease
1316	radiation	I-Disease
1316	.	O
1317	The	O
1317	molecular	O
1317	details	O
1317	of	O
1317	ATM	O
1317	function	O
1317	in	O
1317	the	O
1317	nervous	O
1317	system	O
1317	are	O
1317	unclear	O
1317	,	O
1317	although	O
1317	the	O
1317	neurological	B-Disease
1317	lesion	I-Disease
1317	in	O
1317	ataxia	B-Disease
1317	-	I-Disease
1317	telangiectasia	I-Disease
1317	becomes	O
1317	apparent	O
1317	early	O
1317	in	O
1317	life	O
1317	,	O
1317	suggesting	O
1317	a	O
1317	developmental	O
1317	origin	O
1317	.	O
1318	The	O
1318	central	O
1318	nervous	O
1318	system	O
1318	(	O
1318	CNS	O
1318	)	O
1318	of	O
1318	Atm	O
1318	-	O
1318	mice	O
1318	shows	O
1318	a	O
1318	pronounced	O
1318	defect	O
1318	in	O
1318	apoptosis	O
1318	induced	O
1318	by	O
1318	genotoxic	O
1318	stress	O
1318	,	O
1318	suggesting	O
1318	ATM	O
1318	functions	O
1318	to	O
1318	eliminate	O
1318	neurons	O
1318	with	O
1318	excessive	O
1318	genomic	O
1318	damage	O
1318	.	O
1319	Here	O
1319	,	O
1319	we	O
1319	report	O
1319	that	O
1319	the	O
1319	death	O
1319	effector	O
1319	Bax	O
1319	is	O
1319	required	O
1319	for	O
1319	a	O
1319	large	O
1319	proportion	O
1319	of	O
1319	Atm	O
1319	-	O
1319	dependent	O
1319	apoptosis	O
1319	in	O
1319	the	O
1319	developing	O
1319	CNS	O
1319	after	O
1319	ionizing	O
1319	radiation	O
1319	(	O
1319	IR	O
1319	)	O
1319	.	O
1320	Although	O
1320	many	O
1320	of	O
1320	the	O
1320	same	O
1320	regions	O
1320	of	O
1320	the	O
1320	CNS	O
1320	in	O
1320	both	O
1320	Bax	O
1320	-	O
1320	/	O
1320	-	O
1320	and	O
1320	Atm	O
1320	-	O
1320	/	O
1320	-	O
1320	mice	O
1320	were	O
1320	radioresistant	O
1320	,	O
1320	mice	O
1320	nullizygous	O
1320	for	O
1320	both	O
1320	Bax	O
1320	and	O
1320	Atm	O
1320	showed	O
1320	additional	O
1320	reduction	O
1320	in	O
1320	IR	O
1320	-	O
1320	induced	O
1320	apoptosis	O
1320	in	O
1320	the	O
1320	CNS	O
1320	.	O
1321	Therefore	O
1321	,	O
1321	although	O
1321	the	O
1321	major	O
1321	IR	O
1321	-	O
1321	induced	O
1321	apoptotic	O
1321	pathway	O
1321	in	O
1321	the	O
1321	CNS	O
1321	requires	O
1321	Atm	O
1321	and	O
1321	Bax	O
1321	,	O
1321	a	O
1321	p53	O
1321	-	O
1321	dependent	O
1321	collateral	O
1321	pathway	O
1321	exists	O
1321	that	O
1321	has	O
1321	both	O
1321	Atm	O
1321	-	O
1321	and	O
1321	Bax	O
1321	-	O
1321	independent	O
1321	branches	O
1321	.	O
1322	Further	O
1322	,	O
1322	Atm	O
1322	-	O
1322	and	O
1322	Bax	O
1322	-	O
1322	dependent	O
1322	apoptosis	O
1322	in	O
1322	the	O
1322	CNS	O
1322	also	O
1322	required	O
1322	caspase	O
1322	-	O
1322	3	O
1322	activation	O
1322	.	O
1323	These	O
1323	data	O
1323	implicate	O
1323	Bax	O
1323	and	O
1323	caspase	O
1323	-	O
1323	3	O
1323	as	O
1323	death	O
1323	effectors	O
1323	in	O
1323	neurodegenerative	O
1323	pathways	O
1323	.	O
1323	.	O
1324	Haim	B-Disease
1324	-	I-Disease
1324	Munk	I-Disease
1324	syndrome	I-Disease
1324	and	O
1324	Papillon	B-Disease
1324	-	I-Disease
1324	Lefevre	I-Disease
1324	syndrome	I-Disease
1324	are	O
1324	allelic	O
1324	mutations	O
1324	in	O
1324	cathepsin	O
1324	C	O
1324	.	O
1325	Of	O
1325	the	O
1325	many	O
1325	palmoplantar	B-Disease
1325	keratoderma	I-Disease
1325	(	I-Disease
1325	PPK	I-Disease
1325	)	I-Disease
1325	conditions	I-Disease
1325	,	O
1325	only	O
1325	Papillon	B-Disease
1325	-	I-Disease
1325	Lefevre	I-Disease
1325	syndrome	I-Disease
1325	(	O
1325	PLS	B-Disease
1325	)	O
1325	and	O
1325	Haim	B-Disease
1325	-	I-Disease
1325	Munk	I-Disease
1325	syndrome	I-Disease
1325	(	O
1325	HMS	B-Disease
1325	)	O
1325	are	O
1325	associated	O
1325	with	O
1325	premature	O
1325	periodontal	O
1325	destruction	O
1325	.	O
1326	Although	O
1326	both	O
1326	PLS	B-Disease
1326	and	O
1326	HMS	B-Disease
1326	share	O
1326	the	O
1326	cardinal	O
1326	features	O
1326	of	O
1326	PPK	B-Disease
1326	and	O
1326	severe	O
1326	periodontitis	B-Disease
1326	,	O
1326	a	O
1326	number	O
1326	of	O
1326	additional	O
1326	findings	O
1326	are	O
1326	reported	O
1326	in	O
1326	HMS	B-Disease
1326	including	O
1326	arachnodactyly	B-Disease
1326	,	O
1326	acro	B-Disease
1326	-	I-Disease
1326	osteolysis	I-Disease
1326	,	O
1326	atrophic	B-Disease
1326	changes	I-Disease
1326	of	I-Disease
1326	the	I-Disease
1326	nails	I-Disease
1326	,	O
1326	and	O
1326	a	O
1326	radiographic	B-Disease
1326	deformity	I-Disease
1326	of	I-Disease
1326	the	I-Disease
1326	fingers	I-Disease
1326	.	O
1327	While	O
1327	PLS	B-Disease
1327	cases	O
1327	have	O
1327	been	O
1327	identified	O
1327	throughout	O
1327	the	O
1327	world	O
1327	,	O
1327	HMS	B-Disease
1327	has	O
1327	only	O
1327	been	O
1327	described	O
1327	among	O
1327	descendants	O
1327	of	O
1327	a	O
1327	religious	O
1327	isolate	O
1327	originally	O
1327	from	O
1327	Cochin	O
1327	,	O
1327	India	O
1327	.	O
1328	Parental	O
1328	consanguinity	O
1328	is	O
1328	a	O
1328	characteristic	O
1328	of	O
1328	many	O
1328	cases	O
1328	of	O
1328	both	O
1328	conditions	O
1328	.	O
1329	Although	O
1329	autosomal	O
1329	recessive	O
1329	transmission	O
1329	of	O
1329	PLS	B-Disease
1329	is	O
1329	evident	O
1329	,	O
1329	a	O
1329	more	O
1329	"	NN	O	O
1329	complex	NN	O	O
1329	"	O
1329	autosomal	O
1329	recessive	O
1329	pattern	O
1329	of	O
1329	inheritance	O
1329	with	O
1329	phenotypic	O
1329	influences	O
1329	from	O
1329	a	O
1329	closely	O
1329	linked	O
1329	modifying	O
1329	locus	O
1329	has	O
1329	been	O
1329	hypothesised	O
1329	for	O
1329	HMS	B-Disease
1329	.	O
1330	Recently	O
1330	,	O
1330	mutations	O
1330	of	O
1330	the	O
1330	cathepsin	O
1330	C	O
1330	gene	O
1330	have	O
1330	been	O
1330	identified	O
1330	as	O
1330	the	O
1330	underlying	O
1330	genetic	B-Disease
1330	defect	I-Disease
1330	in	O
1330	PLS	B-Disease
1330	.	O
1331	To	O
1331	determine	O
1331	if	O
1331	a	O
1331	cathepsin	O
1331	C	O
1331	mutation	O
1331	is	O
1331	also	O
1331	responsible	O
1331	for	O
1331	HMS	B-Disease
1331	,	O
1331	we	O
1331	sequenced	O
1331	the	O
1331	gene	O
1331	in	O
1331	affected	O
1331	and	O
1331	unaffected	O
1331	subjects	O
1331	from	O
1331	the	O
1331	Cochin	O
1331	isolate	O
1331	in	O
1331	which	O
1331	both	O
1331	the	O
1331	PLS	B-Disease
1331	and	O
1331	HMS	B-Disease
1331	phenotypes	O
1331	appear	O
1331	.	O
1332	Here	O
1332	we	O
1332	report	O
1332	identification	O
1332	of	O
1332	a	O
1332	mutation	O
1332	of	O
1332	cathepsin	O
1332	C	O
1332	(	O
1332	exon	O
1332	6	O
1332	,	O
1332	2127A	O
1332	-	O
1332	-	O
1332	>	O
1332	G	O
1332	)	O
1332	that	O
1332	changes	O
1332	a	O
1332	highly	O
1332	conserved	O
1332	amino	O
1332	acid	O
1332	in	O
1332	the	O
1332	cathepsin	O
1332	C	O
1332	peptide	O
1332	.	O
1333	This	O
1333	mutation	O
1333	segregates	O
1333	with	O
1333	HMS	B-Disease
1333	in	O
1333	four	O
1333	nuclear	O
1333	families	O
1333	.	O
1334	Additionally	O
1334	,	O
1334	the	O
1334	existence	O
1334	of	O
1334	a	O
1334	shared	O
1334	common	O
1334	haplotype	O
1334	for	O
1334	genetic	O
1334	loci	O
1334	flanking	O
1334	the	O
1334	cathepsin	O
1334	C	O
1334	gene	O
1334	suggests	O
1334	that	O
1334	affected	O
1334	subjects	O
1334	descended	O
1334	from	O
1334	the	O
1334	Cochin	O
1334	isolate	O
1334	are	O
1334	homozygous	O
1334	for	O
1334	a	O
1334	mutation	O
1334	inherited	O
1334	"	NN	O	O
1334	identical	NN	O	O
1334	by	NN	O	O
1334	descent	NN	O	O
1334	"	O
1334	from	O
1334	a	O
1334	common	O
1334	ancestor	O
1334	.	O
1335	This	O
1335	finding	O
1335	supports	O
1335	simple	O
1335	autosomal	O
1335	recessive	O
1335	inheritance	O
1335	for	O
1335	HMS	B-Disease
1335	in	O
1335	these	O
1335	families	O
1335	.	O
1336	We	O
1336	also	O
1336	report	O
1336	a	O
1336	mutation	O
1336	of	O
1336	the	O
1336	same	O
1336	exon	O
1336	6	O
1336	CTSC	O
1336	codon	O
1336	(	O
1336	2126C	O
1336	-	O
1336	-	O
1336	>	O
1336	T	O
1336	)	O
1336	in	O
1336	a	O
1336	Turkish	O
1336	family	O
1336	with	O
1336	classical	O
1336	PLS	B-Disease
1336	.	O
1337	These	O
1337	findings	O
1337	provide	O
1337	evidence	O
1337	that	O
1337	PLS	B-Disease
1337	and	O
1337	HMS	B-Disease
1337	are	O
1337	allelic	O
1337	variants	O
1337	of	O
1337	cathepsin	O
1337	C	O
1337	gene	O
1337	mutations	O
1337	.	O
1337	.	O
1338	ATM	O
1338	-	O
1338	heterozygous	O
1338	germline	O
1338	mutations	O
1338	contribute	O
1338	to	O
1338	breast	B-Disease
1338	cancer	I-Disease
1338	-	O
1338	susceptibility	O
1338	.	O
1339	Approximately	O
1339	0	O
1339	.	O
1340	5	O
1340	%	O
1340	-	O
1340	1	O
1340	%	O
1340	of	O
1340	the	O
1340	general	O
1340	population	O
1340	has	O
1340	been	O
1340	estimated	O
1340	to	O
1340	be	O
1340	heterozygous	O
1340	for	O
1340	a	O
1340	germline	O
1340	mutation	O
1340	in	O
1340	the	O
1340	ATM	O
1340	gene	O
1340	.	O
1341	Mutations	O
1341	in	O
1341	the	O
1341	ATM	O
1341	gene	O
1341	are	O
1341	responsible	O
1341	for	O
1341	the	O
1341	autosomal	B-Disease
1341	recessive	I-Disease
1341	disorder	I-Disease
1341	ataxia	B-Disease
1341	-	I-Disease
1341	telangiectasia	I-Disease
1341	(	O
1341	A	B-Disease
1341	-	I-Disease
1341	T	I-Disease
1341	)	O
1341	(	O
1341	MIM	O
1341	208900	O
1341	)	O
1341	.	O
1342	The	O
1342	finding	O
1342	that	O
1342	ATM	O
1342	-	O
1342	heterozygotes	O
1342	have	O
1342	an	O
1342	increased	O
1342	relative	O
1342	risk	O
1342	for	O
1342	breast	B-Disease
1342	cancer	I-Disease
1342	was	O
1342	supported	O
1342	by	O
1342	some	O
1342	studies	O
1342	but	O
1342	not	O
1342	confirmed	O
1342	by	O
1342	others	O
1342	.	O
1343	In	O
1343	view	O
1343	of	O
1343	this	O
1343	discrepancy	O
1343	,	O
1343	we	O
1343	examined	O
1343	the	O
1343	frequency	O
1343	of	O
1343	ATM	O
1343	germline	O
1343	mutations	O
1343	in	O
1343	a	O
1343	selected	O
1343	group	O
1343	of	O
1343	Dutch	O
1343	patients	O
1343	with	O
1343	breast	B-Disease
1343	cancer	I-Disease
1343	.	O
1344	We	O
1344	have	O
1344	analyzed	O
1344	ATM	O
1344	germline	O
1344	mutations	O
1344	in	O
1344	normal	O
1344	blood	O
1344	lymphocytes	O
1344	,	O
1344	using	O
1344	the	O
1344	protein	O
1344	-	O
1344	truncation	O
1344	test	O
1344	followed	O
1344	by	O
1344	genomic	O
1344	-	O
1344	sequence	O
1344	analysis	O
1344	.	O
1345	A	O
1345	high	O
1345	percentage	O
1345	of	O
1345	ATM	O
1345	germline	O
1345	mutations	O
1345	was	O
1345	demonstrated	O
1345	among	O
1345	patients	O
1345	with	O
1345	sporadic	B-Disease
1345	breast	I-Disease
1345	cancer	I-Disease
1345	.	O
1346	The	O
1346	82	O
1346	patients	O
1346	included	O
1346	in	O
1346	this	O
1346	study	O
1346	had	O
1346	developed	O
1346	breast	B-Disease
1346	cancer	I-Disease
1346	at	O
1346	age	O
1346	<	O
1346	45	O
1346	and	O
1346	had	O
1346	survived	O
1346	>	O
1346	/	O
1346	=	O
1346	5	O
1346	years	O
1346	(	O
1346	mean	O
1346	15	O
1346	years	O
1346	)	O
1346	,	O
1346	and	O
1346	in	O
1346	33	O
1346	(	O
1346	40	O
1346	%	O
1346	)	O
1346	of	O
1346	the	O
1346	patients	O
1346	a	O
1346	contralateral	O
1346	breast	O
1346	tumor	O
1346	had	O
1346	been	O
1346	diagnosed	O
1346	.	O
1347	Among	O
1347	these	O
1347	patients	O
1347	we	O
1347	identified	O
1347	seven	O
1347	(	O
1347	8	O
1347	.	O
1347	5	O
1347	%	O
1347	)	O
1347	ATM	O
1347	germline	O
1347	mutations	O
1347	,	O
1347	of	O
1347	which	O
1347	five	O
1347	are	O
1347	distinct	O
1347	.	O
1348	One	O
1348	splice	O
1348	-	O
1348	site	O
1348	mutation	O
1348	(	O
1348	IVS10	O
1348	-	O
1348	6T	O
1348	-	O
1348	-	O
1348	>	O
1348	G	O
1348	)	O
1348	was	O
1348	detected	O
1348	three	O
1348	times	O
1348	in	O
1348	our	O
1348	series	O
1348	.	O
1349	Four	O
1349	heterozygous	O
1349	carriers	O
1349	were	O
1349	patients	O
1349	with	O
1349	bilateral	O
1349	breast	O
1349	cancer	O
1349	.	O
1350	Our	O
1350	results	O
1350	indicate	O
1350	that	O
1350	the	O
1350	mutations	O
1350	identified	O
1350	in	O
1350	this	O
1350	study	O
1350	are	O
1350	"	NN	O	O
1350	A	NN	O	O
1350	-	NN	O	O
1350	T	NN	O	O
1350	disease	NN	O	O
1350	-	NN	O	O
1350	causing	NN	O	O
1350	"	O
1350	mutations	O
1350	that	O
1350	might	O
1350	be	O
1350	associated	O
1350	with	O
1350	an	O
1350	increased	O
1350	risk	O
1350	of	O
1350	breast	O
1350	cancer	O
1350	in	O
1350	heterozygotes	O
1350	.	O
1351	We	O
1351	conclude	O
1351	that	O
1351	ATM	O
1351	heterozygotes	O
1351	have	O
1351	an	O
1351	approximately	O
1351	ninefold	O
1351	-	O
1351	increased	O
1351	risk	O
1351	of	O
1351	developing	O
1351	a	O
1351	type	O
1351	of	O
1351	breast	O
1351	cancer	O
1351	characterized	O
1351	by	O
1351	frequent	O
1351	bilateral	O
1351	occurrence	O
1351	,	O
1351	early	O
1351	age	O
1351	at	O
1351	onset	O
1351	,	O
1351	and	O
1351	long	O
1351	-	O
1351	term	O
1351	survival	O
1351	.	O
1352	The	O
1352	specific	O
1352	characteristics	O
1352	of	O
1352	our	O
1352	population	O
1352	of	O
1352	patients	O
1352	may	O
1352	explain	O
1352	why	O
1352	such	O
1352	a	O
1352	high	O
1352	frequency	O
1352	was	O
1352	not	O
1352	found	O
1352	in	O
1352	other	O
1352	series	O
1352	.	O
1353	Human	O
1353	mutations	O
1353	in	O
1353	glucose	O
1353	6	O
1353	-	O
1353	phosphate	O
1353	dehydrogenase	O
1353	reflect	O
1353	evolutionary	O
1353	history	O
1353	.	O
1354	Glucose	O
1354	6	O
1354	-	O
1354	phosphate	O
1354	dehydrogenase	O
1354	(	O
1354	G6PD	O
1354	)	O
1354	is	O
1354	a	O
1354	cytosolic	O
1354	enzyme	O
1354	encoded	O
1354	by	O
1354	a	O
1354	housekeeping	O
1354	X	O
1354	-	O
1354	linked	O
1354	gene	O
1354	whose	O
1354	main	O
1354	function	O
1354	is	O
1354	to	O
1354	produce	O
1354	NADPH	O
1354	,	O
1354	a	O
1354	key	O
1354	electron	O
1354	donor	O
1354	in	O
1354	the	O
1354	defense	O
1354	against	O
1354	oxidizing	O
1354	agents	O
1354	and	O
1354	in	O
1354	reductive	O
1354	biosynthetic	O
1354	reactions	O
1354	.	O
1355	Inherited	O
1355	G6PD	B-Disease
1355	deficiency	I-Disease
1355	is	O
1355	associated	O
1355	with	O
1355	either	O
1355	episodic	B-Disease
1355	hemolytic	I-Disease
1355	anemia	I-Disease
1355	(	O
1355	triggered	O
1355	by	O
1355	fava	O
1355	beans	O
1355	or	O
1355	other	O
1355	agents	O
1355	)	O
1355	or	O
1355	life	B-Disease
1355	-	I-Disease
1355	long	I-Disease
1355	hemolytic	I-Disease
1355	anemia	I-Disease
1355	.	O
1356	We	O
1356	show	O
1356	here	O
1356	that	O
1356	an	O
1356	evolutionary	O
1356	analysis	O
1356	is	O
1356	a	O
1356	key	O
1356	to	O
1356	understanding	O
1356	the	O
1356	biology	O
1356	of	O
1356	a	O
1356	housekeeping	O
1356	gene	O
1356	.	O
1357	From	O
1357	the	O
1357	alignment	O
1357	of	O
1357	the	O
1357	amino	O
1357	acid	O
1357	(	O
1357	aa	O
1357	)	O
1357	sequence	O
1357	of	O
1357	52	O
1357	glucose	O
1357	6	O
1357	-	O
1357	phosphate	O
1357	dehydrogenase	O
1357	(	O
1357	G6PD	O
1357	)	O
1357	species	O
1357	from	O
1357	42	O
1357	different	O
1357	organisms	O
1357	,	O
1357	we	O
1357	found	O
1357	a	O
1357	striking	O
1357	correlation	O
1357	between	O
1357	the	O
1357	aa	O
1357	replacements	O
1357	that	O
1357	cause	O
1357	G6PD	B-Disease
1357	deficiency	I-Disease
1357	in	O
1357	humans	O
1357	and	O
1357	the	O
1357	sequence	O
1357	conservation	O
1357	of	O
1357	G6PD	O
1357	two	O
1357	-	O
1357	thirds	O
1357	of	O
1357	such	O
1357	replacements	O
1357	are	O
1357	in	O
1357	highly	O
1357	and	O
1357	moderately	O
1357	conserved	O
1357	(	O
1357	50	O
1357	-	O
1357	99	O
1357	%	O
1357	)	O
1357	aa	O
1357	;	O
1357	relatively	O
1357	few	O
1357	are	O
1357	in	O
1357	fully	O
1357	conserved	O
1357	aa	O
1357	(	O
1357	where	O
1357	they	O
1357	might	O
1357	be	O
1357	lethal	O
1357	)	O
1357	or	O
1357	in	O
1357	poorly	O
1357	conserved	O
1357	aa	O
1357	,	O
1357	where	O
1357	presumably	O
1357	they	O
1357	simply	O
1357	would	O
1357	not	O
1357	cause	O
1357	G6PD	B-Disease
1357	deficiency	I-Disease
1357	.	O
1358	This	O
1358	is	O
1358	consistent	O
1358	with	O
1358	the	O
1358	notion	O
1358	that	O
1358	all	O
1358	human	O
1358	mutants	O
1358	have	O
1358	residual	O
1358	enzyme	O
1358	activity	O
1358	and	O
1358	that	O
1358	mutations	O
1358	are	O
1358	lethal	O
1358	at	O
1358	some	O
1358	stage	O
1358	of	O
1358	development	O
1358	.	O
1359	Comparing	O
1359	the	O
1359	distribution	O
1359	of	O
1359	mutations	O
1359	in	O
1359	a	O
1359	human	O
1359	housekeeping	O
1359	gene	O
1359	with	O
1359	evolutionary	O
1359	conservation	O
1359	is	O
1359	a	O
1359	useful	O
1359	tool	O
1359	for	O
1359	pinpointing	O
1359	amino	O
1359	acid	O
1359	residues	O
1359	important	O
1359	for	O
1359	the	O
1359	stability	O
1359	or	O
1359	the	O
1359	function	O
1359	of	O
1359	the	O
1359	corresponding	O
1359	protein	O
1359	.	O
1360	In	O
1360	view	O
1360	of	O
1360	the	O
1360	current	O
1360	explosive	O
1360	increase	O
1360	in	O
1360	full	O
1360	genome	O
1360	sequencing	O
1360	projects	O
1360	,	O
1360	this	O
1360	tool	O
1360	will	O
1360	become	O
1360	rapidly	O
1360	available	O
1360	for	O
1360	numerous	O
1360	other	O
1360	genes	O
1360	.	O
1360	.	O
1361	Constitutive	O
1361	and	O
1361	regulated	O
1361	modes	O
1361	of	O
1361	splicing	O
1361	produce	O
1361	six	O
1361	major	O
1361	myotonic	B-Disease
1361	dystrophy	I-Disease
1361	protein	O
1361	kinase	O
1361	(	O
1361	DMPK	O
1361	)	O
1361	isoforms	O
1361	with	O
1361	distinct	O
1361	properties	O
1361	.	O
1362	Myotonic	B-Disease
1362	dystrophy	I-Disease
1362	(	O
1362	DM	B-Disease
1362	)	O
1362	is	O
1362	the	O
1362	most	O
1362	prevalent	O
1362	inherited	B-Disease
1362	neuromuscular	I-Disease
1362	disease	I-Disease
1362	in	O
1362	adults	O
1362	.	O
1363	The	O
1363	genetic	B-Disease
1363	defect	I-Disease
1363	is	O
1363	a	O
1363	CTG	O
1363	triplet	O
1363	repeat	O
1363	expansion	O
1363	in	O
1363	the	O
1363	3	O
1363	-	O
1363	untranslated	O
1363	region	O
1363	of	O
1363	the	O
1363	myotonic	B-Disease
1363	dystrophy	I-Disease
1363	protein	O
1363	kinase	O
1363	(	O
1363	DMPK	O
1363	)	O
1363	gene	O
1363	,	O
1363	consisting	O
1363	of	O
1363	15	O
1363	exons	O
1363	.	O
1364	Using	O
1364	a	O
1364	transgenic	O
1364	DMPK	O
1364	-	O
1364	overexpressor	O
1364	mouse	O
1364	model	O
1364	,	O
1364	we	O
1364	demonstrate	O
1364	here	O
1364	that	O
1364	the	O
1364	endogenous	O
1364	mouse	O
1364	DMPK	O
1364	gene	O
1364	and	O
1364	the	O
1364	human	O
1364	DMPK	O
1364	transgene	O
1364	produce	O
1364	six	O
1364	major	O
1364	alternatively	O
1364	spliced	O
1364	mRNAs	O
1364	which	O
1364	have	O
1364	almost	O
1364	identical	O
1364	cell	O
1364	type	O
1364	-	O
1364	dependent	O
1364	distribution	O
1364	frequencies	O
1364	and	O
1364	expression	O
1364	patterns	O
1364	.	O
1365	Use	O
1365	of	O
1365	a	O
1365	cryptic	O
1365	5	O
1365	splice	O
1365	site	O
1365	in	O
1365	exon	O
1365	8	O
1365	,	O
1365	which	O
1365	results	O
1365	in	O
1365	absence	O
1365	or	O
1365	presence	O
1365	of	O
1365	15	O
1365	nucleotides	O
1365	specifying	O
1365	a	O
1365	VSGGG	O
1365	peptide	O
1365	motif	O
1365	,	O
1365	and	O
1365	/	O
1365	or	O
1365	use	O
1365	of	O
1365	a	O
1365	cryptic	O
1365	3	O
1365	splice	O
1365	site	O
1365	in	O
1365	exon	O
1365	14	O
1365	,	O
1365	which	O
1365	leads	O
1365	to	O
1365	a	O
1365	frameshift	O
1365	in	O
1365	the	O
1365	mRNA	O
1365	reading	O
1365	frame	O
1365	,	O
1365	occur	O
1365	as	O
1365	independent	O
1365	stochastic	O
1365	events	O
1365	in	O
1365	all	O
1365	tissues	O
1365	examined	O
1365	.	O
1366	In	O
1366	contrast	O
1366	,	O
1366	the	O
1366	excision	O
1366	of	O
1366	exons	O
1366	13	O
1366	/	O
1366	14	O
1366	that	O
1366	causes	O
1366	a	O
1366	frameshift	O
1366	and	O
1366	creates	O
1366	a	O
1366	C	O
1366	-	O
1366	terminally	O
1366	truncated	O
1366	protein	O
1366	is	O
1366	clearly	O
1366	cell	O
1366	type	O
1366	dependent	O
1366	and	O
1366	occurs	O
1366	predominantly	O
1366	in	O
1366	smooth	O
1366	muscle	O
1366	.	O
1367	We	O
1367	generated	O
1367	all	O
1367	six	O
1367	full	O
1367	-	O
1367	length	O
1367	mouse	O
1367	cDNAs	O
1367	that	O
1367	result	O
1367	from	O
1367	combinations	O
1367	of	O
1367	these	O
1367	three	O
1367	major	O
1367	splicing	O
1367	events	O
1367	and	O
1367	show	O
1367	that	O
1367	their	O
1367	transfection	O
1367	into	O
1367	cells	O
1367	in	O
1367	culture	O
1367	leads	O
1367	to	O
1367	production	O
1367	of	O
1367	four	O
1367	different	O
1367	approximately	O
1367	74	O
1367	kDa	O
1367	full	O
1367	-	O
1367	length	O
1367	(	O
1367	heart	O
1367	-	O
1367	,	O
1367	skeletal	O
1367	muscle	O
1367	-	O
1367	or	O
1367	brain	O
1367	-	O
1367	specific	O
1367	)	O
1367	and	O
1367	two	O
1367	C	O
1367	-	O
1367	terminally	O
1367	truncated	O
1367	approximately	O
1367	68	O
1367	kDa	O
1367	(	O
1367	smooth	O
1367	muscle	O
1367	-	O
1367	specific	O
1367	)	O
1367	isoforms	O
1367	.	O
1368	Information	O
1368	on	O
1368	DMPK	O
1368	mRNA	O
1368	and	O
1368	protein	O
1368	isoform	O
1368	expression	O
1368	patterns	O
1368	will	O
1368	be	O
1368	useful	O
1368	for	O
1368	recognizing	O
1368	differential	O
1368	effects	O
1368	of	O
1368	(	O
1368	CTG	O
1368	)	O
1368	(	O
1368	n	O
1368	)	O
1368	expansion	O
1368	in	O
1368	DM	B-Disease
1368	manifestation	O
1368	.	O
1368	.	O
1369	Genetic	O
1369	analysis	O
1369	,	O
1369	phenotypic	O
1369	diagnosis	O
1369	,	O
1369	and	O
1369	risk	O
1369	of	O
1369	venous	B-Disease
1369	thrombosis	I-Disease
1369	in	O
1369	families	O
1369	with	O
1369	inherited	O
1369	deficiencies	B-Disease
1369	of	I-Disease
1369	protein	I-Disease
1369	S	I-Disease
1369	.	O
1370	Protein	B-Disease
1370	S	I-Disease
1370	deficiency	I-Disease
1370	is	O
1370	a	O
1370	recognized	O
1370	risk	O
1370	factor	O
1370	for	O
1370	venous	B-Disease
1370	thrombosis	I-Disease
1370	.	O
1371	Of	O
1371	all	O
1371	the	O
1371	inherited	O
1371	thrombophilic	B-Disease
1371	conditions	I-Disease
1371	,	O
1371	it	O
1371	remains	O
1371	the	O
1371	most	O
1371	difficult	O
1371	to	O
1371	diagnose	O
1371	because	O
1371	of	O
1371	phenotypic	O
1371	variability	O
1371	,	O
1371	which	O
1371	can	O
1371	lead	O
1371	to	O
1371	inconclusive	O
1371	results	O
1371	.	O
1372	We	O
1372	have	O
1372	overcome	O
1372	this	O
1372	problem	O
1372	by	O
1372	studying	O
1372	a	O
1372	cohort	O
1372	of	O
1372	patients	O
1372	from	O
1372	a	O
1372	single	O
1372	center	O
1372	where	O
1372	the	O
1372	diagnosis	O
1372	was	O
1372	confirmed	O
1372	at	O
1372	the	O
1372	genetic	O
1372	level	O
1372	.	O
1373	Twenty	O
1373	-	O
1373	eight	O
1373	index	O
1373	patients	O
1373	with	O
1373	protein	B-Disease
1373	S	I-Disease
1373	deficiency	I-Disease
1373	and	O
1373	a	O
1373	PROS1	B-Disease
1373	gene	I-Disease
1373	defect	I-Disease
1373	were	O
1373	studied	O
1373	,	O
1373	together	O
1373	with	O
1373	109	O
1373	first	O
1373	-	O
1373	degree	O
1373	relatives	O
1373	.	O
1374	To	O
1374	avoid	O
1374	selection	O
1374	bias	O
1374	,	O
1374	we	O
1374	confined	O
1374	analysis	O
1374	of	O
1374	total	O
1374	and	O
1374	free	O
1374	protein	O
1374	S	O
1374	levels	O
1374	and	O
1374	thrombotic	O
1374	risk	O
1374	to	O
1374	the	O
1374	patients	O
1374	relatives	O
1374	.	O
1375	In	O
1375	this	O
1375	group	O
1375	of	O
1375	relatives	O
1375	,	O
1375	a	O
1375	low	O
1375	free	O
1375	protein	O
1375	S	O
1375	level	O
1375	was	O
1375	the	O
1375	most	O
1375	reliable	O
1375	predictor	O
1375	of	O
1375	a	O
1375	PROS1	B-Disease
1375	gene	I-Disease
1375	defect	I-Disease
1375	(	O
1375	sensitivity	O
1375	97	O
1375	.	O
1375	7	O
1375	%	O
1375	,	O
1375	specificity	O
1375	100	O
1375	%	O
1375	)	O
1375	.	O
1376	First	O
1376	-	O
1376	degree	O
1376	relatives	O
1376	with	O
1376	a	O
1376	PROS1	B-Disease
1376	gene	I-Disease
1376	defect	I-Disease
1376	had	O
1376	a	O
1376	5	O
1376	.	O
1377	0	O
1377	-	O
1377	fold	O
1377	higher	O
1377	risk	O
1377	of	O
1377	thrombosis	B-Disease
1377	(	O
1377	95	O
1377	%	O
1377	confidence	O
1377	interval	O
1377	,	O
1377	1	O
1377	.	O
1377	5	O
1377	-	O
1377	16	O
1377	.	O
1377	8	O
1377	)	O
1377	than	O
1377	those	O
1377	with	O
1377	a	O
1377	normal	O
1377	PROS1	O
1377	gene	O
1377	and	O
1377	no	O
1377	other	O
1377	recognized	O
1377	thrombophilic	B-Disease
1377	defect	I-Disease
1377	.	O
1378	Although	O
1378	pregnancy	O
1378	/	O
1378	puerperium	O
1378	and	O
1378	immobility	O
1378	/	O
1378	trauma	B-Disease
1378	were	O
1378	important	O
1378	precipitating	O
1378	factors	O
1378	for	O
1378	thrombosis	B-Disease
1378	,	O
1378	almost	O
1378	half	O
1378	of	O
1378	the	O
1378	events	O
1378	were	O
1378	spontaneous	O
1378	.	O
1379	Relatives	O
1379	with	O
1379	splice	O
1379	-	O
1379	site	O
1379	or	O
1379	major	O
1379	structural	O
1379	defects	B-Disease
1379	in	I-Disease
1379	the	I-Disease
1379	PROS1	I-Disease
1379	gene	I-Disease
1379	were	O
1379	more	O
1379	likely	O
1379	to	O
1379	have	O
1379	had	O
1379	a	O
1379	thrombotic	O
1379	event	O
1379	and	O
1379	had	O
1379	significantly	O
1379	lower	O
1379	total	O
1379	and	O
1379	free	O
1379	protein	O
1379	S	O
1379	levels	O
1379	than	O
1379	those	O
1379	relatives	O
1379	having	O
1379	missense	O
1379	mutations	O
1379	.	O
1380	We	O
1380	conclude	O
1380	that	O
1380	persons	O
1380	with	O
1380	PROS1	B-Disease
1380	gene	I-Disease
1380	defects	I-Disease
1380	and	O
1380	protein	B-Disease
1380	S	I-Disease
1380	deficiency	I-Disease
1380	are	O
1380	at	O
1380	increased	O
1380	risk	O
1380	of	O
1380	thrombosis	B-Disease
1380	and	O
1380	that	O
1380	free	O
1380	protein	O
1380	S	O
1380	estimation	O
1380	offers	O
1380	the	O
1380	most	O
1380	reliable	O
1380	way	O
1380	of	O
1380	diagnosing	O
1380	the	O
1380	deficiency	O
1380	.	O
1381	(	O
1381	Blood	O
1381	.	O
1381	2000	O
1381	;	O
1381	95	O
1381	1935	O
1381	-	O
1381	1941	O
1381	)	O
1381	.	O
1382	Autoimmune	B-Disease
1382	lymphoproliferative	I-Disease
1382	syndrome	I-Disease
1382	(	O
1382	ALPS	B-Disease
1382	)	O
1382	in	O
1382	a	O
1382	child	O
1382	from	O
1382	consanguineous	O
1382	parents	O
1382	:	O
1382	a	O
1382	dominant	O
1382	or	O
1382	recessive	O
1382	disease	O
1382	?	O
1383	Autoimmune	B-Disease
1383	lymphoproliferative	I-Disease
1383	syndrome	I-Disease
1383	(	O
1383	ALPS	B-Disease
1383	)	O
1383	is	O
1383	characterized	O
1383	by	O
1383	autoimmune	O
1383	features	O
1383	and	O
1383	lymphoproliferations	O
1383	and	O
1383	is	O
1383	generally	O
1383	caused	O
1383	by	O
1383	defective	O
1383	Fas	O
1383	-	O
1383	mediated	O
1383	apoptosis	O
1383	.	O
1384	This	O
1384	report	O
1384	describes	O
1384	a	O
1384	child	O
1384	with	O
1384	clinical	O
1384	features	O
1384	of	O
1384	ALPS	B-Disease
1384	without	O
1384	detectable	O
1384	Fas	O
1384	expression	O
1384	on	O
1384	freshly	O
1384	isolated	O
1384	blood	O
1384	leukocytes	O
1384	.	O
1385	Detection	O
1385	of	O
1385	FAS	O
1385	transcripts	O
1385	via	O
1385	real	O
1385	-	O
1385	time	O
1385	quantitative	O
1385	PCR	O
1385	made	O
1385	a	O
1385	severe	O
1385	transcriptional	O
1385	defect	O
1385	unlikely	O
1385	.	O
1386	Sequencing	O
1386	of	O
1386	the	O
1386	FAS	O
1386	gene	O
1386	revealed	O
1386	a	O
1386	20	O
1386	-	O
1386	nucleotide	O
1386	duplication	O
1386	in	O
1386	the	O
1386	last	O
1386	exon	O
1386	affecting	O
1386	the	O
1386	cytoplasmic	O
1386	signaling	O
1386	domain	O
1386	.	O
1387	The	O
1387	patient	O
1387	was	O
1387	homozygous	O
1387	for	O
1387	this	O
1387	mutation	O
1387	,	O
1387	whereas	O
1387	the	O
1387	consanguineous	O
1387	parents	O
1387	and	O
1387	the	O
1387	siblings	O
1387	were	O
1387	heterozygous	O
1387	.	O
1388	The	O
1388	patient	O
1388	reported	O
1388	here	O
1388	is	O
1388	a	O
1388	human	O
1388	homologue	O
1388	of	O
1388	the	O
1388	Fas	O
1388	-	O
1388	mouse	O
1388	,	O
1388	inasmuch	O
1388	as	O
1388	she	O
1388	carries	O
1388	an	O
1388	autosomal	O
1388	homozygous	O
1388	mutation	O
1388	in	O
1388	the	O
1388	FAS	O
1388	gene	O
1388	and	O
1388	she	O
1388	shows	O
1388	the	O
1388	severe	O
1388	and	O
1388	accelerated	O
1388	ALPS	B-Disease
1388	phenotype	O
1388	.	O
1389	The	O
1389	heterozygous	O
1389	family	O
1389	members	O
1389	did	O
1389	not	O
1389	have	O
1389	the	O
1389	ALPS	B-Disease
1389	phenotype	O
1389	,	O
1389	indicating	O
1389	that	O
1389	the	O
1389	disease	O
1389	-	O
1389	causing	O
1389	FAS	O
1389	mutation	O
1389	in	O
1389	this	O
1389	family	O
1389	is	O
1389	autosomal	O
1389	recessive	O
1389	.	O
1389	.	O
1390	Identification	O
1390	of	O
1390	novel	O
1390	imprinted	O
1390	transcripts	O
1390	in	O
1390	the	O
1390	Prader	B-Disease
1390	-	I-Disease
1390	Willi	I-Disease
1390	syndrome	I-Disease
1390	and	O
1390	Angelman	B-Disease
1390	syndrome	I-Disease
1390	deletion	O
1390	region	O
1390	:	O
1390	further	O
1390	evidence	O
1390	for	O
1390	regional	O
1390	imprinting	O
1390	control	O
1390	.	O
1391	Deletions	O
1391	and	O
1391	other	O
1391	abnormalities	O
1391	of	O
1391	human	O
1391	chromosome	O
1391	15q11	O
1391	-	O
1391	q13	O
1391	are	O
1391	associated	O
1391	with	O
1391	two	O
1391	developmental	O
1391	disorders	O
1391	,	O
1391	Prader	B-Disease
1391	-	I-Disease
1391	Willi	I-Disease
1391	syndrome	I-Disease
1391	(	O
1391	PWS	B-Disease
1391	)	O
1391	and	O
1391	Angelman	B-Disease
1391	syndrome	I-Disease
1391	(	O
1391	AS	B-Disease
1391	)	O
1391	.	O
1392	Loss	O
1392	of	O
1392	expression	O
1392	of	O
1392	imprinted	O
1392	,	O
1392	paternally	O
1392	expressed	O
1392	genes	O
1392	has	O
1392	been	O
1392	implicated	O
1392	in	O
1392	PWS	B-Disease
1392	.	O
1393	However	O
1393	,	O
1393	the	O
1393	number	O
1393	of	O
1393	imprinted	O
1393	genes	O
1393	that	O
1393	contribute	O
1393	to	O
1393	PWS	B-Disease
1393	,	O
1393	and	O
1393	the	O
1393	range	O
1393	over	O
1393	which	O
1393	the	O
1393	imprinting	O
1393	signal	O
1393	acts	O
1393	to	O
1393	silence	O
1393	one	O
1393	copy	O
1393	of	O
1393	the	O
1393	gene	O
1393	in	O
1393	a	O
1393	parent	O
1393	-	O
1393	of	O
1393	-	O
1393	origin	O
1393	-	O
1393	specific	O
1393	manner	O
1393	,	O
1393	are	O
1393	unknown	O
1393	.	O
1394	To	O
1394	identify	O
1394	additional	O
1394	imprinted	O
1394	genes	O
1394	that	O
1394	could	O
1394	contribute	O
1394	to	O
1394	the	O
1394	PWS	B-Disease
1394	phenotype	O
1394	and	O
1394	to	O
1394	understand	O
1394	the	O
1394	regional	O
1394	control	O
1394	of	O
1394	imprinting	O
1394	in	O
1394	15q11	O
1394	-	O
1394	q13	O
1394	,	O
1394	we	O
1394	have	O
1394	constructed	O
1394	an	O
1394	imprinted	O
1394	transcript	O
1394	map	O
1394	of	O
1394	the	O
1394	PWS	O
1394	-	O
1394	AS	O
1394	deletion	O
1394	interval	O
1394	.	O
1395	The	O
1395	imprinting	O
1395	status	O
1395	of	O
1395	22	O
1395	expressed	O
1395	sequence	O
1395	tags	O
1395	derived	O
1395	from	O
1395	the	O
1395	radiation	O
1395	-	O
1395	hybrid	O
1395	human	O
1395	transcript	O
1395	maps	O
1395	or	O
1395	physical	O
1395	maps	O
1395	was	O
1395	determined	O
1395	in	O
1395	a	O
1395	reverse	O
1395	transcriptase	O
1395	-	O
1395	PCR	O
1395	assay	O
1395	and	O
1395	correlated	O
1395	with	O
1395	the	O
1395	position	O
1395	of	O
1395	the	O
1395	transcripts	O
1395	on	O
1395	the	O
1395	physical	O
1395	map	O
1395	.	O
1396	Seven	O
1396	new	O
1396	paternally	O
1396	expressed	O
1396	transcripts	O
1396	localize	O
1396	to	O
1396	an	O
1396	approximately	O
1396	1	O
1396	.	O
1397	5	O
1397	-	O
1397	Mb	O
1397	domain	O
1397	surrounding	O
1397	the	O
1397	SNRPN	O
1397	-	O
1397	associated	O
1397	imprinting	O
1397	center	O
1397	,	O
1397	which	O
1397	already	O
1397	includes	O
1397	four	O
1397	imprinted	O
1397	,	O
1397	paternally	O
1397	expressed	O
1397	genes	O
1397	.	O
1398	All	O
1398	other	O
1398	tested	O
1398	new	O
1398	transcripts	O
1398	in	O
1398	the	O
1398	deletion	O
1398	region	O
1398	were	O
1398	expressed	O
1398	from	O
1398	both	O
1398	alleles	O
1398	.	O
1399	A	O
1399	domain	O
1399	of	O
1399	exclusive	O
1399	paternal	O
1399	expression	O
1399	surrounding	O
1399	the	O
1399	imprinting	O
1399	center	O
1399	suggests	O
1399	strong	O
1399	regional	O
1399	control	O
1399	of	O
1399	the	O
1399	imprinting	O
1399	process	O
1399	.	O
1400	This	O
1400	study	O
1400	provides	O
1400	the	O
1400	means	O
1400	for	O
1400	further	O
1400	investigation	O
1400	of	O
1400	additional	O
1400	genes	O
1400	that	O
1400	cause	O
1400	or	O
1400	modify	O
1400	the	O
1400	phenotypes	O
1400	associated	O
1400	with	O
1400	rearrangements	O
1400	of	O
1400	15q11	O
1400	-	O
1400	q13	O
1400	.	O
1401	Combined	O
1401	analysis	O
1401	of	O
1401	hereditary	B-Disease
1401	prostate	I-Disease
1401	cancer	I-Disease
1401	linkage	O
1401	to	O
1401	1q24	O
1401	-	O
1401	25	O
1401	:	O
1401	results	O
1401	from	O
1401	772	O
1401	hereditary	B-Disease
1401	prostate	I-Disease
1401	cancer	I-Disease
1401	families	O
1401	from	O
1401	the	O
1401	International	O
1401	Consortium	O
1401	for	O
1401	Prostate	B-Disease
1401	Cancer	I-Disease
1401	Genetics	O
1401	.	O
1402	A	O
1402	previous	O
1402	linkage	O
1402	study	O
1402	provided	O
1402	evidence	O
1402	for	O
1402	a	O
1402	prostate	B-Disease
1402	cancer	I-Disease
1402	-	O
1402	susceptibility	O
1402	locus	O
1402	at	O
1402	1q24	O
1402	-	O
1402	25	O
1402	.	O
1403	Subsequent	O
1403	reports	O
1403	in	O
1403	additional	O
1403	collections	O
1403	of	O
1403	families	O
1403	have	O
1403	yielded	O
1403	conflicting	O
1403	results	O
1403	.	O
1404	In	O
1404	addition	O
1404	,	O
1404	evidence	O
1404	for	O
1404	locus	O
1404	heterogeneity	O
1404	has	O
1404	been	O
1404	provided	O
1404	by	O
1404	the	O
1404	identification	O
1404	of	O
1404	other	O
1404	putative	O
1404	hereditary	B-Disease
1404	prostate	I-Disease
1404	cancer	I-Disease
1404	loci	O
1404	on	O
1404	Xq27	O
1404	-	O
1404	28	O
1404	,	O
1404	1q42	O
1404	-	O
1404	43	O
1404	,	O
1404	and	O
1404	1p36	O
1404	.	O
1405	The	O
1405	present	O
1405	study	O
1405	describes	O
1405	a	O
1405	combined	O
1405	analysis	O
1405	for	O
1405	six	O
1405	markers	O
1405	in	O
1405	the	O
1405	1q24	O
1405	-	O
1405	25	O
1405	region	O
1405	in	O
1405	772	O
1405	families	O
1405	affected	O
1405	by	O
1405	hereditary	B-Disease
1405	prostate	I-Disease
1405	cancer	I-Disease
1405	and	O
1405	ascertained	O
1405	by	O
1405	the	O
1405	members	O
1405	of	O
1405	the	O
1405	International	O
1405	Consortium	O
1405	for	O
1405	Prostate	B-Disease
1405	Cancer	I-Disease
1405	Genetics	O
1405	(	O
1405	ICPCG	O
1405	)	O
1405	from	O
1405	North	O
1405	America	O
1405	,	O
1405	Australia	O
1405	,	O
1405	Finland	O
1405	,	O
1405	Norway	O
1405	,	O
1405	Sweden	O
1405	,	O
1405	and	O
1405	the	O
1405	United	O
1405	Kingdom	O
1405	.	O
1406	Overall	O
1406	,	O
1406	there	O
1406	was	O
1406	some	O
1406	evidence	O
1406	for	O
1406	linkage	O
1406	,	O
1406	with	O
1406	a	O
1406	peak	O
1406	parametric	O
1406	multipoint	O
1406	LOD	O
1406	score	O
1406	assuming	O
1406	heterogeneity	O
1406	(	O
1406	HLOD	O
1406	)	O
1406	of	O
1406	1	O
1406	.	O
1407	40	O
1407	(	O
1407	P	O
1407	=	O
1407	.	O
1407	01	O
1407	)	O
1407	at	O
1407	D1S212	O
1407	.	O
1408	The	O
1408	estimated	O
1408	proportion	O
1408	of	O
1408	families	O
1408	(	O
1408	alpha	O
1408	)	O
1408	linked	O
1408	to	O
1408	the	O
1408	locus	O
1408	was	O
1408	.	O
1409	06	O
1409	(	O
1409	1	O
1409	-	O
1409	LOD	O
1409	support	O
1409	interval	O
1409	.	O
1409	01	O
1409	-	O
1409	.	O
1409	12	O
1409	)	O
1409	.	O
1410	This	O
1410	evidence	O
1410	was	O
1410	not	O
1410	observed	O
1410	by	O
1410	a	O
1410	nonparametric	O
1410	approach	O
1410	,	O
1410	presumably	O
1410	because	O
1410	of	O
1410	the	O
1410	extensive	O
1410	heterogeneity	O
1410	.	O
1411	Further	O
1411	parametric	O
1411	analysis	O
1411	revealed	O
1411	a	O
1411	significant	O
1411	effect	O
1411	of	O
1411	the	O
1411	presence	O
1411	of	O
1411	male	O
1411	-	O
1411	to	O
1411	-	O
1411	male	O
1411	disease	O
1411	transmission	O
1411	within	O
1411	the	O
1411	families	O
1411	.	O
1412	In	O
1412	the	O
1412	subset	O
1412	of	O
1412	491	O
1412	such	O
1412	families	O
1412	,	O
1412	the	O
1412	peak	O
1412	HLOD	O
1412	was	O
1412	2	O
1412	.	O
1413	In	O
1413	the	O
1413	subset	O
1413	of	O
1413	491	O
1413	such	O
1413	families	O
1413	,	O
1413	the	O
1413	peak	O
1413	HLOD	O
1413	was	O
1413	2	O
1413	.	O
1414	56	O
1414	(	O
1414	P	O
1414	=	O
1414	.	O
1414	0006	O
1414	)	O
1414	and	O
1414	alpha	O
1414	=	O
1414	.	O
1415	11	O
1415	(	O
1415	1	O
1415	-	O
1415	LOD	O
1415	support	O
1415	interval	O
1415	.	O
1415	04	O
1415	-	O
1415	.	O
1415	19	O
1415	)	O
1415	,	O
1415	compared	O
1415	with	O
1415	HLODs	O
1415	of	O
1415	0	O
1415	in	O
1415	the	O
1415	remaining	O
1415	281	O
1415	families	O
1415	.	O
1416	Within	O
1416	the	O
1416	families	O
1416	with	O
1416	male	O
1416	-	O
1416	to	O
1416	-	O
1416	male	O
1416	disease	O
1416	transmission	O
1416	,	O
1416	alpha	O
1416	increased	O
1416	with	O
1416	the	O
1416	early	O
1416	mean	O
1416	age	O
1416	at	O
1416	diagnosis	O
1416	(	O
1416	<	O
1416	65	O
1416	years	O
1416	,	O
1416	alpha	O
1416	=	O
1416	.	O
1416	19	O
1416	,	O
1416	with	O
1416	1	O
1416	-	O
1416	LOD	O
1416	support	O
1416	interval	O
1416	.	O
1416	06	O
1416	-	O
1416	.	O
1416	34	O
1416	)	O
1416	and	O
1416	the	O
1416	number	O
1416	of	O
1416	affected	O
1416	family	O
1416	members	O
1416	(	O
1416	five	O
1416	or	O
1416	more	O
1416	family	O
1416	members	O
1416	,	O
1416	alpha	O
1416	=	O
1416	.	O
1416	15	O
1416	,	O
1416	with	O
1416	1	O
1416	-	O
1416	LOD	O
1416	support	O
1416	interval	O
1416	.	O
1416	04	O
1416	-	O
1416	.	O
1416	28	O
1416	)	O
1416	.	O
1417	The	O
1417	highest	O
1417	value	O
1417	of	O
1417	alpha	O
1417	was	O
1417	observed	O
1417	for	O
1417	the	O
1417	48	O
1417	families	O
1417	that	O
1417	met	O
1417	all	O
1417	three	O
1417	criteria	O
1417	(	O
1417	peak	O
1417	HLOD	O
1417	=	O
1417	2	O
1417	.	O
1417	25	O
1417	,	O
1417	P	O
1417	=	O
1417	.	O
1417	001	O
1417	,	O
1417	alpha	O
1417	=	O
1417	.	O
1417	29	O
1417	,	O
1417	with	O
1417	1	O
1417	-	O
1417	LOD	O
1417	support	O
1417	interval	O
1417	.	O
1417	08	O
1417	-	O
1417	.	O
1417	53	O
1417	)	O
1417	.	O
1418	These	O
1418	results	O
1418	support	O
1418	the	O
1418	finding	O
1418	of	O
1418	a	O
1418	prostate	B-Disease
1418	cancer	I-Disease
1418	-	O
1418	susceptibility	O
1418	gene	O
1418	linked	O
1418	to	O
1418	1q24	O
1418	-	O
1418	25	O
1418	,	O
1418	albeit	O
1418	in	O
1418	a	O
1418	defined	O
1418	subset	O
1418	of	O
1418	prostate	B-Disease
1418	cancer	I-Disease
1418	families	O
1418	.	O
1419	Although	O
1419	HPC1	O
1419	accounts	O
1419	for	O
1419	only	O
1419	a	O
1419	small	O
1419	proportion	O
1419	of	O
1419	all	O
1419	families	O
1419	affected	O
1419	by	O
1419	hereditary	B-Disease
1419	prostate	I-Disease
1419	cancer	I-Disease
1419	,	O
1419	it	O
1419	appears	O
1419	to	O
1419	play	O
1419	a	O
1419	more	O
1419	prominent	O
1419	role	O
1419	in	O
1419	the	O
1419	subset	O
1419	of	O
1419	families	O
1419	with	O
1419	several	O
1419	members	O
1419	affected	O
1419	at	O
1419	an	O
1419	early	O
1419	age	O
1419	and	O
1419	with	O
1419	male	O
1419	-	O
1419	to	O
1419	-	O
1419	male	O
1419	disease	O
1419	transmission	O
1419	.	O
1420	A	O
1420	recurrent	O
1420	expansion	O
1420	of	O
1420	a	O
1420	maternal	O
1420	allele	O
1420	with	O
1420	36	O
1420	CAG	O
1420	repeats	O
1420	causes	O
1420	Huntington	B-Disease
1420	disease	I-Disease
1420	in	O
1420	two	O
1420	sisters	O
1420	.	O
1421	Large	O
1421	intergenerational	O
1421	repeat	O
1421	expansions	O
1421	of	O
1421	the	O
1421	CAG	O
1421	trinucleotide	O
1421	repeat	O
1421	in	O
1421	the	O
1421	HD	B-Disease
1421	gene	O
1421	have	O
1421	been	O
1421	well	O
1421	documented	O
1421	for	O
1421	the	O
1421	male	O
1421	germline	O
1421	.	O
1422	We	O
1422	describe	O
1422	a	O
1422	recurrent	O
1422	large	O
1422	expansion	O
1422	of	O
1422	a	O
1422	maternal	O
1422	allele	O
1422	with	O
1422	36	O
1422	CAG	O
1422	repeats	O
1422	(	O
1422	to	O
1422	66	O
1422	and	O
1422	57	O
1422	repeats	O
1422	,	O
1422	respectively	O
1422	,	O
1422	in	O
1422	two	O
1422	daughters	O
1422	)	O
1422	associated	O
1422	with	O
1422	onset	O
1422	of	O
1422	Huntington	B-Disease
1422	disease	I-Disease
1422	(	O
1422	HD	B-Disease
1422	)	O
1422	in	O
1422	the	O
1422	second	O
1422	and	O
1422	third	O
1422	decade	O
1422	in	O
1422	a	O
1422	family	O
1422	without	O
1422	history	O
1422	of	O
1422	HD	B-Disease
1422	.	O
1423	Our	O
1423	findings	O
1423	give	O
1423	evidence	O
1423	of	O
1423	a	O
1423	gonadal	O
1423	mosaicism	O
1423	in	O
1423	the	O
1423	unaffected	O
1423	mother	O
1423	.	O
1424	We	O
1424	hypothesize	O
1424	that	O
1424	large	O
1424	expansions	O
1424	also	O
1424	occur	O
1424	in	O
1424	the	O
1424	female	O
1424	germline	O
1424	and	O
1424	that	O
1424	a	O
1424	negative	O
1424	selection	O
1424	of	O
1424	oocytes	O
1424	with	O
1424	long	O
1424	repeats	O
1424	might	O
1424	explain	O
1424	the	O
1424	different	O
1424	instability	O
1424	behavior	O
1424	of	O
1424	the	O
1424	male	O
1424	and	O
1424	the	O
1424	female	O
1424	germlines	O
1424	.	O
1424	.	O
1425	Abnormal	O
1425	development	O
1425	of	O
1425	Purkinje	O
1425	cells	O
1425	and	O
1425	lymphocytes	O
1425	in	O
1425	Atm	O
1425	mutant	O
1425	mice	O
1425	.	O
1426	Motor	B-Disease
1426	incoordination	I-Disease
1426	,	O
1426	immune	B-Disease
1426	deficiencies	I-Disease
1426	,	O
1426	and	O
1426	an	O
1426	increased	O
1426	risk	O
1426	of	O
1426	cancer	B-Disease
1426	are	O
1426	the	O
1426	characteristic	O
1426	features	O
1426	of	O
1426	the	O
1426	hereditary	B-Disease
1426	disease	I-Disease
1426	ataxia	B-Disease
1426	-	I-Disease
1426	telangiectasia	I-Disease
1426	(	O
1426	A	B-Disease
1426	-	I-Disease
1426	T	I-Disease
1426	)	O
1426	,	O
1426	which	O
1426	is	O
1426	caused	O
1426	by	O
1426	mutations	O
1426	in	O
1426	the	O
1426	ATM	O
1426	gene	O
1426	.	O
1427	Through	O
1427	gene	O
1427	targeting	O
1427	,	O
1427	we	O
1427	have	O
1427	generated	O
1427	a	O
1427	line	O
1427	of	O
1427	Atm	O
1427	mutant	O
1427	mice	O
1427	,	O
1427	Atm	O
1427	(	O
1427	y	O
1427	/	O
1427	y	O
1427	)	O
1427	mice	O
1427	.	O
1428	In	O
1428	contrast	O
1428	to	O
1428	other	O
1428	Atm	O
1428	mutant	O
1428	mice	O
1428	,	O
1428	Atm	O
1428	(	O
1428	y	O
1428	/	O
1428	y	O
1428	)	O
1428	mice	O
1428	show	O
1428	a	O
1428	lower	O
1428	incidence	O
1428	of	O
1428	thymic	B-Disease
1428	lymphoma	I-Disease
1428	and	O
1428	survive	O
1428	beyond	O
1428	a	O
1428	few	O
1428	months	O
1428	of	O
1428	age	O
1428	.	O
1429	Atm	O
1429	(	O
1429	y	O
1429	/	O
1429	y	O
1429	)	O
1429	mice	O
1429	exhibit	O
1429	deficits	O
1429	in	O
1429	motor	O
1429	learning	O
1429	indicative	O
1429	of	O
1429	cerebellar	B-Disease
1429	dysfunction	I-Disease
1429	.	O
1430	Even	O
1430	though	O
1430	we	O
1430	found	O
1430	no	O
1430	gross	O
1430	cerebellar	B-Disease
1430	degeneration	I-Disease
1430	in	O
1430	older	O
1430	Atm	O
1430	(	O
1430	y	O
1430	/	O
1430	y	O
1430	)	O
1430	animals	O
1430	,	O
1430	ectopic	O
1430	and	O
1430	abnormally	O
1430	differentiated	O
1430	Purkinje	O
1430	cells	O
1430	were	O
1430	apparent	O
1430	in	O
1430	mutant	O
1430	mice	O
1430	of	O
1430	all	O
1430	ages	O
1430	.	O
1431	These	O
1431	findings	O
1431	establish	O
1431	that	O
1431	some	O
1431	neuropathological	B-Disease
1431	abnormalities	I-Disease
1431	seen	O
1431	in	O
1431	A	B-Disease
1431	-	I-Disease
1431	T	I-Disease
1431	patients	O
1431	also	O
1431	are	O
1431	present	O
1431	in	O
1431	Atm	O
1431	mutant	O
1431	mice	O
1431	.	O
1432	In	O
1432	addition	O
1432	,	O
1432	we	O
1432	report	O
1432	a	O
1432	previously	O
1432	unrecognized	O
1432	effect	O
1432	of	O
1432	Atm	B-Disease
1432	deficiency	I-Disease
1432	on	O
1432	development	O
1432	or	O
1432	maintenance	O
1432	of	O
1432	CD4	O
1432	(	O
1432	+	O
1432	)	O
1432	8	O
1432	(	O
1432	+	O
1432	)	O
1432	thymocytes	O
1432	.	O
1433	We	O
1433	discuss	O
1433	these	O
1433	findings	O
1433	in	O
1433	the	O
1433	context	O
1433	of	O
1433	the	O
1433	hypothesis	O
1433	that	O
1433	abnormal	O
1433	development	O
1433	of	O
1433	Purkinje	O
1433	cells	O
1433	and	O
1433	lymphocytes	O
1433	contributes	O
1433	to	O
1433	the	O
1433	pathogenesis	O
1433	of	O
1433	A	B-Disease
1433	-	I-Disease
1433	T	I-Disease
1433	.	O
1433	.	O
1434	Novel	O
1434	mutations	O
1434	of	O
1434	the	O
1434	ATP7B	O
1434	gene	O
1434	in	O
1434	Japanese	O
1434	patients	O
1434	with	O
1434	Wilson	B-Disease
1434	disease	I-Disease
1434	.	O
1435	Wilson	B-Disease
1435	disease	I-Disease
1435	(	O
1435	WD	B-Disease
1435	)	O
1435	is	O
1435	an	O
1435	autosomal	B-Disease
1435	recessive	I-Disease
1435	disorder	I-Disease
1435	characterized	O
1435	by	O
1435	copper	O
1435	accumulation	O
1435	in	O
1435	the	O
1435	liver	O
1435	,	O
1435	brain	O
1435	,	O
1435	kidneys	O
1435	,	O
1435	and	O
1435	corneas	O
1435	,	O
1435	and	O
1435	culminating	O
1435	in	O
1435	copper	O
1435	toxication	O
1435	in	O
1435	these	O
1435	organs	O
1435	.	O
1436	In	O
1436	this	O
1436	study	O
1436	,	O
1436	we	O
1436	analyzed	O
1436	mutations	O
1436	of	O
1436	the	O
1436	responsible	O
1436	gene	O
1436	,	O
1436	ATP7B	O
1436	,	O
1436	in	O
1436	four	O
1436	Japanese	O
1436	patients	O
1436	with	O
1436	WD	B-Disease
1436	.	O
1437	By	O
1437	direct	O
1437	sequencing	O
1437	,	O
1437	we	O
1437	identified	O
1437	five	O
1437	mutations	O
1437	,	O
1437	of	O
1437	which	O
1437	two	O
1437	were	O
1437	novel	O
1437	,	O
1437	and	O
1437	16	O
1437	polymorphisms	O
1437	,	O
1437	of	O
1437	which	O
1437	6	O
1437	were	O
1437	novel	O
1437	.	O
1438	The	O
1438	mutations	O
1438	2871delC	O
1438	and	O
1438	2513delA	O
1438	shift	O
1438	the	O
1438	reading	O
1438	frame	O
1438	so	O
1438	that	O
1438	truncated	O
1438	abnormal	O
1438	protein	O
1438	is	O
1438	expected	O
1438	.	O
1439	In	O
1439	contrast	O
1439	to	O
1439	these	O
1439	mutations	O
1439	found	O
1439	in	O
1439	patients	O
1439	with	O
1439	hepatic	O
1439	-	O
1439	type	O
1439	of	O
1439	early	O
1439	onset	O
1439	,	O
1439	the	O
1439	mutations	O
1439	A874V	O
1439	,	O
1439	R778L	O
1439	,	O
1439	and	O
1439	3892delGTC	O
1439	were	O
1439	either	O
1439	missense	O
1439	mutations	O
1439	or	O
1439	in	O
1439	frame	O
1439	1	O
1439	-	O
1439	amino	O
1439	acid	O
1439	deletion	O
1439	,	O
1439	and	O
1439	occurred	O
1439	in	O
1439	the	O
1439	patients	O
1439	with	O
1439	hepato	O
1439	-	O
1439	neurologic	O
1439	type	O
1439	of	O
1439	late	O
1439	onset	O
1439	.	O
1440	The	O
1440	mutations	O
1440	2871delC	O
1440	and	O
1440	R778L	O
1440	have	O
1440	been	O
1440	previously	O
1440	reported	O
1440	in	O
1440	a	O
1440	relatively	O
1440	large	O
1440	number	O
1440	of	O
1440	Japanese	O
1440	patients	O
1440	.	O
1441	In	O
1441	particular	O
1441	,	O
1441	R778L	O
1441	is	O
1441	known	O
1441	to	O
1441	be	O
1441	more	O
1441	prevalent	O
1441	in	O
1441	Asian	O
1441	countries	O
1441	than	O
1441	in	O
1441	other	O
1441	countries	O
1441	of	O
1441	the	O
1441	world	O
1441	.	O
1442	Our	O
1442	data	O
1442	are	O
1442	compatible	O
1442	with	O
1442	the	O
1442	hypothesis	O
1442	that	O
1442	the	O
1442	mutations	O
1442	tend	O
1442	to	O
1442	occur	O
1442	in	O
1442	a	O
1442	population	O
1442	-	O
1442	specific	O
1442	manner	O
1442	.	O
1443	Therefore	O
1443	,	O
1443	the	O
1443	accumulation	O
1443	of	O
1443	the	O
1443	types	O
1443	of	O
1443	mutations	O
1443	in	O
1443	Japanese	O
1443	patients	O
1443	with	O
1443	WD	B-Disease
1443	will	O
1443	facilitate	O
1443	the	O
1443	fast	O
1443	and	O
1443	effective	O
1443	genetic	O
1443	diagnosis	O
1443	of	O
1443	WD	B-Disease
1443	in	O
1443	Japanese	O
1443	patients	O
1443	.	O
1443	.	O
1444	Autoinhibition	O
1444	and	O
1444	activation	O
1444	mechanisms	O
1444	of	O
1444	the	O
1444	Wiskott	B-Disease
1444	-	I-Disease
1444	Aldrich	I-Disease
1444	syndrome	I-Disease
1444	protein	O
1444	.	O
1445	The	O
1445	Rho	O
1445	-	O
1445	family	O
1445	GTPase	O
1445	,	O
1445	Cdc42	O
1445	,	O
1445	can	O
1445	regulate	O
1445	the	O
1445	actin	O
1445	cytoskeleton	O
1445	through	O
1445	activation	O
1445	of	O
1445	Wiskott	B-Disease
1445	-	I-Disease
1445	Aldrich	I-Disease
1445	syndrome	I-Disease
1445	protein	O
1445	(	O
1445	WASP	O
1445	)	O
1445	family	O
1445	members	O
1445	.	O
1446	Activation	O
1446	relieves	O
1446	an	O
1446	autoinhibitory	O
1446	contact	O
1446	between	O
1446	the	O
1446	GTPase	O
1446	-	O
1446	binding	O
1446	domain	O
1446	and	O
1446	the	O
1446	carboxy	O
1446	-	O
1446	terminal	O
1446	region	O
1446	of	O
1446	WASP	O
1446	proteins	O
1446	.	O
1447	Here	O
1447	we	O
1447	report	O
1447	the	O
1447	autoinhibited	O
1447	structure	O
1447	of	O
1447	the	O
1447	GTPase	O
1447	-	O
1447	binding	O
1447	domain	O
1447	of	O
1447	WASP	O
1447	,	O
1447	which	O
1447	can	O
1447	be	O
1447	induced	O
1447	by	O
1447	the	O
1447	C	O
1447	-	O
1447	terminal	O
1447	region	O
1447	or	O
1447	by	O
1447	organic	O
1447	co	O
1447	-	O
1447	solvents	O
1447	.	O
1448	In	O
1448	the	O
1448	autoinhibited	O
1448	complex	O
1448	,	O
1448	intramolecular	O
1448	interactions	O
1448	with	O
1448	the	O
1448	GTPase	O
1448	-	O
1448	binding	O
1448	domain	O
1448	occlude	O
1448	residues	O
1448	of	O
1448	the	O
1448	C	O
1448	terminus	O
1448	that	O
1448	regulate	O
1448	the	O
1448	Arp2	O
1448	/	O
1448	3	O
1448	actin	O
1448	-	O
1448	nucleating	O
1448	complex	O
1448	.	O
1449	Binding	O
1449	of	O
1449	Cdc42	O
1449	to	O
1449	the	O
1449	GTPase	O
1449	-	O
1449	binding	O
1449	domain	O
1449	causes	O
1449	a	O
1449	dramatic	O
1449	conformational	O
1449	change	O
1449	,	O
1449	resulting	O
1449	in	O
1449	disruption	O
1449	of	O
1449	the	O
1449	hydrophobic	O
1449	core	O
1449	and	O
1449	release	O
1449	of	O
1449	the	O
1449	C	O
1449	terminus	O
1449	,	O
1449	enabling	O
1449	its	O
1449	interaction	O
1449	with	O
1449	the	O
1449	actin	O
1449	regulatory	O
1449	machinery	O
1449	.	O
1450	These	O
1450	data	O
1450	show	O
1450	that	O
1450	intrinsically	O
1450	unstructured	O
1450	peptides	O
1450	such	O
1450	as	O
1450	the	O
1450	GTPase	O
1450	-	O
1450	binding	O
1450	domain	O
1450	of	O
1450	WASP	O
1450	can	O
1450	be	O
1450	induced	O
1450	into	O
1450	distinct	O
1450	structural	O
1450	and	O
1450	functional	O
1450	states	O
1450	depending	O
1450	on	O
1450	context	O
1450	.	O
1450	.	O
1451	hCds1	O
1451	-	O
1451	mediated	O
1451	phosphorylation	O
1451	of	O
1451	BRCA1	O
1451	regulates	O
1451	the	O
1451	DNA	O
1451	damage	O
1451	response	O
1451	.	O
1452	Mutations	O
1452	in	O
1452	the	O
1452	BRCA1	O
1452	(	O
1452	ref	O
1452	.	O
1452	1	O
1452	)	O
1452	tumour	B-Disease
1452	suppressor	O
1452	gene	O
1452	are	O
1452	found	O
1452	in	O
1452	almost	O
1452	all	O
1452	of	O
1452	the	O
1452	families	O
1452	with	O
1452	inherited	B-Disease
1452	breast	I-Disease
1452	and	I-Disease
1452	ovarian	I-Disease
1452	cancers	I-Disease
1452	and	O
1452	about	O
1452	half	O
1452	of	O
1452	the	O
1452	families	O
1452	with	O
1452	only	O
1452	breast	B-Disease
1452	cancer	I-Disease
1452	.	O
1453	Although	O
1453	the	O
1453	biochemical	O
1453	function	O
1453	of	O
1453	BRCA1	O
1453	is	O
1453	not	O
1453	well	O
1453	understood	O
1453	,	O
1453	it	O
1453	is	O
1453	important	O
1453	for	O
1453	DNA	O
1453	damage	O
1453	repair	O
1453	and	O
1453	cell	O
1453	-	O
1453	cycle	O
1453	checkpoint	O
1453	.	O
1454	BRCA1	O
1454	exists	O
1454	in	O
1454	nuclear	O
1454	foci	O
1454	but	O
1454	is	O
1454	hyperphosphorylated	O
1454	and	O
1454	disperses	O
1454	after	O
1454	DNA	O
1454	damage	O
1454	.	O
1455	It	O
1455	is	O
1455	not	O
1455	known	O
1455	whether	O
1455	BRCA1	O
1455	phosphorylation	O
1455	and	O
1455	dispersion	O
1455	and	O
1455	its	O
1455	function	O
1455	in	O
1455	DNA	O
1455	damage	O
1455	response	O
1455	are	O
1455	related	O
1455	.	O
1456	In	O
1456	yeast	O
1456	the	O
1456	DNA	O
1456	damage	O
1456	response	O
1456	and	O
1456	the	O
1456	replication	O
1456	-	O
1456	block	O
1456	checkpoint	O
1456	are	O
1456	mediated	O
1456	partly	O
1456	through	O
1456	the	O
1456	Cds1	O
1456	kinase	O
1456	family	O
1456	.	O
1457	Here	O
1457	we	O
1457	report	O
1457	that	O
1457	the	O
1457	human	O
1457	Cds1	O
1457	kinase	O
1457	(	O
1457	hCds1	O
1457	/	O
1457	Chk2	O
1457	)	O
1457	regulates	O
1457	BRCA1	O
1457	function	O
1457	after	O
1457	DNA	O
1457	damage	O
1457	by	O
1457	phosphorylating	O
1457	serine	O
1457	988	O
1457	of	O
1457	BRCA1	O
1457	.	O
1458	We	O
1458	show	O
1458	that	O
1458	hCds1	O
1458	and	O
1458	BRCA1	O
1458	interact	O
1458	and	O
1458	co	O
1458	-	O
1458	localize	O
1458	within	O
1458	discrete	O
1458	nuclear	O
1458	foci	O
1458	but	O
1458	separate	O
1458	after	O
1458	gamma	O
1458	irradiation	O
1458	.	O
1459	Phosphorylation	O
1459	of	O
1459	BRCA1	O
1459	at	O
1459	serine	O
1459	988	O
1459	is	O
1459	required	O
1459	for	O
1459	the	O
1459	release	O
1459	of	O
1459	BRCA1	O
1459	from	O
1459	hCds1	O
1459	.	O
1460	This	O
1460	phosphorylation	O
1460	is	O
1460	also	O
1460	important	O
1460	for	O
1460	the	O
1460	ability	O
1460	of	O
1460	BRCA1	O
1460	to	O
1460	restore	O
1460	survival	O
1460	after	O
1460	DNA	O
1460	damage	O
1460	in	O
1460	the	O
1460	BRCA1	O
1460	-	O
1460	mutated	O
1460	cell	O
1460	line	O
1460	HCC1937	O
1460	.	O
1460	.	O
1461	Characterization	O
1461	of	O
1461	the	O
1461	rat	O
1461	spinocerebellar	O
1461	ataxia	O
1461	type	O
1461	3	O
1461	gene	O
1461	.	O
1462	Machado	B-Disease
1462	-	I-Disease
1462	Joseph	I-Disease
1462	disease	I-Disease
1462	(	O
1462	MJD	B-Disease
1462	)	O
1462	belongs	O
1462	to	O
1462	a	O
1462	group	O
1462	of	O
1462	clinically	O
1462	and	O
1462	genetically	O
1462	heterogeneous	O
1462	neurodegenerative	B-Disease
1462	disorders	I-Disease
1462	characterized	O
1462	by	O
1462	progressive	B-Disease
1462	cerebellar	I-Disease
1462	ataxia	I-Disease
1462	.	O
1463	The	O
1463	disease	O
1463	-	O
1463	causing	O
1463	mutation	O
1463	has	O
1463	recently	O
1463	been	O
1463	identified	O
1463	as	O
1463	an	O
1463	unstable	O
1463	and	O
1463	expanded	O
1463	(	O
1463	CAG	O
1463	)	O
1463	n	O
1463	trinucleotide	O
1463	repeat	O
1463	in	O
1463	a	O
1463	novel	O
1463	gene	O
1463	of	O
1463	unknown	O
1463	function	O
1463	.	O
1464	In	O
1464	Caucasians	O
1464	,	O
1464	repeat	O
1464	expansions	O
1464	in	O
1464	the	O
1464	MJD1	O
1464	gene	O
1464	have	O
1464	also	O
1464	been	O
1464	found	O
1464	in	O
1464	patients	O
1464	with	O
1464	the	O
1464	clinically	O
1464	distinct	O
1464	autosomal	O
1464	dominant	O
1464	spinocerebellar	B-Disease
1464	ataxia	I-Disease
1464	type	I-Disease
1464	3	I-Disease
1464	(	O
1464	SCA3	B-Disease
1464	)	O
1464	.	O
1465	In	O
1465	order	O
1465	to	O
1465	gain	O
1465	insight	O
1465	into	O
1465	the	O
1465	biology	O
1465	of	O
1465	the	O
1465	MJD1	O
1465	/	O
1465	SCA3	O
1465	gene	O
1465	we	O
1465	cloned	O
1465	the	O
1465	rat	O
1465	homologue	O
1465	and	O
1465	studied	O
1465	its	O
1465	expression	O
1465	.	O
1466	The	O
1466	rat	O
1466	and	O
1466	human	O
1466	ataxin	O
1466	-	O
1466	3	O
1466	genes	O
1466	are	O
1466	highly	O
1466	homologous	O
1466	with	O
1466	an	O
1466	overall	O
1466	sequence	O
1466	identity	O
1466	of	O
1466	approximately	O
1466	88	O
1466	%	O
1466	.	O
1467	However	O
1467	,	O
1467	the	O
1467	C	O
1467	-	O
1467	terminal	O
1467	end	O
1467	of	O
1467	the	O
1467	putative	O
1467	protein	O
1467	differs	O
1467	strongly	O
1467	from	O
1467	the	O
1467	published	O
1467	human	O
1467	sequence	O
1467	.	O
1468	The	O
1468	(	O
1468	CAG	O
1468	)	O
1468	n	O
1468	block	O
1468	in	O
1468	the	O
1468	rat	O
1468	cDNA	O
1468	consists	O
1468	of	O
1468	just	O
1468	three	O
1468	interrupted	O
1468	units	O
1468	suggesting	O
1468	that	O
1468	a	O
1468	long	O
1468	polyglutamine	O
1468	stretch	O
1468	is	O
1468	not	O
1468	essential	O
1468	for	O
1468	the	O
1468	normal	O
1468	function	O
1468	of	O
1468	the	O
1468	ataxin	O
1468	-	O
1468	3	O
1468	protein	O
1468	in	O
1468	rodents	O
1468	.	O
1469	The	O
1469	expression	O
1469	pattern	O
1469	of	O
1469	the	O
1469	SCA3	O
1469	gene	O
1469	in	O
1469	various	O
1469	rat	O
1469	and	O
1469	human	O
1469	tissues	O
1469	was	O
1469	investigated	O
1469	by	O
1469	Northern	O
1469	blot	O
1469	analyses	O
1469	.	O
1470	The	O
1470	mature	O
1470	transcript	O
1470	is	O
1470	approximately	O
1470	6	O
1470	kb	O
1470	in	O
1470	length	O
1470	.	O
1471	In	O
1471	rat	O
1471	testis	O
1471	,	O
1471	a	O
1471	smaller	O
1471	transcript	O
1471	of	O
1471	1	O
1471	.	O
1472	3	O
1472	kb	O
1472	was	O
1472	identified	O
1472	.	O
1473	Transcription	O
1473	of	O
1473	rsca3	O
1473	was	O
1473	detected	O
1473	in	O
1473	most	O
1473	rat	O
1473	tissues	O
1473	including	O
1473	brain	O
1473	.	O
1474	Analyzing	O
1474	the	O
1474	expression	O
1474	level	O
1474	of	O
1474	the	O
1474	SCA3	O
1474	gene	O
1474	in	O
1474	several	O
1474	human	O
1474	brain	O
1474	sections	O
1474	revealed	O
1474	no	O
1474	significant	O
1474	higher	O
1474	mRNA	O
1474	level	O
1474	in	O
1474	regions	O
1474	predominantly	O
1474	affected	O
1474	in	O
1474	MJD	B-Disease
1474	.	O
1475	Thus	O
1475	additional	O
1475	molecules	O
1475	and	O
1475	/	O
1475	or	O
1475	regulatory	O
1475	events	O
1475	are	O
1475	necessary	O
1475	to	O
1475	explain	O
1475	the	O
1475	exclusive	O
1475	degeneration	B-Disease
1475	of	I-Disease
1475	certain	I-Disease
1475	brain	I-Disease
1475	areas	I-Disease
1475	.	O
1476	Emerin	B-Disease
1476	,	I-Disease
1476	deficiency	I-Disease
1476	of	O
1476	which	O
1476	causes	O
1476	Emery	B-Disease
1476	-	I-Disease
1476	Dreifuss	I-Disease
1476	muscular	I-Disease
1476	dystrophy	I-Disease
1476	,	O
1476	is	O
1476	localized	O
1476	at	O
1476	the	O
1476	inner	O
1476	nuclear	O
1476	membrane	O
1476	.	O
1477	X	B-Disease
1477	-	I-Disease
1477	linked	I-Disease
1477	recessive	I-Disease
1477	Emery	I-Disease
1477	-	I-Disease
1477	Dreifuss	I-Disease
1477	muscular	I-Disease
1477	dystrophy	I-Disease
1477	(	O
1477	EDMD	B-Disease
1477	)	O
1477	is	O
1477	an	O
1477	inherited	B-Disease
1477	muscle	I-Disease
1477	disorder	I-Disease
1477	characterized	O
1477	by	O
1477	the	O
1477	clinical	O
1477	triad	O
1477	of	O
1477	progressive	O
1477	wasting	B-Disease
1477	of	I-Disease
1477	humero	I-Disease
1477	-	I-Disease
1477	peroneal	I-Disease
1477	muscles	I-Disease
1477	,	O
1477	early	O
1477	contractures	B-Disease
1477	of	I-Disease
1477	the	I-Disease
1477	elbows	I-Disease
1477	,	I-Disease
1477	Achilles	I-Disease
1477	tendons	I-Disease
1477	and	I-Disease
1477	postcervical	I-Disease
1477	muscles	I-Disease
1477	,	O
1477	and	O
1477	cardiac	B-Disease
1477	conduction	I-Disease
1477	block	I-Disease
1477	with	O
1477	a	O
1477	high	O
1477	risk	O
1477	of	O
1477	sudden	B-Disease
1477	death	I-Disease
1477	.	O
1478	The	O
1478	gene	O
1478	for	O
1478	EDMD	B-Disease
1478	on	O
1478	Xq28	O
1478	encodes	O
1478	a	O
1478	novel	O
1478	protein	O
1478	named	O
1478	emerin	O
1478	that	O
1478	localizes	O
1478	at	O
1478	the	O
1478	nuclear	O
1478	membrane	O
1478	of	O
1478	skeletal	O
1478	,	O
1478	cardiac	O
1478	and	O
1478	smooth	O
1478	muscles	O
1478	and	O
1478	some	O
1478	other	O
1478	non	O
1478	-	O
1478	muscle	O
1478	tissues	O
1478	.	O
1479	To	O
1479	investigate	O
1479	a	O
1479	possible	O
1479	physiological	O
1479	role	O
1479	for	O
1479	emerin	O
1479	,	O
1479	we	O
1479	examined	O
1479	the	O
1479	ultrastructural	O
1479	localization	O
1479	of	O
1479	the	O
1479	protein	O
1479	in	O
1479	human	O
1479	skeletal	O
1479	muscle	O
1479	and	O
1479	HeLa	O
1479	cells	O
1479	,	O
1479	using	O
1479	ultrathin	O
1479	cryosections	O
1479	.	O
1480	We	O
1480	found	O
1480	that	O
1480	the	O
1480	immune	O
1480	-	O
1480	labeled	O
1480	colloidal	O
1480	gold	O
1480	particles	O
1480	were	O
1480	localized	O
1480	on	O
1480	the	O
1480	nucleoplasmic	O
1480	surface	O
1480	of	O
1480	the	O
1480	inner	O
1480	nuclear	O
1480	membrane	O
1480	,	O
1480	but	O
1480	not	O
1480	on	O
1480	the	O
1480	nuclear	O
1480	pore	O
1480	.	O
1481	Emerin	O
1481	stayed	O
1481	on	O
1481	the	O
1481	cytoplasmic	O
1481	surface	O
1481	of	O
1481	the	O
1481	nuclear	O
1481	lamina	O
1481	,	O
1481	even	O
1481	after	O
1481	detergent	O
1481	treatment	O
1481	that	O
1481	solubilizes	O
1481	membrane	O
1481	lipids	O
1481	and	O
1481	washes	O
1481	out	O
1481	membrane	O
1481	proteins	O
1481	.	O
1482	These	O
1482	results	O
1482	suggest	O
1482	that	O
1482	emerin	O
1482	anchors	O
1482	at	O
1482	the	O
1482	inner	O
1482	nuclear	O
1482	membrane	O
1482	through	O
1482	the	O
1482	hydrophobic	O
1482	stretch	O
1482	,	O
1482	and	O
1482	protrudes	O
1482	from	O
1482	the	O
1482	hydrophilic	O
1482	region	O
1482	to	O
1482	the	O
1482	nucleoplasm	O
1482	where	O
1482	it	O
1482	interacts	O
1482	with	O
1482	the	O
1482	nuclear	O
1482	lamina	O
1482	.	O
1483	We	O
1483	speculate	O
1483	that	O
1483	emerin	O
1483	contributes	O
1483	to	O
1483	maintain	O
1483	the	O
1483	nuclear	O
1483	structure	O
1483	and	O
1483	stability	O
1483	,	O
1483	as	O
1483	well	O
1483	as	O
1483	nuclear	O
1483	functions	O
1483	,	O
1483	particularly	O
1483	in	O
1483	muscle	O
1483	tissues	O
1483	that	O
1483	have	O
1483	severe	O
1483	stress	O
1483	with	O
1483	rigorous	O
1483	contraction	O
1483	-	O
1483	relaxation	O
1483	movements	O
1483	and	O
1483	calcium	O
1483	flux	O
1483	.	O
1483	.	O
1484	Locus	O
1484	heterogeneity	O
1484	in	O
1484	Friedreich	B-Disease
1484	ataxia	I-Disease
1484	.	O
1485	Friedreich	B-Disease
1485	ataxia	I-Disease
1485	(	O
1485	FRDA	B-Disease
1485	)	O
1485	is	O
1485	the	O
1485	most	O
1485	common	O
1485	form	O
1485	of	O
1485	autosomal	B-Disease
1485	recessive	I-Disease
1485	ataxia	I-Disease
1485	.	O
1486	The	O
1486	disease	O
1486	locus	O
1486	was	O
1486	assigned	O
1486	to	O
1486	chromosome	O
1486	9	O
1486	and	O
1486	the	O
1486	disease	O
1486	gene	O
1486	,	O
1486	STM7	O
1486	/	O
1486	X25	O
1486	,	O
1486	has	O
1486	been	O
1486	isolated	O
1486	.	O
1487	To	O
1487	date	O
1487	most	O
1487	data	O
1487	suggest	O
1487	locus	O
1487	homogeneity	O
1487	in	O
1487	FRDA	B-Disease
1487	.	O
1488	We	O
1488	now	O
1488	provide	O
1488	strong	O
1488	evidence	O
1488	of	O
1488	a	O
1488	second	O
1488	FRDA	B-Disease
1488	locus	O
1488	.	O
1489	Studying	O
1489	two	O
1489	siblings	O
1489	with	O
1489	FRDA	B-Disease
1489	from	O
1489	two	O
1489	families	O
1489	we	O
1489	did	O
1489	not	O
1489	detect	O
1489	a	O
1489	mutation	O
1489	in	O
1489	STM7	O
1489	/	O
1489	X25	O
1489	.	O
1490	Haplotype	O
1490	analysis	O
1490	of	O
1490	the	O
1490	STM7	O
1490	/	O
1490	X25	O
1490	region	O
1490	of	O
1490	chromosome	O
1490	9	O
1490	demonstrated	O
1490	that	O
1490	the	O
1490	relevant	O
1490	portion	O
1490	of	O
1490	chromosome	O
1490	9	O
1490	differs	O
1490	in	O
1490	the	O
1490	patients	O
1490	.	O
1491	Although	O
1491	the	O
1491	patients	O
1491	studied	O
1491	had	O
1491	typical	O
1491	FRDA	B-Disease
1491	,	O
1491	one	O
1491	sibpair	O
1491	had	O
1491	the	O
1491	uncommon	O
1491	symptom	O
1491	of	O
1491	retained	O
1491	tendon	O
1491	reflexes	O
1491	.	O
1492	In	O
1492	order	O
1492	to	O
1492	investigate	O
1492	whether	O
1492	retained	O
1492	tendon	O
1492	reflexes	O
1492	are	O
1492	characteristic	O
1492	of	O
1492	FRDA	B-Disease
1492	caused	O
1492	by	O
1492	the	O
1492	second	O
1492	locus	O
1492	,	O
1492	FRDA2	O
1492	,	O
1492	we	O
1492	studied	O
1492	an	O
1492	unrelated	O
1492	FRDA	B-Disease
1492	patient	O
1492	with	O
1492	retained	O
1492	tendon	O
1492	reflexes	O
1492	.	O
1493	The	O
1493	observation	O
1493	of	O
1493	typical	O
1493	mutations	O
1493	in	O
1493	STM7	O
1493	/	O
1493	X25	O
1493	(	O
1493	GAA	O
1493	expansions	O
1493	)	O
1493	in	O
1493	this	O
1493	patient	O
1493	demonstrates	O
1493	that	O
1493	the	O
1493	two	O
1493	genetically	O
1493	different	O
1493	forms	O
1493	of	O
1493	FRDA	B-Disease
1493	cannot	O
1493	be	O
1493	distinguished	O
1493	clinically	O
1493	.	O
1493	.	O
1494	Glycerol	O
1494	as	O
1494	a	O
1494	correlate	O
1494	of	O
1494	impaired	B-Disease
1494	glucose	I-Disease
1494	tolerance	I-Disease
1494	:	O
1494	dissection	O
1494	of	O
1494	a	O
1494	complex	O
1494	system	O
1494	by	O
1494	use	O
1494	of	O
1494	a	O
1494	simple	O
1494	genetic	O
1494	trait	O
1494	.	O
1495	Glycerol	O
1495	kinase	O
1495	(	O
1495	GK	O
1495	)	O
1495	represents	O
1495	the	O
1495	primary	O
1495	entry	O
1495	of	O
1495	glycerol	O
1495	into	O
1495	glucose	O
1495	and	O
1495	triglyceride	O
1495	metabolism	O
1495	.	O
1496	Impaired	B-Disease
1496	glucose	I-Disease
1496	tolerance	I-Disease
1496	(	O
1496	IGT	B-Disease
1496	)	O
1496	and	O
1496	hypertriglyceridemia	B-Disease
1496	are	O
1496	associated	O
1496	with	O
1496	an	O
1496	increased	O
1496	risk	O
1496	of	O
1496	diabetes	B-Disease
1496	mellitus	I-Disease
1496	and	O
1496	cardiovascular	B-Disease
1496	disease	I-Disease
1496	.	O
1497	The	O
1497	relationship	O
1497	between	O
1497	glycerol	O
1497	and	O
1497	the	O
1497	risk	O
1497	of	O
1497	IGT	B-Disease
1497	,	O
1497	however	O
1497	,	O
1497	is	O
1497	poorly	O
1497	understood	O
1497	.	O
1498	We	O
1498	therefore	O
1498	undertook	O
1498	the	O
1498	study	O
1498	of	O
1498	fasting	O
1498	plasma	O
1498	glycerol	O
1498	levels	O
1498	in	O
1498	a	O
1498	cohort	O
1498	of	O
1498	1	O
1498	,	O
1498	056	O
1498	unrelated	O
1498	men	O
1498	and	O
1498	women	O
1498	of	O
1498	French	O
1498	-	O
1498	Canadian	O
1498	descent	O
1498	.	O
1499	Family	O
1499	screening	O
1499	in	O
1499	the	O
1499	initial	O
1499	cohort	O
1499	identified	O
1499	18	O
1499	men	O
1499	from	O
1499	five	O
1499	families	O
1499	with	O
1499	severe	O
1499	hyperglycerolemia	B-Disease
1499	(	O
1499	values	O
1499	above	O
1499	2	O
1499	.	O
1499	0	O
1499	mmol	O
1499	/	O
1499	liter	O
1499	)	O
1499	and	O
1499	demonstrated	O
1499	an	O
1499	X	O
1499	-	O
1499	linked	O
1499	pattern	O
1499	of	O
1499	inheritance	O
1499	.	O
1500	Linkage	O
1500	analysis	O
1500	of	O
1500	the	O
1500	data	O
1500	from	O
1500	12	O
1500	microsatellite	O
1500	markers	O
1500	surrounding	O
1500	the	O
1500	Xp21	O
1500	.	O
1501	3	O
1501	GK	O
1501	gene	O
1501	resulted	O
1501	in	O
1501	a	O
1501	peak	O
1501	LOD	O
1501	score	O
1501	of	O
1501	3	O
1501	.	O
1502	46	O
1502	,	O
1502	centered	O
1502	around	O
1502	marker	O
1502	DXS8039	O
1502	.	O
1503	In	O
1503	addition	O
1503	,	O
1503	since	O
1503	all	O
1503	of	O
1503	the	O
1503	families	O
1503	originated	O
1503	in	O
1503	a	O
1503	population	O
1503	with	O
1503	a	O
1503	proven	O
1503	founder	O
1503	effect	O
1503	-	O
1503	the	O
1503	Saguenay	O
1503	Lac	O
1503	-	O
1503	St	O
1503	.	O
1504	-	O
1504	Jean	O
1504	region	O
1504	of	O
1504	Quebec	O
1504	-	O
1504	a	O
1504	common	O
1504	disease	O
1504	haplotype	O
1504	was	O
1504	sought	O
1504	.	O
1505	Indeed	O
1505	,	O
1505	a	O
1505	six	O
1505	-	O
1505	marker	O
1505	haplotype	O
1505	extending	O
1505	over	O
1505	a	O
1505	region	O
1505	of	O
1505	5	O
1505	.	O
1506	5	O
1506	cM	O
1506	was	O
1506	observed	O
1506	in	O
1506	all	O
1506	families	O
1506	.	O
1507	Resequencing	O
1507	of	O
1507	the	O
1507	GK	O
1507	gene	O
1507	in	O
1507	family	O
1507	members	O
1507	led	O
1507	to	O
1507	the	O
1507	discovery	O
1507	of	O
1507	a	O
1507	N288D	O
1507	missense	O
1507	mutation	O
1507	in	O
1507	exon	O
1507	10	O
1507	,	O
1507	which	O
1507	resulted	O
1507	in	O
1507	the	O
1507	substitution	O
1507	of	O
1507	a	O
1507	highly	O
1507	conserved	O
1507	asparagine	O
1507	residue	O
1507	by	O
1507	a	O
1507	negatively	O
1507	charged	O
1507	aspartic	O
1507	acid	O
1507	.	O
1508	Clinical	O
1508	and	O
1508	molecular	O
1508	genetics	O
1508	of	O
1508	primary	B-Disease
1508	dystonias	I-Disease
1508	.	O
1509	Primary	B-Disease
1509	dystonias	I-Disease
1509	are	O
1509	movement	B-Disease
1509	disorders	I-Disease
1509	with	O
1509	dystonia	B-Disease
1509	as	O
1509	a	O
1509	major	O
1509	symptom	O
1509	.	O
1510	They	O
1510	are	O
1510	frequently	O
1510	inherited	O
1510	as	O
1510	Mendelian	O
1510	traits	O
1510	.	O
1511	There	O
1511	are	O
1511	at	O
1511	least	O
1511	eight	O
1511	clinically	O
1511	distinct	O
1511	autosomal	O
1511	dominant	O
1511	and	O
1511	two	O
1511	X	O
1511	-	O
1511	linked	O
1511	recessive	O
1511	forms	O
1511	.	O
1512	In	O
1512	addition	O
1512	,	O
1512	pedigree	O
1512	analyses	O
1512	suggest	O
1512	the	O
1512	occurrence	O
1512	of	O
1512	an	O
1512	autosomal	O
1512	recessive	O
1512	variant	O
1512	.	O
1513	The	O
1513	clinical	O
1513	classification	O
1513	is	O
1513	increasingly	O
1513	being	O
1513	replaced	O
1513	by	O
1513	a	O
1513	genetic	O
1513	one	O
1513	.	O
1514	To	O
1514	date	O
1514	gene	O
1514	loci	O
1514	have	O
1514	been	O
1514	identified	O
1514	in	O
1514	at	O
1514	least	O
1514	six	O
1514	autosomal	O
1514	dominant	O
1514	forms	O
1514	,	O
1514	i	O
1514	.	O
1514	e	O
1514	.	O
1514	,	O
1514	in	O
1514	idiopathic	B-Disease
1514	torsion	I-Disease
1514	dystonia	I-Disease
1514	(	O
1514	9q34	O
1514	)	O
1514	,	O
1514	focal	B-Disease
1514	dystonia	I-Disease
1514	(	O
1514	18p	O
1514	)	O
1514	,	O
1514	adult	O
1514	-	O
1514	onset	O
1514	idiopathic	B-Disease
1514	torsion	I-Disease
1514	dystonia	I-Disease
1514	of	O
1514	mixed	O
1514	type	O
1514	(	O
1514	8p21	O
1514	-	O
1514	q22	O
1514	)	O
1514	,	O
1514	dopa	B-Disease
1514	-	I-Disease
1514	responsive	I-Disease
1514	dystonia	I-Disease
1514	(	O
1514	14q22	O
1514	.	O
1514	1	O
1514	-	O
1514	q22	O
1514	.	O
1514	2	O
1514	)	O
1514	,	O
1514	and	O
1514	paroxysmal	B-Disease
1514	dystonic	I-Disease
1514	choreoathetosis	I-Disease
1514	(	O
1514	2q25	O
1514	-	O
1514	q33	O
1514	;	O
1514	1p21	O
1514	-	O
1514	p13	O
1514	.	O
1514	3	O
1514	)	O
1514	.	O
1515	Gene	O
1515	loci	O
1515	in	O
1515	the	O
1515	X	O
1515	-	O
1515	linked	O
1515	recessive	O
1515	forms	O
1515	have	O
1515	been	O
1515	assigned	O
1515	to	O
1515	Xq13	O
1515	.	O
1516	1	O
1516	in	O
1516	the	O
1516	X	B-Disease
1516	-	I-Disease
1516	linked	I-Disease
1516	dystonia	I-Disease
1516	parkinsonism	I-Disease
1516	syndrome	I-Disease
1516	and	O
1516	to	O
1516	Xq22	O
1516	in	O
1516	X	B-Disease
1516	-	I-Disease
1516	linked	I-Disease
1516	sensorineural	I-Disease
1516	deafness	I-Disease
1516	,	O
1516	dystonia	B-Disease
1516	,	O
1516	and	O
1516	mental	B-Disease
1516	retardation	I-Disease
1516	.	O
1517	The	O
1517	disease	O
1517	genes	O
1517	have	O
1517	been	O
1517	identified	O
1517	in	O
1517	two	O
1517	autosomal	O
1517	dominant	O
1517	forms	O
1517	and	O
1517	in	O
1517	one	O
1517	X	O
1517	-	O
1517	linked	O
1517	recessive	O
1517	form	O
1517	.	O
1518	Mutations	O
1518	in	O
1518	a	O
1518	gene	O
1518	coding	O
1518	for	O
1518	an	O
1518	ATP	O
1518	-	O
1518	binding	O
1518	protein	O
1518	were	O
1518	detected	O
1518	in	O
1518	idiopathic	B-Disease
1518	torsion	I-Disease
1518	dystonia	I-Disease
1518	(	O
1518	DYT1	O
1518	)	O
1518	,	O
1518	and	O
1518	the	O
1518	GTP	O
1518	cyclohydrolase	O
1518	1	O
1518	gene	O
1518	is	O
1518	mutated	O
1518	in	O
1518	dopa	B-Disease
1518	-	I-Disease
1518	responsive	I-Disease
1518	dystonia	I-Disease
1518	(	O
1518	DYT5	O
1518	)	O
1518	.	O
1519	In	O
1519	sensorineural	B-Disease
1519	deafness	I-Disease
1519	,	O
1519	dystonia	B-Disease
1519	,	O
1519	and	O
1519	mental	B-Disease
1519	retardation	I-Disease
1519	,	O
1519	mutations	O
1519	were	O
1519	found	O
1519	in	O
1519	the	O
1519	gene	O
1519	DDP	O
1519	coding	O
1519	for	O
1519	a	O
1519	polypeptide	O
1519	of	O
1519	unknown	O
1519	function	O
1519	.	O
1520	This	O
1520	article	O
1520	reviews	O
1520	the	O
1520	clinical	O
1520	and	O
1520	molecular	O
1520	genetics	O
1520	of	O
1520	primary	B-Disease
1520	dystonias	I-Disease
1520	,	O
1520	critically	O
1520	discusses	O
1520	present	O
1520	findings	O
1520	,	O
1520	and	O
1520	proposes	O
1520	referring	O
1520	to	O
1520	the	O
1520	known	O
1520	forms	O
1520	,	O
1520	most	O
1520	of	O
1520	which	O
1520	can	O
1520	be	O
1520	distinguished	O
1520	by	O
1520	genetic	O
1520	criteria	O
1520	,	O
1520	as	O
1520	dystonias	B-Disease
1520	1	I-Disease
1520	-	I-Disease
1520	12	I-Disease
1520	.	O
1521	Determination	O
1521	of	O
1521	30	O
1521	X	B-Disease
1521	-	I-Disease
1521	linked	I-Disease
1521	adrenoleukodystrophy	I-Disease
1521	mutations	O
1521	,	O
1521	including	O
1521	15	O
1521	not	O
1521	previously	O
1521	described	O
1521	.	O
1522	X	B-Disease
1522	-	I-Disease
1522	linked	I-Disease
1522	Adrenoleukodystrophy	I-Disease
1522	(	O
1522	X	B-Disease
1522	-	I-Disease
1522	ALD	I-Disease
1522	)	O
1522	is	O
1522	the	O
1522	most	O
1522	frequent	O
1522	peroxisomal	B-Disease
1522	disease	I-Disease
1522	.	O
1523	It	O
1523	mainly	O
1523	involves	O
1523	the	O
1523	nervous	O
1523	system	O
1523	white	O
1523	matter	O
1523	,	O
1523	adrenal	O
1523	cortex	O
1523	and	O
1523	testes	O
1523	.	O
1524	Several	O
1524	distinct	O
1524	clinical	O
1524	phenotypes	O
1524	are	O
1524	known	O
1524	.	O
1525	The	O
1525	principal	O
1525	biochemical	O
1525	abnormality	O
1525	is	O
1525	the	O
1525	accumulation	O
1525	of	O
1525	saturated	O
1525	very	O
1525	-	O
1525	long	O
1525	-	O
1525	chain	O
1525	fatty	O
1525	acids	O
1525	(	O
1525	VLCFAs	O
1525	>	O
1525	C22	O
1525	0	O
1525	,	O
1525	mainly	O
1525	C26	O
1525	0	O
1525	)	O
1525	,	O
1525	which	O
1525	is	O
1525	due	O
1525	to	O
1525	impaired	O
1525	capacity	O
1525	for	O
1525	beta	O
1525	-	O
1525	oxidation	O
1525	in	O
1525	peroxisomes	O
1525	.	O
1526	Diagnosis	O
1526	is	O
1526	usually	O
1526	based	O
1526	on	O
1526	the	O
1526	VLCFA	O
1526	levels	O
1526	in	O
1526	plasma	O
1526	or	O
1526	cultured	O
1526	skin	O
1526	fibroblasts	O
1526	in	O
1526	both	O
1526	patients	O
1526	and	O
1526	carriers	O
1526	.	O
1527	In	O
1527	0	O
1527	.	O
1528	1	O
1528	%	O
1528	of	O
1528	affected	O
1528	males	O
1528	,	O
1528	however	O
1528	,	O
1528	the	O
1528	plasma	O
1528	C26	O
1528	0	O
1528	level	O
1528	is	O
1528	borderline	O
1528	normal	O
1528	,	O
1528	and	O
1528	15	O
1528	%	O
1528	of	O
1528	obligate	O
1528	female	O
1528	carriers	O
1528	have	O
1528	normal	O
1528	results	O
1528	.	O
1529	Effective	O
1529	mutation	O
1529	detection	O
1529	in	O
1529	these	O
1529	families	O
1529	is	O
1529	therefore	O
1529	fundamental	O
1529	to	O
1529	unambiguously	O
1529	determine	O
1529	the	O
1529	genetic	O
1529	status	O
1529	of	O
1529	each	O
1529	individual	O
1529	at	O
1529	risk	O
1529	.	O
1530	Of	O
1530	particular	O
1530	concern	O
1530	are	O
1530	female	O
1530	members	O
1530	of	O
1530	kindreds	O
1530	segregating	O
1530	X	B-Disease
1530	-	I-Disease
1530	ALD	I-Disease
1530	mutations	O
1530	,	O
1530	because	O
1530	normal	O
1530	VLCFA	O
1530	levels	O
1530	do	O
1530	not	O
1530	guarantee	O
1530	lack	O
1530	of	O
1530	carrier	O
1530	status	O
1530	.	O
1531	We	O
1531	describe	O
1531	a	O
1531	fast	O
1531	method	O
1531	for	O
1531	detection	O
1531	of	O
1531	X	B-Disease
1531	-	I-Disease
1531	ALD	I-Disease
1531	mutations	O
1531	.	O
1532	The	O
1532	method	O
1532	is	O
1532	based	O
1532	on	O
1532	SSCP	O
1532	analysis	O
1532	of	O
1532	nested	O
1532	PCR	O
1532	fragments	O
1532	followed	O
1532	by	O
1532	sequence	O
1532	-	O
1532	determination	O
1532	reactions	O
1532	.	O
1533	Using	O
1533	this	O
1533	methodology	O
1533	we	O
1533	have	O
1533	found	O
1533	X	B-Disease
1533	-	I-Disease
1533	ALD	I-Disease
1533	mutations	O
1533	in	O
1533	30	O
1533	kindreds	O
1533	,	O
1533	including	O
1533	15	O
1533	not	O
1533	previously	O
1533	reported	O
1533	.	O
1534	beta	O
1534	-	O
1534	galactosidase	O
1534	gene	O
1534	mutations	O
1534	affecting	O
1534	the	O
1534	lysosomal	O
1534	enzyme	O
1534	and	O
1534	the	O
1534	elastin	O
1534	-	O
1534	binding	O
1534	protein	O
1534	in	O
1534	GM1	B-Disease
1534	-	I-Disease
1534	gangliosidosis	I-Disease
1534	patients	O
1534	with	O
1534	cardiac	B-Disease
1534	involvement	I-Disease
1534	.	O
1535	GM1	B-Disease
1535	-	I-Disease
1535	gangliosidosis	I-Disease
1535	is	O
1535	a	O
1535	lysosomal	B-Disease
1535	storage	I-Disease
1535	disorder	I-Disease
1535	caused	O
1535	by	O
1535	deficiency	B-Disease
1535	of	I-Disease
1535	acid	I-Disease
1535	beta	I-Disease
1535	-	I-Disease
1535	galactosidase	I-Disease
1535	(	O
1535	GLB1	O
1535	)	O
1535	.	O
1536	We	O
1536	report	O
1536	five	O
1536	new	O
1536	beta	O
1536	-	O
1536	galactosidase	O
1536	gene	O
1536	mutations	O
1536	in	O
1536	nine	O
1536	Italian	O
1536	patients	O
1536	and	O
1536	one	O
1536	fetus	O
1536	,	O
1536	segregating	O
1536	in	O
1536	seven	O
1536	unrelated	O
1536	families	O
1536	.	O
1537	Six	O
1537	of	O
1537	the	O
1537	eight	O
1537	patients	O
1537	with	O
1537	the	O
1537	infantile	O
1537	,	O
1537	severe	O
1537	form	O
1537	of	O
1537	the	O
1537	disease	O
1537	presented	O
1537	cardiac	B-Disease
1537	involvement	I-Disease
1537	,	O
1537	a	O
1537	feature	O
1537	rarely	O
1537	associated	O
1537	with	O
1537	GM1	B-Disease
1537	-	I-Disease
1537	gangliosidosis	I-Disease
1537	.	O
1538	Molecular	O
1538	analysis	O
1538	of	O
1538	the	O
1538	patients	O
1538	RNA	O
1538	and	O
1538	DNA	O
1538	identified	O
1538	two	O
1538	new	O
1538	RNA	O
1538	splicing	O
1538	defects	O
1538	,	O
1538	three	O
1538	new	O
1538	and	O
1538	three	O
1538	previously	O
1538	described	O
1538	amino	O
1538	acid	O
1538	substitutions	O
1538	.	O
1539	Interestingly	O
1539	,	O
1539	all	O
1539	patients	O
1539	with	O
1539	cardiac	B-Disease
1539	involvement	I-Disease
1539	were	O
1539	homozygous	O
1539	for	O
1539	one	O
1539	of	O
1539	these	O
1539	mutations	O
1539	R59H	O
1539	,	O
1539	Y591C	O
1539	,	O
1539	Y591N	O
1539	,	O
1539	or	O
1539	IVS14	O
1539	-	O
1539	2A	O
1539	>	O
1539	G	O
1539	.	O
1540	In	O
1540	contrast	O
1540	,	O
1540	all	O
1540	other	O
1540	patients	O
1540	were	O
1540	compound	O
1540	heterozygous	O
1540	for	O
1540	one	O
1540	of	O
1540	the	O
1540	following	O
1540	mutations	O
1540	R201H	O
1540	,	O
1540	R482H	O
1540	,	O
1540	G579D	O
1540	,	O
1540	IVS8	O
1540	+	O
1540	2T	O
1540	>	O
1540	C	O
1540	.	O
1541	Although	O
1541	we	O
1541	could	O
1541	not	O
1541	directly	O
1541	correlate	O
1541	the	O
1541	presence	O
1541	of	O
1541	cardiac	B-Disease
1541	abnormalities	I-Disease
1541	with	O
1541	specific	O
1541	genetic	B-Disease
1541	lesions	I-Disease
1541	,	O
1541	the	O
1541	mutations	O
1541	identified	O
1541	in	O
1541	patients	O
1541	with	O
1541	cardiomyopathy	B-Disease
1541	fell	O
1541	in	O
1541	the	O
1541	GLB1	O
1541	cDNA	O
1541	region	O
1541	common	O
1541	to	O
1541	the	O
1541	lysosomal	O
1541	enzyme	O
1541	and	O
1541	the	O
1541	Hbeta	O
1541	-	O
1541	Gal	O
1541	-	O
1541	related	O
1541	protein	O
1541	,	O
1541	also	O
1541	known	O
1541	as	O
1541	the	O
1541	elastin	O
1541	binding	O
1541	protein	O
1541	(	O
1541	EBP	O
1541	)	O
1541	.	O
1542	Consequently	O
1542	,	O
1542	both	O
1542	molecules	O
1542	are	O
1542	affected	O
1542	by	O
1542	the	O
1542	mutations	O
1542	,	O
1542	and	O
1542	they	O
1542	may	O
1542	contribute	O
1542	differently	O
1542	to	O
1542	the	O
1542	occurrence	O
1542	of	O
1542	specific	O
1542	clinical	O
1542	manifestations	O
1542	.	O
1542	.	O
1543	In	O
1543	vivo	O
1543	modulation	O
1543	of	O
1543	Hmgic	O
1543	reduces	O
1543	obesity	B-Disease
1543	.	O
1544	The	O
1544	HMGI	O
1544	family	O
1544	of	O
1544	proteins	O
1544	consists	O
1544	of	O
1544	three	O
1544	members	O
1544	,	O
1544	HMGIC	O
1544	,	O
1544	HMGI	O
1544	and	O
1544	HMGI	O
1544	(	O
1544	Y	O
1544	)	O
1544	,	O
1544	that	O
1544	function	O
1544	as	O
1544	architectural	O
1544	factors	O
1544	and	O
1544	are	O
1544	essential	O
1544	components	O
1544	of	O
1544	the	O
1544	enhancesome	O
1544	.	O
1545	HMGIC	O
1545	is	O
1545	predominantly	O
1545	expressed	O
1545	in	O
1545	proliferating	O
1545	,	O
1545	undifferentiated	O
1545	mesenchymal	O
1545	cells	O
1545	and	O
1545	is	O
1545	not	O
1545	detected	O
1545	in	O
1545	adult	O
1545	tissues	O
1545	.	O
1546	It	O
1546	is	O
1546	disrupted	O
1546	and	O
1546	misexpressed	O
1546	in	O
1546	a	O
1546	number	O
1546	of	O
1546	mesenchymal	B-Disease
1546	tumour	I-Disease
1546	cell	O
1546	types	O
1546	,	O
1546	including	O
1546	fat	B-Disease
1546	-	I-Disease
1546	cell	I-Disease
1546	tumours	I-Disease
1546	(	O
1546	lipomas	B-Disease
1546	)	O
1546	.	O
1547	In	O
1547	addition	O
1547	Hmgic	O
1547	-	O
1547	/	O
1547	-	O
1547	mice	O
1547	have	O
1547	a	O
1547	deficiency	O
1547	in	O
1547	fat	O
1547	tissue	O
1547	.	O
1548	To	O
1548	study	O
1548	its	O
1548	role	O
1548	in	O
1548	adipogenesis	O
1548	and	O
1548	obesity	B-Disease
1548	,	O
1548	we	O
1548	examined	O
1548	Hmgic	O
1548	expression	O
1548	in	O
1548	the	O
1548	adipose	O
1548	tissue	O
1548	of	O
1548	adult	O
1548	,	O
1548	obese	B-Disease
1548	mice	O
1548	.	O
1549	Mice	O
1549	with	O
1549	a	O
1549	partial	B-Disease
1549	or	I-Disease
1549	complete	I-Disease
1549	deficiency	I-Disease
1549	of	I-Disease
1549	Hmgic	I-Disease
1549	resisted	O
1549	diet	O
1549	-	O
1549	induced	O
1549	obesity	B-Disease
1549	.	O
1550	Disruption	O
1550	of	O
1550	Hmgic	O
1550	caused	O
1550	a	O
1550	reduction	O
1550	in	O
1550	the	O
1550	obesity	B-Disease
1550	induced	O
1550	by	O
1550	leptin	B-Disease
1550	deficiency	I-Disease
1550	(	O
1550	Lepob	O
1550	/	O
1550	Lepob	O
1550	)	O
1550	in	O
1550	a	O
1550	gene	O
1550	-	O
1550	dose	O
1550	-	O
1550	dependent	O
1550	manner	O
1550	.	O
1551	Our	O
1551	studies	O
1551	implicate	O
1551	a	O
1551	role	O
1551	for	O
1551	HMGIC	O
1551	in	O
1551	fat	O
1551	-	O
1551	cell	O
1551	proliferation	O
1551	,	O
1551	indicating	O
1551	that	O
1551	it	O
1551	may	O
1551	be	O
1551	an	O
1551	adipose	O
1551	-	O
1551	specific	O
1551	target	O
1551	for	O
1551	the	O
1551	treatment	O
1551	of	O
1551	obesity	B-Disease
1551	.	O
1551	.	O
1552	Molecular	O
1552	analysis	O
1552	of	O
1552	the	O
1552	genotype	O
1552	-	O
1552	phenotype	O
1552	relationship	O
1552	in	O
1552	factor	B-Disease
1552	X	I-Disease
1552	deficiency	I-Disease
1552	.	O
1553	Factor	B-Disease
1553	X	I-Disease
1553	deficiency	I-Disease
1553	is	O
1553	a	O
1553	rare	O
1553	haemorrhagic	B-Disease
1553	condition	I-Disease
1553	,	O
1553	normally	O
1553	inherited	O
1553	as	O
1553	an	O
1553	autosomal	O
1553	recessive	O
1553	trait	O
1553	,	O
1553	in	O
1553	which	O
1553	a	O
1553	variable	O
1553	clinical	O
1553	presentation	O
1553	correlates	O
1553	poorly	O
1553	with	O
1553	laboratory	O
1553	phenotype	O
1553	.	O
1554	The	O
1554	factor	O
1554	X	O
1554	(	O
1554	F10	O
1554	)	O
1554	genes	O
1554	of	O
1554	14	O
1554	unrelated	O
1554	individuals	O
1554	with	O
1554	factor	B-Disease
1554	X	I-Disease
1554	deficiency	I-Disease
1554	(	O
1554	12	O
1554	familial	O
1554	and	O
1554	two	O
1554	sporadic	O
1554	cases	O
1554	)	O
1554	were	O
1554	sequenced	O
1554	yielding	O
1554	a	O
1554	total	O
1554	of	O
1554	13	O
1554	novel	O
1554	mutations	O
1554	.	O
1555	Family	O
1555	studies	O
1555	were	O
1555	performed	O
1555	in	O
1555	order	O
1555	to	O
1555	distinguish	O
1555	the	O
1555	contributions	O
1555	of	O
1555	individual	O
1555	mutant	O
1555	F10	O
1555	alleles	O
1555	to	O
1555	the	O
1555	clinical	O
1555	and	O
1555	laboratory	O
1555	phenotypes	O
1555	.	O
1556	Missense	O
1556	mutations	O
1556	were	O
1556	studied	O
1556	by	O
1556	means	O
1556	of	O
1556	molecular	O
1556	modelling	O
1556	,	O
1556	whereas	O
1556	single	O
1556	basepair	O
1556	substitutions	O
1556	in	O
1556	splice	O
1556	sites	O
1556	and	O
1556	the	O
1556	5	O
1556	flanking	O
1556	region	O
1556	were	O
1556	examined	O
1556	by	O
1556	in	O
1556	vitro	O
1556	splicing	O
1556	assay	O
1556	and	O
1556	luciferase	O
1556	reporter	O
1556	gene	O
1556	assay	O
1556	respectively	O
1556	.	O
1557	The	O
1557	deletion	O
1557	allele	O
1557	of	O
1557	a	O
1557	novel	O
1557	hexanucleotide	O
1557	insertion	O
1557	/	O
1557	deletion	O
1557	polymorphism	O
1557	in	O
1557	the	O
1557	F10	O
1557	gene	O
1557	promoter	O
1557	region	O
1557	was	O
1557	shown	O
1557	by	O
1557	reporter	O
1557	gene	O
1557	assay	O
1557	,	O
1557	to	O
1557	reduce	O
1557	promoter	O
1557	activity	O
1557	by	O
1557	approximately	O
1557	20	O
1557	%	O
1557	.	O
1558	One	O
1558	family	O
1558	manifesting	O
1558	an	O
1558	autosomal	O
1558	dominant	O
1558	pattern	O
1558	of	O
1558	inheritance	O
1558	possessed	O
1558	three	O
1558	clinically	O
1558	affected	O
1558	members	O
1558	who	O
1558	were	O
1558	heterozygous	O
1558	for	O
1558	a	O
1558	splice	O
1558	-	O
1558	site	O
1558	mutation	O
1558	that	O
1558	was	O
1558	predicted	O
1558	to	O
1558	lead	O
1558	to	O
1558	the	O
1558	production	O
1558	of	O
1558	a	O
1558	truncated	O
1558	protein	O
1558	product	O
1558	.	O
1559	A	O
1559	model	O
1559	which	O
1559	accounts	O
1559	for	O
1559	the	O
1559	dominant	O
1559	negative	O
1559	effect	O
1559	of	O
1559	this	O
1559	lesion	O
1559	is	O
1559	presented	O
1559	.	O
1560	Variation	O
1560	in	O
1560	the	O
1560	antigen	O
1560	level	O
1560	of	O
1560	heterozygous	O
1560	relatives	O
1560	of	O
1560	probands	O
1560	was	O
1560	found	O
1560	to	O
1560	be	O
1560	significantly	O
1560	higher	O
1560	between	O
1560	families	O
1560	than	O
1560	within	O
1560	families	O
1560	,	O
1560	consistent	O
1560	with	O
1560	the	O
1560	view	O
1560	that	O
1560	the	O
1560	nature	O
1560	of	O
1560	the	O
1560	F10	O
1560	lesion	O
1560	(	O
1560	s	O
1560	)	O
1560	segregating	O
1560	in	O
1560	a	O
1560	given	O
1560	family	O
1560	is	O
1560	a	O
1560	prime	O
1560	determinant	O
1560	of	O
1560	the	O
1560	laboratory	O
1560	phenotype	O
1560	.	O
1561	By	O
1561	contrast	O
1561	,	O
1561	no	O
1561	such	O
1561	relationship	O
1561	could	O
1561	be	O
1561	discerned	O
1561	between	O
1561	laboratory	O
1561	phenotype	O
1561	and	O
1561	polymorphism	O
1561	genotype	O
1561	.	O
1561	.	O
1562	Transgenic	O
1562	mice	O
1562	expressing	O
1562	a	O
1562	truncated	O
1562	form	O
1562	of	O
1562	the	O
1562	high	O
1562	mobility	O
1562	group	O
1562	I	O
1562	-	O
1562	C	O
1562	protein	O
1562	develop	O
1562	adiposity	O
1562	and	O
1562	an	O
1562	abnormally	O
1562	high	O
1562	prevalence	O
1562	of	O
1562	lipomas	B-Disease
1562	.	O
1563	Chromosomal	O
1563	translocations	O
1563	in	O
1563	human	O
1563	lipomas	B-Disease
1563	frequently	O
1563	create	O
1563	fusion	O
1563	transcripts	O
1563	encoding	O
1563	high	O
1563	mobility	O
1563	group	O
1563	(	O
1563	HMG	O
1563	)	O
1563	I	O
1563	-	O
1563	C	O
1563	DNA	O
1563	-	O
1563	binding	O
1563	domains	O
1563	and	O
1563	C	O
1563	-	O
1563	terminal	O
1563	sequences	O
1563	from	O
1563	different	O
1563	presumed	O
1563	transcription	O
1563	factors	O
1563	,	O
1563	suggesting	O
1563	a	O
1563	potential	O
1563	role	O
1563	for	O
1563	HMG	O
1563	I	O
1563	-	O
1563	C	O
1563	in	O
1563	the	O
1563	development	O
1563	of	O
1563	lipomas	B-Disease
1563	.	O
1564	To	O
1564	evaluate	O
1564	the	O
1564	role	O
1564	of	O
1564	the	O
1564	HMG	O
1564	I	O
1564	-	O
1564	C	O
1564	component	O
1564	,	O
1564	the	O
1564	three	O
1564	DNA	O
1564	-	O
1564	binding	O
1564	domains	O
1564	of	O
1564	HMG	O
1564	I	O
1564	-	O
1564	C	O
1564	have	O
1564	now	O
1564	been	O
1564	expressed	O
1564	in	O
1564	transgenic	O
1564	mice	O
1564	.	O
1565	Despite	O
1565	the	O
1565	ubiquitous	O
1565	expression	O
1565	of	O
1565	the	O
1565	truncated	O
1565	HMG	O
1565	I	O
1565	-	O
1565	C	O
1565	protein	O
1565	,	O
1565	the	O
1565	transgenic	O
1565	mice	O
1565	develop	O
1565	a	O
1565	selective	O
1565	abundance	O
1565	of	O
1565	fat	O
1565	tissue	O
1565	early	O
1565	in	O
1565	life	O
1565	,	O
1565	show	O
1565	marked	O
1565	adipose	B-Disease
1565	tissue	I-Disease
1565	inflammation	I-Disease
1565	,	O
1565	and	O
1565	have	O
1565	an	O
1565	abnormally	O
1565	high	O
1565	incidence	O
1565	of	O
1565	lipomas	B-Disease
1565	.	O
1566	These	O
1566	findings	O
1566	demonstrate	O
1566	that	O
1566	the	O
1566	DNA	O
1566	-	O
1566	binding	O
1566	domains	O
1566	of	O
1566	HMG	O
1566	I	O
1566	-	O
1566	C	O
1566	,	O
1566	in	O
1566	the	O
1566	absence	O
1566	of	O
1566	a	O
1566	C	O
1566	-	O
1566	terminal	O
1566	fusion	O
1566	partner	O
1566	,	O
1566	are	O
1566	sufficient	O
1566	to	O
1566	perturb	O
1566	adipogenesis	O
1566	and	O
1566	predispose	O
1566	to	O
1566	lipomas	B-Disease
1566	.	O
1567	We	O
1567	provide	O
1567	data	O
1567	supporting	O
1567	the	O
1567	central	O
1567	utility	O
1567	of	O
1567	this	O
1567	animal	O
1567	model	O
1567	as	O
1567	a	O
1567	tool	O
1567	to	O
1567	understand	O
1567	the	O
1567	molecular	O
1567	mechanisms	O
1567	underlying	O
1567	the	O
1567	development	O
1567	of	O
1567	one	O
1567	of	O
1567	the	O
1567	most	O
1567	common	O
1567	kind	O
1567	of	O
1567	human	O
1567	benign	B-Disease
1567	tumors	I-Disease
1567	.	O
1567	.	O
1568	ATM	O
1568	phosphorylates	O
1568	p95	O
1568	/	O
1568	nbs1	O
1568	in	O
1568	an	O
1568	S	O
1568	-	O
1568	phase	O
1568	checkpoint	O
1568	pathway	O
1568	.	O
1569	The	O
1569	rare	B-Disease
1569	diseases	I-Disease
1569	ataxia	B-Disease
1569	-	I-Disease
1569	telangiectasia	I-Disease
1569	(	O
1569	AT	B-Disease
1569	)	O
1569	,	O
1569	caused	O
1569	by	O
1569	mutations	O
1569	in	O
1569	the	O
1569	ATM	O
1569	gene	O
1569	,	O
1569	and	O
1569	Nijmegen	B-Disease
1569	breakage	I-Disease
1569	syndrome	I-Disease
1569	(	O
1569	NBS	B-Disease
1569	)	O
1569	,	O
1569	with	O
1569	mutations	O
1569	in	O
1569	the	O
1569	p95	O
1569	/	O
1569	nbs1	O
1569	gene	O
1569	,	O
1569	share	O
1569	a	O
1569	variety	O
1569	of	O
1569	phenotypic	B-Disease
1569	abnormalities	I-Disease
1569	such	O
1569	as	O
1569	chromosomal	B-Disease
1569	instability	I-Disease
1569	,	O
1569	radiation	O
1569	sensitivity	O
1569	and	O
1569	defects	O
1569	in	O
1569	cell	O
1569	-	O
1569	cycle	O
1569	checkpoints	O
1569	in	O
1569	response	O
1569	to	O
1569	ionizing	O
1569	radiation	O
1569	.	O
1570	The	O
1570	ATM	O
1570	gene	O
1570	encodes	O
1570	a	O
1570	protein	O
1570	kinase	O
1570	that	O
1570	is	O
1570	activated	O
1570	by	O
1570	ionizing	O
1570	radiation	O
1570	or	O
1570	radiomimetic	O
1570	drugs	O
1570	,	O
1570	whereas	O
1570	p95	O
1570	/	O
1570	nbs1	O
1570	is	O
1570	part	O
1570	of	O
1570	a	O
1570	protein	O
1570	complex	O
1570	that	O
1570	is	O
1570	involved	O
1570	in	O
1570	responses	O
1570	to	O
1570	DNA	O
1570	double	O
1570	-	O
1570	strand	O
1570	breaks	O
1570	.	O
1571	Here	O
1571	,	O
1571	because	O
1571	of	O
1571	the	O
1571	similarities	O
1571	between	O
1571	AT	B-Disease
1571	and	O
1571	NBS	B-Disease
1571	,	O
1571	we	O
1571	evaluated	O
1571	the	O
1571	functional	O
1571	interactions	O
1571	between	O
1571	ATM	O
1571	and	O
1571	p95	O
1571	/	O
1571	nbs1	O
1571	.	O
1572	Activation	O
1572	of	O
1572	the	O
1572	ATM	O
1572	kinase	O
1572	by	O
1572	ionizing	O
1572	radiation	O
1572	and	O
1572	induction	O
1572	of	O
1572	ATM	O
1572	-	O
1572	dependent	O
1572	responses	O
1572	in	O
1572	NBS	B-Disease
1572	cells	O
1572	indicated	O
1572	that	O
1572	p95	O
1572	/	O
1572	nbs1	O
1572	may	O
1572	not	O
1572	be	O
1572	required	O
1572	for	O
1572	signalling	O
1572	to	O
1572	ATM	O
1572	after	O
1572	ionizing	O
1572	radiation	O
1572	.	O
1573	However	O
1573	,	O
1573	p95	O
1573	/	O
1573	nbs1	O
1573	was	O
1573	phosphorylated	O
1573	on	O
1573	serine	O
1573	343	O
1573	in	O
1573	an	O
1573	ATM	O
1573	-	O
1573	dependent	O
1573	manner	O
1573	in	O
1573	vitro	O
1573	and	O
1573	in	O
1573	vivo	O
1573	after	O
1573	ionizing	O
1573	radiation	O
1573	.	O
1574	A	O
1574	p95	O
1574	/	O
1574	nbs1	O
1574	construct	O
1574	mutated	O
1574	at	O
1574	the	O
1574	ATM	O
1574	phosphorylation	O
1574	site	O
1574	abrogated	O
1574	an	O
1574	S	O
1574	-	O
1574	phase	O
1574	checkpoint	O
1574	induced	O
1574	by	O
1574	ionizing	O
1574	radiation	O
1574	in	O
1574	normal	O
1574	cells	O
1574	and	O
1574	failed	O
1574	to	O
1574	compensate	O
1574	for	O
1574	this	O
1574	functional	O
1574	deficiency	O
1574	in	O
1574	NBS	B-Disease
1574	cells	O
1574	.	O
1575	These	O
1575	observations	O
1575	link	O
1575	ATM	O
1575	and	O
1575	p95	O
1575	/	O
1575	nbs1	O
1575	in	O
1575	a	O
1575	common	O
1575	signalling	O
1575	pathway	O
1575	and	O
1575	provide	O
1575	an	O
1575	explanation	O
1575	for	O
1575	phenotypic	O
1575	similarities	O
1575	in	O
1575	these	O
1575	two	O
1575	diseases	O
1575	.	O
1575	.	O
1576	Understanding	O
1576	the	O
1576	molecular	O
1576	basis	O
1576	of	O
1576	fragile	B-Disease
1576	X	I-Disease
1576	syndrome	I-Disease
1576	.	O
1577	Fragile	B-Disease
1577	X	I-Disease
1577	syndrome	I-Disease
1577	,	O
1577	a	O
1577	common	O
1577	form	O
1577	of	O
1577	inherited	B-Disease
1577	mental	I-Disease
1577	retardation	I-Disease
1577	,	O
1577	is	O
1577	mainly	O
1577	caused	O
1577	by	O
1577	massive	O
1577	expansion	O
1577	of	O
1577	CGG	O
1577	triplet	O
1577	repeats	O
1577	located	O
1577	in	O
1577	the	O
1577	5	O
1577	-	O
1577	untranslated	O
1577	region	O
1577	of	O
1577	the	O
1577	fragile	B-Disease
1577	X	I-Disease
1577	mental	I-Disease
1577	retardation	I-Disease
1577	-	O
1577	1	O
1577	(	O
1577	FMR1	O
1577	)	O
1577	gene	O
1577	.	O
1578	In	O
1578	patients	O
1578	with	O
1578	fragile	B-Disease
1578	X	I-Disease
1578	syndrome	I-Disease
1578	,	O
1578	the	O
1578	expanded	O
1578	CGG	O
1578	triplet	O
1578	repeats	O
1578	are	O
1578	hypermethylated	O
1578	and	O
1578	the	O
1578	expression	O
1578	of	O
1578	the	O
1578	FMR1	O
1578	gene	O
1578	is	O
1578	repressed	O
1578	,	O
1578	which	O
1578	leads	O
1578	to	O
1578	the	O
1578	absence	O
1578	of	O
1578	FMR1	O
1578	protein	O
1578	(	O
1578	FMRP	O
1578	)	O
1578	and	O
1578	subsequent	O
1578	mental	B-Disease
1578	retardation	I-Disease
1578	.	O
1579	FMRP	O
1579	is	O
1579	an	O
1579	RNA	O
1579	-	O
1579	binding	O
1579	protein	O
1579	that	O
1579	shuttles	O
1579	between	O
1579	the	O
1579	nucleus	O
1579	and	O
1579	cytoplasm	O
1579	.	O
1580	This	O
1580	protein	O
1580	has	O
1580	been	O
1580	implicated	O
1580	in	O
1580	protein	O
1580	translation	O
1580	as	O
1580	it	O
1580	is	O
1580	found	O
1580	associated	O
1580	with	O
1580	polyribosomes	O
1580	and	O
1580	the	O
1580	rough	O
1580	endoplasmic	O
1580	reticulum	O
1580	.	O
1581	We	O
1581	discuss	O
1581	here	O
1581	the	O
1581	recent	O
1581	progress	O
1581	made	O
1581	towards	O
1581	understanding	O
1581	the	O
1581	molecular	O
1581	mechanism	O
1581	of	O
1581	CGG	O
1581	repeat	O
1581	expansion	O
1581	and	O
1581	physiological	O
1581	function	O
1581	(	O
1581	s	O
1581	)	O
1581	of	O
1581	FMRP	O
1581	.	O
1582	These	O
1582	studies	O
1582	will	O
1582	not	O
1582	only	O
1582	help	O
1582	to	O
1582	illuminate	O
1582	the	O
1582	molecular	O
1582	basis	O
1582	of	O
1582	the	O
1582	general	O
1582	class	O
1582	of	O
1582	human	O
1582	diseases	O
1582	with	O
1582	trinucleotide	O
1582	repeat	O
1582	expansion	O
1582	but	O
1582	also	O
1582	provide	O
1582	an	O
1582	avenue	O
1582	to	O
1582	understand	O
1582	aspects	O
1582	of	O
1582	human	O
1582	cognition	O
1582	and	O
1582	intelligence	O
1582	.	O
1582	.	O
1583	Haploinsufficiency	B-Disease
1583	of	I-Disease
1583	the	I-Disease
1583	transcription	I-Disease
1583	factors	I-Disease
1583	FOXC1	I-Disease
1583	and	I-Disease
1583	FOXC2	I-Disease
1583	results	O
1583	in	O
1583	aberrant	O
1583	ocular	O
1583	development	O
1583	.	O
1584	Anterior	B-Disease
1584	segment	I-Disease
1584	developmental	I-Disease
1584	disorders	I-Disease
1584	,	O
1584	including	O
1584	Axenfeld	B-Disease
1584	-	I-Disease
1584	Rieger	I-Disease
1584	anomaly	I-Disease
1584	(	O
1584	ARA	B-Disease
1584	)	O
1584	,	O
1584	variably	O
1584	associate	O
1584	with	O
1584	harmfully	O
1584	elevated	O
1584	intraocular	O
1584	pressure	O
1584	(	O
1584	IOP	O
1584	)	O
1584	,	O
1584	which	O
1584	causes	O
1584	glaucoma	B-Disease
1584	.	O
1585	Clinically	O
1585	observed	O
1585	dysgenesis	O
1585	does	O
1585	not	O
1585	correlate	O
1585	with	O
1585	IOP	O
1585	,	O
1585	however	O
1585	,	O
1585	and	O
1585	the	O
1585	etiology	O
1585	of	O
1585	glaucoma	B-Disease
1585	development	O
1585	is	O
1585	not	O
1585	understood	O
1585	.	O
1586	The	O
1586	forkhead	O
1586	transcription	O
1586	factor	O
1586	genes	O
1586	Foxc1	O
1586	(	O
1586	formerly	O
1586	Mf1	O
1586	)	O
1586	and	O
1586	Foxc2	O
1586	(	O
1586	formerly	O
1586	Mfh1	O
1586	)	O
1586	are	O
1586	expressed	O
1586	in	O
1586	the	O
1586	mesenchyme	O
1586	from	O
1586	which	O
1586	the	O
1586	ocular	O
1586	drainage	O
1586	structures	O
1586	derive	O
1586	.	O
1587	Mutations	O
1587	in	O
1587	the	O
1587	human	O
1587	homolog	O
1587	of	O
1587	Foxc1	O
1587	,	O
1587	FKHL7	O
1587	,	O
1587	cause	O
1587	dominant	O
1587	anterior	B-Disease
1587	segment	I-Disease
1587	defects	I-Disease
1587	and	O
1587	glaucoma	B-Disease
1587	in	O
1587	various	O
1587	families	O
1587	.	O
1588	We	O
1588	show	O
1588	that	O
1588	Foxc1	O
1588	(	O
1588	+	O
1588	/	O
1588	-	O
1588	)	O
1588	mice	O
1588	have	O
1588	anterior	B-Disease
1588	segment	I-Disease
1588	abnormalities	I-Disease
1588	similar	O
1588	to	O
1588	those	O
1588	reported	O
1588	in	O
1588	human	O
1588	patients	O
1588	.	O
1589	These	O
1589	abnormalities	O
1589	include	O
1589	small	O
1589	or	O
1589	absent	O
1589	Schlemms	O
1589	canal	O
1589	,	O
1589	aberrantly	O
1589	developed	O
1589	trabecular	O
1589	meshwork	O
1589	,	O
1589	iris	B-Disease
1589	hypoplasia	I-Disease
1589	,	O
1589	severely	O
1589	eccentric	O
1589	pupils	O
1589	and	O
1589	displaced	O
1589	Schwalbes	O
1589	line	O
1589	.	O
1590	The	O
1590	penetrance	O
1590	of	O
1590	clinically	O
1590	obvious	O
1590	abnormalities	O
1590	varies	O
1590	with	O
1590	genetic	O
1590	background	O
1590	.	O
1591	In	O
1591	some	O
1591	affected	O
1591	eyes	O
1591	,	O
1591	collagen	O
1591	bundles	O
1591	were	O
1591	half	O
1591	normal	O
1591	diameter	O
1591	,	O
1591	or	O
1591	collagen	O
1591	and	O
1591	elastic	O
1591	tissue	O
1591	were	O
1591	very	O
1591	sparse	O
1591	.	O
1592	Thus	O
1592	,	O
1592	abnormalities	O
1592	in	O
1592	extracellular	O
1592	matrix	O
1592	synthesis	O
1592	or	O
1592	organization	O
1592	may	O
1592	contribute	O
1592	to	O
1592	development	O
1592	of	O
1592	the	O
1592	ocular	O
1592	phenotypes	O
1592	.	O
1593	Despite	O
1593	the	O
1593	abnormalities	O
1593	in	O
1593	ocular	O
1593	drainage	O
1593	structures	O
1593	in	O
1593	Foxc1	O
1593	(	O
1593	+	O
1593	/	O
1593	-	O
1593	)	O
1593	mice	O
1593	,	O
1593	IOP	O
1593	was	O
1593	normal	O
1593	in	O
1593	almost	O
1593	all	O
1593	mice	O
1593	analyzed	O
1593	,	O
1593	on	O
1593	all	O
1593	genetic	O
1593	backgrounds	O
1593	and	O
1593	at	O
1593	all	O
1593	ages	O
1593	.	O
1594	Similar	O
1594	abnormalities	O
1594	were	O
1594	found	O
1594	in	O
1594	Foxc2	O
1594	(	O
1594	+	O
1594	/	O
1594	-	O
1594	)	O
1594	mice	O
1594	,	O
1594	but	O
1594	no	O
1594	disease	O
1594	-	O
1594	associated	O
1594	mutations	O
1594	were	O
1594	identified	O
1594	in	O
1594	the	O
1594	human	O
1594	homolog	O
1594	FKHL14	O
1594	in	O
1594	32	O
1594	ARA	B-Disease
1594	patients	O
1594	.	O
1595	Foxc1	O
1595	(	O
1595	+	O
1595	/	O
1595	-	O
1595	)	O
1595	and	O
1595	Foxc2	O
1595	(	O
1595	+	O
1595	/	O
1595	-	O
1595	)	O
1595	mice	O
1595	are	O
1595	useful	O
1595	models	O
1595	for	O
1595	studying	O
1595	anterior	O
1595	segment	O
1595	development	O
1595	and	O
1595	its	O
1595	anomalies	O
1595	,	O
1595	and	O
1595	may	O
1595	allow	O
1595	identification	O
1595	of	O
1595	genes	O
1595	that	O
1595	interact	O
1595	with	O
1595	Foxc1	O
1595	and	O
1595	Foxc2	O
1595	(	O
1595	or	O
1595	FKHL7	O
1595	and	O
1595	FKHL14	O
1595	)	O
1595	to	O
1595	produce	O
1595	a	O
1595	phenotype	O
1595	with	O
1595	elevated	O
1595	IOP	O
1595	and	O
1595	glaucoma	B-Disease
1595	.	O
1595	.	O
1596	(	O
1596	Over	O
1596	)	O
1596	correction	O
1596	of	O
1596	FMR1	B-Disease
1596	deficiency	I-Disease
1596	with	O
1596	YAC	O
1596	transgenics	O
1596	:	O
1596	behavioral	O
1596	and	O
1596	physical	O
1596	features	O
1596	.	O
1597	Fragile	B-Disease
1597	X	I-Disease
1597	syndrome	I-Disease
1597	is	O
1597	a	O
1597	common	O
1597	cause	O
1597	of	O
1597	mental	B-Disease
1597	retardation	I-Disease
1597	involving	O
1597	loss	O
1597	of	O
1597	expression	O
1597	of	O
1597	the	O
1597	FMR1	O
1597	gene	O
1597	.	O
1598	The	O
1598	role	O
1598	of	O
1598	FMR1	O
1598	remains	O
1598	undetermined	O
1598	but	O
1598	the	O
1598	protein	O
1598	appears	O
1598	to	O
1598	be	O
1598	involved	O
1598	in	O
1598	RNA	O
1598	metabolism	O
1598	.	O
1599	Fmr1	O
1599	knockout	O
1599	mice	O
1599	exhibit	O
1599	a	O
1599	phenotype	O
1599	with	O
1599	some	O
1599	similarities	O
1599	to	O
1599	humans	O
1599	,	O
1599	such	O
1599	as	O
1599	macroorchidism	B-Disease
1599	and	O
1599	behavioral	O
1599	abnormalities	O
1599	.	O
1600	As	O
1600	a	O
1600	step	O
1600	toward	O
1600	understanding	O
1600	the	O
1600	function	O
1600	of	O
1600	FMR1	O
1600	and	O
1600	the	O
1600	determination	O
1600	of	O
1600	the	O
1600	potential	O
1600	for	O
1600	therapeutic	O
1600	approaches	O
1600	to	O
1600	fragile	B-Disease
1600	X	I-Disease
1600	syndrome	I-Disease
1600	,	O
1600	yeast	O
1600	artificial	O
1600	chromosome	O
1600	(	O
1600	YAC	O
1600	)	O
1600	transgenic	O
1600	mice	O
1600	were	O
1600	generated	O
1600	in	O
1600	order	O
1600	to	O
1600	determine	O
1600	whether	O
1600	the	O
1600	Fmr1	O
1600	knockout	O
1600	mouse	O
1600	phenotype	O
1600	could	O
1600	be	O
1600	rescued	O
1600	.	O
1601	Several	O
1601	transgenic	O
1601	lines	O
1601	were	O
1601	generated	O
1601	that	O
1601	carried	O
1601	the	O
1601	entire	O
1601	FMR1	O
1601	locus	O
1601	with	O
1601	extensive	O
1601	amounts	O
1601	of	O
1601	flanking	O
1601	sequence	O
1601	.	O
1602	We	O
1602	observed	O
1602	that	O
1602	the	O
1602	YAC	O
1602	transgene	O
1602	supported	O
1602	production	O
1602	of	O
1602	the	O
1602	human	O
1602	protein	O
1602	(	O
1602	FMRP	O
1602	)	O
1602	which	O
1602	was	O
1602	present	O
1602	at	O
1602	levels	O
1602	10	O
1602	to	O
1602	15	O
1602	times	O
1602	that	O
1602	of	O
1602	endogenous	O
1602	protein	O
1602	and	O
1602	was	O
1602	expressed	O
1602	in	O
1602	a	O
1602	cell	O
1602	-	O
1602	and	O
1602	tissue	O
1602	-	O
1602	specific	O
1602	manner	O
1602	.	O
1603	Macro	O
1603	-	O
1603	orchidism	O
1603	was	O
1603	absent	O
1603	in	O
1603	knockout	O
1603	mice	O
1603	carrying	O
1603	the	O
1603	YAC	O
1603	transgene	O
1603	indicating	O
1603	functional	O
1603	rescue	O
1603	by	O
1603	the	O
1603	human	O
1603	protein	O
1603	.	O
1604	Given	O
1604	the	O
1604	complex	O
1604	behavioral	O
1604	phenotype	O
1604	in	O
1604	fragile	B-Disease
1604	X	I-Disease
1604	patients	O
1604	and	O
1604	the	O
1604	mild	O
1604	phenotype	O
1604	previously	O
1604	reported	O
1604	for	O
1604	the	O
1604	Fmr1	O
1604	knockout	O
1604	mouse	O
1604	,	O
1604	we	O
1604	performed	O
1604	a	O
1604	more	O
1604	thorough	O
1604	evaluation	O
1604	of	O
1604	the	O
1604	Fmr1	O
1604	knockout	O
1604	phenotype	O
1604	using	O
1604	additional	O
1604	behavioral	O
1604	assays	O
1604	that	O
1604	had	O
1604	not	O
1604	previously	O
1604	been	O
1604	reported	O
1604	for	O
1604	this	O
1604	animal	O
1604	model	O
1604	.	O
1605	The	O
1605	mouse	O
1605	displayed	O
1605	reduced	O
1605	anxiety	B-Disease
1605	-	O
1605	related	O
1605	responses	O
1605	with	O
1605	increased	O
1605	exploratory	O
1605	behavior	O
1605	.	O
1606	FMR1	O
1606	YAC	O
1606	transgenic	O
1606	mice	O
1606	overexpressing	O
1606	the	O
1606	human	O
1606	protein	O
1606	did	O
1606	produce	O
1606	opposing	O
1606	behavioral	O
1606	responses	O
1606	and	O
1606	additional	O
1606	abnormal	O
1606	behaviors	O
1606	were	O
1606	also	O
1606	observed	O
1606	.	O
1607	These	O
1607	findings	O
1607	have	O
1607	significant	O
1607	implications	O
1607	for	O
1607	gene	O
1607	therapy	O
1607	for	O
1607	fragile	B-Disease
1607	X	I-Disease
1607	syndrome	I-Disease
1607	since	O
1607	overexpression	O
1607	of	O
1607	the	O
1607	gene	O
1607	may	O
1607	harbor	O
1607	its	O
1607	own	O
1607	phenotype	O
1607	.	O
1607	.	O
1608	Transgenic	O
1608	mice	O
1608	carrying	O
1608	large	O
1608	human	O
1608	genomic	O
1608	sequences	O
1608	with	O
1608	expanded	O
1608	CTG	O
1608	repeat	O
1608	mimic	O
1608	closely	O
1608	the	O
1608	DM	B-Disease
1608	CTG	O
1608	repeat	O
1608	intergenerational	O
1608	and	O
1608	somatic	O
1608	instability	O
1608	.	O
1609	Myotonic	B-Disease
1609	dystrophy	I-Disease
1609	(	O
1609	DM	B-Disease
1609	)	O
1609	is	O
1609	caused	O
1609	by	O
1609	a	O
1609	CTG	O
1609	repeat	O
1609	expansion	O
1609	in	O
1609	the	O
1609	3UTR	O
1609	of	O
1609	the	O
1609	DM	B-Disease
1609	protein	O
1609	kinase	O
1609	(	O
1609	DMPK	O
1609	)	O
1609	gene	O
1609	.	O
1610	A	O
1610	very	O
1610	high	O
1610	level	O
1610	of	O
1610	instability	O
1610	is	O
1610	observed	O
1610	through	O
1610	successive	O
1610	generations	O
1610	and	O
1610	the	O
1610	size	O
1610	of	O
1610	the	O
1610	repeat	O
1610	is	O
1610	generally	O
1610	correlated	O
1610	with	O
1610	the	O
1610	severity	O
1610	of	O
1610	the	O
1610	disease	O
1610	and	O
1610	with	O
1610	age	O
1610	at	O
1610	onset	O
1610	.	O
1611	Furthermore	O
1611	,	O
1611	tissues	O
1611	from	O
1611	DM	B-Disease
1611	patients	O
1611	exhibit	O
1611	somatic	O
1611	mosaicism	O
1611	that	O
1611	increases	O
1611	with	O
1611	age	O
1611	.	O
1612	We	O
1612	generated	O
1612	transgenic	O
1612	mice	O
1612	carrying	O
1612	large	O
1612	human	O
1612	genomic	O
1612	sequences	O
1612	with	O
1612	20	O
1612	,	O
1612	55	O
1612	or	O
1612	>	O
1612	300	O
1612	CTG	O
1612	,	O
1612	cloned	O
1612	from	O
1612	patients	O
1612	from	O
1612	the	O
1612	same	O
1612	affected	O
1612	DM	B-Disease
1612	family	O
1612	.	O
1613	Using	O
1613	large	O
1613	human	O
1613	flanking	O
1613	sequences	O
1613	and	O
1613	a	O
1613	large	O
1613	amplification	O
1613	,	O
1613	we	O
1613	demonstrate	O
1613	that	O
1613	the	O
1613	intergenerational	O
1613	CTG	O
1613	repeat	O
1613	instability	O
1613	is	O
1613	reproduced	O
1613	in	O
1613	mice	O
1613	,	O
1613	with	O
1613	a	O
1613	strong	O
1613	bias	O
1613	towards	O
1613	expansions	O
1613	and	O
1613	with	O
1613	the	O
1613	same	O
1613	sex	O
1613	-	O
1613	and	O
1613	size	O
1613	-	O
1613	dependent	O
1613	characteristics	O
1613	as	O
1613	in	O
1613	humans	O
1613	.	O
1614	Moreover	O
1614	,	O
1614	a	O
1614	high	O
1614	level	O
1614	of	O
1614	instability	O
1614	,	O
1614	increasing	O
1614	with	O
1614	age	O
1614	,	O
1614	can	O
1614	be	O
1614	observed	O
1614	in	O
1614	tissues	O
1614	and	O
1614	in	O
1614	sperm	O
1614	.	O
1615	Although	O
1615	we	O
1615	did	O
1615	not	O
1615	observe	O
1615	dramatic	O
1615	expansions	O
1615	(	O
1615	or	O
1615	big	O
1615	jumps	O
1615	over	O
1615	several	O
1615	hundred	O
1615	CTG	O
1615	repeats	O
1615	)	O
1615	as	O
1615	in	O
1615	congenital	O
1615	forms	O
1615	of	O
1615	DM	B-Disease
1615	,	O
1615	our	O
1615	model	O
1615	carrying	O
1615	>	O
1615	300	O
1615	CTG	O
1615	is	O
1615	the	O
1615	first	O
1615	to	O
1615	show	O
1615	instability	O
1615	so	O
1615	close	O
1615	to	O
1615	the	O
1615	human	O
1615	DM	B-Disease
1615	situation	O
1615	.	O
1616	Our	O
1616	three	O
1616	models	O
1616	carrying	O
1616	different	O
1616	sizes	O
1616	of	O
1616	CTG	O
1616	repeat	O
1616	provide	O
1616	insight	O
1616	on	O
1616	the	O
1616	different	O
1616	factors	O
1616	modulating	O
1616	the	O
1616	CTG	O
1616	repeat	O
1616	instability	O
1616	.	O
1616	.	O
1617	Inactivation	O
1617	of	O
1617	the	O
1617	Friedreich	B-Disease
1617	ataxia	I-Disease
1617	mouse	O
1617	gene	O
1617	leads	O
1617	to	O
1617	early	O
1617	embryonic	B-Disease
1617	lethality	I-Disease
1617	without	O
1617	iron	O
1617	accumulation	O
1617	.	O
1618	Friedreich	B-Disease
1618	ataxia	I-Disease
1618	(	O
1618	FRDA	B-Disease
1618	)	O
1618	,	O
1618	the	O
1618	most	O
1618	common	O
1618	autosomal	B-Disease
1618	recessive	I-Disease
1618	ataxia	I-Disease
1618	,	O
1618	is	O
1618	caused	O
1618	in	O
1618	almost	O
1618	all	O
1618	cases	O
1618	by	O
1618	homozygous	O
1618	intronic	O
1618	expansions	O
1618	resulting	O
1618	in	O
1618	the	O
1618	loss	O
1618	of	O
1618	frataxin	O
1618	,	O
1618	a	O
1618	mitochondrial	O
1618	protein	O
1618	conserved	O
1618	through	O
1618	evolution	O
1618	,	O
1618	and	O
1618	involved	O
1618	in	O
1618	mitochondrial	O
1618	iron	O
1618	homeostasis	O
1618	.	O
1619	Yeast	O
1619	knockout	O
1619	models	O
1619	,	O
1619	and	O
1619	histological	O
1619	and	O
1619	biochemical	O
1619	data	O
1619	from	O
1619	patient	O
1619	heart	O
1619	biopsies	O
1619	or	O
1619	autopsies	O
1619	indicate	O
1619	that	O
1619	the	O
1619	frataxin	O
1619	defect	O
1619	causes	O
1619	a	O
1619	specific	O
1619	iron	B-Disease
1619	-	I-Disease
1619	sulfur	I-Disease
1619	protein	I-Disease
1619	deficiency	I-Disease
1619	and	O
1619	mitochondrial	O
1619	iron	O
1619	accumulation	O
1619	leading	O
1619	to	O
1619	the	O
1619	pathological	O
1619	changes	O
1619	.	O
1620	Affected	O
1620	human	O
1620	tissues	O
1620	are	O
1620	rarely	O
1620	available	O
1620	to	O
1620	further	O
1620	examine	O
1620	this	O
1620	hypothesis	O
1620	.	O
1621	To	O
1621	study	O
1621	the	O
1621	mechanism	O
1621	of	O
1621	the	O
1621	disease	O
1621	,	O
1621	we	O
1621	generated	O
1621	a	O
1621	mouse	O
1621	model	O
1621	by	O
1621	deletion	O
1621	of	O
1621	exon	O
1621	4	O
1621	leading	O
1621	to	O
1621	inactivation	O
1621	of	O
1621	the	O
1621	Frda	B-Disease
1621	gene	O
1621	product	O
1621	.	O
1622	We	O
1622	show	O
1622	that	O
1622	homozygous	O
1622	deletions	O
1622	cause	O
1622	embryonic	B-Disease
1622	lethality	I-Disease
1622	a	O
1622	few	O
1622	days	O
1622	after	O
1622	implantation	O
1622	,	O
1622	demonstrating	O
1622	an	O
1622	important	O
1622	role	O
1622	for	O
1622	frataxin	O
1622	during	O
1622	early	O
1622	development	O
1622	.	O
1623	These	O
1623	results	O
1623	suggest	O
1623	that	O
1623	the	O
1623	milder	O
1623	phenotype	O
1623	in	O
1623	humans	O
1623	is	O
1623	due	O
1623	to	O
1623	residual	O
1623	frataxin	O
1623	expression	O
1623	associated	O
1623	with	O
1623	the	O
1623	expansion	O
1623	mutations	O
1623	.	O
1624	Surprisingly	O
1624	,	O
1624	in	O
1624	the	O
1624	frataxin	O
1624	knockout	O
1624	mouse	O
1624	,	O
1624	no	O
1624	iron	O
1624	accumulation	O
1624	was	O
1624	observed	O
1624	during	O
1624	embryonic	O
1624	resorption	O
1624	,	O
1624	suggesting	O
1624	that	O
1624	cell	O
1624	death	O
1624	could	O
1624	be	O
1624	due	O
1624	to	O
1624	a	O
1624	mechanism	O
1624	independent	O
1624	of	O
1624	iron	O
1624	accumulation	O
1624	.	O
1624	.	O
1625	Gaucher	B-Disease
1625	disease	I-Disease
1625	:	O
1625	the	O
1625	origins	O
1625	of	O
1625	the	O
1625	Ashkenazi	O
1625	Jewish	O
1625	N370S	O
1625	and	O
1625	84GG	O
1625	acid	O
1625	beta	O
1625	-	O
1625	glucosidase	O
1625	mutations	O
1625	.	O
1626	Type	O
1626	1	O
1626	Gaucher	B-Disease
1626	disease	I-Disease
1626	(	O
1626	GD	B-Disease
1626	)	O
1626	,	O
1626	a	O
1626	non	O
1626	-	O
1626	neuronopathic	O
1626	lysosomal	B-Disease
1626	storage	I-Disease
1626	disorder	I-Disease
1626	,	O
1626	results	O
1626	from	O
1626	the	O
1626	deficient	O
1626	activity	O
1626	of	O
1626	acid	O
1626	beta	O
1626	-	O
1626	glucosidase	O
1626	(	O
1626	GBA	O
1626	)	O
1626	.	O
1627	Type	O
1627	1	O
1627	disease	O
1627	is	O
1627	panethnic	O
1627	but	O
1627	is	O
1627	more	O
1627	prevalent	O
1627	in	O
1627	individuals	O
1627	of	O
1627	Ashkenazi	O
1627	Jewish	O
1627	(	O
1627	AJ	O
1627	)	O
1627	descent	O
1627	.	O
1628	Of	O
1628	the	O
1628	causative	O
1628	GBA	O
1628	mutations	O
1628	,	O
1628	N370S	O
1628	is	O
1628	particularly	O
1628	frequent	O
1628	in	O
1628	the	O
1628	AJ	O
1628	population	O
1628	,	O
1628	(	O
1628	q	O
1628	approximately	O
1628	.	O
1628	03	O
1628	)	O
1628	,	O
1628	whereas	O
1628	the	O
1628	84GG	O
1628	insertion	O
1628	(	O
1628	q	O
1628	approximately	O
1628	.	O
1628	003	O
1628	)	O
1628	occurs	O
1628	exclusively	O
1628	in	O
1628	the	O
1628	Ashkenazim	O
1628	.	O
1629	To	O
1629	investigate	O
1629	the	O
1629	genetic	O
1629	history	O
1629	of	O
1629	these	O
1629	mutations	O
1629	in	O
1629	the	O
1629	AJ	O
1629	population	O
1629	,	O
1629	short	O
1629	tandem	O
1629	repeat	O
1629	(	O
1629	STR	O
1629	)	O
1629	markers	O
1629	were	O
1629	used	O
1629	to	O
1629	map	O
1629	a	O
1629	9	O
1629	.	O
1630	3	O
1630	-	O
1630	cM	O
1630	region	O
1630	containing	O
1630	the	O
1630	GBA	O
1630	locus	O
1630	and	O
1630	to	O
1630	genotype	O
1630	261	O
1630	AJ	O
1630	N370S	O
1630	chromosomes	O
1630	,	O
1630	60	O
1630	European	O
1630	non	O
1630	-	O
1630	Jewish	O
1630	N370S	O
1630	chromosomes	O
1630	,	O
1630	and	O
1630	62	O
1630	AJ	O
1630	84GG	O
1630	chromosomes	O
1630	.	O
1631	A	O
1631	highly	O
1631	conserved	O
1631	haplotype	O
1631	at	O
1631	four	O
1631	markers	O
1631	flanking	O
1631	GBA	O
1631	(	O
1631	PKLR	O
1631	,	O
1631	D1S1595	O
1631	,	O
1631	D1S2721	O
1631	,	O
1631	and	O
1631	D1S2777	O
1631	)	O
1631	was	O
1631	observed	O
1631	on	O
1631	both	O
1631	the	O
1631	AJ	O
1631	chromosomes	O
1631	and	O
1631	the	O
1631	non	O
1631	-	O
1631	Jewish	O
1631	N370S	O
1631	chromosomes	O
1631	,	O
1631	suggesting	O
1631	the	O
1631	occurrence	O
1631	of	O
1631	a	O
1631	founder	O
1631	common	O
1631	to	O
1631	both	O
1631	populations	O
1631	.	O
1632	Of	O
1632	note	O
1632	,	O
1632	the	O
1632	presence	O
1632	of	O
1632	different	O
1632	divergent	O
1632	haplotypes	O
1632	suggested	O
1632	the	O
1632	occurrence	O
1632	of	O
1632	de	O
1632	novo	O
1632	,	O
1632	recurrent	O
1632	N370S	O
1632	mutations	O
1632	.	O
1633	In	O
1633	contrast	O
1633	,	O
1633	a	O
1633	different	O
1633	conserved	O
1633	haplotype	O
1633	at	O
1633	these	O
1633	markers	O
1633	was	O
1633	identified	O
1633	on	O
1633	the	O
1633	84GG	O
1633	chromosomes	O
1633	,	O
1633	which	O
1633	was	O
1633	unique	O
1633	to	O
1633	the	O
1633	AJ	O
1633	population	O
1633	.	O
1634	On	O
1634	the	O
1634	basis	O
1634	of	O
1634	the	O
1634	linkage	O
1634	disequilibrium	O
1634	(	O
1634	LD	O
1634	)	O
1634	delta	O
1634	values	O
1634	,	O
1634	the	O
1634	non	O
1634	-	O
1634	Jewish	O
1634	European	O
1634	N370S	O
1634	chromosomes	O
1634	had	O
1634	greater	O
1634	haplotype	O
1634	diversity	O
1634	and	O
1634	less	O
1634	LD	O
1634	at	O
1634	the	O
1634	markers	O
1634	flanking	O
1634	the	O
1634	conserved	O
1634	haplotype	O
1634	than	O
1634	did	O
1634	the	O
1634	AJ	O
1634	N370S	O
1634	chromosomes	O
1634	.	O
1635	This	O
1635	finding	O
1635	is	O
1635	consistent	O
1635	with	O
1635	the	O
1635	presence	O
1635	of	O
1635	the	O
1635	N370S	O
1635	mutation	O
1635	in	O
1635	the	O
1635	non	O
1635	-	O
1635	Jewish	O
1635	European	O
1635	population	O
1635	prior	O
1635	to	O
1635	the	O
1635	founding	O
1635	of	O
1635	the	O
1635	AJ	O
1635	population	O
1635	.	O
1636	Coalescence	O
1636	analyses	O
1636	for	O
1636	the	O
1636	N370S	O
1636	and	O
1636	84GG	O
1636	mutations	O
1636	estimated	O
1636	similar	O
1636	coalescence	O
1636	times	O
1636	,	O
1636	of	O
1636	48	O
1636	and	O
1636	55	O
1636	.	O
1636	5	O
1636	generations	O
1636	ago	O
1636	,	O
1636	respectively	O
1636	.	O
1637	The	O
1637	results	O
1637	of	O
1637	these	O
1637	studies	O
1637	are	O
1637	consistent	O
1637	with	O
1637	a	O
1637	significant	O
1637	bottleneck	O
1637	occurring	O
1637	in	O
1637	the	O
1637	AJ	O
1637	population	O
1637	during	O
1637	the	O
1637	first	O
1637	millennium	O
1637	,	O
1637	when	O
1637	the	O
1637	population	O
1637	became	O
1637	established	O
1637	in	O
1637	Europe	O
1637	.	O
1638	HLA	O
1638	B27	O
1638	and	O
1638	the	O
1638	genetics	O
1638	of	O
1638	ankylosing	B-Disease
1638	spondylitis	I-Disease
1638	.	O
1639	One	O
1639	hundred	O
1639	and	O
1639	twenty	O
1639	-	O
1639	eight	O
1639	of	O
1639	145	O
1639	patients	O
1639	with	O
1639	ankylosing	B-Disease
1639	spondylitis	I-Disease
1639	(	O
1639	AS	B-Disease
1639	)	O
1639	were	O
1639	found	O
1639	to	O
1639	be	O
1639	HLA	O
1639	B27	O
1639	positive	O
1639	.	O
1640	Five	O
1640	patients	O
1640	had	O
1640	evidence	O
1640	of	O
1640	a	O
1640	sero	O
1640	-	O
1640	negative	O
1640	peripheral	B-Disease
1640	arthritis	I-Disease
1640	resembling	O
1640	peripheral	B-Disease
1640	psoriatic	I-Disease
1640	arthritis	I-Disease
1640	and	O
1640	3	O
1640	of	O
1640	these	O
1640	were	O
1640	B27	O
1640	negative	O
1640	.	O
1641	One	O
1641	further	O
1641	B27	O
1641	negative	O
1641	patients	O
1641	had	O
1641	a	O
1641	sister	O
1641	with	O
1641	ankylosing	B-Disease
1641	spondylitis	I-Disease
1641	and	O
1641	ulcerative	B-Disease
1641	colitis	I-Disease
1641	and	O
1641	a	O
1641	mother	O
1641	with	O
1641	ulcerative	B-Disease
1641	colitis	I-Disease
1641	.	O
1642	There	O
1642	was	O
1642	evidence	O
1642	of	O
1642	a	O
1642	somewhat	O
1642	later	O
1642	age	O
1642	of	O
1642	onset	O
1642	of	O
1642	symptoms	O
1642	in	O
1642	B27	O
1642	negative	O
1642	patients	O
1642	.	O
1643	These	O
1643	findings	O
1643	are	O
1643	interpreted	O
1643	as	O
1643	suggesting	O
1643	some	O
1643	degree	O
1643	of	O
1643	clinical	O
1643	and	O
1643	genetic	O
1643	heterogeneity	O
1643	in	O
1643	ankylosing	B-Disease
1643	spondylitis	I-Disease
1643	with	O
1643	genes	O
1643	for	O
1643	psoriasis	B-Disease
1643	and	O
1643	inflammatory	B-Disease
1643	bowel	I-Disease
1643	disease	I-Disease
1643	being	O
1643	important	O
1643	in	O
1643	some	O
1643	individuals	O
1643	,	O
1643	particularly	O
1643	those	O
1643	who	O
1643	are	O
1643	B27	O
1643	negative	O
1643	.	O
1644	Twenty	O
1644	-	O
1644	five	O
1644	first	O
1644	-	O
1644	degree	O
1644	relatives	O
1644	with	O
1644	ankylosing	B-Disease
1644	spondylitis	I-Disease
1644	were	O
1644	all	O
1644	B27	O
1644	positive	O
1644	.	O
1645	The	O
1645	only	O
1645	instance	O
1645	of	O
1645	disassociation	O
1645	of	O
1645	B27	O
1645	and	O
1645	spondylitis	B-Disease
1645	in	O
1645	a	O
1645	family	O
1645	was	O
1645	where	O
1645	the	O
1645	proband	O
1645	had	O
1645	ulcerative	B-Disease
1645	colitis	I-Disease
1645	as	O
1645	well	O
1645	as	O
1645	spondylitis	B-Disease
1645	.	O
1646	Of	O
1646	13	O
1646	B27	O
1646	positive	O
1646	fathers	O
1646	3	O
1646	could	O
1646	be	O
1646	diagnosed	O
1646	as	O
1646	having	O
1646	definite	O
1646	ankylosing	B-Disease
1646	spondylitis	I-Disease
1646	(	O
1646	23	O
1646	%	O
1646	)	O
1646	.	O
1647	These	O
1647	findings	O
1647	are	O
1647	thought	O
1647	to	O
1647	provide	O
1647	evidence	O
1647	against	O
1647	the	O
1647	concept	O
1647	that	O
1647	the	O
1647	gene	O
1647	for	O
1647	ankylosing	B-Disease
1647	spondylitis	I-Disease
1647	is	O
1647	not	O
1647	B27	O
1647	but	O
1647	a	O
1647	closely	O
1647	linked	O
1647	gene	O
1647	and	O
1647	favour	O
1647	the	O
1647	occurrence	O
1647	of	O
1647	an	O
1647	environmental	O
1647	event	O
1647	affecting	O
1647	approximately	O
1647	one	O
1647	-	O
1647	fifth	O
1647	of	O
1647	B27	O
1647	positive	O
1647	males	O
1647	to	O
1647	result	O
1647	in	O
1647	disease	O
1647	.	O
1647	.	O
1648	Founder	O
1648	mutations	O
1648	in	O
1648	the	O
1648	BRCA1	O
1648	gene	O
1648	in	O
1648	Polish	O
1648	families	O
1648	with	O
1648	breast	B-Disease
1648	-	I-Disease
1648	ovarian	I-Disease
1648	cancer	I-Disease
1648	.	O
1649	We	O
1649	have	O
1649	undertaken	O
1649	a	O
1649	hospital	O
1649	-	O
1649	based	O
1649	study	O
1649	,	O
1649	to	O
1649	identify	O
1649	possible	O
1649	BRCA1	O
1649	and	O
1649	BRCA2	O
1649	founder	O
1649	mutations	O
1649	in	O
1649	the	O
1649	Polish	O
1649	population	O
1649	.	O
1650	The	O
1650	study	O
1650	group	O
1650	consisted	O
1650	of	O
1650	66	O
1650	Polish	O
1650	families	O
1650	with	O
1650	cancer	B-Disease
1650	who	O
1650	have	O
1650	at	O
1650	least	O
1650	three	O
1650	related	O
1650	females	O
1650	affected	O
1650	with	O
1650	breast	B-Disease
1650	or	I-Disease
1650	ovarian	I-Disease
1650	cancer	I-Disease
1650	and	O
1650	who	O
1650	had	O
1650	cancer	B-Disease
1650	diagnosed	O
1650	,	O
1650	in	O
1650	at	O
1650	least	O
1650	one	O
1650	of	O
1650	the	O
1650	three	O
1650	affected	O
1650	females	O
1650	,	O
1650	at	O
1650	age	O
1650	<	O
1650	50	O
1650	years	O
1650	.	O
1651	A	O
1651	total	O
1651	of	O
1651	26	O
1651	families	O
1651	had	O
1651	both	O
1651	breast	B-Disease
1651	and	I-Disease
1651	ovarian	I-Disease
1651	cancers	I-Disease
1651	,	O
1651	4	O
1651	families	O
1651	had	O
1651	ovarian	B-Disease
1651	cancers	I-Disease
1651	only	O
1651	,	O
1651	and	O
1651	36	O
1651	families	O
1651	had	O
1651	breast	B-Disease
1651	cancers	I-Disease
1651	only	O
1651	.	O
1652	Genomic	O
1652	DNA	O
1652	was	O
1652	prepared	O
1652	from	O
1652	the	O
1652	peripheral	O
1652	blood	O
1652	leukocytes	O
1652	of	O
1652	at	O
1652	least	O
1652	one	O
1652	affected	O
1652	woman	O
1652	from	O
1652	each	O
1652	family	O
1652	.	O
1653	The	O
1653	entire	O
1653	coding	O
1653	region	O
1653	of	O
1653	BRCA1	O
1653	and	O
1653	BRCA2	O
1653	was	O
1653	screened	O
1653	for	O
1653	the	O
1653	presence	O
1653	of	O
1653	germline	O
1653	mutations	O
1653	,	O
1653	by	O
1653	use	O
1653	of	O
1653	SSCP	O
1653	followed	O
1653	by	O
1653	direct	O
1653	sequencing	O
1653	of	O
1653	observed	O
1653	variants	O
1653	.	O
1654	Mutations	O
1654	were	O
1654	found	O
1654	in	O
1654	35	O
1654	(	O
1654	53	O
1654	%	O
1654	)	O
1654	of	O
1654	the	O
1654	66	O
1654	families	O
1654	studied	O
1654	.	O
1655	All	O
1655	but	O
1655	one	O
1655	of	O
1655	the	O
1655	mutations	O
1655	were	O
1655	detected	O
1655	within	O
1655	the	O
1655	BRCA1	O
1655	gene	O
1655	.	O
1656	BRCA1	B-Disease
1656	abnormalities	I-Disease
1656	were	O
1656	identified	O
1656	in	O
1656	all	O
1656	four	O
1656	families	O
1656	with	O
1656	ovarian	B-Disease
1656	cancer	I-Disease
1656	only	O
1656	,	O
1656	in	O
1656	67	O
1656	%	O
1656	of	O
1656	27	O
1656	families	O
1656	with	O
1656	both	O
1656	breast	B-Disease
1656	and	I-Disease
1656	ovarian	I-Disease
1656	cancer	I-Disease
1656	,	O
1656	and	O
1656	in	O
1656	34	O
1656	%	O
1656	of	O
1656	35	O
1656	families	O
1656	with	O
1656	breast	B-Disease
1656	cancer	I-Disease
1656	only	O
1656	.	O
1657	The	O
1657	single	O
1657	family	O
1657	with	O
1657	a	O
1657	BRCA2	O
1657	mutation	O
1657	had	O
1657	the	O
1657	breast	B-Disease
1657	-	I-Disease
1657	ovarian	I-Disease
1657	cancer	I-Disease
1657	syndrome	I-Disease
1657	.	O
1658	Seven	O
1658	distinct	O
1658	mutations	O
1658	were	O
1658	identified	O
1658	;	O
1658	five	O
1658	of	O
1658	these	O
1658	occurred	O
1658	in	O
1658	two	O
1658	or	O
1658	more	O
1658	families	O
1658	.	O
1659	In	O
1659	total	O
1659	,	O
1659	recurrent	O
1659	mutations	O
1659	were	O
1659	found	O
1659	in	O
1659	33	O
1659	(	O
1659	94	O
1659	%	O
1659	)	O
1659	of	O
1659	the	O
1659	35	O
1659	families	O
1659	with	O
1659	detected	O
1659	mutations	O
1659	.	O
1660	Three	O
1660	BRCA1	B-Disease
1660	abnormalities	I-Disease
1660	-	O
1660	5382insC	O
1660	,	O
1660	C61G	O
1660	,	O
1660	and	O
1660	4153delA	O
1660	-	O
1660	accounted	O
1660	for	O
1660	51	O
1660	%	O
1660	,	O
1660	20	O
1660	%	O
1660	,	O
1660	and	O
1660	11	O
1660	%	O
1660	of	O
1660	the	O
1660	identified	O
1660	mutations	O
1660	,	O
1660	respectively	O
1660	.	O
1660	.	O
1661	Molecular	O
1661	basis	O
1661	of	O
1661	very	B-Disease
1661	long	I-Disease
1661	chain	I-Disease
1661	acyl	I-Disease
1661	-	I-Disease
1661	CoA	I-Disease
1661	dehydrogenase	I-Disease
1661	deficiency	I-Disease
1661	in	O
1661	three	O
1661	Israeli	O
1661	patients	O
1661	:	O
1661	identification	O
1661	of	O
1661	a	O
1661	complex	O
1661	mutant	O
1661	allele	O
1661	with	O
1661	P65L	O
1661	and	O
1661	K247Q	O
1661	mutations	O
1661	,	O
1661	the	O
1661	former	O
1661	being	O
1661	an	O
1661	exonic	O
1661	mutation	O
1661	causing	O
1661	exon	O
1661	3	O
1661	skipping	O
1661	.	O
1662	Very	B-Disease
1662	long	I-Disease
1662	chain	I-Disease
1662	acyl	I-Disease
1662	-	I-Disease
1662	CoA	I-Disease
1662	dehydrogenase	I-Disease
1662	(	I-Disease
1662	VLCAD	I-Disease
1662	)	I-Disease
1662	deficiency	I-Disease
1662	is	O
1662	a	O
1662	life	O
1662	-	O
1662	threatening	O
1662	disorder	O
1662	of	O
1662	mitochondrial	O
1662	fatty	O
1662	acid	O
1662	beta	O
1662	-	O
1662	oxidation	O
1662	.	O
1663	We	O
1663	identified	O
1663	four	O
1663	novel	O
1663	mutations	O
1663	in	O
1663	three	O
1663	unrelated	O
1663	patients	O
1663	.	O
1664	All	O
1664	patients	O
1664	had	O
1664	the	O
1664	severe	O
1664	childhood	O
1664	form	O
1664	of	O
1664	VLCAD	B-Disease
1664	deficiency	I-Disease
1664	with	O
1664	early	O
1664	onset	O
1664	and	O
1664	high	O
1664	mortality	O
1664	.	O
1665	Immunoblot	O
1665	analysis	O
1665	revealed	O
1665	that	O
1665	VLCAD	O
1665	protein	O
1665	was	O
1665	undetectable	O
1665	in	O
1665	patients	O
1665	2	O
1665	and	O
1665	3	O
1665	,	O
1665	whereas	O
1665	normal	O
1665	-	O
1665	size	O
1665	VLCAD	O
1665	protein	O
1665	and	O
1665	an	O
1665	aberrant	O
1665	form	O
1665	of	O
1665	VLCAD	O
1665	(	O
1665	4kDa	O
1665	smaller	O
1665	)	O
1665	were	O
1665	detected	O
1665	in	O
1665	patient	O
1665	1	O
1665	.	O
1666	As	O
1666	expected	O
1666	,	O
1666	mutations	O
1666	were	O
1666	found	O
1666	in	O
1666	patients	O
1666	2	O
1666	and	O
1666	3	O
1666	patient	O
1666	2	O
1666	is	O
1666	homozygous	O
1666	for	O
1666	a	O
1666	frameshift	O
1666	mutation	O
1666	,	O
1666	del	O
1666	4	O
1666	bp	O
1666	at	O
1666	798	O
1666	-	O
1666	801	O
1666	,	O
1666	and	O
1666	patient	O
1666	3	O
1666	is	O
1666	homozygous	O
1666	for	O
1666	a	O
1666	nonsense	O
1666	mutation	O
1666	65C	O
1666	>	O
1666	A	O
1666	(	O
1666	S22X	O
1666	)	O
1666	.	O
1667	Patient	O
1667	1	O
1667	was	O
1667	homozygous	O
1667	for	O
1667	a	O
1667	complex	O
1667	mutant	O
1667	allele	O
1667	containing	O
1667	two	O
1667	alterations	O
1667	,	O
1667	including	O
1667	a	O
1667	194C	O
1667	>	O
1667	T	O
1667	transition	O
1667	(	O
1667	P65L	O
1667	)	O
1667	and	O
1667	739A	O
1667	>	O
1667	C	O
1667	transversion	O
1667	(	O
1667	K247Q	O
1667	)	O
1667	;	O
1667	in	O
1667	the	O
1667	case	O
1667	of	O
1667	P65L	O
1667	,	O
1667	the	O
1667	amino	O
1667	acid	O
1667	change	O
1667	does	O
1667	not	O
1667	reduce	O
1667	enzyme	O
1667	activity	O
1667	.	O
1668	However	O
1668	,	O
1668	the	O
1668	nucleotide	O
1668	change	O
1668	resulted	O
1668	in	O
1668	exon	O
1668	3	O
1668	skipping	O
1668	,	O
1668	whereas	O
1668	the	O
1668	latter	O
1668	K247Q	O
1668	mutation	O
1668	had	O
1668	a	O
1668	drastic	O
1668	effect	O
1668	on	O
1668	enzyme	O
1668	activity	O
1668	.	O
1669	We	O
1669	verified	O
1669	these	O
1669	events	O
1669	by	O
1669	in	O
1669	vivo	O
1669	splicing	O
1669	experiments	O
1669	and	O
1669	transient	O
1669	expression	O
1669	analysis	O
1669	of	O
1669	mutant	O
1669	cDNAs	O
1669	.	O
1670	The	O
1670	P65L	O
1670	mutation	O
1670	locates	O
1670	11	O
1670	bases	O
1670	upstream	O
1670	of	O
1670	a	O
1670	splice	O
1670	donor	O
1670	site	O
1670	of	O
1670	intron	O
1670	3	O
1670	.	O
1671	This	O
1671	is	O
1671	an	O
1671	example	O
1671	of	O
1671	an	O
1671	exonic	O
1671	mutation	O
1671	which	O
1671	affects	O
1671	exon	O
1671	-	O
1671	splicing	O
1671	.	O
1671	.	O
1672	Submicroscopic	O
1672	deletion	O
1672	in	O
1672	cousins	O
1672	with	O
1672	Prader	B-Disease
1672	-	I-Disease
1672	Willi	I-Disease
1672	syndrome	I-Disease
1672	causes	O
1672	a	O
1672	grandmatrilineal	O
1672	inheritance	O
1672	pattern	O
1672	:	O
1672	effects	O
1672	of	O
1672	imprinting	O
1672	.	O
1673	The	O
1673	Prader	B-Disease
1673	-	I-Disease
1673	Willi	I-Disease
1673	syndrome	I-Disease
1673	(	O
1673	PWS	B-Disease
1673	)	O
1673	critical	O
1673	region	O
1673	on	O
1673	15q11	O
1673	-	O
1673	q13	O
1673	is	O
1673	subject	O
1673	to	O
1673	imprinting	O
1673	.	O
1674	PWS	B-Disease
1674	becomes	O
1674	apparent	O
1674	when	O
1674	genes	O
1674	on	O
1674	the	O
1674	paternally	O
1674	inherited	O
1674	chromosome	O
1674	are	O
1674	not	O
1674	expressed	O
1674	.	O
1675	Familial	B-Disease
1675	PWS	I-Disease
1675	is	O
1675	rare	O
1675	.	O
1676	We	O
1676	report	O
1676	on	O
1676	a	O
1676	family	O
1676	in	O
1676	which	O
1676	a	O
1676	male	O
1676	and	O
1676	a	O
1676	female	O
1676	paternal	O
1676	first	O
1676	cousin	O
1676	both	O
1676	have	O
1676	PWS	B-Disease
1676	with	O
1676	cytogenetically	O
1676	normal	O
1676	karyotypes	O
1676	.	O
1677	Fluorescence	O
1677	in	O
1677	situ	O
1677	hybridization	O
1677	(	O
1677	FISH	O
1677	)	O
1677	analysis	O
1677	shows	O
1677	a	O
1677	submicroscopic	O
1677	deletion	O
1677	of	O
1677	SNRPN	O
1677	,	O
1677	but	O
1677	not	O
1677	the	O
1677	closely	O
1677	associated	O
1677	loci	O
1677	D15S10	O
1677	,	O
1677	D15S11	O
1677	,	O
1677	D15S63	O
1677	,	O
1677	and	O
1677	GABRB3	O
1677	.	O
1678	The	O
1678	cousins	O
1678	fathers	O
1678	and	O
1678	two	O
1678	paternal	O
1678	aunts	O
1678	have	O
1678	the	O
1678	same	O
1678	deletion	O
1678	and	O
1678	are	O
1678	clinically	O
1678	normal	O
1678	.	O
1679	The	O
1679	grandmother	O
1679	of	O
1679	the	O
1679	cousins	O
1679	is	O
1679	deceased	O
1679	and	O
1679	not	O
1679	available	O
1679	for	O
1679	study	O
1679	,	O
1679	and	O
1679	their	O
1679	grandfather	O
1679	is	O
1679	not	O
1679	deleted	O
1679	for	O
1679	SNRPN	O
1679	.	O
1680	DNA	O
1680	methylation	O
1680	analysis	O
1680	of	O
1680	D15S63	O
1680	is	O
1680	consistent	O
1680	with	O
1680	an	O
1680	abnormality	O
1680	of	O
1680	the	O
1680	imprinting	O
1680	center	O
1680	associated	O
1680	with	O
1680	PWS	B-Disease
1680	.	O
1681	"	NN	O	O
1681	Grandmatrilineal	NN	O	O
1681	"	O
1681	inheritance	O
1681	occurs	O
1681	when	O
1681	a	O
1681	woman	O
1681	with	O
1681	deletion	O
1681	of	O
1681	an	O
1681	imprinted	O
1681	,	O
1681	paternally	O
1681	expressed	O
1681	gene	O
1681	is	O
1681	at	O
1681	risk	O
1681	of	O
1681	having	O
1681	affected	O
1681	grandchildren	O
1681	through	O
1681	her	O
1681	sons	O
1681	.	O
1682	In	O
1682	this	O
1682	case	O
1682	,	O
1682	PWS	B-Disease
1682	does	O
1682	not	O
1682	become	O
1682	evident	O
1682	as	O
1682	long	O
1682	as	O
1682	the	O
1682	deletion	O
1682	is	O
1682	passed	O
1682	through	O
1682	the	O
1682	matrilineal	O
1682	line	O
1682	.	O
1683	This	O
1683	represents	O
1683	a	O
1683	unique	O
1683	inheritance	O
1683	pattern	O
1683	due	O
1683	to	O
1683	imprinting	O
1683	.	O
1683	.	O
1684	Human	O
1684	glycine	O
1684	decarboxylase	O
1684	gene	O
1684	(	O
1684	GLDC	O
1684	)	O
1684	and	O
1684	its	O
1684	highly	O
1684	conserved	O
1684	processed	O
1684	pseudogene	O
1684	(	O
1684	psiGLDC	O
1684	)	O
1684	:	O
1684	their	O
1684	structure	O
1684	and	O
1684	expression	O
1684	,	O
1684	and	O
1684	the	O
1684	identification	O
1684	of	O
1684	a	O
1684	large	O
1684	deletion	O
1684	in	O
1684	a	O
1684	family	O
1684	with	O
1684	nonketotic	B-Disease
1684	hyperglycinemia	I-Disease
1684	.	O
1685	Mutations	O
1685	in	O
1685	the	O
1685	glycine	O
1685	decarboxylase	O
1685	gene	O
1685	(	O
1685	GLDC	O
1685	)	O
1685	cause	O
1685	nonketotic	B-Disease
1685	hyperglycinemia	I-Disease
1685	(	O
1685	NKH	B-Disease
1685	)	O
1685	,	O
1685	an	O
1685	in	B-Disease
1685	-	I-Disease
1685	born	I-Disease
1685	error	I-Disease
1685	of	I-Disease
1685	metabolism	I-Disease
1685	characterized	O
1685	by	O
1685	severe	O
1685	neurological	B-Disease
1685	disturbance	I-Disease
1685	.	O
1686	We	O
1686	have	O
1686	determined	O
1686	the	O
1686	structure	O
1686	of	O
1686	GLDC	O
1686	and	O
1686	of	O
1686	its	O
1686	pseudogene	O
1686	(	O
1686	psiGLDC	O
1686	)	O
1686	and	O
1686	studied	O
1686	their	O
1686	expression	O
1686	for	O
1686	a	O
1686	molecular	O
1686	analysis	O
1686	of	O
1686	NKH	B-Disease
1686	.	O
1687	The	O
1687	GLDC	O
1687	gene	O
1687	spans	O
1687	at	O
1687	least	O
1687	135	O
1687	kb	O
1687	and	O
1687	consists	O
1687	of	O
1687	25	O
1687	exons	O
1687	.	O
1688	All	O
1688	donor	O
1688	and	O
1688	acceptor	O
1688	sites	O
1688	adhere	O
1688	to	O
1688	the	O
1688	canonical	O
1688	GT	O
1688	-	O
1688	AG	O
1688	rule	O
1688	,	O
1688	except	O
1688	for	O
1688	the	O
1688	donor	O
1688	site	O
1688	of	O
1688	intron	O
1688	21	O
1688	,	O
1688	where	O
1688	a	O
1688	variant	O
1688	form	O
1688	GC	O
1688	is	O
1688	used	O
1688	instead	O
1688	of	O
1688	GT	O
1688	.	O
1689	The	O
1689	transcription	O
1689	initiation	O
1689	site	O
1689	has	O
1689	been	O
1689	assigned	O
1689	to	O
1689	a	O
1689	residue	O
1689	163	O
1689	bp	O
1689	upstream	O
1689	from	O
1689	the	O
1689	translation	O
1689	initiation	O
1689	triplet	O
1689	by	O
1689	primer	O
1689	extension	O
1689	analysis	O
1689	.	O
1690	The	O
1690	psiGLDC	O
1690	gene	O
1690	has	O
1690	no	O
1690	intron	O
1690	and	O
1690	shares	O
1690	97	O
1690	.	O
1691	5	O
1691	%	O
1691	homology	O
1691	with	O
1691	the	O
1691	coding	O
1691	region	O
1691	of	O
1691	functional	O
1691	GLDC	O
1691	,	O
1691	suggesting	O
1691	that	O
1691	psiGLDC	O
1691	is	O
1691	a	O
1691	processed	O
1691	pseudogene	O
1691	that	O
1691	arose	O
1691	from	O
1691	the	O
1691	GLDC	O
1691	transcript	O
1691	about	O
1691	4	O
1691	-	O
1691	8	O
1691	million	O
1691	years	O
1691	ago	O
1691	.	O
1692	RNA	O
1692	blotting	O
1692	analysis	O
1692	has	O
1692	revealed	O
1692	that	O
1692	GLDC	O
1692	is	O
1692	expressed	O
1692	in	O
1692	human	O
1692	liver	O
1692	,	O
1692	kidney	O
1692	,	O
1692	brain	O
1692	,	O
1692	and	O
1692	placenta	O
1692	.	O
1693	We	O
1693	have	O
1693	also	O
1693	examined	O
1693	a	O
1693	patient	O
1693	with	O
1693	NKH	B-Disease
1693	with	O
1693	no	O
1693	detectable	O
1693	GLDC	O
1693	mRNA	O
1693	in	O
1693	his	O
1693	lymphoblasts	O
1693	.	O
1694	Exons	O
1694	1	O
1694	-	O
1694	3	O
1694	of	O
1694	the	O
1694	functional	O
1694	GLDC	O
1694	gene	O
1694	from	O
1694	this	O
1694	patient	O
1694	are	O
1694	not	O
1694	amplified	O
1694	by	O
1694	polymerase	O
1694	chain	O
1694	reaction	O
1694	(	O
1694	PCR	O
1694	)	O
1694	,	O
1694	whereas	O
1694	those	O
1694	from	O
1694	control	O
1694	subjects	O
1694	are	O
1694	.	O
1695	These	O
1695	results	O
1695	suggest	O
1695	a	O
1695	large	O
1695	homozygous	O
1695	deletion	O
1695	(	O
1695	at	O
1695	least	O
1695	30	O
1695	kb	O
1695	)	O
1695	in	O
1695	the	O
1695	patient	O
1695	.	O
1696	Furthermore	O
1696	,	O
1696	we	O
1696	have	O
1696	devised	O
1696	a	O
1696	semi	O
1696	-	O
1696	quantitative	O
1696	PCR	O
1696	to	O
1696	estimate	O
1696	the	O
1696	number	O
1696	of	O
1696	GLDC	O
1696	alleles	O
1696	by	O
1696	using	O
1696	psiGLDC	O
1696	as	O
1696	an	O
1696	internal	O
1696	control	O
1696	and	O
1696	have	O
1696	confirmed	O
1696	the	O
1696	homozygosity	O
1696	and	O
1696	heterozygosity	O
1696	of	O
1696	the	O
1696	deletion	O
1696	in	O
1696	the	O
1696	patient	O
1696	and	O
1696	his	O
1696	parents	O
1696	,	O
1696	respectively	O
1696	.	O
1697	Structural	O
1697	information	O
1697	of	O
1697	GLDC	O
1697	and	O
1697	psiGLDC	O
1697	should	O
1697	facilitate	O
1697	the	O
1697	molecular	O
1697	analysis	O
1697	of	O
1697	NKH	B-Disease
1697	.	O
1698	De	O
1698	novo	O
1698	deletions	O
1698	of	O
1698	SNRPN	O
1698	exon	O
1698	1	O
1698	in	O
1698	early	O
1698	human	O
1698	and	O
1698	mouse	O
1698	embryos	O
1698	result	O
1698	in	O
1698	a	O
1698	paternal	O
1698	to	O
1698	maternal	O
1698	imprint	O
1698	switch	O
1698	.	O
1699	Prader	B-Disease
1699	-	I-Disease
1699	Willi	I-Disease
1699	syndrome	I-Disease
1699	(	O
1699	PWS	B-Disease
1699	)	O
1699	is	O
1699	a	O
1699	neurogenetic	B-Disease
1699	disease	I-Disease
1699	characterized	O
1699	by	O
1699	infantile	B-Disease
1699	hypotonia	I-Disease
1699	,	O
1699	gonadal	B-Disease
1699	hypoplasia	I-Disease
1699	,	O
1699	obsessive	O
1699	behaviour	O
1699	and	O
1699	neonatal	O
1699	feeding	O
1699	difficulties	O
1699	followed	O
1699	by	O
1699	hyperphagia	B-Disease
1699	,	O
1699	leading	O
1699	to	O
1699	profound	O
1699	obesity	B-Disease
1699	.	O
1700	PWS	B-Disease
1700	is	O
1700	due	O
1700	to	O
1700	a	O
1700	lack	O
1700	of	O
1700	paternal	O
1700	genetic	O
1700	information	O
1700	at	O
1700	15q11	O
1700	-	O
1700	q13	O
1700	(	O
1700	ref	O
1700	.	O
1700	2	O
1700	)	O
1700	.	O
1701	Five	O
1701	imprinted	O
1701	,	O
1701	paternally	O
1701	expressed	O
1701	genes	O
1701	map	O
1701	to	O
1701	the	O
1701	PWS	B-Disease
1701	region	O
1701	,	O
1701	MKRN3	O
1701	(	O
1701	ref	O
1701	.	O
1701	3	O
1701	)	O
1701	,	O
1701	NDN	O
1701	(	O
1701	ref	O
1701	.	O
1701	4	O
1701	)	O
1701	,	O
1701	NDNL1	O
1701	(	O
1701	ref	O
1701	.	O
1701	5	O
1701	)	O
1701	,	O
1701	SNRPN	O
1701	(	O
1701	refs	O
1701	6	O
1701	-	O
1701	8	O
1701	)	O
1701	and	O
1701	IPW	O
1701	(	O
1701	ref	O
1701	.	O
1701	9	O
1701	)	O
1701	,	O
1701	as	O
1701	well	O
1701	as	O
1701	two	O
1701	poorly	O
1701	characterized	O
1701	framents	O
1701	designated	O
1701	PAR	O
1701	-	O
1701	1	O
1701	and	O
1701	PAR	O
1701	-	O
1701	5	O
1701	(	O
1701	ref	O
1701	.	O
1701	10	O
1701	)	O
1701	.	O
1702	Imprinting	O
1702	of	O
1702	this	O
1702	region	O
1702	involves	O
1702	a	O
1702	bipartite	O
1702	imprinting	O
1702	centre	O
1702	(	O
1702	IC	O
1702	)	O
1702	,	O
1702	which	O
1702	overlaps	O
1702	SNRPN	O
1702	(	O
1702	refs	O
1702	10	O
1702	,	O
1702	11	O
1702	)	O
1702	.	O
1703	Deletion	O
1703	of	O
1703	the	O
1703	SNRPN	O
1703	promoter	O
1703	/	O
1703	exon	O
1703	1	O
1703	region	O
1703	(	O
1703	the	O
1703	PWS	B-Disease
1703	IC	O
1703	element	O
1703	)	O
1703	appears	O
1703	to	O
1703	impair	O
1703	the	O
1703	establishment	O
1703	of	O
1703	the	O
1703	paternal	O
1703	imprint	O
1703	in	O
1703	the	O
1703	male	O
1703	germ	O
1703	line	O
1703	and	O
1703	leads	O
1703	to	O
1703	PWS	B-Disease
1703	.	O
1704	Here	O
1704	we	O
1704	report	O
1704	a	O
1704	PWS	B-Disease
1704	family	O
1704	in	O
1704	which	O
1704	the	O
1704	father	O
1704	is	O
1704	mosaic	O
1704	for	O
1704	an	O
1704	IC	O
1704	deletion	O
1704	on	O
1704	his	O
1704	paternal	O
1704	chromosome	O
1704	.	O
1705	The	O
1705	deletion	O
1705	chromosome	O
1705	has	O
1705	acquired	O
1705	a	O
1705	maternal	O
1705	methylation	O
1705	imprint	O
1705	in	O
1705	his	O
1705	somatic	O
1705	cells	O
1705	.	O
1706	We	O
1706	have	O
1706	made	O
1706	identical	O
1706	findings	O
1706	in	O
1706	chimaeric	O
1706	mice	O
1706	generated	O
1706	from	O
1706	two	O
1706	independent	O
1706	embryonic	O
1706	stem	O
1706	(	O
1706	ES	O
1706	)	O
1706	cell	O
1706	lines	O
1706	harbouring	O
1706	a	O
1706	similar	O
1706	deletion	O
1706	.	O
1707	Our	O
1707	studies	O
1707	demonstrate	O
1707	that	O
1707	the	O
1707	PWS	B-Disease
1707	IC	O
1707	element	O
1707	is	O
1707	not	O
1707	only	O
1707	required	O
1707	for	O
1707	the	O
1707	establishment	O
1707	of	O
1707	the	O
1707	paternal	O
1707	imprint	O
1707	,	O
1707	but	O
1707	also	O
1707	for	O
1707	its	O
1707	postzygotic	O
1707	maintenance	O
1707	.	O
1707	.	O
1708	Mice	O
1708	deficient	B-Disease
1708	in	I-Disease
1708	Six5	I-Disease
1708	develop	O
1708	cataracts	B-Disease
1708	:	O
1708	implications	O
1708	for	O
1708	myotonic	B-Disease
1708	dystrophy	I-Disease
1708	.	O
1709	Expansion	O
1709	of	O
1709	a	O
1709	CTG	O
1709	trinucleotide	O
1709	repeat	O
1709	in	O
1709	the	O
1709	3	O
1709	UTR	O
1709	of	O
1709	the	O
1709	gene	O
1709	DMPK	O
1709	at	O
1709	the	O
1709	DM1	O
1709	locus	O
1709	on	O
1709	chromosome	O
1709	19	O
1709	causes	O
1709	myotonic	B-Disease
1709	dystrophy	I-Disease
1709	,	O
1709	a	O
1709	dominantly	B-Disease
1709	inherited	I-Disease
1709	disease	I-Disease
1709	characterized	O
1709	by	O
1709	skeletal	O
1709	muscle	B-Disease
1709	dystrophy	I-Disease
1709	and	O
1709	myotonia	B-Disease
1709	,	O
1709	cataracts	B-Disease
1709	and	O
1709	cardiac	B-Disease
1709	conduction	I-Disease
1709	defects	I-Disease
1709	.	O
1710	Targeted	O
1710	deletion	O
1710	of	O
1710	Dm15	O
1710	,	O
1710	the	O
1710	mouse	O
1710	orthologue	O
1710	of	O
1710	human	O
1710	DMPK	O
1710	,	O
1710	produced	O
1710	mice	O
1710	with	O
1710	a	O
1710	mild	O
1710	myopathy	B-Disease
1710	and	O
1710	cardiac	B-Disease
1710	conduction	I-Disease
1710	abnormalities	I-Disease
1710	,	O
1710	but	O
1710	without	O
1710	other	O
1710	features	O
1710	of	O
1710	myotonic	B-Disease
1710	dystrophy	I-Disease
1710	,	O
1710	such	O
1710	as	O
1710	myotonia	B-Disease
1710	and	O
1710	cataracts	B-Disease
1710	.	O
1711	We	O
1711	,	O
1711	and	O
1711	others	O
1711	,	O
1711	have	O
1711	demonstrated	O
1711	that	O
1711	repeat	O
1711	expansion	O
1711	decreases	O
1711	expression	O
1711	of	O
1711	the	O
1711	adjacent	O
1711	gene	O
1711	SIX5	O
1711	(	O
1711	refs	O
1711	7	O
1711	,	O
1711	8	O
1711	)	O
1711	,	O
1711	which	O
1711	encodes	O
1711	a	O
1711	homeodomain	O
1711	transcription	O
1711	factor	O
1711	.	O
1712	To	O
1712	determine	O
1712	whether	O
1712	SIX5	B-Disease
1712	deficiency	I-Disease
1712	contributes	O
1712	to	O
1712	the	O
1712	myotonic	B-Disease
1712	dystrophy	I-Disease
1712	phenotype	O
1712	,	O
1712	we	O
1712	disrupted	O
1712	mouse	O
1712	Six5	O
1712	by	O
1712	replacing	O
1712	the	O
1712	first	O
1712	exon	O
1712	with	O
1712	a	O
1712	beta	O
1712	-	O
1712	galactosidase	O
1712	reporter	O
1712	.	O
1713	Six5	O
1713	-	O
1713	mutant	O
1713	mice	O
1713	showed	O
1713	reporter	O
1713	expression	O
1713	in	O
1713	multiple	O
1713	tissues	O
1713	,	O
1713	including	O
1713	the	O
1713	developing	O
1713	lens	O
1713	.	O
1714	Homozygous	O
1714	mutant	O
1714	mice	O
1714	had	O
1714	no	O
1714	apparent	O
1714	abnormalities	B-Disease
1714	of	I-Disease
1714	skeletal	I-Disease
1714	muscle	I-Disease
1714	function	I-Disease
1714	,	O
1714	but	O
1714	developed	O
1714	lenticular	B-Disease
1714	opacities	I-Disease
1714	at	O
1714	a	O
1714	higher	O
1714	rate	O
1714	than	O
1714	controls	O
1714	.	O
1715	Our	O
1715	results	O
1715	suggest	O
1715	that	O
1715	SIX5	B-Disease
1715	deficiency	I-Disease
1715	contributes	O
1715	to	O
1715	the	O
1715	cataract	B-Disease
1715	phenotype	O
1715	in	O
1715	myotonic	B-Disease
1715	dystrophy	I-Disease
1715	,	O
1715	and	O
1715	that	O
1715	myotonic	B-Disease
1715	dystrophy	I-Disease
1715	represents	O
1715	a	O
1715	multigenic	B-Disease
1715	disorder	I-Disease
1715	.	O
1715	.	O
1716	Heterozygous	O
1716	loss	O
1716	of	O
1716	Six5	O
1716	in	O
1716	mice	O
1716	is	O
1716	sufficient	O
1716	to	O
1716	cause	O
1716	ocular	O
1716	cataracts	B-Disease
1716	.	O
1717	Myotonic	B-Disease
1717	dystrophy	I-Disease
1717	(	O
1717	DM	B-Disease
1717	)	O
1717	is	O
1717	an	O
1717	autosomal	B-Disease
1717	dominant	I-Disease
1717	disorder	I-Disease
1717	characterized	O
1717	by	O
1717	skeletal	O
1717	muscle	B-Disease
1717	wasting	I-Disease
1717	,	O
1717	myotonia	B-Disease
1717	,	O
1717	cardiac	B-Disease
1717	arrhythmia	I-Disease
1717	,	O
1717	hyperinsulinaemia	B-Disease
1717	,	O
1717	mental	B-Disease
1717	retardation	I-Disease
1717	and	O
1717	ocular	O
1717	cataracts	B-Disease
1717	.	O
1718	The	O
1718	genetic	B-Disease
1718	defect	I-Disease
1718	in	O
1718	DM	B-Disease
1718	is	O
1718	a	O
1718	CTG	O
1718	repeat	O
1718	expansion	O
1718	located	O
1718	in	O
1718	the	O
1718	3	O
1718	untranslated	O
1718	region	O
1718	of	O
1718	DMPK	O
1718	and	O
1718	5	O
1718	of	O
1718	a	O
1718	homeodomain	O
1718	-	O
1718	encoding	O
1718	gene	O
1718	,	O
1718	SIX5	O
1718	(	O
1718	formerly	O
1718	DMAHP	O
1718	;	O
1718	refs	O
1718	2	O
1718	-	O
1718	5	O
1718	)	O
1718	.	O
1719	There	O
1719	are	O
1719	three	O
1719	mechanisms	O
1719	by	O
1719	which	O
1719	CTG	O
1719	expansion	O
1719	can	O
1719	result	O
1719	in	O
1719	DM	B-Disease
1719	.	O
1720	First	O
1720	,	O
1720	repeat	O
1720	expansion	O
1720	may	O
1720	alter	O
1720	the	O
1720	processing	O
1720	or	O
1720	transport	O
1720	of	O
1720	the	O
1720	mutant	O
1720	DMPK	O
1720	mRNA	O
1720	and	O
1720	consequently	O
1720	reduce	O
1720	DMPK	O
1720	levels	O
1720	.	O
1721	Second	O
1721	,	O
1721	CTG	O
1721	expansion	O
1721	may	O
1721	establish	O
1721	a	O
1721	region	O
1721	of	O
1721	heterochromatin	O
1721	3	O
1721	of	O
1721	the	O
1721	repeat	O
1721	sequence	O
1721	and	O
1721	decrease	O
1721	SIX5	O
1721	transcription	O
1721	.	O
1722	Third	O
1722	,	O
1722	toxic	O
1722	effects	O
1722	of	O
1722	the	O
1722	repeat	O
1722	expansion	O
1722	may	O
1722	be	O
1722	intrinsic	O
1722	to	O
1722	the	O
1722	repeated	O
1722	elements	O
1722	at	O
1722	the	O
1722	level	O
1722	of	O
1722	DNA	O
1722	or	O
1722	RNA	O
1722	(	O
1722	refs	O
1722	10	O
1722	,	O
1722	11	O
1722	)	O
1722	.	O
1723	Previous	O
1723	studies	O
1723	have	O
1723	demonstrated	O
1723	that	O
1723	a	O
1723	dose	O
1723	-	O
1723	dependent	O
1723	loss	O
1723	of	O
1723	Dm15	O
1723	(	O
1723	the	O
1723	mouse	O
1723	DMPK	O
1723	homologue	O
1723	)	O
1723	in	O
1723	mice	O
1723	produces	O
1723	a	O
1723	partial	O
1723	DM	B-Disease
1723	phenotype	O
1723	characterized	O
1723	by	O
1723	decreased	O
1723	development	O
1723	of	O
1723	skeletal	O
1723	muscle	O
1723	force	O
1723	and	O
1723	cardiac	B-Disease
1723	conduction	I-Disease
1723	disorders	I-Disease
1723	.	O
1724	To	O
1724	test	O
1724	the	O
1724	role	O
1724	of	O
1724	Six5	O
1724	loss	O
1724	in	O
1724	DM	B-Disease
1724	,	O
1724	we	O
1724	have	O
1724	analysed	O
1724	a	O
1724	strain	O
1724	of	O
1724	mice	O
1724	in	O
1724	which	O
1724	Six5	O
1724	was	O
1724	deleted	O
1724	.	O
1725	Our	O
1725	results	O
1725	demonstrate	O
1725	that	O
1725	the	O
1725	rate	O
1725	and	O
1725	severity	O
1725	of	O
1725	cataract	B-Disease
1725	formation	O
1725	is	O
1725	inversely	O
1725	related	O
1725	to	O
1725	Six5	O
1725	dosage	O
1725	and	O
1725	is	O
1725	temporally	O
1725	progressive	O
1725	.	O
1726	Six5	O
1726	+	O
1726	/	O
1726	-	O
1726	and	O
1726	Six5	O
1726	-	O
1726	/	O
1726	-	O
1726	mice	O
1726	show	O
1726	increased	O
1726	steady	O
1726	-	O
1726	state	O
1726	levels	O
1726	of	O
1726	the	O
1726	Na	O
1726	+	O
1726	/	O
1726	K	O
1726	+	O
1726	-	O
1726	ATPase	O
1726	alpha	O
1726	-	O
1726	1	O
1726	subunit	O
1726	and	O
1726	decreased	O
1726	Dm15	O
1726	mRNA	O
1726	levels	O
1726	.	O
1727	Thus	O
1727	,	O
1727	altered	O
1727	ion	O
1727	homeostasis	O
1727	within	O
1727	the	O
1727	lens	O
1727	may	O
1727	contribute	O
1727	to	O
1727	cataract	B-Disease
1727	formation	O
1727	.	O
1728	As	O
1728	ocular	O
1728	cataracts	B-Disease
1728	are	O
1728	a	O
1728	characteristic	O
1728	feature	O
1728	of	O
1728	DM	B-Disease
1728	,	O
1728	these	O
1728	results	O
1728	demonstrate	O
1728	that	O
1728	decreased	O
1728	SIX5	O
1728	transcription	O
1728	is	O
1728	important	O
1728	in	O
1728	the	O
1728	aetiology	O
1728	of	O
1728	DM	B-Disease
1728	.	O
1729	Our	O
1729	data	O
1729	support	O
1729	the	O
1729	hypothesis	O
1729	that	O
1729	DM	B-Disease
1729	is	O
1729	a	O
1729	contiguous	O
1729	gene	O
1729	syndrome	O
1729	associated	O
1729	with	O
1729	the	O
1729	partial	O
1729	loss	O
1729	of	O
1729	both	O
1729	DMPK	O
1729	and	O
1729	SIX5	O
1729	.	O
1729	.	O
1730	ATM	O
1730	-	O
1730	dependent	O
1730	phosphorylation	O
1730	of	O
1730	nibrin	O
1730	in	O
1730	response	O
1730	to	O
1730	radiation	O
1730	exposure	O
1730	.	O
1731	Mutations	O
1731	in	O
1731	the	O
1731	gene	O
1731	ATM	O
1731	are	O
1731	responsible	O
1731	for	O
1731	the	O
1731	genetic	B-Disease
1731	disorder	I-Disease
1731	ataxia	B-Disease
1731	-	I-Disease
1731	telangiectasia	I-Disease
1731	(	O
1731	A	B-Disease
1731	-	I-Disease
1731	T	I-Disease
1731	)	O
1731	,	O
1731	which	O
1731	is	O
1731	characterized	O
1731	by	O
1731	cerebellar	B-Disease
1731	dysfunction	I-Disease
1731	,	O
1731	radiosensitivity	O
1731	,	O
1731	chromosomal	O
1731	instability	O
1731	and	O
1731	cancer	B-Disease
1731	predisposition	O
1731	.	O
1732	Both	O
1732	the	O
1732	A	B-Disease
1732	-	I-Disease
1732	T	I-Disease
1732	phenotype	O
1732	and	O
1732	the	O
1732	similarity	O
1732	of	O
1732	the	O
1732	ATM	O
1732	protein	O
1732	to	O
1732	other	O
1732	DNA	O
1732	-	O
1732	damage	O
1732	sensors	O
1732	suggests	O
1732	a	O
1732	role	O
1732	for	O
1732	ATM	O
1732	in	O
1732	biochemical	O
1732	pathways	O
1732	involved	O
1732	in	O
1732	the	O
1732	recognition	O
1732	,	O
1732	signalling	O
1732	and	O
1732	repair	O
1732	of	O
1732	DNA	O
1732	double	O
1732	-	O
1732	strand	O
1732	breaks	O
1732	(	O
1732	DSBs	O
1732	)	O
1732	.	O
1733	There	O
1733	are	O
1733	strong	O
1733	parallels	O
1733	between	O
1733	the	O
1733	pattern	O
1733	of	O
1733	radiosensitivity	O
1733	,	O
1733	chromosomal	O
1733	instability	O
1733	and	O
1733	cancer	B-Disease
1733	predisposition	O
1733	in	O
1733	A	B-Disease
1733	-	I-Disease
1733	T	I-Disease
1733	patients	O
1733	and	O
1733	that	O
1733	in	O
1733	patients	O
1733	with	O
1733	Nijmegen	B-Disease
1733	breakage	I-Disease
1733	syndrome	I-Disease
1733	(	O
1733	NBS	B-Disease
1733	)	O
1733	.	O
1734	The	O
1734	protein	O
1734	defective	O
1734	in	O
1734	NBS	B-Disease
1734	,	O
1734	nibrin	O
1734	(	O
1734	encoded	O
1734	by	O
1734	NBS1	O
1734	)	O
1734	,	O
1734	forms	O
1734	a	O
1734	complex	O
1734	with	O
1734	MRE11	O
1734	and	O
1734	RAD50	O
1734	(	O
1734	refs	O
1734	1	O
1734	,	O
1734	2	O
1734	)	O
1734	.	O
1735	This	O
1735	complex	O
1735	localizes	O
1735	to	O
1735	DSBs	O
1735	within	O
1735	30	O
1735	minutes	O
1735	after	O
1735	cellular	O
1735	exposure	O
1735	to	O
1735	ionizing	O
1735	radiation	O
1735	(	O
1735	IR	O
1735	)	O
1735	and	O
1735	is	O
1735	observed	O
1735	in	O
1735	brightly	O
1735	staining	O
1735	nuclear	O
1735	foci	O
1735	after	O
1735	a	O
1735	longer	O
1735	period	O
1735	of	O
1735	time	O
1735	.	O
1736	The	O
1736	overlap	O
1736	between	O
1736	clinical	O
1736	and	O
1736	cellular	O
1736	phenotypes	O
1736	in	O
1736	A	B-Disease
1736	-	I-Disease
1736	T	I-Disease
1736	and	O
1736	NBS	B-Disease
1736	suggests	O
1736	that	O
1736	ATM	O
1736	and	O
1736	nibrin	O
1736	may	O
1736	function	O
1736	in	O
1736	the	O
1736	same	O
1736	biochemical	O
1736	pathway	O
1736	.	O
1737	Here	O
1737	we	O
1737	demonstrate	O
1737	that	O
1737	nibrin	O
1737	is	O
1737	phosphorylated	O
1737	within	O
1737	one	O
1737	hour	O
1737	of	O
1737	treatment	O
1737	of	O
1737	cells	O
1737	with	O
1737	IR	O
1737	.	O
1738	This	O
1738	response	O
1738	is	O
1738	abrogated	O
1738	in	O
1738	A	B-Disease
1738	-	I-Disease
1738	T	I-Disease
1738	cells	O
1738	that	O
1738	either	O
1738	do	O
1738	not	O
1738	express	O
1738	ATM	O
1738	protein	O
1738	or	O
1738	express	O
1738	near	O
1738	full	O
1738	-	O
1738	length	O
1738	mutant	O
1738	protein	O
1738	.	O
1739	We	O
1739	also	O
1739	show	O
1739	that	O
1739	ATM	O
1739	physically	O
1739	interacts	O
1739	with	O
1739	and	O
1739	phosphorylates	O
1739	nibrin	O
1739	on	O
1739	serine	O
1739	343	O
1739	both	O
1739	in	O
1739	vivo	O
1739	and	O
1739	in	O
1739	vitro	O
1739	.	O
1740	Phosphorylation	O
1740	of	O
1740	this	O
1740	site	O
1740	appears	O
1740	to	O
1740	be	O
1740	functionally	O
1740	important	O
1740	because	O
1740	mutated	O
1740	nibrin	O
1740	(	O
1740	S343A	O
1740	)	O
1740	does	O
1740	not	O
1740	completely	O
1740	complement	O
1740	radiosensitivity	O
1740	in	O
1740	NBS	B-Disease
1740	cells	O
1740	.	O
1741	ATM	O
1741	phosphorylation	O
1741	of	O
1741	nibrin	O
1741	does	O
1741	not	O
1741	affect	O
1741	nibrin	O
1741	-	O
1741	MRE11	O
1741	-	O
1741	RAD50	O
1741	association	O
1741	as	O
1741	revealed	O
1741	by	O
1741	radiation	O
1741	-	O
1741	induced	O
1741	foci	O
1741	formation	O
1741	.	O
1742	Our	O
1742	data	O
1742	provide	O
1742	a	O
1742	biochemical	O
1742	explanation	O
1742	for	O
1742	the	O
1742	similarity	O
1742	in	O
1742	phenotype	O
1742	between	O
1742	A	B-Disease
1742	-	I-Disease
1742	T	I-Disease
1742	and	O
1742	NBS	B-Disease
1742	.	O
1742	.	O
1743	Clinicopathologic	O
1743	features	O
1743	of	O
1743	BRCA	B-Disease
1743	-	I-Disease
1743	linked	I-Disease
1743	and	I-Disease
1743	sporadic	I-Disease
1743	ovarian	I-Disease
1743	cancer	I-Disease
1743	.	O
1744	CONTEXT	O
1744	Most	O
1744	hereditary	B-Disease
1744	ovarian	I-Disease
1744	cancers	I-Disease
1744	are	O
1744	associated	O
1744	with	O
1744	germline	O
1744	mutations	O
1744	in	O
1744	BRCA1	O
1744	or	O
1744	BRCA2	O
1744	.	O
1745	Attempts	O
1745	to	O
1745	define	O
1745	the	O
1745	clinical	O
1745	significance	O
1745	of	O
1745	BRCA	O
1745	mutation	O
1745	status	O
1745	in	O
1745	ovarian	B-Disease
1745	cancer	I-Disease
1745	have	O
1745	produced	O
1745	conflicting	O
1745	results	O
1745	,	O
1745	especially	O
1745	regarding	O
1745	survival	O
1745	.	O
1746	OBJECTIVE	O
1746	To	O
1746	determine	O
1746	whether	O
1746	hereditary	B-Disease
1746	ovarian	I-Disease
1746	cancers	I-Disease
1746	have	O
1746	distinct	O
1746	clinical	O
1746	and	O
1746	pathological	O
1746	features	O
1746	compared	O
1746	with	O
1746	sporadic	B-Disease
1746	(	I-Disease
1746	nonhereditary	I-Disease
1746	)	I-Disease
1746	ovarian	I-Disease
1746	cancers	I-Disease
1746	.	O
1747	DESIGN	O
1747	AND	O
1747	SETTING	O
1747	Retrospective	O
1747	cohort	O
1747	study	O
1747	of	O
1747	a	O
1747	consecutive	O
1747	series	O
1747	of	O
1747	933	O
1747	ovarian	B-Disease
1747	cancers	I-Disease
1747	diagnosed	O
1747	and	O
1747	treated	O
1747	at	O
1747	our	O
1747	institution	O
1747	,	O
1747	which	O
1747	is	O
1747	a	O
1747	comprehensive	O
1747	cancer	B-Disease
1747	center	O
1747	as	O
1747	designated	O
1747	by	O
1747	the	O
1747	National	O
1747	Cancer	B-Disease
1747	Institute	O
1747	,	O
1747	over	O
1747	a	O
1747	12	O
1747	-	O
1747	year	O
1747	period	O
1747	(	O
1747	December	O
1747	1986	O
1747	to	O
1747	August	O
1747	1998	O
1747	)	O
1747	.	O
1748	PATIENTS	O
1748	The	O
1748	study	O
1748	was	O
1748	restricted	O
1748	to	O
1748	patients	O
1748	of	O
1748	Jewish	O
1748	origin	O
1748	because	O
1748	of	O
1748	the	O
1748	ease	O
1748	of	O
1748	BRCA1	O
1748	and	O
1748	BRCA2	O
1748	genotyping	O
1748	in	O
1748	this	O
1748	ethnic	O
1748	group	O
1748	.	O
1749	From	O
1749	the	O
1749	189	O
1749	patients	O
1749	who	O
1749	identified	O
1749	themselves	O
1749	as	O
1749	Jewish	O
1749	,	O
1749	88	O
1749	hereditary	O
1749	cases	O
1749	were	O
1749	identified	O
1749	with	O
1749	the	O
1749	presence	O
1749	of	O
1749	a	O
1749	germline	O
1749	founder	O
1749	mutation	O
1749	in	O
1749	BRCA1	O
1749	or	O
1749	BRCA2	O
1749	.	O
1750	The	O
1750	remaining	O
1750	101	O
1750	cases	O
1750	from	O
1750	the	O
1750	same	O
1750	series	O
1750	not	O
1750	associated	O
1750	with	O
1750	a	O
1750	BRCA	O
1750	mutation	O
1750	and	O
1750	2	O
1750	additional	O
1750	groups	O
1750	(	O
1750	Gynecologic	O
1750	Oncology	O
1750	Group	O
1750	protocols	O
1750	52	O
1750	and	O
1750	111	O
1750	)	O
1750	with	O
1750	ovarian	B-Disease
1750	cancer	I-Disease
1750	from	O
1750	clinical	O
1750	trials	O
1750	(	O
1750	for	O
1750	the	O
1750	survival	O
1750	analysis	O
1750	)	O
1750	were	O
1750	included	O
1750	for	O
1750	comparison	O
1750	.	O
1751	MAIN	O
1751	OUTCOME	O
1751	MEASURES	O
1751	Age	O
1751	at	O
1751	diagnosis	O
1751	,	O
1751	surgical	O
1751	stage	O
1751	,	O
1751	histologic	O
1751	cell	O
1751	type	O
1751	and	O
1751	grade	O
1751	,	O
1751	and	O
1751	surgical	O
1751	outcome	O
1751	;	O
1751	and	O
1751	response	O
1751	to	O
1751	chemotherapy	O
1751	and	O
1751	survival	O
1751	for	O
1751	advanced	O
1751	-	O
1751	stage	O
1751	(	O
1751	II	O
1751	and	O
1751	IV	O
1751	)	O
1751	cases	O
1751	.	O
1752	RESULTS	O
1752	Hereditary	B-Disease
1752	cancers	I-Disease
1752	were	O
1752	rarely	O
1752	diagnosed	O
1752	before	O
1752	age	O
1752	40	O
1752	years	O
1752	and	O
1752	were	O
1752	common	O
1752	after	O
1752	age	O
1752	60	O
1752	years	O
1752	,	O
1752	with	O
1752	mean	O
1752	age	O
1752	at	O
1752	diagnosis	O
1752	being	O
1752	significantly	O
1752	younger	O
1752	for	O
1752	BRCA1	O
1752	-	O
1752	vs	O
1752	BRCA2	O
1752	-	O
1752	linked	O
1752	patients	O
1752	(	O
1752	54	O
1752	vs	O
1752	62	O
1752	years	O
1752	;	O
1752	P	O
1752	=	O
1752	.	O
1752	04	O
1752	)	O
1752	.	O
1753	Histology	O
1753	,	O
1753	grade	O
1753	,	O
1753	stage	O
1753	,	O
1753	and	O
1753	success	O
1753	of	O
1753	cytoreductive	O
1753	surgery	O
1753	were	O
1753	similar	O
1753	for	O
1753	hereditary	O
1753	and	O
1753	sporadic	O
1753	cases	O
1753	.	O
1754	The	O
1754	hereditary	O
1754	group	O
1754	had	O
1754	a	O
1754	longer	O
1754	disease	O
1754	-	O
1754	free	O
1754	interval	O
1754	following	O
1754	primary	O
1754	chemotherapy	O
1754	in	O
1754	comparison	O
1754	with	O
1754	the	O
1754	nonhereditary	O
1754	group	O
1754	,	O
1754	with	O
1754	a	O
1754	median	O
1754	time	O
1754	to	O
1754	recurrence	O
1754	of	O
1754	14	O
1754	months	O
1754	and	O
1754	7	O
1754	months	O
1754	,	O
1754	respectively	O
1754	(	O
1754	P	O
1754	<	O
1754	.	O
1754	001	O
1754	)	O
1754	.	O
1755	Those	O
1755	with	O
1755	hereditary	B-Disease
1755	cancers	I-Disease
1755	had	O
1755	improved	O
1755	survival	O
1755	compared	O
1755	with	O
1755	the	O
1755	nonhereditary	O
1755	group	O
1755	(	O
1755	P	O
1755	=	O
1755	.	O
1755	004	O
1755	)	O
1755	.	O
1756	For	O
1756	stage	B-Disease
1756	III	I-Disease
1756	cancers	I-Disease
1756	,	O
1756	BRCA	O
1756	mutation	O
1756	status	O
1756	was	O
1756	an	O
1756	independent	O
1756	prognostic	O
1756	variable	O
1756	(	O
1756	P	O
1756	=	O
1756	.	O
1756	03	O
1756	)	O
1756	.	O
1757	CONCLUSIONS	O
1757	Although	O
1757	BRCA	B-Disease
1757	-	I-Disease
1757	associated	I-Disease
1757	hereditary	I-Disease
1757	ovarian	I-Disease
1757	cancers	I-Disease
1757	in	O
1757	this	O
1757	population	O
1757	have	O
1757	surgical	O
1757	and	O
1757	pathological	O
1757	characteristics	O
1757	similar	O
1757	to	O
1757	those	O
1757	of	O
1757	sporadic	B-Disease
1757	cancers	I-Disease
1757	,	O
1757	advanced	B-Disease
1757	-	I-Disease
1757	stage	I-Disease
1757	hereditary	I-Disease
1757	cancer	I-Disease
1757	patients	O
1757	survive	O
1757	longer	O
1757	than	O
1757	nonhereditary	B-Disease
1757	cancer	I-Disease
1757	patients	O
1757	.	O
1758	Age	O
1758	penetrance	O
1758	is	O
1758	greater	O
1758	for	O
1758	BRCA1	B-Disease
1758	-	I-Disease
1758	linked	I-Disease
1758	than	I-Disease
1758	for	I-Disease
1758	BRCA2	I-Disease
1758	-	I-Disease
1758	linked	I-Disease
1758	cancers	I-Disease
1758	in	O
1758	this	O
1758	population	O
1758	.	O
1759	The	O
1759	gene	O
1759	for	O
1759	familial	B-Disease
1759	Mediterranean	I-Disease
1759	fever	I-Disease
1759	,	O
1759	MEFV	O
1759	,	O
1759	is	O
1759	expressed	O
1759	in	O
1759	early	O
1759	leukocyte	O
1759	development	O
1759	and	O
1759	is	O
1759	regulated	O
1759	in	O
1759	response	O
1759	to	O
1759	inflammatory	O
1759	mediators	O
1759	.	O
1760	Familial	B-Disease
1760	Mediterranean	I-Disease
1760	fever	I-Disease
1760	(	O
1760	FMF	B-Disease
1760	)	O
1760	is	O
1760	a	O
1760	recessive	B-Disease
1760	disorder	I-Disease
1760	characterized	O
1760	by	O
1760	episodes	O
1760	of	O
1760	fever	B-Disease
1760	and	O
1760	neutrophil	B-Disease
1760	-	I-Disease
1760	mediated	I-Disease
1760	serosal	I-Disease
1760	inflammation	I-Disease
1760	.	O
1761	We	O
1761	recently	O
1761	identified	O
1761	the	O
1761	gene	O
1761	causing	O
1761	FMF	B-Disease
1761	,	O
1761	designated	O
1761	MEFV	O
1761	,	O
1761	and	O
1761	found	O
1761	it	O
1761	to	O
1761	be	O
1761	expressed	O
1761	in	O
1761	mature	O
1761	neutrophils	O
1761	,	O
1761	suggesting	O
1761	that	O
1761	it	O
1761	functions	O
1761	as	O
1761	an	O
1761	inflammatory	O
1761	regulator	O
1761	.	O
1762	To	O
1762	facilitate	O
1762	our	O
1762	understanding	O
1762	of	O
1762	the	O
1762	normal	O
1762	function	O
1762	of	O
1762	MEFV	O
1762	,	O
1762	we	O
1762	extended	O
1762	our	O
1762	previous	O
1762	studies	O
1762	.	O
1763	MEFV	O
1763	messenger	O
1763	RNA	O
1763	was	O
1763	detected	O
1763	by	O
1763	reverse	O
1763	transcriptase	O
1763	-	O
1763	polymerase	O
1763	chain	O
1763	reaction	O
1763	in	O
1763	bone	O
1763	marrow	O
1763	leukocytes	O
1763	,	O
1763	with	O
1763	differential	O
1763	expression	O
1763	observed	O
1763	among	O
1763	cells	O
1763	by	O
1763	in	O
1763	situ	O
1763	hybridization	O
1763	.	O
1764	CD34	O
1764	hematopoietic	O
1764	stem	O
1764	-	O
1764	cell	O
1764	cultures	O
1764	induced	O
1764	toward	O
1764	the	O
1764	granulocytic	O
1764	lineage	O
1764	expressed	O
1764	MEFV	O
1764	at	O
1764	the	O
1764	myelocyte	O
1764	stage	O
1764	,	O
1764	concurrently	O
1764	with	O
1764	lineage	O
1764	commitment	O
1764	.	O
1765	The	O
1765	prepromyelocytic	O
1765	cell	O
1765	line	O
1765	HL60	O
1765	expressed	O
1765	MEFV	O
1765	only	O
1765	at	O
1765	granulocytic	O
1765	and	O
1765	monocytic	O
1765	differentiation	O
1765	.	O
1766	MEFV	O
1766	was	O
1766	also	O
1766	expressed	O
1766	in	O
1766	the	O
1766	monocytic	O
1766	cell	O
1766	lines	O
1766	U937	O
1766	and	O
1766	THP	O
1766	-	O
1766	1	O
1766	.	O
1767	Among	O
1767	peripheral	O
1767	blood	O
1767	leukocytes	O
1767	,	O
1767	MEFV	O
1767	expression	O
1767	was	O
1767	detected	O
1767	in	O
1767	neutrophils	O
1767	,	O
1767	eosinophils	O
1767	,	O
1767	and	O
1767	to	O
1767	varying	O
1767	degrees	O
1767	,	O
1767	monocytes	O
1767	.	O
1768	Consistent	O
1768	with	O
1768	the	O
1768	tissue	O
1768	specificity	O
1768	of	O
1768	expression	O
1768	,	O
1768	complete	O
1768	sequencing	O
1768	and	O
1768	analysis	O
1768	of	O
1768	upstream	O
1768	regulatory	O
1768	regions	O
1768	of	O
1768	MEFV	O
1768	revealed	O
1768	homology	O
1768	to	O
1768	myeloid	O
1768	-	O
1768	specific	O
1768	promoters	O
1768	and	O
1768	to	O
1768	more	O
1768	broadly	O
1768	expressed	O
1768	inflammatory	O
1768	promoter	O
1768	elements	O
1768	.	O
1769	In	O
1769	vitro	O
1769	stimulation	O
1769	of	O
1769	monocytes	O
1769	with	O
1769	the	O
1769	proinflammatory	O
1769	agents	O
1769	interferon	O
1769	(	O
1769	IFN	O
1769	)	O
1769	gamma	O
1769	,	O
1769	tumor	B-Disease
1769	necrosis	O
1769	factor	O
1769	,	O
1769	and	O
1769	lipopolysaccharide	O
1769	induced	O
1769	MEFV	O
1769	expression	O
1769	,	O
1769	whereas	O
1769	the	O
1769	antiinflammatory	O
1769	cytokines	O
1769	interleukin	O
1769	(	O
1769	IL	O
1769	)	O
1769	4	O
1769	,	O
1769	IL	O
1769	-	O
1769	10	O
1769	,	O
1769	and	O
1769	transforming	O
1769	growth	O
1769	factor	O
1769	beta	O
1769	inhibited	O
1769	such	O
1769	expression	O
1769	.	O
1770	Induction	O
1770	by	O
1770	IFN	O
1770	-	O
1770	gamma	O
1770	occurred	O
1770	rapidly	O
1770	and	O
1770	was	O
1770	resistant	O
1770	to	O
1770	cycloheximide	O
1770	.	O
1771	IFN	O
1771	-	O
1771	alpha	O
1771	also	O
1771	induced	O
1771	MEFV	O
1771	expression	O
1771	.	O
1772	In	O
1772	granulocytes	O
1772	,	O
1772	MEFV	O
1772	was	O
1772	up	O
1772	-	O
1772	regulated	O
1772	by	O
1772	IFN	O
1772	-	O
1772	gamma	O
1772	and	O
1772	the	O
1772	combination	O
1772	of	O
1772	IFN	O
1772	-	O
1772	alpha	O
1772	and	O
1772	colchicine	O
1772	.	O
1773	These	O
1773	results	O
1773	refine	O
1773	understanding	O
1773	of	O
1773	MEFV	O
1773	by	O
1773	placing	O
1773	the	O
1773	gene	O
1773	in	O
1773	the	O
1773	myelomonocytic	O
1773	-	O
1773	specific	O
1773	proinflammatory	O
1773	pathway	O
1773	and	O
1773	identifying	O
1773	it	O
1773	as	O
1773	an	O
1773	IFN	O
1773	-	O
1773	gamma	O
1773	immediate	O
1773	early	O
1773	gene	O
1773	.	O
1773	.	O
1774	Biochemical	O
1774	and	O
1774	structural	O
1774	analysis	O
1774	of	O
1774	missense	O
1774	mutations	O
1774	in	O
1774	N	O
1774	-	O
1774	acetylgalactosamine	O
1774	-	O
1774	6	O
1774	-	O
1774	sulfate	O
1774	sulfatase	O
1774	causing	O
1774	mucopolysaccharidosis	B-Disease
1774	IVA	I-Disease
1774	phenotypes	O
1774	.	O
1775	Mucopolysaccharidosis	B-Disease
1775	IVA	I-Disease
1775	(	O
1775	MPS	B-Disease
1775	IVA	I-Disease
1775	;	O
1775	OMIM	O
1775	#	O
1775	253000	O
1775	)	O
1775	,	O
1775	a	O
1775	lysosomal	B-Disease
1775	storage	I-Disease
1775	disorder	I-Disease
1775	caused	O
1775	by	O
1775	a	O
1775	deficiency	B-Disease
1775	of	I-Disease
1775	N	I-Disease
1775	-	I-Disease
1775	acetylgalactosamine	I-Disease
1775	-	I-Disease
1775	6	I-Disease
1775	-	I-Disease
1775	sulfate	I-Disease
1775	sulfatase	I-Disease
1775	(	O
1775	GALNS	O
1775	)	O
1775	,	O
1775	has	O
1775	variable	O
1775	clinical	O
1775	phenotypes	O
1775	.	O
1776	To	O
1776	date	O
1776	we	O
1776	have	O
1776	identified	O
1776	65	O
1776	missense	O
1776	mutations	O
1776	in	O
1776	the	O
1776	GALNS	O
1776	gene	O
1776	from	O
1776	MPS	B-Disease
1776	IVA	I-Disease
1776	patients	O
1776	,	O
1776	but	O
1776	the	O
1776	correlation	O
1776	between	O
1776	genotype	O
1776	and	O
1776	phenotype	O
1776	has	O
1776	remained	O
1776	unclear	O
1776	.	O
1777	We	O
1777	studied	O
1777	17	O
1777	missense	O
1777	mutations	O
1777	using	O
1777	biochemical	O
1777	approaches	O
1777	and	O
1777	32	O
1777	missense	O
1777	mutations	O
1777	,	O
1777	using	O
1777	structural	O
1777	analyses	O
1777	.	O
1778	Fifteen	O
1778	missense	O
1778	mutations	O
1778	and	O
1778	two	O
1778	newly	O
1778	engineered	O
1778	active	O
1778	site	O
1778	mutations	O
1778	(	O
1778	C79S	O
1778	,	O
1778	C79T	O
1778	)	O
1778	were	O
1778	characterized	O
1778	by	O
1778	transient	O
1778	expression	O
1778	analysis	O
1778	.	O
1779	Mutant	O
1779	proteins	O
1779	,	O
1779	except	O
1779	for	O
1779	C79S	O
1779	and	O
1779	C79T	O
1779	,	O
1779	were	O
1779	destabilized	O
1779	and	O
1779	detected	O
1779	as	O
1779	insoluble	O
1779	precursor	O
1779	forms	O
1779	while	O
1779	the	O
1779	C79S	O
1779	and	O
1779	C79T	O
1779	mutants	O
1779	were	O
1779	of	O
1779	a	O
1779	soluble	O
1779	mature	O
1779	size	O
1779	.	O
1780	Mutants	O
1780	found	O
1780	in	O
1780	the	O
1780	severe	O
1780	phenotype	O
1780	had	O
1780	no	O
1780	activity	O
1780	.	O
1781	Mutants	O
1781	found	O
1781	in	O
1781	the	O
1781	mild	O
1781	phenotype	O
1781	had	O
1781	a	O
1781	considerable	O
1781	residual	O
1781	activity	O
1781	(	O
1781	1	O
1781	.	O
1781	3	O
1781	-	O
1781	13	O
1781	.	O
1781	3	O
1781	%	O
1781	of	O
1781	wild	O
1781	-	O
1781	type	O
1781	GALNS	O
1781	activity	O
1781	)	O
1781	.	O
1782	Sulfatases	O
1782	,	O
1782	including	O
1782	GALNS	O
1782	,	O
1782	are	O
1782	members	O
1782	of	O
1782	a	O
1782	highly	O
1782	conserved	O
1782	gene	O
1782	family	O
1782	sharing	O
1782	an	O
1782	extensive	O
1782	sequence	O
1782	homology	O
1782	.	O
1783	Thus	O
1783	,	O
1783	a	O
1783	tertiary	O
1783	structural	O
1783	model	O
1783	of	O
1783	human	O
1783	GALNS	O
1783	was	O
1783	constructed	O
1783	from	O
1783	the	O
1783	X	O
1783	-	O
1783	ray	O
1783	crystal	O
1783	structure	O
1783	of	O
1783	N	O
1783	-	O
1783	acetylgalacto	O
1783	-	O
1783	samine	O
1783	-	O
1783	4	O
1783	-	O
1783	sulfatase	O
1783	and	O
1783	arylsulfatase	O
1783	A	O
1783	,	O
1783	using	O
1783	homology	O
1783	modeling	O
1783	,	O
1783	and	O
1783	32	O
1783	missense	O
1783	mutations	O
1783	were	O
1783	investigated	O
1783	.	O
1784	Consequently	O
1784	,	O
1784	we	O
1784	propose	O
1784	that	O
1784	there	O
1784	are	O
1784	at	O
1784	least	O
1784	three	O
1784	different	O
1784	reasons	O
1784	for	O
1784	the	O
1784	severe	O
1784	phenotype	O
1784	(	O
1784	i	O
1784	)	O
1784	destruction	O
1784	of	O
1784	the	O
1784	hydrophobic	O
1784	core	O
1784	or	O
1784	modification	O
1784	of	O
1784	the	O
1784	packing	O
1784	;	O
1784	(	O
1784	ii	O
1784	)	O
1784	removal	O
1784	of	O
1784	a	O
1784	salt	O
1784	bridge	O
1784	to	O
1784	destabilize	O
1784	the	O
1784	entire	O
1784	conformation	O
1784	;	O
1784	(	O
1784	iii	O
1784	)	O
1784	modification	O
1784	of	O
1784	the	O
1784	active	O
1784	site	O
1784	.	O
1785	In	O
1785	contrast	O
1785	,	O
1785	mild	O
1785	mutations	O
1785	were	O
1785	mostly	O
1785	located	O
1785	on	O
1785	the	O
1785	surface	O
1785	of	O
1785	the	O
1785	GALNS	O
1785	protein	O
1785	.	O
1786	These	O
1786	studies	O
1786	shed	O
1786	further	O
1786	light	O
1786	on	O
1786	the	O
1786	genotype	O
1786	-	O
1786	phenotype	O
1786	correlation	O
1786	of	O
1786	MPS	B-Disease
1786	IVA	I-Disease
1786	and	O
1786	structure	O
1786	-	O
1786	function	O
1786	relationship	O
1786	in	O
1786	the	O
1786	sulfatase	O
1786	family	O
1786	.	O
1787	Mutations	O
1787	at	O
1787	the	O
1787	ataxia	B-Disease
1787	-	I-Disease
1787	telangiectasia	I-Disease
1787	locus	O
1787	and	O
1787	clinical	O
1787	phenotypes	O
1787	of	O
1787	A	B-Disease
1787	-	I-Disease
1787	T	I-Disease
1787	patients	O
1787	.	O
1788	Mutations	O
1788	at	O
1788	the	O
1788	ataxia	B-Disease
1788	-	I-Disease
1788	telangiectasia	I-Disease
1788	(	O
1788	A	B-Disease
1788	-	I-Disease
1788	T	I-Disease
1788	)	O
1788	locus	O
1788	on	O
1788	chromosome	O
1788	band	O
1788	11q22	O
1788	cause	O
1788	a	O
1788	distinctive	O
1788	autosomal	B-Disease
1788	recessive	I-Disease
1788	syndrome	I-Disease
1788	in	O
1788	homozygotes	O
1788	and	O
1788	predispose	O
1788	heterozygotes	O
1788	to	O
1788	cancer	B-Disease
1788	,	O
1788	ischemic	B-Disease
1788	heart	I-Disease
1788	disease	I-Disease
1788	,	O
1788	and	O
1788	early	O
1788	mortality	O
1788	.	O
1789	PCR	O
1789	amplification	O
1789	from	O
1789	genomic	O
1789	DNA	O
1789	and	O
1789	automated	O
1789	sequencing	O
1789	of	O
1789	the	O
1789	entire	O
1789	coding	O
1789	region	O
1789	(	O
1789	66	O
1789	exons	O
1789	)	O
1789	and	O
1789	splice	O
1789	junctions	O
1789	detected	O
1789	77	O
1789	mutations	O
1789	(	O
1789	85	O
1789	%	O
1789	)	O
1789	in	O
1789	90	O
1789	A	B-Disease
1789	-	I-Disease
1789	T	I-Disease
1789	chromosomes	O
1789	.	O
1790	Heteroduplex	O
1790	analysis	O
1790	detected	O
1790	another	O
1790	42	O
1790	mutations	O
1790	at	O
1790	the	O
1790	A	B-Disease
1790	-	I-Disease
1790	T	I-Disease
1790	locus	O
1790	.	O
1791	Out	O
1791	of	O
1791	a	O
1791	total	O
1791	of	O
1791	71	O
1791	unique	O
1791	mutations	O
1791	,	O
1791	50	O
1791	were	O
1791	found	O
1791	only	O
1791	in	O
1791	a	O
1791	single	O
1791	family	O
1791	,	O
1791	and	O
1791	51	O
1791	had	O
1791	not	O
1791	been	O
1791	reported	O
1791	previously	O
1791	.	O
1792	Most	O
1792	(	O
1792	58	O
1792	/	O
1792	71	O
1792	,	O
1792	82	O
1792	%	O
1792	)	O
1792	mutations	O
1792	were	O
1792	frameshift	O
1792	and	O
1792	nonsense	O
1792	mutations	O
1792	that	O
1792	are	O
1792	predicted	O
1792	to	O
1792	cause	O
1792	truncation	O
1792	of	O
1792	the	O
1792	A	B-Disease
1792	-	I-Disease
1792	T	I-Disease
1792	protein	O
1792	;	O
1792	the	O
1792	less	O
1792	common	O
1792	mutation	O
1792	types	O
1792	were	O
1792	missense	O
1792	(	O
1792	9	O
1792	/	O
1792	71	O
1792	,	O
1792	13	O
1792	%	O
1792	)	O
1792	,	O
1792	splicing	O
1792	(	O
1792	3	O
1792	/	O
1792	71	O
1792	,	O
1792	4	O
1792	%	O
1792	)	O
1792	and	O
1792	one	O
1792	in	O
1792	-	O
1792	frame	O
1792	deletion	O
1792	,	O
1792	2546	O
1792	3	O
1792	(	O
1792	1	O
1792	/	O
1792	71	O
1792	,	O
1792	1	O
1792	%	O
1792	)	O
1792	.	O
1793	The	O
1793	mean	O
1793	survival	O
1793	and	O
1793	height	O
1793	distribution	O
1793	of	O
1793	134	O
1793	A	B-Disease
1793	-	I-Disease
1793	T	I-Disease
1793	patients	O
1793	correlated	O
1793	significantly	O
1793	with	O
1793	the	O
1793	specific	O
1793	mutations	O
1793	present	O
1793	in	O
1793	the	O
1793	patients	O
1793	.	O
1794	Patients	O
1794	homozygous	O
1794	for	O
1794	a	O
1794	single	O
1794	truncating	O
1794	mutation	O
1794	,	O
1794	typically	O
1794	near	O
1794	the	O
1794	N	O
1794	-	O
1794	terminal	O
1794	end	O
1794	of	O
1794	the	O
1794	gene	O
1794	,	O
1794	or	O
1794	heterozygous	O
1794	for	O
1794	the	O
1794	in	O
1794	-	O
1794	frame	O
1794	deletion	O
1794	2546	O
1794	3	O
1794	,	O
1794	were	O
1794	shorter	O
1794	and	O
1794	had	O
1794	significantly	O
1794	shorter	O
1794	survival	O
1794	than	O
1794	those	O
1794	heterozygous	O
1794	for	O
1794	a	O
1794	splice	O
1794	site	O
1794	or	O
1794	missense	O
1794	mutation	O
1794	,	O
1794	or	O
1794	heterozygous	O
1794	for	O
1794	two	O
1794	truncating	O
1794	mutations	O
1794	.	O
1795	Alterations	O
1795	of	O
1795	the	O
1795	length	O
1795	or	O
1795	amino	O
1795	acid	O
1795	composition	O
1795	of	O
1795	the	O
1795	A	B-Disease
1795	-	I-Disease
1795	T	I-Disease
1795	gene	O
1795	product	O
1795	affect	O
1795	the	O
1795	A	B-Disease
1795	-	I-Disease
1795	T	I-Disease
1795	clinical	O
1795	phenotype	O
1795	in	O
1795	different	O
1795	ways	O
1795	.	O
1796	Mutation	O
1796	analysis	O
1796	at	O
1796	the	O
1796	A	B-Disease
1796	-	I-Disease
1796	T	I-Disease
1796	locus	O
1796	may	O
1796	help	O
1796	estimate	O
1796	the	O
1796	prognosis	O
1796	of	O
1796	A	B-Disease
1796	-	I-Disease
1796	T	I-Disease
1796	patients	O
1796	.	O
1796	.	O
1797	Isolation	O
1797	,	O
1797	genomic	O
1797	organization	O
1797	,	O
1797	and	O
1797	expression	O
1797	analysis	O
1797	of	O
1797	the	O
1797	mouse	O
1797	and	O
1797	rat	O
1797	homologs	O
1797	of	O
1797	MEFV	O
1797	,	O
1797	the	O
1797	gene	O
1797	for	O
1797	familial	B-Disease
1797	mediterranean	I-Disease
1797	fever	I-Disease
1797	.	O
1798	Familial	B-Disease
1798	Mediterranean	I-Disease
1798	fever	I-Disease
1798	(	O
1798	FMF	B-Disease
1798	)	O
1798	is	O
1798	a	O
1798	recessive	B-Disease
1798	disorder	I-Disease
1798	characterized	O
1798	by	O
1798	episodes	O
1798	of	O
1798	fever	B-Disease
1798	with	O
1798	serositis	B-Disease
1798	or	O
1798	synovitis	B-Disease
1798	.	O
1799	Recently	O
1799	the	O
1799	FMF	B-Disease
1799	gene	O
1799	(	O
1799	MEFV	O
1799	)	O
1799	was	O
1799	cloned	O
1799	;	O
1799	the	O
1799	protein	O
1799	product	O
1799	,	O
1799	pyrin	O
1799	/	O
1799	marenostrin	O
1799	,	O
1799	is	O
1799	thought	O
1799	to	O
1799	regulate	O
1799	inflammation	O
1799	in	O
1799	myeloid	O
1799	cells	O
1799	.	O
1800	In	O
1800	this	O
1800	manuscript	O
1800	we	O
1800	report	O
1800	the	O
1800	mouse	O
1800	and	O
1800	rat	O
1800	homologs	O
1800	of	O
1800	MEFV	O
1800	.	O
1801	The	O
1801	murine	O
1801	gene	O
1801	contains	O
1801	ten	O
1801	exons	O
1801	with	O
1801	a	O
1801	coding	O
1801	sequence	O
1801	of	O
1801	2304	O
1801	bp	O
1801	,	O
1801	while	O
1801	the	O
1801	rat	O
1801	homolog	O
1801	has	O
1801	nine	O
1801	exons	O
1801	with	O
1801	a	O
1801	coding	O
1801	sequence	O
1801	of	O
1801	2253	O
1801	bp	O
1801	.	O
1802	A	O
1802	considerable	O
1802	amino	O
1802	acid	O
1802	sequence	O
1802	homology	O
1802	was	O
1802	observed	O
1802	between	O
1802	the	O
1802	mouse	O
1802	and	O
1802	human	O
1802	(	O
1802	47	O
1802	.	O
1802	6	O
1802	%	O
1802	identity	O
1802	and	O
1802	65	O
1802	.	O
1802	5	O
1802	%	O
1802	similarity	O
1802	)	O
1802	and	O
1802	between	O
1802	the	O
1802	mouse	O
1802	and	O
1802	rat	O
1802	genes	O
1802	(	O
1802	73	O
1802	.	O
1802	5	O
1802	%	O
1802	identity	O
1802	and	O
1802	82	O
1802	.	O
1802	1	O
1802	%	O
1802	similarity	O
1802	)	O
1802	.	O
1803	The	O
1803	predicted	O
1803	rodent	O
1803	proteins	O
1803	have	O
1803	several	O
1803	important	O
1803	domains	O
1803	and	O
1803	signals	O
1803	found	O
1803	in	O
1803	human	O
1803	pyrin	O
1803	,	O
1803	including	O
1803	a	O
1803	B	O
1803	-	O
1803	box	O
1803	zinc	O
1803	finger	O
1803	domain	O
1803	,	O
1803	Robbins	O
1803	-	O
1803	Dingwall	O
1803	nuclear	O
1803	localization	O
1803	signal	O
1803	,	O
1803	and	O
1803	coiled	O
1803	-	O
1803	coil	O
1803	domain	O
1803	.	O
1804	However	O
1804	,	O
1804	perhaps	O
1804	because	O
1804	of	O
1804	an	O
1804	ancient	O
1804	frame	O
1804	-	O
1804	shift	O
1804	mutation	O
1804	,	O
1804	neither	O
1804	the	O
1804	mouse	O
1804	nor	O
1804	the	O
1804	rat	O
1804	protein	O
1804	has	O
1804	an	O
1804	intact	O
1804	C	O
1804	-	O
1804	terminal	O
1804	B30	O
1804	.	O
1805	2	O
1805	domain	O
1805	,	O
1805	in	O
1805	which	O
1805	most	O
1805	FMF	B-Disease
1805	-	O
1805	associated	O
1805	mutations	O
1805	have	O
1805	been	O
1805	found	O
1805	in	O
1805	human	O
1805	MEFV	O
1805	.	O
1806	Nevertheless	O
1806	,	O
1806	like	O
1806	the	O
1806	human	O
1806	gene	O
1806	,	O
1806	mouse	O
1806	Mefv	O
1806	is	O
1806	expressed	O
1806	in	O
1806	peripheral	O
1806	blood	O
1806	granulocytes	O
1806	but	O
1806	not	O
1806	lymphocytes	O
1806	.	O
1807	Consistent	O
1807	with	O
1807	its	O
1807	expression	O
1807	in	O
1807	granulocytes	O
1807	,	O
1807	Mefv	O
1807	was	O
1807	detected	O
1807	at	O
1807	high	O
1807	levels	O
1807	in	O
1807	the	O
1807	primary	O
1807	follicles	O
1807	and	O
1807	marginal	O
1807	zones	O
1807	of	O
1807	the	O
1807	splenic	O
1807	white	O
1807	pulp	O
1807	.	O
1808	Mefv	O
1808	is	O
1808	localized	O
1808	on	O
1808	mouse	O
1808	Chromosome	O
1808	(	O
1808	Chr	O
1808	)	O
1808	16	O
1808	,	O
1808	region	O
1808	A3	O
1808	-	O
1808	B1	O
1808	,	O
1808	extending	O
1808	a	O
1808	region	O
1808	of	O
1808	synteny	O
1808	with	O
1808	human	O
1808	Chr	O
1808	16p13	O
1808	.	O
1809	3	O
1809	.	O
1810	Development	O
1810	of	O
1810	knockout	O
1810	and	O
1810	knockin	O
1810	mouse	O
1810	models	O
1810	may	O
1810	provide	O
1810	further	O
1810	insights	O
1810	into	O
1810	the	O
1810	functional	O
1810	evolution	O
1810	of	O
1810	this	O
1810	gene	O
1810	.	O
1811	Additional	O
1811	copies	O
1811	of	O
1811	the	O
1811	proteolipid	O
1811	protein	O
1811	gene	O
1811	causing	O
1811	Pelizaeus	B-Disease
1811	-	I-Disease
1811	Merzbacher	I-Disease
1811	disease	I-Disease
1811	arise	O
1811	by	O
1811	separate	O
1811	integration	O
1811	into	O
1811	the	O
1811	X	O
1811	chromosome	O
1811	.	O
1812	The	O
1812	proteolipid	O
1812	protein	O
1812	gene	O
1812	(	O
1812	PLP	O
1812	)	O
1812	is	O
1812	normally	O
1812	present	O
1812	at	O
1812	chromosome	O
1812	Xq22	O
1812	.	O
1813	Mutations	O
1813	and	O
1813	duplications	O
1813	of	O
1813	this	O
1813	gene	O
1813	are	O
1813	associated	O
1813	with	O
1813	Pelizaeus	B-Disease
1813	-	I-Disease
1813	Merzbacher	I-Disease
1813	disease	I-Disease
1813	(	O
1813	PMD	B-Disease
1813	)	O
1813	.	O
1814	Here	O
1814	we	O
1814	describe	O
1814	two	O
1814	new	O
1814	families	O
1814	in	O
1814	which	O
1814	males	O
1814	affected	O
1814	with	O
1814	PMD	B-Disease
1814	were	O
1814	found	O
1814	to	O
1814	have	O
1814	a	O
1814	copy	O
1814	of	O
1814	PLP	O
1814	on	O
1814	the	O
1814	short	O
1814	arm	O
1814	of	O
1814	the	O
1814	X	O
1814	chromosome	O
1814	,	O
1814	in	O
1814	addition	O
1814	to	O
1814	a	O
1814	normal	O
1814	copy	O
1814	on	O
1814	Xq22	O
1814	.	O
1815	In	O
1815	the	O
1815	first	O
1815	family	O
1815	,	O
1815	the	O
1815	extra	O
1815	copy	O
1815	was	O
1815	first	O
1815	detected	O
1815	by	O
1815	the	O
1815	presence	O
1815	of	O
1815	heterozygosity	O
1815	of	O
1815	the	O
1815	AhaII	O
1815	dimorphism	O
1815	within	O
1815	the	O
1815	PLP	O
1815	gene	O
1815	.	O
1816	The	O
1816	results	O
1816	of	O
1816	FISH	O
1816	analysis	O
1816	showed	O
1816	an	O
1816	additional	O
1816	copy	O
1816	of	O
1816	PLP	O
1816	in	O
1816	Xp22	O
1816	.	O
1817	1	O
1817	,	O
1817	although	O
1817	no	O
1817	chromosomal	O
1817	rearrangements	O
1817	could	O
1817	be	O
1817	detected	O
1817	by	O
1817	standard	O
1817	karyotype	O
1817	analysis	O
1817	.	O
1818	Another	O
1818	three	O
1818	affected	O
1818	males	O
1818	from	O
1818	the	O
1818	family	O
1818	had	O
1818	similar	O
1818	findings	O
1818	.	O
1819	In	O
1819	a	O
1819	second	O
1819	unrelated	O
1819	family	O
1819	with	O
1819	signs	O
1819	of	O
1819	PMD	B-Disease
1819	,	O
1819	cytogenetic	O
1819	analysis	O
1819	showed	O
1819	a	O
1819	pericentric	O
1819	inversion	O
1819	of	O
1819	the	O
1819	X	O
1819	chromosome	O
1819	.	O
1820	In	O
1820	the	O
1820	inv	O
1820	(	O
1820	X	O
1820	)	O
1820	carried	O
1820	by	O
1820	several	O
1820	affected	O
1820	family	O
1820	members	O
1820	,	O
1820	FISH	O
1820	showed	O
1820	PLP	O
1820	signals	O
1820	at	O
1820	Xp11	O
1820	.	O
1821	4	O
1821	and	O
1821	Xq22	O
1821	.	O
1822	A	O
1822	third	O
1822	family	O
1822	has	O
1822	previously	O
1822	been	O
1822	reported	O
1822	,	O
1822	in	O
1822	which	O
1822	affected	O
1822	members	O
1822	had	O
1822	an	O
1822	extra	O
1822	copy	O
1822	of	O
1822	the	O
1822	PLP	O
1822	gene	O
1822	detected	O
1822	at	O
1822	Xq26	O
1822	in	O
1822	a	O
1822	chromosome	O
1822	with	O
1822	an	O
1822	otherwise	O
1822	normal	O
1822	banding	O
1822	pattern	O
1822	.	O
1823	The	O
1823	identification	O
1823	of	O
1823	three	O
1823	separate	O
1823	families	O
1823	in	O
1823	which	O
1823	PLP	O
1823	is	O
1823	duplicated	O
1823	at	O
1823	a	O
1823	noncontiguous	O
1823	site	O
1823	suggests	O
1823	that	O
1823	such	O
1823	duplications	O
1823	could	O
1823	be	O
1823	a	O
1823	relatively	O
1823	common	O
1823	but	O
1823	previously	O
1823	undetected	O
1823	cause	O
1823	of	O
1823	genetic	B-Disease
1823	disorders	I-Disease
1823	.	O
1824	The	O
1824	exon	O
1824	13	O
1824	duplication	O
1824	in	O
1824	the	O
1824	BRCA1	O
1824	gene	O
1824	is	O
1824	a	O
1824	founder	O
1824	mutation	O
1824	present	O
1824	in	O
1824	geographically	O
1824	diverse	O
1824	populations	O
1824	.	O
1825	The	O
1825	BRCA1	O
1825	Exon	O
1825	13	O
1825	Duplication	O
1825	Screening	O
1825	Group	O
1825	.	O
1826	Recently	O
1826	,	O
1826	a	O
1826	6	O
1826	-	O
1826	kb	O
1826	duplication	O
1826	of	O
1826	exon	O
1826	13	O
1826	,	O
1826	which	O
1826	creates	O
1826	a	O
1826	frameshift	O
1826	in	O
1826	the	O
1826	coding	O
1826	sequence	O
1826	of	O
1826	the	O
1826	BRCA1	O
1826	gene	O
1826	,	O
1826	has	O
1826	been	O
1826	described	O
1826	in	O
1826	three	O
1826	unrelated	O
1826	U	O
1826	.	O
1827	S	O
1827	S	O
1827	.	O
1827	families	O
1827	of	O
1827	European	O
1827	ancestry	O
1827	and	O
1827	in	O
1827	one	O
1827	Portuguese	O
1827	family	O
1827	.	O
1828	Here	O
1828	,	O
1828	our	O
1828	goal	O
1828	was	O
1828	to	O
1828	estimate	O
1828	the	O
1828	frequency	O
1828	and	O
1828	geographic	O
1828	diversity	O
1828	of	O
1828	carriers	O
1828	of	O
1828	this	O
1828	duplication	O
1828	.	O
1829	To	O
1829	do	O
1829	this	O
1829	,	O
1829	a	O
1829	collaborative	O
1829	screening	O
1829	study	O
1829	was	O
1829	set	O
1829	up	O
1829	that	O
1829	involved	O
1829	39	O
1829	institutions	O
1829	from	O
1829	19	O
1829	countries	O
1829	and	O
1829	included	O
1829	3	O
1829	,	O
1829	580	O
1829	unrelated	O
1829	individuals	O
1829	with	O
1829	a	O
1829	family	O
1829	history	O
1829	of	O
1829	the	O
1829	disease	O
1829	and	O
1829	934	O
1829	early	O
1829	-	O
1829	onset	O
1829	breast	B-Disease
1829	and	I-Disease
1829	/	I-Disease
1829	or	I-Disease
1829	ovarian	I-Disease
1829	cancer	I-Disease
1829	cases	O
1829	.	O
1830	A	O
1830	total	O
1830	of	O
1830	11	O
1830	additional	O
1830	families	O
1830	carrying	O
1830	this	O
1830	mutation	O
1830	were	O
1830	identified	O
1830	in	O
1830	Australia	O
1830	(	O
1830	1	O
1830	)	O
1830	,	O
1830	Belgium	O
1830	(	O
1830	1	O
1830	)	O
1830	,	O
1830	Canada	O
1830	(	O
1830	1	O
1830	)	O
1830	,	O
1830	Great	O
1830	Britain	O
1830	(	O
1830	6	O
1830	)	O
1830	,	O
1830	and	O
1830	the	O
1830	United	O
1830	States	O
1830	(	O
1830	2	O
1830	)	O
1830	.	O
1831	Haplotyping	O
1831	showed	O
1831	that	O
1831	they	O
1831	are	O
1831	likely	O
1831	to	O
1831	derive	O
1831	from	O
1831	a	O
1831	common	O
1831	ancestor	O
1831	,	O
1831	possibly	O
1831	of	O
1831	northern	O
1831	British	O
1831	origin	O
1831	.	O
1832	Our	O
1832	results	O
1832	demonstrate	O
1832	that	O
1832	it	O
1832	is	O
1832	strongly	O
1832	advisable	O
1832	,	O
1832	for	O
1832	laboratories	O
1832	carrying	O
1832	out	O
1832	screening	O
1832	either	O
1832	in	O
1832	English	O
1832	-	O
1832	speaking	O
1832	countries	O
1832	or	O
1832	in	O
1832	countries	O
1832	with	O
1832	historical	O
1832	links	O
1832	with	O
1832	Britain	O
1832	,	O
1832	to	O
1832	include	O
1832	within	O
1832	their	O
1832	BRCA1	O
1832	screening	O
1832	protocols	O
1832	the	O
1832	polymerase	O
1832	chain	O
1832	reaction	O
1832	-	O
1832	based	O
1832	assay	O
1832	described	O
1832	in	O
1832	this	O
1832	report	O
1832	.	O
1833	Genotype	O
1833	-	O
1833	phenotype	O
1833	correlations	O
1833	in	O
1833	families	O
1833	with	O
1833	deletions	O
1833	in	O
1833	the	O
1833	von	B-Disease
1833	Hippel	I-Disease
1833	-	I-Disease
1833	Lindau	I-Disease
1833	(	O
1833	VHL	B-Disease
1833	)	O
1833	gene	O
1833	.	O
1834	Von	B-Disease
1834	Hippel	I-Disease
1834	-	I-Disease
1834	Lindau	I-Disease
1834	(	I-Disease
1834	VHL	I-Disease
1834	)	I-Disease
1834	disease	I-Disease
1834	is	O
1834	a	O
1834	hereditary	B-Disease
1834	tumor	I-Disease
1834	syndrome	I-Disease
1834	characterized	O
1834	by	O
1834	predisposition	O
1834	for	O
1834	bilateral	B-Disease
1834	and	I-Disease
1834	multi	I-Disease
1834	-	I-Disease
1834	centric	I-Disease
1834	hemangioblastoma	I-Disease
1834	in	O
1834	the	O
1834	retina	O
1834	and	O
1834	central	O
1834	nervous	O
1834	system	O
1834	,	O
1834	pheochromocytoma	B-Disease
1834	,	O
1834	renal	B-Disease
1834	cell	I-Disease
1834	carcinoma	I-Disease
1834	,	O
1834	and	O
1834	cysts	B-Disease
1834	in	I-Disease
1834	the	I-Disease
1834	kidney	I-Disease
1834	,	I-Disease
1834	pancreas	I-Disease
1834	,	I-Disease
1834	and	I-Disease
1834	epididymis	I-Disease
1834	.	O
1835	We	O
1835	describe	O
1835	five	O
1835	families	O
1835	for	O
1835	which	O
1835	direct	O
1835	sequencing	O
1835	of	O
1835	the	O
1835	coding	O
1835	region	O
1835	of	O
1835	the	O
1835	VHL	B-Disease
1835	gene	O
1835	had	O
1835	failed	O
1835	to	O
1835	identify	O
1835	the	O
1835	family	O
1835	-	O
1835	specific	O
1835	mutation	O
1835	.	O
1836	Further	O
1836	molecular	O
1836	analysis	O
1836	revealed	O
1836	deletions	O
1836	involving	O
1836	the	O
1836	VHL	B-Disease
1836	gene	O
1836	in	O
1836	each	O
1836	of	O
1836	these	O
1836	families	O
1836	.	O
1837	In	O
1837	four	O
1837	families	O
1837	,	O
1837	partial	O
1837	deletions	O
1837	of	O
1837	one	O
1837	or	O
1837	more	O
1837	exons	O
1837	were	O
1837	detected	O
1837	by	O
1837	Southern	O
1837	blot	O
1837	analysis	O
1837	.	O
1838	In	O
1838	the	O
1838	fifth	O
1838	family	O
1838	,	O
1838	FISH	O
1838	analysis	O
1838	demonstrated	O
1838	the	O
1838	deletion	O
1838	of	O
1838	the	O
1838	entire	O
1838	VHL	B-Disease
1838	gene	O
1838	.	O
1839	Our	O
1839	results	O
1839	show	O
1839	that	O
1839	(	O
1839	quantitative	O
1839	)	O
1839	Southern	O
1839	blot	O
1839	analysis	O
1839	is	O
1839	a	O
1839	sensitive	O
1839	method	O
1839	for	O
1839	detecting	O
1839	germline	O
1839	deletions	O
1839	of	O
1839	the	O
1839	VHL	B-Disease
1839	gene	O
1839	and	O
1839	should	O
1839	be	O
1839	implemented	O
1839	in	O
1839	routine	O
1839	DNA	O
1839	diagnosis	O
1839	for	O
1839	VHL	B-Disease
1839	disease	I-Disease
1839	.	O
1840	Our	O
1840	data	O
1840	support	O
1840	the	O
1840	previously	O
1840	established	O
1840	observation	O
1840	that	O
1840	families	O
1840	with	O
1840	a	O
1840	germline	O
1840	deletion	O
1840	have	O
1840	a	O
1840	low	O
1840	risk	O
1840	for	O
1840	pheochromocytoma	B-Disease
1840	.	O
1841	Further	O
1841	unraveling	O
1841	of	O
1841	genotype	O
1841	-	O
1841	phenotype	O
1841	correlations	O
1841	in	O
1841	VHL	B-Disease
1841	disease	I-Disease
1841	has	O
1841	revealed	O
1841	that	O
1841	families	O
1841	with	O
1841	a	O
1841	full	O
1841	or	O
1841	partial	O
1841	deletion	O
1841	of	O
1841	the	O
1841	VHL	B-Disease
1841	gene	O
1841	exhibit	O
1841	a	O
1841	phenotype	O
1841	with	O
1841	a	O
1841	preponderance	O
1841	of	O
1841	central	B-Disease
1841	nervous	I-Disease
1841	system	I-Disease
1841	hemangioblastoma	I-Disease
1841	.	O
1841	.	O
1842	Age	O
1842	of	O
1842	the	O
1842	intronic	O
1842	GAA	O
1842	triplet	O
1842	repeat	O
1842	expansion	O
1842	mutation	O
1842	in	O
1842	Friedreich	B-Disease
1842	ataxia	I-Disease
1842	.	O
1843	Friedreich	B-Disease
1843	ataxia	I-Disease
1843	(	O
1843	FRDA	B-Disease
1843	)	O
1843	,	O
1843	the	O
1843	most	O
1843	frequently	O
1843	inherited	B-Disease
1843	ataxia	I-Disease
1843	,	O
1843	is	O
1843	due	O
1843	in	O
1843	the	O
1843	vast	O
1843	majority	O
1843	of	O
1843	cases	O
1843	to	O
1843	a	O
1843	large	O
1843	expansion	O
1843	of	O
1843	an	O
1843	intronic	O
1843	GAA	O
1843	repeat	O
1843	.	O
1844	Using	O
1844	linkage	O
1844	disequilibrium	O
1844	analysis	O
1844	based	O
1844	on	O
1844	haplotype	O
1844	data	O
1844	of	O
1844	seven	O
1844	polymorphic	O
1844	markers	O
1844	close	O
1844	to	O
1844	the	O
1844	frataxin	O
1844	gene	O
1844	,	O
1844	the	O
1844	age	O
1844	of	O
1844	FRDA	B-Disease
1844	founding	O
1844	mutational	O
1844	event	O
1844	(	O
1844	s	O
1844	)	O
1844	is	O
1844	estimated	O
1844	to	O
1844	be	O
1844	at	O
1844	least	O
1844	682	O
1844	+	O
1844	/	O
1844	-	O
1844	203	O
1844	generations	O
1844	(	O
1844	95	O
1844	%	O
1844	confidence	O
1844	interval	O
1844	564	O
1844	-	O
1844	801	O
1844	g	O
1844	)	O
1844	,	O
1844	a	O
1844	dating	O
1844	which	O
1844	is	O
1844	consistent	O
1844	with	O
1844	little	O
1844	or	O
1844	no	O
1844	negative	O
1844	selection	O
1844	and	O
1844	provides	O
1844	further	O
1844	evidence	O
1844	for	O
1844	an	O
1844	ancient	O
1844	spread	O
1844	of	O
1844	a	O
1844	pre	O
1844	-	O
1844	mutation	O
1844	(	O
1844	at	O
1844	-	O
1844	risk	O
1844	alleles	O
1844	)	O
1844	in	O
1844	western	O
1844	Europe	O
1844	.	O
1844	.	O
1845	Functional	O
1845	link	O
1845	between	O
1845	ataxia	B-Disease
1845	-	I-Disease
1845	telangiectasia	I-Disease
1845	and	O
1845	Nijmegen	B-Disease
1845	breakage	I-Disease
1845	syndrome	I-Disease
1845	gene	O
1845	products	O
1845	.	O
1846	Ataxia	B-Disease
1846	-	I-Disease
1846	telangiectasia	I-Disease
1846	(	O
1846	A	B-Disease
1846	-	I-Disease
1846	T	I-Disease
1846	)	O
1846	and	O
1846	Nijmegen	B-Disease
1846	breakage	I-Disease
1846	syndrome	I-Disease
1846	(	O
1846	NBS	B-Disease
1846	)	O
1846	are	O
1846	recessive	B-Disease
1846	genetic	I-Disease
1846	disorders	I-Disease
1846	with	O
1846	susceptibility	O
1846	to	O
1846	cancer	B-Disease
1846	and	O
1846	similar	O
1846	cellular	O
1846	phenotypes	O
1846	.	O
1847	The	O
1847	protein	O
1847	product	O
1847	of	O
1847	the	O
1847	gene	O
1847	responsible	O
1847	for	O
1847	A	B-Disease
1847	-	I-Disease
1847	T	I-Disease
1847	,	O
1847	designated	O
1847	ATM	O
1847	,	O
1847	is	O
1847	a	O
1847	member	O
1847	of	O
1847	a	O
1847	family	O
1847	of	O
1847	kinases	O
1847	characterized	O
1847	by	O
1847	a	O
1847	carboxy	O
1847	-	O
1847	terminal	O
1847	phosphatidylinositol	O
1847	3	O
1847	-	O
1847	kinase	O
1847	-	O
1847	like	O
1847	domain	O
1847	.	O
1848	The	O
1848	NBS1	O
1848	protein	O
1848	is	O
1848	specifically	O
1848	mutated	O
1848	in	O
1848	patients	O
1848	with	O
1848	Nijmegen	B-Disease
1848	breakage	I-Disease
1848	syndrome	I-Disease
1848	and	O
1848	forms	O
1848	a	O
1848	complex	O
1848	with	O
1848	the	O
1848	DNA	O
1848	repair	O
1848	proteins	O
1848	Rad50	O
1848	and	O
1848	Mrel1	O
1848	.	O
1849	Here	O
1849	we	O
1849	show	O
1849	that	O
1849	phosphorylation	O
1849	of	O
1849	NBS1	O
1849	,	O
1849	induced	O
1849	by	O
1849	ionizing	O
1849	radiation	O
1849	,	O
1849	requires	O
1849	catalytically	O
1849	active	O
1849	ATM	O
1849	.	O
1850	Complexes	O
1850	containing	O
1850	ATM	O
1850	and	O
1850	NBS1	O
1850	exist	O
1850	in	O
1850	vivo	O
1850	in	O
1850	both	O
1850	untreated	O
1850	cells	O
1850	and	O
1850	cells	O
1850	treated	O
1850	with	O
1850	ionizing	O
1850	radiation	O
1850	.	O
1851	We	O
1851	have	O
1851	identified	O
1851	two	O
1851	residues	O
1851	of	O
1851	NBS1	O
1851	,	O
1851	Ser	O
1851	278	O
1851	and	O
1851	Ser	O
1851	343	O
1851	that	O
1851	are	O
1851	phosphorylated	O
1851	in	O
1851	vitro	O
1851	by	O
1851	ATM	O
1851	and	O
1851	whose	O
1851	modification	O
1851	in	O
1851	vivo	O
1851	is	O
1851	essential	O
1851	for	O
1851	the	O
1851	cellular	O
1851	response	O
1851	to	O
1851	DNA	O
1851	damage	O
1851	.	O
1852	This	O
1852	response	O
1852	includes	O
1852	S	O
1852	-	O
1852	phase	O
1852	checkpoint	O
1852	activation	O
1852	,	O
1852	formation	O
1852	of	O
1852	the	O
1852	NBS1	O
1852	/	O
1852	Mrel1	O
1852	/	O
1852	Rad50	O
1852	nuclear	O
1852	foci	O
1852	and	O
1852	rescue	O
1852	of	O
1852	hypersensitivity	B-Disease
1852	to	I-Disease
1852	ionizing	I-Disease
1852	radiation	I-Disease
1852	.	O
1853	Together	O
1853	,	O
1853	these	O
1853	results	O
1853	demonstrate	O
1853	a	O
1853	biochemical	O
1853	link	O
1853	between	O
1853	cell	O
1853	-	O
1853	cycle	O
1853	checkpoints	O
1853	activated	O
1853	by	O
1853	DNA	O
1853	damage	O
1853	and	O
1853	DNA	O
1853	repair	O
1853	in	O
1853	two	O
1853	genetic	B-Disease
1853	diseases	I-Disease
1853	with	O
1853	overlapping	O
1853	phenotypes	O
1853	.	O
1853	.	O
1854	Homozygosity	O
1854	mapping	O
1854	in	O
1854	a	O
1854	family	O
1854	with	O
1854	microcephaly	B-Disease
1854	,	O
1854	mental	B-Disease
1854	retardation	I-Disease
1854	,	O
1854	and	O
1854	short	B-Disease
1854	stature	I-Disease
1854	to	O
1854	a	O
1854	Cohen	B-Disease
1854	syndrome	I-Disease
1854	region	O
1854	on	O
1854	8q21	O
1854	.	O
1854	3	O
1854	-	O
1854	8q22	O
1854	.	O
1854	1	O
1854	:	O
1854	redefining	O
1854	a	O
1854	clinical	O
1854	entity	O
1854	.	O
1855	A	O
1855	syndrome	O
1855	of	O
1855	microcephaly	B-Disease
1855	,	O
1855	progressive	O
1855	postnatal	B-Disease
1855	growth	I-Disease
1855	deficiency	I-Disease
1855	,	O
1855	and	O
1855	mental	B-Disease
1855	retardation	I-Disease
1855	was	O
1855	observed	O
1855	in	O
1855	two	O
1855	brothers	O
1855	and	O
1855	their	O
1855	cousin	O
1855	from	O
1855	a	O
1855	multiply	O
1855	consanguineous	O
1855	kindred	O
1855	of	O
1855	Lebanese	O
1855	descent	O
1855	.	O
1856	Hypotonia	B-Disease
1856	,	O
1856	chorioretinal	B-Disease
1856	dystrophy	I-Disease
1856	,	O
1856	and	O
1856	myopia	B-Disease
1856	were	O
1856	also	O
1856	identified	O
1856	.	O
1857	The	O
1857	severity	O
1857	of	O
1857	the	O
1857	condition	O
1857	varied	O
1857	among	O
1857	the	O
1857	closely	O
1857	related	O
1857	patients	O
1857	.	O
1858	Because	O
1858	of	O
1858	absence	O
1858	of	O
1858	a	O
1858	distinctive	O
1858	facial	O
1858	appearance	O
1858	,	O
1858	the	O
1858	degree	O
1858	of	O
1858	mental	B-Disease
1858	retardation	I-Disease
1858	,	O
1858	and	O
1858	short	B-Disease
1858	stature	I-Disease
1858	,	O
1858	the	O
1858	initially	O
1858	considered	O
1858	clinical	O
1858	diagnosis	O
1858	of	O
1858	Cohen	B-Disease
1858	syndrome	I-Disease
1858	was	O
1858	withdrawn	O
1858	and	O
1858	a	O
1858	novel	O
1858	genetic	O
1858	entity	O
1858	was	O
1858	assumed	O
1858	.	O
1859	Homozygosity	O
1859	mapping	O
1859	in	O
1859	this	O
1859	family	O
1859	assigned	O
1859	the	O
1859	gene	O
1859	to	O
1859	a	O
1859	26	O
1859	.	O
1860	8	O
1860	-	O
1860	cM	O
1860	region	O
1860	on	O
1860	the	O
1860	chromosome	O
1860	band	O
1860	8q21	O
1860	.	O
1861	3	O
1861	-	O
1861	22	O
1861	.	O
1862	1	O
1862	,	O
1862	between	O
1862	the	O
1862	microsatellites	O
1862	at	O
1862	D8S270	O
1862	and	O
1862	D8S514	O
1862	.	O
1863	The	O
1863	maximum	O
1863	two	O
1863	-	O
1863	point	O
1863	LOD	O
1863	score	O
1863	was	O
1863	found	O
1863	for	O
1863	marker	O
1863	at	O
1863	D8S267	O
1863	(	O
1863	Zmax	O
1863	=	O
1863	3	O
1863	.	O
1863	.	O
1863	237	O
1863	at	O
1863	Omax	O
1863	=	O
1863	0	O
1863	.	O
1863	00	O
1863	)	O
1863	.	O
1864	Intriguingly	O
1864	enough	O
1864	,	O
1864	the	O
1864	identified	O
1864	gene	O
1864	region	O
1864	overlaps	O
1864	the	O
1864	refined	O
1864	gene	O
1864	region	O
1864	for	O
1864	Cohen	B-Disease
1864	syndrome	I-Disease
1864	(	O
1864	COH1	O
1864	)	O
1864	[	O
1864	Kolehmainen	O
1864	et	O
1864	al	O
1864	.	O
1864	,	O
1864	1997	O
1864	Euro	O
1864	J	O
1864	Hum	O
1864	Genet	O
1864	5	O
1864	206	O
1864	-	O
1864	213	O
1864	]	O
1864	.	O
1865	This	O
1865	fact	O
1865	encourages	O
1865	the	O
1865	hypothesis	O
1865	that	O
1865	the	O
1865	described	O
1865	kindred	O
1865	segregates	O
1865	for	O
1865	a	O
1865	variant	O
1865	of	O
1865	Cohen	B-Disease
1865	syndrome	I-Disease
1865	and	O
1865	suggests	O
1865	a	O
1865	redefinition	O
1865	of	O
1865	its	O
1865	phenotype	O
1866	Polymorphisms	O
1866	of	O
1866	the	O
1866	CYP2D6	O
1866	gene	O
1866	increase	O
1866	susceptibility	O
1866	to	O
1866	ankylosing	B-Disease
1866	spondylitis	I-Disease
1866	.	O
1867	Ankylosing	B-Disease
1867	spondylitis	I-Disease
1867	(	O
1867	AS	B-Disease
1867	)	O
1867	is	O
1867	a	O
1867	common	O
1867	and	O
1867	highly	O
1867	familial	O
1867	rheumatic	B-Disease
1867	disorder	I-Disease
1867	.	O
1868	The	O
1868	sibling	O
1868	recurrence	O
1868	risk	O
1868	ratio	O
1868	for	O
1868	the	O
1868	disease	O
1868	is	O
1868	63	O
1868	and	O
1868	heritability	O
1868	assessed	O
1868	in	O
1868	twins	O
1868	>	O
1868	90	O
1868	%	O
1868	.	O
1869	Although	O
1869	MHC	O
1869	genes	O
1869	,	O
1869	including	O
1869	HLA	O
1869	-	O
1869	B27	O
1869	,	O
1869	contribute	O
1869	only	O
1869	20	O
1869	-	O
1869	50	O
1869	%	O
1869	of	O
1869	the	O
1869	genetic	O
1869	risk	O
1869	for	O
1869	the	O
1869	disease	O
1869	,	O
1869	no	O
1869	non	O
1869	-	O
1869	MHC	O
1869	gene	O
1869	has	O
1869	yet	O
1869	been	O
1869	convincingly	O
1869	demonstrated	O
1869	to	O
1869	influence	O
1869	either	O
1869	susceptibility	O
1869	to	O
1869	the	O
1869	disease	O
1869	or	O
1869	its	O
1869	phenotypic	O
1869	expression	O
1869	.	O
1870	Previous	O
1870	linkage	O
1870	and	O
1870	association	O
1870	studies	O
1870	have	O
1870	suggested	O
1870	the	O
1870	presence	O
1870	of	O
1870	a	O
1870	susceptibility	O
1870	gene	O
1870	for	O
1870	AS	B-Disease
1870	close	O
1870	to	O
1870	,	O
1870	or	O
1870	within	O
1870	,	O
1870	the	O
1870	cytochrome	O
1870	P450	O
1870	2D6	O
1870	gene	O
1870	(	O
1870	CYP2D6	O
1870	,	O
1870	debrisoquine	O
1870	hydroxylase	O
1870	)	O
1870	located	O
1870	at	O
1870	chromosome	O
1870	22q13	O
1870	.	O
1870	1	O
1870	.	O
1871	We	O
1871	performed	O
1871	a	O
1871	linkage	O
1871	study	O
1871	of	O
1871	chromosome	O
1871	22	O
1871	in	O
1871	200	O
1871	families	O
1871	with	O
1871	AS	B-Disease
1871	affected	O
1871	sibling	O
1871	-	O
1871	pairs	O
1871	.	O
1872	Association	O
1872	of	O
1872	alleles	O
1872	of	O
1872	the	O
1872	CYP2D6	O
1872	gene	O
1872	was	O
1872	examined	O
1872	by	O
1872	both	O
1872	case	O
1872	-	O
1872	control	O
1872	and	O
1872	within	O
1872	-	O
1872	family	O
1872	means	O
1872	.	O
1873	For	O
1873	case	O
1873	-	O
1873	control	O
1873	studies	O
1873	,	O
1873	617	O
1873	unrelated	O
1873	individuals	O
1873	with	O
1873	AS	B-Disease
1873	(	O
1873	361	O
1873	probands	O
1873	from	O
1873	sibling	O
1873	-	O
1873	pair	O
1873	and	O
1873	parent	O
1873	-	O
1873	case	O
1873	trio	O
1873	families	O
1873	and	O
1873	256	O
1873	unrelated	O
1873	non	O
1873	-	O
1873	familial	O
1873	sporadic	O
1873	cases	O
1873	)	O
1873	and	O
1873	402	O
1873	healthy	O
1873	ethnically	O
1873	matched	O
1873	controls	O
1873	were	O
1873	employed	O
1873	.	O
1874	For	O
1874	within	O
1874	-	O
1874	family	O
1874	association	O
1874	studies	O
1874	,	O
1874	361	O
1874	families	O
1874	including	O
1874	161	O
1874	parent	O
1874	-	O
1874	case	O
1874	trios	O
1874	and	O
1874	200	O
1874	affected	O
1874	sibling	O
1874	-	O
1874	pair	O
1874	families	O
1874	were	O
1874	employed	O
1874	.	O
1875	Homozygosity	O
1875	for	O
1875	poor	O
1875	metabolizer	O
1875	alleles	O
1875	was	O
1875	found	O
1875	to	O
1875	be	O
1875	associated	O
1875	with	O
1875	AS	B-Disease
1875	.	O
1876	Heterozygosity	O
1876	for	O
1876	the	O
1876	most	O
1876	frequent	O
1876	poor	O
1876	metabolizer	O
1876	allele	O
1876	(	O
1876	CYP2D6	O
1876	*	O
1876	4	O
1876	)	O
1876	was	O
1876	not	O
1876	associated	O
1876	with	O
1876	increased	O
1876	susceptibility	O
1876	to	O
1876	AS	B-Disease
1876	.	O
1877	Significant	O
1877	within	O
1877	-	O
1877	family	O
1877	association	O
1877	of	O
1877	CYP2D6	O
1877	*	O
1877	4	O
1877	alleles	O
1877	and	O
1877	AS	B-Disease
1877	was	O
1877	demonstrated	O
1877	.	O
1878	Weak	O
1878	linkage	O
1878	was	O
1878	also	O
1878	demonstrated	O
1878	between	O
1878	CYP2D6	O
1878	and	O
1878	AS	B-Disease
1878	.	O
1879	We	O
1879	postulate	O
1879	that	O
1879	altered	O
1879	metabolism	O
1879	of	O
1879	a	O
1879	natural	O
1879	toxin	O
1879	or	O
1879	antigen	O
1879	by	O
1879	the	O
1879	CYP2D6	O
1879	gene	O
1879	may	O
1879	increase	O
1879	susceptibility	O
1879	to	O
1879	AS	B-Disease
1879	.	O
1880	Functional	O
1880	differences	O
1880	of	O
1880	the	O
1880	PDS	B-Disease
1880	gene	O
1880	product	O
1880	are	O
1880	associated	O
1880	with	O
1880	phenotypic	O
1880	variation	O
1880	in	O
1880	patients	O
1880	with	O
1880	Pendred	B-Disease
1880	syndrome	I-Disease
1880	and	O
1880	non	B-Disease
1880	-	I-Disease
1880	syndromic	I-Disease
1880	hearing	I-Disease
1880	loss	I-Disease
1880	(	O
1880	DFNB4	B-Disease
1880	)	O
1880	.	O
1881	The	O
1881	PDS	B-Disease
1881	gene	O
1881	encodes	O
1881	a	O
1881	transmembrane	O
1881	protein	O
1881	,	O
1881	known	O
1881	as	O
1881	pendrin	O
1881	,	O
1881	which	O
1881	functions	O
1881	as	O
1881	a	O
1881	transporter	O
1881	of	O
1881	iodide	O
1881	and	O
1881	chloride	O
1881	.	O
1882	Mutations	O
1882	in	O
1882	this	O
1882	gene	O
1882	are	O
1882	responsible	O
1882	for	O
1882	Pendred	B-Disease
1882	syndrome	I-Disease
1882	and	O
1882	autosomal	B-Disease
1882	recessive	I-Disease
1882	non	I-Disease
1882	-	I-Disease
1882	syndromic	I-Disease
1882	hearing	I-Disease
1882	loss	I-Disease
1882	at	O
1882	the	O
1882	DFNB4	B-Disease
1882	locus	O
1882	on	O
1882	chromosome	O
1882	7q31	O
1882	.	O
1883	A	O
1883	screen	O
1883	of	O
1883	20	O
1883	individuals	O
1883	from	O
1883	the	O
1883	midwestern	O
1883	USA	O
1883	with	O
1883	non	B-Disease
1883	-	I-Disease
1883	syndromic	I-Disease
1883	hearing	I-Disease
1883	loss	I-Disease
1883	and	O
1883	dilated	O
1883	vestibular	O
1883	aqueducts	O
1883	identified	O
1883	three	O
1883	people	O
1883	(	O
1883	15	O
1883	%	O
1883	)	O
1883	with	O
1883	PDS	B-Disease
1883	mutations	O
1883	.	O
1884	To	O
1884	determine	O
1884	whether	O
1884	PDS	B-Disease
1884	mutations	O
1884	in	O
1884	individuals	O
1884	with	O
1884	Pendred	B-Disease
1884	syndrome	I-Disease
1884	differ	O
1884	functionally	O
1884	from	O
1884	PDS	B-Disease
1884	mutations	O
1884	in	O
1884	individuals	O
1884	with	O
1884	non	B-Disease
1884	-	I-Disease
1884	syndromic	I-Disease
1884	hearing	I-Disease
1884	loss	I-Disease
1884	,	O
1884	we	O
1884	compared	O
1884	three	O
1884	common	O
1884	Pendred	B-Disease
1884	syndrome	I-Disease
1884	allele	O
1884	variants	O
1884	(	O
1884	L236P	O
1884	,	O
1884	T416P	O
1884	and	O
1884	E384G	O
1884	)	O
1884	,	O
1884	with	O
1884	three	O
1884	PDS	B-Disease
1884	mutations	O
1884	reported	O
1884	only	O
1884	in	O
1884	individuals	O
1884	with	O
1884	non	B-Disease
1884	-	I-Disease
1884	syndromic	I-Disease
1884	hearing	I-Disease
1884	loss	I-Disease
1884	(	O
1884	V480D	O
1884	,	O
1884	V653A	O
1884	and	O
1884	I490L	O
1884	/	O
1884	G497S	O
1884	)	O
1884	.	O
1885	The	O
1885	mutations	O
1885	associated	O
1885	with	O
1885	Pendred	B-Disease
1885	syndrome	I-Disease
1885	have	O
1885	complete	O
1885	loss	O
1885	of	O
1885	pendrin	O
1885	-	O
1885	induced	O
1885	chloride	O
1885	and	O
1885	iodide	O
1885	transport	O
1885	,	O
1885	while	O
1885	alleles	O
1885	unique	O
1885	to	O
1885	people	O
1885	with	O
1885	DFNB4	B-Disease
1885	are	O
1885	able	O
1885	to	O
1885	transport	O
1885	both	O
1885	iodide	O
1885	and	O
1885	chloride	O
1885	,	O
1885	albeit	O
1885	at	O
1885	a	O
1885	much	O
1885	lower	O
1885	level	O
1885	than	O
1885	wild	O
1885	-	O
1885	type	O
1885	pendrin	O
1885	.	O
1886	We	O
1886	hypothesize	O
1886	that	O
1886	this	O
1886	residual	O
1886	level	O
1886	of	O
1886	anion	O
1886	transport	O
1886	is	O
1886	sufficient	O
1886	to	O
1886	eliminate	O
1886	or	O
1886	postpone	O
1886	the	O
1886	onset	O
1886	of	O
1886	goiter	B-Disease
1886	in	O
1886	individuals	O
1886	with	O
1886	DFNB4	B-Disease
1886	.	O
1887	We	O
1887	propose	O
1887	a	O
1887	model	O
1887	for	O
1887	pendrin	O
1887	function	O
1887	in	O
1887	the	O
1887	thyroid	O
1887	in	O
1887	which	O
1887	pendrin	O
1887	transports	O
1887	iodide	O
1887	across	O
1887	the	O
1887	apical	O
1887	membrane	O
1887	of	O
1887	the	O
1887	thyrocyte	O
1887	into	O
1887	the	O
1887	colloid	O
1887	space	O
1887	.	O
1887	.	O
1888	The	O
1888	human	O
1888	factor	O
1888	IX	O
1888	gene	O
1888	as	O
1888	germline	O
1888	mutagen	O
1888	test	O
1888	:	O
1888	samples	O
1888	from	O
1888	Mainland	O
1888	China	O
1888	have	O
1888	the	O
1888	putatively	O
1888	endogenous	O
1888	pattern	O
1888	of	O
1888	mutation	O
1888	.	O
1889	Germline	O
1889	mutations	O
1889	are	O
1889	the	O
1889	major	O
1889	source	O
1889	of	O
1889	genetic	O
1889	variation	O
1889	that	O
1889	allows	O
1889	a	O
1889	species	O
1889	to	O
1889	evolve	O
1889	over	O
1889	time	O
1889	but	O
1889	at	O
1889	the	O
1889	cost	O
1889	of	O
1889	Mendelian	B-Disease
1889	disease	I-Disease
1889	and	O
1889	genetic	O
1889	predisposition	O
1889	to	O
1889	multifactorial	B-Disease
1889	diseases	I-Disease
1889	.	O
1890	Previous	O
1890	analyses	O
1890	have	O
1890	revealed	O
1890	that	O
1890	the	O
1890	pattern	O
1890	of	O
1890	germline	O
1890	mutations	O
1890	in	O
1890	the	O
1890	factor	O
1890	IX	O
1890	gene	O
1890	(	O
1890	F9	O
1890	)	O
1890	is	O
1890	similar	O
1890	among	O
1890	a	O
1890	variety	O
1890	of	O
1890	ethnically	O
1890	and	O
1890	geographically	O
1890	diverse	O
1890	populations	O
1890	and	O
1890	compatible	O
1890	with	O
1890	the	O
1890	ancient	O
1890	pattern	O
1890	that	O
1890	has	O
1890	shaped	O
1890	the	O
1890	mammalian	O
1890	genome	O
1890	.	O
1891	Here	O
1891	,	O
1891	we	O
1891	compare	O
1891	the	O
1891	pattern	O
1891	of	O
1891	germline	O
1891	mutation	O
1891	in	O
1891	a	O
1891	population	O
1891	of	O
1891	hemophilia	B-Disease
1891	B	I-Disease
1891	patients	O
1891	from	O
1891	Mainland	O
1891	China	O
1891	(	O
1891	n	O
1891	=	O
1891	66	O
1891	)	O
1891	to	O
1891	that	O
1891	in	O
1891	U	O
1891	.	O
1892	S	O
1892	.	O
1893	Caucasians	O
1893	,	O
1893	Blacks	O
1893	,	O
1893	and	O
1893	Mexican	O
1893	Hispanics	O
1893	and	O
1893	stratify	O
1893	by	O
1893	disease	O
1893	severity	O
1893	and	O
1893	ethnicity	O
1893	.	O
1894	The	O
1894	similar	O
1894	pattern	O
1894	of	O
1894	germline	O
1894	mutation	O
1894	in	O
1894	all	O
1894	ethnic	O
1894	groups	O
1894	studied	O
1894	to	O
1894	date	O
1894	provides	O
1894	additional	O
1894	data	O
1894	compatible	O
1894	with	O
1894	the	O
1894	inference	O
1894	that	O
1894	endogenous	O
1894	processes	O
1894	predominate	O
1894	in	O
1894	germline	O
1894	mutations	O
1894	.	O
1895	Fas	O
1895	preassociation	O
1895	required	O
1895	for	O
1895	apoptosis	O
1895	signaling	O
1895	and	O
1895	dominant	O
1895	inhibition	O
1895	by	O
1895	pathogenic	O
1895	mutations	O
1895	.	O
1896	Heterozygous	O
1896	mutations	O
1896	encoding	O
1896	abnormal	O
1896	forms	O
1896	of	O
1896	the	O
1896	death	O
1896	receptor	O
1896	Fas	O
1896	dominantly	O
1896	interfere	O
1896	with	O
1896	Fas	O
1896	-	O
1896	induced	O
1896	lymphocyte	O
1896	apoptosis	O
1896	in	O
1896	human	O
1896	autoimmune	B-Disease
1896	lymphoproliferative	I-Disease
1896	syndrome	I-Disease
1896	.	O
1897	This	O
1897	effect	O
1897	,	O
1897	rather	O
1897	than	O
1897	depending	O
1897	on	O
1897	ligand	O
1897	-	O
1897	induced	O
1897	receptor	O
1897	oligomerization	O
1897	,	O
1897	was	O
1897	found	O
1897	to	O
1897	stem	O
1897	from	O
1897	ligand	O
1897	-	O
1897	independent	O
1897	interaction	O
1897	of	O
1897	wild	O
1897	-	O
1897	type	O
1897	and	O
1897	mutant	O
1897	Fas	O
1897	receptors	O
1897	through	O
1897	a	O
1897	specific	O
1897	region	O
1897	in	O
1897	the	O
1897	extracellular	O
1897	domain	O
1897	.	O
1898	Preassociated	O
1898	Fas	O
1898	complexes	O
1898	were	O
1898	found	O
1898	in	O
1898	living	O
1898	cells	O
1898	by	O
1898	means	O
1898	of	O
1898	fluorescence	O
1898	resonance	O
1898	energy	O
1898	transfer	O
1898	between	O
1898	variants	O
1898	of	O
1898	green	O
1898	fluorescent	O
1898	protein	O
1898	.	O
1899	These	O
1899	results	O
1899	show	O
1899	that	O
1899	formation	O
1899	of	O
1899	preassociated	O
1899	receptor	O
1899	complexes	O
1899	is	O
1899	necessary	O
1899	for	O
1899	Fas	O
1899	signaling	O
1899	and	O
1899	dominant	O
1899	interference	O
1899	in	O
1899	human	O
1899	disease	O
1899	.	O
1899	.	O
1900	Determination	O
1900	of	O
1900	carrier	O
1900	status	O
1900	for	O
1900	the	O
1900	Wiskott	B-Disease
1900	-	I-Disease
1900	Aldrich	I-Disease
1900	syndrome	I-Disease
1900	by	O
1900	flow	O
1900	cytometric	O
1900	analysis	O
1900	of	O
1900	Wiskott	B-Disease
1900	-	I-Disease
1900	Aldrich	I-Disease
1900	syndrome	I-Disease
1900	protein	O
1900	expression	O
1900	in	O
1900	peripheral	O
1900	blood	O
1900	mononuclear	O
1900	cells	O
1900	.	O
1901	The	O
1901	Wiskott	B-Disease
1901	-	I-Disease
1901	Aldrich	I-Disease
1901	syndrome	I-Disease
1901	(	O
1901	WAS	B-Disease
1901	)	O
1901	is	O
1901	caused	O
1901	by	O
1901	defects	O
1901	in	O
1901	the	O
1901	WAS	B-Disease
1901	protein	O
1901	(	O
1901	WASP	O
1901	)	O
1901	gene	O
1901	on	O
1901	the	O
1901	X	O
1901	chromosome	O
1901	.	O
1902	Previous	O
1902	study	O
1902	disclosed	O
1902	that	O
1902	flow	O
1902	cytometric	O
1902	analysis	O
1902	of	O
1902	intracellular	O
1902	WASP	O
1902	expression	O
1902	(	O
1902	FCM	O
1902	-	O
1902	WASP	O
1902	analysis	O
1902	)	O
1902	in	O
1902	lymphocytes	O
1902	was	O
1902	useful	O
1902	for	O
1902	the	O
1902	diagnosis	O
1902	of	O
1902	WAS	B-Disease
1902	patients	O
1902	.	O
1903	Lymphocytes	O
1903	from	O
1903	all	O
1903	WAS	B-Disease
1903	patients	O
1903	showed	O
1903	WASPdim	O
1903	instead	O
1903	of	O
1903	WASPbright	O
1903	.	O
1904	Here	O
1904	we	O
1904	report	O
1904	that	O
1904	FCM	O
1904	-	O
1904	WASP	O
1904	analysis	O
1904	in	O
1904	monocytes	O
1904	could	O
1904	be	O
1904	a	O
1904	useful	O
1904	tool	O
1904	for	O
1904	the	O
1904	WAS	B-Disease
1904	carrier	O
1904	diagnosis	O
1904	.	O
1905	Monocytes	O
1905	from	O
1905	all	O
1905	nine	O
1905	WAS	B-Disease
1905	carriers	O
1905	showed	O
1905	varied	O
1905	population	O
1905	of	O
1905	WASPdim	O
1905	together	O
1905	with	O
1905	WASPbright	O
1905	.	O
1906	None	O
1906	of	O
1906	control	O
1906	individuals	O
1906	possessed	O
1906	the	O
1906	WASPdim	O
1906	population	O
1906	.	O
1907	In	O
1907	contrast	O
1907	,	O
1907	lymphocytes	O
1907	from	O
1907	all	O
1907	the	O
1907	carriers	O
1907	except	O
1907	two	O
1907	lacked	O
1907	the	O
1907	WASPdim	O
1907	population	O
1907	.	O
1908	The	O
1908	difference	O
1908	of	O
1908	the	O
1908	WASPdim	O
1908	population	O
1908	in	O
1908	monocytes	O
1908	and	O
1908	lymphocytes	O
1908	observed	O
1908	in	O
1908	WAS	B-Disease
1908	carriers	O
1908	suggests	O
1908	that	O
1908	WASP	O
1908	plays	O
1908	a	O
1908	more	O
1908	critical	O
1908	role	O
1908	in	O
1908	the	O
1908	development	O
1908	of	O
1908	lymphocytes	O
1908	than	O
1908	in	O
1908	that	O
1908	of	O
1908	monocytes	O
1908	.	O
1909	The	O
1909	present	O
1909	studies	O
1909	suggest	O
1909	that	O
1909	a	O
1909	skewed	O
1909	X	O
1909	-	O
1909	chromosomal	O
1909	inactivation	O
1909	pattern	O
1909	observed	O
1909	in	O
1909	WAS	B-Disease
1909	carrier	O
1909	peripheral	O
1909	blood	O
1909	cells	O
1909	is	O
1909	not	O
1909	fixed	O
1909	at	O
1909	the	O
1909	hemopoietic	O
1909	stem	O
1909	cell	O
1909	level	O
1909	but	O
1909	progresses	O
1909	after	O
1909	the	O
1909	lineage	O
1909	commitment	O
1909	.	O
1909	.	O
1910	Restoration	O
1910	of	O
1910	photoreceptor	O
1910	ultrastructure	O
1910	and	O
1910	function	O
1910	in	O
1910	retinal	B-Disease
1910	degeneration	I-Disease
1910	slow	O
1910	mice	O
1910	by	O
1910	gene	O
1910	therapy	O
1910	.	O
1911	The	O
1911	gene	O
1911	Prph2	O
1911	encodes	O
1911	a	O
1911	photoreceptor	O
1911	-	O
1911	specific	O
1911	membrane	O
1911	glycoprotein	O
1911	,	O
1911	peripherin	O
1911	-	O
1911	2	O
1911	(	O
1911	also	O
1911	known	O
1911	as	O
1911	peripherin	O
1911	/	O
1911	rds	O
1911	)	O
1911	,	O
1911	which	O
1911	is	O
1911	inserted	O
1911	into	O
1911	the	O
1911	rims	O
1911	of	O
1911	photoreceptor	O
1911	outer	O
1911	segment	O
1911	discs	O
1911	in	O
1911	a	O
1911	complex	O
1911	with	O
1911	rom	O
1911	-	O
1911	1	O
1911	(	O
1911	ref	O
1911	.	O
1911	2	O
1911	)	O
1911	.	O
1912	The	O
1912	complex	O
1912	is	O
1912	necessary	O
1912	for	O
1912	the	O
1912	stabilization	O
1912	of	O
1912	the	O
1912	discs	O
1912	,	O
1912	which	O
1912	are	O
1912	renewed	O
1912	constantly	O
1912	throughout	O
1912	life	O
1912	,	O
1912	and	O
1912	which	O
1912	contain	O
1912	the	O
1912	visual	O
1912	pigments	O
1912	necessary	O
1912	for	O
1912	photon	O
1912	capture	O
1912	.	O
1913	Mutations	O
1913	in	O
1913	Prph2	O
1913	have	O
1913	been	O
1913	shown	O
1913	to	O
1913	result	O
1913	in	O
1913	a	O
1913	variety	O
1913	of	O
1913	photoreceptor	B-Disease
1913	dystrophies	I-Disease
1913	,	O
1913	including	O
1913	autosomal	B-Disease
1913	dominant	I-Disease
1913	retinitis	I-Disease
1913	pigmentosa	I-Disease
1913	and	O
1913	macular	B-Disease
1913	dystrophy	I-Disease
1913	.	O
1914	A	O
1914	common	O
1914	feature	O
1914	of	O
1914	these	O
1914	diseases	O
1914	is	O
1914	the	O
1914	loss	O
1914	of	O
1914	photoreceptor	O
1914	function	O
1914	,	O
1914	also	O
1914	seen	O
1914	in	O
1914	the	O
1914	retinal	B-Disease
1914	degeneration	I-Disease
1914	slow	O
1914	(	O
1914	rds	O
1914	or	O
1914	Prph2	O
1914	Rd2	O
1914	/	O
1914	Rd2	O
1914	)	O
1914	mouse	O
1914	,	O
1914	which	O
1914	is	O
1914	homozygous	O
1914	for	O
1914	a	O
1914	mutation	O
1914	in	O
1914	Prph2	O
1914	.	O
1915	It	O
1915	is	O
1915	characterized	O
1915	by	O
1915	a	O
1915	complete	O
1915	failure	O
1915	to	O
1915	develop	O
1915	photoreceptor	O
1915	discs	O
1915	and	O
1915	outer	O
1915	segments	O
1915	,	O
1915	downregulation	O
1915	of	O
1915	rhodopsin	O
1915	and	O
1915	apoptotic	O
1915	loss	O
1915	of	O
1915	photoreceptor	O
1915	cells	O
1915	.	O
1916	The	O
1916	electroretinograms	O
1916	(	O
1916	ERGs	O
1916	)	O
1916	of	O
1916	Prph2Rd2	O
1916	/	O
1916	Rd2	O
1916	mice	O
1916	have	O
1916	greatly	O
1916	diminished	O
1916	a	O
1916	-	O
1916	wave	O
1916	and	O
1916	b	O
1916	-	O
1916	wave	O
1916	amplitudes	O
1916	,	O
1916	which	O
1916	decline	O
1916	to	O
1916	virtually	O
1916	undetectable	O
1916	concentrations	O
1916	by	O
1916	two	O
1916	months	O
1916	.	O
1917	Subretinal	O
1917	injection	O
1917	of	O
1917	recombinant	O
1917	adeno	O
1917	-	O
1917	associated	O
1917	virus	O
1917	(	O
1917	AAV	O
1917	)	O
1917	encoding	O
1917	a	O
1917	Prph2	O
1917	transgene	O
1917	results	O
1917	in	O
1917	stable	O
1917	generation	O
1917	of	O
1917	outer	O
1917	segment	O
1917	structures	O
1917	and	O
1917	formation	O
1917	of	O
1917	new	O
1917	stacks	O
1917	of	O
1917	discs	O
1917	containing	O
1917	both	O
1917	perpherin	O
1917	-	O
1917	2	O
1917	and	O
1917	rhodopsin	O
1917	,	O
1917	which	O
1917	in	O
1917	many	O
1917	cases	O
1917	are	O
1917	morphologically	O
1917	similar	O
1917	to	O
1917	normal	O
1917	outer	O
1917	segments	O
1917	.	O
1918	Moreover	O
1918	,	O
1918	the	O
1918	re	O
1918	-	O
1918	establishment	O
1918	of	O
1918	the	O
1918	structural	O
1918	integrity	O
1918	of	O
1918	the	O
1918	photoreceptor	O
1918	layer	O
1918	also	O
1918	results	O
1918	in	O
1918	electrophysiological	O
1918	correction	O
1918	.	O
1919	These	O
1919	studies	O
1919	demonstrate	O
1919	for	O
1919	the	O
1919	first	O
1919	time	O
1919	that	O
1919	a	O
1919	complex	O
1919	ultrastructural	O
1919	cell	O
1919	defect	O
1919	can	O
1919	be	O
1919	corrected	O
1919	both	O
1919	morphologically	O
1919	and	O
1919	functionally	O
1919	by	O
1919	in	O
1919	vivo	O
1919	gene	O
1919	transfer	O
1919	.	O
1919	.	O
1920	Mutations	O
1920	in	O
1920	the	O
1920	fibrinogen	O
1920	aalpha	O
1920	gene	O
1920	account	O
1920	for	O
1920	the	O
1920	majority	O
1920	of	O
1920	cases	O
1920	of	O
1920	congenital	B-Disease
1920	afibrinogenemia	I-Disease
1920	.	O
1921	Congenital	B-Disease
1921	afibrinogenemia	I-Disease
1921	is	O
1921	a	O
1921	rare	O
1921	,	O
1921	autosomal	B-Disease
1921	,	I-Disease
1921	recessive	I-Disease
1921	disorder	I-Disease
1921	characterized	O
1921	by	O
1921	the	O
1921	complete	O
1921	absence	O
1921	of	O
1921	detectable	O
1921	fibrinogen	O
1921	.	O
1922	We	O
1922	previously	O
1922	identified	O
1922	the	O
1922	first	O
1922	causative	O
1922	mutations	O
1922	in	O
1922	a	O
1922	nonconsanguineous	O
1922	Swiss	O
1922	family	O
1922	;	O
1922	the	O
1922	4	O
1922	affected	O
1922	persons	O
1922	have	O
1922	homozygous	O
1922	deletions	O
1922	of	O
1922	approximately	O
1922	11	O
1922	kb	O
1922	of	O
1922	the	O
1922	fibrinogen	O
1922	alpha	O
1922	(	O
1922	FGA	O
1922	)	O
1922	gene	O
1922	.	O
1923	Haplotype	O
1923	data	O
1923	implied	O
1923	that	O
1923	these	O
1923	deletions	O
1923	occurred	O
1923	on	O
1923	distinct	O
1923	ancestral	O
1923	chromosomes	O
1923	,	O
1923	suggesting	O
1923	that	O
1923	this	O
1923	region	O
1923	may	O
1923	be	O
1923	susceptible	O
1923	to	O
1923	deletion	O
1923	by	O
1923	a	O
1923	common	O
1923	mechanism	O
1923	.	O
1924	We	O
1924	subsequently	O
1924	showed	O
1924	that	O
1924	all	O
1924	the	O
1924	deletions	O
1924	were	O
1924	identical	O
1924	to	O
1924	the	O
1924	base	O
1924	pair	O
1924	and	O
1924	probably	O
1924	resulted	O
1924	from	O
1924	a	O
1924	nonhomologous	O
1924	recombination	O
1924	mediated	O
1924	by	O
1924	7	O
1924	-	O
1924	bp	O
1924	direct	O
1924	repeats	O
1924	.	O
1925	In	O
1925	this	O
1925	study	O
1925	,	O
1925	we	O
1925	have	O
1925	collected	O
1925	data	O
1925	on	O
1925	13	O
1925	additional	O
1925	unrelated	O
1925	patients	O
1925	to	O
1925	identify	O
1925	the	O
1925	causative	O
1925	mutations	O
1925	and	O
1925	to	O
1925	determine	O
1925	the	O
1925	prevalence	O
1925	of	O
1925	the	O
1925	11	O
1925	-	O
1925	kb	O
1925	deletion	O
1925	.	O
1926	A	O
1926	common	O
1926	recurrent	O
1926	mutation	O
1926	,	O
1926	at	O
1926	the	O
1926	donor	O
1926	splice	O
1926	site	O
1926	of	O
1926	FGA	O
1926	intron	O
1926	4	O
1926	(	O
1926	IVS4	O
1926	+	O
1926	1	O
1926	G	O
1926	>	O
1926	T	O
1926	)	O
1926	,	O
1926	accounted	O
1926	for	O
1926	14	O
1926	of	O
1926	the	O
1926	26	O
1926	(	O
1926	54	O
1926	%	O
1926	)	O
1926	alleles	O
1926	.	O
1927	One	O
1927	patient	O
1927	was	O
1927	heterozygous	O
1927	for	O
1927	the	O
1927	previously	O
1927	identified	O
1927	deletion	O
1927	.	O
1928	Three	O
1928	more	O
1928	frameshift	O
1928	mutations	O
1928	,	O
1928	2	O
1928	nonsense	O
1928	mutations	O
1928	,	O
1928	and	O
1928	a	O
1928	second	O
1928	splice	O
1928	site	O
1928	mutation	O
1928	were	O
1928	also	O
1928	identified	O
1928	.	O
1929	Consequently	O
1929	,	O
1929	86	O
1929	%	O
1929	of	O
1929	afibrinogenemia	B-Disease
1929	alleles	O
1929	analyzed	O
1929	to	O
1929	date	O
1929	have	O
1929	truncating	O
1929	mutations	O
1929	of	O
1929	FGA	O
1929	,	O
1929	though	O
1929	mutations	O
1929	in	O
1929	all	O
1929	3	O
1929	fibrinogen	O
1929	genes	O
1929	,	O
1929	FGG	O
1929	,	O
1929	FGA	O
1929	,	O
1929	and	O
1929	FGB	O
1929	,	O
1929	might	O
1929	be	O
1929	predicted	O
1929	to	O
1929	cause	O
1929	congenital	B-Disease
1929	afibrinogenemia	I-Disease
1929	.	O
1929	.	O
1930	Myotonic	B-Disease
1930	dystrophy	I-Disease
1930	:	O
1930	the	O
1930	role	O
1930	of	O
1930	the	O
1930	CUG	O
1930	triplet	O
1930	repeats	O
1930	in	O
1930	splicing	O
1930	of	O
1930	a	O
1930	novel	O
1930	DMPK	O
1930	exon	O
1930	and	O
1930	altered	O
1930	cytoplasmic	O
1930	DMPK	O
1930	mRNA	O
1930	isoform	O
1930	ratios	O
1930	.	O
1931	The	O
1931	mechanism	O
1931	by	O
1931	which	O
1931	(	O
1931	CTG	O
1931	)	O
1931	n	O
1931	expansion	O
1931	in	O
1931	the	O
1931	3	O
1931	UTR	O
1931	of	O
1931	the	O
1931	DMPK	O
1931	gene	O
1931	causes	O
1931	myotonic	B-Disease
1931	dystrophy	I-Disease
1931	(	O
1931	DM	B-Disease
1931	)	O
1931	is	O
1931	unknown	O
1931	.	O
1932	We	O
1932	identified	O
1932	four	O
1932	RNA	O
1932	splicing	O
1932	factors	O
1932	-	O
1932	-	O
1932	hnRNP	O
1932	C	O
1932	,	O
1932	U2AF	O
1932	(	O
1932	U2	O
1932	auxiliary	O
1932	factor	O
1932	)	O
1932	,	O
1932	PTB	O
1932	(	O
1932	polypyrimidine	O
1932	tract	O
1932	binding	O
1932	protein	O
1932	)	O
1932	,	O
1932	and	O
1932	PSF	O
1932	(	O
1932	PTB	O
1932	associated	O
1932	splicing	O
1932	factor	O
1932	)	O
1932	-	O
1932	-	O
1932	that	O
1932	bind	O
1932	to	O
1932	two	O
1932	short	O
1932	regions	O
1932	3	O
1932	of	O
1932	the	O
1932	(	O
1932	CUG	O
1932	)	O
1932	n	O
1932	,	O
1932	and	O
1932	found	O
1932	a	O
1932	novel	O
1932	3	O
1932	DMPK	O
1932	exon	O
1932	resulting	O
1932	in	O
1932	an	O
1932	mRNA	O
1932	lacking	O
1932	the	O
1932	repeats	O
1932	.	O
1933	We	O
1933	propose	O
1933	that	O
1933	the	O
1933	(	O
1933	CUG	O
1933	)	O
1933	n	O
1933	is	O
1933	an	O
1933	essential	O
1933	cis	O
1933	acting	O
1933	element	O
1933	for	O
1933	this	O
1933	splicing	O
1933	event	O
1933	.	O
1934	In	O
1934	contrast	O
1934	to	O
1934	(	O
1934	CUG	O
1934	)	O
1934	n	O
1934	containing	O
1934	mRNAs	O
1934	,	O
1934	the	O
1934	novel	O
1934	isoform	O
1934	is	O
1934	not	O
1934	retained	O
1934	in	O
1934	the	O
1934	nucleus	O
1934	in	O
1934	DM	B-Disease
1934	cells	O
1934	,	O
1934	resulting	O
1934	in	O
1934	imbalances	O
1934	in	O
1934	relative	O
1934	levels	O
1934	of	O
1934	cytoplasmic	O
1934	DMPK	O
1934	mRNA	O
1934	isoforms	O
1934	and	O
1934	a	O
1934	new	O
1934	dominant	O
1934	effect	O
1934	of	O
1934	the	O
1934	mutation	O
1934	on	O
1934	DMPK	O
1934	.	O
1934	.	O
1935	Expression	O
1935	and	O
1935	imprinting	O
1935	of	O
1935	MAGEL2	O
1935	suggest	O
1935	a	O
1935	role	O
1935	in	O
1935	Prader	B-Disease
1935	-	I-Disease
1935	willi	I-Disease
1935	syndrome	I-Disease
1935	and	O
1935	the	O
1935	homologous	O
1935	murine	O
1935	imprinting	O
1935	phenotype	O
1935	.	O
1936	Prader	B-Disease
1936	-	I-Disease
1936	Willi	I-Disease
1936	syndrome	I-Disease
1936	(	O
1936	PWS	B-Disease
1936	)	O
1936	is	O
1936	caused	O
1936	by	O
1936	the	O
1936	loss	O
1936	of	O
1936	expression	O
1936	of	O
1936	imprinted	O
1936	genes	O
1936	in	O
1936	chromosome	O
1936	15q11	O
1936	-	O
1936	q13	O
1936	.	O
1937	Affected	O
1937	individuals	O
1937	exhibit	O
1937	neonatal	B-Disease
1937	hypotonia	I-Disease
1937	,	O
1937	developmental	B-Disease
1937	delay	I-Disease
1937	and	O
1937	childhood	B-Disease
1937	-	I-Disease
1937	onset	I-Disease
1937	obesity	I-Disease
1937	.	O
1938	Necdin	O
1938	,	O
1938	a	O
1938	protein	O
1938	implicated	O
1938	in	O
1938	the	O
1938	terminal	O
1938	differentiation	O
1938	of	O
1938	neurons	O
1938	,	O
1938	is	O
1938	the	O
1938	only	O
1938	PWS	B-Disease
1938	candidate	O
1938	gene	O
1938	to	O
1938	reduce	O
1938	viability	O
1938	when	O
1938	disrupted	O
1938	in	O
1938	a	O
1938	mouse	O
1938	model	O
1938	.	O
1939	In	O
1939	this	O
1939	study	O
1939	,	O
1939	we	O
1939	have	O
1939	characterized	O
1939	MAGEL2	O
1939	(	O
1939	also	O
1939	known	O
1939	as	O
1939	NDNL1	O
1939	)	O
1939	,	O
1939	a	O
1939	gene	O
1939	with	O
1939	51	O
1939	%	O
1939	amino	O
1939	acid	O
1939	sequence	O
1939	similarity	O
1939	to	O
1939	necdin	O
1939	and	O
1939	located	O
1939	41	O
1939	kb	O
1939	distal	O
1939	to	O
1939	NDN	O
1939	in	O
1939	the	O
1939	PWS	B-Disease
1939	deletion	O
1939	region	O
1939	.	O
1940	MAGEL2	O
1940	is	O
1940	expressed	O
1940	predominantly	O
1940	in	O
1940	brain	O
1940	,	O
1940	the	O
1940	primary	O
1940	tissue	O
1940	affected	O
1940	in	O
1940	PWS	B-Disease
1940	and	O
1940	in	O
1940	several	O
1940	fetal	O
1940	tissues	O
1940	as	O
1940	shown	O
1940	by	O
1940	northern	O
1940	blot	O
1940	analysis	O
1940	.	O
1941	MAGEL2	O
1941	is	O
1941	imprinted	O
1941	with	O
1941	monoallelic	O
1941	expression	O
1941	in	O
1941	control	O
1941	brain	O
1941	,	O
1941	and	O
1941	paternal	O
1941	-	O
1941	only	O
1941	expression	O
1941	in	O
1941	the	O
1941	central	O
1941	nervous	O
1941	system	O
1941	as	O
1941	demonstrated	O
1941	by	O
1941	its	O
1941	lack	O
1941	of	O
1941	expression	O
1941	in	O
1941	brain	O
1941	from	O
1941	a	O
1941	PWS	B-Disease
1941	-	O
1941	affected	O
1941	individual	O
1941	.	O
1942	The	O
1942	orthologous	O
1942	mouse	O
1942	gene	O
1942	(	O
1942	Magel2	O
1942	)	O
1942	is	O
1942	located	O
1942	within	O
1942	150	O
1942	kb	O
1942	of	O
1942	NDN	O
1942	,	O
1942	is	O
1942	imprinted	O
1942	with	O
1942	paternal	O
1942	-	O
1942	only	O
1942	expression	O
1942	and	O
1942	is	O
1942	expressed	O
1942	predominantly	O
1942	in	O
1942	late	O
1942	developmental	O
1942	stages	O
1942	and	O
1942	adult	O
1942	brain	O
1942	as	O
1942	shown	O
1942	by	O
1942	northern	O
1942	blotting	O
1942	,	O
1942	RT	O
1942	-	O
1942	PCR	O
1942	and	O
1942	whole	O
1942	-	O
1942	mount	O
1942	RNA	O
1942	in	O
1942	situ	O
1942	hybridization	O
1942	.	O
1943	Magel2	O
1943	distribution	O
1943	partially	O
1943	overlaps	O
1943	that	O
1943	of	O
1943	NDN	O
1943	,	O
1943	with	O
1943	strong	O
1943	expression	O
1943	being	O
1943	detected	O
1943	in	O
1943	the	O
1943	central	O
1943	nervous	O
1943	system	O
1943	in	O
1943	mid	O
1943	-	O
1943	gestation	O
1943	mouse	O
1943	embryos	O
1943	by	O
1943	in	O
1943	situ	O
1943	hybridization	O
1943	.	O
1944	We	O
1944	hypothesize	O
1944	that	O
1944	,	O
1944	although	O
1944	loss	O
1944	of	O
1944	necdin	O
1944	expression	O
1944	may	O
1944	be	O
1944	important	O
1944	in	O
1944	the	O
1944	neonatal	O
1944	presentation	O
1944	of	O
1944	PWS	B-Disease
1944	,	O
1944	loss	O
1944	of	O
1944	MAGEL2	O
1944	may	O
1944	be	O
1944	critical	O
1944	to	O
1944	abnormalities	B-Disease
1944	in	I-Disease
1944	brain	I-Disease
1944	development	I-Disease
1944	and	O
1944	dysmorphic	B-Disease
1944	features	I-Disease
1944	in	O
1944	individuals	O
1944	with	O
1944	PWS	B-Disease
1944	.	O
1944	.	O
1945	Retinoschisin	O
1945	,	O
1945	the	O
1945	X	B-Disease
1945	-	I-Disease
1945	linked	I-Disease
1945	retinoschisis	I-Disease
1945	protein	O
1945	,	O
1945	is	O
1945	a	O
1945	secreted	O
1945	photoreceptor	O
1945	protein	O
1945	,	O
1945	and	O
1945	is	O
1945	expressed	O
1945	and	O
1945	released	O
1945	by	O
1945	Weri	O
1945	-	O
1945	Rb1	O
1945	cells	O
1945	.	O
1946	X	B-Disease
1946	-	I-Disease
1946	linked	I-Disease
1946	retinoschisis	I-Disease
1946	is	O
1946	characterized	O
1946	by	O
1946	microcystic	O
1946	-	O
1946	like	O
1946	changes	O
1946	of	O
1946	the	O
1946	macular	O
1946	region	O
1946	and	O
1946	schisis	O
1946	within	O
1946	the	O
1946	inner	O
1946	retinal	O
1946	layers	O
1946	,	O
1946	leading	O
1946	to	O
1946	visual	B-Disease
1946	deterioration	I-Disease
1946	in	O
1946	males	O
1946	.	O
1947	Many	O
1947	missense	O
1947	and	O
1947	protein	O
1947	-	O
1947	truncating	O
1947	mutations	O
1947	of	O
1947	the	O
1947	causative	O
1947	gene	O
1947	RS1	O
1947	have	O
1947	now	O
1947	been	O
1947	identified	O
1947	and	O
1947	are	O
1947	thought	O
1947	to	O
1947	be	O
1947	inactivating	O
1947	.	O
1948	RS1	O
1948	encodes	O
1948	a	O
1948	224	O
1948	amino	O
1948	acid	O
1948	protein	O
1948	,	O
1948	retinoschisin	O
1948	,	O
1948	which	O
1948	contains	O
1948	a	O
1948	discoidin	O
1948	domain	O
1948	but	O
1948	is	O
1948	of	O
1948	unknown	O
1948	function	O
1948	.	O
1949	We	O
1949	have	O
1949	generated	O
1949	a	O
1949	polyclonal	O
1949	antibody	O
1949	against	O
1949	a	O
1949	peptide	O
1949	from	O
1949	a	O
1949	unique	O
1949	region	O
1949	within	O
1949	retinoschisin	O
1949	,	O
1949	which	O
1949	detects	O
1949	a	O
1949	protein	O
1949	of	O
1949	approximately	O
1949	28	O
1949	kDa	O
1949	in	O
1949	retinal	O
1949	samples	O
1949	reduced	O
1949	with	O
1949	dithiothreitol	O
1949	,	O
1949	but	O
1949	multimers	O
1949	sized	O
1949	>	O
1949	40	O
1949	kDa	O
1949	under	O
1949	non	O
1949	-	O
1949	reducing	O
1949	conditions	O
1949	.	O
1950	A	O
1950	screen	O
1950	of	O
1950	human	O
1950	tissues	O
1950	with	O
1950	this	O
1950	antibody	O
1950	reveals	O
1950	retinoschisin	O
1950	to	O
1950	be	O
1950	retina	O
1950	specific	O
1950	and	O
1950	the	O
1950	antibody	O
1950	detects	O
1950	a	O
1950	protein	O
1950	of	O
1950	similar	O
1950	size	O
1950	in	O
1950	bovine	O
1950	and	O
1950	murine	O
1950	retinae	O
1950	.	O
1951	We	O
1951	investigated	O
1951	the	O
1951	expression	O
1951	pattern	O
1951	in	O
1951	the	O
1951	retina	O
1951	of	O
1951	both	O
1951	RS1	O
1951	mRNA	O
1951	(	O
1951	using	O
1951	in	O
1951	situ	O
1951	hybridization	O
1951	with	O
1951	riboprobes	O
1951	)	O
1951	and	O
1951	retinoschisin	O
1951	(	O
1951	using	O
1951	immunohistochemistry	O
1951	)	O
1951	.	O
1952	The	O
1952	antisense	O
1952	riboprobe	O
1952	detected	O
1952	RS1	O
1952	mRNA	O
1952	only	O
1952	in	O
1952	the	O
1952	photoreceptor	O
1952	layer	O
1952	but	O
1952	the	O
1952	protein	O
1952	product	O
1952	of	O
1952	the	O
1952	gene	O
1952	was	O
1952	present	O
1952	both	O
1952	in	O
1952	the	O
1952	photoreceptors	O
1952	and	O
1952	within	O
1952	the	O
1952	inner	O
1952	portions	O
1952	of	O
1952	the	O
1952	retina	O
1952	.	O
1953	Furthermore	O
1953	,	O
1953	differentiated	O
1953	retinoblastoma	B-Disease
1953	cells	O
1953	(	O
1953	Weri	O
1953	-	O
1953	Rb1	O
1953	cells	O
1953	)	O
1953	were	O
1953	found	O
1953	to	O
1953	express	O
1953	RS1	O
1953	mRNA	O
1953	and	O
1953	to	O
1953	release	O
1953	retinoschisin	O
1953	.	O
1954	These	O
1954	results	O
1954	suggest	O
1954	that	O
1954	retinoschisin	O
1954	is	O
1954	released	O
1954	by	O
1954	photo	O
1954	-	O
1954	receptors	O
1954	and	O
1954	has	O
1954	functions	O
1954	within	O
1954	the	O
1954	inner	O
1954	retinal	O
1954	layers	O
1954	.	O
1955	Thus	O
1955	,	O
1955	X	B-Disease
1955	-	I-Disease
1955	linked	I-Disease
1955	retinoschisis	I-Disease
1955	is	O
1955	caused	O
1955	by	O
1955	abnormalities	O
1955	in	O
1955	a	O
1955	putative	O
1955	secreted	O
1955	photoreceptor	O
1955	protein	O
1955	and	O
1955	is	O
1955	the	O
1955	first	O
1955	example	O
1955	of	O
1955	a	O
1955	secreted	O
1955	photo	O
1955	-	O
1955	receptor	O
1955	protein	O
1955	associated	O
1955	with	O
1955	a	O
1955	retinal	B-Disease
1955	dystrophy	I-Disease
1955	.	O
1955	.	O
1956	Study	O
1956	of	O
1956	the	O
1956	voltage	O
1956	-	O
1956	gated	O
1956	sodium	O
1956	channel	O
1956	beta	O
1956	1	O
1956	subunit	O
1956	gene	O
1956	(	O
1956	SCN1B	O
1956	)	O
1956	in	O
1956	the	O
1956	benign	B-Disease
1956	familial	I-Disease
1956	infantile	I-Disease
1956	convulsions	I-Disease
1956	syndrome	I-Disease
1956	(	O
1956	BFIC	B-Disease
1956	)	O
1956	.	O
1957	Benign	B-Disease
1957	familial	I-Disease
1957	infantile	I-Disease
1957	convulsions	I-Disease
1957	(	O
1957	BFIC	B-Disease
1957	)	O
1957	is	O
1957	a	O
1957	rare	O
1957	autosomal	B-Disease
1957	dominant	I-Disease
1957	epilepsy	I-Disease
1957	syndrome	I-Disease
1957	.	O
1958	This	O
1958	syndrome	O
1958	has	O
1958	been	O
1958	recently	O
1958	described	O
1958	in	O
1958	Italian	O
1958	and	O
1958	French	O
1958	pedigrees	O
1958	.	O
1959	Patients	O
1959	present	O
1959	with	O
1959	partial	O
1959	,	O
1959	then	O
1959	generalized	O
1959	seizures	O
1959	,	O
1959	with	O
1959	onset	O
1959	at	O
1959	age	O
1959	three	O
1959	months	O
1959	.	O
1960	The	O
1960	seizures	O
1960	usually	O
1960	spontaneously	O
1960	cease	O
1960	after	O
1960	one	O
1960	year	O
1960	without	O
1960	treatment	O
1960	,	O
1960	leaving	O
1960	no	O
1960	neurological	B-Disease
1960	abnormalities	I-Disease
1960	.	O
1961	We	O
1961	have	O
1961	mapped	O
1961	BFIC	B-Disease
1961	to	O
1961	chromosome	O
1961	19q	O
1961	in	O
1961	five	O
1961	Italian	O
1961	pedigrees	O
1961	.	O
1962	The	O
1962	sodium	O
1962	channel	O
1962	beta1	O
1962	subunit	O
1962	gene	O
1962	(	O
1962	SCN1B	O
1962	)	O
1962	maps	O
1962	to	O
1962	this	O
1962	candidate	O
1962	region	O
1962	and	O
1962	has	O
1962	been	O
1962	shown	O
1962	to	O
1962	be	O
1962	involved	O
1962	in	O
1962	one	O
1962	Australian	O
1962	pedigree	O
1962	with	O
1962	generalized	B-Disease
1962	epilepsy	I-Disease
1962	and	I-Disease
1962	febrile	I-Disease
1962	seizures	I-Disease
1962	"	NN	O	I-Disease
1962	plus	NN	O	I-Disease
1962	"	I-Disease
1962	(	O
1962	GEFS	O
1962	+	O
1962	)	O
1962	.	O
1963	In	O
1963	this	O
1963	family	O
1963	,	O
1963	a	O
1963	missense	O
1963	mutation	O
1963	in	O
1963	SCN1B	O
1963	cosegregates	O
1963	with	O
1963	the	O
1963	GEFS	O
1963	+	O
1963	phenotype	O
1963	.	O
1964	BFIC	B-Disease
1964	and	O
1964	GEFS	O
1964	+	O
1964	have	O
1964	clinical	O
1964	features	O
1964	in	O
1964	common	O
1964	,	O
1964	therefore	O
1964	SCN1B	O
1964	is	O
1964	a	O
1964	candidate	O
1964	gene	O
1964	for	O
1964	BFIC	B-Disease
1964	.	O
1965	We	O
1965	studied	O
1965	SCN1B	O
1965	exons	O
1965	1	O
1965	,	O
1965	2	O
1965	,	O
1965	3	O
1965	,	O
1965	4	O
1965	,	O
1965	and	O
1965	5	O
1965	,	O
1965	using	O
1965	four	O
1965	SSCP	O
1965	methods	O
1965	in	O
1965	10	O
1965	Caucasian	O
1965	BFIC	B-Disease
1965	probands	O
1965	of	O
1965	Western	O
1965	Europe	O
1965	.	O
1966	We	O
1966	found	O
1966	no	O
1966	exon	O
1966	variants	O
1966	.	O
1967	One	O
1967	variant	O
1967	was	O
1967	identified	O
1967	in	O
1967	intron	O
1967	5	O
1967	(	O
1967	IVS5	O
1967	-	O
1967	10C	O
1967	>	O
1967	G	O
1967	)	O
1967	,	O
1967	which	O
1967	did	O
1967	not	O
1967	segregate	O
1967	with	O
1967	BFIC	B-Disease
1967	and	O
1967	was	O
1967	observed	O
1967	in	O
1967	9	O
1967	.	O
1968	2	O
1968	%	O
1968	controls	O
1968	.	O
1969	A	O
1969	second	O
1969	variant	O
1969	in	O
1969	intron	O
1969	5	O
1969	was	O
1969	identified	O
1969	(	O
1969	IVS5	O
1969	+	O
1969	30G	O
1969	>	O
1969	A	O
1969	)	O
1969	.	O
1970	It	O
1970	was	O
1970	rare	O
1970	,	O
1970	as	O
1970	not	O
1970	observed	O
1970	in	O
1970	controls	O
1970	,	O
1970	but	O
1970	not	O
1970	segregating	O
1970	with	O
1970	the	O
1970	BFIC	B-Disease
1970	phenotype	O
1970	.	O
1971	Inactivation	O
1971	of	O
1971	germline	O
1971	mutant	O
1971	APC	B-Disease
1971	alleles	O
1971	by	O
1971	attenuated	O
1971	somatic	O
1971	mutations	O
1971	:	O
1971	a	O
1971	molecular	O
1971	genetic	O
1971	mechanism	O
1971	for	O
1971	attenuated	B-Disease
1971	familial	I-Disease
1971	adenomatous	I-Disease
1971	polyposis	I-Disease
1971	.	O
1972	Germline	O
1972	mutations	O
1972	of	O
1972	the	O
1972	adenomatous	B-Disease
1972	polyposis	I-Disease
1972	coli	I-Disease
1972	(	I-Disease
1972	APC	I-Disease
1972	)	I-Disease
1972	tumor	I-Disease
1972	-	O
1972	suppressor	O
1972	gene	O
1972	result	O
1972	in	O
1972	familial	B-Disease
1972	adenomatous	I-Disease
1972	polyposis	I-Disease
1972	(	O
1972	FAP	B-Disease
1972	)	O
1972	.	O
1973	Patients	O
1973	with	O
1973	FAP	B-Disease
1973	typically	O
1973	develop	O
1973	hundreds	O
1973	to	O
1973	thousands	O
1973	of	O
1973	benign	B-Disease
1973	colorectal	I-Disease
1973	tumors	I-Disease
1973	and	O
1973	early	O
1973	-	O
1973	onset	O
1973	colorectal	B-Disease
1973	cancer	I-Disease
1973	.	O
1974	A	O
1974	subset	O
1974	of	O
1974	germline	O
1974	APC	B-Disease
1974	mutations	O
1974	results	O
1974	in	O
1974	an	O
1974	attenuated	B-Disease
1974	FAP	I-Disease
1974	(	O
1974	AFAP	B-Disease
1974	)	O
1974	phenotype	O
1974	,	O
1974	in	O
1974	which	O
1974	patients	O
1974	develop	O
1974	fewer	O
1974	tumors	B-Disease
1974	and	O
1974	develop	O
1974	them	O
1974	at	O
1974	an	O
1974	older	O
1974	age	O
1974	.	O
1975	Although	O
1975	a	O
1975	genotype	O
1975	-	O
1975	phenotype	O
1975	correlation	O
1975	between	O
1975	the	O
1975	locations	O
1975	of	O
1975	APC	B-Disease
1975	germline	O
1975	mutations	O
1975	and	O
1975	the	O
1975	development	O
1975	of	O
1975	AFAP	B-Disease
1975	has	O
1975	been	O
1975	well	O
1975	documented	O
1975	,	O
1975	the	O
1975	mechanism	O
1975	for	O
1975	AFAP	B-Disease
1975	has	O
1975	not	O
1975	been	O
1975	well	O
1975	defined	O
1975	.	O
1976	We	O
1976	investigated	O
1976	the	O
1976	mechanism	O
1976	for	O
1976	AFAP	B-Disease
1976	in	O
1976	patients	O
1976	carrying	O
1976	a	O
1976	mutant	O
1976	APC	B-Disease
1976	allele	O
1976	(	O
1976	APC	O
1976	(	O
1976	AS9	O
1976	)	O
1976	)	O
1976	that	O
1976	has	O
1976	a	O
1976	mutation	O
1976	in	O
1976	the	O
1976	alternatively	O
1976	spliced	O
1976	region	O
1976	of	O
1976	exon	O
1976	9	O
1976	.	O
1977	APC	O
1977	(	O
1977	AS9	O
1977	)	O
1977	was	O
1977	found	O
1977	to	O
1977	down	O
1977	-	O
1977	regulate	O
1977	beta	O
1977	-	O
1977	catenin	O
1977	-	O
1977	regulated	O
1977	transcription	O
1977	,	O
1977	the	O
1977	major	O
1977	tumor	B-Disease
1977	-	O
1977	suppressor	O
1977	function	O
1977	of	O
1977	APC	O
1977	,	O
1977	as	O
1977	did	O
1977	the	O
1977	wild	O
1977	-	O
1977	type	O
1977	APC	O
1977	.	O
1978	Mutation	O
1978	analysis	O
1978	showed	O
1978	that	O
1978	both	O
1978	APC	O
1978	(	O
1978	AS9	O
1978	)	O
1978	and	O
1978	the	O
1978	wild	O
1978	-	O
1978	type	O
1978	APC	B-Disease
1978	alleles	O
1978	were	O
1978	somatically	O
1978	mutated	O
1978	in	O
1978	most	O
1978	colorectal	B-Disease
1978	tumors	I-Disease
1978	from	O
1978	these	O
1978	patients	O
1978	.	O
1979	Functional	O
1979	analysis	O
1979	showed	O
1979	that	O
1979	4666insA	O
1979	,	O
1979	a	O
1979	common	O
1979	somatic	O
1979	mutation	O
1979	in	O
1979	APC	O
1979	(	O
1979	AS9	O
1979	)	O
1979	in	O
1979	these	O
1979	tumors	B-Disease
1979	,	O
1979	did	O
1979	not	O
1979	inactivate	O
1979	the	O
1979	wild	O
1979	-	O
1979	type	O
1979	APC	O
1979	.	O
1980	Our	O
1980	results	O
1980	indicate	O
1980	that	O
1980	carriers	O
1980	of	O
1980	APC	O
1980	(	O
1980	AS9	O
1980	)	O
1980	develop	O
1980	fewer	O
1980	colorectal	B-Disease
1980	tumors	I-Disease
1980	than	O
1980	do	O
1980	typical	O
1980	patients	O
1980	with	O
1980	FAP	B-Disease
1980	because	O
1980	somatic	O
1980	inactivation	O
1980	of	O
1980	both	O
1980	APC	B-Disease
1980	alleles	O
1980	is	O
1980	necessary	O
1980	for	O
1980	colorectal	O
1980	tumorigenesis	O
1980	.	O
1981	However	O
1981	,	O
1981	these	O
1981	patients	O
1981	develop	O
1981	colorectal	B-Disease
1981	tumors	I-Disease
1981	more	O
1981	frequently	O
1981	than	O
1981	does	O
1981	the	O
1981	general	O
1981	population	O
1981	because	O
1981	APC	O
1981	(	O
1981	AS9	O
1981	)	O
1981	is	O
1981	inactivated	O
1981	by	O
1981	mutations	O
1981	that	O
1981	do	O
1981	not	O
1981	inactivate	O
1981	the	O
1981	wild	O
1981	-	O
1981	type	O
1981	APC	O
1981	.	O
1981	.	O
1982	Iron	O
1982	-	O
1982	dependent	O
1982	self	O
1982	-	O
1982	assembly	O
1982	of	O
1982	recombinant	O
1982	yeast	O
1982	frataxin	O
1982	:	O
1982	implications	O
1982	for	O
1982	Friedreich	B-Disease
1982	ataxia	I-Disease
1982	.	O
1983	Frataxin	B-Disease
1983	deficiency	I-Disease
1983	is	O
1983	the	O
1983	primary	O
1983	cause	O
1983	of	O
1983	Friedreich	B-Disease
1983	ataxia	I-Disease
1983	(	O
1983	FRDA	B-Disease
1983	)	O
1983	,	O
1983	an	O
1983	autosomal	B-Disease
1983	recessive	I-Disease
1983	cardiodegenerative	I-Disease
1983	and	I-Disease
1983	neurodegenerative	I-Disease
1983	disease	I-Disease
1983	.	O
1984	Frataxin	O
1984	is	O
1984	a	O
1984	nuclear	O
1984	-	O
1984	encoded	O
1984	mitochondrial	O
1984	protein	O
1984	that	O
1984	is	O
1984	widely	O
1984	conserved	O
1984	among	O
1984	eukaryotes	O
1984	.	O
1985	Genetic	O
1985	inactivation	O
1985	of	O
1985	the	O
1985	yeast	O
1985	frataxin	O
1985	homologue	O
1985	(	O
1985	Yfh1p	O
1985	)	O
1985	results	O
1985	in	O
1985	mitochondrial	B-Disease
1985	iron	I-Disease
1985	accumulation	I-Disease
1985	and	O
1985	hypersensitivity	B-Disease
1985	to	I-Disease
1985	oxidative	I-Disease
1985	stress	I-Disease
1985	.	O
1986	Increased	O
1986	iron	O
1986	deposition	O
1986	and	O
1986	evidence	O
1986	of	O
1986	oxidative	O
1986	damage	O
1986	have	O
1986	also	O
1986	been	O
1986	observed	O
1986	in	O
1986	cardiac	O
1986	tissue	O
1986	and	O
1986	cultured	O
1986	fibroblasts	O
1986	from	O
1986	patients	O
1986	with	O
1986	FRDA	B-Disease
1986	.	O
1987	These	O
1987	findings	O
1987	indicate	O
1987	that	O
1987	frataxin	O
1987	is	O
1987	essential	O
1987	for	O
1987	mitochondrial	O
1987	iron	O
1987	homeostasis	O
1987	and	O
1987	protection	O
1987	from	O
1987	iron	O
1987	-	O
1987	induced	O
1987	formation	O
1987	of	O
1987	free	O
1987	radicals	O
1987	.	O
1988	The	O
1988	functional	O
1988	mechanism	O
1988	of	O
1988	frataxin	O
1988	,	O
1988	however	O
1988	,	O
1988	is	O
1988	still	O
1988	unknown	O
1988	.	O
1989	We	O
1989	have	O
1989	expressed	O
1989	the	O
1989	mature	O
1989	form	O
1989	of	O
1989	Yfh1p	O
1989	(	O
1989	mYfh1p	O
1989	)	O
1989	in	O
1989	Escherichia	O
1989	coli	O
1989	and	O
1989	have	O
1989	analyzed	O
1989	its	O
1989	function	O
1989	in	O
1989	vitro	O
1989	.	O
1990	Isolated	O
1990	mYfh1p	O
1990	is	O
1990	a	O
1990	soluble	O
1990	monomer	O
1990	(	O
1990	13	O
1990	,	O
1990	783	O
1990	Da	O
1990	)	O
1990	that	O
1990	contains	O
1990	no	O
1990	iron	O
1990	and	O
1990	shows	O
1990	no	O
1990	significant	O
1990	tendency	O
1990	to	O
1990	self	O
1990	-	O
1990	associate	O
1990	.	O
1991	Aerobic	O
1991	addition	O
1991	of	O
1991	ferrous	O
1991	iron	O
1991	to	O
1991	mYfh1p	O
1991	results	O
1991	in	O
1991	assembly	O
1991	of	O
1991	regular	O
1991	spherical	O
1991	multimers	O
1991	with	O
1991	a	O
1991	molecular	O
1991	mass	O
1991	of	O
1991	approximately	O
1991	1	O
1991	.	O
1992	1	O
1992	MDa	O
1992	(	O
1992	megadaltons	O
1992	)	O
1992	and	O
1992	a	O
1992	diameter	O
1992	of	O
1992	13	O
1992	+	O
1992	/	O
1992	-	O
1992	2	O
1992	nm	O
1992	.	O
1993	Each	O
1993	multimer	O
1993	consists	O
1993	of	O
1993	approximately	O
1993	60	O
1993	subunits	O
1993	and	O
1993	can	O
1993	sequester	O
1993	>	O
1993	3	O
1993	,	O
1993	000	O
1993	atoms	O
1993	of	O
1993	iron	O
1993	.	O
1994	Titration	O
1994	of	O
1994	mYfh1p	O
1994	with	O
1994	increasing	O
1994	iron	O
1994	concentrations	O
1994	supports	O
1994	a	O
1994	stepwise	O
1994	mechanism	O
1994	of	O
1994	multimer	O
1994	assembly	O
1994	.	O
1995	Sequential	O
1995	addition	O
1995	of	O
1995	an	O
1995	iron	O
1995	chelator	O
1995	and	O
1995	a	O
1995	reducing	O
1995	agent	O
1995	results	O
1995	in	O
1995	quantitative	O
1995	iron	O
1995	release	O
1995	with	O
1995	concomitant	O
1995	disassembly	O
1995	of	O
1995	the	O
1995	multimer	O
1995	,	O
1995	indicating	O
1995	that	O
1995	mYfh1p	O
1995	sequesters	O
1995	iron	O
1995	in	O
1995	an	O
1995	available	O
1995	form	O
1995	.	O
1996	In	O
1996	yeast	O
1996	mitochondria	O
1996	,	O
1996	native	O
1996	mYfh1p	O
1996	exists	O
1996	as	O
1996	monomer	O
1996	and	O
1996	a	O
1996	higher	O
1996	-	O
1996	order	O
1996	species	O
1996	with	O
1996	a	O
1996	molecular	O
1996	weight	O
1996	>	O
1996	600	O
1996	,	O
1996	000	O
1996	.	O
1997	After	O
1997	addition	O
1997	of	O
1997	(	O
1997	55	O
1997	)	O
1997	Fe	O
1997	to	O
1997	the	O
1997	medium	O
1997	,	O
1997	immunoprecipitates	O
1997	of	O
1997	this	O
1997	species	O
1997	contain	O
1997	>	O
1997	16	O
1997	atoms	O
1997	of	O
1997	(	O
1997	55	O
1997	)	O
1997	Fe	O
1997	per	O
1997	molecule	O
1997	of	O
1997	mYfh1p	O
1997	.	O
1998	We	O
1998	propose	O
1998	that	O
1998	iron	O
1998	-	O
1998	dependent	O
1998	self	O
1998	-	O
1998	assembly	O
1998	of	O
1998	recombinant	O
1998	mYfh1p	O
1998	reflects	O
1998	a	O
1998	physiological	O
1998	role	O
1998	for	O
1998	frataxin	O
1998	in	O
1998	mitochondrial	O
1998	iron	O
1998	sequestration	O
1998	and	O
1998	bioavailability	O
1998	.	O
1998	.	O
1999	A	O
1999	mutation	O
1999	in	O
1999	the	O
1999	pleckstrin	O
1999	homology	O
1999	(	O
1999	PH	O
1999	)	O
1999	domain	O
1999	of	O
1999	the	O
1999	FGD1	O
1999	gene	O
1999	in	O
1999	an	O
1999	Italian	O
1999	family	O
1999	with	O
1999	faciogenital	B-Disease
1999	dysplasia	I-Disease
1999	(	O
1999	Aarskog	B-Disease
1999	-	I-Disease
1999	Scott	I-Disease
1999	syndrome	I-Disease
1999	)	O
1999	.	O
2000	Aarskog	B-Disease
2000	-	I-Disease
2000	Scott	I-Disease
2000	Syndrome	I-Disease
2000	(	O
2000	AAS	B-Disease
2000	)	O
2000	is	O
2000	an	O
2000	X	B-Disease
2000	-	I-Disease
2000	linked	I-Disease
2000	disorder	I-Disease
2000	characterised	O
2000	by	O
2000	short	B-Disease
2000	stature	I-Disease
2000	and	O
2000	multiple	O
2000	facial	B-Disease
2000	,	I-Disease
2000	limb	I-Disease
2000	and	I-Disease
2000	genital	I-Disease
2000	abnormalities	I-Disease
2000	.	O
2001	A	O
2001	gene	O
2001	,	O
2001	FGD1	O
2001	,	O
2001	altered	O
2001	in	O
2001	a	O
2001	patient	O
2001	with	O
2001	AAS	B-Disease
2001	phenotype	O
2001	,	O
2001	has	O
2001	been	O
2001	identified	O
2001	and	O
2001	found	O
2001	to	O
2001	encode	O
2001	a	O
2001	protein	O
2001	with	O
2001	homology	O
2001	to	O
2001	Rho	O
2001	/	O
2001	Rac	O
2001	guanine	O
2001	nucleotide	O
2001	exchange	O
2001	factors	O
2001	(	O
2001	Rho	O
2001	/	O
2001	Rac	O
2001	GEF	O
2001	)	O
2001	.	O
2002	However	O
2002	,	O
2002	since	O
2002	this	O
2002	original	O
2002	report	O
2002	on	O
2002	identification	O
2002	of	O
2002	a	O
2002	mutated	O
2002	FGD1	O
2002	gene	O
2002	in	O
2002	an	O
2002	AAS	B-Disease
2002	patient	O
2002	,	O
2002	no	O
2002	additional	O
2002	mutations	O
2002	in	O
2002	the	O
2002	FGD1	O
2002	gene	O
2002	have	O
2002	been	O
2002	described	O
2002	.	O
2003	We	O
2003	analysed	O
2003	13	O
2003	independent	O
2003	patients	O
2003	with	O
2003	clinical	O
2003	diagnosis	O
2003	of	O
2003	AAS	B-Disease
2003	.	O
2004	One	O
2004	patient	O
2004	presented	O
2004	a	O
2004	mutation	O
2004	that	O
2004	results	O
2004	in	O
2004	a	O
2004	nucleotide	O
2004	change	O
2004	in	O
2004	exon	O
2004	10	O
2004	of	O
2004	the	O
2004	FGD1	O
2004	gene	O
2004	(	O
2004	G2559	O
2004	>	O
2004	A	O
2004	)	O
2004	substituting	O
2004	a	O
2004	Gln	O
2004	for	O
2004	Arg	O
2004	in	O
2004	position	O
2004	610	O
2004	.	O
2005	The	O
2005	mutation	O
2005	was	O
2005	found	O
2005	to	O
2005	segregate	O
2005	with	O
2005	the	O
2005	AAS	B-Disease
2005	phenotype	O
2005	in	O
2005	affected	O
2005	males	O
2005	and	O
2005	carrier	O
2005	females	O
2005	in	O
2005	the	O
2005	family	O
2005	of	O
2005	this	O
2005	patient	O
2005	.	O
2006	Interestingly	O
2006	,	O
2006	Arg	O
2006	-	O
2006	610	O
2006	is	O
2006	located	O
2006	within	O
2006	one	O
2006	of	O
2006	the	O
2006	two	O
2006	pleckstrin	O
2006	homology	O
2006	(	O
2006	PH	O
2006	)	O
2006	domains	O
2006	of	O
2006	the	O
2006	FGD1	O
2006	gene	O
2006	and	O
2006	it	O
2006	corresponds	O
2006	to	O
2006	a	O
2006	highly	O
2006	conserved	O
2006	residue	O
2006	which	O
2006	has	O
2006	been	O
2006	involved	O
2006	in	O
2006	InsP	O
2006	binding	O
2006	in	O
2006	PH	O
2006	domains	O
2006	of	O
2006	other	O
2006	proteins	O
2006	.	O
2007	The	O
2007	same	O
2007	residue	O
2007	is	O
2007	often	O
2007	mutated	O
2007	in	O
2007	the	O
2007	Brutons	O
2007	tyrosine	O
2007	kinase	O
2007	(	O
2007	Btk	O
2007	)	O
2007	gene	O
2007	in	O
2007	patients	O
2007	with	O
2007	an	O
2007	X	B-Disease
2007	-	I-Disease
2007	linked	I-Disease
2007	agammaglobulinemia	I-Disease
2007	.	O
2008	The	O
2008	Arg610Gln	O
2008	mutation	O
2008	represents	O
2008	the	O
2008	first	O
2008	case	O
2008	of	O
2008	a	O
2008	mutation	O
2008	in	O
2008	the	O
2008	PH	O
2008	domain	O
2008	of	O
2008	the	O
2008	FGD1	O
2008	gene	O
2008	and	O
2008	additional	O
2008	evidence	O
2008	that	O
2008	mutations	O
2008	in	O
2008	PH	O
2008	domains	O
2008	can	O
2008	be	O
2008	associated	O
2008	to	O
2008	human	O
2008	diseases	O
2008	.	O
2008	.	O
2009	Amino	O
2009	-	O
2009	terminal	O
2009	fragments	O
2009	of	O
2009	mutant	O
2009	huntingtin	O
2009	show	O
2009	selective	O
2009	accumulation	O
2009	in	O
2009	striatal	O
2009	neurons	O
2009	and	O
2009	synaptic	O
2009	toxicity	O
2009	.	O
2010	Huntington	B-Disease
2010	disease	I-Disease
2010	(	O
2010	HD	B-Disease
2010	)	O
2010	is	O
2010	caused	O
2010	by	O
2010	expansion	O
2010	of	O
2010	a	O
2010	glutamine	O
2010	repeat	O
2010	in	O
2010	the	O
2010	amino	O
2010	-	O
2010	terminal	O
2010	region	O
2010	of	O
2010	huntingtin	O
2010	.	O
2011	Despite	O
2011	its	O
2011	widespread	O
2011	expression	O
2011	,	O
2011	mutant	O
2011	huntingtin	O
2011	induces	O
2011	selective	O
2011	neuronal	O
2011	loss	O
2011	in	O
2011	striatal	O
2011	neurons	O
2011	.	O
2012	Here	O
2012	we	O
2012	report	O
2012	that	O
2012	,	O
2012	in	O
2012	mutant	O
2012	mice	O
2012	expressing	O
2012	HD	B-Disease
2012	repeats	O
2012	,	O
2012	the	O
2012	production	O
2012	and	O
2012	aggregation	O
2012	of	O
2012	N	O
2012	-	O
2012	terminal	O
2012	huntingtin	O
2012	fragments	O
2012	preferentially	O
2012	occur	O
2012	in	O
2012	HD	B-Disease
2012	-	O
2012	affected	O
2012	neurons	O
2012	and	O
2012	their	O
2012	processes	O
2012	and	O
2012	axonal	O
2012	terminals	O
2012	.	O
2013	N	O
2013	-	O
2013	terminal	O
2013	fragments	O
2013	of	O
2013	mutant	O
2013	huntingtin	O
2013	form	O
2013	aggregates	O
2013	and	O
2013	induce	O
2013	neuritic	B-Disease
2013	degeneration	I-Disease
2013	in	O
2013	cultured	O
2013	striatal	O
2013	neurons	O
2013	.	O
2014	N	O
2014	-	O
2014	terminal	O
2014	mutant	O
2014	huntingtin	O
2014	also	O
2014	binds	O
2014	to	O
2014	synaptic	O
2014	vesicles	O
2014	and	O
2014	inhibits	O
2014	their	O
2014	glutamate	O
2014	uptake	O
2014	in	O
2014	vitro	O
2014	.	O
2015	The	O
2015	specific	O
2015	processing	O
2015	and	O
2015	accumulation	O
2015	of	O
2015	toxic	O
2015	fragments	O
2015	of	O
2015	N	O
2015	-	O
2015	terminal	O
2015	huntingtin	O
2015	in	O
2015	HD	B-Disease
2015	-	O
2015	affected	O
2015	striatal	O
2015	neurons	O
2015	,	O
2015	especially	O
2015	in	O
2015	their	O
2015	neuronal	O
2015	processes	O
2015	and	O
2015	axonal	O
2015	terminals	O
2015	,	O
2015	may	O
2015	contribute	O
2015	to	O
2015	the	O
2015	selective	O
2015	neuropathology	O
2015	of	O
2015	HD	B-Disease
2015	.	O
2015	.	O
2016	BRCA1	O
2016	is	O
2016	associated	O
2016	with	O
2016	a	O
2016	human	O
2016	SWI	O
2016	/	O
2016	SNF	O
2016	-	O
2016	related	O
2016	complex	O
2016	:	O
2016	linking	O
2016	chromatin	O
2016	remodeling	O
2016	to	O
2016	breast	B-Disease
2016	cancer	I-Disease
2016	.	O
2017	Germline	O
2017	mutations	O
2017	in	O
2017	the	O
2017	tumor	B-Disease
2017	suppressor	O
2017	gene	O
2017	,	O
2017	BRCA1	O
2017	,	O
2017	predispose	O
2017	individuals	O
2017	to	O
2017	breast	B-Disease
2017	and	I-Disease
2017	ovarian	I-Disease
2017	cancers	I-Disease
2017	.	O
2018	Using	O
2018	a	O
2018	combination	O
2018	of	O
2018	affinity	O
2018	-	O
2018	and	O
2018	conventional	O
2018	chromatographic	O
2018	techniques	O
2018	,	O
2018	we	O
2018	have	O
2018	isolated	O
2018	a	O
2018	predominant	O
2018	form	O
2018	of	O
2018	a	O
2018	multiprotein	O
2018	BRCA1	O
2018	-	O
2018	containing	O
2018	complex	O
2018	from	O
2018	human	O
2018	cells	O
2018	displaying	O
2018	chromatin	O
2018	-	O
2018	remodeling	O
2018	activity	O
2018	.	O
2019	Mass	O
2019	spectrometric	O
2019	sequencing	O
2019	of	O
2019	components	O
2019	of	O
2019	this	O
2019	complex	O
2019	indicated	O
2019	that	O
2019	BRCA1	O
2019	is	O
2019	associated	O
2019	with	O
2019	a	O
2019	SWI	O
2019	/	O
2019	SNF	O
2019	-	O
2019	related	O
2019	complex	O
2019	.	O
2020	We	O
2020	show	O
2020	that	O
2020	BRCA1	O
2020	can	O
2020	directly	O
2020	interact	O
2020	with	O
2020	the	O
2020	BRG1	O
2020	subunit	O
2020	of	O
2020	the	O
2020	SWI	O
2020	/	O
2020	SNF	O
2020	complex	O
2020	.	O
2021	Moreover	O
2021	,	O
2021	p53	O
2021	-	O
2021	mediated	O
2021	stimulation	O
2021	of	O
2021	transcription	O
2021	by	O
2021	BRCA1	O
2021	was	O
2021	completely	O
2021	abrogated	O
2021	by	O
2021	either	O
2021	a	O
2021	dominant	O
2021	-	O
2021	negative	O
2021	mutant	O
2021	of	O
2021	BRG1	O
2021	or	O
2021	the	O
2021	cancer	B-Disease
2021	-	O
2021	causing	O
2021	deletion	O
2021	in	O
2021	exon	O
2021	11	O
2021	of	O
2021	BRCA1	O
2021	.	O
2022	These	O
2022	findings	O
2022	reveal	O
2022	a	O
2022	direct	O
2022	function	O
2022	for	O
2022	BRCA1	O
2022	in	O
2022	transcriptional	O
2022	control	O
2022	through	O
2022	modulation	O
2022	of	O
2022	chromatin	O
2022	structure	O
2022	.	O
2022	.	O
2023	Asef	O
2023	,	O
2023	a	O
2023	link	O
2023	between	O
2023	the	O
2023	tumor	B-Disease
2023	suppressor	O
2023	APC	O
2023	and	O
2023	G	O
2023	-	O
2023	protein	O
2023	signaling	O
2023	.	O
2024	The	O
2024	adenomatous	B-Disease
2024	polyposis	I-Disease
2024	coli	I-Disease
2024	gene	O
2024	(	O
2024	APC	O
2024	)	O
2024	is	O
2024	mutated	O
2024	in	O
2024	familial	B-Disease
2024	adenomatous	I-Disease
2024	polyposis	I-Disease
2024	and	O
2024	in	O
2024	sporadic	O
2024	colorectal	B-Disease
2024	tumors	I-Disease
2024	.	O
2025	Here	O
2025	the	O
2025	APC	B-Disease
2025	gene	O
2025	product	O
2025	is	O
2025	shown	O
2025	to	O
2025	bind	O
2025	through	O
2025	its	O
2025	armadillo	O
2025	repeat	O
2025	domain	O
2025	to	O
2025	a	O
2025	Rac	O
2025	-	O
2025	specific	O
2025	guanine	O
2025	nucleotide	O
2025	exchange	O
2025	factor	O
2025	(	O
2025	GEF	O
2025	)	O
2025	,	O
2025	termed	O
2025	Asef	O
2025	.	O
2026	Endogenous	O
2026	APC	O
2026	colocalized	O
2026	with	O
2026	Asef	O
2026	in	O
2026	mouse	O
2026	colon	O
2026	epithelial	O
2026	cells	O
2026	and	O
2026	neuronal	O
2026	cells	O
2026	.	O
2027	Furthermore	O
2027	,	O
2027	APC	O
2027	enhanced	O
2027	the	O
2027	GEF	O
2027	activity	O
2027	of	O
2027	Asef	O
2027	and	O
2027	stimulated	O
2027	Asef	O
2027	-	O
2027	mediated	O
2027	cell	O
2027	flattening	O
2027	,	O
2027	membrane	O
2027	ruffling	O
2027	,	O
2027	and	O
2027	lamellipodia	O
2027	formation	O
2027	in	O
2027	MDCK	O
2027	cells	O
2027	.	O
2028	These	O
2028	results	O
2028	suggest	O
2028	that	O
2028	the	O
2028	APC	O
2028	-	O
2028	Asef	O
2028	complex	O
2028	may	O
2028	regulate	O
2028	the	O
2028	actin	O
2028	cytoskeletal	O
2028	network	O
2028	,	O
2028	cell	O
2028	morphology	O
2028	and	O
2028	migration	O
2028	,	O
2028	and	O
2028	neuronal	O
2028	function	O
2028	.	O
2028	.	O
2029	Function	O
2029	of	O
2029	an	O
2029	axonal	O
2029	chemoattractant	O
2029	modulated	O
2029	by	O
2029	metalloprotease	O
2029	activity	O
2029	.	O
2030	The	O
2030	axonal	O
2030	chemoattractant	O
2030	netrin	O
2030	-	O
2030	1	O
2030	guides	O
2030	spinal	O
2030	commissural	O
2030	axons	O
2030	by	O
2030	activating	O
2030	its	O
2030	receptor	O
2030	DCC	O
2030	(	O
2030	Deleted	O
2030	in	O
2030	Colorectal	B-Disease
2030	Cancer	I-Disease
2030	)	O
2030	.	O
2031	We	O
2031	have	O
2031	found	O
2031	that	O
2031	chemical	O
2031	inhibitors	O
2031	of	O
2031	metalloproteases	O
2031	potentiate	O
2031	netrin	O
2031	-	O
2031	mediated	O
2031	axon	O
2031	outgrowth	O
2031	in	O
2031	vitro	O
2031	.	O
2032	We	O
2032	have	O
2032	also	O
2032	found	O
2032	that	O
2032	DCC	O
2032	is	O
2032	a	O
2032	substrate	O
2032	for	O
2032	metalloprotease	O
2032	-	O
2032	dependent	O
2032	ectodomain	O
2032	shedding	O
2032	,	O
2032	and	O
2032	that	O
2032	the	O
2032	inhibitors	O
2032	block	O
2032	proteolytic	O
2032	processing	O
2032	of	O
2032	DCC	O
2032	and	O
2032	cause	O
2032	an	O
2032	increase	O
2032	in	O
2032	DCC	O
2032	protein	O
2032	levels	O
2032	on	O
2032	axons	O
2032	within	O
2032	spinal	O
2032	cord	O
2032	explants	O
2032	.	O
2033	Thus	O
2033	,	O
2033	potentiation	O
2033	of	O
2033	netrin	O
2033	activity	O
2033	by	O
2033	inhibitors	O
2033	may	O
2033	result	O
2033	from	O
2033	stabilization	O
2033	of	O
2033	DCC	O
2033	on	O
2033	the	O
2033	axons	O
2033	,	O
2033	and	O
2033	proteolytic	O
2033	activity	O
2033	may	O
2033	regulate	O
2033	axon	O
2033	migration	O
2033	by	O
2033	controlling	O
2033	the	O
2033	number	O
2033	of	O
2033	functional	O
2033	extracellular	O
2033	axon	O
2033	guidance	O
2033	receptors	O
2033	.	O
2033	.	O
2034	Myotonic	B-Disease
2034	dystrophy	I-Disease
2034	in	O
2034	transgenic	O
2034	mice	O
2034	expressing	O
2034	an	O
2034	expanded	O
2034	CUG	O
2034	repeat	O
2034	.	O
2035	Myotonic	B-Disease
2035	dystrophy	I-Disease
2035	(	O
2035	DM	B-Disease
2035	)	O
2035	,	O
2035	the	O
2035	most	O
2035	common	O
2035	form	O
2035	of	O
2035	muscular	B-Disease
2035	dystrophy	I-Disease
2035	in	O
2035	adult	O
2035	humans	O
2035	,	O
2035	results	O
2035	from	O
2035	expansion	O
2035	of	O
2035	a	O
2035	CTG	O
2035	repeat	O
2035	in	O
2035	the	O
2035	3	O
2035	untranslated	O
2035	region	O
2035	of	O
2035	the	O
2035	DMPK	O
2035	gene	O
2035	.	O
2036	The	O
2036	mutant	O
2036	DMPK	O
2036	messenger	O
2036	RNA	O
2036	(	O
2036	mRNA	O
2036	)	O
2036	contains	O
2036	an	O
2036	expanded	O
2036	CUG	O
2036	repeat	O
2036	and	O
2036	is	O
2036	retained	O
2036	in	O
2036	the	O
2036	nucleus	O
2036	.	O
2037	We	O
2037	have	O
2037	expressed	O
2037	an	O
2037	untranslated	O
2037	CUG	O
2037	repeat	O
2037	in	O
2037	an	O
2037	unrelated	O
2037	mRNA	O
2037	in	O
2037	transgenic	O
2037	mice	O
2037	.	O
2038	Mice	O
2038	that	O
2038	expressed	O
2038	expanded	O
2038	CUG	O
2038	repeats	O
2038	developed	O
2038	myotonia	B-Disease
2038	and	O
2038	myopathy	B-Disease
2038	,	O
2038	whereas	O
2038	mice	O
2038	expressing	O
2038	a	O
2038	nonexpanded	O
2038	repeat	O
2038	did	O
2038	not	O
2038	.	O
2039	Thus	O
2039	,	O
2039	transcripts	O
2039	with	O
2039	expanded	O
2039	CUG	O
2039	repeats	O
2039	are	O
2039	sufficient	O
2039	to	O
2039	generate	O
2039	a	O
2039	DM	B-Disease
2039	phenotype	O
2039	.	O
2040	This	O
2040	result	O
2040	supports	O
2040	a	O
2040	role	O
2040	for	O
2040	RNA	O
2040	gain	O
2040	of	O
2040	function	O
2040	in	O
2040	disease	O
2040	pathogenesis	O
2040	.	O
2040	.	O
2041	Genomic	O
2041	rearrangements	O
2041	of	O
2041	the	O
2041	APC	B-Disease
2041	tumor	I-Disease
2041	-	O
2041	suppressor	O
2041	gene	O
2041	in	O
2041	familial	B-Disease
2041	adenomatous	I-Disease
2041	polyposis	I-Disease
2041	.	O
2042	Germline	O
2042	mutations	O
2042	of	O
2042	the	O
2042	adenomatous	B-Disease
2042	polyposis	I-Disease
2042	coli	I-Disease
2042	(	I-Disease
2042	APC	I-Disease
2042	)	I-Disease
2042	tumor	I-Disease
2042	-	O
2042	suppressor	O
2042	gene	O
2042	result	O
2042	in	O
2042	the	O
2042	hereditary	B-Disease
2042	colorectal	I-Disease
2042	cancer	I-Disease
2042	syndrome	I-Disease
2042	familial	B-Disease
2042	adenomatous	I-Disease
2042	polyposis	I-Disease
2042	(	O
2042	FAP	B-Disease
2042	)	O
2042	.	O
2043	Almost	O
2043	all	O
2043	APC	B-Disease
2043	mutations	O
2043	that	O
2043	have	O
2043	been	O
2043	identified	O
2043	are	O
2043	single	O
2043	-	O
2043	nucleotide	O
2043	alterations	O
2043	,	O
2043	small	O
2043	insertions	O
2043	,	O
2043	or	O
2043	small	O
2043	deletions	O
2043	that	O
2043	would	O
2043	truncate	O
2043	the	O
2043	protein	O
2043	product	O
2043	of	O
2043	the	O
2043	gene	O
2043	.	O
2044	No	O
2044	well	O
2044	-	O
2044	characterized	O
2044	intragenic	O
2044	rearrangement	O
2044	of	O
2044	APC	O
2044	has	O
2044	been	O
2044	described	O
2044	,	O
2044	and	O
2044	the	O
2044	prevalence	O
2044	of	O
2044	this	O
2044	type	O
2044	of	O
2044	mutation	O
2044	in	O
2044	FAP	B-Disease
2044	patients	O
2044	is	O
2044	not	O
2044	clear	O
2044	.	O
2045	We	O
2045	screened	O
2045	49	O
2045	potential	O
2045	FAP	B-Disease
2045	families	O
2045	and	O
2045	identified	O
2045	26	O
2045	different	O
2045	germline	O
2045	APC	B-Disease
2045	mutations	O
2045	in	O
2045	30	O
2045	families	O
2045	.	O
2046	Four	O
2046	of	O
2046	these	O
2046	mutations	O
2046	were	O
2046	genomic	O
2046	rearrangements	O
2046	resulting	O
2046	from	O
2046	homologous	O
2046	and	O
2046	nonhomologous	O
2046	recombinations	O
2046	mediated	O
2046	by	O
2046	Alu	O
2046	elements	O
2046	.	O
2047	Two	O
2047	of	O
2047	these	O
2047	four	O
2047	rearrangements	O
2047	were	O
2047	complex	O
2047	,	O
2047	involving	O
2047	deletion	O
2047	and	O
2047	insertion	O
2047	of	O
2047	nucleotides	O
2047	.	O
2048	Of	O
2048	these	O
2048	four	O
2048	rearrangements	O
2048	,	O
2048	one	O
2048	resulted	O
2048	in	O
2048	the	O
2048	deletion	O
2048	of	O
2048	exons	O
2048	11	O
2048	and	O
2048	12	O
2048	and	O
2048	two	O
2048	others	O
2048	resulted	O
2048	in	O
2048	either	O
2048	complete	O
2048	or	O
2048	partial	O
2048	deletion	O
2048	of	O
2048	exon	O
2048	14	O
2048	.	O
2049	The	O
2049	fourth	O
2049	rearrangement	O
2049	grossly	O
2049	altered	O
2049	the	O
2049	sequence	O
2049	within	O
2049	intron	O
2049	14	O
2049	.	O
2050	Although	O
2050	this	O
2050	rearrangement	O
2050	did	O
2050	not	O
2050	affect	O
2050	any	O
2050	coding	O
2050	sequence	O
2050	of	O
2050	APC	O
2050	at	O
2050	the	O
2050	genomic	O
2050	DNA	O
2050	level	O
2050	,	O
2050	it	O
2050	caused	O
2050	inappropriate	O
2050	splicing	O
2050	of	O
2050	exon	O
2050	14	O
2050	.	O
2051	These	O
2051	rearrangements	O
2051	were	O
2051	initially	O
2051	revealed	O
2051	by	O
2051	analyzing	O
2051	cDNAs	O
2051	and	O
2051	could	O
2051	not	O
2051	have	O
2051	been	O
2051	identified	O
2051	by	O
2051	using	O
2051	mutation	O
2051	detection	O
2051	methods	O
2051	that	O
2051	screened	O
2051	each	O
2051	exon	O
2051	individually	O
2051	.	O
2052	The	O
2052	identification	O
2052	of	O
2052	a	O
2052	rearrangement	O
2052	that	O
2052	did	O
2052	not	O
2052	alter	O
2052	any	O
2052	coding	O
2052	exons	O
2052	yet	O
2052	affected	O
2052	the	O
2052	splicing	O
2052	further	O
2052	underscores	O
2052	the	O
2052	importance	O
2052	of	O
2052	using	O
2052	cDNA	O
2052	for	O
2052	mutation	O
2052	analysis	O
2052	.	O
2053	The	O
2053	identification	O
2053	of	O
2053	four	O
2053	genomic	O
2053	rearrangements	O
2053	among	O
2053	30	O
2053	mutations	O
2053	suggests	O
2053	that	O
2053	genomic	O
2053	rearrangements	O
2053	are	O
2053	frequent	O
2053	germline	O
2053	APC	B-Disease
2053	mutations	O
2053	.	O
2053	.	O
2054	Detection	O
2054	of	O
2054	a	O
2054	novel	O
2054	missense	O
2054	mutation	O
2054	and	O
2054	second	O
2054	recurrent	O
2054	mutation	O
2054	in	O
2054	the	O
2054	CACNA1A	O
2054	gene	O
2054	in	O
2054	individuals	O
2054	with	O
2054	EA	B-Disease
2054	-	I-Disease
2054	2	I-Disease
2054	and	O
2054	FHM	B-Disease
2054	.	O
2055	Mutations	O
2055	in	O
2055	the	O
2055	brain	O
2055	specific	O
2055	P	O
2055	/	O
2055	Q	O
2055	type	O
2055	Ca2	O
2055	+	O
2055	channel	O
2055	alpha1	O
2055	subunit	O
2055	gene	O
2055	,	O
2055	CACNA1A	O
2055	,	O
2055	have	O
2055	been	O
2055	identified	O
2055	in	O
2055	three	O
2055	clinically	O
2055	distinct	O
2055	disorders	O
2055	,	O
2055	viz	O
2055	.	O
2055	episodic	B-Disease
2055	ataxia	I-Disease
2055	type	I-Disease
2055	2	I-Disease
2055	(	O
2055	EA	B-Disease
2055	-	I-Disease
2055	2	I-Disease
2055	)	O
2055	,	O
2055	familial	B-Disease
2055	hemiplegic	I-Disease
2055	migraine	I-Disease
2055	(	O
2055	FHM	B-Disease
2055	)	O
2055	and	O
2055	spinocerebellar	B-Disease
2055	ataxia	I-Disease
2055	6	I-Disease
2055	(	O
2055	SCA6	B-Disease
2055	)	O
2055	.	O
2056	For	O
2056	individuals	O
2056	with	O
2056	EA	B-Disease
2056	-	I-Disease
2056	2	I-Disease
2056	,	O
2056	the	O
2056	mutations	O
2056	described	O
2056	thus	O
2056	far	O
2056	are	O
2056	presumed	O
2056	to	O
2056	result	O
2056	in	O
2056	a	O
2056	truncated	O
2056	protein	O
2056	product	O
2056	.	O
2057	Several	O
2057	different	O
2057	missense	O
2057	mutations	O
2057	have	O
2057	been	O
2057	identified	O
2057	in	O
2057	patients	O
2057	with	O
2057	FHM	B-Disease
2057	.	O
2058	At	O
2058	least	O
2058	two	O
2058	of	O
2058	these	O
2058	mutations	O
2058	have	O
2058	been	O
2058	identified	O
2058	on	O
2058	two	O
2058	different	O
2058	chromosome	O
2058	19p13	O
2058	haplotypes	O
2058	and	O
2058	thus	O
2058	represent	O
2058	recurrent	O
2058	mutations	O
2058	.	O
2059	In	O
2059	the	O
2059	present	O
2059	study	O
2059	,	O
2059	we	O
2059	have	O
2059	screened	O
2059	several	O
2059	individuals	O
2059	for	O
2059	mutations	O
2059	in	O
2059	all	O
2059	47	O
2059	exons	O
2059	in	O
2059	the	O
2059	CACNA1A	O
2059	gene	O
2059	by	O
2059	single	O
2059	-	O
2059	strand	O
2059	conformation	O
2059	analysis	O
2059	.	O
2060	We	O
2060	have	O
2060	characterised	O
2060	a	O
2060	novel	O
2060	missense	O
2060	mutation	O
2060	,	O
2060	G5260A	O
2060	,	O
2060	in	O
2060	exon	O
2060	32	O
2060	in	O
2060	a	O
2060	family	O
2060	segregating	O
2060	for	O
2060	EA	B-Disease
2060	-	I-Disease
2060	2	I-Disease
2060	.	O
2061	The	O
2061	consequence	O
2061	of	O
2061	this	O
2061	mutation	O
2061	is	O
2061	an	O
2061	amino	O
2061	acid	O
2061	substitution	O
2061	at	O
2061	a	O
2061	highly	O
2061	conserved	O
2061	position	O
2061	within	O
2061	the	O
2061	CACNA1A	O
2061	gene	O
2061	.	O
2062	This	O
2062	represents	O
2062	the	O
2062	first	O
2062	point	O
2062	mutation	O
2062	not	O
2062	resulting	O
2062	in	O
2062	a	O
2062	proposed	O
2062	truncated	O
2062	protein	O
2062	.	O
2063	Furthermore	O
2063	,	O
2063	this	O
2063	mutation	O
2063	has	O
2063	been	O
2063	detected	O
2063	in	O
2063	a	O
2063	family	O
2063	member	O
2063	with	O
2063	mild	O
2063	clinical	O
2063	signs	O
2063	including	O
2063	only	O
2063	migraine	B-Disease
2063	.	O
2064	Additionally	O
2064	,	O
2064	a	O
2064	second	O
2064	previously	O
2064	identified	O
2064	recurrent	O
2064	muta	O
2064	tion	O
2064	,	O
2064	C2272T	O
2064	,	O
2064	in	O
2064	exon	O
2064	16	O
2064	has	O
2064	been	O
2064	discovered	O
2064	in	O
2064	a	O
2064	patient	O
2064	with	O
2064	FHM	B-Disease
2064	.	O
2064	.	O
2065	Analbuminemia	B-Disease
2065	in	O
2065	a	O
2065	neonate	O
2065	.	O
2066	A	O
2066	small	O
2066	-	O
2066	for	O
2066	-	O
2066	gestational	O
2066	-	O
2066	age	O
2066	infant	O
2066	,	O
2066	found	O
2066	to	O
2066	have	O
2066	analbuminemia	B-Disease
2066	in	O
2066	the	O
2066	neonatal	O
2066	period	O
2066	,	O
2066	is	O
2066	reported	O
2066	and	O
2066	the	O
2066	twelve	O
2066	cases	O
2066	recorded	O
2066	in	O
2066	the	O
2066	world	O
2066	literature	O
2066	are	O
2066	reviewed	O
2066	.	O
2067	Patients	O
2067	lacking	O
2067	this	O
2067	serum	O
2067	protein	O
2067	are	O
2067	essentially	O
2067	asymptomatic	O
2067	,	O
2067	apart	O
2067	from	O
2067	minimal	O
2067	ankle	B-Disease
2067	edema	I-Disease
2067	and	O
2067	ease	B-Disease
2067	of	I-Disease
2067	fatigue	I-Disease
2067	.	O
2068	Apparent	O
2068	compensatory	O
2068	mechanisms	O
2068	which	O
2068	come	O
2068	into	O
2068	play	O
2068	when	O
2068	serum	O
2068	albumin	O
2068	is	O
2068	low	O
2068	include	O
2068	prolonged	O
2068	half	O
2068	-	O
2068	life	O
2068	of	O
2068	albumin	O
2068	and	O
2068	transferrin	O
2068	,	O
2068	an	O
2068	increase	O
2068	in	O
2068	serum	O
2068	globulins	O
2068	,	O
2068	beta	O
2068	lipoprotein	O
2068	,	O
2068	and	O
2068	glycoproteins	O
2068	,	O
2068	arterial	B-Disease
2068	hypotension	I-Disease
2068	with	O
2068	reduced	O
2068	capillary	O
2068	hydrostatic	O
2068	pressure	O
2068	,	O
2068	and	O
2068	the	O
2068	ability	O
2068	to	O
2068	respond	O
2068	with	O
2068	rapid	O
2068	sodium	O
2068	and	O
2068	chloride	O
2068	diuresis	O
2068	in	O
2068	response	O
2068	to	O
2068	small	O
2068	volume	O
2068	changes	O
2068	.	O
2069	Examination	O
2069	of	O
2069	plasma	O
2069	amino	O
2069	acids	O
2069	,	O
2069	an	O
2069	investigation	O
2069	not	O
2069	previously	O
2069	reported	O
2069	,	O
2069	revealed	O
2069	an	O
2069	extremely	O
2069	low	O
2069	plasma	O
2069	tryptophan	O
2069	level	O
2069	,	O
2069	a	O
2069	finding	O
2069	which	O
2069	may	O
2069	be	O
2069	important	O
2069	in	O
2069	view	O
2069	of	O
2069	the	O
2069	role	O
2069	of	O
2069	tryptophan	O
2069	in	O
2069	albumin	O
2069	synthesis	O
2069	.	O
2069	.	O
2070	Histidinemia	B-Disease
2070	.	O
2071	Classical	O
2071	and	O
2071	atypical	O
2071	form	O
2071	in	O
2071	siblings	O
2071	.	O
2072	Two	O
2072	brothers	O
2072	,	O
2072	6	O
2072	and	O
2072	13	O
2072	years	O
2072	old	O
2072	,	O
2072	had	O
2072	histidinemia	B-Disease
2072	.	O
2073	On	O
2073	the	O
2073	basis	O
2073	of	O
2073	clinical	O
2073	and	O
2073	biochemical	O
2073	observations	O
2073	,	O
2073	the	O
2073	younger	O
2073	boy	O
2073	was	O
2073	considered	O
2073	to	O
2073	have	O
2073	a	O
2073	classical	O
2073	type	O
2073	of	O
2073	the	O
2073	disease	O
2073	,	O
2073	while	O
2073	the	O
2073	older	O
2073	boy	O
2073	had	O
2073	an	O
2073	atypical	O
2073	form	O
2073	characterized	O
2073	by	O
2073	partial	O
2073	impairment	O
2073	of	O
2073	the	O
2073	skin	O
2073	histidase	O
2073	activity	O
2073	and	O
2073	a	O
2073	moderately	O
2073	prolonged	O
2073	half	O
2073	-	O
2073	life	O
2073	of	O
2073	blood	O
2073	histidine	O
2073	.	O
2074	The	O
2074	mother	O
2074	is	O
2074	a	O
2074	heterozygous	O
2074	carrier	O
2074	,	O
2074	while	O
2074	the	O
2074	father	O
2074	and	O
2074	sister	O
2074	seem	O
2074	to	O
2074	be	O
2074	normal	O
2074	.	O
2074	.	O
2075	Carrier	O
2075	detection	O
2075	of	O
2075	pyruvate	B-Disease
2075	carboxylase	I-Disease
2075	deficiency	I-Disease
2075	in	O
2075	fibroblasts	O
2075	and	O
2075	lymphocytes	O
2075	.	O
2076	Pyruvate	O
2076	carboxylase	O
2076	(	O
2076	E	O
2076	.	O
2076	C	O
2076	.	O
2076	6	O
2076	.	O
2076	4	O
2076	.	O
2076	1	O
2076	.	O
2076	1	O
2076	)	O
2076	activity	O
2076	was	O
2076	determined	O
2076	in	O
2076	the	O
2076	circulating	O
2076	peripheral	O
2076	lymphocytes	O
2076	and	O
2076	cultured	O
2076	skin	O
2076	fibroblasts	O
2076	from	O
2076	the	O
2076	family	O
2076	of	O
2076	a	O
2076	patient	O
2076	with	O
2076	hepatic	O
2076	,	O
2076	cerebral	O
2076	,	O
2076	renal	O
2076	cortical	O
2076	,	O
2076	leukocyte	O
2076	,	O
2076	and	O
2076	fibroblast	O
2076	pyruvate	B-Disease
2076	carboxylase	I-Disease
2076	deficiency	I-Disease
2076	(	O
2076	PC	B-Disease
2076	Portland	I-Disease
2076	deficiency	I-Disease
2076	)	O
2076	.	O
2077	Lymphocyte	O
2077	activities	O
2077	were	O
2077	mother	O
2077	,	O
2077	33	O
2077	-	O
2077	-	O
2077	39	O
2077	%	O
2077	;	O
2077	father	O
2077	,	O
2077	11	O
2077	-	O
2077	-	O
2077	29	O
2077	%	O
2077	;	O
2077	brother	O
2077	,	O
2077	82	O
2077	-	O
2077	-	O
2077	103	O
2077	%	O
2077	;	O
2077	and	O
2077	sister	O
2077	,	O
2077	38	O
2077	-	O
2077	-	O
2077	48	O
2077	%	O
2077	of	O
2077	the	O
2077	lowest	O
2077	normal	O
2077	.	O
2078	Fibroblasts	O
2078	from	O
2078	the	O
2078	patients	O
2078	mother	O
2078	and	O
2078	father	O
2078	had	O
2078	42	O
2078	and	O
2078	34	O
2078	%	O
2078	,	O
2078	respectively	O
2078	,	O
2078	of	O
2078	the	O
2078	activity	O
2078	of	O
2078	the	O
2078	lowest	O
2078	normal	O
2078	.	O
2079	These	O
2079	data	O
2079	demonstrate	O
2079	that	O
2079	the	O
2079	disease	O
2079	is	O
2079	inherited	O
2079	in	O
2079	an	O
2079	autosomal	O
2079	recessive	O
2079	manner	O
2079	and	O
2079	that	O
2079	lymphocytes	O
2079	and	O
2079	fibroblasts	O
2079	can	O
2079	be	O
2079	used	O
2079	to	O
2079	detect	O
2079	carriers	O
2079	.	O
2080	Neither	O
2080	pyruvate	O
2080	carboxylase	O
2080	nor	O
2080	mitochondrial	O
2080	PEPCK	O
2080	activity	O
2080	in	O
2080	lymphocytes	O
2080	was	O
2080	increased	O
2080	by	O
2080	a	O
2080	21	O
2080	-	O
2080	hr	O
2080	fast	O
2080	.	O
2081	Glucose	O
2081	-	O
2081	6	O
2081	-	O
2081	phosphate	O
2081	dehydrogenase	O
2081	variants	O
2081	from	O
2081	Italian	O
2081	subjects	O
2081	associated	O
2081	with	O
2081	severe	B-Disease
2081	neonatal	I-Disease
2081	jaundice	I-Disease
2081	.	O
2082	Screening	O
2082	for	O
2082	the	O
2082	G6PD	B-Disease
2082	deficiency	I-Disease
2082	was	O
2082	carried	O
2082	out	O
2082	at	O
2082	the	O
2082	Maternity	O
2082	Division	O
2082	of	O
2082	the	O
2082	Galliera	O
2082	Hospital	O
2082	in	O
2082	Genoa	O
2082	,	O
2082	Italy	O
2082	.	O
2083	Two	O
2083	groups	O
2083	of	O
2083	subjects	O
2083	with	O
2083	hyperbilirubinaemia	B-Disease
2083	of	O
2083	non	O
2083	-	O
2083	immunological	O
2083	origin	O
2083	were	O
2083	examined	O
2083	(	O
2083	a	O
2083	)	O
2083	302	O
2083	newborn	O
2083	babies	O
2083	of	O
2083	Sardinian	O
2083	extraction	O
2083	(	O
2083	on	O
2083	cord	O
2083	blood	O
2083	)	O
2083	and	O
2083	(	O
2083	b	O
2083	)	O
2083	201	O
2083	newborn	O
2083	babies	O
2083	of	O
2083	south	O
2083	Italian	O
2083	ancestry	O
2083	(	O
2083	on	O
2083	peripheral	O
2083	blood	O
2083	)	O
2083	.	O
2084	Among	O
2084	503	O
2084	subjects	O
2084	,	O
2084	43	O
2084	showed	O
2084	an	O
2084	enzyme	O
2084	deficiency	O
2084	;	O
2084	in	O
2084	39	O
2084	the	O
2084	defect	O
2084	was	O
2084	of	O
2084	the	O
2084	Mediterranean	O
2084	type	O
2084	.	O
2085	In	O
2085	one	O
2085	case	O
2085	,	O
2085	previously	O
2085	described	O
2085	,	O
2085	the	O
2085	enzyme	O
2085	was	O
2085	of	O
2085	the	O
2085	A	O
2085	-	O
2085	type	O
2085	.	O
2086	In	O
2086	the	O
2086	remaining	O
2086	cases	O
2086	three	O
2086	different	O
2086	variants	O
2086	were	O
2086	identified	O
2086	.	O
2087	In	O
2087	the	O
2087	present	O
2087	work	O
2087	these	O
2087	three	O
2087	cases	O
2087	,	O
2087	each	O
2087	with	O
2087	severe	B-Disease
2087	neonatal	I-Disease
2087	jaundice	I-Disease
2087	,	O
2087	are	O
2087	reported	O
2087	.	O
2088	Their	O
2088	parents	O
2088	originated	O
2088	from	O
2088	Calabria	O
2088	,	O
2088	from	O
2088	Sardinia	O
2088	and	O
2088	from	O
2088	Sicily	O
2088	.	O
2089	The	O
2089	abnormal	O
2089	enzymes	O
2089	are	O
2089	respectively	O
2089	designated	O
2089	as	O
2089	GdDcbrousse	O
2089	-	O
2089	like	O
2089	,	O
2089	GdGallura	O
2089	and	O
2089	GdAgrigento	O
2089	.	O
2089	.	O
2090	Cytogenetic	O
2090	investigations	O
2090	in	O
2090	families	O
2090	with	O
2090	ataxia	B-Disease
2090	-	I-Disease
2090	telangiectasia	I-Disease
2090	.	O
2091	Chromosomal	O
2091	studies	O
2091	were	O
2091	performed	O
2091	on	O
2091	peripheral	O
2091	blood	O
2091	lymphocytes	O
2091	and	O
2091	cultured	O
2091	skin	O
2091	fibroblasts	O
2091	from	O
2091	five	O
2091	Israeli	O
2091	-	O
2091	Moroccan	O
2091	families	O
2091	with	O
2091	ataxia	B-Disease
2091	-	I-Disease
2091	telangiectasia	I-Disease
2091	.	O
2092	A	O
2092	total	O
2092	of	O
2092	24	O
2092	individuals	O
2092	,	O
2092	including	O
2092	seven	O
2092	propositi	O
2092	,	O
2092	was	O
2092	investigated	O
2092	.	O
2093	Among	O
2093	the	O
2093	probands	O
2093	,	O
2093	significantly	O
2093	elevated	O
2093	rates	O
2093	of	O
2093	chromosome	O
2093	damage	O
2093	were	O
2093	observed	O
2093	in	O
2093	both	O
2093	blood	O
2093	and	O
2093	skin	O
2093	.	O
2094	Skin	O
2094	fibroblasts	O
2094	of	O
2094	affected	O
2094	individuals	O
2094	showed	O
2094	several	O
2094	orders	O
2094	of	O
2094	magnitude	O
2094	more	O
2094	chromosome	O
2094	breakage	O
2094	than	O
2094	lymphocytes	O
2094	.	O
2095	Increased	O
2095	rates	O
2095	of	O
2095	chromosome	O
2095	damage	O
2095	were	O
2095	also	O
2095	observed	O
2095	in	O
2095	the	O
2095	fibroblasts	O
2095	of	O
2095	some	O
2095	phenotypically	O
2095	normal	O
2095	family	O
2095	members	O
2095	(	O
2095	obligate	O
2095	heterozygotes	O
2095	and	O
2095	sibs	O
2095	)	O
2095	when	O
2095	compared	O
2095	to	O
2095	normal	O
2095	controls	O
2095	.	O
2096	An	O
2096	apparent	O
2096	abnormal	O
2096	clone	O
2096	of	O
2096	cells	O
2096	,	O
2096	possessing	O
2096	a	O
2096	large	O
2096	acrocentric	O
2096	marker	O
2096	chromosome	O
2096	(	O
2096	14q	O
2096	+	O
2096	)	O
2096	,	O
2096	was	O
2096	observed	O
2096	in	O
2096	varying	O
2096	proportions	O
2096	among	O
2096	cells	O
2096	of	O
2096	all	O
2096	the	O
2096	propositi	O
2096	(	O
2096	2	O
2096	-	O
2096	5	O
2096	%	O
2096	of	O
2096	lymphocytes	O
2096	;	O
2096	1	O
2096	-	O
2096	9	O
2096	%	O
2096	of	O
2096	fibroblasts	O
2096	)	O
2096	.	O
2096	.	O
2097	Prenatal	O
2097	diagnosis	O
2097	of	O
2097	Wolman	B-Disease
2097	disease	I-Disease
2097	.	O
2098	Two	O
2098	pregnancies	O
2098	at	O
2098	risk	O
2098	for	O
2098	Wolman	B-Disease
2098	disease	I-Disease
2098	were	O
2098	monitored	O
2098	by	O
2098	assay	O
2098	and	O
2098	electrophoresis	O
2098	of	O
2098	acid	O
2098	lipase	O
2098	in	O
2098	cultured	O
2098	amniotic	O
2098	-	O
2098	fluid	O
2098	cells	O
2098	.	O
2099	Cells	O
2099	from	O
2099	patient	O
2099	1	O
2099	had	O
2099	5	O
2099	%	O
2099	of	O
2099	control	O
2099	levels	O
2099	of	O
2099	acid	O
2099	lipase	O
2099	,	O
2099	using	O
2099	14C	O
2099	-	O
2099	triolein	O
2099	as	O
2099	substrate	O
2099	;	O
2099	however	O
2099	,	O
2099	when	O
2099	artificial	O
2099	substrates	O
2099	(	O
2099	esters	O
2099	of	O
2099	4	O
2099	-	O
2099	methylumbelliferone	O
2099	and	O
2099	p	O
2099	-	O
2099	nitrophenol	O
2099	)	O
2099	were	O
2099	used	O
2099	to	O
2099	measure	O
2099	acid	O
2099	lipase	O
2099	,	O
2099	these	O
2099	cells	O
2099	had	O
2099	30	O
2099	%	O
2099	of	O
2099	control	O
2099	levels	O
2099	.	O
2100	Electrophoresis	O
2100	of	O
2100	cell	O
2100	extracts	O
2100	revealed	O
2100	the	O
2100	absence	O
2100	of	O
2100	the	O
2100	A	O
2100	form	O
2100	of	O
2100	acid	O
2100	lipase	O
2100	,	O
2100	consistent	O
2100	with	O
2100	the	O
2100	diagnosis	O
2100	of	O
2100	Wolman	B-Disease
2100	disease	I-Disease
2100	.	O
2101	Analysis	O
2101	of	O
2101	fetal	O
2101	tissues	O
2101	following	O
2101	prostaglandin	O
2101	termination	O
2101	of	O
2101	this	O
2101	pregnancy	O
2101	confirmed	O
2101	the	O
2101	diagnosis	O
2101	.	O
2102	Assay	O
2102	of	O
2102	fetal	O
2102	-	O
2102	skin	O
2102	fibroblasts	O
2102	with	O
2102	14C	O
2102	-	O
2102	triolein	O
2102	,	O
2102	as	O
2102	well	O
2102	as	O
2102	with	O
2102	artificial	O
2102	substrates	O
2102	,	O
2102	showed	O
2102	marked	O
2102	deficiency	O
2102	of	O
2102	acid	O
2102	lipase	O
2102	activity	O
2102	.	O
2103	Electrophoresis	O
2103	of	O
2103	fetal	O
2103	-	O
2103	tissue	O
2103	extracts	O
2103	also	O
2103	demonstrated	O
2103	the	O
2103	absence	O
2103	of	O
2103	the	O
2103	A	O
2103	form	O
2103	of	O
2103	acid	O
2103	lipase	O
2103	.	O
2104	Amniotic	O
2104	-	O
2104	fluid	O
2104	cells	O
2104	from	O
2104	patient	O
2104	2	O
2104	showed	O
2104	normal	O
2104	levels	O
2104	of	O
2104	acid	O
2104	lipase	O
2104	with	O
2104	all	O
2104	substrates	O
2104	tested	O
2104	;	O
2104	the	O
2104	electrophoretic	O
2104	pattern	O
2104	of	O
2104	acid	O
2104	lipase	O
2104	was	O
2104	normal	O
2104	.	O
2105	The	O
2105	results	O
2105	suggest	O
2105	that	O
2105	the	O
2105	prenatal	O
2105	diagnosis	O
2105	of	O
2105	Wolman	B-Disease
2105	disease	I-Disease
2105	be	O
2105	made	O
2105	using	O
2105	the	O
2105	radioassay	O
2105	of	O
2105	acid	O
2105	lipase	O
2105	and	O
2105	/	O
2105	or	O
2105	electrophoresis	O
2105	.	O
2105	.	O
2106	Malignant	B-Disease
2106	neoplasms	I-Disease
2106	in	O
2106	the	O
2106	families	O
2106	of	O
2106	patients	O
2106	with	O
2106	ataxia	B-Disease
2106	-	I-Disease
2106	telangiectasia	I-Disease
2106	.	O
2107	Ataxia	B-Disease
2107	-	I-Disease
2107	telangiectasia	I-Disease
2107	(	O
2107	A	B-Disease
2107	-	I-Disease
2107	T	I-Disease
2107	)	O
2107	is	O
2107	an	O
2107	autosomal	B-Disease
2107	recessive	I-Disease
2107	syndrome	I-Disease
2107	associated	O
2107	with	O
2107	a	O
2107	greatly	O
2107	increased	O
2107	incidence	O
2107	of	O
2107	malignant	B-Disease
2107	neoplasms	I-Disease
2107	in	O
2107	homozygous	O
2107	affected	O
2107	individuals	O
2107	.	O
2108	Heterozygotes	O
2108	for	O
2108	the	O
2108	gene	O
2108	for	O
2108	A	B-Disease
2108	-	I-Disease
2108	T	I-Disease
2108	are	O
2108	thought	O
2108	to	O
2108	comprise	O
2108	about	O
2108	1	O
2108	%	O
2108	of	O
2108	the	O
2108	general	O
2108	population	O
2108	and	O
2108	,	O
2108	therefore	O
2108	,	O
2108	it	O
2108	is	O
2108	important	O
2108	to	O
2108	know	O
2108	whether	O
2108	this	O
2108	gene	O
2108	also	O
2108	predisposes	O
2108	the	O
2108	heterozygous	O
2108	carrier	O
2108	to	O
2108	cancers	B-Disease
2108	.	O
2109	Heterozygous	O
2109	carriers	O
2109	of	O
2109	this	O
2109	gene	O
2109	are	O
2109	common	O
2109	among	O
2109	the	O
2109	close	O
2109	relatives	O
2109	of	O
2109	patients	O
2109	with	O
2109	A	B-Disease
2109	-	I-Disease
2109	T	I-Disease
2109	,	O
2109	although	O
2109	individual	O
2109	carriers	O
2109	cannot	O
2109	be	O
2109	identified	O
2109	by	O
2109	any	O
2109	clinical	O
2109	criterion	O
2109	or	O
2109	laboratory	O
2109	test	O
2109	.	O
2110	For	O
2110	this	O
2110	reason	O
2110	,	O
2110	we	O
2110	compared	O
2110	the	O
2110	incidence	O
2110	of	O
2110	death	O
2110	from	O
2110	malignant	B-Disease
2110	neoplasms	I-Disease
2110	in	O
2110	2	O
2110	families	O
2110	of	O
2110	patients	O
2110	with	O
2110	A	B-Disease
2110	-	I-Disease
2110	T	I-Disease
2110	to	O
2110	that	O
2110	expected	O
2110	in	O
2110	a	O
2110	random	O
2110	sample	O
2110	of	O
2110	the	O
2110	general	O
2110	population	O
2110	.	O
2111	There	O
2111	were	O
2111	59	O
2111	deaths	O
2111	from	O
2111	malignant	B-Disease
2111	neoplasms	I-Disease
2111	in	O
2111	relatives	O
2111	dying	O
2111	before	O
2111	age	O
2111	75	O
2111	,	O
2111	compared	O
2111	to	O
2111	42	O
2111	.	O
2112	6	O
2112	expected	O
2112	(	O
2112	p	O
2112	less	O
2112	than	O
2112	0	O
2112	.	O
2112	02	O
2112	)	O
2112	.	O
2113	For	O
2113	A	B-Disease
2113	-	I-Disease
2113	T	I-Disease
2113	heterozygotes	O
2113	younger	O
2113	than	O
2113	age	O
2113	45	O
2113	,	O
2113	the	O
2113	risk	O
2113	of	O
2113	dying	O
2113	from	O
2113	a	O
2113	malignant	B-Disease
2113	neoplasm	I-Disease
2113	was	O
2113	estimated	O
2113	to	O
2113	be	O
2113	greater	O
2113	than	O
2113	5	O
2113	times	O
2113	the	O
2113	risk	O
2113	for	O
2113	the	O
2113	general	O
2113	population	O
2113	.	O
2114	A	B-Disease
2114	-	I-Disease
2114	T	I-Disease
2114	heterozygotes	O
2114	may	O
2114	comprise	O
2114	more	O
2114	than	O
2114	5	O
2114	%	O
2114	of	O
2114	all	O
2114	persons	O
2114	dying	O
2114	from	O
2114	a	O
2114	cancer	B-Disease
2114	before	O
2114	age	O
2114	45	O
2114	.	O
2115	The	O
2115	incidence	O
2115	of	O
2115	ovarian	B-Disease
2115	,	I-Disease
2115	gastric	I-Disease
2115	,	I-Disease
2115	and	I-Disease
2115	biliary	I-Disease
2115	system	I-Disease
2115	carcinomas	I-Disease
2115	and	O
2115	of	O
2115	leukemia	B-Disease
2115	and	O
2115	lymphoma	B-Disease
2115	was	O
2115	increased	O
2115	in	O
2115	these	O
2115	A	B-Disease
2115	-	I-Disease
2115	T	I-Disease
2115	families	O
2115	.	O
2116	Other	O
2116	neoplasms	B-Disease
2116	that	O
2116	may	O
2116	be	O
2116	associated	O
2116	with	O
2116	this	O
2116	gene	O
2116	in	O
2116	heterozygotes	O
2116	include	O
2116	pancreatic	B-Disease
2116	,	I-Disease
2116	basal	I-Disease
2116	cell	I-Disease
2116	,	I-Disease
2116	colonic	I-Disease
2116	,	I-Disease
2116	breast	I-Disease
2116	,	I-Disease
2116	and	I-Disease
2116	cervical	I-Disease
2116	carcinomas	I-Disease
2116	.	O
2117	Striking	O
2117	prevalence	O
2117	of	O
2117	ankylosing	B-Disease
2117	spondylitis	I-Disease
2117	in	O
2117	"	NN	O	O
2117	healthy	NN	O	O
2117	"	O
2117	w27	O
2117	positive	O
2117	males	O
2117	and	O
2117	females	O
2117	.	O
2118	Ankylosing	B-Disease
2118	spondylitis	I-Disease
2118	is	O
2118	diagnosed	O
2118	once	O
2118	or	O
2118	twice	O
2118	in	O
2118	each	O
2118	1000	O
2118	males	O
2118	and	O
2118	one	O
2118	tenth	O
2118	as	O
2118	frequently	O
2118	in	O
2118	females	O
2118	,	O
2118	but	O
2118	the	O
2118	true	O
2118	prevalence	O
2118	is	O
2118	unknown	O
2118	.	O
2119	Indentification	O
2119	of	O
2119	genetic	O
2119	marker	O
2119	,	O
2119	HL	O
2119	-	O
2119	A	O
2119	W27	O
2119	,	O
2119	for	O
2119	susceptible	O
2119	persons	O
2119	has	O
2119	provided	O
2119	a	O
2119	tool	O
2119	facilitating	O
2119	epidemiologic	O
2119	studies	O
2119	and	O
2119	allowing	O
2119	identification	O
2119	of	O
2119	"	NN	O	O
2119	control	NN	O	O
2119	"	O
2119	populations	O
2119	without	O
2119	the	O
2119	marker	O
2119	.	O
2120	Evaluation	O
2120	by	O
2120	postal	O
2120	questionnaires	O
2120	,	O
2120	and	O
2120	pelvic	O
2120	radiography	O
2120	of	O
2120	78	O
2120	HL	O
2120	-	O
2120	A	O
2120	27W	O
2120	-	O
2120	positive	O
2120	blood	O
2120	donors	O
2120	selected	O
2120	from	O
2120	a	O
2120	group	O
2120	of	O
2120	apparently	O
2120	healthy	O
2120	subjects	O
2120	revealed	O
2120	14	O
2120	who	O
2120	satisfied	O
2120	the	O
2120	criteria	O
2120	for	O
2120	definite	O
2120	ankylosing	B-Disease
2120	spondylitis	I-Disease
2120	.	O
2121	The	O
2121	prevalence	O
2121	was	O
2121	similar	O
2121	in	O
2121	both	O
2121	sexes	O
2121	.	O
2122	One	O
2122	hundred	O
2122	and	O
2122	twenty	O
2122	-	O
2122	six	O
2122	W27	O
2122	-	O
2122	negative	O
2122	controls	O
2122	matched	O
2122	for	O
2122	race	O
2122	,	O
2122	sex	O
2122	,	O
2122	and	O
2122	age	O
2122	failed	O
2122	to	O
2122	yield	O
2122	a	O
2122	single	O
2122	case	O
2122	.	O
2123	For	O
2123	a	O
2123	person	O
2123	of	O
2123	either	O
2123	sex	O
2123	with	O
2123	HL	O
2123	-	O
2123	A	O
2123	W27	O
2123	,	O
2123	there	O
2123	appears	O
2123	to	O
2123	be	O
2123	about	O
2123	a	O
2123	20	O
2123	per	O
2123	cent	O
2123	chance	O
2123	that	O
2123	ankylosing	B-Disease
2123	spondylitis	I-Disease
2123	will	O
2123	develop	O
2123	,	O
2123	suggesting	O
2123	a	O
2123	prevalence	O
2123	of	O
2123	10	O
2123	to	O
2123	15	O
2123	per	O
2123	thousand	O
2123	.	O
2124	Hitherto	O
2124	accepted	O
2124	figures	O
2124	may	O
2124	underestimate	O
2124	the	O
2124	frequency	O
2124	by	O
2124	a	O
2124	factor	O
2124	of	O
2124	10	O
2124	to	O
2124	20	O
2124	.	O
2124	.	O
2125	Analbuminemia	B-Disease
2125	in	O
2125	an	O
2125	American	O
2125	Indian	O
2125	girl	O
2125	.	O
2126	Analbuminemia	B-Disease
2126	was	O
2126	fortuitously	O
2126	detected	O
2126	in	O
2126	a	O
2126	nonedematous	O
2126	12	O
2126	-	O
2126	year	O
2126	-	O
2126	old	O
2126	American	O
2126	Indian	O
2126	girl	O
2126	with	O
2126	atopic	B-Disease
2126	dermatitis	I-Disease
2126	,	O
2126	mild	O
2126	bronchial	B-Disease
2126	asthma	I-Disease
2126	,	O
2126	a	O
2126	mild	O
2126	seizure	B-Disease
2126	disorder	I-Disease
2126	,	O
2126	and	O
2126	hyperlipoproteinemia	B-Disease
2126	with	O
2126	a	O
2126	corneal	B-Disease
2126	arcus	I-Disease
2126	.	O
2127	Immunologic	O
2127	methods	O
2127	revealed	O
2127	trace	O
2127	amounts	O
2127	(	O
2127	17	O
2127	mg	O
2127	/	O
2127	100	O
2127	ml	O
2127	)	O
2127	of	O
2127	apparently	O
2127	normal	O
2127	serum	O
2127	albumin	O
2127	.	O
2128	The	O
2128	patients	O
2128	parents	O
2128	were	O
2128	remotely	O
2128	related	O
2128	.	O
2129	The	O
2129	pedigree	O
2129	and	O
2129	clinical	O
2129	findings	O
2129	were	O
2129	compatible	O
2129	with	O
2129	autosomal	O
2129	recessive	O
2129	transmission	O
2129	of	O
2129	analbuminemia	B-Disease
2129	.	O
2130	Heterozygotes	O
2130	had	O
2130	subnormal	O
2130	levels	O
2130	of	O
2130	serum	O
2130	albumin	O
2130	.	O
2131	The	O
2131	Gc	O
2131	-	O
2131	locus	O
2131	is	O
2131	closely	O
2131	linked	O
2131	to	O
2131	the	O
2131	structural	O
2131	albumin	O
2131	locus	O
2131	.	O
2132	Gc	O
2132	-	O
2132	protein	O
2132	levels	O
2132	were	O
2132	normal	O
2132	in	O
2132	the	O
2132	patient	O
2132	and	O
2132	together	O
2132	with	O
2132	normal	O
2132	chromosomal	O
2132	banding	O
2132	studies	O
2132	make	O
2132	it	O
2132	unlikely	O
2132	that	O
2132	a	O
2132	chromosomal	O
2132	deletion	O
2132	caused	O
2132	analbuminemia	B-Disease
2132	.	O
2133	Gc	O
2133	-	O
2133	types	O
2133	in	O
2133	the	O
2133	family	O
2133	were	O
2133	compatible	O
2133	with	O
2133	,	O
2133	but	O
2133	did	O
2133	not	O
2133	prove	O
2133	,	O
2133	linkage	O
2133	of	O
2133	analbuminemia	B-Disease
2133	to	O
2133	the	O
2133	Gc	O
2133	-	O
2133	locus	O
2133	.	O
2134	These	O
2134	findings	O
2134	suggest	O
2134	a	O
2134	"	NN	O	O
2134	thalassemia	NN	O	B-Disease
2134	"	O
2134	-	O
2134	like	O
2134	mutation	O
2134	for	O
2134	this	O
2134	disorder	O
2134	.	O
2134	.	O
2135	Deletion	O
2135	of	O
2135	the	O
2135	KIT	O
2135	and	O
2135	PDGFRA	O
2135	genes	O
2135	in	O
2135	a	O
2135	patient	O
2135	with	O
2135	piebaldism	B-Disease
2135	.	O
2136	We	O
2136	have	O
2136	previously	O
2136	shown	O
2136	that	O
2136	human	O
2136	piebaldism	B-Disease
2136	results	O
2136	from	O
2136	mutations	O
2136	of	O
2136	the	O
2136	KIT	O
2136	gene	O
2136	,	O
2136	which	O
2136	encodes	O
2136	the	O
2136	receptor	O
2136	for	O
2136	the	O
2136	mast	O
2136	/	O
2136	stem	O
2136	cell	O
2136	growth	O
2136	factor	O
2136	and	O
2136	is	O
2136	located	O
2136	in	O
2136	chromosome	O
2136	segment	O
2136	4q12	O
2136	.	O
2137	Using	O
2137	DNA	O
2137	of	O
2137	a	O
2137	patient	O
2137	with	O
2137	piebaldism	B-Disease
2137	,	O
2137	mental	B-Disease
2137	retardation	I-Disease
2137	,	O
2137	and	O
2137	multiple	B-Disease
2137	congenital	I-Disease
2137	anomalies	I-Disease
2137	associated	O
2137	with	O
2137	a	O
2137	46	O
2137	,	O
2137	XY	O
2137	,	O
2137	del	O
2137	(	O
2137	4	O
2137	)	O
2137	(	O
2137	q12q21	O
2137	.	O
2137	1	O
2137	)	O
2137	karyotype	O
2137	,	O
2137	we	O
2137	carried	O
2137	out	O
2137	quantitative	O
2137	Southern	O
2137	blot	O
2137	hybridization	O
2137	analyses	O
2137	of	O
2137	the	O
2137	KIT	O
2137	gene	O
2137	and	O
2137	the	O
2137	adjacent	O
2137	PDGFRA	O
2137	(	O
2137	platelet	O
2137	-	O
2137	derived	O
2137	growth	O
2137	factor	O
2137	receptor	O
2137	alpha	O
2137	subunit	O
2137	)	O
2137	genes	O
2137	.	O
2138	The	O
2138	patient	O
2138	was	O
2138	hemizygous	O
2138	for	O
2138	both	O
2138	the	O
2138	KIT	O
2138	and	O
2138	PDGFRA	O
2138	genes	O
2138	,	O
2138	indicating	O
2138	that	O
2138	both	O
2138	of	O
2138	these	O
2138	genes	O
2138	are	O
2138	included	O
2138	within	O
2138	the	O
2138	deleted	O
2138	region	O
2138	.	O
2139	Therefore	O
2139	,	O
2139	deletion	O
2139	of	O
2139	the	O
2139	KIT	O
2139	and	O
2139	PDGFRA	O
2139	genes	O
2139	may	O
2139	account	O
2139	for	O
2139	the	O
2139	piebald	B-Disease
2139	phenotype	O
2139	in	O
2139	this	O
2139	patient	O
2139	.	O
2140	A	O
2140	germ	O
2140	line	O
2140	mutation	O
2140	within	O
2140	the	O
2140	coding	O
2140	sequence	O
2140	for	O
2140	the	O
2140	putative	O
2140	5	O
2140	-	O
2140	phosphoribosyl	O
2140	-	O
2140	1	O
2140	-	O
2140	pyrophosphate	O
2140	binding	O
2140	site	O
2140	of	O
2140	hypoxanthine	O
2140	-	O
2140	guanine	O
2140	phosphoribosyltransferase	O
2140	(	O
2140	HPRT	O
2140	)	O
2140	in	O
2140	a	O
2140	Lesch	B-Disease
2140	-	I-Disease
2140	Nyhan	I-Disease
2140	patient	O
2140	:	O
2140	missense	O
2140	mutations	O
2140	within	O
2140	a	O
2140	functionally	O
2140	important	O
2140	region	O
2140	probably	O
2140	cause	O
2140	disease	O
2140	.	O
2141	Lesch	B-Disease
2141	-	I-Disease
2141	Nyhan	I-Disease
2141	syndrome	I-Disease
2141	caused	O
2141	by	O
2141	a	O
2141	complete	B-Disease
2141	deficiency	I-Disease
2141	of	I-Disease
2141	hypoxanthine	I-Disease
2141	guanine	I-Disease
2141	phosphoribosyltransferase	I-Disease
2141	(	O
2141	HPRT	O
2141	)	O
2141	is	O
2141	the	O
2141	result	O
2141	of	O
2141	a	O
2141	heterogeneous	O
2141	group	O
2141	of	O
2141	germ	O
2141	line	O
2141	mutations	O
2141	.	O
2142	Identification	O
2142	of	O
2142	each	O
2142	mutant	O
2142	gene	O
2142	provides	O
2142	valuable	O
2142	information	O
2142	as	O
2142	to	O
2142	the	O
2142	type	O
2142	of	O
2142	mutation	O
2142	that	O
2142	occurs	O
2142	spontaneously	O
2142	.	O
2143	We	O
2143	report	O
2143	here	O
2143	a	O
2143	newly	O
2143	identified	O
2143	HPRT	O
2143	mutation	O
2143	in	O
2143	a	O
2143	Japanese	O
2143	patient	O
2143	with	O
2143	Lesch	B-Disease
2143	-	I-Disease
2143	Nyhan	I-Disease
2143	syndrome	I-Disease
2143	.	O
2144	This	O
2144	gene	O
2144	,	O
2144	designated	O
2144	HPRT	O
2144	Tokyo	O
2144	,	O
2144	had	O
2144	a	O
2144	single	O
2144	nucleotide	O
2144	change	O
2144	from	O
2144	G	O
2144	to	O
2144	A	O
2144	,	O
2144	as	O
2144	identified	O
2144	by	O
2144	sequencing	O
2144	cDNA	O
2144	amplified	O
2144	by	O
2144	the	O
2144	polymerase	O
2144	chain	O
2144	reaction	O
2144	.	O
2145	Allele	O
2145	specific	O
2145	oligonucleotide	O
2145	hybridization	O
2145	analysis	O
2145	using	O
2145	amplified	O
2145	genomic	O
2145	DNA	O
2145	showed	O
2145	that	O
2145	the	O
2145	mutant	O
2145	gene	O
2145	was	O
2145	transmitted	O
2145	from	O
2145	the	O
2145	maternal	O
2145	germ	O
2145	line	O
2145	.	O
2146	This	O
2146	mutation	O
2146	would	O
2146	lead	O
2146	to	O
2146	an	O
2146	amino	O
2146	acid	O
2146	substitution	O
2146	of	O
2146	Asp	O
2146	for	O
2146	Gly	O
2146	at	O
2146	the	O
2146	amino	O
2146	acid	O
2146	position	O
2146	140	O
2146	located	O
2146	within	O
2146	the	O
2146	putative	O
2146	5	O
2146	-	O
2146	phosphoribosyl	O
2146	-	O
2146	1	O
2146	-	O
2146	pyrophosphate	O
2146	(	O
2146	PRPP	O
2146	)	O
2146	binding	O
2146	region	O
2146	.	O
2147	Missense	O
2147	mutations	O
2147	in	O
2147	human	O
2147	HPRT	B-Disease
2147	deficient	I-Disease
2147	patients	O
2147	thus	O
2147	far	O
2147	reported	O
2147	tend	O
2147	to	O
2147	accumulate	O
2147	in	O
2147	this	O
2147	functionally	O
2147	active	O
2147	region	O
2147	.	O
2148	However	O
2148	,	O
2148	a	O
2148	comparison	O
2148	of	O
2148	the	O
2148	data	O
2148	suggested	O
2148	that	O
2148	both	O
2148	missense	O
2148	and	O
2148	synonymous	O
2148	mutations	O
2148	can	O
2148	occur	O
2148	at	O
2148	any	O
2148	coding	O
2148	sequence	O
2148	of	O
2148	the	O
2148	human	O
2148	germ	O
2148	line	O
2148	HPRT	O
2148	gene	O
2148	,	O
2148	but	O
2148	that	O
2148	a	O
2148	limited	O
2148	percentage	O
2148	of	O
2148	all	O
2148	the	O
2148	missense	O
2148	mutations	O
2148	cause	O
2148	disease	O
2148	.	O
2149	The	O
2149	probability	O
2149	that	O
2149	a	O
2149	mutation	O
2149	will	O
2149	cause	O
2149	disease	O
2149	tends	O
2149	to	O
2149	be	O
2149	higher	O
2149	when	O
2149	the	O
2149	missense	O
2149	mutation	O
2149	is	O
2149	within	O
2149	a	O
2149	functionally	O
2149	important	O
2149	sequence	O
2149	.	O
2149	.	O
2150	Characterisation	O
2150	of	O
2150	a	O
2150	new	O
2150	rare	O
2150	fragile	O
2150	site	O
2150	easily	O
2150	confused	O
2150	with	O
2150	the	O
2150	fragile	B-Disease
2150	X	I-Disease
2150	.	O
2151	A	O
2151	new	O
2151	fragile	O
2151	site	O
2151	(	O
2151	FRAXE	O
2151	)	O
2151	in	O
2151	Xq28	O
2151	is	O
2151	described	O
2151	.	O
2152	It	O
2152	appears	O
2152	to	O
2152	be	O
2152	a	O
2152	typical	O
2152	folate	O
2152	sensitive	O
2152	fragile	O
2152	site	O
2152	.	O
2153	The	O
2153	fragile	O
2153	site	O
2153	is	O
2153	not	O
2153	associated	O
2153	with	O
2153	mental	B-Disease
2153	retardation	I-Disease
2153	,	O
2153	it	O
2153	does	O
2153	not	O
2153	give	O
2153	abnormal	O
2153	results	O
2153	when	O
2153	subjected	O
2153	to	O
2153	Southern	O
2153	analysis	O
2153	with	O
2153	probe	O
2153	pfxa3	O
2153	which	O
2153	detects	O
2153	the	O
2153	unstable	O
2153	DNA	O
2153	sequence	O
2153	characteristic	O
2153	of	O
2153	fragile	B-Disease
2153	X	I-Disease
2153	syndrome	I-Disease
2153	.	O
2154	In	O
2154	situ	O
2154	hybridization	O
2154	mapping	O
2154	locates	O
2154	the	O
2154	fragile	O
2154	site	O
2154	between	O
2154	150	O
2154	kb	O
2154	and	O
2154	600	O
2154	kb	O
2154	distal	O
2154	to	O
2154	FRAXA	O
2154	.	O
2155	The	O
2155	distinction	O
2155	between	O
2155	the	O
2155	two	O
2155	fragile	O
2155	sites	O
2155	is	O
2155	important	O
2155	clinically	O
2155	since	O
2155	cytogenetic	O
2155	detection	O
2155	of	O
2155	FRAXE	O
2155	,	O
2155	without	O
2155	molecular	O
2155	analysis	O
2155	,	O
2155	could	O
2155	result	O
2155	in	O
2155	misdiagnosis	O
2155	of	O
2155	fragile	B-Disease
2155	X	I-Disease
2155	syndrome	I-Disease
2155	.	O
2155	.	O
2156	The	O
2156	Norrie	B-Disease
2156	disease	I-Disease
2156	gene	O
2156	maps	O
2156	to	O
2156	a	O
2156	150	O
2156	kb	O
2156	region	O
2156	on	O
2156	chromosome	O
2156	Xp11	O
2156	.	O
2156	3	O
2156	.	O
2157	Norrie	B-Disease
2157	disease	I-Disease
2157	is	O
2157	a	O
2157	human	O
2157	X	B-Disease
2157	-	I-Disease
2157	linked	I-Disease
2157	recessive	I-Disease
2157	disorder	I-Disease
2157	of	O
2157	unknown	O
2157	etiology	O
2157	characterized	O
2157	by	O
2157	congenital	B-Disease
2157	blindness	I-Disease
2157	,	O
2157	sensory	B-Disease
2157	neural	I-Disease
2157	deafness	I-Disease
2157	and	O
2157	mental	B-Disease
2157	retardation	I-Disease
2157	.	O
2158	This	O
2158	disease	O
2158	gene	O
2158	was	O
2158	previously	O
2158	linked	O
2158	to	O
2158	the	O
2158	DXS7	O
2158	(	O
2158	L1	O
2158	.	O
2158	28	O
2158	)	O
2158	locus	O
2158	and	O
2158	the	O
2158	MAO	O
2158	genes	O
2158	in	O
2158	band	O
2158	Xp11	O
2158	.	O
2159	3	O
2159	3	O
2159	.	O
2160	We	O
2160	report	O
2160	here	O
2160	fine	O
2160	physical	O
2160	mapping	O
2160	of	O
2160	the	O
2160	obligate	O
2160	region	O
2160	containing	O
2160	the	O
2160	Norrie	B-Disease
2160	disease	I-Disease
2160	gene	O
2160	(	O
2160	NDP	O
2160	)	O
2160	defined	O
2160	by	O
2160	a	O
2160	recombination	O
2160	and	O
2160	by	O
2160	the	O
2160	smallest	O
2160	submicroscopic	O
2160	chromosomal	O
2160	deletion	O
2160	associated	O
2160	with	O
2160	Norrie	B-Disease
2160	disease	I-Disease
2160	identified	O
2160	to	O
2160	date	O
2160	.	O
2161	Analysis	O
2161	,	O
2161	using	O
2161	in	O
2161	addition	O
2161	two	O
2161	overlapping	O
2161	YAC	O
2161	clones	O
2161	from	O
2161	this	O
2161	region	O
2161	,	O
2161	allowed	O
2161	orientation	O
2161	of	O
2161	the	O
2161	MAOA	O
2161	and	O
2161	MAOB	O
2161	genes	O
2161	in	O
2161	a	O
2161	5	O
2161	-	O
2161	3	O
2161	-	O
2161	3	O
2161	-	O
2161	5	O
2161	configuration	O
2161	.	O
2162	A	O
2162	recombination	O
2162	event	O
2162	between	O
2162	a	O
2162	(	O
2162	GT	O
2162	)	O
2162	n	O
2162	polymorphism	O
2162	in	O
2162	intron	O
2162	2	O
2162	of	O
2162	the	O
2162	MAOB	O
2162	gene	O
2162	and	O
2162	the	O
2162	NDP	O
2162	locus	O
2162	,	O
2162	in	O
2162	a	O
2162	family	O
2162	previously	O
2162	reported	O
2162	to	O
2162	have	O
2162	a	O
2162	recombination	O
2162	between	O
2162	DXS7	O
2162	and	O
2162	NDP	O
2162	,	O
2162	delineates	O
2162	a	O
2162	flanking	O
2162	marker	O
2162	telomeric	O
2162	to	O
2162	this	O
2162	disease	O
2162	gene	O
2162	.	O
2163	An	O
2163	anonymous	O
2163	DNA	O
2163	probe	O
2163	,	O
2163	dc12	O
2163	,	O
2163	present	O
2163	in	O
2163	one	O
2163	of	O
2163	the	O
2163	YACs	O
2163	and	O
2163	in	O
2163	a	O
2163	patient	O
2163	with	O
2163	a	O
2163	submicroscopic	O
2163	deletion	O
2163	which	O
2163	includes	O
2163	MAOA	O
2163	and	O
2163	MAOB	O
2163	but	O
2163	not	O
2163	L1	O
2163	.	O
2164	28	O
2164	,	O
2164	serves	O
2164	as	O
2164	a	O
2164	flanking	O
2164	marker	O
2164	centromeric	O
2164	to	O
2164	the	O
2164	disease	O
2164	gene	O
2164	.	O
2165	An	O
2165	Alu	O
2165	-	O
2165	PCR	O
2165	fragment	O
2165	from	O
2165	the	O
2165	right	O
2165	arm	O
2165	of	O
2165	the	O
2165	MAO	O
2165	YAC	O
2165	(	O
2165	YMAO	O
2165	.	O
2165	AluR	O
2165	)	O
2165	is	O
2165	not	O
2165	deleted	O
2165	in	O
2165	this	O
2165	patient	O
2165	and	O
2165	also	O
2165	delineates	O
2165	the	O
2165	centromeric	O
2165	extent	O
2165	of	O
2165	the	O
2165	obligate	O
2165	disease	O
2165	region	O
2165	.	O
2166	The	O
2166	apparent	O
2166	order	O
2166	of	O
2166	these	O
2166	loci	O
2166	is	O
2166	telomere	O
2166	.	O
2167	DXS7	O
2167	-	O
2167	MAOA	O
2167	-	O
2167	MAOB	O
2167	-	O
2167	NDP	O
2167	-	O
2167	dc12	O
2167	-	O
2167	YMAO	O
2167	DXS7	O
2167	-	O
2167	MAOA	O
2167	-	O
2167	MAOB	O
2167	-	O
2167	NDP	O
2167	-	O
2167	dc12	O
2167	-	O
2167	YMAO	O
2167	.	O
2168	AluR	O
2168	.	O
2168	centromere	O
2168	.	O
2169	Together	O
2169	these	O
2169	data	O
2169	define	O
2169	the	O
2169	obligate	O
2169	region	O
2169	containing	O
2169	the	O
2169	NDP	O
2169	gene	O
2169	to	O
2169	a	O
2169	chromosomal	O
2169	segment	O
2169	less	O
2169	than	O
2169	150	O
2169	kb	O
2169	.	O
2170	Molecular	O
2170	basis	O
2170	of	O
2170	phenylketonuria	B-Disease
2170	and	O
2170	related	O
2170	hyperphenylalaninemias	B-Disease
2170	:	O
2170	mutations	O
2170	and	O
2170	polymorphisms	O
2170	in	O
2170	the	O
2170	human	O
2170	phenylalanine	O
2170	hydroxylase	O
2170	gene	O
2170	.	O
2171	Mutations	O
2171	in	O
2171	the	O
2171	human	O
2171	phenylalanine	O
2171	hydroxylase	O
2171	gene	O
2171	producing	O
2171	phenylketonuria	B-Disease
2171	or	O
2171	hyperphenylalaninemia	B-Disease
2171	have	O
2171	now	O
2171	been	O
2171	identified	O
2171	in	O
2171	many	O
2171	patients	O
2171	from	O
2171	various	O
2171	ethnic	O
2171	groups	O
2171	.	O
2172	These	O
2172	mutations	O
2172	all	O
2172	exhibit	O
2172	a	O
2172	high	O
2172	degree	O
2172	of	O
2172	association	O
2172	with	O
2172	specific	O
2172	restriction	O
2172	fragment	O
2172	-	O
2172	length	O
2172	polymorphism	O
2172	haplotypes	O
2172	at	O
2172	the	O
2172	PAH	O
2172	locus	O
2172	.	O
2173	About	O
2173	50	O
2173	of	O
2173	these	O
2173	mutations	O
2173	are	O
2173	single	O
2173	-	O
2173	base	O
2173	substitutions	O
2173	,	O
2173	including	O
2173	six	O
2173	nonsense	O
2173	mutations	O
2173	and	O
2173	eight	O
2173	splicing	O
2173	mutations	O
2173	,	O
2173	with	O
2173	the	O
2173	remainder	O
2173	being	O
2173	missense	O
2173	mutations	O
2173	.	O
2174	One	O
2174	splicing	O
2174	mutation	O
2174	results	O
2174	in	O
2174	a	O
2174	3	O
2174	amino	O
2174	acid	O
2174	in	O
2174	-	O
2174	frame	O
2174	insertion	O
2174	.	O
2175	Two	O
2175	or	O
2175	3	O
2175	large	O
2175	deletions	O
2175	,	O
2175	2	O
2175	single	O
2175	codon	O
2175	deletions	O
2175	,	O
2175	and	O
2175	2	O
2175	single	O
2175	base	O
2175	deletions	O
2175	have	O
2175	been	O
2175	found	O
2175	.	O
2176	Twelve	O
2176	of	O
2176	the	O
2176	missense	O
2176	mutations	O
2176	apparently	O
2176	result	O
2176	from	O
2176	the	O
2176	methylation	O
2176	and	O
2176	subsequent	O
2176	deamination	O
2176	of	O
2176	highly	O
2176	mutagenic	O
2176	CpG	O
2176	dinucleotides	O
2176	.	O
2177	Recurrent	O
2177	mutation	O
2177	has	O
2177	been	O
2177	observed	O
2177	at	O
2177	several	O
2177	of	O
2177	these	O
2177	sites	O
2177	,	O
2177	producing	O
2177	associations	O
2177	with	O
2177	different	O
2177	haplotypes	O
2177	in	O
2177	different	O
2177	populations	O
2177	.	O
2178	About	O
2178	half	O
2178	of	O
2178	all	O
2178	missense	O
2178	mutations	O
2178	have	O
2178	been	O
2178	examined	O
2178	by	O
2178	in	O
2178	vitro	O
2178	expression	O
2178	analysis	O
2178	,	O
2178	and	O
2178	a	O
2178	significant	O
2178	correlation	O
2178	has	O
2178	been	O
2178	observed	O
2178	between	O
2178	residual	O
2178	PAH	O
2178	activity	O
2178	and	O
2178	disease	O
2178	phenotype	O
2178	.	O
2179	Since	O
2179	continuing	O
2179	advances	O
2179	in	O
2179	molecular	O
2179	methodologies	O
2179	have	O
2179	dramatically	O
2179	accelerated	O
2179	the	O
2179	rate	O
2179	in	O
2179	which	O
2179	new	O
2179	mutations	O
2179	are	O
2179	being	O
2179	identified	O
2179	and	O
2179	characterized	O
2179	,	O
2179	this	O
2179	register	O
2179	of	O
2179	mutations	O
2179	will	O
2179	be	O
2179	updated	O
2179	periodically	O
2179	.	O
2179	.	O
2180	A	O
2180	glycine250	O
2180	-	O
2180	-	O
2180	>	O
2180	aspartate	O
2180	substitution	O
2180	in	O
2180	the	O
2180	alpha	O
2180	-	O
2180	subunit	O
2180	of	O
2180	hexosaminidase	O
2180	A	O
2180	causes	O
2180	juvenile	O
2180	-	O
2180	onset	O
2180	Tay	B-Disease
2180	-	I-Disease
2180	Sachs	I-Disease
2180	disease	I-Disease
2180	in	O
2180	a	O
2180	Lebanese	O
2180	-	O
2180	Canadian	O
2180	family	O
2180	.	O
2181	The	O
2181	mutation	O
2181	causing	O
2181	juvenile	O
2181	Tay	B-Disease
2181	-	I-Disease
2181	Sachs	I-Disease
2181	disease	I-Disease
2181	(	O
2181	TSD	B-Disease
2181	)	O
2181	in	O
2181	two	O
2181	sibs	O
2181	of	O
2181	Lebanese	O
2181	-	O
2181	Maronite	O
2181	origin	O
2181	is	O
2181	described	O
2181	.	O
2182	An	O
2182	mRNA	O
2182	-	O
2182	containing	O
2182	extract	O
2182	of	O
2182	cultured	O
2182	fibroblasts	O
2182	obtained	O
2182	from	O
2182	one	O
2182	of	O
2182	the	O
2182	probands	O
2182	was	O
2182	used	O
2182	as	O
2182	a	O
2182	template	O
2182	to	O
2182	amplify	O
2182	the	O
2182	coding	O
2182	sequence	O
2182	of	O
2182	the	O
2182	hexosaminidase	O
2182	A	O
2182	(	O
2182	Hex	O
2182	A	O
2182	)	O
2182	alpha	O
2182	-	O
2182	subunit	O
2182	.	O
2183	Sequencing	O
2183	of	O
2183	amplified	O
2183	cDNA	O
2183	fragments	O
2183	revealed	O
2183	a	O
2183	single	O
2183	alteration	O
2183	,	O
2183	guanine	O
2183	to	O
2183	adenine	O
2183	at	O
2183	nt	O
2183	749	O
2183	creating	O
2183	a	O
2183	G250D	O
2183	mutation	O
2183	.	O
2184	The	O
2184	mutation	O
2184	introduces	O
2184	a	O
2184	new	O
2184	recognition	O
2184	site	O
2184	for	O
2184	the	O
2184	restriction	O
2184	enzyme	O
2184	Eco	O
2184	RV	O
2184	,	O
2184	permitting	O
2184	identification	O
2184	of	O
2184	heterozygotes	O
2184	for	O
2184	this	O
2184	allele	O
2184	following	O
2184	PCR	O
2184	amplification	O
2184	and	O
2184	Eco	O
2184	RV	O
2184	digestion	O
2184	of	O
2184	exon	O
2184	7	O
2184	sequences	O
2184	from	O
2184	genomic	O
2184	DNA	O
2184	templates	O
2184	.	O
2185	In	O
2185	order	O
2185	to	O
2185	test	O
2185	the	O
2185	effect	O
2185	of	O
2185	this	O
2185	substitution	O
2185	,	O
2185	an	O
2185	in	O
2185	vitro	O
2185	mutagenized	O
2185	cDNA	O
2185	construct	O
2185	was	O
2185	introduced	O
2185	into	O
2185	a	O
2185	mammalian	O
2185	expression	O
2185	vector	O
2185	and	O
2185	transfected	O
2185	into	O
2185	monkey	O
2185	Cos	O
2185	-	O
2185	1	O
2185	cells	O
2185	separately	O
2185	or	O
2185	along	O
2185	with	O
2185	a	O
2185	beta	O
2185	-	O
2185	cDNA	O
2185	expression	O
2185	vector	O
2185	.	O
2186	When	O
2186	the	O
2186	mutant	O
2186	alpha	O
2186	-	O
2186	cDNA	O
2186	was	O
2186	the	O
2186	only	O
2186	gene	O
2186	introduced	O
2186	into	O
2186	COS	O
2186	cells	O
2186	no	O
2186	enzymatic	O
2186	activity	O
2186	above	O
2186	endogenous	O
2186	COS	O
2186	cell	O
2186	activity	O
2186	was	O
2186	detected	O
2186	.	O
2187	Cotransfection	O
2187	of	O
2187	normal	O
2187	alpha	O
2187	-	O
2187	cDNA	O
2187	and	O
2187	beta	O
2187	-	O
2187	cDNA	O
2187	followed	O
2187	by	O
2187	immunoprecipitation	O
2187	of	O
2187	human	O
2187	Hex	O
2187	A	O
2187	resulted	O
2187	in	O
2187	20	O
2187	-	O
2187	fold	O
2187	increase	O
2187	in	O
2187	the	O
2187	ratio	O
2187	between	O
2187	positive	O
2187	and	O
2187	negative	O
2187	(	O
2187	mock	O
2187	transfection	O
2187	)	O
2187	control	O
2187	values	O
2187	.	O
2188	This	O
2188	allowed	O
2188	the	O
2188	detection	O
2188	of	O
2188	some	O
2188	residual	O
2188	activity	O
2188	(	O
2188	12	O
2188	%	O
2188	of	O
2188	the	O
2188	positive	O
2188	control	O
2188	)	O
2188	when	O
2188	the	O
2188	mutant	O
2188	alpha	O
2188	-	O
2188	cDNA	O
2188	replaced	O
2188	its	O
2188	wild	O
2188	-	O
2188	type	O
2188	counterpart	O
2188	.	O
2189	The	O
2189	predicted	O
2189	protein	O
2189	environment	O
2189	in	O
2189	which	O
2189	the	O
2189	mutation	O
2189	occurs	O
2189	is	O
2189	compared	O
2189	to	O
2189	that	O
2189	of	O
2189	the	O
2189	adult	O
2189	-	O
2189	onset	O
2189	Tay	B-Disease
2189	-	I-Disease
2189	Sachs	I-Disease
2189	disease	I-Disease
2189	mutation	O
2189	caused	O
2189	by	O
2189	a	O
2189	Gly269	O
2189	-	O
2189	-	O
2189	>	O
2189	Ser	O
2189	substitution	O
2189	in	O
2189	exon	O
2189	7	O
2189	.	O
2190	(	O
2190	ABSTRACT	O
2190	TRUNCATED	O
2190	AT	O
2190	250	O
2190	WORDS	O
2190	)	O
2190	.	O
2191	Novel	O
2191	Tay	B-Disease
2191	-	I-Disease
2191	Sachs	I-Disease
2191	disease	I-Disease
2191	mutations	O
2191	from	O
2191	China	O
2191	.	O
2192	We	O
2192	describe	O
2192	three	O
2192	HEXA	O
2192	mutations	O
2192	associated	O
2192	with	O
2192	infantile	O
2192	Tay	B-Disease
2192	-	I-Disease
2192	Sachs	I-Disease
2192	disease	I-Disease
2192	(	O
2192	TSD	B-Disease
2192	)	O
2192	in	O
2192	three	O
2192	unrelated	O
2192	nonconsanguineous	O
2192	Chinese	O
2192	families	O
2192	.	O
2193	Novel	O
2193	mutations	O
2193	were	O
2193	found	O
2193	in	O
2193	two	O
2193	of	O
2193	these	O
2193	families	O
2193	.	O
2194	The	O
2194	third	O
2194	is	O
2194	a	O
2194	previously	O
2194	reported	O
2194	mutation	O
2194	(	O
2194	G	O
2194	-	O
2194	-	O
2194	>	O
2194	A	O
2194	transition	O
2194	at	O
2194	nt	O
2194	1444	O
2194	)	O
2194	(	O
2194	Nakano	O
2194	et	O
2194	al	O
2194	.	O
2194	,	O
2194	1988	O
2194	)	O
2194	.	O
2195	Direct	O
2195	sequencing	O
2195	of	O
2195	PCR	O
2195	products	O
2195	identified	O
2195	a	O
2195	novel	O
2195	insertion	O
2195	of	O
2195	an	O
2195	A	O
2195	after	O
2195	nt	O
2195	547	O
2195	in	O
2195	family	O
2195	1	O
2195	.	O
2196	This	O
2196	change	O
2196	generates	O
2196	an	O
2196	early	O
2196	termination	O
2196	codon	O
2196	6	O
2196	bp	O
2196	downstream	O
2196	from	O
2196	the	O
2196	insertion	O
2196	site	O
2196	.	O
2197	Allele	O
2197	-	O
2197	specific	O
2197	oligonucleotide	O
2197	hybridization	O
2197	confirmed	O
2197	homozygosity	O
2197	in	O
2197	the	O
2197	proband	O
2197	.	O
2198	Single	O
2198	strand	O
2198	conformational	O
2198	polymorphism	O
2198	analysis	O
2198	and	O
2198	direct	O
2198	sequencing	O
2198	of	O
2198	amplified	O
2198	exon	O
2198	13	O
2198	revealed	O
2198	a	O
2198	T	O
2198	-	O
2198	-	O
2198	>	O
2198	C	O
2198	transition	O
2198	at	O
2198	nt	O
2198	1453	O
2198	with	O
2198	the	O
2198	corresponding	O
2198	amino	O
2198	acid	O
2198	substitution	O
2198	W485R	O
2198	in	O
2198	the	O
2198	second	O
2198	family	O
2198	.	O
2199	This	O
2199	mutation	O
2199	creates	O
2199	an	O
2199	Fnu4HI	O
2199	restriction	O
2199	site	O
2199	.	O
2200	The	O
2200	proband	O
2200	is	O
2200	homozygous	O
2200	for	O
2200	this	O
2200	allele	O
2200	.	O
2201	When	O
2201	the	O
2201	site	O
2201	-	O
2201	specific	O
2201	mutagenized	O
2201	alpha	O
2201	cDNA	O
2201	carrying	O
2201	the	O
2201	T	O
2201	-	O
2201	-	O
2201	>	O
2201	C	O
2201	transition	O
2201	at	O
2201	nt	O
2201	1453	O
2201	was	O
2201	expressed	O
2201	in	O
2201	COS	O
2201	1	O
2201	cells	O
2201	hexosaminidase	O
2201	S	O
2201	activity	O
2201	was	O
2201	not	O
2201	detectable	O
2201	above	O
2201	background	O
2201	.	O
2202	A	O
2202	G	O
2202	-	O
2202	-	O
2202	>	O
2202	A	O
2202	transition	O
2202	at	O
2202	nt	O
2202	1444	O
2202	(	O
2202	exon	O
2202	13	O
2202	)	O
2202	corresponding	O
2202	to	O
2202	the	O
2202	E482K	O
2202	substitution	O
2202	was	O
2202	found	O
2202	in	O
2202	the	O
2202	third	O
2202	family	O
2202	.	O
2203	This	O
2203	mutation	O
2203	occurs	O
2203	at	O
2203	a	O
2203	CpG	O
2203	dinucleotide	O
2203	.	O
2204	It	O
2204	has	O
2204	been	O
2204	reported	O
2204	in	O
2204	an	O
2204	Italian	O
2204	TSD	B-Disease
2204	proband	O
2204	and	O
2204	causes	O
2204	defective	O
2204	intracellular	O
2204	transport	O
2204	of	O
2204	the	O
2204	alpha	O
2204	-	O
2204	subunit	O
2204	from	O
2204	the	O
2204	rough	O
2204	endoplasmic	O
2204	reticulum	O
2204	to	O
2204	the	O
2204	Golgi	O
2204	apparatus	O
2204	.	O
2205	Two	O
2205	missense	O
2205	mutations	O
2205	causing	O
2205	mild	O
2205	hyperphenylalaninemia	B-Disease
2205	associated	O
2205	with	O
2205	DNA	O
2205	haplotype	O
2205	12	O
2205	.	O
2206	The	O
2206	genetic	B-Disease
2206	defects	I-Disease
2206	responsible	O
2206	for	O
2206	most	O
2206	phenylketonuria	B-Disease
2206	(	O
2206	PKU	B-Disease
2206	)	O
2206	and	O
2206	hyperphenylalaninemia	B-Disease
2206	(	O
2206	HPA	B-Disease
2206	)	O
2206	cases	O
2206	are	O
2206	located	O
2206	in	O
2206	the	O
2206	phenylalanine	O
2206	hydroxylase	O
2206	(	O
2206	PAH	O
2206	)	O
2206	gene	O
2206	.	O
2207	Approximately	O
2207	50	O
2207	-	O
2207	60	O
2207	mutations	O
2207	have	O
2207	been	O
2207	reported	O
2207	in	O
2207	Caucasians	O
2207	and	O
2207	are	O
2207	reflected	O
2207	in	O
2207	a	O
2207	wide	O
2207	range	O
2207	of	O
2207	clinical	O
2207	severities	O
2207	.	O
2208	Most	O
2208	mutations	O
2208	are	O
2208	linked	O
2208	to	O
2208	specific	O
2208	haplotypes	O
2208	,	O
2208	as	O
2208	defined	O
2208	by	O
2208	eight	O
2208	polymorphic	O
2208	restriction	O
2208	sites	O
2208	in	O
2208	the	O
2208	PAH	O
2208	gene	O
2208	.	O
2209	We	O
2209	hypothesized	O
2209	that	O
2209	there	O
2209	is	O
2209	at	O
2209	least	O
2209	one	O
2209	mild	O
2209	mutation	O
2209	linked	O
2209	to	O
2209	haplotype	O
2209	12	O
2209	in	O
2209	the	O
2209	Swedish	O
2209	PKU	B-Disease
2209	/	O
2209	HPA	B-Disease
2209	population	O
2209	,	O
2209	since	O
2209	7	O
2209	of	O
2209	8	O
2209	patients	O
2209	carrying	O
2209	haplotype	O
2209	12	O
2209	had	O
2209	mild	O
2209	HPA	B-Disease
2209	.	O
2210	Sequence	O
2210	analysis	O
2210	revealed	O
2210	a	O
2210	C	O
2210	-	O
2210	to	O
2210	-	O
2210	G	O
2210	transversion	O
2210	at	O
2210	the	O
2210	second	O
2210	base	O
2210	of	O
2210	codon	O
2210	322	O
2210	,	O
2210	resulting	O
2210	in	O
2210	a	O
2210	substitution	O
2210	of	O
2210	glycine	O
2210	for	O
2210	alanine	O
2210	,	O
2210	in	O
2210	four	O
2210	mutant	O
2210	haplotype	O
2210	12	O
2210	genes	O
2210	,	O
2210	and	O
2210	a	O
2210	G	O
2210	-	O
2210	to	O
2210	-	O
2210	A	O
2210	transition	O
2210	at	O
2210	the	O
2210	second	O
2210	base	O
2210	of	O
2210	codon	O
2210	408	O
2210	,	O
2210	resulting	O
2210	in	O
2210	a	O
2210	substitution	O
2210	of	O
2210	glutamine	O
2210	for	O
2210	arginine	O
2210	,	O
2210	in	O
2210	another	O
2210	three	O
2210	mutant	O
2210	haplotype	O
2210	12	O
2210	genes	O
2210	.	O
2211	These	O
2211	mutations	O
2211	segregated	O
2211	with	O
2211	mutant	O
2211	haplotype	O
2211	12	O
2211	alleles	O
2211	in	O
2211	nuclear	O
2211	families	O
2211	but	O
2211	were	O
2211	not	O
2211	present	O
2211	on	O
2211	normal	O
2211	or	O
2211	other	O
2211	mutant	O
2211	alleles	O
2211	.	O
2212	Both	O
2212	mutations	O
2212	were	O
2212	tested	O
2212	in	O
2212	a	O
2212	eukaryotic	O
2212	expression	O
2212	system	O
2212	in	O
2212	which	O
2212	enzyme	O
2212	activities	O
2212	of	O
2212	different	O
2212	mutant	O
2212	PAH	O
2212	enzymes	O
2212	reflect	O
2212	the	O
2212	relative	O
2212	severities	O
2212	of	O
2212	the	O
2212	mutations	O
2212	,	O
2212	although	O
2212	these	O
2212	in	O
2212	vitro	O
2212	activities	O
2212	cannot	O
2212	be	O
2212	translated	O
2212	directly	O
2212	into	O
2212	in	O
2212	vivo	O
2212	hepatic	O
2212	activities	O
2212	.	O
2213	The	O
2213	A322G	O
2213	mutant	O
2213	PAH	O
2213	had	O
2213	about	O
2213	75	O
2213	%	O
2213	and	O
2213	the	O
2213	R408Q	O
2213	mutant	O
2213	PAH	O
2213	about	O
2213	55	O
2213	%	O
2213	of	O
2213	the	O
2213	wild	O
2213	-	O
2213	type	O
2213	PAH	O
2213	enzyme	O
2213	activity	O
2213	.	O
2214	These	O
2214	in	O
2214	vitro	O
2214	activities	O
2214	are	O
2214	the	O
2214	highest	O
2214	reported	O
2214	for	O
2214	mutant	O
2214	PAH	O
2214	enzymes	O
2214	produced	O
2214	in	O
2214	the	O
2214	same	O
2214	expression	O
2214	system	O
2214	.	O
2215	(	O
2215	ABSTRACT	O
2215	TRUNCATED	O
2215	AT	O
2215	250	O
2215	WORDS	O
2215	)	O
2215	.	O
2216	In	O
2216	vitro	O
2216	and	O
2216	in	O
2216	vivo	O
2216	correlations	O
2216	for	O
2216	I65T	O
2216	and	O
2216	M1V	O
2216	mutations	O
2216	at	O
2216	the	O
2216	phenylalanine	O
2216	hydroxylase	O
2216	locus	O
2216	.	O
2217	Mutations	O
2217	at	O
2217	the	O
2217	phenylalanine	O
2217	hydroxylase	O
2217	(	O
2217	PAH	O
2217	)	O
2217	locus	O
2217	are	O
2217	the	O
2217	major	O
2217	cause	O
2217	of	O
2217	hyperphenylalaninemia	B-Disease
2217	.	O
2218	We	O
2218	have	O
2218	previously	O
2218	described	O
2218	four	O
2218	mutations	O
2218	(	O
2218	M1V	O
2218	,	O
2218	IVS12nt1	O
2218	,	O
2218	R408W	O
2218	,	O
2218	and	O
2218	S349P	O
2218	)	O
2218	at	O
2218	the	O
2218	PAH	O
2218	locus	O
2218	in	O
2218	French	O
2218	Canadians	O
2218	with	O
2218	ancestry	O
2218	in	O
2218	eastern	O
2218	Quebec	O
2218	.	O
2219	Here	O
2219	we	O
2219	report	O
2219	(	O
2219	1	O
2219	)	O
2219	identification	O
2219	of	O
2219	another	O
2219	mutation	O
2219	,	O
2219	on	O
2219	a	O
2219	haplotype	O
2219	9	O
2219	chromosome	O
2219	,	O
2219	which	O
2219	converts	O
2219	codon	O
2219	65	O
2219	from	O
2219	isoleucine	O
2219	(	O
2219	ATT	O
2219	)	O
2219	to	O
2219	threonine	O
2219	(	O
2219	ACT	O
2219	)	O
2219	,	O
2219	(	O
2219	2	O
2219	)	O
2219	expression	O
2219	analysis	O
2219	of	O
2219	the	O
2219	I65T	O
2219	mutation	O
2219	in	O
2219	COS	O
2219	cells	O
2219	demonstrating	O
2219	75	O
2219	%	O
2219	loss	O
2219	of	O
2219	both	O
2219	immunoreactive	O
2219	protein	O
2219	and	O
2219	enzyme	O
2219	activity	O
2219	,	O
2219	and	O
2219	(	O
2219	3	O
2219	)	O
2219	expression	O
2219	analysis	O
2219	of	O
2219	the	O
2219	most	O
2219	prevalent	O
2219	PKU	B-Disease
2219	allele	O
2219	(	O
2219	M1V	O
2219	)	O
2219	in	O
2219	eastern	O
2219	Quebec	O
2219	,	O
2219	showing	O
2219	nondetectable	O
2219	levels	O
2219	of	O
2219	PAH	O
2219	protein	O
2219	and	O
2219	activity	O
2219	,	O
2219	a	O
2219	finding	O
2219	compatible	O
2219	with	O
2219	a	O
2219	mutation	O
2219	in	O
2219	the	O
2219	translation	O
2219	initiation	O
2219	codon	O
2219	.	O
2220	Homozygosity	O
2220	for	O
2220	M1V	O
2220	and	O
2220	codominant	O
2220	inheritance	O
2220	of	O
2220	I65T	O
2220	/	O
2220	R408W	O
2220	were	O
2220	both	O
2220	associated	O
2220	with	O
2220	classical	B-Disease
2220	phenylketonuria	I-Disease
2220	.	O
2220	.	O
2221	Molecular	O
2221	basis	O
2221	of	O
2221	hexosaminidase	B-Disease
2221	A	I-Disease
2221	deficiency	I-Disease
2221	and	O
2221	pseudodeficiency	O
2221	in	O
2221	the	O
2221	Berks	O
2221	County	O
2221	Pennsylvania	O
2221	Dutch	O
2221	.	O
2222	Following	O
2222	the	O
2222	birth	O
2222	of	O
2222	two	O
2222	infants	O
2222	with	O
2222	Tay	B-Disease
2222	-	I-Disease
2222	Sachs	I-Disease
2222	disease	I-Disease
2222	(	O
2222	TSD	B-Disease
2222	)	O
2222	,	O
2222	a	O
2222	non	O
2222	-	O
2222	Jewish	O
2222	,	O
2222	Pennsylvania	O
2222	Dutch	O
2222	kindred	O
2222	was	O
2222	screened	O
2222	for	O
2222	TSD	B-Disease
2222	carriers	O
2222	using	O
2222	the	O
2222	biochemical	O
2222	assay	O
2222	.	O
2223	A	O
2223	high	O
2223	frequency	O
2223	of	O
2223	individuals	O
2223	who	O
2223	appeared	O
2223	to	O
2223	be	O
2223	TSD	B-Disease
2223	heterozygotes	O
2223	was	O
2223	detected	O
2223	(	O
2223	Kelly	O
2223	et	O
2223	al	O
2223	.	O
2223	,	O
2223	1975	O
2223	)	O
2223	.	O
2224	Clinical	O
2224	and	O
2224	biochemical	O
2224	evidence	O
2224	suggested	O
2224	that	O
2224	the	O
2224	increased	O
2224	carrier	O
2224	frequency	O
2224	was	O
2224	due	O
2224	to	O
2224	at	O
2224	least	O
2224	two	O
2224	altered	O
2224	alleles	O
2224	for	O
2224	the	O
2224	hexosaminidase	O
2224	A	O
2224	alpha	O
2224	-	O
2224	subunit	O
2224	.	O
2225	We	O
2225	now	O
2225	report	O
2225	two	O
2225	mutant	O
2225	alleles	O
2225	in	O
2225	this	O
2225	Pennsylvania	O
2225	Dutch	O
2225	kindred	O
2225	,	O
2225	and	O
2225	one	O
2225	polymorphism	O
2225	.	O
2226	One	O
2226	allele	O
2226	,	O
2226	reported	O
2226	originally	O
2226	in	O
2226	a	O
2226	French	O
2226	TSD	B-Disease
2226	patient	O
2226	(	O
2226	Akli	O
2226	et	O
2226	al	O
2226	.	O
2226	,	O
2226	1991	O
2226	)	O
2226	,	O
2226	is	O
2226	a	O
2226	GT	O
2226	-	O
2226	-	O
2226	>	O
2226	AT	O
2226	transition	O
2226	at	O
2226	the	O
2226	donor	O
2226	splice	O
2226	-	O
2226	site	O
2226	of	O
2226	intron	O
2226	9	O
2226	.	O
2227	The	O
2227	second	O
2227	,	O
2227	a	O
2227	C	O
2227	-	O
2227	-	O
2227	>	O
2227	T	O
2227	transition	O
2227	at	O
2227	nucleotide	O
2227	739	O
2227	(	O
2227	Arg247Trp	O
2227	)	O
2227	,	O
2227	has	O
2227	been	O
2227	shown	O
2227	by	O
2227	Triggs	O
2227	-	O
2227	Raine	O
2227	et	O
2227	al	O
2227	.	O
2228	(	O
2228	1992	O
2228	)	O
2228	to	O
2228	be	O
2228	a	O
2228	clinically	O
2228	benign	O
2228	"	NN	O	O
2228	pseudodeficient	NN	O	O
2228	"	O
2228	allele	O
2228	associated	O
2228	with	O
2228	reduced	O
2228	enzyme	O
2228	activity	O
2228	against	O
2228	artificial	O
2228	substrate	O
2228	.	O
2229	Finally	O
2229	,	O
2229	a	O
2229	polymorphism	O
2229	[	O
2229	G	O
2229	-	O
2229	-	O
2229	>	O
2229	A	O
2229	(	O
2229	759	O
2229	)	O
2229	]	O
2229	,	O
2229	which	O
2229	leaves	O
2229	valine	O
2229	at	O
2229	codon	O
2229	253	O
2229	unchanged	O
2229	,	O
2229	is	O
2229	described	O
2229	.	O
2230	A	O
2230	mutation	O
2230	common	O
2230	in	O
2230	non	O
2230	-	O
2230	Jewish	O
2230	Tay	B-Disease
2230	-	I-Disease
2230	Sachs	I-Disease
2230	disease	I-Disease
2230	:	O
2230	frequency	O
2230	and	O
2230	RNA	O
2230	studies	O
2230	.	O
2231	Tay	B-Disease
2231	-	I-Disease
2231	Sachs	I-Disease
2231	disease	I-Disease
2231	(	O
2231	TSD	B-Disease
2231	)	O
2231	is	O
2231	an	O
2231	autosomal	B-Disease
2231	recessive	I-Disease
2231	genetic	I-Disease
2231	disorder	I-Disease
2231	resulting	O
2231	from	O
2231	mutation	O
2231	of	O
2231	the	O
2231	HEXA	O
2231	gene	O
2231	encoding	O
2231	the	O
2231	alpha	O
2231	-	O
2231	subunit	O
2231	of	O
2231	the	O
2231	lysosomal	O
2231	enzyme	O
2231	,	O
2231	beta	O
2231	-	O
2231	N	O
2231	-	O
2231	acetylhexosaminidase	O
2231	A	O
2231	(	O
2231	Hex	O
2231	A	O
2231	)	O
2231	.	O
2232	We	O
2232	have	O
2232	discovered	O
2232	that	O
2232	a	O
2232	Tay	B-Disease
2232	-	I-Disease
2232	Sachs	I-Disease
2232	mutation	O
2232	,	O
2232	IVS	O
2232	-	O
2232	9	O
2232	+	O
2232	1	O
2232	G	O
2232	-	O
2232	-	O
2232	>	O
2232	A	O
2232	,	O
2232	first	O
2232	detected	O
2232	by	O
2232	Akli	O
2232	et	O
2232	al	O
2232	.	O
2233	(	O
2233	Genomics	O
2233	11	O
2233	124	O
2233	-	O
2233	134	O
2233	,	O
2233	1991	O
2233	)	O
2233	,	O
2233	is	O
2233	a	O
2233	common	O
2233	disease	O
2233	allele	O
2233	in	O
2233	non	O
2233	-	O
2233	Jewish	O
2233	Caucasians	O
2233	(	O
2233	10	O
2233	/	O
2233	58	O
2233	alleles	O
2233	examined	O
2233	)	O
2233	.	O
2234	A	O
2234	PCR	O
2234	-	O
2234	based	O
2234	diagnostic	O
2234	test	O
2234	,	O
2234	which	O
2234	detects	O
2234	an	O
2234	NlaIII	O
2234	site	O
2234	generated	O
2234	by	O
2234	the	O
2234	mutation	O
2234	,	O
2234	revealed	O
2234	a	O
2234	frequency	O
2234	among	O
2234	enzyme	O
2234	-	O
2234	defined	O
2234	carriers	O
2234	of	O
2234	9	O
2234	/	O
2234	64	O
2234	(	O
2234	14	O
2234	%	O
2234	)	O
2234	.	O
2235	Most	O
2235	of	O
2235	those	O
2235	carrying	O
2235	the	O
2235	allele	O
2235	trace	O
2235	their	O
2235	origins	O
2235	to	O
2235	the	O
2235	United	O
2235	Kingdom	O
2235	,	O
2235	Ireland	O
2235	,	O
2235	or	O
2235	Western	O
2235	Europe	O
2235	.	O
2236	It	O
2236	was	O
2236	not	O
2236	identified	O
2236	among	O
2236	12	O
2236	Black	O
2236	American	O
2236	TSD	B-Disease
2236	alleles	O
2236	or	O
2236	in	O
2236	any	O
2236	of	O
2236	18	O
2236	Ashkenazi	O
2236	Jewish	O
2236	,	O
2236	enzyme	O
2236	-	O
2236	defined	O
2236	carriers	O
2236	who	O
2236	did	O
2236	not	O
2236	carry	O
2236	any	O
2236	of	O
2236	the	O
2236	mutations	O
2236	common	O
2236	to	O
2236	this	O
2236	population	O
2236	.	O
2237	No	O
2237	normally	O
2237	spliced	O
2237	RNA	O
2237	was	O
2237	detected	O
2237	in	O
2237	PCR	O
2237	products	O
2237	generated	O
2237	from	O
2237	reverse	O
2237	transcription	O
2237	of	O
2237	RNA	O
2237	carrying	O
2237	the	O
2237	IVS	O
2237	-	O
2237	9	O
2237	mutation	O
2237	.	O
2238	Instead	O
2238	,	O
2238	the	O
2238	low	O
2238	levels	O
2238	of	O
2238	mRNA	O
2238	from	O
2238	this	O
2238	allele	O
2238	were	O
2238	comprised	O
2238	of	O
2238	aberrant	O
2238	species	O
2238	resulting	O
2238	from	O
2238	the	O
2238	use	O
2238	of	O
2238	either	O
2238	of	O
2238	two	O
2238	cryptic	O
2238	donor	O
2238	sites	O
2238	,	O
2238	one	O
2238	truncating	O
2238	exon	O
2238	9	O
2238	and	O
2238	the	O
2238	other	O
2238	within	O
2238	IVS	O
2238	-	O
2238	9	O
2238	,	O
2238	spliced	O
2238	to	O
2238	exon	O
2238	10	O
2238	.	O
2239	Numerous	O
2239	additional	O
2239	splice	O
2239	products	O
2239	were	O
2239	detected	O
2239	,	O
2239	most	O
2239	involving	O
2239	skipping	O
2239	of	O
2239	one	O
2239	or	O
2239	more	O
2239	surrounding	O
2239	exons	O
2239	.	O
2240	Together	O
2240	with	O
2240	a	O
2240	recently	O
2240	identified	O
2240	allele	O
2240	responsible	O
2240	for	O
2240	Hex	O
2240	A	O
2240	pseudodeficiency	O
2240	(	O
2240	Triggs	O
2240	-	O
2240	Raine	O
2240	et	O
2240	al	O
2240	.	O
2240	Am	O
2240	J	O
2240	Hum	O
2240	Genet	O
2240	,	O
2240	1992	O
2240	)	O
2240	,	O
2240	these	O
2240	two	O
2240	alleles	O
2240	accounted	O
2240	for	O
2240	almost	O
2240	50	O
2240	%	O
2240	(	O
2240	29	O
2240	/	O
2240	64	O
2240	)	O
2240	of	O
2240	TSD	B-Disease
2240	or	O
2240	carrier	O
2240	alleles	O
2240	ascertained	O
2240	by	O
2240	enzyme	O
2240	screening	O
2240	tests	O
2240	in	O
2240	non	O
2240	-	O
2240	Jewish	O
2240	Caucasians	O
2240	.	O
2240	.	O
2241	Aberrant	O
2241	splicing	O
2241	of	O
2241	the	O
2241	CHM	B-Disease
2241	gene	O
2241	is	O
2241	a	O
2241	significant	O
2241	cause	O
2241	of	O
2241	choroideremia	B-Disease
2241	.	O
2242	Choroideremia	B-Disease
2242	(	O
2242	CHM	B-Disease
2242	)	O
2242	is	O
2242	an	O
2242	X	B-Disease
2242	-	I-Disease
2242	linked	I-Disease
2242	progressive	I-Disease
2242	degeneration	I-Disease
2242	of	I-Disease
2242	the	I-Disease
2242	choroid	I-Disease
2242	and	I-Disease
2242	retina	I-Disease
2242	.	O
2243	12	O
2243	%	O
2243	of	O
2243	unrelated	O
2243	male	O
2243	patients	O
2243	carry	O
2243	deletions	O
2243	of	O
2243	the	O
2243	partially	O
2243	cloned	O
2243	CHM	B-Disease
2243	gene	O
2243	.	O
2244	In	O
2244	Finland	O
2244	,	O
2244	there	O
2244	are	O
2244	more	O
2244	than	O
2244	120	O
2244	living	O
2244	CHM	B-Disease
2244	patients	O
2244	belonging	O
2244	to	O
2244	eight	O
2244	apparently	O
2244	unrelated	O
2244	pedigrees	O
2244	.	O
2245	Molecular	O
2245	deletions	O
2245	involving	O
2245	the	O
2245	CHM	B-Disease
2245	gene	O
2245	have	O
2245	been	O
2245	detected	O
2245	in	O
2245	three	O
2245	families	O
2245	.	O
2246	We	O
2246	have	O
2246	screened	O
2246	the	O
2246	remaining	O
2246	five	O
2246	families	O
2246	for	O
2246	point	O
2246	mutations	O
2246	.	O
2247	In	O
2247	one	O
2247	large	O
2247	family	O
2247	a	O
2247	single	O
2247	nucleotide	O
2247	(	O
2247	T	O
2247	)	O
2247	insertion	O
2247	into	O
2247	the	O
2247	donor	O
2247	splice	O
2247	site	O
2247	of	O
2247	exon	O
2247	C	O
2247	leads	O
2247	to	O
2247	two	O
2247	aberrantly	O
2247	spliced	O
2247	mRNAs	O
2247	both	O
2247	producing	O
2247	a	O
2247	premature	O
2247	stop	O
2247	codon	O
2247	.	O
2248	The	O
2248	mutation	O
2248	can	O
2248	be	O
2248	assayed	O
2248	easily	O
2248	by	O
2248	amplification	O
2248	and	O
2248	digestion	O
2248	with	O
2248	Msel	O
2248	.	O
2249	Our	O
2249	findings	O
2249	provide	O
2249	additional	O
2249	evidence	O
2249	for	O
2249	the	O
2249	pathogenetic	O
2249	role	O
2249	of	O
2249	CHM	B-Disease
2249	mutations	O
2249	and	O
2249	provide	O
2249	a	O
2249	diagnostic	O
2249	tool	O
2249	for	O
2249	one	O
2249	fifth	O
2249	of	O
2249	the	O
2249	worlds	O
2249	known	O
2249	CHM	B-Disease
2249	patients	O
2249	.	O
2249	.	O
2250	Germline	O
2250	intronic	O
2250	and	O
2250	exonic	O
2250	mutations	O
2250	in	O
2250	the	O
2250	Wilms	B-Disease
2250	'	I-Disease
2250	tumour	I-Disease
2250	gene	O
2250	(	O
2250	WT1	O
2250	)	O
2250	affecting	O
2250	urogenital	O
2250	development	O
2250	.	O
2251	Denys	B-Disease
2251	-	I-Disease
2251	Drash	I-Disease
2251	syndrome	I-Disease
2251	is	O
2251	a	O
2251	rare	O
2251	human	O
2251	developmental	B-Disease
2251	disorder	I-Disease
2251	affecting	O
2251	the	O
2251	urogenital	O
2251	system	O
2251	and	O
2251	leading	O
2251	to	O
2251	renal	B-Disease
2251	failure	I-Disease
2251	,	O
2251	intersex	B-Disease
2251	disorders	I-Disease
2251	and	O
2251	Wilms	B-Disease
2251	tumour	I-Disease
2251	.	O
2252	In	O
2252	this	O
2252	report	O
2252	,	O
2252	four	O
2252	individuals	O
2252	with	O
2252	this	O
2252	syndrome	O
2252	are	O
2252	described	O
2252	carrying	O
2252	germline	O
2252	point	O
2252	mutations	O
2252	in	O
2252	the	O
2252	Wilms	B-Disease
2252	tumour	I-Disease
2252	suppressor	O
2252	gene	O
2252	,	O
2252	WT1	O
2252	.	O
2253	Three	O
2253	of	O
2253	these	O
2253	mutations	O
2253	were	O
2253	in	O
2253	the	O
2253	zinc	O
2253	finger	O
2253	domains	O
2253	of	O
2253	WT1	O
2253	.	O
2254	The	O
2254	fourth	O
2254	occurred	O
2254	within	O
2254	intron	O
2254	9	O
2254	,	O
2254	preventing	O
2254	splicing	O
2254	at	O
2254	one	O
2254	of	O
2254	the	O
2254	alternatively	O
2254	chosen	O
2254	splice	O
2254	donor	O
2254	sites	O
2254	of	O
2254	exon	O
2254	9	O
2254	when	O
2254	assayed	O
2254	in	O
2254	vitro	O
2254	.	O
2255	These	O
2255	results	O
2255	provide	O
2255	genetic	O
2255	evidence	O
2255	for	O
2255	distinct	O
2255	functional	O
2255	roles	O
2255	of	O
2255	the	O
2255	WT1	O
2255	isoforms	O
2255	in	O
2255	urogenital	O
2255	development	O
2255	.	O
2255	.	O
2256	Characterization	O
2256	of	O
2256	the	O
2256	myotonic	B-Disease
2256	dystrophy	I-Disease
2256	region	O
2256	predicts	O
2256	multiple	O
2256	protein	O
2256	isoform	O
2256	-	O
2256	encoding	O
2256	mRNAs	O
2256	.	O
2257	The	O
2257	mutation	O
2257	underlying	O
2257	myotonic	B-Disease
2257	dystrophy	I-Disease
2257	(	O
2257	DM	B-Disease
2257	)	O
2257	has	O
2257	been	O
2257	identified	O
2257	as	O
2257	an	O
2257	expansion	O
2257	of	O
2257	a	O
2257	polymorphic	O
2257	CTG	O
2257	-	O
2257	repeat	O
2257	in	O
2257	a	O
2257	gene	O
2257	encoding	O
2257	protein	O
2257	kinase	O
2257	activity	O
2257	.	O
2258	Brain	O
2258	and	O
2258	heart	O
2258	transcripts	O
2258	of	O
2258	the	O
2258	DM	O
2258	-	O
2258	kinase	O
2258	(	O
2258	DMR	O
2258	-	O
2258	B15	O
2258	)	O
2258	gene	O
2258	are	O
2258	subject	O
2258	to	O
2258	alternative	O
2258	RNA	O
2258	splicing	O
2258	in	O
2258	both	O
2258	human	O
2258	and	O
2258	mouse	O
2258	.	O
2259	The	O
2259	unstable	O
2259	[	O
2259	CTG	O
2259	]	O
2259	5	O
2259	-	O
2259	30	O
2259	motif	O
2259	is	O
2259	found	O
2259	uniquely	O
2259	in	O
2259	humans	O
2259	,	O
2259	although	O
2259	the	O
2259	flanking	O
2259	nucleotides	O
2259	are	O
2259	also	O
2259	present	O
2259	in	O
2259	mouse	O
2259	.	O
2260	Characterization	O
2260	of	O
2260	the	O
2260	DM	B-Disease
2260	region	O
2260	of	O
2260	both	O
2260	species	O
2260	reveals	O
2260	another	O
2260	active	O
2260	gene	O
2260	(	O
2260	DMR	O
2260	-	O
2260	N9	O
2260	)	O
2260	in	O
2260	close	O
2260	proximity	O
2260	to	O
2260	the	O
2260	kinase	O
2260	gene	O
2260	.	O
2261	DMR	O
2261	-	O
2261	N9	O
2261	transcripts	O
2261	,	O
2261	mainly	O
2261	expressed	O
2261	in	O
2261	brain	O
2261	and	O
2261	testis	O
2261	,	O
2261	possess	O
2261	a	O
2261	single	O
2261	,	O
2261	large	O
2261	open	O
2261	reading	O
2261	frame	O
2261	,	O
2261	but	O
2261	the	O
2261	function	O
2261	of	O
2261	its	O
2261	protein	O
2261	product	O
2261	is	O
2261	unknown	O
2261	.	O
2262	Clinical	O
2262	manifestation	O
2262	of	O
2262	DM	B-Disease
2262	may	O
2262	be	O
2262	caused	O
2262	by	O
2262	the	O
2262	expanded	O
2262	CTG	O
2262	-	O
2262	repeat	O
2262	compromising	O
2262	the	O
2262	(	O
2262	alternative	O
2262	)	O
2262	expression	O
2262	of	O
2262	DM	O
2262	-	O
2262	kinase	O
2262	or	O
2262	DMR	O
2262	-	O
2262	N9	O
2262	proteins	O
2262	.	O
2262	.	O
2263	Fragile	B-Disease
2263	X	I-Disease
2263	syndrome	I-Disease
2263	without	O
2263	CCG	O
2263	amplification	O
2263	has	O
2263	an	O
2263	FMR1	O
2263	deletion	O
2263	.	O
2264	We	O
2264	describe	O
2264	a	O
2264	patient	O
2264	with	O
2264	typical	O
2264	clinical	O
2264	features	O
2264	of	O
2264	the	O
2264	fragile	B-Disease
2264	X	I-Disease
2264	syndrome	I-Disease
2264	,	O
2264	but	O
2264	without	O
2264	cytogenetic	O
2264	expression	O
2264	of	O
2264	the	O
2264	fragile	B-Disease
2264	X	I-Disease
2264	or	O
2264	an	O
2264	amplified	O
2264	CCG	O
2264	trinucleotide	O
2264	repeat	O
2264	fragment	O
2264	.	O
2265	The	O
2265	patient	O
2265	has	O
2265	a	O
2265	previously	O
2265	uncharacterized	O
2265	submicroscopic	O
2265	deletion	O
2265	encompassing	O
2265	the	O
2265	CCG	O
2265	repeat	O
2265	,	O
2265	the	O
2265	entire	O
2265	FMR1	O
2265	gene	O
2265	and	O
2265	about	O
2265	2	O
2265	.	O
2266	5	O
2266	megabases	O
2266	of	O
2266	flanking	O
2266	sequences	O
2266	.	O
2267	This	O
2267	finding	O
2267	confirms	O
2267	that	O
2267	the	O
2267	fragile	B-Disease
2267	X	I-Disease
2267	phenotype	O
2267	can	O
2267	exist	O
2267	,	O
2267	without	O
2267	amplification	O
2267	of	O
2267	the	O
2267	CCG	O
2267	repeat	O
2267	or	O
2267	cytogenetic	O
2267	expression	O
2267	of	O
2267	the	O
2267	fragile	B-Disease
2267	X	I-Disease
2267	,	O
2267	and	O
2267	that	O
2267	fragile	B-Disease
2267	X	I-Disease
2267	syndrome	I-Disease
2267	is	O
2267	a	O
2267	genetically	O
2267	homogeneous	O
2267	disorder	O
2267	involving	O
2267	FMR1	O
2267	.	O
2268	We	O
2268	also	O
2268	found	O
2268	random	O
2268	X	O
2268	-	O
2268	inactivation	O
2268	in	O
2268	the	O
2268	mother	O
2268	of	O
2268	the	O
2268	patient	O
2268	who	O
2268	was	O
2268	shown	O
2268	to	O
2268	be	O
2268	a	O
2268	carrier	O
2268	of	O
2268	this	O
2268	deletion	O
2268	.	O
2269	Cloning	O
2269	of	O
2269	the	O
2269	Huntington	B-Disease
2269	disease	I-Disease
2269	region	O
2269	in	O
2269	yeast	O
2269	artificial	O
2269	chromosomes	O
2269	.	O
2270	The	O
2270	gene	O
2270	responsible	O
2270	for	O
2270	Huntington	B-Disease
2270	disease	I-Disease
2270	has	O
2270	been	O
2270	localized	O
2270	to	O
2270	a	O
2270	2	O
2270	.	O
2271	5	O
2271	million	O
2271	base	O
2271	pair	O
2271	(	O
2271	Mb	O
2271	)	O
2271	region	O
2271	between	O
2271	the	O
2271	loci	O
2271	D4S10	O
2271	and	O
2271	D4S168	O
2271	on	O
2271	the	O
2271	short	O
2271	arm	O
2271	of	O
2271	chromosome	O
2271	4	O
2271	.	O
2272	As	O
2272	part	O
2272	of	O
2272	a	O
2272	strategy	O
2272	to	O
2272	clone	O
2272	the	O
2272	HD	B-Disease
2272	gene	O
2272	on	O
2272	the	O
2272	basis	O
2272	of	O
2272	its	O
2272	chromosomal	O
2272	location	O
2272	,	O
2272	we	O
2272	isolated	O
2272	genomic	O
2272	DNA	O
2272	from	O
2272	the	O
2272	HD	B-Disease
2272	region	O
2272	as	O
2272	a	O
2272	set	O
2272	of	O
2272	overlapping	O
2272	yeast	O
2272	artificial	O
2272	chromosome	O
2272	(	O
2272	YAC	O
2272	)	O
2272	clones	O
2272	.	O
2273	Twenty	O
2273	-	O
2273	eight	O
2273	YAC	O
2273	clones	O
2273	were	O
2273	identified	O
2273	by	O
2273	screening	O
2273	human	O
2273	YAC	O
2273	libraries	O
2273	with	O
2273	twelve	O
2273	PCR	O
2273	-	O
2273	based	O
2273	sequence	O
2273	-	O
2273	tagged	O
2273	sites	O
2273	(	O
2273	STSs	O
2273	)	O
2273	from	O
2273	the	O
2273	region	O
2273	.	O
2274	We	O
2274	assembled	O
2274	the	O
2274	YAC	O
2274	clones	O
2274	into	O
2274	overlapping	O
2274	sets	O
2274	by	O
2274	hybridizing	O
2274	them	O
2274	to	O
2274	a	O
2274	large	O
2274	number	O
2274	of	O
2274	DNA	O
2274	probes	O
2274	from	O
2274	the	O
2274	HD	B-Disease
2274	region	O
2274	,	O
2274	including	O
2274	the	O
2274	STSs	O
2274	.	O
2275	In	O
2275	addition	O
2275	,	O
2275	we	O
2275	isolated	O
2275	the	O
2275	ends	O
2275	of	O
2275	the	O
2275	human	O
2275	DNA	O
2275	inserts	O
2275	of	O
2275	most	O
2275	of	O
2275	the	O
2275	YAC	O
2275	clones	O
2275	to	O
2275	assist	O
2275	in	O
2275	the	O
2275	construction	O
2275	of	O
2275	the	O
2275	contig	O
2275	.	O
2276	Although	O
2276	almost	O
2276	half	O
2276	of	O
2276	the	O
2276	YACs	O
2276	appear	O
2276	to	O
2276	contain	O
2276	chimeric	O
2276	inserts	O
2276	and	O
2276	several	O
2276	contain	O
2276	internal	O
2276	deletions	O
2276	or	O
2276	other	O
2276	rearrangements	O
2276	,	O
2276	we	O
2276	were	O
2276	able	O
2276	to	O
2276	obtain	O
2276	over	O
2276	2	O
2276	.	O
2277	2	O
2277	Mb	O
2277	of	O
2277	the	O
2277	HD	B-Disease
2277	region	O
2277	in	O
2277	YACs	O
2277	,	O
2277	including	O
2277	one	O
2277	continuous	O
2277	segment	O
2277	of	O
2277	2	O
2277	.	O
2278	0	O
2278	Mb	O
2278	covering	O
2278	the	O
2278	region	O
2278	that	O
2278	most	O
2278	likely	O
2278	contains	O
2278	the	O
2278	HD	B-Disease
2278	gene	O
2278	.	O
2279	Ten	O
2279	of	O
2279	the	O
2279	twenty	O
2279	eight	O
2279	YAC	O
2279	clones	O
2279	comprise	O
2279	a	O
2279	minimal	O
2279	set	O
2279	spanning	O
2279	the	O
2279	2	O
2279	.	O
2280	2	O
2280	Mb	O
2280	.	O
2281	These	O
2281	clones	O
2281	provide	O
2281	reagents	O
2281	for	O
2281	the	O
2281	complete	O
2281	characterization	O
2281	of	O
2281	this	O
2281	region	O
2281	of	O
2281	the	O
2281	genome	O
2281	and	O
2281	for	O
2281	the	O
2281	eventual	O
2281	isolation	O
2281	of	O
2281	the	O
2281	HD	B-Disease
2281	gene	O
2281	.	O
2282	Characterization	O
2282	of	O
2282	a	O
2282	YAC	O
2282	containing	O
2282	part	O
2282	or	O
2282	all	O
2282	of	O
2282	the	O
2282	Norrie	B-Disease
2282	disease	I-Disease
2282	locus	O
2282	.	O
2283	It	O
2283	has	O
2283	been	O
2283	shown	O
2283	from	O
2283	pulsed	O
2283	-	O
2283	field	O
2283	gel	O
2283	electrophoresis	O
2283	(	O
2283	PFGE	O
2283	)	O
2283	that	O
2283	the	O
2283	monoamine	O
2283	oxidase	O
2283	genes	O
2283	A	O
2283	and	O
2283	B	O
2283	(	O
2283	MAOA	O
2283	&	O
2283	MAOB	O
2283	)	O
2283	and	O
2283	DXS7	O
2283	loci	O
2283	are	O
2283	physically	O
2283	very	O
2283	close	O
2283	.	O
2284	We	O
2284	have	O
2284	therefore	O
2284	extended	O
2284	studies	O
2284	on	O
2284	their	O
2284	relationship	O
2284	through	O
2284	the	O
2284	characterisation	O
2284	of	O
2284	a	O
2284	650	O
2284	kb	O
2284	YAC	O
2284	isolated	O
2284	using	O
2284	L1	O
2284	.	O
2285	28	O
2285	(	O
2285	recognising	O
2285	the	O
2285	DXS7	O
2285	locus	O
2285	)	O
2285	as	O
2285	a	O
2285	probe	O
2285	.	O
2286	Restriction	O
2286	mapping	O
2286	of	O
2286	the	O
2286	YAC	O
2286	indicates	O
2286	that	O
2286	it	O
2286	contains	O
2286	both	O
2286	MAOA	O
2286	and	O
2286	MAOB	O
2286	genes	O
2286	in	O
2286	addition	O
2286	to	O
2286	the	O
2286	DXS7	O
2286	locus	O
2286	.	O
2287	The	O
2287	map	O
2287	derived	O
2287	from	O
2287	the	O
2287	YL1	O
2287	.	O
2288	28	O
2288	-	O
2288	YAC	O
2288	is	O
2288	compatible	O
2288	both	O
2288	with	O
2288	the	O
2288	map	O
2288	from	O
2288	an	O
2288	independently	O
2288	derived	O
2288	YAC	O
2288	carrying	O
2288	MAOA	O
2288	and	O
2288	B	O
2288	genes	O
2288	and	O
2288	with	O
2288	the	O
2288	long	O
2288	range	O
2288	genomic	O
2288	map	O
2288	for	O
2288	the	O
2288	region	O
2288	.	O
2289	A	O
2289	series	O
2289	of	O
2289	subclones	O
2289	prepared	O
2289	from	O
2289	a	O
2289	phage	O
2289	library	O
2289	(	O
2289	lambda	O
2289	DASH	O
2289	II	O
2289	)	O
2289	of	O
2289	the	O
2289	YAC	O
2289	have	O
2289	been	O
2289	characterised	O
2289	and	O
2289	have	O
2289	been	O
2289	employed	O
2289	to	O
2289	determine	O
2289	the	O
2289	end	O
2289	point	O
2289	of	O
2289	the	O
2289	deletion	O
2289	of	O
2289	a	O
2289	Norrie	B-Disease
2289	disease	I-Disease
2289	(	O
2289	NDP	B-Disease
2289	)	O
2289	patient	O
2289	who	O
2289	has	O
2289	been	O
2289	shown	O
2289	to	O
2289	lack	O
2289	both	O
2289	DXS7	O
2289	and	O
2289	MAO	O
2289	coding	O
2289	sequences	O
2289	.	O
2290	The	O
2290	pattern	O
2290	of	O
2290	retention	O
2290	of	O
2290	subclones	O
2290	in	O
2290	the	O
2290	deletion	O
2290	patient	O
2290	place	O
2290	the	O
2290	end	O
2290	point	O
2290	of	O
2290	the	O
2290	deletion	O
2290	within	O
2290	30	O
2290	-	O
2290	130	O
2290	kb	O
2290	of	O
2290	the	O
2290	proximal	O
2290	end	O
2290	of	O
2290	the	O
2290	YAC	O
2290	.	O
2291	By	O
2291	combining	O
2291	the	O
2291	data	O
2291	with	O
2291	established	O
2291	recombination	O
2291	analysis	O
2291	,	O
2291	we	O
2291	provide	O
2291	evidence	O
2291	that	O
2291	all	O
2291	or	O
2291	part	O
2291	of	O
2291	the	O
2291	NDP	O
2291	lies	O
2291	in	O
2291	the	O
2291	interval	O
2291	of	O
2291	approximately	O
2291	250kb	O
2291	within	O
2291	the	O
2291	YAC	O
2291	.	O
2292	Both	O
2292	mutations	O
2292	in	O
2292	G6PD	O
2292	A	O
2292	-	O
2292	are	O
2292	necessary	O
2292	to	O
2292	produce	O
2292	the	O
2292	G6PD	B-Disease
2292	deficient	I-Disease
2292	phenotype	O
2292	.	O
2293	The	O
2293	high	O
2293	prevalence	O
2293	of	O
2293	glucose	B-Disease
2293	6	I-Disease
2293	-	I-Disease
2293	phosphate	I-Disease
2293	dehydrogenase	I-Disease
2293	(	I-Disease
2293	G6PD	I-Disease
2293	)	I-Disease
2293	deficiency	I-Disease
2293	in	O
2293	African	O
2293	populations	O
2293	is	O
2293	due	O
2293	almost	O
2293	entirely	O
2293	to	O
2293	the	O
2293	enzyme	O
2293	variant	O
2293	A	O
2293	-	O
2293	,	O
2293	which	O
2293	differs	O
2293	from	O
2293	the	O
2293	wild	O
2293	-	O
2293	type	O
2293	G6PD	O
2293	B	O
2293	by	O
2293	two	O
2293	amino	O
2293	acid	O
2293	replacements	O
2293	,	O
2293	68	O
2293	Val	O
2293	-	O
2293	-	O
2293	>	O
2293	Met	O
2293	and	O
2293	126	O
2293	Asn	O
2293	-	O
2293	-	O
2293	>	O
2293	Asp	O
2293	.	O
2294	The	O
2294	non	O
2294	-	O
2294	deficient	O
2294	polymorphic	O
2294	variant	O
2294	G6PD	O
2294	A	O
2294	contains	O
2294	only	O
2294	the	O
2294	mutation	O
2294	126	O
2294	Asn	O
2294	-	O
2294	-	O
2294	>	O
2294	Asp	O
2294	.	O
2295	The	O
2295	frequencies	O
2295	of	O
2295	the	O
2295	G6PD	O
2295	A	O
2295	and	O
2295	of	O
2295	the	O
2295	G6PD	O
2295	A	O
2295	-	O
2295	genes	O
2295	in	O
2295	parts	O
2295	of	O
2295	Africa	O
2295	are	O
2295	both	O
2295	about	O
2295	0	O
2295	.	O
2296	2	O
2296	.	O
2297	The	O
2297	68	O
2297	Val	O
2297	-	O
2297	-	O
2297	>	O
2297	Met	O
2297	mutation	O
2297	has	O
2297	not	O
2297	been	O
2297	found	O
2297	in	O
2297	a	O
2297	B	O
2297	background	O
2297	.	O
2298	This	O
2298	could	O
2298	be	O
2298	because	O
2298	the	O
2298	68	O
2298	Val	O
2298	-	O
2298	-	O
2298	>	O
2298	Met	O
2298	mutation	O
2298	happened	O
2298	to	O
2298	arise	O
2298	in	O
2298	an	O
2298	A	O
2298	gene	O
2298	in	O
2298	the	O
2298	first	O
2298	instance	O
2298	,	O
2298	or	O
2298	because	O
2298	the	O
2298	68	O
2298	Val	O
2298	-	O
2298	-	O
2298	>	O
2298	Met	O
2298	mutation	O
2298	alone	O
2298	is	O
2298	not	O
2298	sufficient	O
2298	to	O
2298	cause	O
2298	G6PD	B-Disease
2298	deficiency	I-Disease
2298	.	O
2299	We	O
2299	have	O
2299	approached	O
2299	this	O
2299	question	O
2299	by	O
2299	producing	O
2299	G6PD	O
2299	B	O
2299	,	O
2299	A	O
2299	,	O
2299	A	O
2299	-	O
2299	,	O
2299	and	O
2299	G6PD	O
2299	68	O
2299	Val	O
2299	-	O
2299	-	O
2299	>	O
2299	Met	O
2299	in	O
2299	a	O
2299	bacterial	O
2299	expression	O
2299	system	O
2299	and	O
2299	analysing	O
2299	their	O
2299	biochemical	O
2299	properties	O
2299	.	O
2300	With	O
2300	each	O
2300	single	O
2300	mutation	O
2300	we	O
2300	found	O
2300	a	O
2300	slight	O
2300	decrease	O
2300	in	O
2300	both	O
2300	the	O
2300	specific	O
2300	activity	O
2300	and	O
2300	the	O
2300	yield	O
2300	of	O
2300	enzyme	O
2300	when	O
2300	compared	O
2300	to	O
2300	G6PD	O
2300	B	O
2300	.	O
2301	When	O
2301	both	O
2301	mutations	O
2301	were	O
2301	introduced	O
2301	together	O
2301	,	O
2301	there	O
2301	was	O
2301	a	O
2301	roughly	O
2301	additive	O
2301	effect	O
2301	on	O
2301	specific	O
2301	activity	O
2301	,	O
2301	but	O
2301	a	O
2301	much	O
2301	more	O
2301	drastic	O
2301	effect	O
2301	on	O
2301	enzyme	O
2301	yield	O
2301	(	O
2301	4	O
2301	%	O
2301	of	O
2301	normal	O
2301	)	O
2301	.	O
2302	This	O
2302	synergistic	O
2302	effect	O
2302	was	O
2302	also	O
2302	demonstrated	O
2302	on	O
2302	thermal	O
2302	stability	O
2302	,	O
2302	especially	O
2302	at	O
2302	low	O
2302	NADP	O
2302	concentrations	O
2302	.	O
2303	Comparable	O
2303	results	O
2303	were	O
2303	produced	O
2303	when	O
2303	the	O
2303	replacement	O
2303	119	O
2303	Gln	O
2303	-	O
2303	-	O
2303	>	O
2303	Glu	O
2303	was	O
2303	studied	O
2303	instead	O
2303	of	O
2303	126	O
2303	Asn	O
2303	-	O
2303	-	O
2303	>	O
2303	Asp	O
2303	.	O
2304	We	O
2304	infer	O
2304	that	O
2304	the	O
2304	coexistence	O
2304	of	O
2304	the	O
2304	two	O
2304	mutations	O
2304	is	O
2304	responsible	O
2304	for	O
2304	enzyme	B-Disease
2304	deficiency	I-Disease
2304	in	I-Disease
2304	G6PD	I-Disease
2304	A	O
2304	-	O
2304	because	O
2304	they	O
2304	act	O
2304	synergistically	O
2304	in	O
2304	causing	O
2304	instability	O
2304	of	O
2304	the	O
2304	enzyme	O
2304	.	O
2305	Small	O
2305	nuclear	O
2305	ribonucleoprotein	O
2305	polypeptide	O
2305	N	O
2305	(	O
2305	SNRPN	O
2305	)	O
2305	,	O
2305	an	O
2305	expressed	O
2305	gene	O
2305	in	O
2305	the	O
2305	Prader	B-Disease
2305	-	I-Disease
2305	Willi	I-Disease
2305	syndrome	I-Disease
2305	critical	O
2305	region	O
2305	.	O
2306	Prader	B-Disease
2306	-	I-Disease
2306	Willi	I-Disease
2306	syndrome	I-Disease
2306	(	O
2306	PWS	B-Disease
2306	)	O
2306	is	O
2306	associated	O
2306	with	O
2306	paternally	O
2306	derived	O
2306	chromosomal	O
2306	deletions	O
2306	in	O
2306	region	O
2306	15q11	O
2306	-	O
2306	13	O
2306	or	O
2306	with	O
2306	maternal	B-Disease
2306	disomy	I-Disease
2306	for	I-Disease
2306	chromosome	I-Disease
2306	15	I-Disease
2306	.	O
2307	Therefore	O
2307	,	O
2307	loss	O
2307	of	O
2307	the	O
2307	expressed	O
2307	paternal	O
2307	alleles	O
2307	of	O
2307	maternally	O
2307	imprinted	O
2307	genes	O
2307	must	O
2307	be	O
2307	responsible	O
2307	for	O
2307	the	O
2307	PWS	B-Disease
2307	phenotype	O
2307	.	O
2308	We	O
2308	have	O
2308	mapped	O
2308	the	O
2308	gene	O
2308	encoding	O
2308	the	O
2308	small	O
2308	nuclear	O
2308	RNA	O
2308	associated	O
2308	polypeptide	O
2308	SmN	O
2308	(	O
2308	SNRPN	O
2308	)	O
2308	to	O
2308	human	O
2308	chromosome	O
2308	15q12	O
2308	and	O
2308	a	O
2308	processed	O
2308	pseudogene	O
2308	SNRPNP1	O
2308	to	O
2308	chromosome	O
2308	region	O
2308	6pter	O
2308	-	O
2308	p21	O
2308	.	O
2309	Furthermore	O
2309	,	O
2309	SNRPN	O
2309	was	O
2309	mapped	O
2309	to	O
2309	the	O
2309	minimal	O
2309	deletion	O
2309	interval	O
2309	that	O
2309	is	O
2309	critical	O
2309	for	O
2309	PWS	B-Disease
2309	.	O
2310	The	O
2310	fact	O
2310	that	O
2310	the	O
2310	mouse	O
2310	Snrpn	O
2310	gene	O
2310	is	O
2310	maternally	O
2310	imprinted	O
2310	in	O
2310	brain	O
2310	suggests	O
2310	that	O
2310	loss	O
2310	of	O
2310	the	O
2310	paternally	O
2310	derived	O
2310	SNRPN	O
2310	allele	O
2310	may	O
2310	be	O
2310	involved	O
2310	in	O
2310	the	O
2310	PWS	B-Disease
2310	phenotype	O
2310	.	O
2310	.	O
2311	The	O
2311	presence	O
2311	of	O
2311	two	O
2311	different	O
2311	infantile	O
2311	Tay	B-Disease
2311	-	I-Disease
2311	Sachs	I-Disease
2311	disease	I-Disease
2311	mutations	O
2311	in	O
2311	a	O
2311	Cajun	O
2311	population	O
2311	.	O
2312	A	O
2312	study	O
2312	was	O
2312	undertaken	O
2312	to	O
2312	characterize	O
2312	the	O
2312	mutation	O
2312	(	O
2312	s	O
2312	)	O
2312	responsible	O
2312	for	O
2312	Tay	B-Disease
2312	-	I-Disease
2312	Sachs	I-Disease
2312	disease	I-Disease
2312	(	O
2312	TSD	B-Disease
2312	)	O
2312	in	O
2312	a	O
2312	Cajun	O
2312	population	O
2312	in	O
2312	southwest	O
2312	Louisiana	O
2312	and	O
2312	to	O
2312	identify	O
2312	the	O
2312	origins	O
2312	of	O
2312	these	O
2312	mutations	O
2312	.	O
2313	Eleven	O
2313	of	O
2313	12	O
2313	infantile	O
2313	TSD	B-Disease
2313	alleles	O
2313	examined	O
2313	in	O
2313	six	O
2313	families	O
2313	had	O
2313	the	O
2313	beta	O
2313	-	O
2313	hexosaminidase	O
2313	A	O
2313	(	O
2313	Hex	O
2313	A	O
2313	)	O
2313	alpha	O
2313	-	O
2313	subunit	O
2313	exon	O
2313	11	O
2313	insertion	O
2313	mutation	O
2313	that	O
2313	is	O
2313	present	O
2313	in	O
2313	approximately	O
2313	70	O
2313	%	O
2313	of	O
2313	Ashkenazi	O
2313	Jewish	O
2313	TSD	B-Disease
2313	heterozygotes	O
2313	.	O
2314	The	O
2314	mutation	O
2314	in	O
2314	the	O
2314	remaining	O
2314	allele	O
2314	was	O
2314	a	O
2314	single	O
2314	-	O
2314	base	O
2314	transition	O
2314	in	O
2314	the	O
2314	donor	O
2314	splice	O
2314	site	O
2314	of	O
2314	the	O
2314	alpha	O
2314	-	O
2314	subunit	O
2314	intron	O
2314	9	O
2314	.	O
2315	To	O
2315	determine	O
2315	the	O
2315	origins	O
2315	of	O
2315	these	O
2315	two	O
2315	mutations	O
2315	in	O
2315	the	O
2315	Cajun	O
2315	population	O
2315	,	O
2315	the	O
2315	TSD	B-Disease
2315	carrier	O
2315	status	O
2315	was	O
2315	enzymatically	O
2315	determined	O
2315	for	O
2315	90	O
2315	members	O
2315	of	O
2315	four	O
2315	of	O
2315	the	O
2315	six	O
2315	families	O
2315	,	O
2315	and	O
2315	extensive	O
2315	pedigrees	O
2315	were	O
2315	constructed	O
2315	for	O
2315	all	O
2315	carriers	O
2315	.	O
2316	A	O
2316	single	O
2316	ancestral	O
2316	couple	O
2316	from	O
2316	France	O
2316	was	O
2316	found	O
2316	to	O
2316	be	O
2316	common	O
2316	to	O
2316	most	O
2316	of	O
2316	the	O
2316	carriers	O
2316	of	O
2316	the	O
2316	exon	O
2316	11	O
2316	insertion	O
2316	.	O
2317	Pedigree	O
2317	data	O
2317	suggest	O
2317	that	O
2317	this	O
2317	mutation	O
2317	has	O
2317	been	O
2317	in	O
2317	the	O
2317	Cajun	O
2317	population	O
2317	since	O
2317	its	O
2317	founding	O
2317	over	O
2317	2	O
2317	centuries	O
2317	ago	O
2317	and	O
2317	that	O
2317	it	O
2317	may	O
2317	be	O
2317	widely	O
2317	distributed	O
2317	within	O
2317	the	O
2317	population	O
2317	.	O
2318	In	O
2318	contrast	O
2318	,	O
2318	the	O
2318	intron	O
2318	9	O
2318	mutation	O
2318	apparently	O
2318	was	O
2318	introduced	O
2318	within	O
2318	the	O
2318	last	O
2318	century	O
2318	and	O
2318	probably	O
2318	is	O
2318	limited	O
2318	to	O
2318	a	O
2318	few	O
2318	Louisiana	O
2318	families	O
2318	.	O
2318	.	O
2319	Mutations	O
2319	in	O
2319	the	O
2319	candidate	O
2319	gene	O
2319	for	O
2319	Norrie	B-Disease
2319	disease	I-Disease
2319	.	O
2320	Recently	O
2320	,	O
2320	we	O
2320	and	O
2320	others	O
2320	have	O
2320	isolated	O
2320	a	O
2320	candidate	O
2320	gene	O
2320	for	O
2320	X	B-Disease
2320	linked	I-Disease
2320	Norrie	I-Disease
2320	disease	I-Disease
2320	(	O
2320	ND	B-Disease
2320	)	O
2320	which	O
2320	was	O
2320	found	O
2320	to	O
2320	be	O
2320	deleted	O
2320	or	O
2320	disrupted	O
2320	in	O
2320	several	O
2320	patients	O
2320	.	O
2321	As	O
2321	a	O
2321	prerequisite	O
2321	for	O
2321	the	O
2321	identification	O
2321	of	O
2321	point	O
2321	mutations	O
2321	in	O
2321	the	O
2321	ND	B-Disease
2321	gene	O
2321	we	O
2321	have	O
2321	established	O
2321	the	O
2321	exon	O
2321	-	O
2321	intron	O
2321	structure	O
2321	of	O
2321	this	O
2321	gene	O
2321	.	O
2322	In	O
2322	17	O
2322	unrelated	O
2322	patients	O
2322	and	O
2322	15	O
2322	controls	O
2322	,	O
2322	PCR	O
2322	products	O
2322	derived	O
2322	from	O
2322	the	O
2322	promoter	O
2322	region	O
2322	,	O
2322	exons	O
2322	1	O
2322	and	O
2322	2	O
2322	as	O
2322	well	O
2322	as	O
2322	the	O
2322	coding	O
2322	part	O
2322	of	O
2322	exon	O
2322	3	O
2322	were	O
2322	analysed	O
2322	with	O
2322	the	O
2322	single	O
2322	strand	O
2322	conformation	O
2322	polymorphism	O
2322	(	O
2322	SSCP	O
2322	)	O
2322	technique	O
2322	.	O
2323	In	O
2323	12	O
2323	patients	O
2323	altered	O
2323	PCR	O
2323	fragments	O
2323	were	O
2323	detected	O
2323	which	O
2323	were	O
2323	studied	O
2323	in	O
2323	detail	O
2323	by	O
2323	direct	O
2323	sequencing	O
2323	.	O
2324	Eleven	O
2324	different	O
2324	mutations	O
2324	were	O
2324	found	O
2324	,	O
2324	and	O
2324	all	O
2324	but	O
2324	one	O
2324	are	O
2324	likely	O
2324	to	O
2324	give	O
2324	rise	O
2324	to	O
2324	significant	O
2324	structural	O
2324	changes	O
2324	in	O
2324	the	O
2324	predicted	O
2324	protein	O
2324	.	O
2325	These	O
2325	findings	O
2325	,	O
2325	and	O
2325	the	O
2325	absence	O
2325	of	O
2325	functionally	O
2325	relevant	O
2325	base	O
2325	changes	O
2325	in	O
2325	healthy	O
2325	controls	O
2325	,	O
2325	emphasize	O
2325	the	O
2325	causal	O
2325	role	O
2325	of	O
2325	this	O
2325	candidate	O
2325	gene	O
2325	in	O
2325	Norrie	B-Disease
2325	disease	I-Disease
2325	and	O
2325	pave	O
2325	the	O
2325	way	O
2325	for	O
2325	reliable	O
2325	diagnosis	O
2325	and	O
2325	carrier	O
2325	detection	O
2325	.	O
2325	.	O
2326	Detection	O
2326	of	O
2326	a	O
2326	nonsense	O
2326	mutation	O
2326	in	O
2326	the	O
2326	dystrophin	O
2326	gene	O
2326	by	O
2326	multiple	O
2326	SSCP	O
2326	.	O
2327	A	O
2327	combination	O
2327	of	O
2327	multiplex	O
2327	PCR	O
2327	with	O
2327	the	O
2327	single	O
2327	strand	O
2327	conformation	O
2327	polymorphism	O
2327	(	O
2327	SSCP	O
2327	)	O
2327	technique	O
2327	was	O
2327	employed	O
2327	to	O
2327	screen	O
2327	for	O
2327	point	O
2327	mutations	O
2327	in	O
2327	the	O
2327	human	O
2327	dystrophin	O
2327	gene	O
2327	.	O
2328	Co	O
2328	-	O
2328	amplification	O
2328	of	O
2328	11	O
2328	exons	O
2328	from	O
2328	genomic	O
2328	DNA	O
2328	of	O
2328	Duchenne	B-Disease
2328	and	I-Disease
2328	Becker	I-Disease
2328	muscular	I-Disease
2328	dystrophy	I-Disease
2328	(	O
2328	DMD	B-Disease
2328	/	O
2328	BMD	B-Disease
2328	)	O
2328	patients	O
2328	with	O
2328	no	O
2328	deletion	O
2328	or	O
2328	duplication	O
2328	was	O
2328	performed	O
2328	and	O
2328	the	O
2328	samples	O
2328	subjected	O
2328	to	O
2328	multiple	O
2328	SSCP	O
2328	analysis	O
2328	.	O
2329	We	O
2329	report	O
2329	the	O
2329	case	O
2329	of	O
2329	a	O
2329	nonsense	O
2329	mutation	O
2329	in	O
2329	a	O
2329	Duchenne	B-Disease
2329	patient	O
2329	identified	O
2329	by	O
2329	this	O
2329	approach	O
2329	.	O
2330	The	O
2330	mutation	O
2330	introduces	O
2330	a	O
2330	termination	O
2330	codon	O
2330	within	O
2330	exon	O
2330	8	O
2330	of	O
2330	the	O
2330	dystrophin	O
2330	gene	O
2330	.	O
2331	It	O
2331	is	O
2331	predicted	O
2331	to	O
2331	cause	O
2331	a	O
2331	very	O
2331	premature	O
2331	translational	O
2331	termination	O
2331	accounting	O
2331	for	O
2331	the	O
2331	severe	O
2331	phenotype	O
2331	observed	O
2331	.	O
2332	The	O
2332	patient	O
2332	inherited	O
2332	this	O
2332	mutation	O
2332	from	O
2332	his	O
2332	mother	O
2332	.	O
2333	In	O
2333	addition	O
2333	the	O
2333	analysis	O
2333	revealed	O
2333	5	O
2333	polymorphisms	O
2333	useful	O
2333	for	O
2333	internal	O
2333	control	O
2333	.	O
2333	.	O
2334	Proliferation	O
2334	-	O
2334	related	O
2334	expression	O
2334	of	O
2334	p19	O
2334	/	O
2334	nm23	O
2334	nucleoside	O
2334	diphosphate	O
2334	kinase	O
2334	.	O
2335	High	O
2335	level	O
2335	expression	O
2335	of	O
2335	the	O
2335	nm23	O
2335	-	O
2335	H1	O
2335	gene	O
2335	,	O
2335	which	O
2335	encodes	O
2335	for	O
2335	a	O
2335	nucleoside	O
2335	diphosphate	O
2335	kinase	O
2335	,	O
2335	has	O
2335	been	O
2335	found	O
2335	to	O
2335	correlate	O
2335	with	O
2335	diminished	O
2335	metastasis	O
2335	in	O
2335	some	O
2335	tumors	B-Disease
2335	but	O
2335	not	O
2335	in	O
2335	others	O
2335	.	O
2336	We	O
2336	have	O
2336	previously	O
2336	identified	O
2336	the	O
2336	protein	O
2336	product	O
2336	of	O
2336	the	O
2336	nm23	O
2336	-	O
2336	H1	O
2336	gene	O
2336	in	O
2336	two	O
2336	-	O
2336	dimensional	O
2336	electrophoretic	O
2336	gels	O
2336	and	O
2336	have	O
2336	designated	O
2336	it	O
2336	p19	O
2336	/	O
2336	nm23	O
2336	.	O
2337	In	O
2337	neuroblastoma	B-Disease
2337	,	O
2337	higher	O
2337	levels	O
2337	of	O
2337	p19	O
2337	/	O
2337	nm23	O
2337	,	O
2337	which	O
2337	are	O
2337	associated	O
2337	with	O
2337	amplification	O
2337	of	O
2337	the	O
2337	N	O
2337	-	O
2337	myc	O
2337	oncogene	O
2337	,	O
2337	large	O
2337	tumor	B-Disease
2337	mass	O
2337	,	O
2337	and	O
2337	metastasis	O
2337	,	O
2337	were	O
2337	observed	O
2337	in	O
2337	advanced	O
2337	stage	O
2337	tumors	B-Disease
2337	compared	O
2337	with	O
2337	limited	O
2337	stage	O
2337	disease	O
2337	.	O
2338	Because	O
2338	of	O
2338	the	O
2338	variable	O
2338	expression	O
2338	of	O
2338	nm23	O
2338	-	O
2338	H1	O
2338	in	O
2338	different	O
2338	tumors	B-Disease
2338	,	O
2338	we	O
2338	have	O
2338	investigated	O
2338	the	O
2338	relationship	O
2338	between	O
2338	amounts	O
2338	of	O
2338	the	O
2338	protein	O
2338	and	O
2338	cell	O
2338	proliferation	O
2338	.	O
2339	The	O
2339	levels	O
2339	of	O
2339	p19	O
2339	/	O
2339	nm23	O
2339	were	O
2339	compared	O
2339	between	O
2339	resting	O
2339	and	O
2339	mitotically	O
2339	stimulated	O
2339	normal	O
2339	human	O
2339	PBLs	O
2339	and	O
2339	in	O
2339	leukemia	B-Disease
2339	cells	O
2339	.	O
2340	The	O
2340	amount	O
2340	of	O
2340	p19	O
2340	/	O
2340	nm23	O
2340	increased	O
2340	in	O
2340	normal	O
2340	lymphocytes	O
2340	in	O
2340	response	O
2340	to	O
2340	mitotic	O
2340	stimulation	O
2340	and	O
2340	paralleled	O
2340	the	O
2340	increase	O
2340	in	O
2340	DNA	O
2340	synthesis	O
2340	.	O
2341	In	O
2341	leukemia	B-Disease
2341	cells	O
2341	obtained	O
2341	from	O
2341	patients	O
2341	with	O
2341	different	O
2341	subtypes	O
2341	of	O
2341	acute	B-Disease
2341	leukemia	I-Disease
2341	,	O
2341	p19	O
2341	/	O
2341	nm23	O
2341	levels	O
2341	were	O
2341	also	O
2341	increased	O
2341	relative	O
2341	to	O
2341	resting	O
2341	normal	O
2341	lymphocytes	O
2341	.	O
2342	Treatment	O
2342	of	O
2342	mitotically	O
2342	stimulated	O
2342	lymphocytes	O
2342	with	O
2342	cyclosporin	O
2342	,	O
2342	which	O
2342	inhibits	O
2342	proliferation	O
2342	,	O
2342	blocked	O
2342	the	O
2342	increase	O
2342	in	O
2342	p19	O
2342	/	O
2342	nm23	O
2342	;	O
2342	treatment	O
2342	of	O
2342	the	O
2342	leukemia	B-Disease
2342	cell	O
2342	line	O
2342	HL	O
2342	-	O
2342	60	O
2342	with	O
2342	dimethylsulfoxide	O
2342	,	O
2342	which	O
2342	induces	O
2342	terminal	O
2342	differentiation	O
2342	,	O
2342	resulted	O
2342	in	O
2342	diminished	O
2342	levels	O
2342	of	O
2342	p19	O
2342	/	O
2342	nm23	O
2342	.	O
2343	Our	O
2343	data	O
2343	therefore	O
2343	provide	O
2343	evidence	O
2343	that	O
2343	nm23	O
2343	-	O
2343	H1	O
2343	expression	O
2343	is	O
2343	related	O
2343	to	O
2343	cell	O
2343	proliferative	O
2343	activity	O
2343	.	O
2343	.	O
2344	An	O
2344	intrachromosomal	O
2344	insertion	O
2344	causing	O
2344	5q22	O
2344	deletion	O
2344	and	O
2344	familial	B-Disease
2344	adenomatous	I-Disease
2344	polyposis	I-Disease
2344	coli	I-Disease
2344	in	O
2344	two	O
2344	generations	O
2344	.	O
2345	We	O
2345	report	O
2345	familial	B-Disease
2345	adenomatous	I-Disease
2345	polyposis	I-Disease
2345	coli	I-Disease
2345	(	O
2345	FAPC	B-Disease
2345	)	O
2345	with	O
2345	epidermoid	B-Disease
2345	cysts	I-Disease
2345	,	O
2345	osteomata	B-Disease
2345	,	O
2345	and	O
2345	areas	O
2345	of	O
2345	congenital	B-Disease
2345	hypertrophy	I-Disease
2345	of	I-Disease
2345	the	I-Disease
2345	retinal	I-Disease
2345	pigment	I-Disease
2345	epithelium	I-Disease
2345	(	O
2345	CHRPEs	B-Disease
2345	)	O
2345	in	O
2345	a	O
2345	male	O
2345	patient	O
2345	and	O
2345	his	O
2345	maternal	O
2345	aunt	O
2345	,	O
2345	both	O
2345	of	O
2345	whom	O
2345	suffered	O
2345	a	O
2345	mild	O
2345	to	O
2345	moderate	O
2345	degree	O
2345	of	O
2345	mental	B-Disease
2345	handicap	I-Disease
2345	.	O
2346	Both	O
2346	had	O
2346	an	O
2346	interstitial	O
2346	deletion	O
2346	of	O
2346	the	O
2346	long	O
2346	arm	O
2346	of	O
2346	chromosome	O
2346	5	O
2346	(	O
2346	del	O
2346	(	O
2346	5	O
2346	)	O
2346	(	O
2346	q22q23	O
2346	.	O
2346	2	O
2346	)	O
2346	)	O
2346	.	O
2347	Two	O
2347	other	O
2347	normal	O
2347	family	O
2347	members	O
2347	had	O
2347	the	O
2347	underlying	O
2347	direct	O
2347	insertion	O
2347	of	O
2347	chromosome	O
2347	5	O
2347	(	O
2347	dir	O
2347	ins	O
2347	(	O
2347	5	O
2347	)	O
2347	(	O
2347	q31	O
2347	.	O
2347	3q22q23	O
2347	3q22q23	O
2347	.	O
2347	2	O
2347	)	O
2347	)	O
2347	.	O
2348	Molecular	O
2348	genetic	O
2348	and	O
2348	fluorescent	O
2348	hybridisation	O
2348	studies	O
2348	have	O
2348	shown	O
2348	that	O
2348	loci	O
2348	D5S37	O
2348	and	O
2348	D5S98	O
2348	are	O
2348	outside	O
2348	the	O
2348	deletion	O
2348	whereas	O
2348	loci	O
2348	detected	O
2348	by	O
2348	probes	O
2348	EF5	O
2348	.	O
2349	44	O
2349	and	O
2349	YN5	O
2349	.	O
2350	48	O
2350	are	O
2350	lost	O
2350	.	O
2351	As	O
2351	expected	O
2351	,	O
2351	the	O
2351	molecular	O
2351	analyses	O
2351	indicate	O
2351	loss	O
2351	of	O
2351	one	O
2351	allele	O
2351	at	O
2351	the	O
2351	MCC	O
2351	and	O
2351	APC	B-Disease
2351	loci	O
2351	.	O
2352	The	O
2352	APC	B-Disease
2352	gene	O
2352	is	O
2352	located	O
2352	within	O
2352	band	O
2352	5q22	O
2352	.	O
2353	Familial	O
2353	direct	O
2353	insertions	O
2353	should	O
2353	be	O
2353	considered	O
2353	as	O
2353	a	O
2353	cause	O
2353	of	O
2353	recurrent	O
2353	microdeletion	O
2353	syndromes	O
2353	.	O
2354	Chromosome	O
2354	mapping	O
2354	of	O
2354	the	O
2354	rod	O
2354	photoreceptor	O
2354	cGMP	O
2354	phosphodiesterase	O
2354	beta	O
2354	-	O
2354	subunit	O
2354	gene	O
2354	in	O
2354	mouse	O
2354	and	O
2354	human	O
2354	:	O
2354	tight	O
2354	linkage	O
2354	to	O
2354	the	O
2354	Huntington	B-Disease
2354	disease	I-Disease
2354	region	O
2354	(	O
2354	4p16	O
2354	.	O
2354	3	O
2354	)	O
2354	.	O
2355	The	O
2355	retinal	B-Disease
2355	degeneration	I-Disease
2355	mouse	O
2355	(	O
2355	gene	O
2355	symbol	O
2355	,	O
2355	rd	O
2355	)	O
2355	is	O
2355	an	O
2355	animal	O
2355	model	O
2355	for	O
2355	certain	O
2355	forms	O
2355	of	O
2355	human	O
2355	hereditary	B-Disease
2355	retinopathies	I-Disease
2355	.	O
2356	Recent	O
2356	findings	O
2356	of	O
2356	a	O
2356	nonsense	O
2356	mutation	O
2356	in	O
2356	the	O
2356	rd	O
2356	mouse	O
2356	PDE	O
2356	beta	O
2356	-	O
2356	subunit	O
2356	gene	O
2356	(	O
2356	Pdeb	O
2356	)	O
2356	prompted	O
2356	us	O
2356	to	O
2356	investigate	O
2356	the	O
2356	chromosome	O
2356	locations	O
2356	of	O
2356	the	O
2356	mouse	O
2356	and	O
2356	human	O
2356	genes	O
2356	.	O
2357	We	O
2357	have	O
2357	utilized	O
2357	backcross	O
2357	analysis	O
2357	in	O
2357	mice	O
2357	to	O
2357	verify	O
2357	and	O
2357	define	O
2357	more	O
2357	precisely	O
2357	the	O
2357	location	O
2357	of	O
2357	the	O
2357	Pdeb	O
2357	locus	O
2357	6	O
2357	.	O
2358	1	O
2358	+	O
2358	/	O
2358	-	O
2358	2	O
2358	.	O
2359	3	O
2359	cM	O
2359	distal	O
2359	of	O
2359	Mgsa	O
2359	on	O
2359	mouse	O
2359	chromosome	O
2359	5	O
2359	.	O
2360	We	O
2360	have	O
2360	determined	O
2360	that	O
2360	the	O
2360	human	O
2360	gene	O
2360	(	O
2360	PDEB	O
2360	)	O
2360	maps	O
2360	to	O
2360	4p16	O
2360	.	O
2361	3	O
2361	,	O
2361	very	O
2361	close	O
2361	to	O
2361	the	O
2361	Huntington	B-Disease
2361	disease	I-Disease
2361	(	O
2361	HD	B-Disease
2361	)	O
2361	region	O
2361	.	O
2362	Analysis	O
2362	of	O
2362	the	O
2362	comparative	O
2362	map	O
2362	for	O
2362	mice	O
2362	and	O
2362	humans	O
2362	shows	O
2362	that	O
2362	the	O
2362	mouse	O
2362	homologue	O
2362	of	O
2362	the	O
2362	HD	B-Disease
2362	gene	O
2362	will	O
2362	reside	O
2362	on	O
2362	chromosome	O
2362	5	O
2362	.	O
2363	Linkage	O
2363	of	O
2363	the	O
2363	mouse	O
2363	Pdeb	O
2363	locus	O
2363	with	O
2363	other	O
2363	homologues	O
2363	in	O
2363	the	O
2363	human	O
2363	4p16	O
2363	.	O
2364	3	O
2364	region	O
2364	is	O
2364	maintained	O
2364	but	O
2364	gene	O
2364	order	O
2364	is	O
2364	not	O
2364	,	O
2364	suggesting	O
2364	at	O
2364	least	O
2364	three	O
2364	possible	O
2364	sites	O
2364	for	O
2364	the	O
2364	corresponding	O
2364	mouse	O
2364	HD	B-Disease
2364	gene	O
2364	.	O
2365	Coincident	O
2365	Kaposi	B-Disease
2365	sarcoma	I-Disease
2365	and	O
2365	T	B-Disease
2365	-	I-Disease
2365	cell	I-Disease
2365	lymphoma	I-Disease
2365	in	O
2365	a	O
2365	patient	O
2365	with	O
2365	the	O
2365	Wiskott	B-Disease
2365	-	I-Disease
2365	Aldrich	I-Disease
2365	syndrome	I-Disease
2365	.	O
2366	A	O
2366	24	O
2366	year	O
2366	old	O
2366	male	O
2366	with	O
2366	a	O
2366	history	O
2366	of	O
2366	eczema	B-Disease
2366	,	O
2366	recurrent	O
2366	mild	O
2366	infections	O
2366	,	O
2366	and	O
2366	thrombocytopenia	B-Disease
2366	consistent	O
2366	with	O
2366	the	O
2366	Wiskott	B-Disease
2366	-	I-Disease
2366	Aldrich	I-Disease
2366	syndrome	I-Disease
2366	(	O
2366	WAS	B-Disease
2366	)	O
2366	presented	O
2366	with	O
2366	a	O
2366	mediastinal	O
2366	mass	O
2366	,	O
2366	generalized	O
2366	lymphadenopathy	B-Disease
2366	,	O
2366	splenomegaly	B-Disease
2366	,	O
2366	and	O
2366	severe	O
2366	thrombocytopenia	B-Disease
2366	.	O
2367	Studies	O
2367	of	O
2367	immune	O
2367	function	O
2367	including	O
2367	immunoglobulin	O
2367	levels	O
2367	and	O
2367	T	O
2367	-	O
2367	cell	O
2367	subsets	O
2367	were	O
2367	normal	O
2367	.	O
2368	Furthermore	O
2368	,	O
2368	his	O
2368	T	O
2368	lymphocytes	O
2368	proliferated	O
2368	normally	O
2368	in	O
2368	response	O
2368	to	O
2368	phytohemagglutinin	O
2368	,	O
2368	concanavalin	O
2368	A	O
2368	,	O
2368	and	O
2368	the	O
2368	combination	O
2368	of	O
2368	neuraminidase	O
2368	/	O
2368	galactose	O
2368	oxidase	O
2368	.	O
2369	However	O
2369	,	O
2369	their	O
2369	proliferative	O
2369	responses	O
2369	to	O
2369	anti	O
2369	-	O
2369	CD43	O
2369	antibody	O
2369	and	O
2369	periodate	O
2369	were	O
2369	diminished	O
2369	,	O
2369	consistent	O
2369	with	O
2369	the	O
2369	clinical	O
2369	diagnosis	O
2369	of	O
2369	WAS	B-Disease
2369	.	O
2370	An	O
2370	initial	O
2370	inguinal	O
2370	lymph	O
2370	node	O
2370	biopsy	O
2370	surprisingly	O
2370	revealed	O
2370	Kaposi	B-Disease
2370	sarcoma	I-Disease
2370	.	O
2371	However	O
2371	,	O
2371	following	O
2371	splenectomy	O
2371	to	O
2371	increase	O
2371	the	O
2371	platelet	O
2371	count	O
2371	,	O
2371	biopsy	O
2371	of	O
2371	the	O
2371	mediastinal	O
2371	mass	O
2371	revealed	O
2371	T	B-Disease
2371	-	I-Disease
2371	cell	I-Disease
2371	large	I-Disease
2371	cell	I-Disease
2371	lymphoma	I-Disease
2371	.	O
2372	Studies	O
2372	of	O
2372	biopsied	O
2372	tissue	O
2372	for	O
2372	the	O
2372	presence	O
2372	of	O
2372	Epstein	B-Disease
2372	-	I-Disease
2372	Barr	I-Disease
2372	virus	I-Disease
2372	and	O
2372	cytomegalovirus	B-Disease
2372	were	O
2372	negative	O
2372	,	O
2372	as	O
2372	were	O
2372	studies	O
2372	of	O
2372	blood	O
2372	,	O
2372	including	O
2372	the	O
2372	polymerase	O
2372	chain	O
2372	reaction	O
2372	,	O
2372	for	O
2372	the	O
2372	presence	O
2372	of	O
2372	the	O
2372	human	B-Disease
2372	immunodeficiency	I-Disease
2372	virus	I-Disease
2372	(	O
2372	HIV	B-Disease
2372	)	O
2372	.	O
2373	This	O
2373	is	O
2373	the	O
2373	first	O
2373	report	O
2373	of	O
2373	Kaposi	B-Disease
2373	sarcoma	I-Disease
2373	arising	O
2373	in	O
2373	a	O
2373	patient	O
2373	with	O
2373	a	O
2373	congenital	B-Disease
2373	immunodeficiency	I-Disease
2373	syndrome	I-Disease
2373	.	O
2374	Although	O
2374	Kaposi	B-Disease
2374	sarcoma	I-Disease
2374	can	O
2374	arise	O
2374	in	O
2374	the	O
2374	face	O
2374	of	O
2374	the	O
2374	severe	O
2374	immunosuppression	O
2374	that	O
2374	follows	O
2374	allograft	O
2374	transplantation	O
2374	and	O
2374	in	O
2374	patients	O
2374	infected	O
2374	with	O
2374	HIV	B-Disease
2374	,	O
2374	we	O
2374	postulate	O
2374	that	O
2374	longevity	O
2374	in	O
2374	the	O
2374	face	O
2374	of	O
2374	mild	O
2374	immunosuppression	O
2374	was	O
2374	the	O
2374	major	O
2374	factor	O
2374	in	O
2374	the	O
2374	development	O
2374	of	O
2374	Kaposi	B-Disease
2374	sarcoma	I-Disease
2374	in	O
2374	this	O
2374	patient	O
2374	.	O
2374	.	O
2375	The	O
2375	APC	B-Disease
2375	gene	O
2375	,	O
2375	responsible	O
2375	for	O
2375	familial	B-Disease
2375	adenomatous	I-Disease
2375	polyposis	I-Disease
2375	,	O
2375	is	O
2375	mutated	O
2375	in	O
2375	human	O
2375	gastric	B-Disease
2375	cancer	I-Disease
2375	.	O
2376	Although	O
2376	gastric	B-Disease
2376	cancer	I-Disease
2376	is	O
2376	the	O
2376	most	O
2376	common	O
2376	cancer	B-Disease
2376	in	O
2376	the	O
2376	world	O
2376	,	O
2376	genetic	O
2376	changes	O
2376	during	O
2376	its	O
2376	carcinogenesis	O
2376	are	O
2376	not	O
2376	well	O
2376	understood	O
2376	.	O
2377	Since	O
2377	some	O
2377	gastric	B-Disease
2377	cancers	I-Disease
2377	are	O
2377	considered	O
2377	to	O
2377	originate	O
2377	from	O
2377	the	O
2377	intestinal	O
2377	metaplasia	O
2377	,	O
2377	it	O
2377	is	O
2377	likely	O
2377	that	O
2377	the	O
2377	adenomatous	B-Disease
2377	polyposis	I-Disease
2377	coli	I-Disease
2377	(	O
2377	APC	B-Disease
2377	)	O
2377	gene	O
2377	,	O
2377	the	O
2377	mutation	O
2377	of	O
2377	which	O
2377	causes	O
2377	adenomatous	B-Disease
2377	polyps	I-Disease
2377	in	I-Disease
2377	the	I-Disease
2377	colon	I-Disease
2377	,	O
2377	is	O
2377	associated	O
2377	with	O
2377	carcinogenesis	O
2377	of	O
2377	gastric	B-Disease
2377	cancer	I-Disease
2377	.	O
2378	Based	O
2378	on	O
2378	this	O
2378	idea	O
2378	,	O
2378	DNAs	O
2378	isolated	O
2378	from	O
2378	gastric	B-Disease
2378	cancers	I-Disease
2378	were	O
2378	examined	O
2378	by	O
2378	means	O
2378	of	O
2378	a	O
2378	RNase	O
2378	protection	O
2378	analysis	O
2378	coupled	O
2378	with	O
2378	polymerase	O
2378	chain	O
2378	reaction	O
2378	followed	O
2378	by	O
2378	sequencing	O
2378	of	O
2378	the	O
2378	polymerase	O
2378	chain	O
2378	reaction	O
2378	products	O
2378	.	O
2379	By	O
2379	screening	O
2379	nearly	O
2379	one	O
2379	-	O
2379	half	O
2379	of	O
2379	the	O
2379	coding	O
2379	region	O
2379	of	O
2379	the	O
2379	APC	B-Disease
2379	gene	O
2379	in	O
2379	44	O
2379	tumors	B-Disease
2379	,	O
2379	somatic	O
2379	mutations	O
2379	were	O
2379	detected	O
2379	in	O
2379	three	O
2379	tumors	B-Disease
2379	a	O
2379	missense	O
2379	mutation	O
2379	,	O
2379	a	O
2379	nonsense	O
2379	mutation	O
2379	,	O
2379	and	O
2379	a	O
2379	5	O
2379	-	O
2379	base	O
2379	pair	O
2379	deletion	O
2379	resulting	O
2379	in	O
2379	a	O
2379	frame	O
2379	shift	O
2379	which	O
2379	causes	O
2379	truncation	O
2379	of	O
2379	the	O
2379	gene	O
2379	product	O
2379	.	O
2380	These	O
2380	results	O
2380	suggest	O
2380	that	O
2380	the	O
2380	mutation	O
2380	of	O
2380	the	O
2380	APC	B-Disease
2380	gene	O
2380	also	O
2380	plays	O
2380	an	O
2380	important	O
2380	role	O
2380	during	O
2380	the	O
2380	carcinogenesis	O
2380	of	O
2380	at	O
2380	least	O
2380	some	O
2380	gastric	B-Disease
2380	cancers	I-Disease
2380	.	O
2380	.	O
2381	A	O
2381	71	O
2381	-	O
2381	kilodalton	O
2381	protein	O
2381	is	O
2381	a	O
2381	major	O
2381	product	O
2381	of	O
2381	the	O
2381	Duchenne	B-Disease
2381	muscular	I-Disease
2381	dystrophy	I-Disease
2381	gene	O
2381	in	O
2381	brain	O
2381	and	O
2381	other	O
2381	nonmuscle	O
2381	tissues	O
2381	.	O
2382	The	O
2382	known	O
2382	Duchenne	B-Disease
2382	muscular	I-Disease
2382	dystrophy	I-Disease
2382	(	O
2382	DMD	B-Disease
2382	)	O
2382	gene	O
2382	products	O
2382	,	O
2382	the	O
2382	muscle	O
2382	-	O
2382	and	O
2382	brain	O
2382	-	O
2382	type	O
2382	dystrophin	O
2382	isoforms	O
2382	,	O
2382	are	O
2382	427	O
2382	-	O
2382	kDa	O
2382	proteins	O
2382	translated	O
2382	from	O
2382	14	O
2382	-	O
2382	kilobase	O
2382	(	O
2382	kb	O
2382	)	O
2382	mRNAs	O
2382	.	O
2383	Recently	O
2383	we	O
2383	described	O
2383	a	O
2383	6	O
2383	.	O
2384	5	O
2384	-	O
2384	kb	O
2384	mRNA	O
2384	that	O
2384	also	O
2384	is	O
2384	transcribed	O
2384	from	O
2384	the	O
2384	DMD	B-Disease
2384	gene	O
2384	.	O
2385	Cloning	O
2385	and	O
2385	in	O
2385	vitro	O
2385	transcription	O
2385	and	O
2385	translation	O
2385	of	O
2385	the	O
2385	entire	O
2385	coding	O
2385	region	O
2385	show	O
2385	that	O
2385	the	O
2385	6	O
2385	.	O
2386	5	O
2386	-	O
2386	kb	O
2386	mRNA	O
2386	encodes	O
2386	a	O
2386	70	O
2386	.	O
2387	8	O
2387	-	O
2387	kDa	O
2387	protein	O
2387	that	O
2387	is	O
2387	a	O
2387	major	O
2387	product	O
2387	of	O
2387	the	O
2387	DMD	B-Disease
2387	gene	O
2387	.	O
2388	It	O
2388	contains	O
2388	the	O
2388	C	O
2388	-	O
2388	terminal	O
2388	and	O
2388	the	O
2388	cysteine	O
2388	-	O
2388	rich	O
2388	domains	O
2388	of	O
2388	dystrophin	O
2388	,	O
2388	seven	O
2388	additional	O
2388	amino	O
2388	acids	O
2388	at	O
2388	the	O
2388	N	O
2388	terminus	O
2388	,	O
2388	and	O
2388	some	O
2388	modifications	O
2388	formed	O
2388	by	O
2388	alternative	O
2388	splicing	O
2388	in	O
2388	the	O
2388	C	O
2388	-	O
2388	terminal	O
2388	domain	O
2388	.	O
2389	It	O
2389	lacks	O
2389	the	O
2389	entire	O
2389	large	O
2389	domain	O
2389	of	O
2389	spectrin	O
2389	-	O
2389	like	O
2389	repeats	O
2389	and	O
2389	the	O
2389	actin	O
2389	-	O
2389	binding	O
2389	N	O
2389	-	O
2389	terminal	O
2389	domain	O
2389	of	O
2389	dystrophin	O
2389	.	O
2390	This	O
2390	protein	O
2390	is	O
2390	the	O
2390	major	O
2390	DMD	B-Disease
2390	gene	O
2390	product	O
2390	in	O
2390	brain	O
2390	and	O
2390	other	O
2390	nonmuscle	O
2390	tissues	O
2390	but	O
2390	is	O
2390	undetectable	O
2390	in	O
2390	skeletal	O
2390	muscle	O
2390	extracts	O
2390	.	O
2391	Correlation	O
2391	between	O
2391	the	O
2391	location	O
2391	of	O
2391	germ	O
2391	-	O
2391	line	O
2391	mutations	O
2391	in	O
2391	the	O
2391	APC	B-Disease
2391	gene	O
2391	and	O
2391	the	O
2391	number	O
2391	of	O
2391	colorectal	B-Disease
2391	polyps	I-Disease
2391	in	O
2391	familial	B-Disease
2391	adenomatous	I-Disease
2391	polyposis	I-Disease
2391	patients	O
2391	.	O
2392	Recently	O
2392	we	O
2392	have	O
2392	isolated	O
2392	the	O
2392	adenomatous	B-Disease
2392	polyposis	I-Disease
2392	coli	I-Disease
2392	(	O
2392	APC	B-Disease
2392	)	O
2392	gene	O
2392	which	O
2392	causes	O
2392	familial	B-Disease
2392	adenomatous	I-Disease
2392	polyposis	I-Disease
2392	(	O
2392	FAP	B-Disease
2392	)	O
2392	,	O
2392	and	O
2392	its	O
2392	germ	O
2392	-	O
2392	line	O
2392	mutations	O
2392	in	O
2392	a	O
2392	substantial	O
2392	number	O
2392	of	O
2392	FAP	B-Disease
2392	patients	O
2392	have	O
2392	been	O
2392	identified	O
2392	.	O
2393	On	O
2393	the	O
2393	basis	O
2393	of	O
2393	this	O
2393	information	O
2393	,	O
2393	we	O
2393	compared	O
2393	the	O
2393	location	O
2393	of	O
2393	germ	O
2393	-	O
2393	line	O
2393	mutations	O
2393	in	O
2393	the	O
2393	APC	B-Disease
2393	gene	O
2393	in	O
2393	22	O
2393	unrelated	O
2393	patients	O
2393	(	O
2393	12	O
2393	of	O
2393	whom	O
2393	have	O
2393	been	O
2393	reported	O
2393	previously	O
2393	)	O
2393	with	O
2393	the	O
2393	number	O
2393	of	O
2393	colorectal	B-Disease
2393	polyps	I-Disease
2393	developed	O
2393	in	O
2393	FAP	B-Disease
2393	patients	O
2393	;	O
2393	17	O
2393	were	O
2393	sparse	O
2393	types	O
2393	and	O
2393	five	O
2393	were	O
2393	profuse	O
2393	types	O
2393	.	O
2394	All	O
2394	but	O
2394	one	O
2394	of	O
2394	the	O
2394	mutations	O
2394	were	O
2394	considered	O
2394	to	O
2394	cause	O
2394	truncation	O
2394	of	O
2394	the	O
2394	gene	O
2394	product	O
2394	by	O
2394	frame	O
2394	-	O
2394	shift	O
2394	due	O
2394	to	O
2394	deletion	O
2394	(	O
2394	14	O
2394	cases	O
2394	)	O
2394	or	O
2394	nonsense	O
2394	mutation	O
2394	(	O
2394	seven	O
2394	cases	O
2394	)	O
2394	.	O
2395	The	O
2395	location	O
2395	of	O
2395	the	O
2395	germ	O
2395	-	O
2395	line	O
2395	mutations	O
2395	seems	O
2395	to	O
2395	correlate	O
2395	with	O
2395	the	O
2395	two	O
2395	clinical	O
2395	types	O
2395	;	O
2395	germ	O
2395	-	O
2395	line	O
2395	mutations	O
2395	in	O
2395	five	O
2395	FAP	B-Disease
2395	patients	O
2395	with	O
2395	profuse	O
2395	polyps	B-Disease
2395	were	O
2395	observed	O
2395	between	O
2395	codon	O
2395	1250	O
2395	and	O
2395	codon	O
2395	1464	O
2395	,	O
2395	whereas	O
2395	mutations	O
2395	in	O
2395	17	O
2395	FAP	B-Disease
2395	patients	O
2395	with	O
2395	fewer	O
2395	polyps	B-Disease
2395	were	O
2395	observed	O
2395	in	O
2395	the	O
2395	other	O
2395	regions	O
2395	of	O
2395	the	O
2395	APC	B-Disease
2395	gene	O
2395	.	O
2396	The	O
2396	result	O
2396	suggests	O
2396	that	O
2396	the	O
2396	number	O
2396	of	O
2396	colorectal	B-Disease
2396	polyps	I-Disease
2396	in	O
2396	FAP	B-Disease
2396	patients	O
2396	may	O
2396	be	O
2396	associated	O
2396	with	O
2396	a	O
2396	difference	O
2396	in	O
2396	the	O
2396	stability	O
2396	or	O
2396	biological	O
2396	function	O
2396	of	O
2396	the	O
2396	truncated	O
2396	APC	B-Disease
2396	protein	O
2396	.	O
2396	.	O
2397	Identification	O
2397	and	O
2397	rapid	O
2397	detection	O
2397	of	O
2397	three	O
2397	Tay	B-Disease
2397	-	I-Disease
2397	Sachs	I-Disease
2397	mutations	O
2397	in	O
2397	the	O
2397	Moroccan	O
2397	Jewish	O
2397	population	O
2397	.	O
2398	Infantile	O
2398	Tay	B-Disease
2398	-	I-Disease
2398	Sachs	I-Disease
2398	disease	I-Disease
2398	(	O
2398	TSD	B-Disease
2398	)	O
2398	is	O
2398	caused	O
2398	by	O
2398	mutations	O
2398	in	O
2398	the	O
2398	HEXA	O
2398	gene	O
2398	that	O
2398	result	O
2398	in	O
2398	the	O
2398	complete	O
2398	absence	O
2398	of	O
2398	beta	O
2398	-	O
2398	hexosaminidase	O
2398	A	O
2398	activity	O
2398	.	O
2399	It	O
2399	is	O
2399	well	O
2399	known	O
2399	that	O
2399	an	O
2399	elevated	O
2399	frequency	O
2399	of	O
2399	TSD	B-Disease
2399	mutations	O
2399	exists	O
2399	among	O
2399	Ashkenazi	O
2399	Jews	O
2399	.	O
2400	More	O
2400	recently	O
2400	it	O
2400	has	O
2400	become	O
2400	apparent	O
2400	that	O
2400	elevated	O
2400	carrier	O
2400	frequencies	O
2400	for	O
2400	TSD	B-Disease
2400	also	O
2400	occur	O
2400	in	O
2400	several	O
2400	other	O
2400	ethnic	O
2400	groups	O
2400	,	O
2400	including	O
2400	Moroccan	O
2400	Jews	O
2400	,	O
2400	a	O
2400	subgroup	O
2400	of	O
2400	Sephardic	O
2400	Jews	O
2400	.	O
2401	Elsewhere	O
2401	we	O
2401	reported	O
2401	an	O
2401	in	O
2401	-	O
2401	frame	O
2401	deletion	O
2401	of	O
2401	one	O
2401	of	O
2401	the	O
2401	two	O
2401	adjacent	O
2401	phenylalanine	O
2401	codons	O
2401	at	O
2401	position	O
2401	304	O
2401	or	O
2401	305	O
2401	(	O
2401	delta	O
2401	F304	O
2401	/	O
2401	305	O
2401	)	O
2401	in	O
2401	one	O
2401	HEXA	O
2401	allele	O
2401	of	O
2401	a	O
2401	Moroccan	O
2401	Jewish	O
2401	TSD	B-Disease
2401	patient	O
2401	and	O
2401	in	O
2401	three	O
2401	obligate	O
2401	carriers	O
2401	from	O
2401	six	O
2401	unrelated	O
2401	Moroccan	O
2401	Jewish	O
2401	families	O
2401	.	O
2402	We	O
2402	have	O
2402	now	O
2402	identified	O
2402	two	O
2402	additional	O
2402	mutations	O
2402	within	O
2402	exon	O
2402	5	O
2402	of	O
2402	the	O
2402	HEXA	O
2402	gene	O
2402	that	O
2402	account	O
2402	for	O
2402	the	O
2402	remaining	O
2402	TSD	B-Disease
2402	alleles	O
2402	in	O
2402	the	O
2402	patient	O
2402	and	O
2402	carriers	O
2402	.	O
2403	One	O
2403	of	O
2403	the	O
2403	mutations	O
2403	is	O
2403	a	O
2403	novel	O
2403	C	O
2403	-	O
2403	to	O
2403	-	O
2403	G	O
2403	transversion	O
2403	,	O
2403	resulting	O
2403	in	O
2403	a	O
2403	replacement	O
2403	of	O
2403	Tyr180	O
2403	by	O
2403	a	O
2403	stop	O
2403	codon	O
2403	.	O
2404	The	O
2404	other	O
2404	mutation	O
2404	is	O
2404	a	O
2404	G	O
2404	-	O
2404	to	O
2404	-	O
2404	A	O
2404	transition	O
2404	resulting	O
2404	in	O
2404	an	O
2404	Arg170	O
2404	-	O
2404	to	O
2404	-	O
2404	Gln	O
2404	substitution	O
2404	.	O
2405	This	O
2405	mutation	O
2405	is	O
2405	at	O
2405	a	O
2405	CpG	O
2405	site	O
2405	in	O
2405	a	O
2405	Japanese	O
2405	infant	O
2405	with	O
2405	Tay	B-Disease
2405	-	I-Disease
2405	Sachs	I-Disease
2405	disease	I-Disease
2405	and	O
2405	was	O
2405	described	O
2405	elsewhere	O
2405	.	O
2406	Analysis	O
2406	of	O
2406	nine	O
2406	obligate	O
2406	carriers	O
2406	from	O
2406	seven	O
2406	unrelated	O
2406	families	O
2406	showed	O
2406	that	O
2406	four	O
2406	harbor	O
2406	the	O
2406	delta	O
2406	F304	O
2406	/	O
2406	305	O
2406	mutation	O
2406	,	O
2406	two	O
2406	the	O
2406	Arg170	O
2406	-	O
2406	-	O
2406	-	O
2406	-	O
2406	Gln	O
2406	mutation	O
2406	,	O
2406	and	O
2406	one	O
2406	the	O
2406	Tyr180	O
2406	-	O
2406	-	O
2406	-	O
2406	-	O
2406	Stop	O
2406	mutation	O
2406	.	O
2407	We	O
2407	also	O
2407	have	O
2407	developed	O
2407	rapid	O
2407	,	O
2407	nonradioactive	O
2407	assays	O
2407	for	O
2407	the	O
2407	detection	O
2407	of	O
2407	each	O
2407	mutation	O
2407	,	O
2407	which	O
2407	should	O
2407	be	O
2407	helpful	O
2407	for	O
2407	carrier	O
2407	screening	O
2407	.	O
2407	.	O
2408	Molecular	O
2408	characterization	O
2408	of	O
2408	glucose	B-Disease
2408	-	I-Disease
2408	6	I-Disease
2408	-	I-Disease
2408	phosphate	I-Disease
2408	dehydrogenase	I-Disease
2408	(	I-Disease
2408	G6PD	I-Disease
2408	)	I-Disease
2408	deficiency	I-Disease
2408	by	O
2408	natural	O
2408	and	O
2408	amplification	O
2408	created	O
2408	restriction	O
2408	sites	O
2408	:	O
2408	five	O
2408	mutations	O
2408	account	O
2408	for	O
2408	most	O
2408	G6PD	B-Disease
2408	deficiency	I-Disease
2408	cases	O
2408	in	O
2408	Taiwan	O
2408	.	O
2409	We	O
2409	have	O
2409	developed	O
2409	a	O
2409	rapid	O
2409	and	O
2409	simple	O
2409	method	O
2409	to	O
2409	diagnose	O
2409	the	O
2409	molecular	O
2409	defects	O
2409	of	O
2409	glucose	B-Disease
2409	-	I-Disease
2409	6	I-Disease
2409	-	I-Disease
2409	phosphate	I-Disease
2409	dehydrogenase	I-Disease
2409	(	I-Disease
2409	G6PD	I-Disease
2409	)	I-Disease
2409	deficiency	I-Disease
2409	in	O
2409	Chinese	O
2409	in	O
2409	Taiwan	O
2409	.	O
2410	This	O
2410	method	O
2410	involves	O
2410	the	O
2410	selective	O
2410	amplification	O
2410	of	O
2410	a	O
2410	DNA	O
2410	fragment	O
2410	from	O
2410	human	O
2410	G6PD	O
2410	gene	O
2410	with	O
2410	specific	O
2410	oligonucleotide	O
2410	primers	O
2410	followed	O
2410	by	O
2410	digestion	O
2410	with	O
2410	restriction	O
2410	enzymes	O
2410	that	O
2410	recognize	O
2410	artificially	O
2410	created	O
2410	or	O
2410	naturally	O
2410	occurring	O
2410	restriction	O
2410	sites	O
2410	.	O
2411	Ninety	O
2411	-	O
2411	four	O
2411	Chinese	O
2411	males	O
2411	with	O
2411	G6PD	B-Disease
2411	deficiency	I-Disease
2411	were	O
2411	studied	O
2411	.	O
2412	The	O
2412	results	O
2412	show	O
2412	that	O
2412	50	O
2412	%	O
2412	(	O
2412	47	O
2412	of	O
2412	94	O
2412	)	O
2412	were	O
2412	G	O
2412	to	O
2412	T	O
2412	mutation	O
2412	at	O
2412	nucleotide	O
2412	(	O
2412	nt	O
2412	)	O
2412	1376	O
2412	,	O
2412	21	O
2412	.	O
2413	3	O
2413	%	O
2413	(	O
2413	20	O
2413	of	O
2413	94	O
2413	)	O
2413	were	O
2413	G	O
2413	to	O
2413	A	O
2413	mutation	O
2413	at	O
2413	nt	O
2413	1388	O
2413	,	O
2413	7	O
2413	.	O
2414	4	O
2414	%	O
2414	(	O
2414	7	O
2414	of	O
2414	94	O
2414	)	O
2414	were	O
2414	A	O
2414	to	O
2414	G	O
2414	mutation	O
2414	at	O
2414	nt	O
2414	493	O
2414	,	O
2414	7	O
2414	.	O
2415	4	O
2415	%	O
2415	(	O
2415	7	O
2415	of	O
2415	94	O
2415	)	O
2415	were	O
2415	A	O
2415	to	O
2415	G	O
2415	mutation	O
2415	at	O
2415	nt	O
2415	95	O
2415	,	O
2415	4	O
2415	.	O
2416	2	O
2416	%	O
2416	(	O
2416	4	O
2416	of	O
2416	94	O
2416	)	O
2416	were	O
2416	C	O
2416	to	O
2416	T	O
2416	mutation	O
2416	at	O
2416	nt	O
2416	1024	O
2416	,	O
2416	1	O
2416	.	O
2417	1	O
2417	%	O
2417	(	O
2417	1	O
2417	of	O
2417	94	O
2417	)	O
2417	was	O
2417	G	O
2417	to	O
2417	T	O
2417	mutation	O
2417	at	O
2417	nt	O
2417	392	O
2417	,	O
2417	and	O
2417	1	O
2417	.	O
2418	1	O
2418	%	O
2418	(	O
2418	1	O
2418	of	O
2418	94	O
2418	)	O
2418	was	O
2418	G	O
2418	to	O
2418	A	O
2418	mutation	O
2418	at	O
2418	nt	O
2418	487	O
2418	.	O
2419	These	O
2419	results	O
2419	show	O
2419	that	O
2419	the	O
2419	former	O
2419	five	O
2419	mutations	O
2419	account	O
2419	for	O
2419	more	O
2419	than	O
2419	90	O
2419	%	O
2419	of	O
2419	G6PD	B-Disease
2419	deficiency	I-Disease
2419	cases	O
2419	in	O
2419	Taiwan	O
2419	.	O
2420	Aside	O
2420	from	O
2420	showing	O
2420	that	O
2420	G	O
2420	to	O
2420	T	O
2420	change	O
2420	at	O
2420	nt	O
2420	1376	O
2420	is	O
2420	the	O
2420	most	O
2420	common	O
2420	mutation	O
2420	,	O
2420	our	O
2420	research	O
2420	indicates	O
2420	that	O
2420	nt	O
2420	493	O
2420	mutation	O
2420	is	O
2420	a	O
2420	frequent	O
2420	mutation	O
2420	among	O
2420	Chinese	O
2420	in	O
2420	Taiwan	O
2420	.	O
2421	We	O
2421	compared	O
2421	G6PD	O
2421	activity	O
2421	among	O
2421	different	O
2421	mutations	O
2421	,	O
2421	without	O
2421	discovering	O
2421	significant	O
2421	differences	O
2421	between	O
2421	them	O
2421	.	O
2422	Eight	O
2422	novel	O
2422	inactivating	O
2422	germ	O
2422	line	O
2422	mutations	O
2422	at	O
2422	the	O
2422	APC	B-Disease
2422	gene	O
2422	identified	O
2422	by	O
2422	denaturing	O
2422	gradient	O
2422	gel	O
2422	electrophoresis	O
2422	.	O
2423	Familial	B-Disease
2423	adenomatous	I-Disease
2423	polyposis	I-Disease
2423	(	O
2423	FAP	B-Disease
2423	)	O
2423	is	O
2423	a	O
2423	dominantly	O
2423	inherited	O
2423	condition	O
2423	predisposing	O
2423	to	O
2423	colorectal	B-Disease
2423	cancer	I-Disease
2423	.	O
2424	The	O
2424	recent	O
2424	isolation	O
2424	of	O
2424	the	O
2424	responsible	O
2424	gene	O
2424	(	O
2424	adenomatous	B-Disease
2424	polyposis	I-Disease
2424	coli	I-Disease
2424	or	O
2424	APC	B-Disease
2424	)	O
2424	has	O
2424	facilitated	O
2424	the	O
2424	search	O
2424	for	O
2424	germ	O
2424	line	O
2424	mutations	O
2424	in	O
2424	affected	O
2424	individuals	O
2424	.	O
2425	Previous	O
2425	authors	O
2425	have	O
2425	used	O
2425	the	O
2425	RNase	O
2425	protection	O
2425	assay	O
2425	and	O
2425	the	O
2425	single	O
2425	-	O
2425	strand	O
2425	conformation	O
2425	polymorphisms	O
2425	procedure	O
2425	to	O
2425	screen	O
2425	for	O
2425	mutations	O
2425	.	O
2426	In	O
2426	this	O
2426	study	O
2426	we	O
2426	used	O
2426	denaturing	O
2426	gradient	O
2426	gel	O
2426	electrophoresis	O
2426	(	O
2426	DGGE	O
2426	)	O
2426	.	O
2427	DGGE	O
2427	analysis	O
2427	of	O
2427	10	O
2427	APC	B-Disease
2427	exons	O
2427	(	O
2427	4	O
2427	,	O
2427	5	O
2427	,	O
2427	7	O
2427	,	O
2427	8	O
2427	,	O
2427	9	O
2427	,	O
2427	10	O
2427	,	O
2427	12	O
2427	,	O
2427	13	O
2427	,	O
2427	14	O
2427	,	O
2427	and	O
2427	part	O
2427	of	O
2427	15	O
2427	)	O
2427	in	O
2427	33	O
2427	unrelated	O
2427	Dutch	O
2427	FAP	B-Disease
2427	patients	O
2427	has	O
2427	led	O
2427	to	O
2427	the	O
2427	identification	O
2427	of	O
2427	eight	O
2427	novel	O
2427	germ	O
2427	line	O
2427	mutations	O
2427	resulting	O
2427	in	O
2427	stop	O
2427	codons	O
2427	or	O
2427	frameshifts	O
2427	.	O
2428	The	O
2428	results	O
2428	reported	O
2428	here	O
2428	indicate	O
2428	that	O
2428	(	O
2428	1	O
2428	)	O
2428	familial	B-Disease
2428	adenomatous	I-Disease
2428	polyposis	I-Disease
2428	is	O
2428	caused	O
2428	by	O
2428	an	O
2428	extremely	O
2428	heterogeneous	O
2428	spectrum	O
2428	of	O
2428	point	O
2428	mutations	O
2428	;	O
2428	(	O
2428	2	O
2428	)	O
2428	all	O
2428	the	O
2428	mutations	O
2428	found	O
2428	in	O
2428	this	O
2428	study	O
2428	are	O
2428	chain	O
2428	terminating	O
2428	;	O
2428	and	O
2428	(	O
2428	3	O
2428	)	O
2428	DGGE	O
2428	represents	O
2428	a	O
2428	rapid	O
2428	and	O
2428	sensitive	O
2428	technique	O
2428	for	O
2428	the	O
2428	detection	O
2428	of	O
2428	mutations	O
2428	in	O
2428	the	O
2428	unusually	O
2428	large	O
2428	APC	B-Disease
2428	gene	O
2428	.	O
2429	An	O
2429	extension	O
2429	of	O
2429	the	O
2429	DGGE	O
2429	analysis	O
2429	to	O
2429	the	O
2429	entire	O
2429	coding	O
2429	region	O
2429	in	O
2429	a	O
2429	sufficient	O
2429	number	O
2429	of	O
2429	clinically	O
2429	well	O
2429	-	O
2429	characterized	O
2429	,	O
2429	unrelated	O
2429	patients	O
2429	will	O
2429	facilitate	O
2429	the	O
2429	establishment	O
2429	of	O
2429	genotype	O
2429	-	O
2429	phenotype	O
2429	correlations	O
2429	.	O
2430	On	O
2430	the	O
2430	other	O
2430	hand	O
2430	,	O
2430	the	O
2430	occurrence	O
2430	of	O
2430	an	O
2430	extremely	O
2430	heterogeneous	O
2430	spectrum	O
2430	of	O
2430	mutations	O
2430	spread	O
2430	throughout	O
2430	the	O
2430	entire	O
2430	length	O
2430	of	O
2430	the	O
2430	large	O
2430	APC	B-Disease
2430	gene	O
2430	among	O
2430	the	O
2430	FAP	B-Disease
2430	patients	O
2430	indicates	O
2430	that	O
2430	this	O
2430	approach	O
2430	may	O
2430	not	O
2430	be	O
2430	useful	O
2430	as	O
2430	a	O
2430	rapid	O
2430	presymptomatic	O
2430	diagnostic	O
2430	procedure	O
2430	in	O
2430	a	O
2430	routine	O
2430	laboratory	O
2430	.	O
2431	Nevertheless	O
2431	,	O
2431	the	O
2431	above	O
2431	DGGE	O
2431	approach	O
2431	has	O
2431	incidentally	O
2431	led	O
2431	to	O
2431	the	O
2431	identification	O
2431	of	O
2431	a	O
2431	common	O
2431	polymorphism	O
2431	in	O
2431	exon	O
2431	13	O
2431	.	O
2432	Such	O
2432	intragenic	O
2432	polymorphisms	O
2432	offer	O
2432	a	O
2432	practical	O
2432	approach	O
2432	to	O
2432	a	O
2432	more	O
2432	rapid	O
2432	procedure	O
2432	for	O
2432	presymptomatic	O
2432	diagnosis	O
2432	of	O
2432	FAP	B-Disease
2432	by	O
2432	linkage	O
2432	analysis	O
2432	in	O
2432	informative	O
2432	families	O
2432	.	O
2432	.	O
2433	Yeast	O
2433	artificial	O
2433	chromosomes	O
2433	for	O
2433	the	O
2433	molecular	O
2433	analysis	O
2433	of	O
2433	the	O
2433	familial	B-Disease
2433	polyposis	I-Disease
2433	APC	I-Disease
2433	gene	O
2433	region	O
2433	.	O
2434	Two	O
2434	yeast	O
2434	artificial	O
2434	chromosomes	O
2434	(	O
2434	YACs	O
2434	)	O
2434	spanning	O
2434	a	O
2434	total	O
2434	distance	O
2434	of	O
2434	1	O
2434	.	O
2435	1	O
2435	megabase	O
2435	pairs	O
2435	of	O
2435	DNA	O
2435	around	O
2435	the	O
2435	MCC	O
2435	(	O
2435	for	O
2435	mutated	O
2435	in	O
2435	colorectal	B-Disease
2435	carcinoma	I-Disease
2435	)	O
2435	and	O
2435	APC	B-Disease
2435	(	O
2435	for	O
2435	adenomatous	B-Disease
2435	polyposis	I-Disease
2435	coli	I-Disease
2435	)	O
2435	genes	O
2435	at	O
2435	5q21	O
2435	have	O
2435	been	O
2435	isolated	O
2435	and	O
2435	characterized	O
2435	.	O
2436	Starting	O
2436	from	O
2436	the	O
2436	MCC	O
2436	gene	O
2436	,	O
2436	a	O
2436	strategy	O
2436	was	O
2436	undertaken	O
2436	to	O
2436	identify	O
2436	constitutional	O
2436	submicroscopic	O
2436	deletions	O
2436	in	O
2436	familial	B-Disease
2436	adenomatous	I-Disease
2436	polyposis	I-Disease
2436	patients	O
2436	that	O
2436	might	O
2436	considerably	O
2436	narrow	O
2436	down	O
2436	the	O
2436	position	O
2436	of	O
2436	the	O
2436	APC	B-Disease
2436	gene	O
2436	.	O
2437	To	O
2437	this	O
2437	end	O
2437	,	O
2437	YACs	O
2437	identified	O
2437	by	O
2437	the	O
2437	MCC	O
2437	gene	O
2437	were	O
2437	screened	O
2437	across	O
2437	a	O
2437	chromosome	O
2437	5	O
2437	-	O
2437	specific	O
2437	cosmid	O
2437	library	O
2437	to	O
2437	provide	O
2437	a	O
2437	source	O
2437	of	O
2437	DNA	O
2437	probes	O
2437	for	O
2437	genomic	O
2437	scanning	O
2437	.	O
2438	The	O
2438	cosmids	O
2438	isolated	O
2438	from	O
2438	these	O
2438	experiments	O
2438	were	O
2438	used	O
2438	to	O
2438	screen	O
2438	a	O
2438	panel	O
2438	of	O
2438	somatic	O
2438	cell	O
2438	hybrids	O
2438	containing	O
2438	chromosome	O
2438	5	O
2438	segregated	O
2438	from	O
2438	patients	O
2438	suspected	O
2438	to	O
2438	carry	O
2438	putative	O
2438	interstitial	O
2438	deletions	O
2438	.	O
2439	This	O
2439	screening	O
2439	approach	O
2439	led	O
2439	to	O
2439	the	O
2439	confirmation	O
2439	of	O
2439	a	O
2439	small	O
2439	heterozygous	O
2439	deletion	O
2439	in	O
2439	a	O
2439	polyposis	B-Disease
2439	patient	O
2439	that	O
2439	overlaps	O
2439	one	O
2439	of	O
2439	the	O
2439	two	O
2439	isolated	O
2439	YACs	O
2439	.	O
2440	This	O
2440	YAC	O
2440	has	O
2440	been	O
2440	shown	O
2440	to	O
2440	contain	O
2440	the	O
2440	entire	O
2440	APC	B-Disease
2440	gene	O
2440	,	O
2440	in	O
2440	addition	O
2440	to	O
2440	a	O
2440	significant	O
2440	portion	O
2440	of	O
2440	DNA	O
2440	flanking	O
2440	the	O
2440	5	O
2440	end	O
2440	of	O
2440	the	O
2440	gene	O
2440	,	O
2440	and	O
2440	should	O
2440	therefore	O
2440	prove	O
2440	a	O
2440	valuable	O
2440	resource	O
2440	for	O
2440	functional	O
2440	studies	O
2440	by	O
2440	transfer	O
2440	to	O
2440	colorectal	B-Disease
2440	tumor	I-Disease
2440	-	O
2440	derived	O
2440	cell	O
2440	lines	O
2440	.	O
2441	Inherited	O
2441	WT1	O
2441	mutation	O
2441	in	O
2441	Denys	B-Disease
2441	-	I-Disease
2441	Drash	I-Disease
2441	syndrome	I-Disease
2441	.	O
2442	Patients	O
2442	with	O
2442	the	O
2442	Denys	B-Disease
2442	-	I-Disease
2442	Drash	I-Disease
2442	syndrome	I-Disease
2442	(	O
2442	Wilms	B-Disease
2442	tumor	I-Disease
2442	,	O
2442	genital	B-Disease
2442	anomalies	I-Disease
2442	,	O
2442	and	O
2442	nephropathy	B-Disease
2442	)	O
2442	have	O
2442	been	O
2442	demonstrated	O
2442	to	O
2442	carry	O
2442	de	O
2442	novo	O
2442	constitutional	O
2442	mutations	O
2442	in	O
2442	WT1	O
2442	,	O
2442	the	O
2442	Wilms	B-Disease
2442	tumor	I-Disease
2442	gene	O
2442	at	O
2442	chromosome	O
2442	11p13	O
2442	.	O
2443	We	O
2443	report	O
2443	three	O
2443	new	O
2443	cases	O
2443	,	O
2443	two	O
2443	carrying	O
2443	a	O
2443	previously	O
2443	described	O
2443	WT1	O
2443	exon	O
2443	9	O
2443	mutation	O
2443	and	O
2443	one	O
2443	with	O
2443	a	O
2443	novel	O
2443	WT1	O
2443	exon	O
2443	8	O
2443	mutation	O
2443	.	O
2444	However	O
2444	,	O
2444	unlike	O
2444	patients	O
2444	in	O
2444	previous	O
2444	reports	O
2444	,	O
2444	one	O
2444	of	O
2444	our	O
2444	three	O
2444	patients	O
2444	inherited	O
2444	the	O
2444	affected	O
2444	allele	O
2444	from	O
2444	his	O
2444	phenotypically	O
2444	unaffected	O
2444	father	O
2444	.	O
2445	This	O
2445	observation	O
2445	indicates	O
2445	that	O
2445	the	O
2445	WT1	O
2445	exon	O
2445	9	O
2445	mutation	O
2445	affecting	O
2445	394Arg	O
2445	demonstrated	O
2445	in	O
2445	over	O
2445	one	O
2445	-	O
2445	half	O
2445	of	O
2445	the	O
2445	patients	O
2445	with	O
2445	the	O
2445	Denys	B-Disease
2445	-	I-Disease
2445	Drash	I-Disease
2445	syndrome	I-Disease
2445	may	O
2445	exhibit	O
2445	incomplete	O
2445	penetrance	O
2445	.	O
2446	Consequently	O
2446	,	O
2446	familial	O
2446	studies	O
2446	in	O
2446	patients	O
2446	affected	O
2446	by	O
2446	this	O
2446	syndrome	O
2446	are	O
2446	recommended	O
2446	.	O
2446	.	O
2447	Submicroscopic	O
2447	deletions	O
2447	at	O
2447	the	O
2447	WAGR	B-Disease
2447	locus	O
2447	,	O
2447	revealed	O
2447	by	O
2447	nonradioactive	O
2447	in	O
2447	situ	O
2447	hybridization	O
2447	.	O
2448	Fluorescence	O
2448	in	O
2448	situ	O
2448	hybridization	O
2448	(	O
2448	FISH	O
2448	)	O
2448	with	O
2448	biotin	O
2448	-	O
2448	labeled	O
2448	probes	O
2448	mapping	O
2448	to	O
2448	11p13	O
2448	has	O
2448	been	O
2448	used	O
2448	for	O
2448	the	O
2448	molecular	O
2448	analysis	O
2448	of	O
2448	deletions	O
2448	of	O
2448	the	O
2448	WAGR	B-Disease
2448	(	O
2448	Wilms	B-Disease
2448	tumor	I-Disease
2448	,	O
2448	aniridia	B-Disease
2448	,	O
2448	genitourinary	B-Disease
2448	abnormalities	I-Disease
2448	,	O
2448	and	O
2448	mental	B-Disease
2448	retardation	I-Disease
2448	)	O
2448	locus	O
2448	.	O
2449	We	O
2449	have	O
2449	detected	O
2449	a	O
2449	submicroscopic	O
2449	11p13	O
2449	deletion	O
2449	in	O
2449	a	O
2449	child	O
2449	with	O
2449	inherited	O
2449	aniridia	B-Disease
2449	who	O
2449	subsequently	O
2449	presented	O
2449	with	O
2449	Wilms	B-Disease
2449	tumor	I-Disease
2449	in	O
2449	a	O
2449	horseshoe	O
2449	kidney	O
2449	,	O
2449	only	O
2449	revealed	O
2449	at	O
2449	surgery	O
2449	.	O
2450	The	O
2450	mother	O
2450	,	O
2450	who	O
2450	has	O
2450	aniridia	B-Disease
2450	,	O
2450	was	O
2450	also	O
2450	found	O
2450	to	O
2450	carry	O
2450	a	O
2450	deletion	O
2450	including	O
2450	both	O
2450	the	O
2450	aniridia	B-Disease
2450	candidate	O
2450	gene	O
2450	(	O
2450	AN2	O
2450	)	O
2450	and	O
2450	the	O
2450	Wilms	B-Disease
2450	tumor	I-Disease
2450	predisposition	O
2450	gene	O
2450	(	O
2450	WT1	O
2450	)	O
2450	.	O
2451	This	O
2451	is	O
2451	therefore	O
2451	a	O
2451	rare	O
2451	case	O
2451	of	O
2451	an	O
2451	inherited	O
2451	WAGR	B-Disease
2451	deletion	O
2451	.	O
2452	Wilms	B-Disease
2452	tumor	I-Disease
2452	has	O
2452	so	O
2452	far	O
2452	only	O
2452	been	O
2452	associated	O
2452	with	O
2452	sporadic	O
2452	de	O
2452	novo	O
2452	aniridia	B-Disease
2452	cases	O
2452	.	O
2453	We	O
2453	have	O
2453	shown	O
2453	that	O
2453	a	O
2453	cosmid	O
2453	probe	O
2453	for	O
2453	a	O
2453	candidate	O
2453	aniridia	B-Disease
2453	gene	O
2453	,	O
2453	homologous	O
2453	to	O
2453	the	O
2453	mouse	O
2453	Pax	O
2453	-	O
2453	6	O
2453	gene	O
2453	,	O
2453	is	O
2453	deleted	O
2453	in	O
2453	cell	O
2453	lines	O
2453	from	O
2453	aniridia	B-Disease
2453	patients	O
2453	with	O
2453	previously	O
2453	characterized	O
2453	deletions	O
2453	at	O
2453	11p13	O
2453	,	O
2453	while	O
2453	another	O
2453	cosmid	O
2453	marker	O
2453	mapping	O
2453	between	O
2453	two	O
2453	aniridia	B-Disease
2453	-	O
2453	associated	O
2453	translocation	O
2453	breakpoints	O
2453	(	O
2453	and	O
2453	hence	O
2453	a	O
2453	second	O
2453	candidate	O
2453	marker	O
2453	)	O
2453	is	O
2453	present	O
2453	on	O
2453	both	O
2453	chromosomes	O
2453	.	O
2454	These	O
2454	results	O
2454	support	O
2454	the	O
2454	Pax	O
2454	-	O
2454	6	O
2454	homologue	O
2454	as	O
2454	a	O
2454	strong	O
2454	candidate	O
2454	for	O
2454	the	O
2454	AN2	O
2454	gene	O
2454	.	O
2455	FISH	O
2455	with	O
2455	cosmid	O
2455	probes	O
2455	has	O
2455	proved	O
2455	to	O
2455	be	O
2455	a	O
2455	fast	O
2455	and	O
2455	reliable	O
2455	technique	O
2455	for	O
2455	the	O
2455	molecular	O
2455	analysis	O
2455	of	O
2455	deletions	O
2455	.	O
2456	It	O
2456	can	O
2456	be	O
2456	used	O
2456	with	O
2456	limited	O
2456	amounts	O
2456	of	O
2456	material	O
2456	and	O
2456	has	O
2456	strong	O
2456	potential	O
2456	for	O
2456	clinical	O
2456	applications	O
2456	.	O
2456	.	O
2457	Linkage	O
2457	of	O
2457	gene	O
2457	for	O
2457	C2	B-Disease
2457	deficiency	I-Disease
2457	and	O
2457	the	O
2457	major	O
2457	histocompatibility	O
2457	complex	O
2457	MHC	O
2457	in	O
2457	man	O
2457	.	O
2458	Family	O
2458	study	O
2458	of	O
2458	a	O
2458	further	O
2458	case	O
2458	.	O
2459	Close	O
2459	linkage	O
2459	between	O
2459	HL	O
2459	-	O
2459	A	O
2459	and	O
2459	C2	B-Disease
2459	deficiency	I-Disease
2459	was	O
2459	first	O
2459	reported	O
2459	by	O
2459	FU	O
2459	and	O
2459	co	O
2459	-	O
2459	workers	O
2459	in	O
2459	1974	O
2459	.	O
2460	We	O
2460	present	O
2460	here	O
2460	a	O
2460	pedigree	O
2460	of	O
2460	a	O
2460	31	O
2460	-	O
2460	year	O
2460	-	O
2460	old	O
2460	C2	B-Disease
2460	-	I-Disease
2460	deficient	I-Disease
2460	individual	O
2460	with	O
2460	clinical	O
2460	manifestations	O
2460	of	O
2460	Hodgkins	B-Disease
2460	disease	I-Disease
2460	.	O
2461	The	O
2461	following	O
2461	markers	O
2461	were	O
2461	tested	O
2461	C2	O
2461	levels	O
2461	,	O
2461	factor	O
2461	B	O
2461	polymorphism	O
2461	,	O
2461	blood	O
2461	groups	O
2461	,	O
2461	and	O
2461	enzyme	O
2461	typing	O
2461	.	O
2462	In	O
2462	addition	O
2462	to	O
2462	close	O
2462	linkage	O
2462	between	O
2462	HL	O
2462	-	O
2462	A	O
2462	and	O
2462	C2	B-Disease
2462	deficiency	I-Disease
2462	,	O
2462	both	O
2462	parents	O
2462	were	O
2462	heterozygous	O
2462	for	O
2462	Bf	O
2462	(	O
2462	HL	O
2462	-	O
2462	A	O
2462	linked	O
2462	,	O
2462	electrophoretic	O
2462	variation	O
2462	of	O
2462	B	O
2462	)	O
2462	.	O
2463	The	O
2463	two	O
2463	HL	O
2463	-	O
2463	A	O
2463	haplotypes	O
2463	closely	O
2463	linked	O
2463	to	O
2463	C2	B-Disease
2463	deficiency	I-Disease
2463	are	O
2463	different	O
2463	2	O
2463	,	O
2463	W18	O
2463	and	O
2463	W24	O
2463	,	O
2463	W18	O
2463	.	O
2464	They	O
2464	share	O
2464	,	O
2464	however	O
2464	,	O
2464	the	O
2464	SD2	O
2464	antigen	O
2464	W18	O
2464	and	O
2464	the	O
2464	LD	O
2464	type	O
2464	7a	O
2464	.	O
2464	.	O
2465	Screening	O
2465	for	O
2465	germ	O
2465	-	O
2465	line	O
2465	mutations	O
2465	in	O
2465	familial	B-Disease
2465	adenomatous	I-Disease
2465	polyposis	I-Disease
2465	patients	O
2465	:	O
2465	61	O
2465	new	O
2465	patients	O
2465	and	O
2465	a	O
2465	summary	O
2465	of	O
2465	150	O
2465	unrelated	O
2465	patients	O
2465	.	O
2466	We	O
2466	report	O
2466	here	O
2466	the	O
2466	result	O
2466	of	O
2466	a	O
2466	screening	O
2466	for	O
2466	germ	O
2466	-	O
2466	line	O
2466	mutations	O
2466	in	O
2466	the	O
2466	adenomatous	B-Disease
2466	polyposis	I-Disease
2466	coli	I-Disease
2466	(	O
2466	APC	B-Disease
2466	)	O
2466	gene	O
2466	in	O
2466	61	O
2466	new	O
2466	familial	B-Disease
2466	adenomatous	I-Disease
2466	polyposis	I-Disease
2466	(	O
2466	FAP	B-Disease
2466	)	O
2466	patients	O
2466	as	O
2466	well	O
2466	as	O
2466	a	O
2466	summary	O
2466	of	O
2466	the	O
2466	results	O
2466	of	O
2466	150	O
2466	patients	O
2466	.	O
2467	Examination	O
2467	of	O
2467	the	O
2467	entire	O
2467	coding	O
2467	region	O
2467	of	O
2467	the	O
2467	APC	B-Disease
2467	gene	O
2467	,	O
2467	based	O
2467	on	O
2467	a	O
2467	ribonuclease	O
2467	protection	O
2467	assay	O
2467	coupled	O
2467	with	O
2467	the	O
2467	polymerase	O
2467	chain	O
2467	reaction	O
2467	(	O
2467	PCR	O
2467	)	O
2467	,	O
2467	disclosed	O
2467	mutations	O
2467	that	O
2467	were	O
2467	considered	O
2467	to	O
2467	cause	O
2467	significant	O
2467	defects	O
2467	in	O
2467	the	O
2467	APC	B-Disease
2467	product	O
2467	in	O
2467	97	O
2467	of	O
2467	150	O
2467	unrelated	O
2467	FAP	B-Disease
2467	patients	O
2467	.	O
2468	Our	O
2468	findings	O
2468	revealed	O
2468	the	O
2468	following	O
2468	characteristics	O
2468	of	O
2468	the	O
2468	germ	O
2468	-	O
2468	line	O
2468	mutations	O
2468	of	O
2468	APC	O
2468	1	O
2468	)	O
2468	the	O
2468	great	O
2468	majority	O
2468	of	O
2468	the	O
2468	mutations	O
2468	were	O
2468	found	O
2468	to	O
2468	truncate	O
2468	the	O
2468	APC	B-Disease
2468	product	O
2468	;	O
2468	2	O
2468	)	O
2468	almost	O
2468	all	O
2468	of	O
2468	the	O
2468	mutations	O
2468	were	O
2468	located	O
2468	within	O
2468	the	O
2468	first	O
2468	half	O
2468	of	O
2468	the	O
2468	coding	O
2468	region	O
2468	;	O
2468	3	O
2468	)	O
2468	no	O
2468	correlation	O
2468	was	O
2468	observed	O
2468	between	O
2468	the	O
2468	locations	O
2468	of	O
2468	germ	O
2468	-	O
2468	line	O
2468	mutations	O
2468	and	O
2468	extracolonic	O
2468	manifestations	O
2468	in	O
2468	FAP	B-Disease
2468	patients	O
2468	;	O
2468	4	O
2468	)	O
2468	more	O
2468	than	O
2468	80	O
2468	%	O
2468	of	O
2468	base	O
2468	substitutions	O
2468	in	O
2468	the	O
2468	APC	B-Disease
2468	gene	O
2468	were	O
2468	from	O
2468	cytosine	O
2468	to	O
2468	other	O
2468	nucleotides	O
2468	,	O
2468	nearly	O
2468	one	O
2468	-	O
2468	third	O
2468	of	O
2468	which	O
2468	occurred	O
2468	at	O
2468	the	O
2468	GpG	O
2468	site	O
2468	.	O
2469	Our	O
2469	results	O
2469	provide	O
2469	information	O
2469	helpful	O
2469	to	O
2469	an	O
2469	understanding	O
2469	of	O
2469	the	O
2469	APC	B-Disease
2469	gene	O
2469	and	O
2469	will	O
2469	also	O
2469	contribute	O
2469	to	O
2469	presymptomatic	O
2469	diagnosis	O
2469	of	O
2469	members	O
2469	in	O
2469	FAP	B-Disease
2469	families	O
2469	.	O
2469	.	O
2470	Somatic	O
2470	mutations	O
2470	of	O
2470	the	O
2470	APC	B-Disease
2470	gene	O
2470	in	O
2470	colorectal	B-Disease
2470	tumors	I-Disease
2470	:	O
2470	mutation	O
2470	cluster	O
2470	region	O
2470	in	O
2470	the	O
2470	APC	B-Disease
2470	gene	O
2470	.	O
2471	We	O
2471	examined	O
2471	somatic	O
2471	mutations	O
2471	of	O
2471	the	O
2471	adenomatous	B-Disease
2471	polyposis	I-Disease
2471	coli	I-Disease
2471	(	O
2471	APC	B-Disease
2471	)	O
2471	gene	O
2471	in	O
2471	63	O
2471	colorectal	B-Disease
2471	tumors	I-Disease
2471	(	O
2471	16	O
2471	adenomas	B-Disease
2471	and	O
2471	47	O
2471	carcinomas	B-Disease
2471	)	O
2471	developed	O
2471	in	O
2471	familial	B-Disease
2471	adenomatous	I-Disease
2471	polyposis	I-Disease
2471	(	O
2471	FAP	B-Disease
2471	)	O
2471	and	O
2471	non	O
2471	-	O
2471	FAP	O
2471	patients	O
2471	.	O
2472	In	O
2472	addition	O
2472	to	O
2472	loss	O
2472	of	O
2472	heterozygosity	O
2472	(	O
2472	LOH	O
2472	)	O
2472	at	O
2472	the	O
2472	APC	B-Disease
2472	locus	O
2472	in	O
2472	30	O
2472	tumors	B-Disease
2472	,	O
2472	43	O
2472	other	O
2472	somatic	O
2472	mutations	O
2472	were	O
2472	detected	O
2472	.	O
2473	Twenty	O
2473	-	O
2473	one	O
2473	of	O
2473	them	O
2473	were	O
2473	point	O
2473	mutations	O
2473	;	O
2473	16	O
2473	nonsense	O
2473	and	O
2473	two	O
2473	missense	O
2473	mutations	O
2473	,	O
2473	and	O
2473	three	O
2473	occurred	O
2473	in	O
2473	introns	O
2473	at	O
2473	the	O
2473	splicing	O
2473	site	O
2473	.	O
2474	Twenty	O
2474	-	O
2474	two	O
2474	tumors	B-Disease
2474	had	O
2474	frameshift	O
2474	mutations	O
2474	due	O
2474	to	O
2474	deletion	O
2474	or	O
2474	insertion	O
2474	;	O
2474	nineteen	O
2474	of	O
2474	them	O
2474	were	O
2474	deletions	O
2474	of	O
2474	one	O
2474	to	O
2474	31	O
2474	bp	O
2474	and	O
2474	three	O
2474	were	O
2474	a	O
2474	1	O
2474	-	O
2474	bp	O
2474	insertion	O
2474	.	O
2475	One	O
2475	tumor	B-Disease
2475	had	O
2475	a	O
2475	1	O
2475	-	O
2475	bp	O
2475	deletion	O
2475	in	O
2475	an	O
2475	intron	O
2475	near	O
2475	the	O
2475	splicing	O
2475	site	O
2475	.	O
2476	Hence	O
2476	,	O
2476	41	O
2476	(	O
2476	95	O
2476	%	O
2476	)	O
2476	of	O
2476	43	O
2476	mutations	O
2476	resulted	O
2476	in	O
2476	truncation	O
2476	of	O
2476	the	O
2476	APC	B-Disease
2476	protein	O
2476	.	O
2477	Over	O
2477	60	O
2477	%	O
2477	of	O
2477	the	O
2477	somatic	O
2477	mutations	O
2477	in	O
2477	the	O
2477	APC	B-Disease
2477	gene	O
2477	were	O
2477	clustered	O
2477	within	O
2477	a	O
2477	small	O
2477	region	O
2477	of	O
2477	exon	O
2477	15	O
2477	,	O
2477	designated	O
2477	as	O
2477	MCR	O
2477	(	O
2477	mutation	O
2477	cluster	O
2477	region	O
2477	)	O
2477	,	O
2477	which	O
2477	accounted	O
2477	for	O
2477	less	O
2477	than	O
2477	10	O
2477	%	O
2477	of	O
2477	the	O
2477	coding	O
2477	region	O
2477	.	O
2478	Combining	O
2478	these	O
2478	data	O
2478	and	O
2478	the	O
2478	results	O
2478	of	O
2478	LOH	O
2478	,	O
2478	more	O
2478	than	O
2478	80	O
2478	%	O
2478	of	O
2478	tumors	B-Disease
2478	(	O
2478	14	O
2478	adenomas	B-Disease
2478	and	O
2478	39	O
2478	carcinomas	B-Disease
2478	)	O
2478	had	O
2478	at	O
2478	least	O
2478	one	O
2478	mutation	O
2478	in	O
2478	the	O
2478	APC	B-Disease
2478	gene	O
2478	,	O
2478	of	O
2478	which	O
2478	more	O
2478	than	O
2478	60	O
2478	%	O
2478	(	O
2478	9	O
2478	adenomas	B-Disease
2478	and	O
2478	23	O
2478	carcinomas	B-Disease
2478	)	O
2478	had	O
2478	two	O
2478	mutations	O
2478	.	O
2479	These	O
2479	results	O
2479	strongly	O
2479	suggest	O
2479	that	O
2479	somatic	O
2479	mutations	O
2479	of	O
2479	the	O
2479	APC	B-Disease
2479	gene	O
2479	are	O
2479	associated	O
2479	with	O
2479	development	O
2479	of	O
2479	a	O
2479	great	O
2479	majority	O
2479	of	O
2479	colorectal	B-Disease
2479	tumors	I-Disease
2479	.	O
2479	.	O
2480	Constitutional	O
2480	mutations	O
2480	in	O
2480	the	O
2480	WT1	O
2480	gene	O
2480	in	O
2480	patients	O
2480	with	O
2480	Denys	B-Disease
2480	-	I-Disease
2480	Drash	I-Disease
2480	syndrome	I-Disease
2480	.	O
2481	The	O
2481	Denys	B-Disease
2481	-	I-Disease
2481	Drash	I-Disease
2481	syndrome	I-Disease
2481	is	O
2481	characterised	O
2481	by	O
2481	a	O
2481	typical	O
2481	nephropathy	B-Disease
2481	,	O
2481	genital	B-Disease
2481	abnormalities	I-Disease
2481	and	O
2481	also	O
2481	predisposes	O
2481	to	O
2481	the	O
2481	development	O
2481	of	O
2481	Wilms	B-Disease
2481	tumor	I-Disease
2481	.	O
2482	These	O
2482	patients	O
2482	eventually	O
2482	go	O
2482	into	O
2482	end	O
2482	stage	O
2482	renal	B-Disease
2482	failure	I-Disease
2482	.	O
2483	A	O
2483	candidate	O
2483	Wilms	B-Disease
2483	tumor	I-Disease
2483	gene	O
2483	,	O
2483	WT1	O
2483	,	O
2483	from	O
2483	the	O
2483	11p13	O
2483	chromosome	O
2483	region	O
2483	has	O
2483	recently	O
2483	been	O
2483	cloned	O
2483	.	O
2484	We	O
2484	have	O
2484	analysed	O
2484	the	O
2484	DNA	O
2484	sequence	O
2484	in	O
2484	constitutional	O
2484	cells	O
2484	from	O
2484	eight	O
2484	patients	O
2484	and	O
2484	have	O
2484	shown	O
2484	heterozygous	O
2484	mutations	O
2484	in	O
2484	six	O
2484	of	O
2484	them	O
2484	.	O
2485	Four	O
2485	of	O
2485	the	O
2485	mutations	O
2485	were	O
2485	in	O
2485	exon	O
2485	9	O
2485	,	O
2485	all	O
2485	resulting	O
2485	in	O
2485	missense	O
2485	mutations	O
2485	.	O
2486	Three	O
2486	were	O
2486	at	O
2486	nucleotide	O
2486	position	O
2486	1180	O
2486	resulting	O
2486	in	O
2486	an	O
2486	arg	O
2486	>	O
2486	trp	O
2486	amino	O
2486	acid	O
2486	change	O
2486	.	O
2487	The	O
2487	other	O
2487	was	O
2487	at	O
2487	position	O
2487	1186	O
2487	converting	O
2487	an	O
2487	asp	O
2487	>	O
2487	asn	O
2487	in	O
2487	the	O
2487	predicted	O
2487	resultant	O
2487	protein	O
2487	.	O
2488	One	O
2488	patient	O
2488	had	O
2488	a	O
2488	missense	O
2488	mutation	O
2488	in	O
2488	exon	O
2488	8	O
2488	,	O
2488	converting	O
2488	an	O
2488	arg	O
2488	>	O
2488	his	O
2488	.	O
2489	A	O
2489	single	O
2489	base	O
2489	pair	O
2489	insertion	O
2489	at	O
2489	nucleotide	O
2489	position	O
2489	821	O
2489	in	O
2489	exon	O
2489	6	O
2489	resulted	O
2489	in	O
2489	the	O
2489	generation	O
2489	of	O
2489	a	O
2489	premature	O
2489	stop	O
2489	codon	O
2489	in	O
2489	the	O
2489	last	O
2489	patient	O
2489	.	O
2490	We	O
2490	were	O
2490	unable	O
2490	to	O
2490	find	O
2490	a	O
2490	mutation	O
2490	in	O
2490	one	O
2490	patient	O
2490	despite	O
2490	complete	O
2490	sequencing	O
2490	of	O
2490	the	O
2490	genomic	O
2490	sequence	O
2490	of	O
2490	the	O
2490	gene	O
2490	.	O
2491	The	O
2491	last	O
2491	patient	O
2491	carried	O
2491	a	O
2491	constitutional	O
2491	deletion	O
2491	of	O
2491	the	O
2491	11p13	O
2491	region	O
2491	and	O
2491	no	O
2491	additional	O
2491	mutation	O
2491	was	O
2491	found	O
2491	.	O
2492	There	O
2492	was	O
2492	no	O
2492	obvious	O
2492	correlation	O
2492	between	O
2492	the	O
2492	type	O
2492	of	O
2492	mutation	O
2492	and	O
2492	phenotypic	O
2492	expression	O
2492	.	O
2493	These	O
2493	results	O
2493	further	O
2493	demonstrate	O
2493	that	O
2493	the	O
2493	WT1	O
2493	gene	O
2493	is	O
2493	important	O
2493	in	O
2493	both	O
2493	the	O
2493	development	O
2493	of	O
2493	the	O
2493	kidney	O
2493	and	O
2493	the	O
2493	genito	O
2493	-	O
2493	urinary	O
2493	system	O
2493	.	O
2493	.	O
2494	Linkage	O
2494	disequilibrium	O
2494	mapping	O
2494	in	O
2494	isolated	O
2494	founder	O
2494	populations	O
2494	:	O
2494	diastrophic	B-Disease
2494	dysplasia	I-Disease
2494	in	O
2494	Finland	O
2494	.	O
2495	Linkage	O
2495	disequilibrium	O
2495	mapping	O
2495	in	O
2495	isolated	O
2495	populations	O
2495	provides	O
2495	a	O
2495	powerful	O
2495	tool	O
2495	for	O
2495	fine	O
2495	structure	O
2495	localization	O
2495	of	O
2495	disease	O
2495	genes	O
2495	.	O
2496	Here	O
2496	,	O
2496	Luria	O
2496	and	O
2496	Delbrucks	O
2496	classical	O
2496	methods	O
2496	for	O
2496	analysing	O
2496	bacterial	O
2496	cultures	O
2496	are	O
2496	adapted	O
2496	to	O
2496	the	O
2496	study	O
2496	of	O
2496	human	O
2496	isolated	O
2496	founder	O
2496	populations	O
2496	in	O
2496	order	O
2496	to	O
2496	estimate	O
2496	(	O
2496	i	O
2496	)	O
2496	the	O
2496	recombination	O
2496	fraction	O
2496	between	O
2496	a	O
2496	disease	O
2496	locus	O
2496	and	O
2496	a	O
2496	marker	O
2496	;	O
2496	(	O
2496	ii	O
2496	)	O
2496	the	O
2496	expected	O
2496	degree	O
2496	of	O
2496	allelic	O
2496	homogeneity	O
2496	in	O
2496	a	O
2496	population	O
2496	;	O
2496	and	O
2496	(	O
2496	iii	O
2496	)	O
2496	the	O
2496	mutation	O
2496	rate	O
2496	of	O
2496	marker	O
2496	loci	O
2496	.	O
2497	Using	O
2497	these	O
2497	methods	O
2497	,	O
2497	we	O
2497	report	O
2497	striking	O
2497	linkage	O
2497	disequilibrium	O
2497	for	O
2497	diastrophic	B-Disease
2497	dysplasia	I-Disease
2497	(	O
2497	DTD	B-Disease
2497	)	O
2497	in	O
2497	Finland	O
2497	indicating	O
2497	that	O
2497	the	O
2497	DTD	B-Disease
2497	gene	O
2497	should	O
2497	lie	O
2497	within	O
2497	0	O
2497	.	O
2498	06	O
2498	centimorgans	O
2498	(	O
2498	or	O
2498	about	O
2498	60	O
2498	kilobases	O
2498	)	O
2498	of	O
2498	the	O
2498	CSF1R	O
2498	gene	O
2498	.	O
2499	Predictions	O
2499	about	O
2499	allelic	O
2499	homogeneity	O
2499	in	O
2499	Finland	O
2499	and	O
2499	mutation	O
2499	rates	O
2499	in	O
2499	simple	O
2499	sequence	O
2499	repeats	O
2499	are	O
2499	confirmed	O
2499	by	O
2499	independent	O
2499	observations	O
2499	.	O
2500	The	O
2500	Wiskott	B-Disease
2500	-	I-Disease
2500	Aldrich	I-Disease
2500	syndrome	I-Disease
2500	:	O
2500	refinement	O
2500	of	O
2500	the	O
2500	localization	O
2500	on	O
2500	Xp	O
2500	and	O
2500	identification	O
2500	of	O
2500	another	O
2500	closely	O
2500	linked	O
2500	marker	O
2500	locus	O
2500	,	O
2500	OATL1	O
2500	.	O
2501	The	O
2501	Wiskott	B-Disease
2501	-	I-Disease
2501	Aldrich	I-Disease
2501	syndrome	I-Disease
2501	(	O
2501	WAS	B-Disease
2501	)	O
2501	has	O
2501	previously	O
2501	been	O
2501	mapped	O
2501	to	O
2501	the	O
2501	proximal	O
2501	short	O
2501	arm	O
2501	of	O
2501	the	O
2501	X	O
2501	chromosome	O
2501	between	O
2501	the	O
2501	DXS14	O
2501	and	O
2501	DXS7	O
2501	loci	O
2501	.	O
2502	In	O
2502	this	O
2502	study	O
2502	,	O
2502	further	O
2502	segregation	O
2502	analysis	O
2502	has	O
2502	been	O
2502	performed	O
2502	using	O
2502	a	O
2502	newly	O
2502	identified	O
2502	WAS	B-Disease
2502	family	O
2502	as	O
2502	well	O
2502	as	O
2502	an	O
2502	additional	O
2502	marker	O
2502	probe	O
2502	,	O
2502	HOATL1	O
2502	.	O
2503	The	O
2503	results	O
2503	indicate	O
2503	close	O
2503	linkage	O
2503	between	O
2503	the	O
2503	WAS	B-Disease
2503	and	O
2503	OATL1	O
2503	loci	O
2503	(	O
2503	Z	O
2503	=	O
2503	6	O
2503	.	O
2503	08	O
2503	at	O
2503	theta	O
2503	=	O
2503	0	O
2503	.	O
2503	00	O
2503	)	O
2503	and	O
2503	localize	O
2503	the	O
2503	TIMP	O
2503	,	O
2503	OATL1	O
2503	,	O
2503	DXS255	O
2503	,	O
2503	and	O
2503	WAS	B-Disease
2503	loci	O
2503	distal	O
2503	to	O
2503	DXS146	O
2503	and	O
2503	the	O
2503	OATL1	O
2503	and	O
2503	WAS	B-Disease
2503	loci	O
2503	proximal	O
2503	to	O
2503	TIMP	O
2503	.	O
2504	These	O
2504	linkage	O
2504	data	O
2504	narrow	O
2504	the	O
2504	boundaries	O
2504	within	O
2504	which	O
2504	the	O
2504	WAS	B-Disease
2504	locus	O
2504	maps	O
2504	to	O
2504	the	O
2504	chromosomal	O
2504	region	O
2504	bracketed	O
2504	by	O
2504	TIMP	O
2504	and	O
2504	DXS146	O
2504	and	O
2504	support	O
2504	the	O
2504	loci	O
2504	order	O
2504	Xpter	O
2504	-	O
2504	DXS7	O
2504	-	O
2504	TIMP	O
2504	-	O
2504	(	O
2504	OATL1	O
2504	,	O
2504	WAS	O
2504	,	O
2504	DXS255	O
2504	)	O
2504	-	O
2504	DXS146	O
2504	.	O
2505	Detection	O
2505	of	O
2505	an	O
2505	unstable	O
2505	fragment	O
2505	of	O
2505	DNA	O
2505	specific	O
2505	to	O
2505	individuals	O
2505	with	O
2505	myotonic	B-Disease
2505	dystrophy	I-Disease
2505	.	O
2506	Myotonic	B-Disease
2506	dystrophy	I-Disease
2506	(	O
2506	DM	B-Disease
2506	)	O
2506	is	O
2506	the	O
2506	most	O
2506	common	O
2506	form	O
2506	of	O
2506	adult	O
2506	muscular	B-Disease
2506	dystrophy	I-Disease
2506	,	O
2506	with	O
2506	a	O
2506	prevalence	O
2506	of	O
2506	2	O
2506	-	O
2506	14	O
2506	per	O
2506	100	O
2506	,	O
2506	000	O
2506	individuals	O
2506	.	O
2507	The	O
2507	disease	O
2507	is	O
2507	characterized	O
2507	by	O
2507	progressive	O
2507	muscle	B-Disease
2507	weakness	I-Disease
2507	and	O
2507	sustained	B-Disease
2507	muscle	I-Disease
2507	contraction	I-Disease
2507	,	O
2507	often	O
2507	with	O
2507	a	O
2507	wide	O
2507	range	O
2507	of	O
2507	accompanying	O
2507	symptoms	O
2507	.	O
2508	The	O
2508	age	O
2508	at	O
2508	onset	O
2508	and	O
2508	severity	O
2508	of	O
2508	the	O
2508	disease	O
2508	show	O
2508	extreme	O
2508	variation	O
2508	,	O
2508	both	O
2508	within	O
2508	and	O
2508	between	O
2508	families	O
2508	.	O
2509	Despite	O
2509	its	O
2509	clinical	O
2509	variability	O
2509	,	O
2509	this	O
2509	dominant	O
2509	condition	O
2509	segregates	O
2509	as	O
2509	a	O
2509	single	O
2509	locus	O
2509	at	O
2509	chromosome	O
2509	19q13	O
2509	.	O
2510	3	O
2510	in	O
2510	every	O
2510	population	O
2510	studied	O
2510	.	O
2511	It	O
2511	is	O
2511	flanked	O
2511	by	O
2511	the	O
2511	tightly	O
2511	linked	O
2511	genetic	O
2511	markers	O
2511	ERCC1	O
2511	proximally	O
2511	and	O
2511	D19S51	O
2511	distally	O
2511	;	O
2511	these	O
2511	define	O
2511	the	O
2511	DM	B-Disease
2511	critical	O
2511	region	O
2511	.	O
2512	We	O
2512	report	O
2512	the	O
2512	isolation	O
2512	of	O
2512	an	O
2512	expressed	O
2512	sequence	O
2512	from	O
2512	this	O
2512	region	O
2512	which	O
2512	detects	O
2512	a	O
2512	DNA	O
2512	fragment	O
2512	that	O
2512	is	O
2512	larger	O
2512	in	O
2512	affected	O
2512	individuals	O
2512	than	O
2512	in	O
2512	normal	O
2512	siblings	O
2512	or	O
2512	unaffected	O
2512	controls	O
2512	.	O
2513	The	O
2513	size	O
2513	of	O
2513	this	O
2513	fragment	O
2513	varies	O
2513	between	O
2513	affected	O
2513	siblings	O
2513	,	O
2513	and	O
2513	increases	O
2513	in	O
2513	size	O
2513	through	O
2513	generations	O
2513	in	O
2513	parallel	O
2513	with	O
2513	increasing	O
2513	severity	O
2513	of	O
2513	the	O
2513	disease	O
2513	.	O
2514	We	O
2514	postulate	O
2514	that	O
2514	this	O
2514	unstable	O
2514	DNA	O
2514	sequence	O
2514	is	O
2514	the	O
2514	molecular	O
2514	feature	O
2514	that	O
2514	underlies	O
2514	DM	B-Disease
2514	.	O
2515	Common	O
2515	sequence	O
2515	motifs	O
2515	at	O
2515	the	O
2515	rearrangement	O
2515	sites	O
2515	of	O
2515	a	O
2515	constitutional	O
2515	X	O
2515	/	O
2515	autosome	O
2515	translocation	O
2515	and	O
2515	associated	O
2515	deletion	O
2515	.	O
2516	Reciprocal	O
2516	chromosome	O
2516	translocations	O
2516	are	O
2516	common	O
2516	de	O
2516	novo	O
2516	rearrangements	O
2516	that	O
2516	occur	O
2516	randomly	O
2516	throughout	O
2516	the	O
2516	human	O
2516	genome	O
2516	.	O
2517	To	O
2517	learn	O
2517	about	O
2517	causative	O
2517	mechanisms	O
2517	,	O
2517	we	O
2517	have	O
2517	cloned	O
2517	and	O
2517	sequenced	O
2517	the	O
2517	breakpoints	O
2517	of	O
2517	a	O
2517	cytologically	O
2517	balanced	O
2517	constitutional	O
2517	reciprocal	O
2517	translocation	O
2517	,	O
2517	t	O
2517	(	O
2517	X	O
2517	;	O
2517	4	O
2517	)	O
2517	(	O
2517	p21	O
2517	.	O
2517	2	O
2517	;	O
2517	q31	O
2517	.	O
2517	22	O
2517	)	O
2517	,	O
2517	present	O
2517	in	O
2517	a	O
2517	girl	O
2517	with	O
2517	Duchenne	B-Disease
2517	muscular	I-Disease
2517	dystrophy	I-Disease
2517	(	O
2517	DMD	B-Disease
2517	)	O
2517	.	O
2518	Physical	O
2518	mapping	O
2518	of	O
2518	the	O
2518	derivative	O
2518	chromosomes	O
2518	,	O
2518	after	O
2518	their	O
2518	separation	O
2518	in	O
2518	somatic	O
2518	cell	O
2518	hybrids	O
2518	,	O
2518	reveals	O
2518	that	O
2518	the	O
2518	translocation	O
2518	disrupts	O
2518	the	O
2518	DMD	B-Disease
2518	gene	O
2518	in	O
2518	Xp21	O
2518	within	O
2518	the	O
2518	18	O
2518	-	O
2518	kb	O
2518	intron	O
2518	16	O
2518	.	O
2519	Restriction	O
2519	mapping	O
2519	and	O
2519	sequencing	O
2519	of	O
2519	clones	O
2519	that	O
2519	span	O
2519	both	O
2519	translocation	O
2519	breakpoints	O
2519	as	O
2519	well	O
2519	as	O
2519	the	O
2519	corresponding	O
2519	normal	O
2519	regions	O
2519	indicate	O
2519	the	O
2519	loss	O
2519	of	O
2519	approximately	O
2519	5	O
2519	kb	O
2519	in	O
2519	the	O
2519	formation	O
2519	of	O
2519	the	O
2519	derivative	O
2519	X	O
2519	chromosome	O
2519	,	O
2519	with	O
2519	4	O
2519	-	O
2519	6	O
2519	bp	O
2519	deleted	O
2519	from	O
2519	chromosome	O
2519	4	O
2519	.	O
2520	RFLP	O
2520	and	O
2520	Southern	O
2520	analyses	O
2520	indicate	O
2520	that	O
2520	the	O
2520	de	O
2520	novo	O
2520	translocation	O
2520	is	O
2520	a	O
2520	paternal	O
2520	origin	O
2520	and	O
2520	that	O
2520	the	O
2520	fathers	O
2520	X	O
2520	chromosome	O
2520	contains	O
2520	the	O
2520	DNA	O
2520	that	O
2520	is	O
2520	deleted	O
2520	in	O
2520	the	O
2520	derivative	O
2520	X	O
2520	.	O
2521	Most	O
2521	likely	O
2521	,	O
2521	deletion	O
2521	and	O
2521	translation	O
2521	arose	O
2521	simultaneously	O
2521	from	O
2521	a	O
2521	complex	O
2521	rearrangement	O
2521	event	O
2521	that	O
2521	involves	O
2521	three	O
2521	chromosomal	O
2521	breakpoints	O
2521	.	O
2522	Short	O
2522	regions	O
2522	of	O
2522	sequence	O
2522	homology	O
2522	were	O
2522	present	O
2522	at	O
2522	the	O
2522	three	O
2522	sites	O
2522	.	O
2523	A	O
2523	5	O
2523	-	O
2523	bp	O
2523	sequence	O
2523	,	O
2523	GGAAT	O
2523	,	O
2523	found	O
2523	exactly	O
2523	at	O
2523	the	O
2523	translocation	O
2523	breakpoints	O
2523	on	O
2523	both	O
2523	normal	O
2523	chromosomes	O
2523	X	O
2523	and	O
2523	4	O
2523	,	O
2523	has	O
2523	been	O
2523	preserved	O
2523	only	O
2523	on	O
2523	the	O
2523	der	O
2523	(	O
2523	4	O
2523	)	O
2523	chromosome	O
2523	.	O
2524	It	O
2524	is	O
2524	likely	O
2524	that	O
2524	the	O
2524	X	O
2524	-	O
2524	derived	O
2524	sequence	O
2524	GGAATCA	O
2524	has	O
2524	been	O
2524	lost	O
2524	in	O
2524	the	O
2524	formation	O
2524	of	O
2524	the	O
2524	der	O
2524	(	O
2524	X	O
2524	)	O
2524	chromosome	O
2524	,	O
2524	as	O
2524	it	O
2524	matches	O
2524	an	O
2524	inverted	O
2524	GAATCA	O
2524	sequence	O
2524	present	O
2524	on	O
2524	the	O
2524	opposite	O
2524	strand	O
2524	exactly	O
2524	at	O
2524	the	O
2524	other	O
2524	end	O
2524	of	O
2524	the	O
2524	deleted	O
2524	5	O
2524	-	O
2524	kb	O
2524	fragment	O
2524	.	O
2525	A	O
2525	genetic	O
2525	etiology	O
2525	for	O
2525	DiGeorge	B-Disease
2525	syndrome	I-Disease
2525	:	O
2525	consistent	O
2525	deletions	O
2525	and	O
2525	microdeletions	O
2525	of	O
2525	22q11	O
2525	.	O
2526	DiGeorge	B-Disease
2526	syndrome	I-Disease
2526	(	O
2526	DGS	B-Disease
2526	)	O
2526	,	O
2526	a	O
2526	developmental	O
2526	field	O
2526	defect	O
2526	of	O
2526	the	O
2526	third	O
2526	and	O
2526	fourth	O
2526	pharyngeal	O
2526	pouches	O
2526	,	O
2526	is	O
2526	characterized	O
2526	by	O
2526	aplasia	B-Disease
2526	or	I-Disease
2526	hypoplasia	I-Disease
2526	of	I-Disease
2526	the	I-Disease
2526	thymus	I-Disease
2526	and	I-Disease
2526	parathyroid	I-Disease
2526	glands	I-Disease
2526	and	O
2526	by	O
2526	conotruncal	B-Disease
2526	cardiac	I-Disease
2526	malformations	I-Disease
2526	.	O
2527	Cytogenetic	O
2527	studies	O
2527	support	O
2527	the	O
2527	presence	O
2527	of	O
2527	a	O
2527	DGS	B-Disease
2527	critical	O
2527	region	O
2527	in	O
2527	band	O
2527	22q11	O
2527	.	O
2528	In	O
2528	the	O
2528	present	O
2528	study	O
2528	,	O
2528	we	O
2528	report	O
2528	the	O
2528	results	O
2528	of	O
2528	clinical	O
2528	,	O
2528	cytogenetic	O
2528	,	O
2528	and	O
2528	molecular	O
2528	studies	O
2528	of	O
2528	14	O
2528	patients	O
2528	with	O
2528	DGS	B-Disease
2528	.	O
2529	Chromosome	O
2529	analysis	O
2529	,	O
2529	utilizing	O
2529	high	O
2529	-	O
2529	resolution	O
2529	banding	O
2529	techniques	O
2529	,	O
2529	detected	O
2529	interstitial	O
2529	deletions	O
2529	in	O
2529	five	O
2529	probands	O
2529	and	O
2529	was	O
2529	inconclusive	O
2529	for	O
2529	a	O
2529	deletion	O
2529	in	O
2529	three	O
2529	probands	O
2529	.	O
2530	The	O
2530	remaining	O
2530	six	O
2530	patients	O
2530	had	O
2530	normal	O
2530	karyotypes	O
2530	.	O
2531	In	O
2531	contrast	O
2531	,	O
2531	molecular	O
2531	analysis	O
2531	detected	O
2531	DNA	O
2531	deletions	O
2531	in	O
2531	all	O
2531	14	O
2531	probands	O
2531	.	O
2532	Two	O
2532	of	O
2532	10	O
2532	loci	O
2532	tested	O
2532	,	O
2532	D22S75	O
2532	and	O
2532	D22S259	O
2532	,	O
2532	are	O
2532	deleted	O
2532	in	O
2532	all	O
2532	14	O
2532	patients	O
2532	.	O
2533	A	O
2533	third	O
2533	locus	O
2533	,	O
2533	D22S66	O
2533	,	O
2533	is	O
2533	deleted	O
2533	in	O
2533	the	O
2533	eight	O
2533	DGS	B-Disease
2533	probands	O
2533	tested	O
2533	.	O
2534	Physical	O
2534	mapping	O
2534	using	O
2534	somatic	O
2534	cell	O
2534	hybrids	O
2534	places	O
2534	D22S66	O
2534	between	O
2534	D22S75	O
2534	and	O
2534	D22S259	O
2534	,	O
2534	suggesting	O
2534	that	O
2534	it	O
2534	should	O
2534	be	O
2534	deleted	O
2534	in	O
2534	the	O
2534	remaining	O
2534	six	O
2534	cases	O
2534	.	O
2535	Parent	O
2535	-	O
2535	of	O
2535	-	O
2535	origin	O
2535	studies	O
2535	were	O
2535	performed	O
2535	in	O
2535	five	O
2535	families	O
2535	.	O
2536	Four	O
2536	probands	O
2536	failed	O
2536	to	O
2536	inherit	O
2536	a	O
2536	maternal	O
2536	allele	O
2536	,	O
2536	and	O
2536	one	O
2536	failed	O
2536	to	O
2536	inherit	O
2536	a	O
2536	paternal	O
2536	allele	O
2536	.	O
2537	On	O
2537	the	O
2537	basis	O
2537	of	O
2537	these	O
2537	families	O
2537	,	O
2537	and	O
2537	of	O
2537	six	O
2537	maternally	O
2537	and	O
2537	five	O
2537	paternally	O
2537	derived	O
2537	unbalanced	O
2537	-	O
2537	translocation	O
2537	DGS	B-Disease
2537	probands	O
2537	in	O
2537	the	O
2537	literature	O
2537	,	O
2537	parent	O
2537	of	O
2537	origin	O
2537	or	O
2537	imprinting	O
2537	does	O
2537	not	O
2537	appear	O
2537	to	O
2537	play	O
2537	an	O
2537	important	O
2537	role	O
2537	in	O
2537	the	O
2537	pathogenesis	O
2537	of	O
2537	DGS	B-Disease
2537	.	O
2538	Deletion	O
2538	of	O
2538	the	O
2538	same	O
2538	three	O
2538	loci	O
2538	in	O
2538	all	O
2538	14	O
2538	DGS	B-Disease
2538	probands	O
2538	begins	O
2538	to	O
2538	delineate	O
2538	the	O
2538	region	O
2538	of	O
2538	chromosome	O
2538	22	O
2538	critical	O
2538	for	O
2538	DGS	B-Disease
2538	and	O
2538	confirms	O
2538	the	O
2538	hypothesis	O
2538	that	O
2538	submicroscopic	O
2538	deletions	O
2538	of	O
2538	22q11	O
2538	are	O
2538	etiologic	O
2538	in	O
2538	the	O
2538	vast	O
2538	majority	O
2538	of	O
2538	cases	O
2538	.	O
2538	.	O
2539	Loss	O
2539	of	O
2539	normal	O
2539	allele	O
2539	of	O
2539	the	O
2539	APC	B-Disease
2539	gene	O
2539	in	O
2539	an	O
2539	adrenocortical	B-Disease
2539	carcinoma	I-Disease
2539	from	O
2539	a	O
2539	patient	O
2539	with	O
2539	familial	B-Disease
2539	adenomatous	I-Disease
2539	polyposis	I-Disease
2539	.	O
2540	Endocrine	B-Disease
2540	neoplasms	I-Disease
2540	have	O
2540	been	O
2540	reported	O
2540	occasionally	O
2540	in	O
2540	patients	O
2540	with	O
2540	familial	B-Disease
2540	adenomatous	I-Disease
2540	polyposis	I-Disease
2540	(	O
2540	FAP	B-Disease
2540	)	O
2540	.	O
2541	An	O
2541	adrenocorotical	B-Disease
2541	carcinoma	I-Disease
2541	was	O
2541	studied	O
2541	in	O
2541	a	O
2541	patient	O
2541	with	O
2541	a	O
2541	family	O
2541	history	O
2541	of	O
2541	FAP	B-Disease
2541	.	O
2542	Loss	O
2542	of	O
2542	heterozygosity	O
2542	(	O
2542	LOH	O
2542	)	O
2542	in	O
2542	the	O
2542	region	O
2542	close	O
2542	to	O
2542	the	O
2542	adenomatous	B-Disease
2542	polyposis	I-Disease
2542	coli	I-Disease
2542	(	O
2542	APC	B-Disease
2542	)	O
2542	gene	O
2542	was	O
2542	detected	O
2542	in	O
2542	this	O
2542	carcinoma	B-Disease
2542	,	O
2542	and	O
2542	evidence	O
2542	was	O
2542	obtained	O
2542	that	O
2542	there	O
2542	was	O
2542	a	O
2542	loss	O
2542	of	O
2542	the	O
2542	normal	O
2542	allele	O
2542	of	O
2542	the	O
2542	APC	B-Disease
2542	gene	O
2542	.	O
2543	This	O
2543	is	O
2543	the	O
2543	first	O
2543	demonstration	O
2543	of	O
2543	LOH	O
2543	at	O
2543	the	O
2543	APC	B-Disease
2543	locus	O
2543	in	O
2543	adrenocortical	B-Disease
2543	tumors	I-Disease
2543	.	O
2544	The	O
2544	present	O
2544	results	O
2544	and	O
2544	our	O
2544	previous	O
2544	data	O
2544	on	O
2544	LOH	O
2544	in	O
2544	a	O
2544	recurring	O
2544	desmoid	B-Disease
2544	tumor	I-Disease
2544	suggest	O
2544	that	O
2544	the	O
2544	heterozygous	O
2544	mutant	O
2544	/	O
2544	wild	O
2544	-	O
2544	type	O
2544	condition	O
2544	of	O
2544	the	O
2544	APC	B-Disease
2544	gene	O
2544	may	O
2544	give	O
2544	rise	O
2544	to	O
2544	benign	B-Disease
2544	tumors	I-Disease
2544	,	O
2544	and	O
2544	that	O
2544	functional	O
2544	loss	O
2544	of	O
2544	this	O
2544	gene	O
2544	leads	O
2544	to	O
2544	development	O
2544	of	O
2544	tumors	B-Disease
2544	not	O
2544	only	O
2544	in	O
2544	the	O
2544	colon	O
2544	but	O
2544	also	O
2544	in	O
2544	other	O
2544	various	O
2544	parts	O
2544	of	O
2544	the	O
2544	body	O
2544	in	O
2544	FAP	B-Disease
2544	patients	O
2544	.	O
2544	.	O
2545	Oncogenic	O
2545	point	O
2545	mutations	O
2545	in	O
2545	exon	O
2545	20	O
2545	of	O
2545	the	O
2545	RB1	O
2545	gene	O
2545	in	O
2545	families	O
2545	showing	O
2545	incomplete	O
2545	penetrance	O
2545	and	O
2545	mild	O
2545	expression	O
2545	of	O
2545	the	O
2545	retinoblastoma	B-Disease
2545	phenotype	O
2545	.	O
2546	The	O
2546	retinoblastoma	B-Disease
2546	-	O
2546	predisposition	O
2546	gene	O
2546	,	O
2546	RB1	O
2546	,	O
2546	segregates	O
2546	as	O
2546	an	O
2546	autosomal	O
2546	dominant	O
2546	trait	O
2546	with	O
2546	high	O
2546	(	O
2546	90	O
2546	%	O
2546	)	O
2546	penetrance	O
2546	.	O
2547	Certain	O
2547	families	O
2547	,	O
2547	however	O
2547	,	O
2547	show	O
2547	an	O
2547	unusual	O
2547	low	O
2547	-	O
2547	penetrance	O
2547	phenotype	O
2547	with	O
2547	many	O
2547	individuals	O
2547	being	O
2547	unaffected	O
2547	,	O
2547	unilaterally	O
2547	affected	O
2547	,	O
2547	or	O
2547	with	O
2547	evidence	O
2547	of	O
2547	spontaneously	O
2547	regressed	O
2547	tumors	B-Disease
2547	.	O
2548	We	O
2548	have	O
2548	used	O
2548	single	O
2548	-	O
2548	strand	O
2548	conformation	O
2548	polymorphism	O
2548	analysis	O
2548	and	O
2548	PCR	O
2548	sequencing	O
2548	to	O
2548	study	O
2548	two	O
2548	such	O
2548	families	O
2548	.	O
2549	Mutations	O
2549	were	O
2549	found	O
2549	in	O
2549	exon	O
2549	20	O
2549	of	O
2549	RB1	O
2549	in	O
2549	both	O
2549	cases	O
2549	.	O
2550	In	O
2550	one	O
2550	family	O
2550	a	O
2550	C	O
2550	-	O
2550	-	O
2550	-	O
2550	-	O
2550	T	O
2550	transition	O
2550	in	O
2550	codon	O
2550	661	O
2550	converts	O
2550	an	O
2550	arginine	O
2550	(	O
2550	CGG	O
2550	)	O
2550	to	O
2550	a	O
2550	tryptophan	O
2550	(	O
2550	TGG	O
2550	)	O
2550	codon	O
2550	.	O
2551	In	O
2551	this	O
2551	family	O
2551	,	O
2551	incomplete	O
2551	penetrance	O
2551	and	O
2551	mild	O
2551	phenotypic	O
2551	expression	O
2551	were	O
2551	observed	O
2551	in	O
2551	virtually	O
2551	all	O
2551	patients	O
2551	,	O
2551	possibly	O
2551	indicating	O
2551	that	O
2551	single	O
2551	amino	O
2551	acid	O
2551	changes	O
2551	may	O
2551	modify	O
2551	protein	O
2551	structure	O
2551	/	O
2551	function	O
2551	such	O
2551	that	O
2551	tumorigenesis	O
2551	is	O
2551	not	O
2551	inevitable	O
2551	.	O
2552	In	O
2552	the	O
2552	second	O
2552	family	O
2552	the	O
2552	mutation	O
2552	in	O
2552	codon	O
2552	675	O
2552	is	O
2552	a	O
2552	G	O
2552	-	O
2552	-	O
2552	-	O
2552	-	O
2552	T	O
2552	transversion	O
2552	that	O
2552	converts	O
2552	a	O
2552	glutamine	O
2552	(	O
2552	GAA	O
2552	)	O
2552	to	O
2552	a	O
2552	stop	O
2552	(	O
2552	TAA	O
2552	)	O
2552	codon	O
2552	.	O
2553	However	O
2553	,	O
2553	this	O
2553	mutation	O
2553	also	O
2553	occurs	O
2553	near	O
2553	a	O
2553	potential	O
2553	cryptic	O
2553	splice	O
2553	acceptor	O
2553	site	O
2553	,	O
2553	raising	O
2553	the	O
2553	possibility	O
2553	of	O
2553	alternative	O
2553	splicing	O
2553	resulting	O
2553	in	O
2553	a	O
2553	less	O
2553	severely	O
2553	disrupted	O
2553	protein	O
2553	.	O
2553	.	O
2554	Late	O
2554	-	O
2554	onset	O
2554	metachromatic	B-Disease
2554	leukodystrophy	I-Disease
2554	:	O
2554	molecular	O
2554	pathology	O
2554	in	O
2554	two	O
2554	siblings	O
2554	.	O
2555	We	O
2555	report	O
2555	on	O
2555	a	O
2555	new	O
2555	allele	O
2555	at	O
2555	the	O
2555	arylsulfatase	O
2555	A	O
2555	(	O
2555	ARSA	O
2555	)	O
2555	locus	O
2555	causing	O
2555	late	O
2555	-	O
2555	onset	O
2555	metachromatic	B-Disease
2555	leukodystrophy	I-Disease
2555	(	O
2555	MLD	B-Disease
2555	)	O
2555	.	O
2556	In	O
2556	that	O
2556	allele	O
2556	arginine84	O
2556	,	O
2556	a	O
2556	residue	O
2556	that	O
2556	is	O
2556	highly	O
2556	conserved	O
2556	in	O
2556	the	O
2556	arylsulfatase	O
2556	gene	O
2556	family	O
2556	,	O
2556	is	O
2556	replaced	O
2556	by	O
2556	glutamine	O
2556	.	O
2557	In	O
2557	contrast	O
2557	to	O
2557	alleles	O
2557	that	O
2557	cause	O
2557	early	O
2557	-	O
2557	onset	O
2557	MLD	B-Disease
2557	,	O
2557	the	O
2557	arginine84	O
2557	to	O
2557	glutamine	O
2557	substitution	O
2557	is	O
2557	associated	O
2557	with	O
2557	some	O
2557	residual	O
2557	ARSA	O
2557	activity	O
2557	.	O
2558	A	O
2558	comparison	O
2558	of	O
2558	genotypes	O
2558	,	O
2558	ARSA	O
2558	activities	O
2558	,	O
2558	and	O
2558	clinical	O
2558	data	O
2558	on	O
2558	4	O
2558	individuals	O
2558	carrying	O
2558	the	O
2558	allele	O
2558	of	O
2558	81	O
2558	patients	O
2558	with	O
2558	MLD	B-Disease
2558	examined	O
2558	,	O
2558	further	O
2558	validates	O
2558	the	O
2558	concept	O
2558	that	O
2558	different	O
2558	degrees	O
2558	of	O
2558	residual	O
2558	ARSA	O
2558	activity	O
2558	are	O
2558	the	O
2558	basis	O
2558	of	O
2558	phenotypical	O
2558	variation	O
2558	in	O
2558	MLD	B-Disease
2558	.	O
2558	.	O
2559	Trisomy	B-Disease
2559	15	I-Disease
2559	with	O
2559	loss	O
2559	of	O
2559	the	O
2559	paternal	O
2559	15	O
2559	as	O
2559	a	O
2559	cause	O
2559	of	O
2559	Prader	B-Disease
2559	-	I-Disease
2559	Willi	I-Disease
2559	syndrome	I-Disease
2559	due	O
2559	to	O
2559	maternal	B-Disease
2559	disomy	I-Disease
2559	.	O
2560	Uniparental	B-Disease
2560	disomy	I-Disease
2560	has	O
2560	recently	O
2560	been	O
2560	recognized	O
2560	to	O
2560	cause	O
2560	human	O
2560	disorders	O
2560	,	O
2560	including	O
2560	Prader	B-Disease
2560	-	I-Disease
2560	Willi	I-Disease
2560	syndrome	I-Disease
2560	(	O
2560	PWS	B-Disease
2560	)	O
2560	.	O
2561	We	O
2561	describe	O
2561	a	O
2561	particularly	O
2561	instructive	O
2561	case	O
2561	which	O
2561	raises	O
2561	important	O
2561	issues	O
2561	concerning	O
2561	the	O
2561	mechanisms	O
2561	producing	O
2561	uniparental	B-Disease
2561	disomy	I-Disease
2561	and	O
2561	whose	O
2561	evaluation	O
2561	provides	O
2561	evidence	O
2561	that	O
2561	trisomy	O
2561	may	O
2561	precede	O
2561	uniparental	B-Disease
2561	disomy	I-Disease
2561	in	O
2561	a	O
2561	fetus	O
2561	.	O
2562	Chorionic	O
2562	villus	O
2562	sampling	O
2562	performed	O
2562	for	O
2562	advanced	O
2562	maternal	O
2562	age	O
2562	revealed	O
2562	trisomy	B-Disease
2562	15	I-Disease
2562	in	O
2562	all	O
2562	direct	O
2562	and	O
2562	cultured	O
2562	cells	O
2562	,	O
2562	though	O
2562	the	O
2562	fetus	O
2562	appeared	O
2562	normal	O
2562	.	O
2563	Chromosome	O
2563	analysis	O
2563	of	O
2563	amniocytes	O
2563	obtained	O
2563	at	O
2563	15	O
2563	wk	O
2563	was	O
2563	normal	O
2563	in	O
2563	over	O
2563	100	O
2563	cells	O
2563	studied	O
2563	.	O
2564	The	O
2564	child	O
2564	was	O
2564	hypotonic	B-Disease
2564	at	O
2564	birth	O
2564	,	O
2564	and	O
2564	high	O
2564	-	O
2564	resolution	O
2564	banding	O
2564	failed	O
2564	to	O
2564	reveal	O
2564	the	O
2564	deletion	O
2564	of	O
2564	15q11	O
2564	-	O
2564	13	O
2564	,	O
2564	a	O
2564	deletion	O
2564	which	O
2564	is	O
2564	found	O
2564	in	O
2564	50	O
2564	%	O
2564	-	O
2564	70	O
2564	%	O
2564	of	O
2564	patients	O
2564	with	O
2564	PWS	B-Disease
2564	.	O
2565	Over	O
2565	time	O
2565	,	O
2565	typical	O
2565	features	O
2565	of	O
2565	PWS	B-Disease
2565	developed	O
2565	.	O
2566	Molecular	O
2566	genetic	O
2566	analysis	O
2566	using	O
2566	probes	O
2566	for	O
2566	chromosome	O
2566	15	O
2566	revealed	O
2566	maternal	O
2566	disomy	O
2566	.	O
2567	Maternal	O
2567	nondisjunction	O
2567	with	O
2567	fertilization	O
2567	of	O
2567	a	O
2567	disomic	O
2567	egg	O
2567	by	O
2567	a	O
2567	normal	O
2567	sperm	O
2567	,	O
2567	followed	O
2567	by	O
2567	loss	O
2567	of	O
2567	the	O
2567	paternal	O
2567	15	O
2567	,	O
2567	is	O
2567	a	O
2567	likely	O
2567	cause	O
2567	of	O
2567	confined	O
2567	placental	O
2567	mosaicism	O
2567	and	O
2567	uniparental	B-Disease
2567	disomy	I-Disease
2567	in	O
2567	this	O
2567	case	O
2567	of	O
2567	PWS	B-Disease
2567	,	O
2567	and	O
2567	advanced	O
2567	maternal	O
2567	age	O
2567	may	O
2567	be	O
2567	a	O
2567	predisposing	O
2567	factor	O
2567	.	O
2567	.	O
2568	Genetic	O
2568	heterogeneity	O
2568	in	O
2568	X	B-Disease
2568	-	I-Disease
2568	linked	I-Disease
2568	amelogenesis	I-Disease
2568	imperfecta	I-Disease
2568	.	O
2569	The	O
2569	AMELX	O
2569	gene	O
2569	located	O
2569	at	O
2569	Xp22	O
2569	.	O
2570	1	O
2570	-	O
2570	p22	O
2570	.	O
2571	3	O
2571	encodes	O
2571	for	O
2571	the	O
2571	enamel	O
2571	protein	O
2571	amelogenin	O
2571	and	O
2571	has	O
2571	been	O
2571	implicated	O
2571	as	O
2571	the	O
2571	gene	O
2571	responsible	O
2571	for	O
2571	the	O
2571	inherited	B-Disease
2571	dental	I-Disease
2571	abnormality	I-Disease
2571	X	B-Disease
2571	-	I-Disease
2571	linked	I-Disease
2571	amelogenesis	I-Disease
2571	imperfecta	I-Disease
2571	(	O
2571	XAI	B-Disease
2571	)	O
2571	.	O
2572	Three	O
2572	families	O
2572	with	O
2572	XAI	B-Disease
2572	have	O
2572	been	O
2572	investigated	O
2572	using	O
2572	polymorphic	O
2572	DNA	O
2572	markers	O
2572	flanking	O
2572	the	O
2572	position	O
2572	of	O
2572	AMELX	O
2572	.	O
2573	Using	O
2573	two	O
2573	-	O
2573	point	O
2573	linkage	O
2573	analysis	O
2573	,	O
2573	linkage	O
2573	was	O
2573	established	O
2573	between	O
2573	XAI	B-Disease
2573	and	O
2573	several	O
2573	of	O
2573	these	O
2573	markers	O
2573	in	O
2573	two	O
2573	families	O
2573	,	O
2573	with	O
2573	a	O
2573	combined	O
2573	lod	O
2573	score	O
2573	of	O
2573	6	O
2573	.	O
2574	05	O
2574	for	O
2574	DXS16	O
2574	at	O
2574	theta	O
2574	=	O
2574	0	O
2574	.	O
2575	04	O
2575	04	O
2575	.	O
2576	This	O
2576	supports	O
2576	the	O
2576	involvement	O
2576	of	O
2576	AMELX	O
2576	,	O
2576	located	O
2576	close	O
2576	to	O
2576	DXS16	O
2576	,	O
2576	in	O
2576	the	O
2576	XAI	B-Disease
2576	disease	I-Disease
2576	process	O
2576	(	O
2576	AIH1	O
2576	)	O
2576	in	O
2576	those	O
2576	families	O
2576	.	O
2577	Using	O
2577	multipoint	O
2577	linkage	O
2577	analysis	O
2577	,	O
2577	the	O
2577	combined	O
2577	maximum	O
2577	lod	O
2577	score	O
2577	for	O
2577	these	O
2577	two	O
2577	families	O
2577	was	O
2577	7	O
2577	.	O
2578	30	O
2578	for	O
2578	a	O
2578	location	O
2578	of	O
2578	AIH1	O
2578	at	O
2578	2	O
2578	cM	O
2578	distal	O
2578	to	O
2578	DXS16	O
2578	.	O
2579	The	O
2579	support	O
2579	interval	O
2579	around	O
2579	this	O
2579	location	O
2579	extended	O
2579	about	O
2579	8	O
2579	cM	O
2579	proximal	O
2579	to	O
2579	DXS92	O
2579	,	O
2579	and	O
2579	the	O
2579	AIH1	O
2579	location	O
2579	could	O
2579	not	O
2579	be	O
2579	precisely	O
2579	defined	O
2579	by	O
2579	multipoint	O
2579	mapping	O
2579	.	O
2580	Study	O
2580	of	O
2580	recombination	O
2580	events	O
2580	indicated	O
2580	that	O
2580	AIH1	O
2580	lies	O
2580	in	O
2580	the	O
2580	interval	O
2580	between	O
2580	DXS143	O
2580	and	O
2580	DXS85	O
2580	.	O
2581	There	O
2581	was	O
2581	significant	O
2581	evidence	O
2581	against	O
2581	linkage	O
2581	to	O
2581	this	O
2581	region	O
2581	in	O
2581	the	O
2581	third	O
2581	family	O
2581	,	O
2581	indicating	O
2581	locus	O
2581	heterogeneity	O
2581	in	O
2581	XAI	B-Disease
2581	.	O
2582	Further	O
2582	analysis	O
2582	with	O
2582	markers	O
2582	on	O
2582	the	O
2582	long	O
2582	arm	O
2582	of	O
2582	the	O
2582	X	O
2582	chromosome	O
2582	showed	O
2582	evidence	O
2582	of	O
2582	linkage	O
2582	to	O
2582	DXS144E	O
2582	and	O
2582	F9	O
2582	with	O
2582	no	O
2582	recombination	O
2582	with	O
2582	either	O
2582	of	O
2582	these	O
2582	markers	O
2582	.	O
2583	Two	O
2583	-	O
2583	point	O
2583	analysis	O
2583	gave	O
2583	a	O
2583	peak	O
2583	lod	O
2583	score	O
2583	at	O
2583	DXS144E	O
2583	with	O
2583	a	O
2583	maximum	O
2583	lod	O
2583	score	O
2583	of	O
2583	2	O
2583	.	O
2584	83	O
2584	at	O
2584	theta	O
2584	=	O
2584	0	O
2584	,	O
2584	with	O
2584	a	O
2584	peak	O
2584	lod	O
2584	score	O
2584	in	O
2584	multipoint	O
2584	linkage	O
2584	analysis	O
2584	of	O
2584	2	O
2584	.	O
2585	84	O
2585	at	O
2585	theta	O
2585	=	O
2585	0	O
2585	.	O
2586	The	O
2586	support	O
2586	interval	O
2586	extended	O
2586	9	O
2586	cM	O
2586	proximal	O
2586	to	O
2586	DXS144E	O
2586	and	O
2586	14	O
2586	cM	O
2586	distal	O
2586	to	O
2586	F9	O
2586	.	O
2587	(	O
2587	ABSTRACT	O
2587	TRUNCATED	O
2587	AT	O
2587	250	O
2587	WORDS	O
2587	)	O
2587	.	O
2588	Multiple	O
2588	origins	O
2588	for	O
2588	phenylketonuria	B-Disease
2588	in	O
2588	Europe	O
2588	.	O
2589	Phenylketonuria	B-Disease
2589	(	O
2589	PKU	B-Disease
2589	)	O
2589	,	O
2589	a	O
2589	disorder	B-Disease
2589	of	I-Disease
2589	amino	I-Disease
2589	acid	I-Disease
2589	metabolism	I-Disease
2589	prevalent	O
2589	among	O
2589	Caucasians	O
2589	and	O
2589	other	O
2589	ethnic	O
2589	groups	O
2589	,	O
2589	is	O
2589	caused	O
2589	primarily	O
2589	by	O
2589	a	O
2589	deficiency	B-Disease
2589	of	I-Disease
2589	the	I-Disease
2589	hepatic	I-Disease
2589	enzyme	I-Disease
2589	phenylalanine	I-Disease
2589	hydroxylase	I-Disease
2589	(	O
2589	PAH	O
2589	)	O
2589	.	O
2590	PKU	B-Disease
2590	is	O
2590	a	O
2590	highly	O
2590	heterogeneous	O
2590	disorder	O
2590	,	O
2590	with	O
2590	more	O
2590	than	O
2590	60	O
2590	molecular	O
2590	lesions	O
2590	identified	O
2590	in	O
2590	the	O
2590	PAH	O
2590	gene	O
2590	.	O
2591	The	O
2591	haplotype	O
2591	associations	O
2591	,	O
2591	relative	O
2591	frequencies	O
2591	,	O
2591	and	O
2591	distributions	O
2591	of	O
2591	five	O
2591	prevalent	O
2591	PAH	O
2591	mutations	O
2591	(	O
2591	R158Q	O
2591	,	O
2591	R261Q	O
2591	,	O
2591	IVS10nt546	O
2591	,	O
2591	R408W	O
2591	,	O
2591	and	O
2591	IVS12n1	O
2591	)	O
2591	were	O
2591	established	O
2591	in	O
2591	a	O
2591	comprehensive	O
2591	European	O
2591	sample	O
2591	population	O
2591	and	O
2591	subsequently	O
2591	were	O
2591	examined	O
2591	to	O
2591	determine	O
2591	the	O
2591	potential	O
2591	roles	O
2591	of	O
2591	several	O
2591	genetic	O
2591	mechanisms	O
2591	in	O
2591	explaining	O
2591	the	O
2591	present	O
2591	distribution	O
2591	of	O
2591	the	O
2591	major	O
2591	PKU	B-Disease
2591	alleles	O
2591	.	O
2592	Each	O
2592	of	O
2592	these	O
2592	five	O
2592	mutations	O
2592	was	O
2592	strongly	O
2592	associated	O
2592	with	O
2592	only	O
2592	one	O
2592	of	O
2592	the	O
2592	more	O
2592	than	O
2592	70	O
2592	chromosomal	O
2592	haplotypes	O
2592	defined	O
2592	by	O
2592	eight	O
2592	RFLPs	O
2592	in	O
2592	or	O
2592	near	O
2592	the	O
2592	PAH	O
2592	gene	O
2592	.	O
2593	These	O
2593	findings	O
2593	suggest	O
2593	that	O
2593	each	O
2593	of	O
2593	these	O
2593	mutations	O
2593	arose	O
2593	through	O
2593	a	O
2593	single	O
2593	founding	O
2593	event	O
2593	that	O
2593	occurred	O
2593	within	O
2593	time	O
2593	periods	O
2593	ranging	O
2593	from	O
2593	several	O
2593	hundred	O
2593	to	O
2593	several	O
2593	thousand	O
2593	years	O
2593	ago	O
2593	.	O
2594	From	O
2594	the	O
2594	significant	O
2594	differences	O
2594	observed	O
2594	in	O
2594	the	O
2594	relative	O
2594	frequencies	O
2594	and	O
2594	distributions	O
2594	of	O
2594	these	O
2594	five	O
2594	alleles	O
2594	throughout	O
2594	Europe	O
2594	,	O
2594	four	O
2594	of	O
2594	these	O
2594	putative	O
2594	founding	O
2594	events	O
2594	could	O
2594	be	O
2594	localized	O
2594	to	O
2594	specific	O
2594	ethnic	O
2594	subgroups	O
2594	.	O
2595	Together	O
2595	,	O
2595	these	O
2595	data	O
2595	suggest	O
2595	that	O
2595	there	O
2595	were	O
2595	multiple	O
2595	,	O
2595	geographically	O
2595	and	O
2595	ethnically	O
2595	distinct	O
2595	origins	O
2595	for	O
2595	PKU	B-Disease
2595	within	O
2595	the	O
2595	European	O
2595	population	O
2595	.	O
2595	.	O
2596	Complement	B-Disease
2596	factor	I-Disease
2596	2	I-Disease
2596	deficiency	I-Disease
2596	:	O
2596	a	O
2596	clinical	O
2596	and	O
2596	serological	O
2596	family	O
2596	study	O
2596	.	O
2597	Inherited	B-Disease
2597	complement	I-Disease
2597	deficiencies	I-Disease
2597	are	O
2597	associated	O
2597	with	O
2597	a	O
2597	variety	O
2597	of	O
2597	connective	O
2597	tissue	O
2597	diseases	O
2597	.	O
2598	A	O
2598	family	O
2598	with	O
2598	inherited	B-Disease
2598	deficiency	I-Disease
2598	of	I-Disease
2598	complement	I-Disease
2598	factor	I-Disease
2598	2	I-Disease
2598	(	O
2598	C2	O
2598	)	O
2598	is	O
2598	described	O
2598	in	O
2598	which	O
2598	two	O
2598	family	O
2598	members	O
2598	with	O
2598	homozygous	O
2598	C2	B-Disease
2598	deficiency	I-Disease
2598	developed	O
2598	cutaneous	B-Disease
2598	vasculitis	I-Disease
2598	and	O
2598	sicca	B-Disease
2598	syndrome	I-Disease
2598	.	O
2599	The	O
2599	other	O
2599	family	O
2599	members	O
2599	had	O
2599	heterozygous	O
2599	C2	B-Disease
2599	deficiency	I-Disease
2599	and	O
2599	each	O
2599	member	O
2599	had	O
2599	the	O
2599	HLA	O
2599	-	O
2599	A25	O
2599	,	O
2599	B18	O
2599	,	O
2599	DR2	O
2599	(	O
2599	w15	O
2599	)	O
2599	haplotype	O
2599	.	O
2600	The	O
2600	mother	O
2600	had	O
2600	seropositive	B-Disease
2600	rheumatoid	I-Disease
2600	arthritis	I-Disease
2600	.	O
2601	Further	O
2601	studies	O
2601	showed	O
2601	the	O
2601	presence	O
2601	of	O
2601	cryoglobulins	O
2601	,	O
2601	antibodies	O
2601	against	O
2601	endothelial	O
2601	cells	O
2601	,	O
2601	and	O
2601	anticardiolipin	O
2601	antibodies	O
2601	.	O
2601	.	O
2602	New	O
2602	variant	O
2602	in	O
2602	exon	O
2602	3	O
2602	of	O
2602	the	O
2602	proteolipid	O
2602	protein	O
2602	(	O
2602	PLP	O
2602	)	O
2602	gene	O
2602	in	O
2602	a	O
2602	family	O
2602	with	O
2602	Pelizaeus	B-Disease
2602	-	I-Disease
2602	Merzbacher	I-Disease
2602	disease	I-Disease
2602	.	O
2603	A	O
2603	C	O
2603	-	O
2603	-	O
2603	greater	O
2603	than	O
2603	G	O
2603	transversion	O
2603	has	O
2603	been	O
2603	found	O
2603	in	O
2603	exon	O
2603	3	O
2603	of	O
2603	the	O
2603	PLP	O
2603	gene	O
2603	of	O
2603	affected	O
2603	males	O
2603	and	O
2603	their	O
2603	mother	O
2603	in	O
2603	a	O
2603	single	O
2603	sibship	O
2603	with	O
2603	Pelizaeus	B-Disease
2603	-	I-Disease
2603	merzbacher	I-Disease
2603	disease	I-Disease
2603	(	O
2603	PMD	B-Disease
2603	)	O
2603	.	O
2604	The	O
2604	transversion	O
2604	should	O
2604	not	O
2604	result	O
2604	in	O
2604	an	O
2604	amino	O
2604	acid	O
2604	change	O
2604	in	O
2604	the	O
2604	protein	O
2604	but	O
2604	it	O
2604	does	O
2604	result	O
2604	in	O
2604	the	O
2604	loss	O
2604	of	O
2604	a	O
2604	HaeIII	O
2604	restriction	O
2604	endonuclease	O
2604	cleavage	O
2604	site	O
2604	.	O
2605	It	O
2605	is	O
2605	concordant	O
2605	with	O
2605	the	O
2605	disease	O
2605	in	O
2605	this	O
2605	family	O
2605	.	O
2606	One	O
2606	-	O
2606	hundred	O
2606	-	O
2606	ten	O
2606	unrelated	O
2606	X	O
2606	chromosomes	O
2606	are	O
2606	negative	O
2606	for	O
2606	this	O
2606	mutation	O
2606	.	O
2607	No	O
2607	other	O
2607	sequence	O
2607	defect	O
2607	was	O
2607	found	O
2607	in	O
2607	the	O
2607	PLP	O
2607	exons	O
2607	of	O
2607	the	O
2607	affected	O
2607	males	O
2607	.	O
2608	The	O
2608	cause	O
2608	of	O
2608	disease	O
2608	in	O
2608	this	O
2608	family	O
2608	remains	O
2608	unknown	O
2608	,	O
2608	but	O
2608	the	O
2608	association	O
2608	between	O
2608	this	O
2608	rare	O
2608	mutation	O
2608	and	O
2608	PMD	B-Disease
2608	is	O
2608	intriguing	O
2608	.	O
2609	The	O
2609	mutation	O
2609	can	O
2609	serve	O
2609	as	O
2609	a	O
2609	marker	O
2609	for	O
2609	following	O
2609	segregation	O
2609	of	O
2609	the	O
2609	PLP	O
2609	gene	O
2609	.	O
2609	.	O
2610	Uncoupling	O
2610	of	O
2610	hypomyelination	B-Disease
2610	and	O
2610	glial	B-Disease
2610	cell	I-Disease
2610	death	I-Disease
2610	by	O
2610	a	O
2610	mutation	O
2610	in	O
2610	the	O
2610	proteolipid	O
2610	protein	O
2610	gene	O
2610	.	O
2611	Proteolipid	O
2611	protein	O
2611	(	O
2611	PLP	O
2611	;	O
2611	M	O
2611	(	O
2611	r	O
2611	)	O
2611	30	O
2611	,	O
2611	000	O
2611	)	O
2611	is	O
2611	a	O
2611	highly	O
2611	conserved	O
2611	major	O
2611	polytopic	O
2611	membrane	O
2611	protein	O
2611	in	O
2611	myelin	O
2611	but	O
2611	its	O
2611	cellular	O
2611	function	O
2611	remains	O
2611	obscure	O
2611	.	O
2612	Neurological	O
2612	mutant	O
2612	mice	O
2612	can	O
2612	often	O
2612	provide	O
2612	model	O
2612	systems	O
2612	for	O
2612	human	O
2612	genetic	B-Disease
2612	disorders	I-Disease
2612	.	O
2613	Mutations	O
2613	of	O
2613	the	O
2613	X	O
2613	-	O
2613	chromosome	O
2613	-	O
2613	linked	O
2613	PLP	O
2613	gene	O
2613	are	O
2613	lethal	O
2613	,	O
2613	identified	O
2613	first	O
2613	in	O
2613	the	O
2613	jimpy	O
2613	mouse	O
2613	and	O
2613	subsequently	O
2613	in	O
2613	patients	O
2613	with	O
2613	Pelizaeus	B-Disease
2613	-	I-Disease
2613	Merzbacher	I-Disease
2613	disease	I-Disease
2613	.	O
2614	The	O
2614	unexplained	O
2614	phenotype	O
2614	of	O
2614	these	O
2614	mutations	O
2614	includes	O
2614	degeneration	B-Disease
2614	and	I-Disease
2614	premature	I-Disease
2614	cell	I-Disease
2614	death	I-Disease
2614	of	I-Disease
2614	oligodendrocytes	I-Disease
2614	with	O
2614	associated	O
2614	hypomyelination	B-Disease
2614	.	O
2615	Here	O
2615	we	O
2615	show	O
2615	that	O
2615	a	O
2615	new	O
2615	mouse	O
2615	mutant	O
2615	rumpshaker	O
2615	is	O
2615	defined	O
2615	by	O
2615	the	O
2615	amino	O
2615	-	O
2615	acid	O
2615	substitution	O
2615	Ile	O
2615	-	O
2615	to	O
2615	-	O
2615	Thr	O
2615	at	O
2615	residue	O
2615	186	O
2615	in	O
2615	a	O
2615	membrane	O
2615	-	O
2615	embedded	O
2615	domain	O
2615	of	O
2615	PLP	O
2615	.	O
2616	Surprisingly	O
2616	,	O
2616	rumpshaker	O
2616	mice	O
2616	,	O
2616	although	O
2616	myelin	B-Disease
2616	-	I-Disease
2616	deficient	I-Disease
2616	,	O
2616	have	O
2616	normal	O
2616	longevity	O
2616	and	O
2616	a	O
2616	full	O
2616	complement	O
2616	of	O
2616	morphologically	O
2616	normal	O
2616	oligodendrocytes	O
2616	.	O
2617	Hypomyelination	B-Disease
2617	can	O
2617	thus	O
2617	be	O
2617	genetically	O
2617	separated	O
2617	from	O
2617	the	O
2617	PLP	O
2617	-	O
2617	dependent	O
2617	oligodendrocyte	B-Disease
2617	degeneration	I-Disease
2617	.	O
2618	We	O
2618	suggest	O
2618	that	O
2618	PLP	O
2618	has	O
2618	a	O
2618	vital	O
2618	function	O
2618	in	O
2618	glial	O
2618	cell	O
2618	development	O
2618	,	O
2618	distinct	O
2618	from	O
2618	its	O
2618	later	O
2618	role	O
2618	in	O
2618	myelin	O
2618	assembly	O
2618	,	O
2618	and	O
2618	that	O
2618	this	O
2618	dichotomy	O
2618	of	O
2618	action	O
2618	may	O
2618	explain	O
2618	the	O
2618	clinical	O
2618	spectrum	O
2618	of	O
2618	Pelizaeus	B-Disease
2618	-	I-Disease
2618	Merzbacher	I-Disease
2618	disease	I-Disease
2618	.	O
2618	.	O
2619	A	O
2619	pseudodeficiency	O
2619	allele	O
2619	common	O
2619	in	O
2619	non	O
2619	-	O
2619	Jewish	O
2619	Tay	B-Disease
2619	-	I-Disease
2619	Sachs	I-Disease
2619	carriers	O
2619	:	O
2619	implications	O
2619	for	O
2619	carrier	O
2619	screening	O
2619	.	O
2620	Deficiency	B-Disease
2620	of	I-Disease
2620	beta	I-Disease
2620	-	I-Disease
2620	hexosaminidase	I-Disease
2620	A	I-Disease
2620	(	O
2620	Hex	O
2620	A	O
2620	)	O
2620	activity	O
2620	typically	O
2620	results	O
2620	in	O
2620	Tay	B-Disease
2620	-	I-Disease
2620	Sachs	I-Disease
2620	disease	I-Disease
2620	.	O
2621	However	O
2621	,	O
2621	healthy	O
2621	subjects	O
2621	found	O
2621	to	O
2621	be	O
2621	deficient	B-Disease
2621	in	I-Disease
2621	Hex	I-Disease
2621	A	I-Disease
2621	activity	O
2621	(	O
2621	i	O
2621	.	O
2621	e	O
2621	.	O
2621	,	O
2621	pseudodeficient	O
2621	)	O
2621	by	O
2621	means	O
2621	of	O
2621	in	O
2621	vitro	O
2621	biochemical	O
2621	tests	O
2621	have	O
2621	been	O
2621	described	O
2621	.	O
2622	We	O
2622	analyzed	O
2622	the	O
2622	HEXA	O
2622	gene	O
2622	of	O
2622	one	O
2622	pseudodeficient	O
2622	subject	O
2622	and	O
2622	identified	O
2622	both	O
2622	a	O
2622	C739	O
2622	-	O
2622	to	O
2622	-	O
2622	T	O
2622	substitution	O
2622	that	O
2622	changes	O
2622	Arg247	O
2622	-	O
2622	-	O
2622	-	O
2622	-	O
2622	Trp	O
2622	on	O
2622	one	O
2622	allele	O
2622	and	O
2622	a	O
2622	previously	O
2622	identified	O
2622	Tay	B-Disease
2622	-	I-Disease
2622	Sachs	I-Disease
2622	disease	I-Disease
2622	mutation	O
2622	on	O
2622	the	O
2622	second	O
2622	allele	O
2622	.	O
2623	Six	O
2623	additional	O
2623	pseudodeficient	O
2623	subjects	O
2623	were	O
2623	found	O
2623	to	O
2623	have	O
2623	the	O
2623	C739	O
2623	-	O
2623	to	O
2623	-	O
2623	T	O
2623	mutation	O
2623	.	O
2624	This	O
2624	allele	O
2624	accounted	O
2624	for	O
2624	32	O
2624	%	O
2624	(	O
2624	20	O
2624	/	O
2624	62	O
2624	)	O
2624	of	O
2624	non	O
2624	-	O
2624	Jewish	O
2624	enzyme	O
2624	-	O
2624	defined	O
2624	Tay	B-Disease
2624	-	I-Disease
2624	Sachs	I-Disease
2624	disease	I-Disease
2624	carriers	O
2624	but	O
2624	for	O
2624	none	O
2624	of	O
2624	36	O
2624	Jewish	O
2624	enzyme	O
2624	-	O
2624	defined	O
2624	carriers	O
2624	who	O
2624	did	O
2624	not	O
2624	have	O
2624	one	O
2624	of	O
2624	three	O
2624	known	O
2624	mutations	O
2624	common	O
2624	to	O
2624	this	O
2624	group	O
2624	.	O
2625	The	O
2625	C739	O
2625	-	O
2625	to	O
2625	-	O
2625	T	O
2625	allele	O
2625	,	O
2625	together	O
2625	with	O
2625	a	O
2625	"	NN	O	O
2625	true	NN	O	O
2625	"	O
2625	Tay	B-Disease
2625	-	I-Disease
2625	Sachs	I-Disease
2625	disease	I-Disease
2625	allele	O
2625	,	O
2625	causes	O
2625	Hex	O
2625	A	O
2625	pseudodeficiency	O
2625	.	O
2626	Given	O
2626	both	O
2626	the	O
2626	large	O
2626	proportion	O
2626	of	O
2626	non	O
2626	-	O
2626	Jewish	O
2626	carriers	O
2626	with	O
2626	this	O
2626	allele	O
2626	and	O
2626	that	O
2626	standard	O
2626	biochemical	O
2626	screening	O
2626	cannot	O
2626	differentiate	O
2626	between	O
2626	heterozygotes	O
2626	for	O
2626	the	O
2626	C739	O
2626	-	O
2626	to	O
2626	-	O
2626	T	O
2626	mutations	O
2626	and	O
2626	Tay	B-Disease
2626	-	I-Disease
2626	Sachs	I-Disease
2626	disease	I-Disease
2626	carriers	O
2626	,	O
2626	DNA	O
2626	testing	O
2626	for	O
2626	this	O
2626	mutation	O
2626	in	O
2626	at	O
2626	-	O
2626	risk	O
2626	couples	O
2626	is	O
2626	essential	O
2626	.	O
2627	Pelizaeus	B-Disease
2627	-	I-Disease
2627	Merzbacher	I-Disease
2627	disease	I-Disease
2627	:	O
2627	detection	O
2627	of	O
2627	mutations	O
2627	Thr181	O
2627	-	O
2627	-	O
2627	-	O
2627	-	O
2627	Pro	O
2627	and	O
2627	Leu223	O
2627	-	O
2627	-	O
2627	-	O
2627	-	O
2627	Pro	O
2627	in	O
2627	the	O
2627	proteolipid	O
2627	protein	O
2627	gene	O
2627	,	O
2627	and	O
2627	prenatal	O
2627	diagnosis	O
2627	.	O
2628	A	O
2628	family	O
2628	with	O
2628	an	O
2628	apparent	O
2628	history	O
2628	of	O
2628	X	O
2628	-	O
2628	linked	O
2628	Pelizaeus	B-Disease
2628	-	I-Disease
2628	Merzbacher	I-Disease
2628	disease	I-Disease
2628	presented	O
2628	for	O
2628	genetic	O
2628	counseling	O
2628	,	O
2628	requesting	O
2628	carrier	O
2628	detection	O
2628	and	O
2628	prenatal	O
2628	diagnosis	O
2628	.	O
2629	RFLP	O
2629	analysis	O
2629	using	O
2629	the	O
2629	proteolipid	O
2629	protein	O
2629	(	O
2629	PLP	O
2629	)	O
2629	gene	O
2629	probe	O
2629	was	O
2629	uninformative	O
2629	in	O
2629	this	O
2629	family	O
2629	.	O
2630	A	O
2630	prenatal	O
2630	diagnosis	O
2630	on	O
2630	a	O
2630	chorionic	O
2630	villus	O
2630	sample	O
2630	(	O
2630	CVS	O
2630	)	O
2630	was	O
2630	carried	O
2630	out	O
2630	using	O
2630	single	O
2630	-	O
2630	strand	O
2630	conformation	O
2630	polymorphism	O
2630	(	O
2630	SSCP	O
2630	)	O
2630	analysis	O
2630	of	O
2630	a	O
2630	variant	O
2630	in	O
2630	exon	O
2630	4	O
2630	of	O
2630	the	O
2630	PLP	O
2630	gene	O
2630	.	O
2631	The	O
2631	fetus	O
2631	was	O
2631	predicted	O
2631	to	O
2631	be	O
2631	unaffected	O
2631	.	O
2632	Sequencing	O
2632	of	O
2632	the	O
2632	exon	O
2632	from	O
2632	the	O
2632	CVS	O
2632	,	O
2632	the	O
2632	predicted	O
2632	-	O
2632	carrier	O
2632	mother	O
2632	,	O
2632	and	O
2632	the	O
2632	obligate	O
2632	-	O
2632	carrier	O
2632	grandmother	O
2632	revealed	O
2632	an	O
2632	A	O
2632	-	O
2632	to	O
2632	-	O
2632	C	O
2632	change	O
2632	at	O
2632	nucleotide	O
2632	541	O
2632	in	O
2632	the	O
2632	two	O
2632	women	O
2632	but	O
2632	not	O
2632	in	O
2632	the	O
2632	fetus	O
2632	.	O
2633	As	O
2633	this	O
2633	change	O
2633	results	O
2633	in	O
2633	a	O
2633	Thr	O
2633	-	O
2633	to	O
2633	-	O
2633	Pro	O
2633	change	O
2633	at	O
2633	amino	O
2633	acid	O
2633	181	O
2633	in	O
2633	a	O
2633	region	O
2633	of	O
2633	the	O
2633	gene	O
2633	predicted	O
2633	to	O
2633	be	O
2633	part	O
2633	of	O
2633	a	O
2633	transmembrane	O
2633	segment	O
2633	,	O
2633	it	O
2633	was	O
2633	concluded	O
2633	that	O
2633	this	O
2633	was	O
2633	the	O
2633	mutation	O
2633	causing	O
2633	the	O
2633	disease	O
2633	in	O
2633	this	O
2633	family	O
2633	.	O
2634	In	O
2634	addition	O
2634	,	O
2634	in	O
2634	a	O
2634	second	O
2634	family	O
2634	,	O
2634	an	O
2634	exon	O
2634	5	O
2634	variant	O
2634	band	O
2634	pattern	O
2634	on	O
2634	SSCP	O
2634	analysis	O
2634	was	O
2634	shown	O
2634	by	O
2634	sequencing	O
2634	to	O
2634	be	O
2634	due	O
2634	to	O
2634	a	O
2634	T	O
2634	-	O
2634	to	O
2634	-	O
2634	C	O
2634	change	O
2634	at	O
2634	nucleotide	O
2634	668	O
2634	.	O
2635	This	O
2635	results	O
2635	in	O
2635	a	O
2635	Leu	O
2635	-	O
2635	to	O
2635	-	O
2635	Pro	O
2635	change	O
2635	in	O
2635	a	O
2635	carrier	O
2635	mother	O
2635	and	O
2635	in	O
2635	her	O
2635	two	O
2635	affected	O
2635	sons	O
2635	.	O
2636	These	O
2636	results	O
2636	provide	O
2636	further	O
2636	examples	O
2636	of	O
2636	mutations	O
2636	in	O
2636	PLP	O
2636	that	O
2636	cause	O
2636	Pelizaeus	B-Disease
2636	-	I-Disease
2636	Merzbacher	I-Disease
2636	disease	I-Disease
2636	and	O
2636	illustrate	O
2636	the	O
2636	value	O
2636	of	O
2636	SSCP	O
2636	in	O
2636	genetic	O
2636	analysis	O
2636	.	O
2636	.	O
2637	von	B-Disease
2637	Willebrand	I-Disease
2637	disease	I-Disease
2637	type	I-Disease
2637	B	I-Disease
2637	:	O
2637	a	O
2637	missense	O
2637	mutation	O
2637	selectively	O
2637	abolishes	O
2637	ristocetin	O
2637	-	O
2637	induced	O
2637	von	B-Disease
2637	Willebrand	I-Disease
2637	factor	O
2637	binding	O
2637	to	O
2637	platelet	O
2637	glycoprotein	O
2637	Ib	O
2637	.	O
2638	von	B-Disease
2638	Willebrand	I-Disease
2638	factor	O
2638	(	O
2638	vWF	O
2638	)	O
2638	is	O
2638	a	O
2638	multimeric	O
2638	glycoprotein	O
2638	that	O
2638	mediates	O
2638	the	O
2638	adhesion	O
2638	of	O
2638	platelets	O
2638	to	O
2638	the	O
2638	subendothelium	O
2638	by	O
2638	binding	O
2638	to	O
2638	platelet	O
2638	glycoprotein	O
2638	Ib	O
2638	.	O
2639	For	O
2639	human	O
2639	vWF	O
2639	,	O
2639	this	O
2639	interaction	O
2639	can	O
2639	be	O
2639	induced	O
2639	in	O
2639	vitro	O
2639	by	O
2639	the	O
2639	antibiotic	O
2639	ristocetin	O
2639	or	O
2639	the	O
2639	snake	O
2639	venom	O
2639	protein	O
2639	botrocetin	O
2639	.	O
2640	A	O
2640	missense	O
2640	mutation	O
2640	,	O
2640	Gly	O
2640	-	O
2640	561	O
2640	-	O
2640	-	O
2640	>	O
2640	Ser	O
2640	,	O
2640	was	O
2640	identified	O
2640	within	O
2640	the	O
2640	proposed	O
2640	glycoprotein	O
2640	Ib	O
2640	binding	O
2640	domain	O
2640	of	O
2640	vWF	O
2640	in	O
2640	the	O
2640	proband	O
2640	with	O
2640	von	B-Disease
2640	Willebrand	I-Disease
2640	disease	I-Disease
2640	type	I-Disease
2640	B	I-Disease
2640	,	O
2640	a	O
2640	unique	O
2640	variant	O
2640	characterized	O
2640	by	O
2640	no	O
2640	ristocetin	O
2640	-	O
2640	induced	O
2640	,	O
2640	but	O
2640	normal	O
2640	botrocetin	O
2640	-	O
2640	induced	O
2640	,	O
2640	binding	O
2640	to	O
2640	glycoprotein	O
2640	Ib	O
2640	.	O
2641	The	O
2641	corresponding	O
2641	mutant	O
2641	recombinant	O
2641	protein	O
2641	,	O
2641	rvWF	O
2641	(	O
2641	G561S	O
2641	)	O
2641	,	O
2641	formed	O
2641	normal	O
2641	multimers	O
2641	and	O
2641	exhibited	O
2641	the	O
2641	same	O
2641	functional	O
2641	defect	O
2641	as	O
2641	the	O
2641	patients	O
2641	plasma	O
2641	vWF	O
2641	,	O
2641	confirming	O
2641	that	O
2641	this	O
2641	mutation	O
2641	causes	O
2641	von	B-Disease
2641	Willebrand	I-Disease
2641	disease	I-Disease
2641	type	I-Disease
2641	B	I-Disease
2641	.	O
2642	These	O
2642	data	O
2642	show	O
2642	that	O
2642	botrocetin	O
2642	and	O
2642	ristocetin	O
2642	cofactor	O
2642	activities	O
2642	of	O
2642	vWF	O
2642	can	O
2642	be	O
2642	dissociated	O
2642	by	O
2642	a	O
2642	point	O
2642	mutation	O
2642	and	O
2642	confirm	O
2642	that	O
2642	these	O
2642	mediators	O
2642	promote	O
2642	vWF	O
2642	binding	O
2642	to	O
2642	platelets	O
2642	by	O
2642	different	O
2642	mechanisms	O
2642	.	O
2643	The	O
2643	normal	O
2643	botrocetin	O
2643	-	O
2643	induced	O
2643	binding	O
2643	and	O
2643	the	O
2643	defective	O
2643	ristocetin	O
2643	-	O
2643	induced	O
2643	binding	O
2643	of	O
2643	rvWF	O
2643	(	O
2643	G561S	O
2643	)	O
2643	suggest	O
2643	that	O
2643	the	O
2643	primary	O
2643	defect	O
2643	in	O
2643	von	B-Disease
2643	Willebrand	I-Disease
2643	disease	I-Disease
2643	type	I-Disease
2643	B	I-Disease
2643	may	O
2643	be	O
2643	a	O
2643	failure	O
2643	of	O
2643	normal	O
2643	allosteric	O
2643	regulation	O
2643	of	O
2643	the	O
2643	glycoprotein	O
2643	Ib	O
2643	binding	O
2643	function	O
2643	of	O
2643	vWF	O
2643	.	O
2643	.	O
2644	Typical	O
2644	and	O
2644	partial	O
2644	cat	B-Disease
2644	eye	I-Disease
2644	syndrome	I-Disease
2644	:	O
2644	identification	O
2644	of	O
2644	the	O
2644	marker	O
2644	chromosome	O
2644	by	O
2644	FISH	O
2644	.	O
2645	Three	O
2645	children	O
2645	are	O
2645	reported	O
2645	with	O
2645	typical	O
2645	cat	B-Disease
2645	eye	I-Disease
2645	syndrome	I-Disease
2645	(	O
2645	CES	B-Disease
2645	)	O
2645	and	O
2645	three	O
2645	more	O
2645	children	O
2645	with	O
2645	partial	O
2645	CES	B-Disease
2645	because	O
2645	of	O
2645	absence	O
2645	of	O
2645	coloboma	O
2645	,	O
2645	in	O
2645	which	O
2645	the	O
2645	supernumerary	O
2645	marker	O
2645	chromosome	O
2645	was	O
2645	studied	O
2645	by	O
2645	FISH	O
2645	.	O
2646	Using	O
2646	a	O
2646	genomic	O
2646	library	O
2646	,	O
2646	and	O
2646	also	O
2646	a	O
2646	centromeric	O
2646	and	O
2646	particularly	O
2646	a	O
2646	cosmid	O
2646	probe	O
2646	of	O
2646	22q11	O
2646	,	O
2646	partial	O
2646	tetrasomy	B-Disease
2646	was	O
2646	shown	O
2646	in	O
2646	all	O
2646	cases	O
2646	.	O
2646	.	O
2647	[	O
2647	Genetic	O
2647	heterogeneity	O
2647	of	O
2647	G6PD	B-Disease
2647	deficiency	I-Disease
2647	:	O
2647	mutant	O
2647	alleles	O
2647	of	O
2647	G6PD	O
2647	in	O
2647	the	O
2647	Shekii	O
2647	district	O
2647	of	O
2647	Azerbaijan	O
2647	]	O
2648	Examination	O
2648	on	O
2648	G6PD	B-Disease
2648	deficiency	I-Disease
2648	in	O
2648	349	O
2648	patients	O
2648	of	O
2648	Shekii	O
2648	district	O
2648	hospital	O
2648	(	O
2648	Azerbaijan	O
2648	)	O
2648	revealed	O
2648	16	O
2648	hemi	O
2648	-	O
2648	,	O
2648	4	O
2648	homo	O
2648	-	O
2648	and	O
2648	9	O
2648	heterozygotic	O
2648	carriers	O
2648	of	O
2648	the	O
2648	defect	O
2648	.	O
2649	Gd	O
2649	-	O
2649	frequency	O
2649	,	O
2649	calculated	O
2649	from	O
2649	the	O
2649	data	O
2649	obtained	O
2649	(	O
2649	7	O
2649	.	O
2649	7	O
2649	%	O
2649	)	O
2649	,	O
2649	may	O
2649	be	O
2649	compared	O
2649	to	O
2649	neighbouring	O
2649	regions	O
2649	frequencies	O
2649	(	O
2649	6	O
2649	-	O
2649	30	O
2649	%	O
2649	)	O
2649	.	O
2650	Carriers	O
2650	of	O
2650	G6PD	B-Disease
2650	deficiency	I-Disease
2650	are	O
2650	residents	O
2650	of	O
2650	11	O
2650	villages	O
2650	located	O
2650	in	O
2650	Alasani	O
2650	-	O
2650	Aphtalan	O
2650	valley	O
2650	,	O
2650	highly	O
2650	endemic	O
2650	with	O
2650	malaria	B-Disease
2650	in	O
2650	the	O
2650	past	O
2650	;	O
2650	nearly	O
2650	all	O
2650	marriages	O
2650	are	O
2650	endogamic	O
2650	.	O
2651	Physico	O
2651	-	O
2651	chemical	O
2651	and	O
2651	kinetic	O
2651	study	O
2651	of	O
2651	10	O
2651	mutant	O
2651	forms	O
2651	of	O
2651	G6PD	O
2651	,	O
2651	according	O
2651	to	O
2651	WHO	O
2651	program	O
2651	,	O
2651	led	O
2651	to	O
2651	identification	O
2651	of	O
2651	5	O
2651	variants	O
2651	of	O
2651	the	O
2651	II	O
2651	class	O
2651	(	O
2651	Shekii	O
2651	,	O
2651	Bideiz	O
2651	,	O
2651	Shirin	O
2651	-	O
2651	Bulakh	O
2651	,	O
2651	Okhut	O
2651	I	O
2651	and	O
2651	Zakataly	O
2651	)	O
2651	and	O
2651	2	O
2651	variants	O
2651	of	O
2651	the	O
2651	III	O
2651	class	O
2651	(	O
2651	Okhut	O
2651	II	O
2651	and	O
2651	Martinique	O
2651	-	O
2651	like	O
2651	)	O
2651	.	O
2652	Resemblance	O
2652	of	O
2652	the	O
2652	majority	O
2652	of	O
2652	variants	O
2652	in	O
2652	electrophoretic	O
2652	mobility	O
2652	and	O
2652	the	O
2652	level	O
2652	of	O
2652	erythrocyte	O
2652	enzyme	O
2652	activity	O
2652	permit	O
2652	to	O
2652	suggest	O
2652	the	O
2652	existence	O
2652	of	O
2652	a	O
2652	common	O
2652	parental	O
2652	mutant	O
2652	G6PD	O
2652	allele	O
2652	distributed	O
2652	in	O
2652	this	O
2652	area	O
2652	.	O
2653	Craniofrontonasal	B-Disease
2653	dysplasia	I-Disease
2653	.	O
2654	We	O
2654	report	O
2654	on	O
2654	nine	O
2654	patients	O
2654	with	O
2654	craniofrontonasal	B-Disease
2654	dysplasia	I-Disease
2654	(	O
2654	CFND	B-Disease
2654	)	O
2654	.	O
2655	Seven	O
2655	classical	O
2655	cases	O
2655	had	O
2655	facial	O
2655	features	O
2655	suggestive	O
2655	of	O
2655	frontonasal	B-Disease
2655	dysplasia	I-Disease
2655	and	O
2655	coronal	B-Disease
2655	craniosynostosis	I-Disease
2655	.	O
2656	Extracranial	B-Disease
2656	abnormalities	I-Disease
2656	such	O
2656	as	O
2656	brittle	B-Disease
2656	nails	I-Disease
2656	with	I-Disease
2656	prominent	I-Disease
2656	longitudinal	I-Disease
2656	grooves	I-Disease
2656	or	O
2656	syndactyly	B-Disease
2656	of	I-Disease
2656	fingers	I-Disease
2656	and	I-Disease
2656	toes	I-Disease
2656	were	O
2656	observed	O
2656	in	O
2656	individual	O
2656	patients	O
2656	.	O
2657	In	O
2657	two	O
2657	families	O
2657	the	O
2657	father	O
2657	of	O
2657	classical	O
2657	cases	O
2657	showed	O
2657	a	O
2657	milder	O
2657	pattern	O
2657	of	O
2657	abnormalities	O
2657	,	O
2657	consistent	O
2657	with	O
2657	the	O
2657	diagnosis	O
2657	.	O
2658	We	O
2658	present	O
2658	a	O
2658	2	O
2658	-	O
2658	to	O
2658	13	O
2658	-	O
2658	year	O
2658	follow	O
2658	-	O
2658	up	O
2658	on	O
2658	our	O
2658	patients	O
2658	.	O
2659	Hypotonia	B-Disease
2659	and	O
2659	laxity	B-Disease
2659	of	I-Disease
2659	joints	I-Disease
2659	are	O
2659	common	O
2659	and	O
2659	may	O
2659	necessitate	O
2659	supportive	O
2659	measures	O
2659	.	O
2660	Mild	O
2660	developmental	B-Disease
2660	delay	I-Disease
2660	was	O
2660	noted	O
2660	in	O
2660	three	O
2660	out	O
2660	of	O
2660	six	O
2660	classical	O
2660	cases	O
2660	studied	O
2660	in	O
2660	detail	O
2660	.	O
2661	Unlike	O
2661	almost	O
2661	all	O
2661	other	O
2661	X	B-Disease
2661	-	I-Disease
2661	linked	I-Disease
2661	disorders	I-Disease
2661	,	O
2661	clinical	O
2661	expression	O
2661	in	O
2661	CFND	B-Disease
2661	is	O
2661	generally	O
2661	much	O
2661	more	O
2661	severe	O
2661	in	O
2661	females	O
2661	than	O
2661	in	O
2661	males	O
2661	.	O
2662	In	O
2662	contrast	O
2662	to	O
2662	previous	O
2662	reports	O
2662	of	O
2662	this	O
2662	condition	O
2662	,	O
2662	one	O
2662	of	O
2662	our	O
2662	severely	O
2662	affected	O
2662	cases	O
2662	is	O
2662	a	O
2662	male	O
2662	.	O
2662	.	O
2663	The	O
2663	intron	O
2663	7	O
2663	donor	O
2663	splice	O
2663	site	O
2663	transition	O
2663	:	O
2663	a	O
2663	second	O
2663	Tay	B-Disease
2663	-	I-Disease
2663	Sachs	I-Disease
2663	disease	I-Disease
2663	mutation	O
2663	in	O
2663	French	O
2663	Canada	O
2663	.	O
2664	Mutations	O
2664	at	O
2664	the	O
2664	hexosaminidase	O
2664	A	O
2664	(	O
2664	HEXA	O
2664	)	O
2664	gene	O
2664	which	O
2664	cause	O
2664	Tay	B-Disease
2664	-	I-Disease
2664	Sachs	I-Disease
2664	disease	I-Disease
2664	(	O
2664	TSD	B-Disease
2664	)	O
2664	have	O
2664	elevated	O
2664	frequency	O
2664	in	O
2664	the	O
2664	Ashkenazi	O
2664	Jewish	O
2664	and	O
2664	French	O
2664	-	O
2664	Canadian	O
2664	populations	O
2664	.	O
2665	We	O
2665	report	O
2665	a	O
2665	novel	O
2665	TSD	B-Disease
2665	allele	O
2665	in	O
2665	the	O
2665	French	O
2665	-	O
2665	Canadian	O
2665	population	O
2665	associated	O
2665	with	O
2665	the	O
2665	infantile	O
2665	form	O
2665	of	O
2665	the	O
2665	disease	O
2665	.	O
2666	The	O
2666	mutation	O
2666	,	O
2666	a	O
2666	G	O
2666	-	O
2666	-	O
2666	>	O
2666	A	O
2666	transition	O
2666	at	O
2666	the	O
2666	+	O
2666	1	O
2666	position	O
2666	of	O
2666	intron	O
2666	7	O
2666	,	O
2666	abolishes	O
2666	the	O
2666	donor	O
2666	splice	O
2666	site	O
2666	.	O
2667	Cultured	O
2667	human	O
2667	fibroblasts	O
2667	from	O
2667	a	O
2667	compound	O
2667	heterozygote	O
2667	for	O
2667	this	O
2667	transition	O
2667	(	O
2667	and	O
2667	for	O
2667	a	O
2667	deletion	O
2667	mutation	O
2667	)	O
2667	produce	O
2667	no	O
2667	detectable	O
2667	HEXA	O
2667	mRNA	O
2667	.	O
2668	The	O
2668	intron	O
2668	7	O
2668	+	O
2668	1	O
2668	mutation	O
2668	occurs	O
2668	in	O
2668	the	O
2668	base	O
2668	adjacent	O
2668	to	O
2668	the	O
2668	site	O
2668	of	O
2668	the	O
2668	adult	O
2668	-	O
2668	onset	O
2668	TSD	B-Disease
2668	mutation	O
2668	(	O
2668	G805A	O
2668	)	O
2668	.	O
2669	In	O
2669	both	O
2669	mutations	O
2669	a	O
2669	restriction	O
2669	site	O
2669	for	O
2669	the	O
2669	endonuclease	O
2669	EcoRII	O
2669	is	O
2669	abolished	O
2669	.	O
2670	Unambiguous	O
2670	diagnosis	O
2670	,	O
2670	therefore	O
2670	,	O
2670	requires	O
2670	allele	O
2670	-	O
2670	specific	O
2670	oligonucleotide	O
2670	hybridization	O
2670	to	O
2670	distinguish	O
2670	between	O
2670	these	O
2670	two	O
2670	mutant	O
2670	alleles	O
2670	.	O
2671	The	O
2671	intron	O
2671	7	O
2671	+	O
2671	1	O
2671	mutation	O
2671	has	O
2671	been	O
2671	detected	O
2671	in	O
2671	three	O
2671	unrelated	O
2671	families	O
2671	.	O
2672	Obligate	O
2672	heterozygotes	O
2672	for	O
2672	the	O
2672	intron	O
2672	7	O
2672	+	O
2672	1	O
2672	mutation	O
2672	were	O
2672	born	O
2672	in	O
2672	the	O
2672	Saguenay	O
2672	-	O
2672	Lac	O
2672	-	O
2672	St	O
2672	-	O
2672	Jean	O
2672	region	O
2672	of	O
2672	Quebec	O
2672	.	O
2673	The	O
2673	most	O
2673	recent	O
2673	ancestors	O
2673	common	O
2673	to	O
2673	obligate	O
2673	carriers	O
2673	of	O
2673	this	O
2673	mutation	O
2673	were	O
2673	from	O
2673	the	O
2673	Charlevoix	O
2673	region	O
2673	of	O
2673	the	O
2673	province	O
2673	of	O
2673	Quebec	O
2673	.	O
2674	This	O
2674	mutation	O
2674	thus	O
2674	has	O
2674	a	O
2674	different	O
2674	geographic	O
2674	centre	O
2674	of	O
2674	diffusion	O
2674	and	O
2674	is	O
2674	probably	O
2674	less	O
2674	common	O
2674	than	O
2674	the	O
2674	exon	O
2674	1	O
2674	deletion	O
2674	TSD	B-Disease
2674	mutation	O
2674	in	O
2674	French	O
2674	Canadians	O
2674	.	O
2675	Neither	O
2675	mutation	O
2675	has	O
2675	been	O
2675	detected	O
2675	in	O
2675	France	O
2675	,	O
2675	the	O
2675	ancestral	O
2675	homeland	O
2675	of	O
2675	French	O
2675	Canada	O
2675	.	O
2675	.	O
2676	Assignment	O
2676	of	O
2676	the	O
2676	aspartylglucosaminidase	O
2676	gene	O
2676	(	O
2676	AGA	O
2676	)	O
2676	to	O
2676	4q33	O
2676	-	O
2676	-	O
2676	-	O
2676	-	O
2676	q35	O
2676	based	O
2676	on	O
2676	decreased	O
2676	activity	O
2676	in	O
2676	a	O
2676	girl	O
2676	with	O
2676	a	O
2676	46	O
2676	,	O
2676	XX	O
2676	,	O
2676	del	O
2676	(	O
2676	4	O
2676	)	O
2676	(	O
2676	q33	O
2676	)	O
2676	karyotype	O
2676	.	O
2677	Aspartylglucosaminuria	B-Disease
2677	(	O
2677	AGU	B-Disease
2677	)	O
2677	is	O
2677	a	O
2677	recessive	O
2677	autosomally	O
2677	inherited	O
2677	lysosomal	B-Disease
2677	storage	I-Disease
2677	disorder	I-Disease
2677	due	O
2677	to	O
2677	deficiency	B-Disease
2677	of	I-Disease
2677	the	I-Disease
2677	enzyme	I-Disease
2677	aspartylglucosaminidase	I-Disease
2677	(	O
2677	AGA	O
2677	)	O
2677	.	O
2678	The	O
2678	structural	O
2678	gene	O
2678	for	O
2678	this	O
2678	human	O
2678	enzyme	O
2678	(	O
2678	AGA	O
2678	)	O
2678	has	O
2678	been	O
2678	assigned	O
2678	to	O
2678	the	O
2678	region	O
2678	4q21	O
2678	-	O
2678	-	O
2678	-	O
2678	-	O
2678	qter	O
2678	.	O
2679	We	O
2679	determined	O
2679	the	O
2679	AGA	O
2679	activity	O
2679	in	O
2679	cultured	O
2679	fibroblasts	O
2679	of	O
2679	a	O
2679	girl	O
2679	with	O
2679	a	O
2679	46	O
2679	,	O
2679	XX	O
2679	,	O
2679	del	O
2679	(	O
2679	4	O
2679	)	O
2679	(	O
2679	q33	O
2679	)	O
2679	karyotype	O
2679	.	O
2680	The	O
2680	results	O
2680	indicate	O
2680	that	O
2680	the	O
2680	girl	O
2680	is	O
2680	a	O
2680	hemizygote	O
2680	for	O
2680	AGA	O
2680	,	O
2680	permitting	O
2680	the	O
2680	assignment	O
2680	of	O
2680	human	O
2680	AGA	O
2680	to	O
2680	the	O
2680	region	O
2680	4q33	O
2680	-	O
2680	-	O
2680	-	O
2680	-	O
2680	qter	O
2680	.	O
2680	.	O
2681	Resolution	O
2681	of	O
2681	the	O
2681	two	O
2681	loci	O
2681	for	O
2681	autosomal	O
2681	dominant	O
2681	aniridia	B-Disease
2681	,	O
2681	AN1	O
2681	and	O
2681	AN2	O
2681	,	O
2681	to	O
2681	a	O
2681	single	O
2681	locus	O
2681	on	O
2681	chromosome	O
2681	11p13	O
2681	.	O
2682	Two	O
2682	distinct	O
2682	loci	O
2682	have	O
2682	been	O
2682	proposed	O
2682	for	O
2682	aniridia	B-Disease
2682	;	O
2682	AN1	O
2682	for	O
2682	autosomal	O
2682	dominant	O
2682	aniridia	B-Disease
2682	on	O
2682	chromosome	O
2682	2p	O
2682	and	O
2682	AN2	O
2682	for	O
2682	the	O
2682	aniridia	B-Disease
2682	in	O
2682	the	O
2682	WAGR	B-Disease
2682	contiguous	I-Disease
2682	gene	I-Disease
2682	syndrome	I-Disease
2682	on	O
2682	chromosome	O
2682	11p13	O
2682	.	O
2683	In	O
2683	this	O
2683	report	O
2683	,	O
2683	the	O
2683	kindred	O
2683	segregating	O
2683	for	O
2683	autosomal	O
2683	dominant	O
2683	aniridia	B-Disease
2683	,	O
2683	which	O
2683	suggested	O
2683	linkage	O
2683	to	O
2683	acid	O
2683	phosphatase	O
2683	-	O
2683	1	O
2683	(	O
2683	ACP1	O
2683	)	O
2683	and	O
2683	led	O
2683	to	O
2683	the	O
2683	assignment	O
2683	of	O
2683	the	O
2683	AN1	O
2683	locus	O
2683	on	O
2683	chromosome	O
2683	2p	O
2683	,	O
2683	has	O
2683	been	O
2683	updated	O
2683	and	O
2683	expanded	O
2683	.	O
2684	Linkage	O
2684	analysis	O
2684	between	O
2684	the	O
2684	aniridia	B-Disease
2684	phenotype	O
2684	and	O
2684	ACP1	O
2684	does	O
2684	not	O
2684	support	O
2684	the	O
2684	original	O
2684	linkage	O
2684	results	O
2684	,	O
2684	excluding	O
2684	linkage	O
2684	up	O
2684	to	O
2684	theta	O
2684	=	O
2684	0	O
2684	.	O
2685	17	O
2685	with	O
2685	Z	O
2685	=	O
2685	-	O
2685	2	O
2685	.	O
2686	Tests	O
2686	for	O
2686	linkage	O
2686	to	O
2686	other	O
2686	chromosome	O
2686	2p	O
2686	markers	O
2686	.	O
2687	APOB	O
2687	,	O
2687	D2S71	O
2687	,	O
2687	D2S5	O
2687	,	O
2687	and	O
2687	D2S1	O
2687	,	O
2687	also	O
2687	excluded	O
2687	linkage	O
2687	to	O
2687	aniridia	B-Disease
2687	.	O
2688	Markers	O
2688	that	O
2688	have	O
2688	been	O
2688	isolated	O
2688	from	O
2688	the	O
2688	chromosome	O
2688	11p13	O
2688	region	O
2688	were	O
2688	then	O
2688	analyzed	O
2688	in	O
2688	this	O
2688	aniridia	B-Disease
2688	family	O
2688	.	O
2689	Two	O
2689	RFLPs	O
2689	at	O
2689	the	O
2689	D11S323	O
2689	locus	O
2689	give	O
2689	significant	O
2689	evidence	O
2689	for	O
2689	linkage	O
2689	.	O
2690	The	O
2690	PvuII	O
2690	polymorphism	O
2690	detected	O
2690	by	O
2690	probe	O
2690	p5S1	O
2690	.	O
2691	6	O
2691	detects	O
2691	no	O
2691	recombinants	O
2691	,	O
2691	with	O
2691	a	O
2691	maximum	O
2691	lod	O
2691	score	O
2691	of	O
2691	Z	O
2691	=	O
2691	6	O
2691	.	O
2692	97	O
2692	at	O
2692	theta	O
2692	=	O
2692	0	O
2692	.	O
2693	00	O
2693	00	O
2693	.	O
2694	The	O
2694	HaeIII	O
2694	polymorphism	O
2694	detected	O
2694	by	O
2694	the	O
2694	probe	O
2694	p5BE1	O
2694	.	O
2695	2	O
2695	gives	O
2695	a	O
2695	maximum	O
2695	lod	O
2695	score	O
2695	of	O
2695	Z	O
2695	=	O
2695	2	O
2695	.	O
2696	57	O
2696	at	O
2696	theta	O
2696	=	O
2696	0	O
2696	.	O
2697	00	O
2697	00	O
2697	.	O
2698	Locus	O
2698	D11S325	O
2698	gives	O
2698	a	O
2698	lod	O
2698	score	O
2698	of	O
2698	Z	O
2698	=	O
2698	1	O
2698	.	O
2699	53	O
2699	at	O
2699	theta	O
2699	=	O
2699	0	O
2699	.	O
2700	00	O
2700	00	O
2700	.	O
2701	These	O
2701	data	O
2701	suggest	O
2701	that	O
2701	a	O
2701	locus	O
2701	for	O
2701	aniridia	B-Disease
2701	(	O
2701	AN1	O
2701	)	O
2701	on	O
2701	chromosome	O
2701	2p	O
2701	has	O
2701	been	O
2701	misassigned	O
2701	and	O
2701	that	O
2701	this	O
2701	autosomal	O
2701	dominant	O
2701	aniridia	B-Disease
2701	family	O
2701	is	O
2701	segregating	O
2701	for	O
2701	an	O
2701	aniridia	B-Disease
2701	mutation	O
2701	linked	O
2701	to	O
2701	markers	O
2701	in	O
2701	the	O
2701	11p13	O
2701	region	O
2701	.	O
2702	Fatal	O
2702	pyoderma	B-Disease
2702	gangrenosum	I-Disease
2702	in	O
2702	association	O
2702	with	O
2702	C7	B-Disease
2702	deficiency	I-Disease
2702	.	O
2703	Although	O
2703	pyoderma	B-Disease
2703	gangrenosum	I-Disease
2703	(	O
2703	PG	B-Disease
2703	)	O
2703	is	O
2703	often	O
2703	associated	O
2703	with	O
2703	systemic	B-Disease
2703	diseases	I-Disease
2703	,	O
2703	it	O
2703	has	O
2703	not	O
2703	been	O
2703	reported	O
2703	in	O
2703	association	O
2703	with	O
2703	congenital	B-Disease
2703	complement	I-Disease
2703	deficiencies	I-Disease
2703	.	O
2704	We	O
2704	describe	O
2704	an	O
2704	aggressive	O
2704	and	O
2704	ultimately	O
2704	fatal	O
2704	case	O
2704	of	O
2704	PG	B-Disease
2704	in	O
2704	a	O
2704	patient	O
2704	with	O
2704	a	O
2704	congenital	O
2704	C7	B-Disease
2704	deficiency	I-Disease
2704	.	O
2705	Deficiencies	B-Disease
2705	of	I-Disease
2705	C7	I-Disease
2705	can	O
2705	be	O
2705	associated	O
2705	with	O
2705	decreased	O
2705	neutrophil	O
2705	chemotaxis	O
2705	,	O
2705	phagocytosis	O
2705	,	O
2705	and	O
2705	opsonization	O
2705	,	O
2705	similar	O
2705	to	O
2705	the	O
2705	immunologic	B-Disease
2705	abnormalities	I-Disease
2705	described	O
2705	in	O
2705	patients	O
2705	with	O
2705	PG	B-Disease
2705	.	O
2706	Our	O
2706	patients	O
2706	decreased	O
2706	complement	O
2706	level	O
2706	,	O
2706	if	O
2706	not	O
2706	directly	O
2706	related	O
2706	to	O
2706	the	O
2706	development	O
2706	of	O
2706	PG	B-Disease
2706	,	O
2706	may	O
2706	have	O
2706	contributed	O
2706	to	O
2706	the	O
2706	aggressive	O
2706	nature	O
2706	of	O
2706	her	O
2706	disease	O
2706	.	O
2706	.	O
2707	Diverse	O
2707	point	O
2707	mutations	O
2707	result	O
2707	in	O
2707	glucose	O
2707	-	O
2707	6	O
2707	-	O
2707	phosphate	O
2707	dehydrogenase	O
2707	(	O
2707	G6PD	O
2707	)	O
2707	polymorphism	O
2707	in	O
2707	Taiwan	O
2707	.	O
2708	Glucose	B-Disease
2708	-	I-Disease
2708	6	I-Disease
2708	-	I-Disease
2708	PHOSPHATE	I-Disease
2708	dehydrogenase	I-Disease
2708	(	I-Disease
2708	G6PD	I-Disease
2708	;	I-Disease
2708	EC	I-Disease
2708	1	I-Disease
2708	.	I-Disease
2708	1	I-Disease
2708	.	I-Disease
2708	1	I-Disease
2708	.	I-Disease
2708	49	I-Disease
2708	)	I-Disease
2708	deficiency	I-Disease
2708	is	O
2708	the	O
2708	most	O
2708	common	O
2708	human	O
2708	enzymopathy	B-Disease
2708	,	O
2708	affecting	O
2708	more	O
2708	than	O
2708	200	O
2708	million	O
2708	people	O
2708	worldwide	O
2708	.	O
2709	Although	O
2709	greater	O
2709	than	O
2709	400	O
2709	variants	O
2709	have	O
2709	been	O
2709	described	O
2709	based	O
2709	on	O
2709	clinical	O
2709	and	O
2709	biochemical	O
2709	criteria	O
2709	,	O
2709	little	O
2709	is	O
2709	known	O
2709	about	O
2709	the	O
2709	molecular	O
2709	basis	O
2709	of	O
2709	these	O
2709	G6PD	B-Disease
2709	deficiencies	I-Disease
2709	.	O
2710	Recently	O
2710	,	O
2710	the	O
2710	gene	O
2710	that	O
2710	encodes	O
2710	human	O
2710	G6PD	O
2710	has	O
2710	been	O
2710	cloned	O
2710	and	O
2710	sequenced	O
2710	,	O
2710	which	O
2710	enables	O
2710	us	O
2710	to	O
2710	examine	O
2710	directly	O
2710	the	O
2710	heterogeneity	O
2710	of	O
2710	G6PD	O
2710	at	O
2710	the	O
2710	DNA	O
2710	level	O
2710	.	O
2711	During	O
2711	the	O
2711	past	O
2711	10	O
2711	years	O
2711	,	O
2711	we	O
2711	examined	O
2711	the	O
2711	G6PD	O
2711	activity	O
2711	in	O
2711	21	O
2711	,	O
2711	271	O
2711	newborn	O
2711	Chinese	O
2711	infants	O
2711	(	O
2711	11	O
2711	,	O
2711	400	O
2711	males	O
2711	and	O
2711	9	O
2711	,	O
2711	871	O
2711	females	O
2711	)	O
2711	and	O
2711	identified	O
2711	314	O
2711	(	O
2711	2	O
2711	.	O
2711	8	O
2711	%	O
2711	)	O
2711	males	O
2711	and	O
2711	246	O
2711	(	O
2711	2	O
2711	.	O
2711	5	O
2711	%	O
2711	)	O
2711	females	O
2711	having	O
2711	low	O
2711	G6PD	O
2711	activity	O
2711	.	O
2712	The	O
2712	G6PD	O
2712	gene	O
2712	from	O
2712	10	O
2712	randomly	O
2712	selected	O
2712	affected	O
2712	individuals	O
2712	and	O
2712	their	O
2712	relatives	O
2712	was	O
2712	polymerase	O
2712	chain	O
2712	reaction	O
2712	(	O
2712	PCR	O
2712	)	O
2712	amplified	O
2712	,	O
2712	subcloned	O
2712	,	O
2712	and	O
2712	sequenced	O
2712	.	O
2713	Our	O
2713	results	O
2713	indicate	O
2713	that	O
2713	at	O
2713	least	O
2713	four	O
2713	types	O
2713	of	O
2713	mutation	O
2713	are	O
2713	responsible	O
2713	for	O
2713	the	O
2713	G6PD	O
2713	polymorphism	O
2713	in	O
2713	Taiwan	O
2713	.	O
2714	The	O
2714	first	O
2714	type	O
2714	of	O
2714	mutation	O
2714	(	O
2714	487	O
2714	G	O
2714	-	O
2714	-	O
2714	-	O
2714	-	O
2714	A	O
2714	)	O
2714	was	O
2714	found	O
2714	in	O
2714	an	O
2714	affected	O
2714	Chinese	O
2714	with	O
2714	a	O
2714	G	O
2714	to	O
2714	A	O
2714	change	O
2714	at	O
2714	nucleotide	O
2714	487	O
2714	,	O
2714	which	O
2714	results	O
2714	in	O
2714	a	O
2714	(	O
2714	163	O
2714	)	O
2714	Gly	O
2714	to	O
2714	Ser	O
2714	substitution	O
2714	.	O
2715	The	O
2715	second	O
2715	type	O
2715	of	O
2715	mutation	O
2715	(	O
2715	493	O
2715	A	O
2715	-	O
2715	-	O
2715	-	O
2715	-	O
2715	G	O
2715	)	O
2715	is	O
2715	a	O
2715	novel	O
2715	mutation	O
2715	that	O
2715	has	O
2715	not	O
2715	been	O
2715	reported	O
2715	in	O
2715	any	O
2715	other	O
2715	ethnic	O
2715	group	O
2715	and	O
2715	was	O
2715	identified	O
2715	in	O
2715	two	O
2715	affected	O
2715	Chinese	O
2715	.	O
2716	This	O
2716	mutation	O
2716	causes	O
2716	an	O
2716	A	O
2716	to	O
2716	G	O
2716	change	O
2716	at	O
2716	nucleotide	O
2716	position	O
2716	493	O
2716	,	O
2716	producing	O
2716	an	O
2716	(	O
2716	165	O
2716	)	O
2716	Asn	O
2716	to	O
2716	Asp	O
2716	substitution	O
2716	.	O
2717	Interestingly	O
2717	,	O
2717	the	O
2717	487	O
2717	G	O
2717	-	O
2717	-	O
2717	-	O
2717	-	O
2717	A	O
2717	and	O
2717	493	O
2717	A	O
2717	-	O
2717	-	O
2717	-	O
2717	-	O
2717	G	O
2717	mutations	O
2717	create	O
2717	Alu	O
2717	I	O
2717	and	O
2717	Ava	O
2717	II	O
2717	recognition	O
2717	sites	O
2717	,	O
2717	respectively	O
2717	,	O
2717	which	O
2717	enabled	O
2717	us	O
2717	to	O
2717	rapidly	O
2717	detect	O
2717	these	O
2717	two	O
2717	mutations	O
2717	by	O
2717	PCR	O
2717	/	O
2717	restriction	O
2717	enzyme	O
2717	(	O
2717	RE	O
2717	)	O
2717	digestion	O
2717	method	O
2717	.	O
2718	The	O
2718	third	O
2718	mutation	O
2718	(	O
2718	1376	O
2718	G	O
2718	-	O
2718	-	O
2718	-	O
2718	-	O
2718	T	O
2718	)	O
2718	was	O
2718	found	O
2718	in	O
2718	four	O
2718	affected	O
2718	Chinese	O
2718	.	O
2719	This	O
2719	mutation	O
2719	causes	O
2719	a	O
2719	G	O
2719	to	O
2719	T	O
2719	change	O
2719	at	O
2719	nucleotide	O
2719	position	O
2719	1376	O
2719	that	O
2719	results	O
2719	in	O
2719	an	O
2719	(	O
2719	459	O
2719	)	O
2719	Arg	O
2719	to	O
2719	Leu	O
2719	substitution	O
2719	.	O
2720	The	O
2720	1376	O
2720	G	O
2720	-	O
2720	-	O
2720	-	O
2720	-	O
2720	T	O
2720	mutation	O
2720	seems	O
2720	to	O
2720	be	O
2720	the	O
2720	dominant	O
2720	allele	O
2720	that	O
2720	causes	O
2720	G6PD	B-Disease
2720	deficiency	I-Disease
2720	in	O
2720	Taiwan	O
2720	.	O
2721	Finally	O
2721	,	O
2721	two	O
2721	affected	O
2721	Chinese	O
2721	were	O
2721	identified	O
2721	as	O
2721	having	O
2721	the	O
2721	fourth	O
2721	mutation	O
2721	(	O
2721	1388	O
2721	G	O
2721	-	O
2721	-	O
2721	-	O
2721	-	O
2721	A	O
2721	)	O
2721	.	O
2722	This	O
2722	mutation	O
2722	causes	O
2722	a	O
2722	G	O
2722	to	O
2722	A	O
2722	change	O
2722	at	O
2722	nucleotide	O
2722	1388	O
2722	that	O
2722	produces	O
2722	an	O
2722	(	O
2722	463	O
2722	)	O
2722	Arg	O
2722	to	O
2722	His	O
2722	substitution	O
2722	.	O
2723	Our	O
2723	studies	O
2723	provide	O
2723	the	O
2723	direct	O
2723	proof	O
2723	of	O
2723	the	O
2723	genetic	O
2723	heterogeneity	O
2723	of	O
2723	G6PD	B-Disease
2723	deficiency	I-Disease
2723	in	O
2723	the	O
2723	Chinese	O
2723	populations	O
2723	of	O
2723	Taiwan	O
2723	and	O
2723	the	O
2723	PCR	O
2723	/	O
2723	RE	O
2723	digestion	O
2723	method	O
2723	is	O
2723	suitable	O
2723	for	O
2723	simultaneous	O
2723	detection	O
2723	of	O
2723	the	O
2723	487	O
2723	G	O
2723	-	O
2723	-	O
2723	-	O
2723	-	O
2723	A	O
2723	and	O
2723	493	O
2723	A	O
2723	-	O
2723	-	O
2723	-	O
2723	-	O
2723	G	O
2723	mutations	O
2723	.	O
2724	An	O
2724	error	O
2724	in	O
2724	dystrophin	O
2724	mRNA	O
2724	processing	O
2724	in	O
2724	golden	B-Disease
2724	retriever	I-Disease
2724	muscular	I-Disease
2724	dystrophy	I-Disease
2724	,	O
2724	an	O
2724	animal	O
2724	homologue	O
2724	of	O
2724	Duchenne	B-Disease
2724	muscular	I-Disease
2724	dystrophy	I-Disease
2724	.	O
2725	Golden	B-Disease
2725	retriever	I-Disease
2725	muscular	I-Disease
2725	dystrophy	I-Disease
2725	(	O
2725	GRMD	B-Disease
2725	)	O
2725	is	O
2725	a	O
2725	spontaneous	O
2725	,	O
2725	X	O
2725	-	O
2725	linked	O
2725	,	O
2725	progressively	O
2725	fatal	O
2725	disease	O
2725	of	O
2725	dogs	O
2725	and	O
2725	is	O
2725	also	O
2725	a	O
2725	homologue	O
2725	of	O
2725	Duchenne	B-Disease
2725	muscular	I-Disease
2725	dystrophy	I-Disease
2725	(	O
2725	DMD	B-Disease
2725	)	O
2725	.	O
2726	Two	O
2726	-	O
2726	thirds	O
2726	of	O
2726	DMD	B-Disease
2726	patients	O
2726	carry	O
2726	detectable	O
2726	deletions	O
2726	in	O
2726	their	O
2726	dystrophin	O
2726	gene	O
2726	.	O
2727	The	O
2727	defect	O
2727	underlying	O
2727	the	O
2727	remaining	O
2727	one	O
2727	-	O
2727	third	O
2727	of	O
2727	DMD	B-Disease
2727	patients	O
2727	is	O
2727	undetermined	O
2727	.	O
2728	Analysis	O
2728	of	O
2728	the	O
2728	canine	O
2728	dystrophin	O
2728	gene	O
2728	in	O
2728	normal	O
2728	and	O
2728	GRMD	B-Disease
2728	dogs	O
2728	has	O
2728	failed	O
2728	to	O
2728	demonstrate	O
2728	any	O
2728	detectable	O
2728	loss	O
2728	of	O
2728	exons	O
2728	.	O
2729	Here	O
2729	,	O
2729	we	O
2729	have	O
2729	demonstrated	O
2729	a	O
2729	RNA	O
2729	processing	O
2729	error	O
2729	in	O
2729	GRMD	B-Disease
2729	that	O
2729	results	O
2729	from	O
2729	a	O
2729	single	O
2729	base	O
2729	change	O
2729	in	O
2729	the	O
2729	3	O
2729	consensus	O
2729	splice	O
2729	site	O
2729	of	O
2729	intron	O
2729	6	O
2729	.	O
2730	The	O
2730	seventh	O
2730	exon	O
2730	is	O
2730	then	O
2730	skipped	O
2730	,	O
2730	which	O
2730	predicts	O
2730	a	O
2730	termination	O
2730	of	O
2730	the	O
2730	dystrophin	O
2730	reading	O
2730	frame	O
2730	within	O
2730	its	O
2730	N	O
2730	-	O
2730	terminal	O
2730	domain	O
2730	in	O
2730	exon	O
2730	8	O
2730	.	O
2731	This	O
2731	is	O
2731	the	O
2731	first	O
2731	example	O
2731	of	O
2731	dystrophin	B-Disease
2731	deficiency	I-Disease
2731	caused	O
2731	by	O
2731	a	O
2731	splice	O
2731	-	O
2731	site	O
2731	mutation	O
2731	.	O
2731	.	O
2732	Type	B-Disease
2732	I	I-Disease
2732	human	I-Disease
2732	complement	I-Disease
2732	C2	I-Disease
2732	deficiency	I-Disease
2732	.	O
2733	A	O
2733	28	O
2733	-	O
2733	base	O
2733	pair	O
2733	gene	O
2733	deletion	O
2733	causes	O
2733	skipping	O
2733	of	O
2733	exon	O
2733	6	O
2733	during	O
2733	RNA	O
2733	splicing	O
2733	.	O
2734	Two	O
2734	variants	O
2734	of	O
2734	a	O
2734	genetic	O
2734	deficiency	B-Disease
2734	of	I-Disease
2734	complement	I-Disease
2734	protein	I-Disease
2734	C2	I-Disease
2734	(	O
2734	C2D	O
2734	)	O
2734	have	O
2734	been	O
2734	previously	O
2734	identified	O
2734	.	O
2735	No	O
2735	C2	O
2735	protein	O
2735	translation	O
2735	is	O
2735	detected	O
2735	in	O
2735	type	O
2735	I	O
2735	deficiency	O
2735	,	O
2735	while	O
2735	type	O
2735	II	O
2735	deficiency	O
2735	is	O
2735	characterized	O
2735	by	O
2735	a	O
2735	selective	O
2735	block	O
2735	in	O
2735	C2	O
2735	secretion	O
2735	.	O
2736	Type	B-Disease
2736	I	I-Disease
2736	C2	I-Disease
2736	deficiency	I-Disease
2736	was	O
2736	described	O
2736	in	O
2736	a	O
2736	family	O
2736	in	O
2736	which	O
2736	the	O
2736	C2	O
2736	allele	O
2736	(	O
2736	C2Q0	O
2736	)	O
2736	is	O
2736	associated	O
2736	with	O
2736	the	O
2736	major	O
2736	histocompatibility	O
2736	haplotype	O
2736	/	O
2736	complotype	O
2736	HLA	O
2736	-	O
2736	A25	O
2736	,	O
2736	B18	O
2736	,	O
2736	C2Q0	O
2736	,	O
2736	BfS	O
2736	,	O
2736	C4A4	O
2736	,	O
2736	C4B2	O
2736	,	O
2736	Drw2	O
2736	;	O
2736	this	O
2736	extended	O
2736	haplotype	O
2736	occurs	O
2736	in	O
2736	over	O
2736	90	O
2736	%	O
2736	of	O
2736	C2	B-Disease
2736	-	I-Disease
2736	deficient	I-Disease
2736	individuals	O
2736	(	O
2736	common	O
2736	complotype	O
2736	/	O
2736	haplotype	O
2736	)	O
2736	.	O
2737	To	O
2737	determine	O
2737	the	O
2737	molecular	O
2737	basis	O
2737	of	O
2737	type	B-Disease
2737	I	I-Disease
2737	C2	I-Disease
2737	deficiency	I-Disease
2737	,	O
2737	the	O
2737	C2	O
2737	gene	O
2737	and	O
2737	cDNA	O
2737	were	O
2737	characterized	O
2737	from	O
2737	a	O
2737	homozygous	O
2737	type	B-Disease
2737	I	I-Disease
2737	C2	I-Disease
2737	-	I-Disease
2737	deficient	I-Disease
2737	individual	O
2737	with	O
2737	the	O
2737	common	O
2737	associated	O
2737	haplotype	O
2737	/	O
2737	complotype	O
2737	.	O
2738	We	O
2738	found	O
2738	a	O
2738	28	O
2738	-	O
2738	base	O
2738	pair	O
2738	deletion	O
2738	in	O
2738	the	O
2738	type	O
2738	I	O
2738	C2Q0	O
2738	gene	O
2738	,	O
2738	beginning	O
2738	9	O
2738	base	O
2738	pairs	O
2738	upstream	O
2738	of	O
2738	the	O
2738	3	O
2738	-	O
2738	end	O
2738	of	O
2738	exon	O
2738	6	O
2738	,	O
2738	that	O
2738	generates	O
2738	a	O
2738	C2	O
2738	transcript	O
2738	with	O
2738	a	O
2738	complete	O
2738	deletion	O
2738	of	O
2738	exon	O
2738	6	O
2738	(	O
2738	134	O
2738	base	O
2738	pair	O
2738	)	O
2738	and	O
2738	a	O
2738	premature	O
2738	termination	O
2738	codon	O
2738	.	O
2739	In	O
2739	studies	O
2739	of	O
2739	eight	O
2739	kindred	O
2739	,	O
2739	the	O
2739	28	O
2739	-	O
2739	base	O
2739	pair	O
2739	deletion	O
2739	was	O
2739	observed	O
2739	in	O
2739	all	O
2739	C2Q0	O
2739	alleles	O
2739	associated	O
2739	with	O
2739	the	O
2739	common	O
2739	type	O
2739	I	O
2739	deficient	O
2739	complotype	O
2739	/	O
2739	haplotype	O
2739	;	O
2739	this	O
2739	deletion	O
2739	was	O
2739	not	O
2739	present	O
2739	in	O
2739	normal	O
2739	C2	O
2739	nor	O
2739	in	O
2739	type	B-Disease
2739	II	I-Disease
2739	C2	I-Disease
2739	-	I-Disease
2739	deficient	I-Disease
2739	genes	O
2739	.	O
2740	These	O
2740	data	O
2740	demonstrate	O
2740	that	O
2740	1	O
2740	)	O
2740	type	B-Disease
2740	I	I-Disease
2740	human	I-Disease
2740	complement	I-Disease
2740	C2	I-Disease
2740	deficiency	I-Disease
2740	is	O
2740	caused	O
2740	by	O
2740	a	O
2740	28	O
2740	-	O
2740	base	O
2740	pair	O
2740	genomic	O
2740	deletion	O
2740	that	O
2740	causes	O
2740	skipping	O
2740	of	O
2740	exon	O
2740	6	O
2740	during	O
2740	RNA	O
2740	splicing	O
2740	,	O
2740	resulting	O
2740	in	O
2740	generation	O
2740	of	O
2740	a	O
2740	premature	O
2740	termination	O
2740	codon	O
2740	,	O
2740	2	O
2740	)	O
2740	the	O
2740	28	O
2740	-	O
2740	base	O
2740	pair	O
2740	deletion	O
2740	in	O
2740	the	O
2740	type	O
2740	I	O
2740	C2Q0	O
2740	gene	O
2740	is	O
2740	strongly	O
2740	associated	O
2740	with	O
2740	the	O
2740	HLA	O
2740	haplotype	O
2740	/	O
2740	complotype	O
2740	A25	O
2740	,	O
2740	B18	O
2740	,	O
2740	C2Q0	O
2740	,	O
2740	BfS	O
2740	,	O
2740	C4A4	O
2740	,	O
2740	C4B2	O
2740	,	O
2740	Drw2	O
2740	,	O
2740	suggesting	O
2740	that	O
2740	all	O
2740	C2	B-Disease
2740	-	I-Disease
2740	deficient	I-Disease
2740	individuals	O
2740	with	O
2740	this	O
2740	haplotype	O
2740	/	O
2740	complotype	O
2740	will	O
2740	harbor	O
2740	the	O
2740	28	O
2740	-	O
2740	base	O
2740	pair	O
2740	C2	O
2740	gene	O
2740	deletion	O
2740	,	O
2740	and	O
2740	3	O
2740	)	O
2740	type	B-Disease
2740	II	I-Disease
2740	C2	I-Disease
2740	deficiency	I-Disease
2740	is	O
2740	caused	O
2740	by	O
2740	a	O
2740	different	O
2740	,	O
2740	as	O
2740	yet	O
2740	uncharacterized	O
2740	,	O
2740	molecular	O
2740	genetic	B-Disease
2740	defect	I-Disease
2740	.	O
2740	.	O
2741	Molecular	O
2741	characterization	O
2741	of	O
2741	two	O
2741	galactosemia	B-Disease
2741	mutations	O
2741	and	O
2741	one	O
2741	polymorphism	O
2741	:	O
2741	implications	O
2741	for	O
2741	structure	O
2741	-	O
2741	function	O
2741	analysis	O
2741	of	O
2741	human	O
2741	galactose	O
2741	-	O
2741	1	O
2741	-	O
2741	phosphate	O
2741	uridyltransferase	O
2741	.	O
2742	We	O
2742	report	O
2742	here	O
2742	the	O
2742	molecular	O
2742	characterization	O
2742	of	O
2742	two	O
2742	galactosemia	B-Disease
2742	mutations	O
2742	,	O
2742	L74P	O
2742	and	O
2742	F171S	O
2742	,	O
2742	and	O
2742	one	O
2742	polymorphism	O
2742	,	O
2742	S135L	O
2742	,	O
2742	in	O
2742	human	O
2742	galactose	O
2742	-	O
2742	1	O
2742	-	O
2742	phosphate	O
2742	uridyltransferase	O
2742	(	O
2742	GALT	O
2742	)	O
2742	.	O
2743	Both	O
2743	galactosemia	B-Disease
2743	mutations	O
2743	result	O
2743	in	O
2743	reduced	O
2743	enzymatic	O
2743	activity	O
2743	when	O
2743	reconstructed	O
2743	in	O
2743	the	O
2743	cDNA	O
2743	and	O
2743	overexpressed	O
2743	.	O
2744	The	O
2744	polymorphism	O
2744	,	O
2744	in	O
2744	contrast	O
2744	,	O
2744	has	O
2744	near	O
2744	normal	O
2744	activity	O
2744	.	O
2745	Both	O
2745	mutations	O
2745	affect	O
2745	evolutionarily	O
2745	conserved	O
2745	residues	O
2745	,	O
2745	suggesting	O
2745	that	O
2745	they	O
2745	are	O
2745	functionally	O
2745	important	O
2745	,	O
2745	while	O
2745	the	O
2745	polymorphism	O
2745	occurs	O
2745	in	O
2745	a	O
2745	nonconserved	O
2745	domain	O
2745	which	O
2745	is	O
2745	presumably	O
2745	not	O
2745	critical	O
2745	for	O
2745	enzymatic	O
2745	function	O
2745	.	O
2746	The	O
2746	F171S	O
2746	mutation	O
2746	is	O
2746	close	O
2746	to	O
2746	the	O
2746	putative	O
2746	active	O
2746	-	O
2746	site	O
2746	nucleophile	O
2746	.	O
2747	Our	O
2747	data	O
2747	further	O
2747	support	O
2747	the	O
2747	notion	O
2747	of	O
2747	molecular	O
2747	heterogeneity	O
2747	of	O
2747	galactosemia	B-Disease
2747	and	O
2747	suggest	O
2747	that	O
2747	galactosemia	B-Disease
2747	mutations	O
2747	and	O
2747	GALT	O
2747	polymorphisms	O
2747	may	O
2747	be	O
2747	useful	O
2747	tools	O
2747	in	O
2747	highlighting	O
2747	different	O
2747	functional	O
2747	domains	O
2747	in	O
2747	human	O
2747	GALT	O
2747	.	O
2747	.	O
2748	Linkage	O
2748	relationship	O
2748	of	O
2748	C2	B-Disease
2748	deficiency	I-Disease
2748	,	O
2748	HLA	O
2748	and	O
2748	glyoxalase	O
2748	I	O
2748	loci	O
2748	.	O
2749	Immunogenetic	O
2749	analysis	O
2749	of	O
2749	a	O
2749	homozygous	O
2749	C2	B-Disease
2749	-	I-Disease
2749	deficient	I-Disease
2749	individual	O
2749	and	O
2749	family	O
2749	members	O
2749	demonstrated	O
2749	linkage	O
2749	of	O
2749	HLA	O
2749	-	O
2749	A25	O
2749	,	O
2749	B18	O
2749	and	O
2749	C2o	O
2749	.	O
2750	HLA	O
2750	-	O
2750	D	O
2750	typing	O
2750	showed	O
2750	that	O
2750	5	O
2750	members	O
2750	typed	O
2750	with	O
2750	homozygous	O
2750	Dw2	O
2750	typing	O
2750	cells	O
2750	from	O
2750	an	O
2750	individual	O
2750	with	O
2750	C2	B-Disease
2750	deficiency	I-Disease
2750	but	O
2750	not	O
2750	with	O
2750	Dw2	O
2750	typing	O
2750	cells	O
2750	from	O
2750	2	O
2750	individuals	O
2750	with	O
2750	normal	O
2750	C2	O
2750	.	O
2751	The	O
2751	homozygous	O
2751	C2	B-Disease
2751	-	I-Disease
2751	deficient	I-Disease
2751	propositus	O
2751	and	O
2751	brother	O
2751	were	O
2751	HLA	O
2751	-	O
2751	A	O
2751	and	O
2751	B	O
2751	homozygous	O
2751	but	O
2751	heterozygous	O
2751	at	O
2751	the	O
2751	HLA	O
2751	-	O
2751	D	O
2751	and	O
2751	glyoxalase	O
2751	I	O
2751	loci	O
2751	.	O
2752	Therefore	O
2752	,	O
2752	in	O
2752	this	O
2752	family	O
2752	,	O
2752	the	O
2752	C2o	O
2752	gene	O
2752	is	O
2752	linked	O
2752	with	O
2752	two	O
2752	distinct	O
2752	haplotypes	O
2752	HLA	O
2752	-	O
2752	A25	O
2752	,	O
2752	B18	O
2752	,	O
2752	Dw2	O
2752	,	O
2752	GLO1	O
2752	and	O
2752	HLA	O
2752	-	O
2752	A25	O
2752	,	O
2752	B18	O
2752	,	O
2752	D	O
2752	unknown	O
2752	,	O
2752	GL02	O
2752	.	O
2753	These	O
2753	results	O
2753	could	O
2753	be	O
2753	explained	O
2753	by	O
2753	an	O
2753	ancestral	O
2753	recombinant	O
2753	event	O
2753	,	O
2753	which	O
2753	occurred	O
2753	between	O
2753	the	O
2753	C2o	O
2753	locus	O
2753	and	O
2753	HLA	O
2753	-	O
2753	D	O
2753	locus	O
2753	in	O
2753	which	O
2753	C2o	O
2753	segregated	O
2753	with	O
2753	HLA	O
2753	-	O
2753	B	O
2753	.	O
2754	This	O
2754	would	O
2754	suggest	O
2754	that	O
2754	the	O
2754	locus	O
2754	for	O
2754	the	O
2754	C2o	O
2754	gene	O
2754	maps	O
2754	between	O
2754	HLA	O
2754	-	O
2754	B	O
2754	and	O
2754	HLA	O
2754	-	O
2754	D	O
2754	on	O
2754	the	O
2754	sixth	O
2754	chromosome	O
2754	.	O
2754	.	O
2755	Germline	O
2755	mutations	O
2755	in	O
2755	the	O
2755	Wilms	B-Disease
2755	'	I-Disease
2755	tumor	I-Disease
2755	suppressor	O
2755	gene	O
2755	are	O
2755	associated	O
2755	with	O
2755	abnormal	O
2755	urogenital	O
2755	development	O
2755	in	O
2755	Denys	B-Disease
2755	-	I-Disease
2755	Drash	I-Disease
2755	syndrome	I-Disease
2755	.	O
2756	Denys	B-Disease
2756	-	I-Disease
2756	Drash	I-Disease
2756	syndrome	I-Disease
2756	is	O
2756	a	O
2756	rare	O
2756	human	O
2756	condition	O
2756	in	O
2756	which	O
2756	severe	O
2756	urogenital	B-Disease
2756	aberrations	I-Disease
2756	result	O
2756	in	O
2756	renal	B-Disease
2756	failure	I-Disease
2756	,	O
2756	pseudohermaphroditism	B-Disease
2756	,	O
2756	and	O
2756	Wilms	B-Disease
2756	tumor	I-Disease
2756	(	O
2756	nephroblastoma	B-Disease
2756	)	O
2756	.	O
2757	To	O
2757	investigate	O
2757	its	O
2757	possible	O
2757	role	O
2757	,	O
2757	we	O
2757	have	O
2757	analyzed	O
2757	the	O
2757	coding	O
2757	exons	O
2757	of	O
2757	the	O
2757	Wilms	B-Disease
2757	tumor	I-Disease
2757	suppressor	O
2757	gene	O
2757	(	O
2757	WT1	O
2757	)	O
2757	for	O
2757	germline	O
2757	mutations	O
2757	.	O
2758	In	O
2758	ten	O
2758	independent	O
2758	cases	O
2758	of	O
2758	Denys	B-Disease
2758	-	I-Disease
2758	Drash	I-Disease
2758	syndrome	I-Disease
2758	,	O
2758	point	O
2758	mutations	O
2758	in	O
2758	the	O
2758	zinc	O
2758	finger	O
2758	domains	O
2758	of	O
2758	one	O
2758	WT1	O
2758	gene	O
2758	copy	O
2758	were	O
2758	found	O
2758	.	O
2759	Nine	O
2759	of	O
2759	these	O
2759	mutations	O
2759	are	O
2759	found	O
2759	within	O
2759	exon	O
2759	9	O
2759	(	O
2759	zinc	O
2759	finger	O
2759	III	O
2759	)	O
2759	;	O
2759	the	O
2759	remaining	O
2759	mutation	O
2759	is	O
2759	in	O
2759	exon	O
2759	8	O
2759	(	O
2759	zinc	O
2759	finger	O
2759	II	O
2759	)	O
2759	.	O
2760	These	O
2760	mutations	O
2760	directly	O
2760	affect	O
2760	DNA	O
2760	sequence	O
2760	recognition	O
2760	.	O
2761	In	O
2761	two	O
2761	families	O
2761	analyzed	O
2761	,	O
2761	the	O
2761	mutations	O
2761	were	O
2761	shown	O
2761	to	O
2761	arise	O
2761	de	O
2761	novo	O
2761	.	O
2762	Wilms	B-Disease
2762	tumors	I-Disease
2762	from	O
2762	three	O
2762	individuals	O
2762	and	O
2762	one	O
2762	juvenile	O
2762	granulosa	O
2762	cell	O
2762	tumor	B-Disease
2762	demonstrate	O
2762	reduction	O
2762	to	O
2762	homozygosity	O
2762	for	O
2762	the	O
2762	mutated	O
2762	WT1	O
2762	allele	O
2762	.	O
2763	Our	O
2763	results	O
2763	provide	O
2763	evidence	O
2763	of	O
2763	a	O
2763	direct	O
2763	role	O
2763	for	O
2763	WT1	O
2763	in	O
2763	Denys	B-Disease
2763	-	I-Disease
2763	Drash	I-Disease
2763	syndrome	I-Disease
2763	and	O
2763	thus	O
2763	urogenital	O
2763	system	O
2763	development	O
2763	.	O
2763	.	O
2764	Linkage	O
2764	analysis	O
2764	in	O
2764	X	B-Disease
2764	-	I-Disease
2764	linked	I-Disease
2764	adrenoleukodystrophy	I-Disease
2764	and	O
2764	application	O
2764	in	O
2764	post	O
2764	-	O
2764	and	O
2764	prenatal	O
2764	diagnosis	O
2764	.	O
2765	We	O
2765	have	O
2765	performed	O
2765	linkage	O
2765	analysis	O
2765	with	O
2765	the	O
2765	DNA	O
2765	markers	O
2765	DXS52	O
2765	and	O
2765	the	O
2765	clotting	O
2765	factor	O
2765	VIII	O
2765	gene	O
2765	(	O
2765	F8C	O
2765	)	O
2765	,	O
2765	in	O
2765	several	O
2765	large	O
2765	families	O
2765	with	O
2765	X	B-Disease
2765	-	I-Disease
2765	linked	I-Disease
2765	adrenoleukodystrophy	I-Disease
2765	(	O
2765	ALD	B-Disease
2765	)	O
2765	.	O
2766	The	O
2766	tight	O
2766	linkage	O
2766	to	O
2766	DXS52	O
2766	could	O
2766	be	O
2766	extended	O
2766	giving	O
2766	a	O
2766	maximal	O
2766	LOD	O
2766	score	O
2766	of	O
2766	22	O
2766	.	O
2767	5	O
2767	at	O
2767	1	O
2767	cM	O
2767	.	O
2768	F8C	O
2768	was	O
2768	also	O
2768	tightly	O
2768	linked	O
2768	to	O
2768	ALD	B-Disease
2768	with	O
2768	a	O
2768	maximal	O
2768	LOD	O
2768	score	O
2768	of	O
2768	7	O
2768	.	O
2769	8	O
2769	without	O
2769	recombination	O
2769	.	O
2770	Multipoint	O
2770	linkage	O
2770	analysis	O
2770	with	O
2770	the	O
2770	markers	O
2770	DXS304	O
2770	,	O
2770	DXS52	O
2770	,	O
2770	and	O
2770	F8C	O
2770	indicated	O
2770	that	O
2770	both	O
2770	the	O
2770	gene	O
2770	for	O
2770	ALD	B-Disease
2770	and	O
2770	for	O
2770	F8C	O
2770	are	O
2770	distal	O
2770	to	O
2770	DXS52	O
2770	.	O
2771	In	O
2771	four	O
2771	patients	O
2771	with	O
2771	ALD	B-Disease
2771	,	O
2771	no	O
2771	major	O
2771	structural	O
2771	rearrangement	O
2771	in	O
2771	the	O
2771	Xqter	O
2771	region	O
2771	was	O
2771	observed	O
2771	;	O
2771	in	O
2771	particular	O
2771	,	O
2771	there	O
2771	were	O
2771	no	O
2771	abnormalities	B-Disease
2771	in	I-Disease
2771	the	I-Disease
2771	vision	I-Disease
2771	blindness	I-Disease
2771	genes	I-Disease
2771	.	O
2772	DNA	O
2772	analysis	O
2772	appeared	O
2772	to	O
2772	be	O
2772	of	O
2772	use	O
2772	in	O
2772	determination	O
2772	of	O
2772	the	O
2772	carrier	O
2772	status	O
2772	of	O
2772	females	O
2772	at	O
2772	risk	O
2772	,	O
2772	for	O
2772	the	O
2772	determination	O
2772	of	O
2772	the	O
2772	origin	O
2772	of	O
2772	the	O
2772	mutation	O
2772	in	O
2772	a	O
2772	particular	O
2772	family	O
2772	,	O
2772	and	O
2772	for	O
2772	prenatal	O
2772	diagnosis	O
2772	.	O
2773	Two	O
2773	distinct	O
2773	mutations	O
2773	at	O
2773	a	O
2773	single	O
2773	BamHI	O
2773	site	O
2773	in	O
2773	phenylketonuria	B-Disease
2773	.	O
2774	Classical	B-Disease
2774	phenylketonuria	I-Disease
2774	is	O
2774	an	O
2774	autosomal	B-Disease
2774	recessive	I-Disease
2774	disease	I-Disease
2774	caused	O
2774	by	O
2774	a	O
2774	deficiency	B-Disease
2774	of	I-Disease
2774	hepatic	I-Disease
2774	phenylalanine	I-Disease
2774	hydroxylase	I-Disease
2774	(	O
2774	PAH	O
2774	)	O
2774	.	O
2775	The	O
2775	abolition	O
2775	of	O
2775	an	O
2775	invariant	O
2775	BamHI	O
2775	site	O
2775	located	O
2775	in	O
2775	the	O
2775	coding	O
2775	sequence	O
2775	of	O
2775	the	O
2775	PAH	O
2775	gene	O
2775	(	O
2775	exon	O
2775	7	O
2775	)	O
2775	led	O
2775	to	O
2775	the	O
2775	recognition	O
2775	of	O
2775	two	O
2775	new	O
2775	point	O
2775	mutations	O
2775	at	O
2775	codon	O
2775	272	O
2775	and	O
2775	273	O
2775	(	O
2775	272gly	O
2775	-	O
2775	-	O
2775	-	O
2775	-	O
2775	stop	O
2775	and	O
2775	273ser	O
2775	-	O
2775	-	O
2775	-	O
2775	-	O
2775	phe	O
2775	,	O
2775	respectively	O
2775	)	O
2775	.	O
2776	Both	O
2776	mutations	O
2776	were	O
2776	detected	O
2776	in	O
2776	north	O
2776	eastern	O
2776	France	O
2776	or	O
2776	Belgium	O
2776	and	O
2776	occurred	O
2776	on	O
2776	the	O
2776	background	O
2776	of	O
2776	RFLP	O
2776	haplotype	O
2776	7	O
2776	alleles	O
2776	.	O
2777	The	O
2777	present	O
2777	study	O
2777	supports	O
2777	the	O
2777	view	O
2777	that	O
2777	the	O
2777	clinical	O
2777	heterogeneity	O
2777	in	O
2777	PKU	B-Disease
2777	is	O
2777	accounted	O
2777	for	O
2777	by	O
2777	the	O
2777	large	O
2777	variety	O
2777	of	O
2777	mutant	O
2777	genotypes	O
2777	associated	O
2777	with	O
2777	PAH	B-Disease
2777	deficiencies	I-Disease
2777	.	O
2777	.	O
2778	A	O
2778	detailed	O
2778	multipoint	O
2778	map	O
2778	of	O
2778	human	O
2778	chromosome	O
2778	4	O
2778	provides	O
2778	evidence	O
2778	for	O
2778	linkage	O
2778	heterogeneity	O
2778	and	O
2778	position	O
2778	-	O
2778	specific	O
2778	recombination	O
2778	rates	O
2778	.	O
2779	Utilizing	O
2779	the	O
2779	CEPH	O
2779	reference	O
2779	panel	O
2779	and	O
2779	genotypic	O
2779	data	O
2779	for	O
2779	53	O
2779	markers	O
2779	,	O
2779	we	O
2779	have	O
2779	constructed	O
2779	a	O
2779	20	O
2779	-	O
2779	locus	O
2779	multipoint	O
2779	genetic	O
2779	map	O
2779	of	O
2779	human	O
2779	chromosome	O
2779	4	O
2779	.	O
2780	New	O
2780	RFLPs	O
2780	are	O
2780	reported	O
2780	for	O
2780	four	O
2780	loci	O
2780	.	O
2781	The	O
2781	map	O
2781	integrates	O
2781	a	O
2781	high	O
2781	-	O
2781	resolution	O
2781	genetic	O
2781	map	O
2781	of	O
2781	4p16	O
2781	into	O
2781	a	O
2781	continuous	O
2781	map	O
2781	extending	O
2781	to	O
2781	4q31	O
2781	and	O
2781	an	O
2781	unlinked	O
2781	cluster	O
2781	of	O
2781	three	O
2781	loci	O
2781	at	O
2781	4q35	O
2781	.	O
2782	The	O
2782	20	O
2782	linked	O
2782	markers	O
2782	form	O
2782	a	O
2782	continuous	O
2782	linkage	O
2782	group	O
2782	of	O
2782	152	O
2782	cM	O
2782	in	O
2782	males	O
2782	and	O
2782	202	O
2782	cM	O
2782	in	O
2782	females	O
2782	.	O
2783	Likely	O
2783	genetic	O
2783	locations	O
2783	are	O
2783	provided	O
2783	for	O
2783	25	O
2783	polymorphic	O
2783	anonymous	O
2783	sequences	O
2783	and	O
2783	28	O
2783	gene	O
2783	-	O
2783	specific	O
2783	RFLPs	O
2783	.	O
2784	The	O
2784	map	O
2784	was	O
2784	constructed	O
2784	employing	O
2784	the	O
2784	LINKAGE	O
2784	and	O
2784	CRIMAP	O
2784	computational	O
2784	methodologies	O
2784	to	O
2784	build	O
2784	the	O
2784	multipoint	O
2784	map	O
2784	via	O
2784	a	O
2784	stepwise	O
2784	algorithm	O
2784	.	O
2785	A	O
2785	detailed	O
2785	10	O
2785	-	O
2785	point	O
2785	map	O
2785	of	O
2785	the	O
2785	4p16	O
2785	region	O
2785	constructed	O
2785	from	O
2785	the	O
2785	CEPH	O
2785	panel	O
2785	provides	O
2785	evidence	O
2785	for	O
2785	heterogeneity	O
2785	in	O
2785	the	O
2785	linkage	O
2785	maps	O
2785	constructed	O
2785	from	O
2785	families	O
2785	segregating	O
2785	for	O
2785	Huntington	B-Disease
2785	disease	I-Disease
2785	(	O
2785	HD	B-Disease
2785	)	O
2785	.	O
2786	It	O
2786	additionally	O
2786	provides	O
2786	evidence	O
2786	for	O
2786	position	O
2786	-	O
2786	specific	O
2786	recombination	O
2786	frequencies	O
2786	in	O
2786	the	O
2786	telomeric	O
2786	region	O
2786	of	O
2786	4p	O
2786	.	O
2786	.	O
2787	Carrier	O
2787	detection	O
2787	and	O
2787	prenatal	O
2787	diagnosis	O
2787	of	O
2787	Pelizaeus	B-Disease
2787	-	I-Disease
2787	Merzbacher	I-Disease
2787	disease	I-Disease
2787	using	O
2787	a	O
2787	combination	O
2787	of	O
2787	anonymous	O
2787	DNA	O
2787	polymorphisms	O
2787	and	O
2787	the	O
2787	proteolipid	O
2787	protein	O
2787	(	O
2787	PLP	O
2787	)	O
2787	gene	O
2787	cDNA	O
2787	.	O
2788	We	O
2788	report	O
2788	carrier	O
2788	identification	O
2788	and	O
2788	a	O
2788	prenatal	O
2788	diagnosis	O
2788	using	O
2788	DNA	O
2788	polymorphisms	O
2788	in	O
2788	2	O
2788	families	O
2788	with	O
2788	X	B-Disease
2788	-	I-Disease
2788	linked	I-Disease
2788	Pelizaeus	I-Disease
2788	-	I-Disease
2788	Merzbacher	I-Disease
2788	disease	I-Disease
2788	(	O
2788	PMD	B-Disease
2788	)	O
2788	.	O
2789	In	O
2789	both	O
2789	families	O
2789	,	O
2789	the	O
2789	proteolipid	O
2789	protein	O
2789	(	O
2789	PLP	O
2789	)	O
2789	gene	O
2789	in	O
2789	the	O
2789	single	O
2789	affected	O
2789	male	O
2789	could	O
2789	be	O
2789	traced	O
2789	back	O
2789	to	O
2789	his	O
2789	unaffected	O
2789	maternal	O
2789	grandfather	O
2789	.	O
2790	Therefore	O
2790	,	O
2790	each	O
2790	family	O
2790	contains	O
2790	a	O
2790	new	O
2790	mutation	O
2790	.	O
2791	In	O
2791	the	O
2791	case	O
2791	of	O
2791	the	O
2791	prenatal	O
2791	diagnosis	O
2791	,	O
2791	the	O
2791	fetus	O
2791	was	O
2791	shown	O
2791	by	O
2791	cytogenetic	O
2791	analysis	O
2791	to	O
2791	be	O
2791	a	O
2791	female	O
2791	,	O
2791	who	O
2791	we	O
2791	predict	O
2791	will	O
2791	be	O
2791	a	O
2791	noncarrier	O
2791	of	O
2791	PMD	B-Disease
2791	based	O
2791	on	O
2791	her	O
2791	genotype	O
2791	with	O
2791	the	O
2791	PLP	O
2791	intragenic	O
2791	polymorphism	O
2791	.	O
2791	.	O
2792	Identification	O
2792	of	O
2792	deletion	O
2792	mutations	O
2792	and	O
2792	three	O
2792	new	O
2792	genes	O
2792	at	O
2792	the	O
2792	familial	B-Disease
2792	polyposis	I-Disease
2792	locus	O
2792	.	O
2793	Small	O
2793	(	O
2793	100	O
2793	-	O
2793	260	O
2793	kb	O
2793	)	O
2793	,	O
2793	nested	O
2793	deletions	O
2793	were	O
2793	characterized	O
2793	in	O
2793	DNA	O
2793	from	O
2793	two	O
2793	unrelated	O
2793	patients	O
2793	with	O
2793	familial	B-Disease
2793	adenomatous	I-Disease
2793	polyposis	I-Disease
2793	coli	I-Disease
2793	(	O
2793	APC	B-Disease
2793	)	O
2793	.	O
2794	Three	O
2794	candidate	O
2794	genes	O
2794	located	O
2794	within	O
2794	the	O
2794	deleted	O
2794	region	O
2794	were	O
2794	ascertained	O
2794	and	O
2794	a	O
2794	previous	O
2794	candidate	O
2794	gene	O
2794	,	O
2794	MCC	O
2794	,	O
2794	was	O
2794	shown	O
2794	to	O
2794	be	O
2794	located	O
2794	outside	O
2794	the	O
2794	deleted	O
2794	region	O
2794	.	O
2795	One	O
2795	of	O
2795	the	O
2795	new	O
2795	genes	O
2795	contained	O
2795	sequence	O
2795	identical	O
2795	to	O
2795	SRP19	O
2795	,	O
2795	the	O
2795	gene	O
2795	coding	O
2795	for	O
2795	the	O
2795	19	O
2795	kd	O
2795	component	O
2795	of	O
2795	the	O
2795	ribosomal	O
2795	signal	O
2795	recognition	O
2795	particle	O
2795	.	O
2796	The	O
2796	second	O
2796	,	O
2796	provisionally	O
2796	designated	O
2796	DP1	O
2796	(	O
2796	deleted	O
2796	in	O
2796	polyposis	O
2796	1	O
2796	)	O
2796	,	O
2796	was	O
2796	found	O
2796	to	O
2796	be	O
2796	transcribed	O
2796	in	O
2796	the	O
2796	same	O
2796	orientation	O
2796	as	O
2796	MCC	O
2796	.	O
2797	Two	O
2797	other	O
2797	cDNAs	O
2797	,	O
2797	DP2	O
2797	and	O
2797	DP3	O
2797	,	O
2797	were	O
2797	found	O
2797	to	O
2797	overlap	O
2797	,	O
2797	forming	O
2797	a	O
2797	single	O
2797	gene	O
2797	,	O
2797	DP2	O
2797	.	O
2798	5	O
2798	,	O
2798	that	O
2798	is	O
2798	transcribed	O
2798	in	O
2798	the	O
2798	same	O
2798	orientation	O
2798	as	O
2798	SRP19	O
2798	.	O
2799	Exclusion	O
2799	of	O
2799	linkage	O
2799	between	O
2799	familial	B-Disease
2799	Mediterranean	I-Disease
2799	fever	I-Disease
2799	and	O
2799	the	O
2799	human	O
2799	serum	O
2799	amyloid	O
2799	A	O
2799	(	O
2799	SAA	O
2799	)	O
2799	gene	O
2799	cluster	O
2799	.	O
2800	We	O
2800	studied	O
2800	the	O
2800	relationship	O
2800	between	O
2800	the	O
2800	autosomal	O
2800	recessive	O
2800	trait	O
2800	familial	B-Disease
2800	Mediterranean	I-Disease
2800	fever	I-Disease
2800	(	O
2800	FMF	B-Disease
2800	)	O
2800	and	O
2800	the	O
2800	serum	O
2800	amyloid	O
2800	A	O
2800	(	O
2800	SAA	O
2800	)	O
2800	genes	O
2800	by	O
2800	comparing	O
2800	alleles	O
2800	of	O
2800	a	O
2800	highly	O
2800	polymorphic	O
2800	dinucleotide	O
2800	repeat	O
2800	and	O
2800	a	O
2800	conventional	O
2800	restriction	O
2800	fragment	O
2800	length	O
2800	polymorphism	O
2800	(	O
2800	RFLP	O
2800	)	O
2800	in	O
2800	the	O
2800	SAA	O
2800	gene	O
2800	cluster	O
2800	in	O
2800	Israeli	O
2800	FMF	B-Disease
2800	kindreds	O
2800	.	O
2801	By	O
2801	haplotype	O
2801	analysis	O
2801	,	O
2801	our	O
2801	data	O
2801	indicate	O
2801	a	O
2801	minimum	O
2801	crossover	O
2801	frequency	O
2801	of	O
2801	22	O
2801	%	O
2801	between	O
2801	the	O
2801	SAA	O
2801	gene	O
2801	marker	O
2801	and	O
2801	FMF	B-Disease
2801	.	O
2802	By	O
2802	conventional	O
2802	linkage	O
2802	analysis	O
2802	this	O
2802	eliminates	O
2802	a	O
2802	minimum	O
2802	of	O
2802	10	O
2802	.	O
2803	4	O
2803	cM	O
2803	including	O
2803	and	O
2803	surrounding	O
2803	the	O
2803	SAA	O
2803	gene	O
2803	cluster	O
2803	as	O
2803	the	O
2803	site	O
2803	of	O
2803	the	O
2803	FMF	B-Disease
2803	mutation	O
2803	although	O
2803	SAA	O
2803	proteins	O
2803	are	O
2803	prominent	O
2803	physiologic	O
2803	markers	O
2803	of	O
2803	the	O
2803	acute	O
2803	attacks	O
2803	.	O
2804	PRAD1	O
2804	,	O
2804	a	O
2804	candidate	O
2804	BCL1	O
2804	oncogene	O
2804	:	O
2804	mapping	O
2804	and	O
2804	expression	O
2804	in	O
2804	centrocytic	B-Disease
2804	lymphoma	I-Disease
2804	.	O
2805	Rearrangement	O
2805	of	O
2805	the	O
2805	BCL1	O
2805	(	O
2805	B	O
2805	-	O
2805	cell	O
2805	lymphoma	O
2805	1	O
2805	)	O
2805	region	O
2805	on	O
2805	chromosome	O
2805	11q13	O
2805	appears	O
2805	to	O
2805	be	O
2805	highly	O
2805	characteristic	O
2805	of	O
2805	centrocytic	B-Disease
2805	lymphoma	I-Disease
2805	and	O
2805	also	O
2805	is	O
2805	found	O
2805	infrequently	O
2805	in	O
2805	other	O
2805	B	B-Disease
2805	-	I-Disease
2805	cell	I-Disease
2805	neoplasms	I-Disease
2805	.	O
2806	Rearrangement	O
2806	is	O
2806	thought	O
2806	to	O
2806	deregulate	O
2806	a	O
2806	nearby	O
2806	protooncogene	O
2806	,	O
2806	but	O
2806	transcribed	O
2806	sequences	O
2806	in	O
2806	the	O
2806	immediate	O
2806	vicinity	O
2806	of	O
2806	BCL1	O
2806	breakpoints	O
2806	had	O
2806	not	O
2806	been	O
2806	identified	O
2806	.	O
2807	PRAD1	O
2807	,	O
2807	previously	O
2807	designated	O
2807	D11S287E	O
2807	,	O
2807	was	O
2807	identified	O
2807	on	O
2807	11q13	O
2807	as	O
2807	a	O
2807	chromosomal	O
2807	breakpoint	O
2807	region	O
2807	rearranged	O
2807	with	O
2807	the	O
2807	parathyroid	O
2807	hormone	O
2807	gene	O
2807	in	O
2807	a	O
2807	subset	O
2807	of	O
2807	parathyroid	B-Disease
2807	adenomas	I-Disease
2807	;	O
2807	this	O
2807	highly	O
2807	conserved	O
2807	putative	O
2807	oncogene	O
2807	,	O
2807	which	O
2807	encodes	O
2807	a	O
2807	novel	O
2807	cyclin	O
2807	,	O
2807	has	O
2807	been	O
2807	linked	O
2807	to	O
2807	BCL1	O
2807	and	O
2807	implicated	O
2807	also	O
2807	in	O
2807	subsets	O
2807	of	O
2807	breast	B-Disease
2807	and	I-Disease
2807	squamous	I-Disease
2807	cell	I-Disease
2807	neoplasms	I-Disease
2807	with	O
2807	11q13	O
2807	amplification	O
2807	.	O
2808	We	O
2808	report	O
2808	pulsed	O
2808	-	O
2808	field	O
2808	gel	O
2808	electrophoresis	O
2808	data	O
2808	showing	O
2808	BCL1	O
2808	and	O
2808	PRAD1	O
2808	to	O
2808	be	O
2808	no	O
2808	more	O
2808	than	O
2808	130	O
2808	kilobases	O
2808	apart	O
2808	.	O
2809	PRAD1	O
2809	mRNA	O
2809	is	O
2809	abundantly	O
2809	expressed	O
2809	in	O
2809	seven	O
2809	of	O
2809	seven	O
2809	centrocytic	B-Disease
2809	lymphomas	I-Disease
2809	(	O
2809	Kiel	O
2809	classification	O
2809	)	O
2809	,	O
2809	in	O
2809	contrast	O
2809	to	O
2809	13	O
2809	closely	O
2809	related	O
2809	but	O
2809	noncentrocytic	B-Disease
2809	lymphomas	I-Disease
2809	.	O
2810	Three	O
2810	of	O
2810	the	O
2810	seven	O
2810	centrocytic	B-Disease
2810	lymphomas	I-Disease
2810	had	O
2810	detectable	O
2810	BCL1	O
2810	DNA	O
2810	rearrangement	O
2810	.	O
2811	Also	O
2811	,	O
2811	two	O
2811	unusual	O
2811	cases	O
2811	of	O
2811	CLL	O
2811	with	O
2811	BCL1	O
2811	rearrangement	O
2811	overexpressed	O
2811	PRAD1	O
2811	,	O
2811	in	O
2811	contrast	O
2811	to	O
2811	five	O
2811	CLL	O
2811	controls	O
2811	.	O
2812	Thus	O
2812	,	O
2812	PRAD1	O
2812	is	O
2812	an	O
2812	excellent	O
2812	candidate	O
2812	"	NN	O	O
2812	BCL1	NN	O	O
2812	oncogene	NN	O	O
2812	.	NN	O	O

2813	"	O
2813	Its	O
2813	overexpression	O
2813	may	O
2813	be	O
2813	a	O
2813	key	O
2813	consequence	O
2813	of	O
2813	rearrangement	O
2813	of	O
2813	the	O
2813	BCL1	O
2813	vicinity	O
2813	in	O
2813	B	B-Disease
2813	-	I-Disease
2813	cell	I-Disease
2813	neoplasms	I-Disease
2813	and	O
2813	a	O
2813	unifying	O
2813	pathogenetic	O
2813	feature	O
2813	in	O
2813	centrocytic	B-Disease
2813	lymphoma	I-Disease
2813	.	O
2814	Two	O
2814	new	O
2814	arylsulfatase	O
2814	A	O
2814	(	O
2814	ARSA	O
2814	)	O
2814	mutations	O
2814	in	O
2814	a	O
2814	juvenile	O
2814	metachromatic	B-Disease
2814	leukodystrophy	I-Disease
2814	(	O
2814	MLD	B-Disease
2814	)	O
2814	patient	O
2814	.	O
2815	Fragments	O
2815	of	O
2815	the	O
2815	arylsulfatase	O
2815	A	O
2815	(	O
2815	ARSA	O
2815	)	O
2815	gene	O
2815	from	O
2815	a	O
2815	patient	O
2815	with	O
2815	juvenile	O
2815	-	O
2815	onset	O
2815	metachromatic	B-Disease
2815	leukodystrophy	I-Disease
2815	(	O
2815	MLD	B-Disease
2815	)	O
2815	were	O
2815	amplified	O
2815	by	O
2815	PCR	O
2815	and	O
2815	ligated	O
2815	into	O
2815	MP13	O
2815	cloning	O
2815	vectors	O
2815	.	O
2816	Clones	O
2816	hybridizing	O
2816	with	O
2816	cDNA	O
2816	for	O
2816	human	O
2816	ARSA	O
2816	were	O
2816	selected	O
2816	,	O
2816	examined	O
2816	for	O
2816	appropriate	O
2816	size	O
2816	inserts	O
2816	,	O
2816	and	O
2816	used	O
2816	to	O
2816	prepare	O
2816	single	O
2816	-	O
2816	stranded	O
2816	phage	O
2816	DNA	O
2816	.	O
2817	Examination	O
2817	of	O
2817	the	O
2817	entire	O
2817	coding	O
2817	and	O
2817	most	O
2817	of	O
2817	the	O
2817	intronic	O
2817	sequence	O
2817	revealed	O
2817	two	O
2817	putative	O
2817	disease	O
2817	-	O
2817	related	O
2817	mutations	O
2817	.	O
2818	One	O
2818	,	O
2818	a	O
2818	point	O
2818	mutation	O
2818	in	O
2818	exon	O
2818	3	O
2818	,	O
2818	resulted	O
2818	in	O
2818	the	O
2818	substitution	O
2818	of	O
2818	isoleucine	O
2818	by	O
2818	serine	O
2818	.	O
2819	Introduction	O
2819	of	O
2819	this	O
2819	alteration	O
2819	into	O
2819	the	O
2819	normal	O
2819	ARSA	O
2819	cDNA	O
2819	sequence	O
2819	resulted	O
2819	in	O
2819	a	O
2819	substantial	O
2819	decrease	O
2819	in	O
2819	ARSA	O
2819	activity	O
2819	on	O
2819	transient	O
2819	expression	O
2819	in	O
2819	cultured	O
2819	baby	O
2819	hamster	O
2819	kidney	O
2819	cells	O
2819	.	O
2820	About	O
2820	5	O
2820	%	O
2820	of	O
2820	the	O
2820	control	O
2820	expression	O
2820	was	O
2820	observed	O
2820	,	O
2820	suggesting	O
2820	a	O
2820	small	O
2820	residual	O
2820	activity	O
2820	in	O
2820	the	O
2820	mutated	O
2820	ARSA	O
2820	.	O
2821	The	O
2821	second	O
2821	mutation	O
2821	,	O
2821	a	O
2821	G	O
2821	-	O
2821	to	O
2821	-	O
2821	A	O
2821	transition	O
2821	,	O
2821	occurred	O
2821	in	O
2821	the	O
2821	other	O
2821	allele	O
2821	and	O
2821	resulted	O
2821	in	O
2821	an	O
2821	altered	O
2821	splice	O
2821	-	O
2821	recognition	O
2821	sequence	O
2821	between	O
2821	exon	O
2821	7	O
2821	and	O
2821	the	O
2821	following	O
2821	intron	O
2821	.	O
2822	The	O
2822	mutation	O
2822	also	O
2822	resulted	O
2822	in	O
2822	the	O
2822	loss	O
2822	of	O
2822	a	O
2822	restriction	O
2822	site	O
2822	.	O
2823	Apparently	O
2823	normal	O
2823	levels	O
2823	of	O
2823	mRNA	O
2823	were	O
2823	generated	O
2823	from	O
2823	this	O
2823	allele	O
2823	,	O
2823	but	O
2823	no	O
2823	ARSA	O
2823	activity	O
2823	or	O
2823	immuno	O
2823	-	O
2823	cross	O
2823	-	O
2823	reactive	O
2823	material	O
2823	could	O
2823	be	O
2823	detected	O
2823	.	O
2824	A	O
2824	collection	O
2824	of	O
2824	DNA	O
2824	samples	O
2824	from	O
2824	known	O
2824	or	O
2824	suspected	O
2824	MLD	B-Disease
2824	patients	O
2824	,	O
2824	members	O
2824	of	O
2824	their	O
2824	families	O
2824	,	O
2824	and	O
2824	normal	O
2824	controls	O
2824	was	O
2824	screened	O
2824	for	O
2824	these	O
2824	mutations	O
2824	.	O
2825	Four	O
2825	additional	O
2825	individuals	O
2825	carrying	O
2825	each	O
2825	of	O
2825	the	O
2825	mutations	O
2825	were	O
2825	found	O
2825	among	O
2825	the	O
2825	nearly	O
2825	100	O
2825	MLD	B-Disease
2825	patients	O
2825	in	O
2825	the	O
2825	sample	O
2825	.	O
2826	Gene	O
2826	segregation	O
2826	in	O
2826	the	O
2826	original	O
2826	patients	O
2826	family	O
2826	was	O
2826	consistent	O
2826	with	O
2826	available	O
2826	clinical	O
2826	and	O
2826	biochemical	O
2826	data	O
2826	.	O
2827	No	O
2827	individuals	O
2827	homozygous	O
2827	for	O
2827	either	O
2827	of	O
2827	these	O
2827	two	O
2827	mutations	O
2827	were	O
2827	identified	O
2827	.	O
2828	However	O
2828	,	O
2828	combinations	O
2828	with	O
2828	other	O
2828	MLD	B-Disease
2828	mutations	O
2828	suggest	O
2828	that	O
2828	the	O
2828	point	O
2828	mutation	O
2828	in	O
2828	exon	O
2828	3	O
2828	does	O
2828	result	O
2828	in	O
2828	some	O
2828	residual	O
2828	enzyme	O
2828	activity	O
2828	and	O
2828	is	O
2828	associated	O
2828	with	O
2828	late	O
2828	-	O
2828	onset	O
2828	forms	O
2828	of	O
2828	the	O
2828	disease	O
2828	.	O
2829	The	O
2829	splice	O
2829	-	O
2829	site	O
2829	mutation	O
2829	following	O
2829	exon	O
2829	7	O
2829	produces	O
2829	late	O
2829	-	O
2829	infantile	O
2829	MLD	B-Disease
2829	when	O
2829	combined	O
2829	with	O
2829	other	O
2829	enzyme	O
2829	-	O
2829	mutations	O
2829	,	O
2829	implying	O
2829	that	O
2829	it	O
2829	is	O
2829	completely	O
2829	silent	O
2829	enzymatically	O
2829	.	O
2829	.	O
2830	Analysis	O
2830	of	O
2830	X	O
2830	-	O
2830	chromosome	O
2830	inactivation	O
2830	and	O
2830	presumptive	O
2830	expression	O
2830	of	O
2830	the	O
2830	Wiskott	B-Disease
2830	-	I-Disease
2830	Aldrich	I-Disease
2830	syndrome	I-Disease
2830	(	O
2830	WAS	B-Disease
2830	)	O
2830	gene	O
2830	in	O
2830	hematopoietic	O
2830	cell	O
2830	lineages	O
2830	of	O
2830	a	O
2830	thrombocytopenic	O
2830	carrier	O
2830	female	O
2830	of	O
2830	WAS	B-Disease
2830	.	O
2831	We	O
2831	report	O
2831	on	O
2831	a	O
2831	thrombocytopenic	B-Disease
2831	female	O
2831	belonging	O
2831	to	O
2831	a	O
2831	pedigree	O
2831	with	O
2831	the	O
2831	Wiskott	B-Disease
2831	-	I-Disease
2831	Aldrich	I-Disease
2831	syndrome	I-Disease
2831	(	O
2831	WAS	B-Disease
2831	)	O
2831	.	O
2832	Restriction	O
2832	fragment	O
2832	length	O
2832	polymorphism	O
2832	(	O
2832	RFLP	O
2832	)	O
2832	analysis	O
2832	with	O
2832	probe	O
2832	M27	O
2832	beta	O
2832	,	O
2832	closely	O
2832	linked	O
2832	to	O
2832	the	O
2832	WAS	B-Disease
2832	gene	O
2832	,	O
2832	demonstrated	O
2832	that	O
2832	she	O
2832	is	O
2832	a	O
2832	carrier	O
2832	of	O
2832	WAS	B-Disease
2832	.	O
2833	Both	O
2833	small	O
2833	-	O
2833	sized	O
2833	and	O
2833	normal	O
2833	-	O
2833	sized	O
2833	platelets	O
2833	were	O
2833	present	O
2833	,	O
2833	suggesting	O
2833	that	O
2833	,	O
2833	unlike	O
2833	the	O
2833	vast	O
2833	majority	O
2833	of	O
2833	WAS	B-Disease
2833	carriers	O
2833	,	O
2833	she	O
2833	does	O
2833	not	O
2833	manifest	O
2833	nonrandom	O
2833	X	O
2833	-	O
2833	chromosome	O
2833	inactivation	O
2833	in	O
2833	the	O
2833	thrombopoietic	O
2833	cell	O
2833	lineage	O
2833	.	O
2834	Study	O
2834	of	O
2834	X	O
2834	-	O
2834	chromosome	O
2834	inactivation	O
2834	by	O
2834	means	O
2834	of	O
2834	RFLP	O
2834	and	O
2834	methylation	O
2834	analysis	O
2834	demonstrated	O
2834	that	O
2834	the	O
2834	pattern	O
2834	of	O
2834	X	O
2834	-	O
2834	chromosome	O
2834	inactivation	O
2834	was	O
2834	nonrandom	O
2834	in	O
2834	T	O
2834	lymphocytes	O
2834	,	O
2834	but	O
2834	random	O
2834	in	O
2834	granulocytes	O
2834	.	O
2835	While	O
2835	this	O
2835	is	O
2835	the	O
2835	first	O
2835	complete	O
2835	report	O
2835	on	O
2835	the	O
2835	occurrence	O
2835	of	O
2835	thrombocytopenia	B-Disease
2835	in	O
2835	a	O
2835	carrier	O
2835	female	O
2835	of	O
2835	WAS	B-Disease
2835	as	O
2835	the	O
2835	result	O
2835	of	O
2835	atypical	O
2835	lyonization	O
2835	,	O
2835	it	O
2835	also	O
2835	suggests	O
2835	that	O
2835	expression	O
2835	of	O
2835	the	O
2835	WAS	B-Disease
2835	gene	O
2835	occurs	O
2835	at	O
2835	(	O
2835	or	O
2835	extends	O
2835	up	O
2835	to	O
2835	)	O
2835	a	O
2835	later	O
2835	stage	O
2835	than	O
2835	the	O
2835	multipotent	O
2835	stem	O
2835	cell	O
2835	along	O
2835	the	O
2835	hematopoietic	O
2835	differentiation	O
2835	pathway	O
2835	.	O
2835	.	O
2836	A	O
2836	new	O
2836	mutation	O
2836	in	O
2836	the	O
2836	proteolipid	O
2836	protein	O
2836	(	O
2836	PLP	O
2836	)	O
2836	gene	O
2836	in	O
2836	a	O
2836	German	O
2836	family	O
2836	with	O
2836	Pelizaeus	B-Disease
2836	-	I-Disease
2836	Merzbacher	I-Disease
2836	disease	I-Disease
2836	.	O
2837	A	O
2837	C	O
2837	-	O
2837	to	O
2837	-	O
2837	T	O
2837	transition	O
2837	in	O
2837	exon	O
2837	4	O
2837	of	O
2837	the	O
2837	PLP	O
2837	gene	O
2837	was	O
2837	found	O
2837	in	O
2837	2	O
2837	affected	O
2837	males	O
2837	and	O
2837	two	O
2837	obligate	O
2837	carriers	O
2837	in	O
2837	a	O
2837	German	O
2837	family	O
2837	with	O
2837	Pelizaeus	B-Disease
2837	-	I-Disease
2837	Merzbacher	I-Disease
2837	disease	I-Disease
2837	.	O
2838	The	O
2838	mutation	O
2838	,	O
2838	which	O
2838	causes	O
2838	loss	O
2838	of	O
2838	an	O
2838	HphI	O
2838	site	O
2838	and	O
2838	changes	O
2838	amino	O
2838	acid	O
2838	155	O
2838	from	O
2838	threonine	O
2838	to	O
2838	isoleucine	O
2838	,	O
2838	was	O
2838	absent	O
2838	from	O
2838	108	O
2838	normal	O
2838	chromosomes	O
2838	.	O
2839	There	O
2839	are	O
2839	5	O
2839	concordances	O
2839	and	O
2839	1	O
2839	discrepancy	O
2839	between	O
2839	these	O
2839	results	O
2839	and	O
2839	those	O
2839	obtained	O
2839	by	O
2839	magnetic	O
2839	resonance	O
2839	imaging	O
2839	in	O
2839	this	O
2839	family	O
2839	.	O
2839	.	O
2840	A	O
2840	3	O
2840	-	O
2840	base	O
2840	pair	O
2840	in	O
2840	-	O
2840	frame	O
2840	deletion	O
2840	of	O
2840	the	O
2840	phenylalanine	O
2840	hydroxylase	O
2840	gene	O
2840	results	O
2840	in	O
2840	a	O
2840	kinetic	O
2840	variant	O
2840	of	O
2840	phenylketonuria	B-Disease
2840	.	O
2841	Phenylketonuria	B-Disease
2841	(	O
2841	PKU	B-Disease
2841	)	O
2841	is	O
2841	an	O
2841	autosomal	B-Disease
2841	recessive	I-Disease
2841	disease	I-Disease
2841	due	O
2841	to	O
2841	deficiency	B-Disease
2841	of	I-Disease
2841	a	I-Disease
2841	hepatic	I-Disease
2841	enzyme	I-Disease
2841	,	I-Disease
2841	phenylalanine	I-Disease
2841	hydroxylase	I-Disease
2841	(	O
2841	PAH	O
2841	)	O
2841	.	O
2842	The	O
2842	absence	O
2842	of	O
2842	PAH	O
2842	activity	O
2842	results	O
2842	in	O
2842	typical	O
2842	PKU	B-Disease
2842	while	O
2842	persistence	O
2842	of	O
2842	a	O
2842	residual	O
2842	enzyme	O
2842	activity	O
2842	gives	O
2842	rise	O
2842	to	O
2842	variant	O
2842	forms	O
2842	of	O
2842	the	O
2842	disease	O
2842	.	O
2843	We	O
2843	report	O
2843	here	O
2843	a	O
2843	3	O
2843	-	O
2843	base	O
2843	pair	O
2843	in	O
2843	-	O
2843	frame	O
2843	deletion	O
2843	of	O
2843	the	O
2843	PAH	O
2843	gene	O
2843	(	O
2843	delta	O
2843	194	O
2843	)	O
2843	in	O
2843	a	O
2843	mild	O
2843	variant	O
2843	,	O
2843	with	O
2843	markedly	O
2843	reduced	O
2843	affinity	O
2843	of	O
2843	the	O
2843	enzyme	O
2843	for	O
2843	phenylalanine	O
2843	(	O
2843	Km	O
2843	=	O
2843	160	O
2843	nM	O
2843	)	O
2843	,	O
2843	and	O
2843	we	O
2843	provide	O
2843	functional	O
2843	evidence	O
2843	for	O
2843	responsibility	O
2843	of	O
2843	the	O
2843	deletion	O
2843	in	O
2843	the	O
2843	mutant	O
2843	phenotype	O
2843	.	O
2844	Since	O
2844	the	O
2844	deletion	O
2844	was	O
2844	located	O
2844	in	O
2844	the	O
2844	third	O
2844	exon	O
2844	of	O
2844	the	O
2844	gene	O
2844	,	O
2844	which	O
2844	presents	O
2844	no	O
2844	homology	O
2844	with	O
2844	other	O
2844	hydroxylases	O
2844	,	O
2844	we	O
2844	suggest	O
2844	that	O
2844	exon	O
2844	3	O
2844	is	O
2844	involved	O
2844	in	O
2844	the	O
2844	specificity	O
2844	of	O
2844	the	O
2844	enzyme	O
2844	for	O
2844	phenylalanine	O
2844	.	O
2845	Finally	O
2845	,	O
2845	since	O
2845	none	O
2845	of	O
2845	the	O
2845	98	O
2845	PKU	B-Disease
2845	patients	O
2845	tested	O
2845	were	O
2845	found	O
2845	to	O
2845	carry	O
2845	this	O
2845	particular	O
2845	deletion	O
2845	,	O
2845	our	O
2845	study	O
2845	suggests	O
2845	that	O
2845	this	O
2845	molecular	O
2845	event	O
2845	probably	O
2845	occurred	O
2845	recently	O
2845	on	O
2845	the	O
2845	background	O
2845	of	O
2845	a	O
2845	haplotype	O
2845	2	O
2845	gene	O
2845	in	O
2845	Portugal	O
2845	.	O
2845	.	O
2846	Mutation	O
2846	of	O
2846	the	O
2846	KIT	O
2846	(	O
2846	mast	O
2846	/	O
2846	stem	O
2846	cell	O
2846	growth	O
2846	factor	O
2846	receptor	O
2846	)	O
2846	protooncogene	O
2846	in	O
2846	human	O
2846	piebaldism	B-Disease
2846	.	O
2847	Piebaldism	B-Disease
2847	is	O
2847	an	O
2847	autosomal	B-Disease
2847	dominant	I-Disease
2847	genetic	I-Disease
2847	disorder	I-Disease
2847	characterized	O
2847	by	O
2847	cogenital	O
2847	patches	O
2847	of	O
2847	skin	O
2847	and	O
2847	hair	O
2847	from	O
2847	which	O
2847	melanocytes	O
2847	are	O
2847	completely	O
2847	absent	O
2847	.	O
2848	A	O
2848	similar	O
2848	disorder	O
2848	of	O
2848	mouse	O
2848	,	O
2848	dominant	O
2848	white	O
2848	spotting	O
2848	(	O
2848	W	O
2848	)	O
2848	,	O
2848	results	O
2848	from	O
2848	mutations	O
2848	of	O
2848	the	O
2848	c	O
2848	-	O
2848	Kit	O
2848	protooncogene	O
2848	,	O
2848	which	O
2848	encodes	O
2848	and	O
2848	receptor	O
2848	for	O
2848	mast	O
2848	/	O
2848	stem	O
2848	cell	O
2848	growth	O
2848	factor	O
2848	.	O
2849	We	O
2849	identified	O
2849	a	O
2849	KIT	O
2849	gene	O
2849	mutation	O
2849	in	O
2849	a	O
2849	proband	O
2849	with	O
2849	classic	O
2849	autosomal	O
2849	dominant	O
2849	piebaldism	B-Disease
2849	.	O
2850	This	O
2850	mutation	O
2850	results	O
2850	in	O
2850	a	O
2850	Gly	O
2850	-	O
2850	-	O
2850	-	O
2850	-	O
2850	Arg	O
2850	substitution	O
2850	at	O
2850	codon	O
2850	664	O
2850	,	O
2850	within	O
2850	the	O
2850	tyrosine	O
2850	kinase	O
2850	domain	O
2850	.	O
2851	This	O
2851	substitution	O
2851	was	O
2851	not	O
2851	seen	O
2851	in	O
2851	any	O
2851	normal	O
2851	individuals	O
2851	and	O
2851	was	O
2851	completely	O
2851	linked	O
2851	to	O
2851	the	O
2851	piebald	B-Disease
2851	phenotype	O
2851	in	O
2851	the	O
2851	probands	O
2851	family	O
2851	.	O
2852	Piebaldism	B-Disease
2852	in	O
2852	this	O
2852	family	O
2852	thus	O
2852	appears	O
2852	to	O
2852	be	O
2852	the	O
2852	human	O
2852	homologue	O
2852	to	O
2852	dominant	O
2852	white	O
2852	spotting	O
2852	(	O
2852	W	O
2852	)	O
2852	of	O
2852	the	O
2852	mouse	O
2852	.	O
2852	.	O
2853	Genetic	O
2853	analysis	O
2853	of	O
2853	a	O
2853	Japanese	O
2853	family	O
2853	with	O
2853	normotriglyceridemic	B-Disease
2853	abetalipoproteinemia	I-Disease
2853	indicates	O
2853	a	O
2853	lack	O
2853	of	O
2853	linkage	O
2853	to	O
2853	the	O
2853	apolipoprotein	O
2853	B	O
2853	gene	O
2853	.	O
2854	Normotriglyceridemic	B-Disease
2854	abetalipoproteinemia	I-Disease
2854	is	O
2854	a	O
2854	rare	O
2854	familial	B-Disease
2854	disorder	I-Disease
2854	characterized	O
2854	by	O
2854	an	O
2854	isolated	O
2854	deficiency	B-Disease
2854	of	I-Disease
2854	apoB	I-Disease
2854	-	I-Disease
2854	100	I-Disease
2854	.	O
2855	We	O
2855	have	O
2855	previously	O
2855	reported	O
2855	a	O
2855	patient	O
2855	with	O
2855	this	O
2855	disease	O
2855	,	O
2855	who	O
2855	had	O
2855	normal	O
2855	apoB	O
2855	-	O
2855	48	O
2855	but	O
2855	no	O
2855	apoB	O
2855	-	O
2855	100	O
2855	.	O
2856	To	O
2856	elucidate	O
2856	the	O
2856	genetic	B-Disease
2856	abnormalities	I-Disease
2856	in	O
2856	this	O
2856	family	O
2856	,	O
2856	we	O
2856	studied	O
2856	the	O
2856	linkage	O
2856	of	O
2856	apoB	O
2856	gene	O
2856	using	O
2856	three	O
2856	genetic	O
2856	markers	O
2856	.	O
2857	The	O
2857	proband	O
2857	and	O
2857	her	O
2857	affected	O
2857	brother	O
2857	showed	O
2857	completely	O
2857	different	O
2857	apoB	O
2857	gene	O
2857	alleles	O
2857	,	O
2857	suggesting	O
2857	that	O
2857	the	O
2857	apoB	O
2857	gene	O
2857	itself	O
2857	is	O
2857	not	O
2857	related	O
2857	to	O
2857	this	O
2857	disorder	O
2857	in	O
2857	this	O
2857	family	O
2857	.	O
2858	By	O
2858	contrast	O
2858	,	O
2858	an	O
2858	American	O
2858	case	O
2858	had	O
2858	a	O
2858	point	O
2858	substitution	O
2858	in	O
2858	the	O
2858	apoB	O
2858	gene	O
2858	generating	O
2858	an	O
2858	in	O
2858	-	O
2858	frame	O
2858	stop	O
2858	codon	O
2858	.	O
2859	These	O
2859	results	O
2859	indicate	O
2859	that	O
2859	this	O
2859	disorder	O
2859	can	O
2859	be	O
2859	caused	O
2859	by	O
2859	defect	O
2859	(	O
2859	s	O
2859	)	O
2859	of	O
2859	either	O
2859	an	O
2859	apoB	O
2859	gene	O
2859	or	O
2859	other	O
2859	genes	O
2859	.	O
2859	.	O
2860	Localisation	O
2860	of	O
2860	the	O
2860	gene	O
2860	for	O
2860	Norrie	B-Disease
2860	disease	I-Disease
2860	to	O
2860	between	O
2860	DXS7	O
2860	and	O
2860	DXS426	O
2860	on	O
2860	Xp	O
2860	.	O
2861	A	O
2861	highly	O
2861	informative	O
2861	microsatellite	O
2861	marker	O
2861	,	O
2861	DXS426	O
2861	,	O
2861	which	O
2861	maps	O
2861	proximal	O
2861	to	O
2861	DXS7	O
2861	in	O
2861	the	O
2861	interval	O
2861	Xp11	O
2861	.	O
2862	4	O
2862	-	O
2862	Xp11	O
2862	4	O
2862	-	O
2862	Xp11	O
2862	.	O
2863	23	O
2863	,	O
2863	has	O
2863	been	O
2863	used	O
2863	to	O
2863	refine	O
2863	further	O
2863	the	O
2863	localisation	O
2863	of	O
2863	the	O
2863	gene	O
2863	for	O
2863	Norrie	B-Disease
2863	disease	I-Disease
2863	(	O
2863	NDP	B-Disease
2863	)	O
2863	.	O
2864	The	O
2864	results	O
2864	from	O
2864	a	O
2864	multiply	O
2864	informative	O
2864	crossover	O
2864	localize	O
2864	the	O
2864	NDP	B-Disease
2864	gene	O
2864	proximal	O
2864	to	O
2864	DXS7	O
2864	.	O
2865	In	O
2865	conjunction	O
2865	with	O
2865	information	O
2865	from	O
2865	2	O
2865	NDP	B-Disease
2865	patients	O
2865	who	O
2865	have	O
2865	a	O
2865	deletion	O
2865	for	O
2865	DXS7	O
2865	but	O
2865	not	O
2865	for	O
2865	DSX426	O
2865	,	O
2865	our	O
2865	data	O
2865	indicate	O
2865	that	O
2865	the	O
2865	NDP	B-Disease
2865	gene	O
2865	lies	O
2865	between	O
2865	DXS7	O
2865	and	O
2865	DXS426	O
2865	on	O
2865	proximal	O
2865	Xp	O
2865	.	O
2866	Aberrant	O
2866	splicing	O
2866	of	O
2866	phenylalanine	O
2866	hydroxylase	O
2866	mRNA	O
2866	:	O
2866	the	O
2866	major	O
2866	cause	O
2866	for	O
2866	phenylketonuria	B-Disease
2866	in	O
2866	parts	O
2866	of	O
2866	southern	O
2866	Europe	O
2866	.	O
2867	We	O
2867	report	O
2867	a	O
2867	mutation	O
2867	within	O
2867	the	O
2867	phenylalanine	O
2867	hydroxylase	O
2867	(	O
2867	PAH	O
2867	)	O
2867	gene	O
2867	that	O
2867	causes	O
2867	aberrant	O
2867	splicing	O
2867	of	O
2867	the	O
2867	mRNA	O
2867	and	O
2867	that	O
2867	is	O
2867	in	O
2867	tight	O
2867	association	O
2867	with	O
2867	chromosomal	O
2867	haplotypes	O
2867	6	O
2867	,	O
2867	10	O
2867	,	O
2867	and	O
2867	36	O
2867	.	O
2868	Because	O
2868	of	O
2868	the	O
2868	high	O
2868	frequency	O
2868	of	O
2868	these	O
2868	particular	O
2868	haplotypes	O
2868	in	O
2868	Bulgaria	O
2868	,	O
2868	Italy	O
2868	,	O
2868	and	O
2868	Turkey	O
2868	,	O
2868	it	O
2868	appears	O
2868	to	O
2868	be	O
2868	one	O
2868	of	O
2868	the	O
2868	more	O
2868	frequent	O
2868	defects	O
2868	in	O
2868	the	O
2868	PAH	O
2868	gene	O
2868	causing	O
2868	classical	O
2868	phenylketonuria	B-Disease
2868	in	O
2868	this	O
2868	part	O
2868	of	O
2868	Europe	O
2868	.	O
2869	The	O
2869	mutation	O
2869	is	O
2869	a	O
2869	G	O
2869	to	O
2869	A	O
2869	transition	O
2869	at	O
2869	position	O
2869	546	O
2869	in	O
2869	intron	O
2869	10	O
2869	of	O
2869	the	O
2869	PAH	O
2869	gene	O
2869	,	O
2869	11	O
2869	bp	O
2869	upstream	O
2869	from	O
2869	the	O
2869	intron	O
2869	10	O
2869	/	O
2869	exon	O
2869	11	O
2869	boundary	O
2869	.	O
2870	It	O
2870	activates	O
2870	a	O
2870	cryptic	O
2870	splice	O
2870	site	O
2870	and	O
2870	results	O
2870	in	O
2870	an	O
2870	in	O
2870	-	O
2870	frame	O
2870	insertion	O
2870	of	O
2870	9	O
2870	nucleotides	O
2870	between	O
2870	exon	O
2870	10	O
2870	and	O
2870	exon	O
2870	11	O
2870	of	O
2870	the	O
2870	processed	O
2870	mRNA	O
2870	.	O
2871	Normal	O
2871	amounts	O
2871	of	O
2871	liver	O
2871	PAH	O
2871	protein	O
2871	are	O
2871	present	O
2871	in	O
2871	homozygous	O
2871	patients	O
2871	,	O
2871	but	O
2871	no	O
2871	catalytic	O
2871	activity	O
2871	can	O
2871	be	O
2871	detected	O
2871	.	O
2872	This	O
2872	loss	O
2872	of	O
2872	enzyme	O
2872	activity	O
2872	is	O
2872	probably	O
2872	caused	O
2872	by	O
2872	conformational	O
2872	changes	O
2872	resulting	O
2872	from	O
2872	the	O
2872	insertion	O
2872	of	O
2872	three	O
2872	additional	O
2872	amino	O
2872	acids	O
2872	(	O
2872	Gly	O
2872	-	O
2872	Leu	O
2872	-	O
2872	Gln	O
2872	)	O
2872	between	O
2872	the	O
2872	normal	O
2872	sequences	O
2872	encoded	O
2872	by	O
2872	exon	O
2872	10	O
2872	and	O
2872	exon	O
2872	11	O
2872	.	O
2872	.	O
2873	Gardner	B-Disease
2873	syndrome	I-Disease
2873	in	O
2873	a	O
2873	boy	O
2873	with	O
2873	interstitial	O
2873	deletion	O
2873	of	O
2873	the	O
2873	long	O
2873	arm	O
2873	of	O
2873	chromosome	O
2873	5	O
2873	.	O
2874	We	O
2874	described	O
2874	a	O
2874	15	O
2874	-	O
2874	year	O
2874	-	O
2874	old	O
2874	boy	O
2874	with	O
2874	Gardner	B-Disease
2874	syndrome	I-Disease
2874	(	O
2874	GS	B-Disease
2874	)	O
2874	,	O
2874	mental	B-Disease
2874	retardation	I-Disease
2874	,	O
2874	and	O
2874	craniofacial	B-Disease
2874	abnormalities	I-Disease
2874	.	O
2875	High	O
2875	-	O
2875	resolution	O
2875	banding	O
2875	analysis	O
2875	showed	O
2875	an	O
2875	interstitial	O
2875	deletion	O
2875	of	O
2875	the	O
2875	long	O
2875	arm	O
2875	of	O
2875	chromosome	O
2875	5	O
2875	(	O
2875	q22	O
2875	.	O
2875	1	O
2875	-	O
2875	-	O
2875	-	O
2875	-	O
2875	q31	O
2875	1	O
2875	-	O
2875	-	O
2875	-	O
2875	-	O
2875	q31	O
2875	.	O
2875	1	O
2875	)	O
2875	.	O
2876	The	O
2876	breakpoints	O
2876	in	O
2876	the	O
2876	present	O
2876	case	O
2876	and	O
2876	in	O
2876	3	O
2876	previously	O
2876	reported	O
2876	5q	O
2876	-	O
2876	patients	O
2876	with	O
2876	adenomatous	B-Disease
2876	polyposis	I-Disease
2876	coli	I-Disease
2876	suggest	O
2876	that	O
2876	the	O
2876	gene	O
2876	responsible	O
2876	for	O
2876	GS	B-Disease
2876	/	O
2876	or	O
2876	familial	B-Disease
2876	polyposis	I-Disease
2876	coli	I-Disease
2876	(	O
2876	FPC	B-Disease
2876	)	O
2876	is	O
2876	in	O
2876	the	O
2876	5q22	O
2876	region	O
2876	,	O
2876	a	O
2876	result	O
2876	consistent	O
2876	with	O
2876	the	O
2876	findings	O
2876	of	O
2876	linkage	O
2876	studies	O
2877	Huntington	B-Disease
2877	disease	I-Disease
2877	and	O
2877	childhood	O
2877	-	O
2877	onset	O
2877	Tourette	B-Disease
2877	syndrome	I-Disease
2877	.	O
2878	A	O
2878	40	O
2878	-	O
2878	year	O
2878	-	O
2878	old	O
2878	man	O
2878	with	O
2878	childhood	O
2878	-	O
2878	onset	O
2878	Tourette	B-Disease
2878	syndrome	I-Disease
2878	(	O
2878	TS	B-Disease
2878	)	O
2878	developed	O
2878	Huntington	B-Disease
2878	disease	I-Disease
2878	(	O
2878	HD	B-Disease
2878	)	O
2878	.	O
2879	We	O
2879	believe	O
2879	this	O
2879	to	O
2879	be	O
2879	the	O
2879	first	O
2879	reported	O
2879	case	O
2879	of	O
2879	childhood	O
2879	-	O
2879	onset	O
2879	TS	B-Disease
2879	with	O
2879	adult	O
2879	onset	O
2879	HD	B-Disease
2879	.	O
2880	Discovery	O
2880	of	O
2880	other	O
2880	cases	O
2880	with	O
2880	both	O
2880	disorders	O
2880	may	O
2880	provide	O
2880	clues	O
2880	to	O
2880	the	O
2880	pathophysiology	O
2880	of	O
2880	both	O
2880	conditions	O
2880	.	O
2880	.	O
2881	Sequence	O
2881	of	O
2881	DNA	O
2881	flanking	O
2881	the	O
2881	exons	O
2881	of	O
2881	the	O
2881	HEXA	O
2881	gene	O
2881	,	O
2881	and	O
2881	identification	O
2881	of	O
2881	mutations	O
2881	in	O
2881	Tay	B-Disease
2881	-	I-Disease
2881	Sachs	I-Disease
2881	disease	I-Disease
2881	.	O
2882	The	O
2882	rapid	O
2882	identification	O
2882	of	O
2882	mutations	O
2882	causing	O
2882	Tay	B-Disease
2882	-	I-Disease
2882	Sachs	I-Disease
2882	disease	I-Disease
2882	requires	O
2882	the	O
2882	capacity	O
2882	to	O
2882	readily	O
2882	screen	O
2882	the	O
2882	regions	O
2882	of	O
2882	the	O
2882	HEXA	O
2882	gene	O
2882	most	O
2882	likely	O
2882	to	O
2882	be	O
2882	affected	O
2882	by	O
2882	mutation	O
2882	.	O
2883	We	O
2883	have	O
2883	sequenced	O
2883	the	O
2883	portions	O
2883	of	O
2883	the	O
2883	introns	O
2883	flanking	O
2883	each	O
2883	of	O
2883	the	O
2883	14	O
2883	HEXA	O
2883	exons	O
2883	in	O
2883	order	O
2883	to	O
2883	specify	O
2883	oligonucleotide	O
2883	primers	O
2883	for	O
2883	the	O
2883	PCR	O
2883	-	O
2883	dependent	O
2883	amplification	O
2883	of	O
2883	each	O
2883	exon	O
2883	and	O
2883	splice	O
2883	-	O
2883	junction	O
2883	sequence	O
2883	.	O
2884	The	O
2884	amplified	O
2884	products	O
2884	were	O
2884	analyzed	O
2884	,	O
2884	by	O
2884	electrophoresis	O
2884	in	O
2884	nondenaturing	O
2884	polyacrylamide	O
2884	gels	O
2884	,	O
2884	for	O
2884	the	O
2884	presence	O
2884	of	O
2884	either	O
2884	heteroduplexes	O
2884	,	O
2884	derived	O
2884	from	O
2884	the	O
2884	annealing	O
2884	of	O
2884	normal	O
2884	and	O
2884	mutant	O
2884	DNA	O
2884	strands	O
2884	,	O
2884	or	O
2884	single	O
2884	-	O
2884	strand	O
2884	conformational	O
2884	polymorphisms	O
2884	(	O
2884	SSCP	O
2884	)	O
2884	,	O
2884	derived	O
2884	from	O
2884	the	O
2884	renaturation	O
2884	of	O
2884	single	O
2884	-	O
2884	stranded	O
2884	DNA	O
2884	.	O
2885	Five	O
2885	novel	O
2885	mutations	O
2885	from	O
2885	Tay	B-Disease
2885	-	I-Disease
2885	Sachs	I-Disease
2885	disease	I-Disease
2885	patients	O
2885	were	O
2885	detected	O
2885	a	O
2885	5	O
2885	-	O
2885	bp	O
2885	deletion	O
2885	of	O
2885	TCTCC	O
2885	in	O
2885	IVS	O
2885	-	O
2885	9	O
2885	;	O
2885	a	O
2885	2	O
2885	-	O
2885	bp	O
2885	deletion	O
2885	of	O
2885	TG	O
2885	in	O
2885	exon	O
2885	5	O
2885	;	O
2885	G78	O
2885	to	O
2885	A	O
2885	,	O
2885	giving	O
2885	a	O
2885	stop	O
2885	codon	O
2885	in	O
2885	exon	O
2885	1	O
2885	;	O
2885	G533	O
2885	to	O
2885	T	O
2885	in	O
2885	exon	O
2885	5	O
2885	,	O
2885	producing	O
2885	the	O
2885	third	O
2885	amino	O
2885	acid	O
2885	substitution	O
2885	detected	O
2885	at	O
2885	this	O
2885	site	O
2885	;	O
2885	and	O
2885	G	O
2885	to	O
2885	C	O
2885	at	O
2885	position	O
2885	1	O
2885	of	O
2885	IVS	O
2885	-	O
2885	2	O
2885	,	O
2885	expected	O
2885	to	O
2885	produce	O
2885	abnormal	O
2885	splicing	O
2885	.	O
2886	In	O
2886	addition	O
2886	,	O
2886	two	O
2886	mutations	O
2886	,	O
2886	(	O
2886	G1496	O
2886	to	O
2886	A	O
2886	in	O
2886	exon	O
2886	13	O
2886	and	O
2886	a	O
2886	4	O
2886	-	O
2886	bp	O
2886	insertion	O
2886	in	O
2886	exon	O
2886	11	O
2886	)	O
2886	that	O
2886	have	O
2886	previously	O
2886	been	O
2886	reported	O
2886	were	O
2886	identified	O
2886	.	O
2886	.	O
2887	Molecular	O
2887	characterization	O
2887	of	O
2887	two	O
2887	galactosemia	B-Disease
2887	mutations	O
2887	:	O
2887	correlation	O
2887	of	O
2887	mutations	O
2887	with	O
2887	highly	O
2887	conserved	O
2887	domains	O
2887	in	O
2887	galactose	O
2887	-	O
2887	1	O
2887	-	O
2887	phosphate	O
2887	uridyl	O
2887	transferase	O
2887	.	O
2888	Galactosemia	B-Disease
2888	is	O
2888	an	O
2888	autosomal	B-Disease
2888	recessive	I-Disease
2888	disorder	I-Disease
2888	of	I-Disease
2888	human	I-Disease
2888	galactose	I-Disease
2888	metabolism	I-Disease
2888	caused	O
2888	by	O
2888	deficiency	B-Disease
2888	of	I-Disease
2888	the	I-Disease
2888	enzyme	I-Disease
2888	galactose	I-Disease
2888	-	I-Disease
2888	1	I-Disease
2888	-	I-Disease
2888	phosphate	I-Disease
2888	uridyl	I-Disease
2888	transferase	I-Disease
2888	(	O
2888	GALT	O
2888	)	O
2888	.	O
2889	The	O
2889	molecular	O
2889	basis	O
2889	of	O
2889	this	O
2889	disorder	O
2889	is	O
2889	at	O
2889	present	O
2889	not	O
2889	well	O
2889	understood	O
2889	.	O
2890	We	O
2890	report	O
2890	here	O
2890	two	O
2890	missense	O
2890	mutations	O
2890	which	O
2890	result	O
2890	in	O
2890	low	O
2890	or	O
2890	undetectable	O
2890	enzymatic	O
2890	activity	O
2890	.	O
2891	First	O
2891	,	O
2891	we	O
2891	identified	O
2891	at	O
2891	nucleotide	O
2891	591	O
2891	a	O
2891	transition	O
2891	which	O
2891	substitutes	O
2891	glutamine	O
2891	188	O
2891	by	O
2891	arginine	O
2891	.	O
2892	The	O
2892	mutated	O
2892	glutamine	O
2892	is	O
2892	not	O
2892	only	O
2892	highly	O
2892	conserved	O
2892	in	O
2892	evolution	O
2892	(	O
2892	conserved	O
2892	also	O
2892	in	O
2892	Escherichia	O
2892	coli	O
2892	and	O
2892	Saccharomyces	O
2892	cerevisiae	O
2892	)	O
2892	,	O
2892	but	O
2892	is	O
2892	also	O
2892	two	O
2892	amino	O
2892	acid	O
2892	residues	O
2892	downstream	O
2892	from	O
2892	the	O
2892	active	O
2892	site	O
2892	histidine	O
2892	-	O
2892	proline	O
2892	-	O
2892	histidine	O
2892	triad	O
2892	and	O
2892	results	O
2892	in	O
2892	about	O
2892	10	O
2892	%	O
2892	of	O
2892	normal	O
2892	enzymatic	O
2892	activity	O
2892	.	O
2893	The	O
2893	arginine	O
2893	188	O
2893	mutation	O
2893	is	O
2893	the	O
2893	most	O
2893	common	O
2893	galactosemia	B-Disease
2893	mutation	O
2893	characterized	O
2893	to	O
2893	date	O
2893	.	O
2894	It	O
2894	accounts	O
2894	for	O
2894	one	O
2894	-	O
2894	fourth	O
2894	of	O
2894	the	O
2894	galactosemia	B-Disease
2894	alleles	O
2894	studied	O
2894	.	O
2895	Second	O
2895	,	O
2895	we	O
2895	report	O
2895	the	O
2895	substitution	O
2895	of	O
2895	arginine	O
2895	333	O
2895	by	O
2895	tryptophan	O
2895	,	O
2895	caused	O
2895	by	O
2895	a	O
2895	transition	O
2895	at	O
2895	nucleotide	O
2895	1025	O
2895	.	O
2896	The	O
2896	area	O
2896	surrounding	O
2896	this	O
2896	missense	O
2896	mutation	O
2896	is	O
2896	the	O
2896	most	O
2896	highly	O
2896	conserved	O
2896	domain	O
2896	in	O
2896	the	O
2896	homologous	O
2896	enzymes	O
2896	from	O
2896	E	O
2896	.	O
2896	coli	O
2896	,	O
2896	yeast	O
2896	,	O
2896	and	O
2896	humans	O
2896	,	O
2896	and	O
2896	this	O
2896	mutation	O
2896	results	O
2896	in	O
2896	undetectable	O
2896	enzymatic	O
2896	activity	O
2896	,	O
2896	suggesting	O
2896	that	O
2896	this	O
2896	is	O
2896	a	O
2896	severe	O
2896	mutation	O
2896	.	O
2897	This	O
2897	second	O
2897	mutation	O
2897	appears	O
2897	to	O
2897	be	O
2897	rare	O
2897	,	O
2897	since	O
2897	it	O
2897	was	O
2897	found	O
2897	only	O
2897	in	O
2897	the	O
2897	patient	O
2897	we	O
2897	sequenced	O
2897	.	O
2898	Our	O
2898	data	O
2898	provide	O
2898	further	O
2898	evidence	O
2898	for	O
2898	the	O
2898	heterogeneity	O
2898	of	O
2898	galactosemia	B-Disease
2898	at	O
2898	the	O
2898	molecular	O
2898	level	O
2898	,	O
2898	heterogeneity	O
2898	which	O
2898	might	O
2898	be	O
2898	related	O
2898	to	O
2898	the	O
2898	variable	O
2898	clinical	O
2898	outcome	O
2898	observed	O
2898	in	O
2898	this	O
2898	disorder	O
2898	.	O
2898	.	O
2899	Hypoxanthine	B-Disease
2899	-	I-Disease
2899	guanine	I-Disease
2899	phosphoribosyltransferase	I-Disease
2899	deficiency	I-Disease
2899	:	O
2899	analysis	O
2899	of	O
2899	HPRT	O
2899	mutations	O
2899	by	O
2899	direct	O
2899	sequencing	O
2899	and	O
2899	allele	O
2899	-	O
2899	specific	O
2899	amplification	O
2899	.	O
2900	The	O
2900	Lesch	B-Disease
2900	-	I-Disease
2900	Nyhan	I-Disease
2900	syndrome	I-Disease
2900	is	O
2900	a	O
2900	severe	O
2900	X	B-Disease
2900	chromosome	I-Disease
2900	-	I-Disease
2900	linked	I-Disease
2900	human	I-Disease
2900	disease	I-Disease
2900	caused	O
2900	by	O
2900	a	O
2900	virtual	O
2900	absence	B-Disease
2900	of	I-Disease
2900	hypoxanthine	I-Disease
2900	-	I-Disease
2900	guanine	I-Disease
2900	phosphoribosyltransferase	I-Disease
2900	(	I-Disease
2900	HPRT	I-Disease
2900	)	I-Disease
2900	activity	I-Disease
2900	.	O
2901	A	O
2901	partial	O
2901	deficiency	O
2901	in	O
2901	the	O
2901	activity	O
2901	of	O
2901	this	O
2901	enzyme	O
2901	can	O
2901	result	O
2901	in	O
2901	gouty	B-Disease
2901	arthritis	I-Disease
2901	.	O
2902	To	O
2902	determine	O
2902	the	O
2902	genetic	O
2902	basis	O
2902	for	O
2902	reduction	O
2902	or	O
2902	loss	O
2902	of	O
2902	enzyme	O
2902	activity	O
2902	,	O
2902	we	O
2902	have	O
2902	amplified	O
2902	and	O
2902	sequenced	O
2902	the	O
2902	coding	O
2902	region	O
2902	of	O
2902	HPRT	O
2902	cDNA	O
2902	from	O
2902	four	O
2902	patients	O
2902	one	O
2902	with	O
2902	Lesch	B-Disease
2902	-	I-Disease
2902	Nyhan	I-Disease
2902	syndrome	I-Disease
2902	(	O
2902	HPRTPerth	O
2902	)	O
2902	and	O
2902	three	O
2902	with	O
2902	partial	B-Disease
2902	deficiencies	I-Disease
2902	of	I-Disease
2902	HPRT	I-Disease
2902	activity	I-Disease
2902	,	O
2902	which	O
2902	have	O
2902	been	O
2902	designated	O
2902	HPRTUrangan	O
2902	,	O
2902	HPRTSwan	O
2902	and	O
2902	HPRTToowong	O
2902	.	O
2903	In	O
2903	all	O
2903	four	O
2903	patients	O
2903	,	O
2903	the	O
2903	only	O
2903	mutation	O
2903	identified	O
2903	was	O
2903	a	O
2903	single	O
2903	base	O
2903	substitution	O
2903	in	O
2903	exons	O
2903	2	O
2903	or	O
2903	3	O
2903	of	O
2903	the	O
2903	coding	O
2903	region	O
2903	,	O
2903	which	O
2903	in	O
2903	each	O
2903	case	O
2903	predicts	O
2903	a	O
2903	single	O
2903	amino	O
2903	acid	O
2903	substitution	O
2903	in	O
2903	the	O
2903	translated	O
2903	protein	O
2903	.	O
2904	Each	O
2904	base	O
2904	change	O
2904	was	O
2904	confirmed	O
2904	by	O
2904	allele	O
2904	-	O
2904	specific	O
2904	amplification	O
2904	of	O
2904	the	O
2904	patients	O
2904	genomic	O
2904	DNA	O
2904	.	O
2905	It	O
2905	is	O
2905	interesting	O
2905	to	O
2905	note	O
2905	that	O
2905	the	O
2905	mutation	O
2905	found	O
2905	for	O
2905	HPRTPerth	O
2905	is	O
2905	identical	O
2905	to	O
2905	that	O
2905	reported	O
2905	for	O
2905	HPRTFlint	O
2905	.	O
2906	It	O
2906	appears	O
2906	that	O
2906	the	O
2906	two	O
2906	mutations	O
2906	are	O
2906	de	O
2906	novo	O
2906	events	O
2906	.	O
2906	.	O
2907	Molecular	O
2907	and	O
2907	metabolic	O
2907	basis	O
2907	for	O
2907	the	O
2907	metabolic	B-Disease
2907	disorder	I-Disease
2907	normotriglyceridemic	B-Disease
2907	abetalipoproteinemia	I-Disease
2907	.	O
2908	We	O
2908	have	O
2908	previously	O
2908	described	O
2908	a	O
2908	disorder	O
2908	,	O
2908	normotriglyceridemic	B-Disease
2908	abetalipoproteinemia	I-Disease
2908	,	O
2908	that	O
2908	is	O
2908	characterized	O
2908	by	O
2908	the	O
2908	virtual	O
2908	absence	O
2908	of	O
2908	plasma	O
2908	low	O
2908	density	O
2908	lipoproteins	O
2908	and	O
2908	complete	O
2908	absence	O
2908	of	O
2908	apoB	O
2908	-	O
2908	100	O
2908	,	O
2908	but	O
2908	with	O
2908	apparently	O
2908	normal	O
2908	secretion	O
2908	of	O
2908	triglyceride	O
2908	-	O
2908	rich	O
2908	lipoproteins	O
2908	containing	O
2908	apoB	O
2908	-	O
2908	48	O
2908	.	O
2909	The	O
2909	patients	O
2909	plasma	O
2909	lipoproteins	O
2909	were	O
2909	shown	O
2909	on	O
2909	polyacrylamide	O
2909	gels	O
2909	and	O
2909	by	O
2909	antibody	O
2909	mapping	O
2909	to	O
2909	have	O
2909	a	O
2909	new	O
2909	truncated	O
2909	apoB	O
2909	variant	O
2909	,	O
2909	apoB	O
2909	-	O
2909	50	O
2909	,	O
2909	circulating	O
2909	along	O
2909	with	O
2909	her	O
2909	apoB	O
2909	-	O
2909	48	O
2909	.	O
2910	We	O
2910	have	O
2910	found	O
2910	this	O
2910	individual	O
2910	to	O
2910	be	O
2910	homozygous	O
2910	for	O
2910	a	O
2910	single	O
2910	C	O
2910	-	O
2910	to	O
2910	-	O
2910	T	O
2910	nucleotide	O
2910	substitution	O
2910	at	O
2910	apoB	O
2910	codon	O
2910	2252	O
2910	,	O
2910	which	O
2910	produces	O
2910	a	O
2910	premature	O
2910	in	O
2910	-	O
2910	frame	O
2910	stop	O
2910	codon	O
2910	.	O
2911	Thus	O
2911	,	O
2911	this	O
2911	is	O
2911	a	O
2911	rare	O
2911	example	O
2911	of	O
2911	homozygous	B-Disease
2911	hypobetalipoproteinemia	I-Disease
2911	.	O
2912	Electron	O
2912	photomicrographs	O
2912	revealed	O
2912	that	O
2912	the	O
2912	diameters	O
2912	of	O
2912	particles	O
2912	in	O
2912	the	O
2912	d	O
2912	less	O
2912	than	O
2912	1	O
2912	.	O
2913	006	O
2913	g	O
2913	/	O
2913	ml	O
2913	lipoprotein	O
2913	fraction	O
2913	,	O
2913	in	O
2913	both	O
2913	the	O
2913	postprandial	O
2913	and	O
2913	postabsorptive	O
2913	state	O
2913	,	O
2913	are	O
2913	bimodally	O
2913	distributed	O
2913	.	O
2914	The	O
2914	molar	O
2914	ratio	O
2914	of	O
2914	apoE	O
2914	to	O
2914	apoB	O
2914	in	O
2914	these	O
2914	particles	O
2914	is	O
2914	3	O
2914	.	O
2915	5	O
2915	1	O
2915	,	O
2915	similar	O
2915	to	O
2915	normal	O
2915	VLDL	O
2915	.	O
2916	The	O
2916	plasma	O
2916	LDL	O
2916	interval	O
2916	contains	O
2916	both	O
2916	spherical	O
2916	and	O
2916	cuboidal	O
2916	particles	O
2916	.	O
2917	Autologous	O
2917	reinfusion	O
2917	of	O
2917	labeled	O
2917	d	O
2917	less	O
2917	than	O
2917	1	O
2917	.	O
2918	006	O
2918	g	O
2918	/	O
2918	ml	O
2918	lipoproteins	O
2918	showed	O
2918	exponential	O
2918	disappearance	O
2918	from	O
2918	plasma	O
2918	,	O
2918	with	O
2918	an	O
2918	apparent	O
2918	half	O
2918	-	O
2918	removal	O
2918	time	O
2918	of	O
2918	50	O
2918	min	O
2918	,	O
2918	somewhat	O
2918	slower	O
2918	than	O
2918	for	O
2918	normal	O
2918	chylomicrons	O
2918	but	O
2918	within	O
2918	the	O
2918	normal	O
2918	range	O
2918	for	O
2918	VLDL	O
2918	.	O
2919	The	O
2919	calculated	O
2919	production	O
2919	rate	O
2919	for	O
2919	apoB	O
2919	was	O
2919	within	O
2919	the	O
2919	normal	O
2919	range	O
2919	in	O
2919	this	O
2919	subject	O
2919	.	O
2920	A	O
2920	single	O
2920	origin	O
2920	of	O
2920	phenylketonuria	B-Disease
2920	in	O
2920	Yemenite	O
2920	Jews	O
2920	.	O
2921	Phenylketonuria	B-Disease
2921	(	O
2921	PKU	B-Disease
2921	)	O
2921	is	O
2921	a	O
2921	metabolic	B-Disease
2921	disease	I-Disease
2921	caused	O
2921	by	O
2921	recessive	O
2921	mutations	O
2921	of	O
2921	the	O
2921	gene	O
2921	encoding	O
2921	the	O
2921	hepatic	O
2921	enzyme	O
2921	phenylalanine	O
2921	hydroxylase	O
2921	(	O
2921	PAH	O
2921	)	O
2921	.	O
2922	The	O
2922	incidence	O
2922	of	O
2922	PKU	B-Disease
2922	varies	O
2922	widely	O
2922	across	O
2922	different	O
2922	geographic	O
2922	areas	O
2922	,	O
2922	and	O
2922	is	O
2922	highest	O
2922	(	O
2922	about	O
2922	1	O
2922	in	O
2922	5	O
2922	,	O
2922	000	O
2922	live	O
2922	births	O
2922	)	O
2922	in	O
2922	Ireland	O
2922	and	O
2922	western	O
2922	Scotland	O
2922	,	O
2922	and	O
2922	among	O
2922	Yemenite	O
2922	Jews	O
2922	.	O
2923	A	O
2923	limited	O
2923	number	O
2923	of	O
2923	point	O
2923	mutations	O
2923	account	O
2923	for	O
2923	most	O
2923	of	O
2923	the	O
2923	PKU	B-Disease
2923	cases	O
2923	in	O
2923	the	O
2923	European	O
2923	population	O
2923	.	O
2924	Here	O
2924	we	O
2924	report	O
2924	that	O
2924	a	O
2924	single	O
2924	molecular	O
2924	defect	O
2924	-	O
2924	-	O
2924	a	O
2924	deletion	O
2924	spanning	O
2924	the	O
2924	third	O
2924	exon	O
2924	of	O
2924	the	O
2924	PAH	O
2924	gene	O
2924	-	O
2924	-	O
2924	is	O
2924	responsible	O
2924	for	O
2924	all	O
2924	the	O
2924	PKU	B-Disease
2924	cases	O
2924	among	O
2924	the	O
2924	Yemenite	O
2924	Jews	O
2924	.	O
2925	Examination	O
2925	of	O
2925	a	O
2925	random	O
2925	sample	O
2925	of	O
2925	Yemenite	O
2925	Jews	O
2925	using	O
2925	a	O
2925	molecular	O
2925	probe	O
2925	that	O
2925	detects	O
2925	the	O
2925	carriers	O
2925	of	O
2925	this	O
2925	deletion	O
2925	indicated	O
2925	a	O
2925	high	O
2925	frequency	O
2925	of	O
2925	the	O
2925	defective	O
2925	gene	O
2925	in	O
2925	this	O
2925	community	O
2925	.	O
2926	Although	O
2926	the	O
2926	deleted	O
2926	PAH	O
2926	gene	O
2926	was	O
2926	traced	O
2926	to	O
2926	25	O
2926	different	O
2926	locations	O
2926	throughout	O
2926	Yemen	O
2926	,	O
2926	family	O
2926	histories	O
2926	and	O
2926	official	O
2926	documents	O
2926	of	O
2926	the	O
2926	Yemenite	O
2926	Jewish	O
2926	community	O
2926	showed	O
2926	that	O
2926	the	O
2926	common	O
2926	ancestor	O
2926	of	O
2926	all	O
2926	the	O
2926	carriers	O
2926	of	O
2926	this	O
2926	genetic	B-Disease
2926	defect	I-Disease
2926	lived	O
2926	in	O
2926	Sana	O
2926	,	O
2926	the	O
2926	capital	O
2926	of	O
2926	Yemen	O
2926	,	O
2926	before	O
2926	the	O
2926	eighteenth	O
2926	century	O
2926	.	O
2926	.	O
2927	Linkage	O
2927	of	O
2927	aspartylglucosaminuria	B-Disease
2927	(	O
2927	AGU	B-Disease
2927	)	O
2927	to	O
2927	marker	O
2927	loci	O
2927	on	O
2927	the	O
2927	long	O
2927	arm	O
2927	of	O
2927	chromosome	O
2927	4	O
2927	.	O
2928	Aspartylglucosaminuria	B-Disease
2928	(	O
2928	AGU	B-Disease
2928	)	O
2928	is	O
2928	caused	O
2928	by	O
2928	deficient	O
2928	activity	O
2928	of	O
2928	the	O
2928	enzyme	O
2928	aspartylglucosaminidase	O
2928	(	O
2928	AGA	O
2928	)	O
2928	.	O
2929	The	O
2929	structural	O
2929	gene	O
2929	for	O
2929	AGA	O
2929	has	O
2929	been	O
2929	assigned	O
2929	to	O
2929	the	O
2929	region	O
2929	4q21	O
2929	-	O
2929	qter	O
2929	of	O
2929	chromosome	O
2929	4	O
2929	.	O
2930	We	O
2930	have	O
2930	studied	O
2930	the	O
2930	map	O
2930	position	O
2930	of	O
2930	the	O
2930	AGU	O
2930	locus	O
2930	in	O
2930	relation	O
2930	to	O
2930	other	O
2930	marker	O
2930	loci	O
2930	on	O
2930	the	O
2930	long	O
2930	arm	O
2930	of	O
2930	chromosome	O
2930	4	O
2930	using	O
2930	linkage	O
2930	analyses	O
2930	.	O
2931	Restriction	O
2931	fragment	O
2931	length	O
2931	polymorphism	O
2931	alleles	O
2931	for	O
2931	the	O
2931	ADH2	O
2931	,	O
2931	ADH3	O
2931	,	O
2931	EGF	O
2931	,	O
2931	FG	O
2931	alpha	O
2931	and	O
2931	FG	O
2931	beta	O
2931	loci	O
2931	and	O
2931	blood	O
2931	group	O
2931	antigens	O
2931	for	O
2931	the	O
2931	MNS	O
2931	locus	O
2931	were	O
2931	determined	O
2931	in	O
2931	a	O
2931	panel	O
2931	of	O
2931	12	O
2931	Finnish	O
2931	AGU	B-Disease
2931	families	O
2931	.	O
2932	The	O
2932	heterozygous	O
2932	family	O
2932	members	O
2932	were	O
2932	identified	O
2932	by	O
2932	reduced	O
2932	activity	O
2932	of	O
2932	AGA	O
2932	in	O
2932	lymphocytes	O
2932	.	O
2933	Linkage	O
2933	studies	O
2933	were	O
2933	performed	O
2933	using	O
2933	both	O
2933	pairwise	O
2933	and	O
2933	multipoint	O
2933	analyses	O
2933	.	O
2934	Loose	O
2934	linkage	O
2934	of	O
2934	the	O
2934	AGU	B-Disease
2934	locus	O
2934	to	O
2934	the	O
2934	FG	O
2934	and	O
2934	MNS	O
2934	loci	O
2934	was	O
2934	observed	O
2934	(	O
2934	z	O
2934	=	O
2934	1	O
2934	.	O
2934	16	O
2934	,	O
2934	z	O
2934	=	O
2934	1	O
2934	.	O
2934	39	O
2934	,	O
2934	respectively	O
2934	)	O
2934	.	O
2935	Multipoint	O
2935	analysis	O
2935	to	O
2935	the	O
2935	fixed	O
2935	map	O
2935	[	O
2935	ADH	O
2935	-	O
2935	(	O
2935	0	O
2935	.	O
2935	03	O
2935	)	O
2935	-	O
2935	EGF	O
2935	-	O
2935	(	O
2935	0	O
2935	.	O
2935	35	O
2935	)	O
2935	-	O
2935	FG	O
2935	-	O
2935	(	O
2935	0	O
2935	.	O
2935	11	O
2935	)	O
2935	-	O
2935	MNS	O
2935	]	O
2935	suggests	O
2935	that	O
2935	the	O
2935	location	O
2935	of	O
2935	the	O
2935	AGU	O
2935	locus	O
2935	is	O
2935	0	O
2935	.	O
2936	05	O
2936	-	O
2936	0	O
2936	.	O
2937	30	O
2937	recombination	O
2937	units	O
2937	distal	O
2937	to	O
2937	MNS	O
2937	(	O
2937	z	O
2937	=	O
2937	3	O
2937	.	O
2937	03	O
2937	)	O
2937	.	O
2938	The	O
2938	order	O
2938	cen	O
2938	-	O
2938	ADH	O
2938	-	O
2938	EGF	O
2938	-	O
2938	FG	O
2938	-	O
2938	MNS	O
2938	-	O
2938	AGU	O
2938	is	O
2938	35	O
2938	times	O
2938	more	O
2938	likely	O
2938	than	O
2938	the	O
2938	next	O
2938	best	O
2938	order	O
2938	cen	O
2938	-	O
2938	ADH	O
2938	-	O
2938	EGF	O
2938	-	O
2938	AGU	O
2938	-	O
2938	FG	O
2938	-	O
2938	MNS	O
2938	.	O
2939	Linkage	O
2939	relationships	O
2939	of	O
2939	the	O
2939	apolipoprotein	O
2939	C1	O
2939	gene	O
2939	and	O
2939	a	O
2939	cytochrome	O
2939	P450	O
2939	gene	O
2939	(	O
2939	CYP2A	O
2939	)	O
2939	to	O
2939	myotonic	B-Disease
2939	dystrophy	I-Disease
2939	.	O
2940	We	O
2940	have	O
2940	studied	O
2940	the	O
2940	genetic	O
2940	linkage	O
2940	of	O
2940	two	O
2940	markers	O
2940	,	O
2940	the	O
2940	apolipoprotein	O
2940	C1	O
2940	(	O
2940	APOC1	O
2940	)	O
2940	gene	O
2940	and	O
2940	a	O
2940	cytochrome	O
2940	P450	O
2940	(	O
2940	CYP2A	O
2940	)	O
2940	gene	O
2940	,	O
2940	in	O
2940	relation	O
2940	to	O
2940	the	O
2940	gene	O
2940	for	O
2940	myotonic	B-Disease
2940	dystrophy	I-Disease
2940	(	O
2940	DM	B-Disease
2940	)	O
2940	.	O
2941	A	O
2941	peak	O
2941	lod	O
2941	score	O
2941	of	O
2941	9	O
2941	.	O
2942	29	O
2942	at	O
2942	2	O
2942	cM	O
2942	was	O
2942	observed	O
2942	for	O
2942	APOC1	O
2942	-	O
2942	DM	O
2942	,	O
2942	with	O
2942	a	O
2942	lod	O
2942	score	O
2942	of	O
2942	8	O
2942	.	O
2943	55	O
2943	at	O
2943	4	O
2943	cM	O
2943	for	O
2943	CYP2A	O
2943	-	O
2943	DM	O
2943	.	O
2944	These	O
2944	two	O
2944	markers	O
2944	also	O
2944	show	O
2944	close	O
2944	linkage	O
2944	to	O
2944	each	O
2944	other	O
2944	(	O
2944	theta	O
2944	max	O
2944	=	O
2944	0	O
2944	.	O
2944	05	O
2944	,	O
2944	Zmax	O
2944	=	O
2944	9	O
2944	.	O
2944	09	O
2944	)	O
2944	.	O
2945	From	O
2945	examination	O
2945	of	O
2945	the	O
2945	genotypes	O
2945	of	O
2945	the	O
2945	recombinant	O
2945	individuals	O
2945	,	O
2945	CYP2A	O
2945	appears	O
2945	to	O
2945	map	O
2945	proximal	O
2945	to	O
2945	DM	O
2945	because	O
2945	in	O
2945	one	O
2945	recombinant	O
2945	individual	O
2945	CYP2A	O
2945	,	O
2945	APOC2	O
2945	and	O
2945	CKMM	O
2945	had	O
2945	all	O
2945	recombined	O
2945	with	O
2945	DM	O
2945	.	O
2946	Evidence	O
2946	from	O
2946	another	O
2946	CYP2A	O
2946	-	O
2946	DM	O
2946	recombinant	O
2946	individual	O
2946	places	O
2946	CYP2A	O
2946	proximal	O
2946	to	O
2946	APOC2	O
2946	and	O
2946	CKMM	O
2946	.	O
2947	Localisation	O
2947	of	O
2947	CYP2A	O
2947	on	O
2947	a	O
2947	panel	O
2947	of	O
2947	somatic	O
2947	cell	O
2947	hybrids	O
2947	also	O
2947	suggests	O
2947	that	O
2947	it	O
2947	is	O
2947	proximal	O
2947	to	O
2947	DM	O
2947	and	O
2947	APOC2	O
2947	/	O
2947	C1	O
2947	/	O
2947	E	O
2947	gene	O
2947	cluster	O
2947	.	O
2948	Genetic	O
2948	linkage	O
2948	map	O
2948	of	O
2948	six	O
2948	polymorphic	O
2948	DNA	O
2948	markers	O
2948	around	O
2948	the	O
2948	gene	O
2948	for	O
2948	familial	B-Disease
2948	adenomatous	I-Disease
2948	polyposis	I-Disease
2948	on	O
2948	chromosome	O
2948	5	O
2948	.	O
2949	A	O
2949	genetic	O
2949	linkage	O
2949	map	O
2949	of	O
2949	six	O
2949	polymorphic	O
2949	DNA	O
2949	markers	O
2949	close	O
2949	to	O
2949	the	O
2949	gene	O
2949	(	O
2949	APC	O
2949	)	O
2949	for	O
2949	familial	B-Disease
2949	adenomatous	I-Disease
2949	polyposis	I-Disease
2949	(	O
2949	FAP	B-Disease
2949	)	O
2949	on	O
2949	chromosome	O
2949	5q	O
2949	is	O
2949	reported	O
2949	.	O
2950	One	O
2950	hundred	O
2950	fifty	O
2950	-	O
2950	five	O
2950	typed	O
2950	members	O
2950	of	O
2950	nine	O
2950	FAP	B-Disease
2950	kindred	O
2950	provided	O
2950	more	O
2950	than	O
2950	90	O
2950	meioses	O
2950	for	O
2950	linkage	O
2950	analysis	O
2950	.	O
2951	A	O
2951	number	O
2951	of	O
2951	crucial	O
2951	recombination	O
2951	events	O
2951	have	O
2951	been	O
2951	identified	O
2951	which	O
2951	are	O
2951	informative	O
2951	at	O
2951	three	O
2951	or	O
2951	more	O
2951	loci	O
2951	,	O
2951	allowing	O
2951	confident	O
2951	ordering	O
2951	of	O
2951	parts	O
2951	of	O
2951	the	O
2951	map	O
2951	.	O
2952	There	O
2952	was	O
2952	no	O
2952	evidence	O
2952	of	O
2952	genetic	O
2952	heterogeneity	O
2952	,	O
2952	with	O
2952	all	O
2952	families	O
2952	showing	O
2952	linkage	O
2952	of	O
2952	at	O
2952	least	O
2952	one	O
2952	chromosome	O
2952	5	O
2952	marker	O
2952	to	O
2952	the	O
2952	gene	O
2952	.	O
2953	Recombination	O
2953	data	O
2953	and	O
2953	two	O
2953	-	O
2953	point	O
2953	linkage	O
2953	analysis	O
2953	support	O
2953	a	O
2953	locus	O
2953	order	O
2953	of	O
2953	centromere	O
2953	-	O
2953	pi	O
2953	227	O
2953	-	O
2953	C11P11	O
2953	-	O
2953	ECB27	O
2953	-	O
2953	L5	O
2953	.	O
2954	62	O
2954	-	O
2954	APC	O
2954	-	O
2954	EF5	O
2954	62	O
2954	-	O
2954	APC	O
2954	-	O
2954	EF5	O
2954	.	O
2955	44	O
2955	-	O
2955	YN5	O
2955	44	O
2955	-	O
2955	YN5	O
2955	.	O
2956	48	O
2956	-	O
2956	telomer	O
2956	e	O
2956	,	O
2956	although	O
2956	EF5	O
2956	.	O
2957	44	O
2957	could	O
2957	lie	O
2957	in	O
2957	the	O
2957	interval	O
2957	L5	O
2957	.	O
2958	62	O
2958	-	O
2958	APC	O
2958	or	O
2958	ECB27	O
2958	-	O
2958	L5	O
2958	.	O
2959	62	O
2959	.	O
2960	No	O
2960	recombinants	O
2960	were	O
2960	identified	O
2960	between	O
2960	APC	O
2960	and	O
2960	either	O
2960	EF5	O
2960	.	O
2961	44	O
2961	or	O
2961	YN5	O
2961	.	O
2962	48	O
2962	,	O
2962	but	O
2962	published	O
2962	deletion	O
2962	mapping	O
2962	in	O
2962	colorectal	B-Disease
2962	carcinomas	I-Disease
2962	and	O
2962	linkage	O
2962	analysis	O
2962	in	O
2962	FAP	B-Disease
2962	suggest	O
2962	that	O
2962	YN5	O
2962	.	O
2963	48	O
2963	is	O
2963	1	O
2963	-	O
2963	3	O
2963	cM	O
2963	from	O
2963	APC	O
2963	.	O
2964	The	O
2964	present	O
2964	study	O
2964	suggests	O
2964	that	O
2964	YN5	O
2964	.	O
2965	48	O
2965	and	O
2965	L5	O
2965	.	O
2966	62	O
2966	delineate	O
2966	a	O
2966	small	O
2966	region	O
2966	of	O
2966	chromosome	O
2966	5	O
2966	within	O
2966	which	O
2966	the	O
2966	EF5	O
2966	.	O
2967	44	O
2967	locus	O
2967	lies	O
2967	very	O
2967	close	O
2967	to	O
2967	the	O
2967	APC	B-Disease
2967	gene	O
2967	.	O
2968	These	O
2968	data	O
2968	not	O
2968	only	O
2968	allow	O
2968	use	O
2968	of	O
2968	flanking	O
2968	markers	O
2968	for	O
2968	presymptomatic	O
2968	diagnosis	O
2968	of	O
2968	FAP	B-Disease
2968	but	O
2968	also	O
2968	provide	O
2968	a	O
2968	high	O
2968	-	O
2968	density	O
2968	map	O
2968	of	O
2968	the	O
2968	region	O
2968	for	O
2968	isolation	O
2968	of	O
2968	the	O
2968	APC	B-Disease
2968	gene	O
2968	itself	O
2968	and	O
2968	for	O
2968	further	O
2968	assessment	O
2968	of	O
2968	the	O
2968	role	O
2968	of	O
2968	chromosome	O
2968	5	O
2968	deletions	O
2968	in	O
2968	the	O
2968	biology	O
2968	of	O
2968	sporadic	O
2968	colorectal	B-Disease
2968	cancer	I-Disease
2968	.	O
2969	Serum	O
2969	amyloid	O
2969	A	O
2969	and	O
2969	P	O
2969	protein	O
2969	genes	O
2969	in	O
2969	familial	B-Disease
2969	Mediterranean	I-Disease
2969	fever	I-Disease
2969	.	O
2970	Two	O
2970	recent	O
2970	studies	O
2970	have	O
2970	suggested	O
2970	the	O
2970	involvement	O
2970	of	O
2970	serum	O
2970	amyloid	O
2970	A	O
2970	(	O
2970	SAA	O
2970	)	O
2970	and	O
2970	P	O
2970	(	O
2970	APCS	O
2970	)	O
2970	genes	O
2970	in	O
2970	familial	B-Disease
2970	Mediterranean	I-Disease
2970	fever	I-Disease
2970	(	O
2970	MEF	B-Disease
2970	)	O
2970	.	O
2971	To	O
2971	test	O
2971	the	O
2971	role	O
2971	of	O
2971	SAA	O
2971	and	O
2971	APCS	O
2971	in	O
2971	MEF	B-Disease
2971	and	O
2971	MEF	B-Disease
2971	-	I-Disease
2971	amyloidosis	I-Disease
2971	,	O
2971	we	O
2971	studied	O
2971	17	O
2971	informative	O
2971	families	O
2971	(	O
2971	15	O
2971	Armenians	O
2971	,	O
2971	2	O
2971	non	O
2971	-	O
2971	Ashkenazi	O
2971	Jews	O
2971	)	O
2971	and	O
2971	8	O
2971	MEF	B-Disease
2971	patients	O
2971	with	O
2971	amyloidosis	B-Disease
2971	using	O
2971	a	O
2971	candidate	O
2971	gene	O
2971	approach	O
2971	.	O
2972	No	O
2972	evidence	O
2972	for	O
2972	any	O
2972	MEF	B-Disease
2972	-	O
2972	associated	O
2972	polymorphism	O
2972	was	O
2972	found	O
2972	in	O
2972	any	O
2972	of	O
2972	the	O
2972	41	O
2972	Armenian	O
2972	and	O
2972	Jewish	O
2972	MEF	B-Disease
2972	patients	O
2972	tested	O
2972	.	O
2973	Our	O
2973	family	O
2973	studies	O
2973	allowed	O
2973	us	O
2973	to	O
2973	rule	O
2973	out	O
2973	tight	O
2973	linkage	O
2973	between	O
2973	SAA	O
2973	and	O
2973	MEF	B-Disease
2973	(	O
2973	lod	O
2973	score	O
2973	=	O
2973	-	O
2973	2	O
2973	.	O
2973	16	O
2973	,	O
2973	theta	O
2973	less	O
2973	than	O
2973	or	O
2973	equal	O
2973	to	O
2973	0	O
2973	.	O
2973	06	O
2973	)	O
2973	.	O
2974	For	O
2974	APCS	O
2974	we	O
2974	found	O
2974	that	O
2974	the	O
2974	allele	O
2974	frequency	O
2974	in	O
2974	the	O
2974	MEF	B-Disease
2974	-	I-Disease
2974	amyloidosis	I-Disease
2974	patients	O
2974	was	O
2974	similar	O
2974	to	O
2974	that	O
2974	in	O
2974	18	O
2974	unrelated	O
2974	MEF	B-Disease
2974	patients	O
2974	without	O
2974	amyloidosis	B-Disease
2974	and	O
2974	their	O
2974	33	O
2974	healthy	O
2974	parents	O
2974	.	O
2975	Some	O
2975	Mexican	O
2975	glucose	O
2975	-	O
2975	6	O
2975	-	O
2975	phosphate	O
2975	dehydrogenase	O
2975	variants	O
2975	revisited	O
2975	.	O
2976	Glucose	B-Disease
2976	-	I-Disease
2976	6	I-Disease
2976	-	I-Disease
2976	phosphate	I-Disease
2976	dehydrogenase	I-Disease
2976	(	I-Disease
2976	G6PD	I-Disease
2976	)	I-Disease
2976	deficiency	I-Disease
2976	appears	O
2976	to	O
2976	be	O
2976	fairly	O
2976	common	O
2976	in	O
2976	Mexico	O
2976	.	O
2977	We	O
2977	have	O
2977	now	O
2977	examined	O
2977	the	O
2977	DNA	O
2977	of	O
2977	three	O
2977	previously	O
2977	reported	O
2977	electrophoretically	O
2977	fast	O
2977	Mexican	O
2977	G6PD	O
2977	variants	O
2977	,	O
2977	-	O
2977	G6PD	O
2977	Distrito	O
2977	Federal	O
2977	,	O
2977	G6PD	O
2977	Tepic	O
2977	,	O
2977	and	O
2977	G6PD	O
2977	Castilla	O
2977	.	O
2978	All	O
2978	three	O
2978	of	O
2978	these	O
2978	variants	O
2978	,	O
2978	believed	O
2978	on	O
2978	the	O
2978	basis	O
2978	of	O
2978	biochemical	O
2978	characterization	O
2978	and	O
2978	population	O
2978	origin	O
2978	to	O
2978	be	O
2978	unique	O
2978	,	O
2978	have	O
2978	the	O
2978	G	O
2978	-	O
2978	-	O
2978	-	O
2978	-	O
2978	A	O
2978	transition	O
2978	at	O
2978	nucleotide	O
2978	202	O
2978	and	O
2978	the	O
2978	A	O
2978	-	O
2978	-	O
2978	-	O
2978	-	O
2978	G	O
2978	transition	O
2978	at	O
2978	nucleotide	O
2978	376	O
2978	,	O
2978	mutations	O
2978	that	O
2978	we	O
2978	now	O
2978	recognize	O
2978	to	O
2978	be	O
2978	characteristic	O
2978	of	O
2978	G6PD	O
2978	A	O
2978	-	O
2978	.	O
2979	Two	O
2979	other	O
2979	Mexican	O
2979	males	O
2979	with	O
2979	G6PD	B-Disease
2979	deficiency	I-Disease
2979	were	O
2979	found	O
2979	to	O
2979	have	O
2979	the	O
2979	same	O
2979	mutation	O
2979	.	O
2980	All	O
2980	five	O
2980	have	O
2980	the	O
2980	(	O
2980	NlaIII	O
2980	/	O
2980	FokI	O
2980	/	O
2980	PvuII	O
2980	/	O
2980	PstI	O
2980	)	O
2980	haplotype	O
2980	characteristic	O
2980	of	O
2980	G6PD	O
2980	A	O
2980	-	O
2980	in	O
2980	Africa	O
2980	.	O
2981	Since	O
2981	the	O
2981	PvuII	O
2981	+	O
2981	genotype	O
2981	seems	O
2981	to	O
2981	be	O
2981	rare	O
2981	in	O
2981	Europe	O
2981	,	O
2981	we	O
2981	conclude	O
2981	that	O
2981	all	O
2981	of	O
2981	these	O
2981	G6PD	O
2981	A	O
2981	-	O
2981	genes	O
2981	had	O
2981	their	O
2981	ancient	O
2981	origin	O
2981	in	O
2981	Africa	O
2981	,	O
2981	although	O
2981	in	O
2981	many	O
2981	of	O
2981	the	O
2981	Mexican	O
2981	patients	O
2981	with	O
2981	G6PD	O
2981	A	O
2981	-	O
2981	202A	O
2981	/	O
2981	376G	O
2981	the	O
2981	gene	O
2981	may	O
2981	have	O
2981	been	O
2981	imported	O
2981	more	O
2981	recently	O
2981	from	O
2981	Spain	O
2981	,	O
2981	where	O
2981	this	O
2981	variant	O
2981	,	O
2981	formerly	O
2981	known	O
2981	as	O
2981	G6PD	O
2981	Betica	O
2981	,	O
2981	is	O
2981	also	O
2981	prevalent	O
2981	.	O
2981	.	O
2982	Hereditary	O
2982	deficiency	B-Disease
2982	of	I-Disease
2982	C5	I-Disease
2982	in	O
2982	association	O
2982	with	O
2982	discoid	B-Disease
2982	lupus	I-Disease
2982	erythematosus	I-Disease
2982	.	O
2983	A	O
2983	29	O
2983	-	O
2983	year	O
2983	-	O
2983	old	O
2983	woman	O
2983	with	O
2983	discoid	B-Disease
2983	lupus	I-Disease
2983	erythematosus	I-Disease
2983	had	O
2983	undetectable	O
2983	classic	O
2983	pathway	O
2983	complement	O
2983	activity	O
2983	.	O
2984	Hypocomplementemia	B-Disease
2984	was	O
2984	due	O
2984	to	O
2984	selective	O
2984	deficiency	B-Disease
2984	of	I-Disease
2984	C5	I-Disease
2984	.	O
2985	One	O
2985	of	O
2985	her	O
2985	children	O
2985	was	O
2985	also	O
2985	deficient	O
2985	.	O
2986	To	O
2986	our	O
2986	knowledge	O
2986	this	O
2986	is	O
2986	the	O
2986	first	O
2986	documented	O
2986	case	O
2986	of	O
2986	an	O
2986	association	O
2986	between	O
2986	discoid	B-Disease
2986	lupus	I-Disease
2986	erythematosus	I-Disease
2986	and	O
2986	C5	B-Disease
2986	deficiency	I-Disease
2986	.	O
2986	.	O
2987	Founder	O
2987	effect	O
2987	of	O
2987	a	O
2987	prevalent	O
2987	phenylketonuria	B-Disease
2987	mutation	O
2987	in	O
2987	the	O
2987	Oriental	O
2987	population	O
2987	.	O
2988	A	O
2988	missense	O
2988	mutation	O
2988	has	O
2988	been	O
2988	identified	O
2988	in	O
2988	the	O
2988	human	O
2988	phenylalanine	O
2988	hydroxylase	O
2988	[	O
2988	PAH	O
2988	;	O
2988	phenylalanine	O
2988	4	O
2988	-	O
2988	monooxygenase	O
2988	;	O
2988	L	O
2988	-	O
2988	phenylalanine	O
2988	,	O
2988	tetrahydrobiopterin	O
2988	oxygen	O
2988	oxidoreductase	O
2988	(	O
2988	4	O
2988	-	O
2988	hydroxylating	O
2988	)	O
2988	,	O
2988	EC	O
2988	1	O
2988	.	O
2988	14	O
2988	.	O
2988	16	O
2988	.	O
2988	1	O
2988	]	O
2988	gene	O
2988	in	O
2988	a	O
2988	Chinese	O
2988	patient	O
2988	with	O
2988	classic	O
2988	phenylketonuria	B-Disease
2988	(	O
2988	PKU	B-Disease
2988	)	O
2988	.	O
2989	A	O
2989	G	O
2989	-	O
2989	to	O
2989	-	O
2989	C	O
2989	transition	O
2989	at	O
2989	the	O
2989	second	O
2989	base	O
2989	of	O
2989	codon	O
2989	413	O
2989	in	O
2989	exon	O
2989	12	O
2989	of	O
2989	the	O
2989	gene	O
2989	results	O
2989	in	O
2989	the	O
2989	substitution	O
2989	of	O
2989	Pro413	O
2989	for	O
2989	Arg413	O
2989	in	O
2989	the	O
2989	mutant	O
2989	protein	O
2989	.	O
2990	This	O
2990	mutation	O
2990	(	O
2990	R413P	O
2990	)	O
2990	results	O
2990	in	O
2990	negligible	O
2990	enzymatic	O
2990	activity	O
2990	when	O
2990	expressed	O
2990	in	O
2990	heterologous	O
2990	mammalian	O
2990	cells	O
2990	and	O
2990	is	O
2990	compatible	O
2990	with	O
2990	a	O
2990	classic	O
2990	PKU	B-Disease
2990	phenotype	O
2990	in	O
2990	the	O
2990	patient	O
2990	.	O
2991	Population	O
2991	genetic	O
2991	studies	O
2991	reveal	O
2991	that	O
2991	this	O
2991	mutation	O
2991	is	O
2991	tightly	O
2991	linked	O
2991	to	O
2991	restriction	O
2991	fragment	O
2991	length	O
2991	polymorphism	O
2991	haplotype	O
2991	4	O
2991	,	O
2991	which	O
2991	is	O
2991	the	O
2991	predominant	O
2991	haplotype	O
2991	of	O
2991	the	O
2991	PAH	O
2991	locus	O
2991	in	O
2991	the	O
2991	Oriental	O
2991	population	O
2991	.	O
2992	It	O
2992	accounts	O
2992	for	O
2992	13	O
2992	.	O
2993	8	O
2993	%	O
2993	of	O
2993	northern	O
2993	Chinese	O
2993	and	O
2993	27	O
2993	%	O
2993	of	O
2993	Japanese	O
2993	PKU	B-Disease
2993	alleles	O
2993	,	O
2993	but	O
2993	it	O
2993	is	O
2993	rare	O
2993	in	O
2993	southern	O
2993	Chinese	O
2993	(	O
2993	2	O
2993	.	O
2993	2	O
2993	%	O
2993	)	O
2993	and	O
2993	is	O
2993	absent	O
2993	in	O
2993	the	O
2993	Caucasian	O
2993	population	O
2993	.	O
2994	The	O
2994	data	O
2994	demonstrate	O
2994	unambiguously	O
2994	that	O
2994	the	O
2994	mutation	O
2994	occurred	O
2994	after	O
2994	racial	O
2994	divergence	O
2994	of	O
2994	Orientals	O
2994	and	O
2994	Caucasians	O
2994	and	O
2994	suggest	O
2994	that	O
2994	the	O
2994	allele	O
2994	has	O
2994	spread	O
2994	throughout	O
2994	the	O
2994	Orient	O
2994	by	O
2994	a	O
2994	founder	O
2994	effect	O
2994	.	O
2995	Previous	O
2995	protein	O
2995	polymorphism	O
2995	studies	O
2995	in	O
2995	eastern	O
2995	Asia	O
2995	have	O
2995	led	O
2995	to	O
2995	the	O
2995	hypothesis	O
2995	that	O
2995	"	NN	O	O
2995	northern	NN	O	O
2995	Mongoloids	NN	O	O
2995	"	O
2995	represented	O
2995	a	O
2995	founding	O
2995	population	O
2995	in	O
2995	Asia	O
2995	.	O
2996	Our	O
2996	results	O
2996	are	O
2996	compatible	O
2996	with	O
2996	this	O
2996	hypothesis	O
2996	in	O
2996	that	O
2996	the	O
2996	PKU	B-Disease
2996	mutation	O
2996	might	O
2996	have	O
2996	occurred	O
2996	in	O
2996	northern	O
2996	Mongoloids	O
2996	and	O
2996	subsequently	O
2996	spread	O
2996	to	O
2996	the	O
2996	Chinese	O
2996	and	O
2996	Japanese	O
2996	populations	O
2996	.	O
2997	Glucose	B-Disease
2997	/	I-Disease
2997	galactose	I-Disease
2997	malabsorption	I-Disease
2997	caused	O
2997	by	O
2997	a	O
2997	defect	O
2997	in	O
2997	the	O
2997	Na	O
2997	+	O
2997	/	O
2997	glucose	O
2997	cotransporter	O
2997	.	O
2998	Glucose	B-Disease
2998	/	I-Disease
2998	galactose	I-Disease
2998	malabsorption	I-Disease
2998	(	O
2998	GGM	B-Disease
2998	)	O
2998	is	O
2998	an	O
2998	autosomal	B-Disease
2998	recessive	I-Disease
2998	disease	I-Disease
2998	manifesting	O
2998	within	O
2998	the	O
2998	first	O
2998	weeks	O
2998	of	O
2998	life	O
2998	and	O
2998	characterized	O
2998	by	O
2998	a	O
2998	selective	O
2998	failure	O
2998	to	O
2998	absorb	O
2998	dietary	O
2998	glucose	O
2998	and	O
2998	galactose	O
2998	from	O
2998	the	O
2998	intestine	O
2998	.	O
2999	The	O
2999	consequent	O
2999	severe	O
2999	diarrhoea	B-Disease
2999	and	O
2999	dehydration	B-Disease
2999	are	O
2999	usually	O
2999	fatal	O
2999	unless	O
2999	these	O
2999	sugars	O
2999	are	O
2999	eliminated	O
2999	from	O
2999	the	O
2999	diet	O
2999	.	O
3000	Intestinal	O
3000	biopsies	O
3000	of	O
3000	GGM	B-Disease
3000	patients	O
3000	have	O
3000	revealed	O
3000	a	O
3000	specific	O
3000	defect	O
3000	in	O
3000	Na	O
3000	(	O
3000	+	O
3000	)	O
3000	-	O
3000	dependent	O
3000	absorption	O
3000	of	O
3000	glucose	O
3000	in	O
3000	the	O
3000	brush	O
3000	border	O
3000	.	O
3001	Normal	O
3001	glucose	O
3001	absorption	O
3001	is	O
3001	mediated	O
3001	by	O
3001	the	O
3001	Na	O
3001	+	O
3001	/	O
3001	glucose	O
3001	cotransporter	O
3001	in	O
3001	the	O
3001	brush	O
3001	border	O
3001	membrane	O
3001	of	O
3001	the	O
3001	intestinal	O
3001	epithelium	O
3001	.	O
3002	Cellular	O
3002	influx	O
3002	is	O
3002	driven	O
3002	by	O
3002	the	O
3002	transmembrane	O
3002	Na	O
3002	+	O
3002	electrochemical	O
3002	potential	O
3002	gradient	O
3002	;	O
3002	thereafter	O
3002	the	O
3002	sugar	O
3002	moves	O
3002	to	O
3002	the	O
3002	blood	O
3002	across	O
3002	the	O
3002	basolateral	O
3002	membrane	O
3002	via	O
3002	the	O
3002	facilitated	O
3002	glucose	O
3002	carrier	O
3002	.	O
3003	We	O
3003	have	O
3003	previously	O
3003	cloned	O
3003	and	O
3003	sequenced	O
3003	a	O
3003	Na	O
3003	+	O
3003	/	O
3003	glucose	O
3003	cotransporter	O
3003	from	O
3003	normal	O
3003	human	O
3003	ileum	O
3003	and	O
3003	shown	O
3003	that	O
3003	this	O
3003	gene	O
3003	,	O
3003	SGLT1	O
3003	,	O
3003	resides	O
3003	on	O
3003	the	O
3003	distal	O
3003	q	O
3003	arm	O
3003	of	O
3003	chromosome	O
3003	22	O
3003	.	O
3004	We	O
3004	have	O
3004	now	O
3004	amplified	O
3004	SGLT1	O
3004	complementary	O
3004	DNA	O
3004	and	O
3004	genomic	O
3004	DNA	O
3004	from	O
3004	members	O
3004	of	O
3004	a	O
3004	family	O
3004	affected	O
3004	with	O
3004	GGM	B-Disease
3004	by	O
3004	the	O
3004	polymerase	O
3004	chain	O
3004	reaction	O
3004	.	O
3005	Sequence	O
3005	analysis	O
3005	of	O
3005	the	O
3005	amplified	O
3005	products	O
3005	has	O
3005	revealed	O
3005	a	O
3005	single	O
3005	missense	O
3005	mutation	O
3005	in	O
3005	SGLT1	O
3005	which	O
3005	cosegregates	O
3005	with	O
3005	the	O
3005	GGM	B-Disease
3005	phenotype	O
3005	and	O
3005	results	O
3005	in	O
3005	a	O
3005	complete	O
3005	loss	O
3005	of	O
3005	Na	O
3005	(	O
3005	+	O
3005	)	O
3005	-	O
3005	dependent	O
3005	glucose	O
3005	transport	O
3005	in	O
3005	Xenopus	O
3005	oocytes	O
3005	injected	O
3005	with	O
3005	this	O
3005	complementary	O
3005	RNA	O
3005	.	O
3005	.	O
3006	A	O
3006	de	O
3006	novo	O
3006	unbalanced	O
3006	reciprocal	O
3006	translocation	O
3006	identified	O
3006	as	O
3006	paternal	O
3006	in	O
3006	origin	O
3006	in	O
3006	the	O
3006	Prader	B-Disease
3006	-	I-Disease
3006	Willi	I-Disease
3006	syndrome	I-Disease
3006	.	O
3007	Interstitial	O
3007	cytogenetic	O
3007	deletions	O
3007	involving	O
3007	the	O
3007	paternally	O
3007	derived	O
3007	chromosome	O
3007	15q11	O
3007	-	O
3007	13	O
3007	have	O
3007	been	O
3007	described	O
3007	in	O
3007	patients	O
3007	with	O
3007	the	O
3007	Prader	B-Disease
3007	-	I-Disease
3007	Willi	I-Disease
3007	syndrome	I-Disease
3007	(	O
3007	PWS	B-Disease
3007	)	O
3007	.	O
3008	We	O
3008	report	O
3008	a	O
3008	child	O
3008	with	O
3008	PWS	B-Disease
3008	and	O
3008	a	O
3008	de	O
3008	novo	O
3008	unbalanced	O
3008	karyotype	O
3008	-	O
3008	45	O
3008	,	O
3008	XY	O
3008	,	O
3008	-	O
3008	9	O
3008	,	O
3008	-	O
3008	15	O
3008	,	O
3008	+	O
3008	der	O
3008	(	O
3008	9	O
3008	)	O
3008	t	O
3008	(	O
3008	9	O
3008	;	O
3008	15	O
3008	)	O
3008	(	O
3008	q34	O
3008	;	O
3008	q13	O
3008	)	O
3008	.	O
3009	Molecular	O
3009	studies	O
3009	with	O
3009	the	O
3009	DNA	O
3009	probe	O
3009	pML34	O
3009	confirmed	O
3009	that	O
3009	only	O
3009	a	O
3009	single	O
3009	Prader	B-Disease
3009	Willi	I-Disease
3009	critical	O
3009	region	O
3009	(	O
3009	PWCR	O
3009	15q11	O
3009	.	O
3009	2	O
3009	-	O
3009	q12	O
3009	)	O
3009	copy	O
3009	was	O
3009	present	O
3009	.	O
3010	Hybridisation	O
3010	of	O
3010	patient	O
3010	and	O
3010	parental	O
3010	DNA	O
3010	with	O
3010	the	O
3010	multi	O
3010	-	O
3010	allelic	O
3010	probe	O
3010	CMW1	O
3010	,	O
3010	which	O
3010	maps	O
3010	to	O
3010	pter	O
3010	-	O
3010	15q13	O
3010	,	O
3010	showed	O
3010	that	O
3010	the	O
3010	chromosome	O
3010	involved	O
3010	in	O
3010	the	O
3010	translocation	O
3010	was	O
3010	paternal	O
3010	in	O
3010	origin	O
3010	.	O
3011	This	O
3011	is	O
3011	the	O
3011	first	O
3011	example	O
3011	of	O
3011	a	O
3011	paternally	O
3011	-	O
3011	derived	O
3011	PWCR	O
3011	allele	O
3011	loss	O
3011	caused	O
3011	by	O
3011	an	O
3011	unbalanced	O
3011	translocation	O
3011	that	O
3011	has	O
3011	arisen	O
3011	de	O
3011	novo	O
3011	.	O
3012	Localisation	O
3012	of	O
3012	the	O
3012	myotonic	B-Disease
3012	dystrophy	I-Disease
3012	locus	O
3012	to	O
3012	19q13	O
3012	.	O
3012	2	O
3012	-	O
3012	19q13	O
3012	.	O
3012	3	O
3012	and	O
3012	its	O
3012	relationship	O
3012	to	O
3012	twelve	O
3012	polymorphic	O
3012	loci	O
3012	on	O
3012	19q	O
3012	.	O
3013	The	O
3013	order	O
3013	of	O
3013	fourteen	O
3013	polymorphic	O
3013	markers	O
3013	localised	O
3013	to	O
3013	the	O
3013	long	O
3013	arm	O
3013	of	O
3013	human	O
3013	chromosome	O
3013	19	O
3013	has	O
3013	been	O
3013	established	O
3013	by	O
3013	multipoint	O
3013	mapping	O
3013	in	O
3013	a	O
3013	set	O
3013	of	O
3013	40	O
3013	CEPH	O
3013	(	O
3013	Centre	O
3013	dEtude	O
3013	de	O
3013	Polymorphisme	O
3013	Humain	O
3013	,	O
3013	Paris	O
3013	)	O
3013	reference	O
3013	families	O
3013	.	O
3014	We	O
3014	report	O
3014	here	O
3014	the	O
3014	linkage	O
3014	relationship	O
3014	of	O
3014	the	O
3014	myotonic	B-Disease
3014	dystrophy	I-Disease
3014	(	O
3014	DM	B-Disease
3014	)	O
3014	locus	O
3014	to	O
3014	twelve	O
3014	of	O
3014	these	O
3014	markers	O
3014	as	O
3014	studied	O
3014	in	O
3014	45	O
3014	families	O
3014	with	O
3014	DM	B-Disease
3014	.	O
3015	The	O
3015	resulting	O
3015	genetic	O
3015	map	O
3015	is	O
3015	supported	O
3015	by	O
3015	the	O
3015	localisation	O
3015	of	O
3015	the	O
3015	DNA	O
3015	markers	O
3015	in	O
3015	a	O
3015	panel	O
3015	of	O
3015	somatic	O
3015	cell	O
3015	hybrids	O
3015	.	O
3016	Ten	O
3016	of	O
3016	the	O
3016	twelve	O
3016	markers	O
3016	have	O
3016	been	O
3016	shown	O
3016	to	O
3016	be	O
3016	proximal	O
3016	to	O
3016	the	O
3016	DM	B-Disease
3016	gene	O
3016	and	O
3016	two	O
3016	,	O
3016	PRKCG	O
3016	and	O
3016	D19S22	O
3016	,	O
3016	distal	O
3016	but	O
3016	at	O
3016	distances	O
3016	of	O
3016	approximately	O
3016	25	O
3016	cM	O
3016	and	O
3016	15	O
3016	cM	O
3016	,	O
3016	respectively	O
3016	.	O
3017	The	O
3017	closest	O
3017	proximal	O
3017	markers	O
3017	are	O
3017	APOC2	O
3017	(	O
3017	apolipoprotein	O
3017	C	O
3017	-	O
3017	II	O
3017	)	O
3017	and	O
3017	CKM	O
3017	(	O
3017	creatine	O
3017	kinase	O
3017	,	O
3017	muscle	O
3017	)	O
3017	approximately	O
3017	3	O
3017	cM	O
3017	and	O
3017	2	O
3017	cM	O
3017	from	O
3017	the	O
3017	DM	B-Disease
3017	gene	O
3017	respectively	O
3017	,	O
3017	in	O
3017	the	O
3017	order	O
3017	APOC2	O
3017	-	O
3017	CKM	O
3017	-	O
3017	DM	O
3017	.	O
3018	The	O
3018	distance	O
3018	between	O
3018	APOC2	O
3018	,	O
3018	CKM	O
3018	and	O
3018	DM	B-Disease
3018	(	O
3018	of	O
3018	the	O
3018	order	O
3018	of	O
3018	2	O
3018	million	O
3018	base	O
3018	pairs	O
3018	)	O
3018	and	O
3018	their	O
3018	known	O
3018	orientation	O
3018	should	O
3018	permit	O
3018	directional	O
3018	chromosome	O
3018	walking	O
3018	and	O
3018	jumping	O
3018	.	O
3019	The	O
3019	data	O
3019	presented	O
3019	here	O
3019	should	O
3019	enable	O
3019	us	O
3019	to	O
3019	determine	O
3019	whether	O
3019	or	O
3019	not	O
3019	new	O
3019	markers	O
3019	are	O
3019	distal	O
3019	to	O
3019	APOC2	O
3019	/	O
3019	CKM	O
3019	and	O
3019	thus	O
3019	potentially	O
3019	flank	O
3019	the	O
3019	DM	B-Disease
3019	gene	O
3019	.	O
3019	.	O
3020	Localization	O
3020	of	O
3020	histidase	O
3020	to	O
3020	human	O
3020	chromosome	O
3020	region	O
3020	12q22	O
3020	-	O
3020	-	O
3020	-	O
3020	-	O
3020	q24	O
3020	.	O
3020	1	O
3020	and	O
3020	mouse	O
3020	chromosome	O
3020	region	O
3020	10C2	O
3020	-	O
3020	-	O
3020	-	O
3020	-	O
3020	D1	O
3020	.	O
3021	The	O
3021	human	O
3021	gene	O
3021	for	O
3021	histidase	O
3021	(	O
3021	histidine	O
3021	ammonia	O
3021	-	O
3021	lyase	O
3021	;	O
3021	HAL	O
3021	)	O
3021	,	O
3021	the	O
3021	enzyme	O
3021	deficient	O
3021	in	O
3021	histidinemia	B-Disease
3021	,	O
3021	was	O
3021	assigned	O
3021	to	O
3021	human	O
3021	chromosome	O
3021	12	O
3021	by	O
3021	Southern	O
3021	blot	O
3021	analysis	O
3021	of	O
3021	human	O
3021	X	O
3021	mouse	O
3021	somatic	O
3021	cell	O
3021	hybrid	O
3021	DNA	O
3021	.	O
3022	The	O
3022	gene	O
3022	was	O
3022	sublocalized	O
3022	to	O
3022	region	O
3022	12q22	O
3022	-	O
3022	-	O
3022	-	O
3022	-	O
3022	q24	O
3022	.	O
3023	1	O
3023	by	O
3023	in	O
3023	situ	O
3023	hybridization	O
3023	,	O
3023	using	O
3023	a	O
3023	human	O
3023	histidase	O
3023	cDNA	O
3023	.	O
3024	The	O
3024	homologous	O
3024	locus	O
3024	in	O
3024	the	O
3024	mouse	O
3024	(	O
3024	Hal	O
3024	)	O
3024	was	O
3024	mapped	O
3024	to	O
3024	region	O
3024	10C2	O
3024	-	O
3024	-	O
3024	-	O
3024	-	O
3024	D1	O
3024	by	O
3024	in	O
3024	situ	O
3024	hybridization	O
3024	,	O
3024	using	O
3024	a	O
3024	cell	O
3024	line	O
3024	from	O
3024	a	O
3024	mouse	O
3024	homozygous	O
3024	for	O
3024	a	O
3024	1	O
3024	.	O
3025	10	O
3025	Robertsonian	O
3025	translocation	O
3025	.	O
3026	These	O
3026	assignments	O
3026	extend	O
3026	the	O
3026	conserved	O
3026	syntenic	O
3026	region	O
3026	between	O
3026	human	O
3026	chromosome	O
3026	12	O
3026	and	O
3026	mouse	O
3026	chromosome	O
3026	10	O
3026	that	O
3026	includes	O
3026	the	O
3026	genes	O
3026	for	O
3026	phenylalanine	O
3026	hydroxylase	O
3026	,	O
3026	gamma	O
3026	interferon	O
3026	,	O
3026	peptidase	O
3026	,	O
3026	and	O
3026	citrate	O
3026	synthase	O
3026	.	O
3027	The	O
3027	localization	O
3027	of	O
3027	histidase	O
3027	to	O
3027	mouse	O
3027	chromosome	O
3027	10	O
3027	suggests	O
3027	that	O
3027	the	O
3027	histidase	O
3027	regulatory	O
3027	locus	O
3027	(	O
3027	Hsd	O
3027	)	O
3027	and	O
3027	the	O
3027	histidinemia	O
3027	mutation	O
3027	(	O
3027	his	O
3027	)	O
3027	,	O
3027	which	O
3027	are	O
3027	both	O
3027	known	O
3027	to	O
3027	be	O
3027	on	O
3027	chromosome	O
3027	10	O
3027	,	O
3027	may	O
3027	be	O
3027	alleles	O
3027	of	O
3027	the	O
3027	histidase	O
3027	structural	O
3027	gene	O
3027	locus	O
3027	.	O
3028	Determination	O
3028	of	O
3028	the	O
3028	mutations	O
3028	responsible	O
3028	for	O
3028	the	O
3028	Lesch	B-Disease
3028	-	I-Disease
3028	Nyhan	I-Disease
3028	syndrome	I-Disease
3028	in	O
3028	17	O
3028	subjects	O
3028	.	O
3029	Hypoxanthine	O
3029	-	O
3029	-	O
3029	guanine	O
3029	phosphoribosyltransferase	O
3029	(	O
3029	HPRT	O
3029	)	O
3029	is	O
3029	a	O
3029	purine	O
3029	salvage	O
3029	enzyme	O
3029	that	O
3029	catalyzes	O
3029	the	O
3029	conversion	O
3029	of	O
3029	hypoxanthine	O
3029	to	O
3029	inosine	O
3029	monophosphate	O
3029	and	O
3029	guanine	O
3029	to	O
3029	guanosine	O
3029	monophosphate	O
3029	.	O
3030	Previous	O
3030	studies	O
3030	of	O
3030	mutant	O
3030	HPRT	O
3030	proteins	O
3030	analyzed	O
3030	at	O
3030	the	O
3030	molecular	O
3030	level	O
3030	have	O
3030	shown	O
3030	a	O
3030	significant	O
3030	heterogeneity	O
3030	.	O
3031	This	O
3031	investigation	O
3031	further	O
3031	verifies	O
3031	this	O
3031	heterogeneity	O
3031	and	O
3031	identifies	O
3031	insertions	O
3031	,	O
3031	deletions	O
3031	,	O
3031	and	O
3031	point	O
3031	mutations	O
3031	.	O
3032	The	O
3032	direct	O
3032	sequencing	O
3032	of	O
3032	the	O
3032	polymerase	O
3032	chain	O
3032	reaction	O
3032	-	O
3032	amplified	O
3032	product	O
3032	of	O
3032	reverse	O
3032	-	O
3032	transcribed	O
3032	HPRT	O
3032	mRNA	O
3032	enabled	O
3032	the	O
3032	rapid	O
3032	identification	O
3032	of	O
3032	the	O
3032	mutations	O
3032	found	O
3032	in	O
3032	17	O
3032	previously	O
3032	uncharacterized	O
3032	cell	O
3032	lines	O
3032	derived	O
3032	from	O
3032	patients	O
3032	with	O
3032	the	O
3032	Lesch	B-Disease
3032	-	I-Disease
3032	Nyhan	I-Disease
3032	syndrome	I-Disease
3032	.	O
3032	.	O
3033	Linkage	O
3033	of	O
3033	DNA	O
3033	markers	O
3033	at	O
3033	Xq28	O
3033	to	O
3033	adrenoleukodystrophy	B-Disease
3033	and	O
3033	adrenomyeloneuropathy	B-Disease
3033	present	O
3033	within	O
3033	the	O
3033	same	O
3033	family	O
3033	.	O
3034	We	O
3034	present	O
3034	a	O
3034	large	O
3034	kindred	O
3034	that	O
3034	contained	O
3034	patients	O
3034	with	O
3034	either	O
3034	adrenoleukodystrophy	B-Disease
3034	(	O
3034	ALD	B-Disease
3034	)	O
3034	or	O
3034	adrenomyeloneuropathy	B-Disease
3034	(	O
3034	AMN	B-Disease
3034	)	O
3034	.	O
3035	The	O
3035	pedigree	O
3035	clearly	O
3035	supported	O
3035	the	O
3035	X	O
3035	-	O
3035	linked	O
3035	mode	O
3035	of	O
3035	inheritance	O
3035	of	O
3035	the	O
3035	nonneonatal	O
3035	form	O
3035	of	O
3035	ALD	B-Disease
3035	/	O
3035	AMN	B-Disease
3035	.	O
3036	Analysis	O
3036	with	O
3036	DNA	O
3036	markers	O
3036	at	O
3036	Xq28	O
3036	suggested	O
3036	segregation	O
3036	of	O
3036	both	O
3036	ALD	B-Disease
3036	and	O
3036	AMN	B-Disease
3036	with	O
3036	an	O
3036	identical	O
3036	haplotype	O
3036	.	O
3037	This	O
3037	indicated	O
3037	that	O
3037	nonneonatal	O
3037	ALD	B-Disease
3037	and	O
3037	AMN	B-Disease
3037	are	O
3037	caused	O
3037	by	O
3037	a	O
3037	mutation	O
3037	in	O
3037	the	O
3037	same	O
3037	gene	O
3037	at	O
3037	Xq28	O
3037	.	O
3038	It	O
3038	showed	O
3038	,	O
3038	furthermore	O
3038	,	O
3038	that	O
3038	phenotypic	O
3038	differences	O
3038	between	O
3038	ALD	B-Disease
3038	and	O
3038	AMN	B-Disease
3038	are	O
3038	not	O
3038	necessarily	O
3038	the	O
3038	consequence	O
3038	of	O
3038	allelic	O
3038	heterogeneity	O
3038	due	O
3038	to	O
3038	different	O
3038	mutations	O
3038	within	O
3038	the	O
3038	same	O
3038	gene	O
3038	.	O
3039	The	O
3039	maximal	O
3039	lod	O
3039	score	O
3039	for	O
3039	linkage	O
3039	of	O
3039	the	O
3039	ALD	B-Disease
3039	/	O
3039	AMN	B-Disease
3039	gene	O
3039	and	O
3039	the	O
3039	multiallelic	O
3039	anonymous	O
3039	DNA	O
3039	marker	O
3039	at	O
3039	DXS52	O
3039	was	O
3039	3	O
3039	.	O
3040	0	O
3040	at	O
3040	a	O
3040	recombination	O
3040	fraction	O
3040	of	O
3040	0	O
3040	.	O
3041	00	O
3041	.	O
3042	This	O
3042	made	O
3042	a	O
3042	prenatal	O
3042	or	O
3042	presymptomatic	O
3042	diagnosis	O
3042	and	O
3042	heterozygote	O
3042	detection	O
3042	by	O
3042	DNA	O
3042	analysis	O
3042	with	O
3042	this	O
3042	marker	O
3042	reliable	O
3042	.	O
3043	Skewed	O
3043	X	O
3043	inactivation	O
3043	in	O
3043	a	O
3043	female	O
3043	MZ	O
3043	twin	O
3043	results	O
3043	in	O
3043	Duchenne	B-Disease
3043	muscular	I-Disease
3043	dystrophy	I-Disease
3043	.	O
3044	One	O
3044	of	O
3044	female	O
3044	MZ	O
3044	twins	O
3044	presented	O
3044	with	O
3044	muscular	B-Disease
3044	dystrophy	I-Disease
3044	.	O
3045	Physical	O
3045	examination	O
3045	,	O
3045	creatine	O
3045	phosphokinase	O
3045	levels	O
3045	,	O
3045	and	O
3045	muscle	O
3045	biopsy	O
3045	were	O
3045	consistent	O
3045	with	O
3045	Duchenne	B-Disease
3045	muscular	I-Disease
3045	dystrophy	I-Disease
3045	(	O
3045	DMD	B-Disease
3045	)	O
3045	.	O
3046	However	O
3046	,	O
3046	because	O
3046	of	O
3046	her	O
3046	sex	O
3046	she	O
3046	was	O
3046	diagnosed	O
3046	as	O
3046	having	O
3046	limb	B-Disease
3046	-	I-Disease
3046	girdle	I-Disease
3046	muscular	I-Disease
3046	dystrophy	I-Disease
3046	.	O
3047	With	O
3047	cDNA	O
3047	probes	O
3047	to	O
3047	the	O
3047	DMD	B-Disease
3047	gene	O
3047	,	O
3047	a	O
3047	gene	O
3047	deletion	O
3047	was	O
3047	detected	O
3047	in	O
3047	the	O
3047	twins	O
3047	and	O
3047	their	O
3047	mother	O
3047	.	O
3048	The	O
3048	de	O
3048	novo	O
3048	mutation	O
3048	which	O
3048	arose	O
3048	in	O
3048	the	O
3048	mother	O
3048	was	O
3048	shown	O
3048	by	O
3048	novel	O
3048	junction	O
3048	fragments	O
3048	generated	O
3048	by	O
3048	HindIII	O
3048	,	O
3048	PstI	O
3048	,	O
3048	or	O
3048	TaqI	O
3048	when	O
3048	probed	O
3048	with	O
3048	cDNA8	O
3048	.	O
3049	Additional	O
3049	evidence	O
3049	of	O
3049	a	O
3049	large	O
3049	gene	O
3049	deletion	O
3049	was	O
3049	given	O
3049	by	O
3049	novel	O
3049	SfiI	O
3049	junction	O
3049	fragments	O
3049	detected	O
3049	by	O
3049	probes	O
3049	p20	O
3049	,	O
3049	J	O
3049	-	O
3049	Bir	O
3049	,	O
3049	and	O
3049	J	O
3049	-	O
3049	66	O
3049	on	O
3049	pulsed	O
3049	-	O
3049	field	O
3049	gel	O
3049	electrophoresis	O
3049	(	O
3049	PFGE	O
3049	)	O
3049	.	O
3050	Immunoblot	O
3050	analysis	O
3050	of	O
3050	muscle	O
3050	from	O
3050	the	O
3050	affected	O
3050	twin	O
3050	showed	O
3050	dystrophin	O
3050	of	O
3050	normal	O
3050	size	O
3050	but	O
3050	of	O
3050	reduced	O
3050	amount	O
3050	.	O
3051	Immunofluorescent	O
3051	visualization	O
3051	of	O
3051	dystrophin	O
3051	revealed	O
3051	foci	O
3051	of	O
3051	dystrophin	O
3051	-	O
3051	positive	O
3051	fibers	O
3051	adjacent	O
3051	to	O
3051	foci	O
3051	of	O
3051	dystrophin	O
3051	-	O
3051	negative	O
3051	fibers	O
3051	.	O
3052	These	O
3052	data	O
3052	indicate	O
3052	that	O
3052	the	O
3052	affected	O
3052	twin	O
3052	is	O
3052	a	O
3052	manifesting	O
3052	carrier	O
3052	of	O
3052	an	O
3052	abnormal	O
3052	DMD	B-Disease
3052	gene	O
3052	,	O
3052	her	O
3052	myopathy	B-Disease
3052	being	O
3052	a	O
3052	direct	O
3052	result	O
3052	of	O
3052	underexpression	O
3052	of	O
3052	dystrophin	O
3052	.	O
3053	Cytogenetic	O
3053	analysis	O
3053	revealed	O
3053	normal	O
3053	karyotypes	O
3053	,	O
3053	eliminating	O
3053	the	O
3053	possibility	O
3053	of	O
3053	a	O
3053	translocation	O
3053	affecting	O
3053	DMD	B-Disease
3053	gene	O
3053	function	O
3053	.	O
3054	Both	O
3054	linkage	O
3054	analysis	O
3054	and	O
3054	DNA	O
3054	fingerprint	O
3054	analysis	O
3054	revealed	O
3054	that	O
3054	each	O
3054	twin	O
3054	has	O
3054	two	O
3054	different	O
3054	X	O
3054	chromosomes	O
3054	,	O
3054	eliminating	O
3054	the	O
3054	possibility	O
3054	of	O
3054	uniparental	B-Disease
3054	disomy	I-Disease
3054	as	O
3054	a	O
3054	mechanism	O
3054	for	O
3054	DMD	B-Disease
3054	expression	O
3054	.	O
3055	On	O
3055	the	O
3055	basis	O
3055	of	O
3055	methylation	O
3055	differences	O
3055	of	O
3055	the	O
3055	paternal	O
3055	and	O
3055	maternal	O
3055	X	O
3055	chromosomes	O
3055	in	O
3055	these	O
3055	MZ	O
3055	twins	O
3055	,	O
3055	we	O
3055	propose	O
3055	uneven	O
3055	lyonization	O
3055	(	O
3055	X	O
3055	chromosome	O
3055	inactivation	O
3055	)	O
3055	as	O
3055	the	O
3055	underlying	O
3055	mechanism	O
3055	for	O
3055	disease	O
3055	expression	O
3055	in	O
3055	the	O
3055	affected	O
3055	female	O
3055	.	O
3055	.	O
3056	Adrenoleukodystrophy	B-Disease
3056	and	O
3056	adrenomyeloneuropathy	B-Disease
3056	associated	O
3056	with	O
3056	partial	O
3056	adrenal	B-Disease
3056	insufficiency	I-Disease
3056	in	O
3056	three	O
3056	generations	O
3056	of	O
3056	a	O
3056	kindred	O
3056	.	O
3057	Four	O
3057	cases	O
3057	of	O
3057	adrenoleukodystrophy	B-Disease
3057	(	O
3057	ALD	B-Disease
3057	)	O
3057	and	O
3057	one	O
3057	case	O
3057	of	O
3057	adrenomyeloneuropathy	B-Disease
3057	(	O
3057	AMN	B-Disease
3057	)	O
3057	have	O
3057	developed	O
3057	in	O
3057	a	O
3057	kindred	O
3057	over	O
3057	three	O
3057	generations	O
3057	demonstrating	O
3057	that	O
3057	AMN	B-Disease
3057	is	O
3057	a	O
3057	clinical	O
3057	variant	O
3057	of	O
3057	ALD	B-Disease
3057	.	O
3058	Pituitary	O
3058	-	O
3058	adrenal	O
3058	function	O
3058	studies	O
3058	were	O
3058	performed	O
3058	in	O
3058	10	O
3058	family	O
3058	members	O
3058	,	O
3058	including	O
3058	two	O
3058	affected	O
3058	males	O
3058	and	O
3058	four	O
3058	females	O
3058	identified	O
3058	as	O
3058	carriers	O
3058	of	O
3058	ALD	B-Disease
3058	/	O
3058	AMN	B-Disease
3058	.	O
3059	No	O
3059	pituitary	B-Disease
3059	-	I-Disease
3059	adrenal	I-Disease
3059	abnormality	I-Disease
3059	was	O
3059	found	O
3059	in	O
3059	the	O
3059	carriers	O
3059	.	O
3060	However	O
3060	,	O
3060	basal	O
3060	morning	O
3060	plasma	O
3060	adrenocorticotropic	O
3060	hormone	O
3060	(	O
3060	ACTH	O
3060	)	O
3060	levels	O
3060	were	O
3060	markedly	O
3060	elevated	O
3060	in	O
3060	the	O
3060	two	O
3060	males	O
3060	with	O
3060	ALD	B-Disease
3060	and	O
3060	AMN	B-Disease
3060	,	O
3060	despite	O
3060	the	O
3060	fact	O
3060	that	O
3060	they	O
3060	had	O
3060	no	O
3060	clinical	O
3060	signs	O
3060	of	O
3060	adrenal	B-Disease
3060	insufficiency	I-Disease
3060	and	O
3060	that	O
3060	morning	O
3060	plasma	O
3060	cortisol	O
3060	levels	O
3060	and	O
3060	their	O
3060	response	O
3060	to	O
3060	maximal	O
3060	exogenous	O
3060	ACTH	O
3060	stimulation	O
3060	appeared	O
3060	to	O
3060	be	O
3060	normal	O
3060	.	O
3061	In	O
3061	addition	O
3061	,	O
3061	the	O
3061	integrated	O
3061	24	O
3061	-	O
3061	hour	O
3061	response	O
3061	to	O
3061	the	O
3061	administration	O
3061	were	O
3061	also	O
3061	subnormal	O
3061	in	O
3061	these	O
3061	two	O
3061	cases	O
3061	.	O
3062	Thus	O
3062	,	O
3062	people	O
3062	with	O
3062	ALD	B-Disease
3062	and	O
3062	AMN	B-Disease
3062	may	O
3062	have	O
3062	subclinical	O
3062	partial	O
3062	adrenocrotical	B-Disease
3062	insufficiency	I-Disease
3062	.	O
3063	No	O
3063	other	O
3063	endocrinologic	B-Disease
3063	dysfunction	I-Disease
3063	was	O
3063	identified	O
3063	.	O
3063	.	O
3064	Regional	O
3064	localisation	O
3064	of	O
3064	the	O
3064	Friedreich	B-Disease
3064	ataxia	I-Disease
3064	locus	O
3064	to	O
3064	human	O
3064	chromosome	O
3064	9q13	O
3064	-	O
3064	-	O
3064	-	O
3064	-	O
3064	q21	O
3064	.	O
3064	1	O
3064	.	O
3065	We	O
3065	have	O
3065	previously	O
3065	assigned	O
3065	the	O
3065	Friedreich	B-Disease
3065	ataxia	I-Disease
3065	locus	O
3065	(	O
3065	FRDA	O
3065	)	O
3065	to	O
3065	chromosome	O
3065	9	O
3065	;	O
3065	the	O
3065	current	O
3065	maximal	O
3065	lod	O
3065	score	O
3065	between	O
3065	FRDA	O
3065	and	O
3065	MCT112	O
3065	(	O
3065	D9S15	O
3065	)	O
3065	is	O
3065	greater	O
3065	than	O
3065	50	O
3065	at	O
3065	a	O
3065	recombination	O
3065	fraction	O
3065	of	O
3065	theta	O
3065	=	O
3065	0	O
3065	.	O
3066	The	O
3066	physical	O
3066	assignment	O
3066	of	O
3066	the	O
3066	locus	O
3066	defined	O
3066	by	O
3066	MCT112	O
3066	,	O
3066	and	O
3066	hence	O
3066	FRDA	O
3066	,	O
3066	has	O
3066	not	O
3066	been	O
3066	determined	O
3066	,	O
3066	although	O
3066	linkage	O
3066	analysis	O
3066	of	O
3066	MCT112	O
3066	with	O
3066	other	O
3066	chromosome	O
3066	9	O
3066	markers	O
3066	inferred	O
3066	a	O
3066	location	O
3066	close	O
3066	to	O
3066	the	O
3066	centromere	O
3066	.	O
3067	We	O
3067	have	O
3067	used	O
3067	in	O
3067	situ	O
3067	hybridisation	O
3067	with	O
3067	MCT112	O
3067	,	O
3067	a	O
3067	corresponding	O
3067	cosmid	O
3067	MJ1	O
3067	,	O
3067	and	O
3067	DR47	O
3067	(	O
3067	D9S5	O
3067	)	O
3067	,	O
3067	coupled	O
3067	with	O
3067	mapping	O
3067	studies	O
3067	on	O
3067	hybrid	O
3067	cell	O
3067	panels	O
3067	,	O
3067	to	O
3067	define	O
3067	more	O
3067	precisely	O
3067	the	O
3067	location	O
3067	of	O
3067	the	O
3067	disease	O
3067	locus	O
3067	.	O
3068	The	O
3068	in	O
3068	situ	O
3068	location	O
3068	of	O
3068	all	O
3068	three	O
3068	probes	O
3068	is	O
3068	9q13	O
3068	-	O
3068	-	O
3068	-	O
3068	-	O
3068	q21	O
3068	.	O
3069	1	O
3069	,	O
3069	distal	O
3069	to	O
3069	the	O
3069	variable	O
3069	heterochromatin	O
3069	region	O
3069	.	O
3070	Physical	O
3070	assignment	O
3070	of	O
3070	FRDA	O
3070	will	O
3070	allow	O
3070	us	O
3070	to	O
3070	identify	O
3070	hybrid	O
3070	cell	O
3070	lines	O
3070	containing	O
3070	the	O
3070	mutated	O
3070	gene	O
3070	.	O
3071	Increased	O
3071	high	O
3071	-	O
3071	density	O
3071	lipoprotein	O
3071	levels	O
3071	caused	O
3071	by	O
3071	a	O
3071	common	O
3071	cholesteryl	O
3071	-	O
3071	ester	O
3071	transfer	O
3071	protein	O
3071	gene	O
3071	mutation	O
3071	.	O
3072	BACKGROUND	O
3072	AND	O
3072	METHODS	O
3072	.	O
3073	The	O
3073	plasma	O
3073	cholesteryl	O
3073	-	O
3073	ester	O
3073	transfer	O
3073	protein	O
3073	(	O
3073	CETP	O
3073	)	O
3073	catalyzes	O
3073	the	O
3073	transfer	O
3073	of	O
3073	cholesteryl	O
3073	esters	O
3073	from	O
3073	high	O
3073	-	O
3073	density	O
3073	lipoprotein	O
3073	(	O
3073	HDL	O
3073	)	O
3073	to	O
3073	other	O
3073	lipoproteins	O
3073	.	O
3074	We	O
3074	recently	O
3074	described	O
3074	a	O
3074	Japanese	O
3074	family	O
3074	with	O
3074	increased	O
3074	HDL	O
3074	levels	O
3074	and	O
3074	CETP	B-Disease
3074	deficiency	I-Disease
3074	due	O
3074	to	O
3074	a	O
3074	splicing	O
3074	defect	O
3074	of	O
3074	the	O
3074	CETP	O
3074	gene	O
3074	.	O
3075	To	O
3075	assess	O
3075	the	O
3075	frequency	O
3075	and	O
3075	phenotype	O
3075	of	O
3075	this	O
3075	condition	O
3075	,	O
3075	we	O
3075	screened	O
3075	11	O
3075	additional	O
3075	families	O
3075	with	O
3075	high	O
3075	HDL	O
3075	levels	O
3075	by	O
3075	means	O
3075	of	O
3075	a	O
3075	radioimmunoassay	O
3075	for	O
3075	CETP	O
3075	and	O
3075	DNA	O
3075	analysis	O
3075	.	O
3076	RESULTS	O
3076	.	O
3077	We	O
3077	found	O
3077	the	O
3077	same	O
3077	CETP	O
3077	gene	O
3077	mutation	O
3077	in	O
3077	four	O
3077	families	O
3077	from	O
3077	three	O
3077	different	O
3077	regions	O
3077	of	O
3077	Japan	O
3077	.	O
3078	Analysis	O
3078	of	O
3078	restriction	O
3078	-	O
3078	fragment	O
3078	-	O
3078	length	O
3078	polymorphisms	O
3078	of	O
3078	the	O
3078	mutant	O
3078	CETP	O
3078	allele	O
3078	showed	O
3078	that	O
3078	all	O
3078	probands	O
3078	were	O
3078	homozygous	O
3078	for	O
3078	the	O
3078	identical	O
3078	haplotype	O
3078	.	O
3079	Family	O
3079	members	O
3079	homozygous	O
3079	for	O
3079	CETP	B-Disease
3079	deficiency	I-Disease
3079	(	O
3079	n	O
3079	=	O
3079	10	O
3079	)	O
3079	had	O
3079	moderate	O
3079	hypercholesterolemia	B-Disease
3079	(	O
3079	mean	O
3079	total	O
3079	cholesterol	O
3079	level	O
3079	[	O
3079	+	O
3079	/	O
3079	-	O
3079	SD	O
3079	]	O
3079	,	O
3079	7	O
3079	.	O
3079	01	O
3079	+	O
3079	/	O
3079	-	O
3079	0	O
3079	.	O
3079	83	O
3079	mmol	O
3079	per	O
3079	liter	O
3079	)	O
3079	,	O
3079	markedly	O
3079	increased	O
3079	levels	O
3079	of	O
3079	HDL	O
3079	cholesterol	O
3079	(	O
3079	4	O
3079	.	O
3079	24	O
3079	+	O
3079	/	O
3079	-	O
3079	1	O
3079	.	O
3079	01	O
3079	mmol	O
3079	per	O
3079	liter	O
3079	)	O
3079	and	O
3079	apolipoprotein	O
3079	A	O
3079	-	O
3079	I	O
3079	,	O
3079	and	O
3079	decreased	O
3079	levels	O
3079	of	O
3079	low	O
3079	-	O
3079	density	O
3079	lipoprotein	O
3079	cholesterol	O
3079	(	O
3079	1	O
3079	.	O
3079	99	O
3079	+	O
3079	/	O
3079	-	O
3079	0	O
3079	.	O
3079	80	O
3079	mmol	O
3079	per	O
3079	liter	O
3079	)	O
3079	and	O
3079	apolipoprotein	O
3079	B	O
3079	.	O
3080	Members	O
3080	heterozygous	O
3080	for	O
3080	the	O
3080	deficiency	O
3080	(	O
3080	n	O
3080	=	O
3080	20	O
3080	)	O
3080	,	O
3080	whose	O
3080	CETP	O
3080	levels	O
3080	were	O
3080	in	O
3080	the	O
3080	lower	O
3080	part	O
3080	of	O
3080	the	O
3080	normal	O
3080	range	O
3080	,	O
3080	had	O
3080	moderately	O
3080	increased	O
3080	levels	O
3080	of	O
3080	HDL	O
3080	cholesterol	O
3080	and	O
3080	apolipoprotein	O
3080	A	O
3080	-	O
3080	I	O
3080	and	O
3080	an	O
3080	increased	O
3080	ratio	O
3080	of	O
3080	HDL	O
3080	subclass	O
3080	2	O
3080	to	O
3080	HDL	O
3080	subclass	O
3080	3	O
3080	,	O
3080	as	O
3080	compared	O
3080	with	O
3080	unaffected	O
3080	family	O
3080	members	O
3080	(	O
3080	1	O
3080	.	O
3080	5	O
3080	+	O
3080	/	O
3080	-	O
3080	0	O
3080	.	O
3080	8	O
3080	vs	O
3080	.	O
3080	0	O
3080	.	O
3080	7	O
3080	+	O
3080	/	O
3080	-	O
3080	0	O
3080	.	O
3080	4	O
3080	)	O
3080	.	O
3081	CETP	B-Disease
3081	deficiency	I-Disease
3081	was	O
3081	not	O
3081	found	O
3081	in	O
3081	six	O
3081	unrelated	O
3081	subjects	O
3081	with	O
3081	elevated	O
3081	HDL	O
3081	cholesterol	O
3081	levels	O
3081	who	O
3081	were	O
3081	from	O
3081	different	O
3081	parts	O
3081	of	O
3081	the	O
3081	United	O
3081	States	O
3081	.	O
3082	CONCLUSIONS	O
3082	.	O
3083	CETP	B-Disease
3083	deficiency	I-Disease
3083	appears	O
3083	to	O
3083	be	O
3083	a	O
3083	frequent	O
3083	cause	O
3083	of	O
3083	increased	O
3083	HDL	O
3083	levels	O
3083	in	O
3083	the	O
3083	population	O
3083	of	O
3083	Japan	O
3083	,	O
3083	possibly	O
3083	because	O
3083	of	O
3083	a	O
3083	founder	O
3083	effect	O
3083	.	O
3084	The	O
3084	results	O
3084	that	O
3084	we	O
3084	observed	O
3084	in	O
3084	heterozygotes	O
3084	suggest	O
3084	that	O
3084	CETP	O
3084	normally	O
3084	plays	O
3084	a	O
3084	part	O
3084	in	O
3084	the	O
3084	regulation	O
3084	of	O
3084	levels	O
3084	of	O
3084	HDL	O
3084	subclass	O
3084	2	O
3084	.	O
3085	There	O
3085	was	O
3085	no	O
3085	evidence	O
3085	of	O
3085	premature	B-Disease
3085	atherosclerosis	I-Disease
3085	in	O
3085	the	O
3085	families	O
3085	with	O
3085	CETP	B-Disease
3085	deficiency	I-Disease
3085	.	O
3086	In	O
3086	fact	O
3086	,	O
3086	the	O
3086	lipoprotein	O
3086	profile	O
3086	of	O
3086	persons	O
3086	with	O
3086	CETP	B-Disease
3086	deficiency	I-Disease
3086	is	O
3086	potentially	O
3086	antiatherogenic	O
3086	and	O
3086	may	O
3086	be	O
3086	associated	O
3086	with	O
3086	an	O
3086	increased	O
3086	life	O
3086	span	O
3086	.	O
3087	Further	O
3087	mapping	O
3087	of	O
3087	an	O
3087	ataxia	B-Disease
3087	-	I-Disease
3087	telangiectasia	I-Disease
3087	locus	O
3087	to	O
3087	the	O
3087	chromosome	O
3087	11q23	O
3087	region	O
3087	.	O
3088	We	O
3088	recently	O
3088	mapped	O
3088	the	O
3088	gene	O
3088	for	O
3088	ataxia	B-Disease
3088	-	I-Disease
3088	telangiectasia	I-Disease
3088	group	O
3088	A	O
3088	(	O
3088	ATA	O
3088	)	O
3088	to	O
3088	chromosome	O
3088	11q22	O
3088	-	O
3088	23	O
3088	by	O
3088	linkage	O
3088	analysis	O
3088	,	O
3088	using	O
3088	the	O
3088	genetic	O
3088	markers	O
3088	THY1	O
3088	and	O
3088	pYNB3	O
3088	.	O
3089	12	O
3089	(	O
3089	D11S144	O
3089	)	O
3089	.	O
3090	The	O
3090	most	O
3090	likely	O
3090	order	O
3090	was	O
3090	cent	O
3090	-	O
3090	AT	O
3090	-	O
3090	S144	O
3090	-	O
3090	THY1	O
3090	.	O
3091	The	O
3091	present	O
3091	paper	O
3091	describes	O
3091	further	O
3091	mapping	O
3091	of	O
3091	the	O
3091	AT	B-Disease
3091	locus	O
3091	by	O
3091	means	O
3091	of	O
3091	a	O
3091	panel	O
3091	of	O
3091	10	O
3091	markers	O
3091	that	O
3091	span	O
3091	approximately	O
3091	60	O
3091	cM	O
3091	in	O
3091	the	O
3091	11q22	O
3091	-	O
3091	23	O
3091	region	O
3091	centered	O
3091	around	O
3091	S144	O
3091	and	O
3091	THY1	O
3091	.	O
3092	Location	O
3092	scores	O
3092	indicate	O
3092	that	O
3092	three	O
3092	contiguous	O
3092	subsegments	O
3092	within	O
3092	the	O
3092	[	O
3092	S144	O
3092	-	O
3092	THY1	O
3092	]	O
3092	segment	O
3092	,	O
3092	as	O
3092	well	O
3092	as	O
3092	three	O
3092	contiguous	O
3092	segments	O
3092	telomeric	O
3092	to	O
3092	THY1	O
3092	,	O
3092	are	O
3092	each	O
3092	unlikely	O
3092	to	O
3092	contain	O
3092	the	O
3092	AT	B-Disease
3092	locus	O
3092	,	O
3092	while	O
3092	the	O
3092	more	O
3092	centromeric	O
3092	[	O
3092	STMY	O
3092	-	O
3092	S144	O
3092	]	O
3092	segment	O
3092	is	O
3092	most	O
3092	likely	O
3092	to	O
3092	contain	O
3092	the	O
3092	AT	B-Disease
3092	locus	O
3092	.	O
3093	These	O
3093	data	O
3093	,	O
3093	together	O
3093	with	O
3093	recent	O
3093	refinements	O
3093	in	O
3093	the	O
3093	linkage	O
3093	and	O
3093	physical	O
3093	maps	O
3093	of	O
3093	11q22	O
3093	-	O
3093	23	O
3093	,	O
3093	place	O
3093	the	O
3093	AT	B-Disease
3093	locus	O
3093	at	O
3093	11q23	O
3093	.	O
3094	Recurrent	O
3094	meningitis	B-Disease
3094	in	O
3094	a	O
3094	patient	O
3094	with	O
3094	congenital	B-Disease
3094	deficiency	I-Disease
3094	of	I-Disease
3094	the	I-Disease
3094	C9	I-Disease
3094	component	I-Disease
3094	of	I-Disease
3094	complement	I-Disease
3094	.	O
3095	First	O
3095	case	O
3095	of	O
3095	C9	B-Disease
3095	deficiency	I-Disease
3095	in	O
3095	Europe	O
3095	.	O
3096	We	O
3096	describe	O
3096	the	O
3096	first	O
3096	cases	O
3096	,	O
3096	to	O
3096	our	O
3096	knowledge	O
3096	,	O
3096	of	O
3096	C9	B-Disease
3096	deficiency	I-Disease
3096	in	O
3096	Europe	O
3096	that	O
3096	were	O
3096	detected	O
3096	in	O
3096	a	O
3096	Swiss	O
3096	family	O
3096	,	O
3096	of	O
3096	which	O
3096	two	O
3096	members	O
3096	-	O
3096	-	O
3096	one	O
3096	with	O
3096	a	O
3096	complete	O
3096	deficiency	O
3096	and	O
3096	the	O
3096	other	O
3096	with	O
3096	approximately	O
3096	half	O
3096	-	O
3096	normal	O
3096	C9	O
3096	levels	O
3096	-	O
3096	-	O
3096	experienced	O
3096	bacterial	B-Disease
3096	meningitis	I-Disease
3096	.	O
3097	The	O
3097	index	O
3097	patient	O
3097	,	O
3097	a	O
3097	56	O
3097	-	O
3097	year	O
3097	-	O
3097	old	O
3097	white	O
3097	man	O
3097	with	O
3097	a	O
3097	history	O
3097	of	O
3097	purulent	B-Disease
3097	meningitis	I-Disease
3097	at	O
3097	the	O
3097	age	O
3097	of	O
3097	23	O
3097	years	O
3097	,	O
3097	presented	O
3097	with	O
3097	an	O
3097	acute	B-Disease
3097	meningococcal	I-Disease
3097	meningitis	I-Disease
3097	.	O
3098	No	O
3098	impairment	B-Disease
3098	of	I-Disease
3098	cellular	I-Disease
3098	immunity	I-Disease
3098	or	O
3098	immunoglobulin	B-Disease
3098	deficiency	I-Disease
3098	could	O
3098	be	O
3098	found	O
3098	.	O
3099	Complement	O
3099	assays	O
3099	showed	O
3099	a	O
3099	complete	B-Disease
3099	deficiency	I-Disease
3099	of	I-Disease
3099	the	I-Disease
3099	C9	I-Disease
3099	component	I-Disease
3099	,	O
3099	while	O
3099	the	O
3099	other	O
3099	individual	O
3099	component	O
3099	levels	O
3099	were	O
3099	normal	O
3099	and	O
3099	the	O
3099	hemolytic	O
3099	activity	O
3099	(	O
3099	measured	O
3099	using	O
3099	the	O
3099	CH50	O
3099	assay	O
3099	)	O
3099	was	O
3099	only	O
3099	slightly	O
3099	reduced	O
3099	.	O
3100	A	O
3100	family	O
3100	study	O
3100	revealed	O
3100	complete	B-Disease
3100	C9	I-Disease
3100	deficiency	I-Disease
3100	in	O
3100	the	O
3100	patients	O
3100	healthy	O
3100	brother	O
3100	and	O
3100	half	O
3100	-	O
3100	normal	O
3100	C9	O
3100	concentrations	O
3100	in	O
3100	his	O
3100	sister	O
3100	,	O
3100	his	O
3100	son	O
3100	(	O
3100	who	O
3100	also	O
3100	had	O
3100	experienced	O
3100	an	O
3100	episode	O
3100	of	O
3100	bacterial	B-Disease
3100	meningitis	I-Disease
3100	)	O
3100	,	O
3100	and	O
3100	his	O
3100	niece	O
3100	,	O
3100	consistent	O
3100	with	O
3100	an	O
3100	inherited	O
3100	C9	B-Disease
3100	deficiency	I-Disease
3100	.	O
3101	This	O
3101	first	O
3101	case	O
3101	of	O
3101	recurrent	B-Disease
3101	meningitis	I-Disease
3101	in	O
3101	a	O
3101	white	O
3101	patient	O
3101	with	O
3101	complete	B-Disease
3101	C9	I-Disease
3101	deficiency	I-Disease
3101	suggests	O
3101	that	O
3101	this	O
3101	complement	B-Disease
3101	defect	I-Disease
3101	may	O
3101	also	O
3101	be	O
3101	a	O
3101	risk	O
3101	factor	O
3101	for	O
3101	bacterial	B-Disease
3101	,	I-Disease
3101	especially	I-Disease
3101	neisserial	I-Disease
3101	,	I-Disease
3101	infections	I-Disease
3101	.	O
3101	.	O
3102	Detection	O
3102	of	O
3102	98	O
3102	%	O
3102	of	O
3102	DMD	B-Disease
3102	/	O
3102	BMD	B-Disease
3102	gene	O
3102	deletions	O
3102	by	O
3102	polymerase	O
3102	chain	O
3102	reaction	O
3102	.	O
3103	We	O
3103	describe	O
3103	oligonucleotide	O
3103	primer	O
3103	sequences	O
3103	that	O
3103	can	O
3103	be	O
3103	used	O
3103	to	O
3103	amplify	O
3103	eight	O
3103	exons	O
3103	plus	O
3103	the	O
3103	muscle	O
3103	promoter	O
3103	of	O
3103	the	O
3103	dystrophin	O
3103	gene	O
3103	in	O
3103	a	O
3103	single	O
3103	multiplex	O
3103	polymerase	O
3103	chain	O
3103	reaction	O
3103	(	O
3103	PCR	O
3103	)	O
3103	.	O
3104	When	O
3104	used	O
3104	in	O
3104	conjunction	O
3104	with	O
3104	an	O
3104	existing	O
3104	primer	O
3104	set	O
3104	,	O
3104	these	O
3104	two	O
3104	multiplex	O
3104	reactions	O
3104	detect	O
3104	about	O
3104	98	O
3104	%	O
3104	of	O
3104	deletions	O
3104	in	O
3104	patients	O
3104	with	O
3104	Duchenne	B-Disease
3104	or	I-Disease
3104	Becker	I-Disease
3104	muscular	I-Disease
3104	dystrophy	I-Disease
3104	(	O
3104	DMD	B-Disease
3104	,	O
3104	BMD	B-Disease
3104	)	O
3104	.	O
3105	Furthermore	O
3105	,	O
3105	these	O
3105	primers	O
3105	amplify	O
3105	most	O
3105	of	O
3105	the	O
3105	exons	O
3105	in	O
3105	the	O
3105	deletion	O
3105	prone	O
3105	"	NN	O	O
3105	hot	NN	O	O
3105	spot	NN	O	O
3105	"	O
3105	region	O
3105	around	O
3105	exons	O
3105	44	O
3105	to	O
3105	53	O
3105	,	O
3105	allowing	O
3105	determination	O
3105	of	O
3105	deletion	O
3105	endpoints	O
3105	and	O
3105	prediction	O
3105	of	O
3105	mutational	O
3105	effects	O
3105	on	O
3105	the	O
3105	translational	O
3105	reading	O
3105	frame	O
3105	.	O
3106	Thus	O
3106	,	O
3106	use	O
3106	of	O
3106	these	O
3106	PCR	O
3106	-	O
3106	based	O
3106	assays	O
3106	will	O
3106	allow	O
3106	deletion	O
3106	detection	O
3106	and	O
3106	prenatal	O
3106	diagnosis	O
3106	for	O
3106	most	O
3106	DMD	B-Disease
3106	/	O
3106	BMD	B-Disease
3106	patients	O
3106	in	O
3106	a	O
3106	fraction	O
3106	of	O
3106	the	O
3106	time	O
3106	required	O
3106	for	O
3106	Southern	O
3106	blot	O
3106	analysis	O
3106	.	O
3106	.	O
3107	Genetic	O
3107	heterogeneity	O
3107	at	O
3107	the	O
3107	glucose	O
3107	-	O
3107	6	O
3107	-	O
3107	phosphate	O
3107	dehydrogenase	O
3107	locus	O
3107	in	O
3107	southern	O
3107	Italy	O
3107	:	O
3107	a	O
3107	study	O
3107	on	O
3107	a	O
3107	population	O
3107	from	O
3107	the	O
3107	Matera	O
3107	district	O
3107	.	O
3108	Glucose	O
3108	-	O
3108	6	O
3108	-	O
3108	phosphate	O
3108	dehydrogenase	O
3108	(	O
3108	G6PD	O
3108	)	O
3108	has	O
3108	been	O
3108	analyzed	O
3108	by	O
3108	gel	O
3108	electrophoresis	O
3108	and	O
3108	by	O
3108	quantitative	O
3108	assay	O
3108	in	O
3108	an	O
3108	unselected	O
3108	sample	O
3108	of	O
3108	1524	O
3108	schoolboys	O
3108	from	O
3108	the	O
3108	province	O
3108	of	O
3108	Matera	O
3108	(	O
3108	Lucania	O
3108	)	O
3108	in	O
3108	southern	O
3108	Italy	O
3108	.	O
3109	We	O
3109	have	O
3109	identified	O
3109	43	O
3109	subjects	O
3109	with	O
3109	a	O
3109	G6PD	O
3109	variant	O
3109	.	O
3110	Of	O
3110	these	O
3110	,	O
3110	31	O
3110	had	O
3110	severe	O
3110	G6PD	B-Disease
3110	deficiency	I-Disease
3110	,	O
3110	nine	O
3110	had	O
3110	mild	O
3110	to	O
3110	moderate	O
3110	deficiency	O
3110	,	O
3110	and	O
3110	three	O
3110	had	O
3110	a	O
3110	non	O
3110	-	O
3110	deficient	O
3110	electrophoretic	O
3110	variant	O
3110	.	O
3111	The	O
3111	overall	O
3111	rate	O
3111	of	O
3111	G6PD	B-Disease
3111	deficiency	I-Disease
3111	was	O
3111	2	O
3111	.	O
3112	6	O
3112	%	O
3112	.	O
3113	The	O
3113	frequency	O
3113	of	O
3113	G6PD	B-Disease
3113	deficiency	I-Disease
3113	,	O
3113	ranging	O
3113	from	O
3113	7	O
3113	.	O
3114	2	O
3114	%	O
3114	on	O
3114	the	O
3114	Ionian	O
3114	Coast	O
3114	to	O
3114	zero	O
3114	on	O
3114	the	O
3114	eastern	O
3114	side	O
3114	of	O
3114	the	O
3114	Lucanian	O
3114	Apennines	O
3114	,	O
3114	appears	O
3114	to	O
3114	be	O
3114	inversely	O
3114	related	O
3114	to	O
3114	the	O
3114	distance	O
3114	of	O
3114	each	O
3114	town	O
3114	examined	O
3114	from	O
3114	the	O
3114	Ionian	O
3114	Coast	O
3114	,	O
3114	suggesting	O
3114	that	O
3114	this	O
3114	geographic	O
3114	distribution	O
3114	may	O
3114	reflect	O
3114	,	O
3114	at	O
3114	least	O
3114	in	O
3114	part	O
3114	,	O
3114	gene	O
3114	flow	O
3114	from	O
3114	Greek	O
3114	settlers	O
3114	.	O
3115	Biochemical	O
3115	characterization	O
3115	has	O
3115	shown	O
3115	that	O
3115	most	O
3115	of	O
3115	the	O
3115	G6PD	B-Disease
3115	deficiency	I-Disease
3115	in	O
3115	this	O
3115	population	O
3115	is	O
3115	accounted	O
3115	for	O
3115	by	O
3115	G6PD	O
3115	Mediterranean	O
3115	.	O
3116	In	O
3116	addition	O
3116	,	O
3116	we	O
3116	have	O
3116	found	O
3116	several	O
3116	examples	O
3116	of	O
3116	two	O
3116	other	O
3116	known	O
3116	polymorphic	O
3116	variants	O
3116	(	O
3116	G6PD	O
3116	Cagliari	O
3116	and	O
3116	G6PD	O
3116	A	O
3116	-	O
3116	)	O
3116	;	O
3116	three	O
3116	new	O
3116	polymorphic	O
3116	variants	O
3116	,	O
3116	G6PD	O
3116	Metaponto	O
3116	(	O
3116	class	O
3116	III	O
3116	)	O
3116	,	O
3116	G6PD	O
3116	Montalbano	O
3116	(	O
3116	class	O
3116	III	O
3116	)	O
3116	,	O
3116	and	O
3116	G6PD	O
3116	Pisticci	O
3116	(	O
3116	class	O
3116	IV	O
3116	)	O
3116	;	O
3116	and	O
3116	two	O
3116	sporadic	O
3116	variants	O
3116	,	O
3116	G6PD	O
3116	Tursi	O
3116	(	O
3116	class	O
3116	III	O
3116	)	O
3116	and	O
3116	G6PD	O
3116	Ferrandina	O
3116	(	O
3116	class	O
3116	II	O
3116	)	O
3116	.	O
3117	These	O
3117	data	O
3117	provide	O
3117	further	O
3117	evidence	O
3117	for	O
3117	the	O
3117	marked	O
3117	genetic	O
3117	heterogeneity	O
3117	of	O
3117	G6PD	B-Disease
3117	deficiency	I-Disease
3117	within	O
3117	a	O
3117	relatively	O
3117	narrow	O
3117	geographic	O
3117	area	O
3117	and	O
3117	they	O
3117	prove	O
3117	the	O
3117	presence	O
3117	in	O
3117	the	O
3117	Italian	O
3117	peninsula	O
3117	of	O
3117	a	O
3117	gene	O
3117	(	O
3117	GdA	O
3117	-	O
3117	)	O
3117	regarded	O
3117	as	O
3117	characteristically	O
3117	African	O
3117	.	O
3118	Deficiency	B-Disease
3118	of	I-Disease
3118	the	I-Disease
3118	murine	I-Disease
3118	fifth	I-Disease
3118	complement	I-Disease
3118	component	I-Disease
3118	(	I-Disease
3118	C5	I-Disease
3118	)	I-Disease
3118	.	O
3119	A	O
3119	2	O
3119	-	O
3119	base	O
3119	pair	O
3119	gene	O
3119	deletion	O
3119	in	O
3119	a	O
3119	5	O
3119	'	O
3119	-	O
3119	exon	O
3119	.	O
3120	To	O
3120	ascertain	O
3120	the	O
3120	molecular	O
3120	mechanism	O
3120	that	O
3120	causes	O
3120	murine	O
3120	C5	B-Disease
3120	deficiency	I-Disease
3120	,	O
3120	genomic	O
3120	and	O
3120	cDNA	O
3120	libraries	O
3120	were	O
3120	constructed	O
3120	from	O
3120	mouse	O
3120	liver	O
3120	DNA	O
3120	and	O
3120	mRNA	O
3120	employing	O
3120	the	O
3120	congenic	O
3120	strains	O
3120	B10	O
3120	.	O
3121	D2	O
3121	/	O
3121	nSnJ	O
3121	and	O
3121	B10	O
3121	.	O
3122	D2	O
3122	/	O
3122	oSnJ	O
3122	that	O
3122	are	O
3122	sufficient	O
3122	and	O
3122	deficient	B-Disease
3122	for	I-Disease
3122	C5	I-Disease
3122	,	O
3122	respectively	O
3122	.	O
3123	Genomic	O
3123	fragments	O
3123	were	O
3123	isolated	O
3123	which	O
3123	correspond	O
3123	to	O
3123	PvuII	O
3123	and	O
3123	HindIII	O
3123	restriction	O
3123	fragment	O
3123	length	O
3123	polymorphisms	O
3123	associated	O
3123	with	O
3123	C5	B-Disease
3123	deficiency	I-Disease
3123	.	O
3124	Sequence	O
3124	analyses	O
3124	demonstrated	O
3124	that	O
3124	each	O
3124	of	O
3124	these	O
3124	polymorphisms	O
3124	resulted	O
3124	from	O
3124	single	O
3124	base	O
3124	pair	O
3124	substitutions	O
3124	and	O
3124	that	O
3124	neither	O
3124	substitution	O
3124	would	O
3124	probably	O
3124	cause	O
3124	or	O
3124	contribute	O
3124	to	O
3124	the	O
3124	C5	B-Disease
3124	deficiency	I-Disease
3124	.	O
3125	Sequence	O
3125	analyses	O
3125	of	O
3125	C5	O
3125	sufficient	O
3125	and	O
3125	deficient	O
3125	cDNAs	O
3125	revealed	O
3125	a	O
3125	2	O
3125	base	O
3125	-	O
3125	pair	O
3125	deletion	O
3125	in	O
3125	the	O
3125	deficient	O
3125	cDNAs	O
3125	.	O
3126	The	O
3126	"	NN	O	O
3126	TA	NN	O	O
3126	"	O
3126	deletion	O
3126	was	O
3126	located	O
3126	near	O
3126	the	O
3126	5	O
3126	end	O
3126	of	O
3126	the	O
3126	cDNA	O
3126	.	O
3127	This	O
3127	deletion	O
3127	shifts	O
3127	the	O
3127	reading	O
3127	frame	O
3127	of	O
3127	the	O
3127	C5	O
3127	mRNA	O
3127	so	O
3127	that	O
3127	the	O
3127	termination	O
3127	codon	O
3127	UGA	O
3127	is	O
3127	present	O
3127	4	O
3127	base	O
3127	pairs	O
3127	downstream	O
3127	from	O
3127	the	O
3127	deletion	O
3127	.	O
3128	Genomic	O
3128	DNA	O
3128	was	O
3128	amplified	O
3128	and	O
3128	sequenced	O
3128	corresponding	O
3128	to	O
3128	the	O
3128	area	O
3128	surrounding	O
3128	the	O
3128	2	O
3128	-	O
3128	base	O
3128	pair	O
3128	deletion	O
3128	.	O
3129	Six	O
3129	C5	B-Disease
3129	-	I-Disease
3129	deficient	I-Disease
3129	strains	O
3129	,	O
3129	A	O
3129	/	O
3129	HeJ	O
3129	,	O
3129	AKR	O
3129	/	O
3129	J	O
3129	,	O
3129	DBA	O
3129	/	O
3129	2J	O
3129	,	O
3129	NZB	O
3129	/	O
3129	B1NJ	O
3129	,	O
3129	SWR	O
3129	/	O
3129	J	O
3129	,	O
3129	and	O
3129	B10	O
3129	.	O
3130	D2	O
3130	/	O
3130	oSnJ	O
3130	,	O
3130	and	O
3130	four	O
3130	C5	O
3130	-	O
3130	sufficient	O
3130	strains	O
3130	,	O
3130	Balb	O
3130	/	O
3130	CJ	O
3130	,	O
3130	C57Bl	O
3130	/	O
3130	6J	O
3130	,	O
3130	DBA	O
3130	/	O
3130	1J	O
3130	,	O
3130	and	O
3130	B10	O
3130	.	O
3131	D2	O
3131	/	O
3131	nSnJ	O
3131	,	O
3131	were	O
3131	analyzed	O
3131	.	O
3132	The	O
3132	sequencing	O
3132	data	O
3132	revealed	O
3132	that	O
3132	the	O
3132	2	O
3132	base	O
3132	pairs	O
3132	were	O
3132	deleted	O
3132	from	O
3132	the	O
3132	C5	O
3132	gene	O
3132	of	O
3132	each	O
3132	deficient	O
3132	mouse	O
3132	tested	O
3132	but	O
3132	not	O
3132	from	O
3132	the	O
3132	C5	O
3132	gene	O
3132	of	O
3132	any	O
3132	sufficient	O
3132	mouse	O
3132	.	O
3133	These	O
3133	data	O
3133	demonstrate	O
3133	that	O
3133	1	O
3133	)	O
3133	there	O
3133	is	O
3133	an	O
3133	identical	O
3133	2	O
3133	-	O
3133	base	O
3133	pair	O
3133	deletion	O
3133	in	O
3133	an	O
3133	exon	O
3133	of	O
3133	the	O
3133	C5	O
3133	gene	O
3133	in	O
3133	several	O
3133	different	O
3133	C5	B-Disease
3133	-	I-Disease
3133	deficient	I-Disease
3133	mouse	O
3133	strains	O
3133	;	O
3133	2	O
3133	)	O
3133	the	O
3133	mRNA	O
3133	transcribed	O
3133	from	O
3133	the	O
3133	C5D	O
3133	gene	O
3133	retains	O
3133	this	O
3133	deletion	O
3133	;	O
3133	and	O
3133	3	O
3133	)	O
3133	this	O
3133	mutation	O
3133	should	O
3133	result	O
3133	in	O
3133	C5	B-Disease
3133	protein	I-Disease
3133	deficiency	I-Disease
3133	.	O
3134	Molecular	O
3134	genetics	O
3134	of	O
3134	PKU	B-Disease
3134	in	O
3134	eastern	O
3134	Europe	O
3134	:	O
3134	a	O
3134	nonsense	O
3134	mutation	O
3134	associated	O
3134	with	O
3134	haplotype	O
3134	4	O
3134	of	O
3134	the	O
3134	phenylalanine	O
3134	hydroxylase	O
3134	gene	O
3134	.	O
3135	Phenylketonuria	B-Disease
3135	(	O
3135	PKU	B-Disease
3135	)	O
3135	is	O
3135	a	O
3135	genetic	B-Disease
3135	disorder	I-Disease
3135	secondary	O
3135	to	O
3135	a	O
3135	deficiency	B-Disease
3135	of	I-Disease
3135	hepatic	I-Disease
3135	phenylalanine	I-Disease
3135	hydroxylase	I-Disease
3135	(	O
3135	PAH	O
3135	)	O
3135	.	O
3136	Several	O
3136	mutations	O
3136	in	O
3136	the	O
3136	PAH	O
3136	gene	O
3136	have	O
3136	recently	O
3136	been	O
3136	reported	O
3136	,	O
3136	and	O
3136	linkage	O
3136	disequilibrium	O
3136	was	O
3136	observed	O
3136	between	O
3136	RFLP	O
3136	haplotypes	O
3136	and	O
3136	specific	O
3136	mutations	O
3136	.	O
3137	A	O
3137	new	O
3137	molecular	B-Disease
3137	lesion	I-Disease
3137	has	O
3137	been	O
3137	identified	O
3137	in	O
3137	exon	O
3137	7	O
3137	of	O
3137	the	O
3137	PAH	O
3137	gene	O
3137	in	O
3137	a	O
3137	Hungarian	O
3137	PKU	B-Disease
3137	patient	O
3137	by	O
3137	direct	O
3137	sequencing	O
3137	of	O
3137	PCR	O
3137	-	O
3137	amplified	O
3137	DNA	O
3137	.	O
3138	The	O
3138	C	O
3138	-	O
3138	to	O
3138	-	O
3138	T	O
3138	transition	O
3138	causes	O
3138	the	O
3138	substitution	O
3138	of	O
3138	Arg243	O
3138	to	O
3138	a	O
3138	termination	O
3138	codon	O
3138	,	O
3138	and	O
3138	the	O
3138	mutant	O
3138	allele	O
3138	is	O
3138	associated	O
3138	with	O
3138	haplotype	O
3138	4	O
3138	of	O
3138	the	O
3138	PAH	O
3138	gene	O
3138	.	O
3139	The	O
3139	mutation	O
3139	is	O
3139	present	O
3139	in	O
3139	two	O
3139	of	O
3139	nine	O
3139	mutant	O
3139	haplotype	O
3139	4	O
3139	alleles	O
3139	among	O
3139	Eastern	O
3139	Europeans	O
3139	and	O
3139	is	O
3139	not	O
3139	present	O
3139	among	O
3139	Western	O
3139	Europeans	O
3139	and	O
3139	Asians	O
3139	.	O
3140	The	O
3140	rarity	O
3140	of	O
3140	this	O
3140	mutant	O
3140	allele	O
3140	and	O
3140	its	O
3140	restricted	O
3140	geographic	O
3140	distribution	O
3140	suggest	O
3140	that	O
3140	the	O
3140	mutational	O
3140	event	O
3140	occurred	O
3140	recently	O
3140	on	O
3140	a	O
3140	normal	O
3140	haplotype	O
3140	4	O
3140	background	O
3140	in	O
3140	Eastern	O
3140	Europe	O
3140	.	O
3140	.	O
3141	The	O
3141	red	O
3141	-	O
3141	green	O
3141	visual	O
3141	pigment	O
3141	gene	O
3141	region	O
3141	in	O
3141	adrenoleukodystrophy	B-Disease
3141	.	O
3142	Although	O
3142	recent	O
3142	data	O
3142	established	O
3142	that	O
3142	a	O
3142	specific	O
3142	very	O
3142	-	O
3142	long	O
3142	-	O
3142	chain	O
3142	fatty	O
3142	acyl	O
3142	-	O
3142	CoA	O
3142	synthetase	O
3142	is	O
3142	defective	O
3142	in	O
3142	X	B-Disease
3142	-	I-Disease
3142	linked	I-Disease
3142	adrenoleukodystrophy	I-Disease
3142	(	O
3142	ALD	B-Disease
3142	)	O
3142	,	O
3142	the	O
3142	ALD	B-Disease
3142	gene	O
3142	is	O
3142	still	O
3142	unidentified	O
3142	.	O
3143	The	O
3143	ALD	B-Disease
3143	locus	O
3143	has	O
3143	been	O
3143	mapped	O
3143	to	O
3143	Xq28	O
3143	,	O
3143	like	O
3143	the	O
3143	red	O
3143	and	O
3143	green	O
3143	color	O
3143	pigment	O
3143	genes	O
3143	.	O
3144	Abnormal	B-Disease
3144	color	I-Disease
3144	vision	I-Disease
3144	has	O
3144	been	O
3144	observed	O
3144	in	O
3144	12	O
3144	of	O
3144	27	O
3144	patients	O
3144	with	O
3144	adrenomyeloneuropathy	B-Disease
3144	(	O
3144	AMN	B-Disease
3144	)	O
3144	,	O
3144	a	O
3144	milder	O
3144	form	O
3144	of	O
3144	ALD	B-Disease
3144	.	O
3145	Furthermore	O
3145	,	O
3145	rearrangements	O
3145	of	O
3145	the	O
3145	color	O
3145	vision	O
3145	gene	O
3145	cluster	O
3145	were	O
3145	found	O
3145	in	O
3145	four	O
3145	of	O
3145	eight	O
3145	ALD	B-Disease
3145	kindreds	O
3145	.	O
3146	This	O
3146	led	O
3146	us	O
3146	to	O
3146	propose	O
3146	that	O
3146	a	O
3146	single	O
3146	DNA	O
3146	rearrangement	O
3146	could	O
3146	underlie	O
3146	both	O
3146	ALD	B-Disease
3146	and	O
3146	abnormal	B-Disease
3146	color	I-Disease
3146	vision	I-Disease
3146	in	O
3146	these	O
3146	patients	O
3146	.	O
3147	Study	O
3147	of	O
3147	34	O
3147	French	O
3147	ALD	B-Disease
3147	patients	O
3147	failed	O
3147	to	O
3147	reveal	O
3147	a	O
3147	higher	O
3147	than	O
3147	expected	O
3147	frequency	O
3147	of	O
3147	green	O
3147	/	O
3147	red	O
3147	visual	O
3147	pigment	O
3147	rearrangements	O
3147	3	O
3147	to	O
3147	the	O
3147	red	O
3147	/	O
3147	green	O
3147	color	O
3147	vision	O
3147	gene	O
3147	complex	O
3147	.	O
3148	The	O
3148	previous	O
3148	report	O
3148	of	O
3148	such	O
3148	rearrangements	O
3148	was	O
3148	based	O
3148	on	O
3148	small	O
3148	numbers	O
3148	and	O
3148	lack	O
3148	of	O
3148	knowledge	O
3148	that	O
3148	the	O
3148	frequency	O
3148	of	O
3148	"	NN	O	O
3148	abnormal	NN	O	O
3148	"	O
3148	color	O
3148	vision	O
3148	arrays	O
3148	on	O
3148	molecular	O
3148	analysis	O
3148	was	O
3148	twice	O
3148	as	O
3148	high	O
3148	as	O
3148	expected	O
3148	on	O
3148	the	O
3148	basis	O
3148	of	O
3148	the	O
3148	frequency	O
3148	of	O
3148	phenotypic	B-Disease
3148	color	I-Disease
3148	vision	I-Disease
3148	defects	I-Disease
3148	.	O
3149	The	O
3149	red	O
3149	/	O
3149	green	O
3149	color	O
3149	pigment	O
3149	(	O
3149	R	O
3149	/	O
3149	GCP	O
3149	)	O
3149	region	O
3149	was	O
3149	studied	O
3149	by	O
3149	pulsed	O
3149	-	O
3149	field	O
3149	gel	O
3149	electrophoresis	O
3149	in	O
3149	14	O
3149	of	O
3149	these	O
3149	patients	O
3149	,	O
3149	and	O
3149	we	O
3149	did	O
3149	not	O
3149	find	O
3149	any	O
3149	fragment	O
3149	size	O
3149	difference	O
3149	between	O
3149	the	O
3149	patients	O
3149	and	O
3149	normal	O
3149	individuals	O
3149	who	O
3149	have	O
3149	the	O
3149	same	O
3149	number	O
3149	of	O
3149	pigment	O
3149	genes	O
3149	.	O
3150	The	O
3150	R	O
3150	/	O
3150	GCP	O
3150	region	O
3150	was	O
3150	also	O
3150	analyzed	O
3150	in	O
3150	29	O
3150	French	O
3150	and	O
3150	seven	O
3150	North	O
3150	American	O
3150	ALD	B-Disease
3150	patients	O
3150	by	O
3150	using	O
3150	six	O
3150	genomic	O
3150	DNA	O
3150	probes	O
3150	,	O
3150	isolated	O
3150	from	O
3150	a	O
3150	cosmid	O
3150	walk	O
3150	,	O
3150	that	O
3150	flank	O
3150	the	O
3150	color	O
3150	vision	O
3150	genes	O
3150	.	O
3151	No	O
3151	deletions	O
3151	were	O
3151	found	O
3151	with	O
3151	probes	O
3151	that	O
3151	lie	O
3151	3	O
3151	of	O
3151	the	O
3151	green	O
3151	pigment	O
3151	genes	O
3151	.	O
3152	One	O
3152	of	O
3152	the	O
3152	eight	O
3152	previously	O
3152	reported	O
3152	ALD	B-Disease
3152	individuals	O
3152	has	O
3152	a	O
3152	long	O
3152	deletion	O
3152	5	O
3152	of	O
3152	the	O
3152	red	O
3152	pigment	O
3152	gene	O
3152	,	O
3152	a	O
3152	deletion	O
3152	causing	O
3152	blue	O
3152	cone	O
3152	monochromacy	O
3152	.	O
3153	This	O
3153	finding	O
3153	and	O
3153	the	O
3153	previous	O
3153	findings	O
3153	of	O
3153	a	O
3153	45	O
3153	%	O
3153	frequency	O
3153	of	O
3153	phenotypic	O
3153	color	O
3153	vision	O
3153	defects	O
3153	in	O
3153	patients	O
3153	with	O
3153	AMN	B-Disease
3153	may	O
3153	suggest	O
3153	that	O
3153	the	O
3153	ALD	B-Disease
3153	/	O
3153	AMN	B-Disease
3153	gene	O
3153	lies	O
3153	5	O
3153	to	O
3153	the	O
3153	red	O
3153	pigment	O
3153	gene	O
3153	and	O
3153	that	O
3153	the	O
3153	frequent	O
3153	phenotypic	O
3153	color	B-Disease
3153	vision	I-Disease
3153	anomalies	I-Disease
3153	owe	O
3153	their	O
3153	origin	O
3153	to	O
3153	deleted	O
3153	DNA	O
3153	that	O
3153	includes	O
3153	regulatory	O
3153	genes	O
3153	for	O
3153	color	O
3153	vision	O
3153	.	O
3154	It	O
3154	is	O
3154	possible	O
3154	,	O
3154	however	O
3154	,	O
3154	that	O
3154	phenotypic	O
3154	color	B-Disease
3154	vision	I-Disease
3154	anomalies	I-Disease
3154	in	O
3154	AMN	B-Disease
3154	may	O
3154	be	O
3154	phenocopies	O
3154	secondary	O
3154	to	O
3154	retinal	O
3154	or	O
3154	neural	O
3154	involvement	O
3154	by	O
3154	the	O
3154	disease	O
3154	.	O
3155	The	O
3155	single	O
3155	case	O
3155	of	O
3155	blue	O
3155	cone	O
3155	monochromacy	O
3155	may	O
3155	therefore	O
3155	be	O
3155	a	O
3155	fortuitous	O
3155	coincidence	O
3155	of	O
3155	two	O
3155	diseases	O
3155	.	O
3155	.	O
3156	Paroxysmal	B-Disease
3156	nocturnal	I-Disease
3156	haemoglobinuria	I-Disease
3156	with	O
3156	coexisting	O
3156	deficiency	B-Disease
3156	of	I-Disease
3156	the	I-Disease
3156	ninth	I-Disease
3156	component	I-Disease
3156	of	I-Disease
3156	complement	I-Disease
3156	:	O
3156	lack	O
3156	of	O
3156	massive	O
3156	haemolytic	B-Disease
3156	attack	I-Disease
3156	.	O
3157	A	O
3157	47	O
3157	-	O
3157	year	O
3157	-	O
3157	old	O
3157	woman	O
3157	with	O
3157	paroxysmal	B-Disease
3157	nocturnal	I-Disease
3157	haemoglobinuria	I-Disease
3157	(	O
3157	PNH	B-Disease
3157	)	O
3157	was	O
3157	found	O
3157	to	O
3157	have	O
3157	an	O
3157	inherited	B-Disease
3157	deficiency	I-Disease
3157	in	I-Disease
3157	the	I-Disease
3157	ninth	I-Disease
3157	complement	I-Disease
3157	component	I-Disease
3157	(	O
3157	C9	O
3157	)	O
3157	.	O
3158	In	O
3158	complement	O
3158	-	O
3158	sensitivity	O
3158	lysis	O
3158	tests	O
3158	,	O
3158	80	O
3158	%	O
3158	of	O
3158	her	O
3158	erythrocytes	O
3158	were	O
3158	markedly	O
3158	complement	O
3158	-	O
3158	sensitive	O
3158	(	O
3158	PNH	O
3158	-	O
3158	III	O
3158	)	O
3158	.	O
3159	Laser	O
3159	cytofluorimetry	O
3159	with	O
3159	a	O
3159	monoclonal	O
3159	antibody	O
3159	against	O
3159	decay	O
3159	-	O
3159	accelerating	O
3159	factor	O
3159	(	O
3159	DAF	O
3159	)	O
3159	revealed	O
3159	that	O
3159	95	O
3159	%	O
3159	of	O
3159	her	O
3159	erythrocytes	O
3159	were	O
3159	DAF	O
3159	-	O
3159	negative	O
3159	.	O
3160	Surprisingly	O
3160	,	O
3160	she	O
3160	has	O
3160	suffered	O
3160	only	O
3160	mild	O
3160	haemolysis	B-Disease
3160	and	O
3160	has	O
3160	never	O
3160	experienced	O
3160	massive	O
3160	spontaneous	O
3160	haemolysis	B-Disease
3160	.	O
3161	Gross	O
3161	haemoglobinuria	B-Disease
3161	and	O
3161	jaundice	B-Disease
3161	occurred	O
3161	only	O
3161	after	O
3161	receiving	O
3161	postoperative	O
3161	transfusion	O
3161	of	O
3161	whole	O
3161	blood	O
3161	.	O
3162	In	O
3162	her	O
3162	serum	O
3162	,	O
3162	C9	O
3162	was	O
3162	not	O
3162	detectable	O
3162	either	O
3162	by	O
3162	immunological	O
3162	or	O
3162	by	O
3162	functional	O
3162	assays	O
3162	.	O
3163	Both	O
3163	the	O
3163	Ham	O
3163	test	O
3163	and	O
3163	the	O
3163	sugar	O
3163	water	O
3163	test	O
3163	using	O
3163	normal	O
3163	human	O
3163	serum	O
3163	or	O
3163	plasma	O
3163	yielded	O
3163	marked	O
3163	haemolysis	O
3163	of	O
3163	the	O
3163	patients	O
3163	erythrocytes	O
3163	.	O
3164	When	O
3164	the	O
3164	patients	O
3164	serum	O
3164	or	O
3164	plasma	O
3164	was	O
3164	used	O
3164	,	O
3164	only	O
3164	a	O
3164	trace	O
3164	of	O
3164	lysis	O
3164	was	O
3164	detected	O
3164	.	O
3165	Addition	O
3165	of	O
3165	purified	O
3165	human	O
3165	C9	O
3165	to	O
3165	her	O
3165	plasma	O
3165	fully	O
3165	restored	O
3165	haemolysis	O
3165	.	O
3166	These	O
3166	observations	O
3166	indicated	O
3166	that	O
3166	C9	O
3166	may	O
3166	play	O
3166	a	O
3166	critical	O
3166	role	O
3166	in	O
3166	haemolytic	B-Disease
3166	attacks	I-Disease
3166	in	O
3166	patients	O
3166	with	O
3166	PNH	B-Disease
3166	and	O
3166	that	O
3166	characteristic	O
3166	haemolysis	B-Disease
3166	in	O
3166	PNH	B-Disease
3166	may	O
3166	be	O
3166	tempered	O
3166	by	O
3166	coexisting	O
3166	C9	B-Disease
3166	deficiency	I-Disease
3166	.	O
3166	.	O
3167	Duplicational	O
3167	mutation	O
3167	at	O
3167	the	O
3167	Duchenne	B-Disease
3167	muscular	I-Disease
3167	dystrophy	I-Disease
3167	locus	O
3167	:	O
3167	its	O
3167	frequency	O
3167	,	O
3167	distribution	O
3167	,	O
3167	origin	O
3167	,	O
3167	and	O
3167	phenotypegenotype	O
3167	correlation	O
3167	.	O
3168	Partial	O
3168	gene	O
3168	deletion	O
3168	is	O
3168	the	O
3168	major	O
3168	cause	O
3168	of	O
3168	mutation	O
3168	leading	O
3168	to	O
3168	Duchenne	B-Disease
3168	muscular	I-Disease
3168	dystrophy	I-Disease
3168	(	O
3168	DMD	B-Disease
3168	)	O
3168	and	O
3168	Becker	B-Disease
3168	muscular	I-Disease
3168	dystrophy	I-Disease
3168	(	O
3168	BMD	B-Disease
3168	)	O
3168	.	O
3169	Partial	O
3169	gene	O
3169	duplication	O
3169	has	O
3169	also	O
3169	been	O
3169	recognized	O
3169	in	O
3169	a	O
3169	few	O
3169	cases	O
3169	.	O
3170	We	O
3170	have	O
3170	conducted	O
3170	a	O
3170	survey	O
3170	for	O
3170	duplication	O
3170	in	O
3170	72	O
3170	unrelated	O
3170	nondeletion	O
3170	patients	O
3170	,	O
3170	analyzed	O
3170	by	O
3170	Southern	O
3170	blot	O
3170	hybridization	O
3170	with	O
3170	clones	O
3170	representing	O
3170	the	O
3170	entire	O
3170	DMD	B-Disease
3170	cDNA	O
3170	.	O
3171	With	O
3171	careful	O
3171	quantitative	O
3171	analysis	O
3171	of	O
3171	hybridization	O
3171	band	O
3171	intensity	O
3171	,	O
3171	10	O
3171	cases	O
3171	were	O
3171	found	O
3171	to	O
3171	carry	O
3171	a	O
3171	duplication	O
3171	of	O
3171	part	O
3171	of	O
3171	the	O
3171	gene	O
3171	,	O
3171	a	O
3171	frequency	O
3171	of	O
3171	14	O
3171	%	O
3171	for	O
3171	nondeletion	O
3171	cases	O
3171	(	O
3171	10	O
3171	/	O
3171	72	O
3171	)	O
3171	,	O
3171	or	O
3171	6	O
3171	%	O
3171	for	O
3171	all	O
3171	cases	O
3171	(	O
3171	10	O
3171	/	O
3171	181	O
3171	)	O
3171	.	O
3172	The	O
3172	extent	O
3172	of	O
3172	these	O
3172	duplications	O
3172	has	O
3172	been	O
3172	characterized	O
3172	according	O
3172	to	O
3172	the	O
3172	published	O
3172	exon	O
3172	-	O
3172	containing	O
3172	HindIII	O
3172	fragment	O
3172	map	O
3172	,	O
3172	and	O
3172	in	O
3172	six	O
3172	of	O
3172	the	O
3172	10	O
3172	duplications	O
3172	a	O
3172	novel	O
3172	restriction	O
3172	fragment	O
3172	that	O
3172	spanned	O
3172	the	O
3172	duplication	O
3172	junction	O
3172	was	O
3172	detected	O
3172	.	O
3173	The	O
3173	resulting	O
3173	translational	O
3173	reading	O
3173	frame	O
3173	of	O
3173	mRNA	O
3173	has	O
3173	been	O
3173	predicted	O
3173	for	O
3173	nine	O
3173	duplications	O
3173	.	O
3174	A	O
3174	shift	O
3174	of	O
3174	the	O
3174	reading	O
3174	frame	O
3174	was	O
3174	predicted	O
3174	in	O
3174	four	O
3174	of	O
3174	the	O
3174	six	O
3174	DMD	B-Disease
3174	cases	O
3174	and	O
3174	in	O
3174	one	O
3174	of	O
3174	the	O
3174	two	O
3174	intermediate	O
3174	cases	O
3174	,	O
3174	while	O
3174	the	O
3174	reading	O
3174	frame	O
3174	remained	O
3174	uninterrupted	O
3174	in	O
3174	both	O
3174	BMD	B-Disease
3174	cases	O
3174	.	O
3175	RFLP	O
3175	and	O
3175	quantitative	O
3175	Southern	O
3175	blot	O
3175	analyses	O
3175	revealed	O
3175	a	O
3175	grandpaternal	O
3175	origin	O
3175	of	O
3175	duplication	O
3175	in	O
3175	four	O
3175	families	O
3175	and	O
3175	grandmaternal	O
3175	origin	O
3175	in	O
3175	one	O
3175	family	O
3175	.	O
3176	In	O
3176	all	O
3176	five	O
3176	families	O
3176	,	O
3176	the	O
3176	duplication	O
3176	was	O
3176	found	O
3176	to	O
3176	originate	O
3176	from	O
3176	a	O
3176	single	O
3176	X	O
3176	chromosome	O
3176	.	O
3177	Unequal	O
3177	sister	O
3177	-	O
3177	chromatid	O
3177	exchange	O
3177	is	O
3177	proposed	O
3177	to	O
3177	be	O
3177	the	O
3177	mechanism	O
3177	for	O
3177	the	O
3177	formation	O
3177	of	O
3177	these	O
3177	duplications	O
3177	.	O
3177	.	O
3178	Glucose	O
3178	6	O
3178	-	O
3178	phosphate	O
3178	dehydrogenase	O
3178	variants	O
3178	:	O
3178	Gd	O
3178	(	O
3178	+	O
3178	)	O
3178	Alexandra	O
3178	associated	O
3178	with	O
3178	neonatal	B-Disease
3178	jaundice	I-Disease
3178	and	O
3178	Gd	O
3178	(	O
3178	-	O
3178	)	O
3178	Camperdown	O
3178	in	O
3178	a	O
3178	young	O
3178	man	O
3178	with	O
3178	lamellar	B-Disease
3178	cataracts	I-Disease
3178	.	O
3179	Two	O
3179	male	O
3179	subjects	O
3179	are	O
3179	described	O
3179	,	O
3179	with	O
3179	unusual	O
3179	clinical	O
3179	presentations	O
3179	and	O
3179	with	O
3179	hitherto	O
3179	undescribed	O
3179	G6PD	O
3179	variants	O
3179	.	O
3180	The	O
3180	first	O
3180	,	O
3180	of	O
3180	Italian	O
3180	extraction	O
3180	,	O
3180	suffered	O
3180	from	O
3180	severe	O
3180	neonatal	B-Disease
3180	jaundice	I-Disease
3180	following	O
3180	maternal	O
3180	ingestion	O
3180	of	O
3180	fresh	O
3180	broad	O
3180	beans	O
3180	(	O
3180	Vicia	O
3180	fava	O
3180	)	O
3180	both	O
3180	prenatally	O
3180	and	O
3180	postnatally	O
3180	the	O
3180	expression	O
3180	of	O
3180	the	O
3180	enzymatic	O
3180	defect	O
3180	was	O
3180	much	O
3180	more	O
3180	severe	O
3180	in	O
3180	the	O
3180	neonatal	O
3180	period	O
3180	than	O
3180	on	O
3180	retesting	O
3180	in	O
3180	adolescence	O
3180	,	O
3180	when	O
3180	biochemical	O
3180	characterization	O
3180	showed	O
3180	unique	O
3180	features	O
3180	which	O
3180	justify	O
3180	designation	O
3180	as	O
3180	a	O
3180	new	O
3180	variant	O
3180	Gd	O
3180	(	O
3180	+	O
3180	)	O
3180	Alexandra	O
3180	.	O
3181	The	O
3181	second	O
3181	patient	O
3181	,	O
3181	a	O
3181	boy	O
3181	of	O
3181	Maltese	O
3181	extraction	O
3181	who	O
3181	was	O
3181	found	O
3181	to	O
3181	have	O
3181	bilateral	B-Disease
3181	lamellar	I-Disease
3181	cataracts	I-Disease
3181	at	O
3181	the	O
3181	age	O
3181	of	O
3181	4	O
3181	years	O
3181	,	O
3181	was	O
3181	identified	O
3181	as	O
3181	G6PD	B-Disease
3181	deficient	I-Disease
3181	only	O
3181	as	O
3181	a	O
3181	result	O
3181	of	O
3181	a	O
3181	survey	O
3181	of	O
3181	children	O
3181	of	O
3181	Mediterranean	O
3181	origin	O
3181	with	O
3181	unexplained	O
3181	cataract	B-Disease
3181	formation	O
3181	;	O
3181	he	O
3181	has	O
3181	approximately	O
3181	15	O
3181	%	O
3181	of	O
3181	normal	O
3181	enzyme	O
3181	activity	O
3181	,	O
3181	with	O
3181	another	O
3181	unique	O
3181	combination	O
3181	of	O
3181	biochemical	O
3181	characteristics	O
3181	which	O
3181	has	O
3181	led	O
3181	to	O
3181	its	O
3181	designation	O
3181	as	O
3181	Gd	O
3181	(	O
3181	-	O
3181	)	O
3181	Camperdown	O
3181	.	O
3182	Although	O
3182	this	O
3182	association	O
3182	may	O
3182	be	O
3182	coincidental	O
3182	,	O
3182	it	O
3182	prompts	O
3182	further	O
3182	attention	O
3182	to	O
3182	the	O
3182	possibility	O
3182	that	O
3182	under	O
3182	certain	O
3182	circumstances	O
3182	G6PD	B-Disease
3182	deficiency	I-Disease
3182	may	O
3182	favor	O
3182	cataract	B-Disease
3182	formation	O
3182	.	O
3183	The	O
3183	two	O
3183	cases	O
3183	illustrate	O
3183	the	O
3183	value	O
3183	of	O
3183	characterization	O
3183	of	O
3183	the	O
3183	mutant	O
3183	enzyme	O
3183	whenever	O
3183	unexpected	O
3183	clinical	O
3183	or	O
3183	laboratory	O
3183	results	O
3183	are	O
3183	obtained	O
3183	.	O
3183	.	O
3184	Statistical	O
3184	analysis	O
3184	of	O
3184	the	O
3184	two	O
3184	stage	O
3184	mutation	O
3184	model	O
3184	in	O
3184	von	B-Disease
3184	Hippel	I-Disease
3184	-	I-Disease
3184	Lindau	I-Disease
3184	disease	I-Disease
3184	,	O
3184	and	O
3184	in	O
3184	sporadic	B-Disease
3184	cerebellar	I-Disease
3184	haemangioblastoma	I-Disease
3184	and	O
3184	renal	B-Disease
3184	cell	I-Disease
3184	carcinoma	I-Disease
3184	.	O
3185	Analysis	O
3185	of	O
3185	the	O
3185	age	O
3185	incidence	O
3185	curves	O
3185	for	O
3185	unilateral	B-Disease
3185	and	I-Disease
3185	bilateral	I-Disease
3185	retinoblastoma	I-Disease
3185	led	O
3185	Knudson	O
3185	to	O
3185	propose	O
3185	that	O
3185	hereditary	B-Disease
3185	tumours	I-Disease
3185	may	O
3185	arise	O
3185	by	O
3185	a	O
3185	single	O
3185	event	O
3185	and	O
3185	sporadic	B-Disease
3185	tumours	I-Disease
3185	by	O
3185	a	O
3185	two	O
3185	stage	O
3185	mutation	O
3185	process	O
3185	.	O
3186	It	O
3186	has	O
3186	been	O
3186	suggested	O
3186	recently	O
3186	that	O
3186	sporadic	B-Disease
3186	renal	I-Disease
3186	cell	I-Disease
3186	carcinoma	I-Disease
3186	may	O
3186	arise	O
3186	from	O
3186	a	O
3186	two	O
3186	stage	O
3186	mutation	O
3186	process	O
3186	.	O
3187	We	O
3187	analysed	O
3187	the	O
3187	age	O
3187	incidence	O
3187	curves	O
3187	for	O
3187	symptomatic	O
3187	renal	B-Disease
3187	cell	I-Disease
3187	carcinoma	I-Disease
3187	(	O
3187	n	O
3187	=	O
3187	26	O
3187	)	O
3187	and	O
3187	cerebellar	B-Disease
3187	haemangioblastoma	I-Disease
3187	(	O
3187	n	O
3187	=	O
3187	68	O
3187	)	O
3187	in	O
3187	109	O
3187	patients	O
3187	with	O
3187	von	B-Disease
3187	Hippel	I-Disease
3187	-	I-Disease
3187	Lindau	I-Disease
3187	(	I-Disease
3187	VHL	I-Disease
3187	)	I-Disease
3187	disease	I-Disease
3187	,	O
3187	and	O
3187	compared	O
3187	them	O
3187	to	O
3187	104	O
3187	patients	O
3187	with	O
3187	sporadic	B-Disease
3187	renal	I-Disease
3187	cell	I-Disease
3187	carcinoma	I-Disease
3187	and	O
3187	43	O
3187	patients	O
3187	with	O
3187	sporadic	B-Disease
3187	cerebellar	I-Disease
3187	haemangioblastoma	I-Disease
3187	.	O
3188	The	O
3188	age	O
3188	incidence	O
3188	curves	O
3188	for	O
3188	renal	B-Disease
3188	cell	I-Disease
3188	carcinoma	I-Disease
3188	and	O
3188	cerebellar	B-Disease
3188	haemangioblastoma	I-Disease
3188	in	O
3188	VHL	B-Disease
3188	disease	I-Disease
3188	were	O
3188	compatible	O
3188	with	O
3188	a	O
3188	single	O
3188	mutation	O
3188	model	O
3188	,	O
3188	whereas	O
3188	the	O
3188	age	O
3188	incidence	O
3188	curves	O
3188	for	O
3188	sporadic	B-Disease
3188	renal	I-Disease
3188	cell	I-Disease
3188	carcinoma	I-Disease
3188	and	O
3188	cerebellar	B-Disease
3188	haemangioblastoma	I-Disease
3188	suggested	O
3188	a	O
3188	two	O
3188	stage	O
3188	mutation	O
3188	process	O
3188	.	O
3189	These	O
3189	data	O
3189	are	O
3189	compatible	O
3189	with	O
3189	the	O
3189	VHL	B-Disease
3189	gene	O
3189	functioning	O
3189	as	O
3189	a	O
3189	recessive	O
3189	tumour	B-Disease
3189	suppressor	O
3189	gene	O
3189	.	O
3190	Sporadic	B-Disease
3190	cerebellar	I-Disease
3190	haemangioblastoma	I-Disease
3190	and	O
3190	some	O
3190	renal	B-Disease
3190	cell	I-Disease
3190	carcinoma	I-Disease
3190	may	O
3190	arise	O
3190	from	O
3190	somatic	O
3190	mutations	O
3190	inactivating	O
3190	both	O
3190	alleles	O
3190	at	O
3190	the	O
3190	VHL	B-Disease
3190	locus	O
3190	.	O
3190	.	O
3191	Screening	O
3191	for	O
3191	carriers	O
3191	of	O
3191	Tay	B-Disease
3191	-	I-Disease
3191	Sachs	I-Disease
3191	disease	I-Disease
3191	among	O
3191	Ashkenazi	O
3191	Jews	O
3191	.	O
3192	A	O
3192	comparison	O
3192	of	O
3192	DNA	O
3192	-	O
3192	based	O
3192	and	O
3192	enzyme	O
3192	-	O
3192	based	O
3192	tests	O
3192	.	O
3193	BACKGROUND	O
3193	AND	O
3193	METHODS	O
3193	.	O
3194	The	O
3194	prevention	O
3194	of	O
3194	Tay	B-Disease
3194	-	I-Disease
3194	Sachs	I-Disease
3194	disease	I-Disease
3194	(	O
3194	GM2	B-Disease
3194	gangliosidosis	I-Disease
3194	,	I-Disease
3194	type	I-Disease
3194	1	I-Disease
3194	)	O
3194	depends	O
3194	on	O
3194	the	O
3194	identification	O
3194	of	O
3194	carriers	O
3194	of	O
3194	the	O
3194	gene	O
3194	for	O
3194	this	O
3194	autosomal	B-Disease
3194	recessive	I-Disease
3194	disorder	I-Disease
3194	.	O
3195	We	O
3195	compared	O
3195	the	O
3195	enzyme	O
3195	-	O
3195	based	O
3195	test	O
3195	widely	O
3195	used	O
3195	in	O
3195	screening	O
3195	for	O
3195	Tay	B-Disease
3195	-	I-Disease
3195	Sachs	I-Disease
3195	disease	I-Disease
3195	with	O
3195	a	O
3195	test	O
3195	based	O
3195	on	O
3195	analysis	O
3195	of	O
3195	DNA	O
3195	.	O
3196	We	O
3196	developed	O
3196	methods	O
3196	to	O
3196	detect	O
3196	the	O
3196	three	O
3196	mutations	O
3196	in	O
3196	the	O
3196	HEXA	O
3196	gene	O
3196	that	O
3196	occur	O
3196	with	O
3196	high	O
3196	frequency	O
3196	among	O
3196	Ashkenazi	O
3196	Jews	O
3196	two	O
3196	mutations	O
3196	cause	O
3196	infantile	O
3196	Tay	B-Disease
3196	-	I-Disease
3196	Sachs	I-Disease
3196	disease	I-Disease
3196	,	O
3196	and	O
3196	the	O
3196	third	O
3196	causes	O
3196	the	O
3196	adult	O
3196	-	O
3196	onset	O
3196	form	O
3196	of	O
3196	the	O
3196	disease	O
3196	.	O
3197	DNA	O
3197	segments	O
3197	containing	O
3197	these	O
3197	mutation	O
3197	sites	O
3197	were	O
3197	amplified	O
3197	with	O
3197	the	O
3197	polymerase	O
3197	chain	O
3197	reaction	O
3197	and	O
3197	analyzed	O
3197	for	O
3197	the	O
3197	presence	O
3197	of	O
3197	the	O
3197	mutations	O
3197	.	O
3198	RESULTS	O
3198	.	O
3199	Among	O
3199	62	O
3199	Ashkenazi	O
3199	obligate	O
3199	carriers	O
3199	of	O
3199	Tay	B-Disease
3199	-	I-Disease
3199	Sachs	I-Disease
3199	disease	I-Disease
3199	,	O
3199	the	O
3199	three	O
3199	specific	O
3199	mutations	O
3199	accounted	O
3199	for	O
3199	all	O
3199	but	O
3199	one	O
3199	of	O
3199	the	O
3199	mutant	O
3199	alleles	O
3199	(	O
3199	98	O
3199	percent	O
3199	)	O
3199	.	O
3200	In	O
3200	216	O
3200	Ashkenazi	O
3200	carriers	O
3200	identified	O
3200	by	O
3200	the	O
3200	enzyme	O
3200	test	O
3200	,	O
3200	DNA	O
3200	analysis	O
3200	showed	O
3200	that	O
3200	177	O
3200	(	O
3200	82	O
3200	percent	O
3200	)	O
3200	had	O
3200	one	O
3200	of	O
3200	the	O
3200	identified	O
3200	mutations	O
3200	.	O
3201	Of	O
3201	the	O
3201	177	O
3201	,	O
3201	79	O
3201	percent	O
3201	had	O
3201	the	O
3201	exon	O
3201	11	O
3201	insertion	O
3201	mutation	O
3201	,	O
3201	18	O
3201	percent	O
3201	had	O
3201	the	O
3201	intron	O
3201	12	O
3201	splice	O
3201	-	O
3201	junction	O
3201	mutation	O
3201	,	O
3201	and	O
3201	3	O
3201	percent	O
3201	had	O
3201	the	O
3201	less	O
3201	severe	O
3201	exon	O
3201	7	O
3201	mutation	O
3201	associated	O
3201	with	O
3201	adult	O
3201	-	O
3201	onset	O
3201	disease	O
3201	.	O
3202	The	O
3202	results	O
3202	of	O
3202	the	O
3202	enzyme	O
3202	tests	O
3202	in	O
3202	the	O
3202	39	O
3202	subjects	O
3202	(	O
3202	18	O
3202	percent	O
3202	)	O
3202	who	O
3202	were	O
3202	defined	O
3202	as	O
3202	carriers	O
3202	but	O
3202	in	O
3202	whom	O
3202	DNA	O
3202	analysis	O
3202	did	O
3202	not	O
3202	identify	O
3202	a	O
3202	mutant	O
3202	allele	O
3202	were	O
3202	probably	O
3202	false	O
3202	positive	O
3202	(	O
3202	although	O
3202	there	O
3202	remains	O
3202	some	O
3202	possibility	O
3202	of	O
3202	unidentified	O
3202	mutations	O
3202	)	O
3202	.	O
3203	In	O
3203	addition	O
3203	,	O
3203	of	O
3203	152	O
3203	persons	O
3203	defined	O
3203	as	O
3203	noncarriers	O
3203	by	O
3203	the	O
3203	enzyme	O
3203	-	O
3203	based	O
3203	test	O
3203	,	O
3203	1	O
3203	was	O
3203	identified	O
3203	as	O
3203	a	O
3203	carrier	O
3203	by	O
3203	DNA	O
3203	analysis	O
3203	(	O
3203	i	O
3203	.	O
3203	e	O
3203	e	O
3203	.	O
3203	,	O
3203	a	O
3203	false	O
3203	negative	O
3203	enzyme	O
3203	-	O
3203	test	O
3203	result	O
3203	)	O
3203	.	O
3204	CONCLUSIONS	O
3204	.	O
3205	The	O
3205	increased	O
3205	specificity	O
3205	and	O
3205	predictive	O
3205	value	O
3205	of	O
3205	the	O
3205	DNA	O
3205	-	O
3205	based	O
3205	test	O
3205	make	O
3205	it	O
3205	a	O
3205	useful	O
3205	adjunct	O
3205	to	O
3205	the	O
3205	diagnostic	O
3205	tests	O
3205	currently	O
3205	used	O
3205	to	O
3205	screen	O
3205	for	O
3205	carriers	O
3205	of	O
3205	Tay	B-Disease
3205	-	I-Disease
3205	Sachs	I-Disease
3205	disease	I-Disease
3205	.	O
3206	Total	B-Disease
3206	deficiency	I-Disease
3206	of	I-Disease
3206	plasma	I-Disease
3206	cholesteryl	I-Disease
3206	ester	I-Disease
3206	transfer	I-Disease
3206	protein	I-Disease
3206	in	O
3206	subjects	O
3206	homozygous	O
3206	and	O
3206	heterozygous	O
3206	for	O
3206	the	O
3206	intron	O
3206	14	O
3206	splicing	O
3206	defect	O
3206	.	O
3207	The	O
3207	molecular	O
3207	basis	O
3207	of	O
3207	cholesteryl	B-Disease
3207	ester	I-Disease
3207	transfer	I-Disease
3207	protein	I-Disease
3207	(	I-Disease
3207	CETP	I-Disease
3207	)	I-Disease
3207	deficiency	I-Disease
3207	was	O
3207	investigated	O
3207	in	O
3207	4	O
3207	unrelated	O
3207	CETP	B-Disease
3207	-	I-Disease
3207	deficient	I-Disease
3207	families	O
3207	.	O
3208	The	O
3208	high	O
3208	density	O
3208	lipoprotein	O
3208	-	O
3208	cholesterol	O
3208	levels	O
3208	of	O
3208	the	O
3208	probands	O
3208	exceeded	O
3208	150	O
3208	mg	O
3208	/	O
3208	dl	O
3208	.	O
3209	The	O
3209	plasma	O
3209	of	O
3209	the	O
3209	probands	O
3209	was	O
3209	totally	O
3209	deficient	O
3209	in	O
3209	CETP	O
3209	activity	O
3209	and	O
3209	mass	O
3209	.	O
3210	The	O
3210	genomic	O
3210	DNA	O
3210	of	O
3210	the	O
3210	patients	O
3210	was	O
3210	amplified	O
3210	by	O
3210	polymerase	O
3210	chain	O
3210	reaction	O
3210	,	O
3210	using	O
3210	two	O
3210	oligonucleotide	O
3210	primers	O
3210	located	O
3210	in	O
3210	the	O
3210	intron	O
3210	12	O
3210	and	O
3210	14	O
3210	of	O
3210	the	O
3210	CETP	O
3210	gene	O
3210	,	O
3210	and	O
3210	the	O
3210	amplified	O
3210	products	O
3210	were	O
3210	directly	O
3210	sequenced	O
3210	.	O
3211	Two	O
3211	patients	O
3211	were	O
3211	homozygous	O
3211	for	O
3211	a	O
3211	G	O
3211	-	O
3211	to	O
3211	-	O
3211	A	O
3211	change	O
3211	at	O
3211	the	O
3211	5	O
3211	-	O
3211	splice	O
3211	donor	O
3211	site	O
3211	of	O
3211	the	O
3211	intron	O
3211	14	O
3211	.	O
3212	The	O
3212	G	O
3212	-	O
3212	to	O
3212	-	O
3212	A	O
3212	change	O
3212	would	O
3212	cause	O
3212	impaired	O
3212	splicing	O
3212	of	O
3212	pre	O
3212	-	O
3212	messenger	O
3212	RNA	O
3212	.	O
3213	The	O
3213	other	O
3213	two	O
3213	probands	O
3213	were	O
3213	heterozygous	O
3213	for	O
3213	the	O
3213	mutation	O
3213	,	O
3213	but	O
3213	totally	O
3213	lacked	O
3213	CETP	O
3213	.	O
3214	Their	O
3214	lipoprotein	O
3214	patterns	O
3214	were	O
3214	also	O
3214	similar	O
3214	to	O
3214	those	O
3214	of	O
3214	the	O
3214	two	O
3214	homozygotes	O
3214	.	O
3215	Thus	O
3215	,	O
3215	other	O
3215	genetic	B-Disease
3215	defects	I-Disease
3215	or	O
3215	metabolic	O
3215	factors	O
3215	influencing	O
3215	CETP	O
3215	expression	O
3215	are	O
3215	implicated	O
3215	.	O
3216	The	O
3216	data	O
3216	suggest	O
3216	that	O
3216	the	O
3216	G	O
3216	-	O
3216	to	O
3216	-	O
3216	A	O
3216	mutation	O
3216	may	O
3216	be	O
3216	common	O
3216	in	O
3216	human	O
3216	plasma	O
3216	CETP	B-Disease
3216	deficiency	I-Disease
3216	.	O
3217	Furthermore	O
3217	,	O
3217	there	O
3217	could	O
3217	be	O
3217	compound	O
3217	heterozygotes	O
3217	who	O
3217	totally	O
3217	lack	O
3217	plasma	O
3217	CETP	O
3217	and	O
3217	have	O
3217	lipoprotein	O
3217	profiles	O
3217	similar	O
3217	to	O
3217	those	O
3217	of	O
3217	homozygotes	O
3217	.	O
3217	.	O
3218	Molecular	O
3218	genetics	O
3218	of	O
3218	the	O
3218	glucose	O
3218	-	O
3218	6	O
3218	-	O
3218	phosphate	O
3218	dehydrogenase	O
3218	(	O
3218	G6PD	O
3218	)	O
3218	Mediterranean	O
3218	variant	O
3218	and	O
3218	description	O
3218	of	O
3218	a	O
3218	new	O
3218	G6PD	O
3218	mutant	O
3218	,	O
3218	G6PD	O
3218	Andalus1361A	O
3218	.	O
3219	Glucose	B-Disease
3219	-	I-Disease
3219	6	I-Disease
3219	-	I-Disease
3219	phosphate	I-Disease
3219	dehydrogenase	I-Disease
3219	(	I-Disease
3219	G6PD	I-Disease
3219	;	I-Disease
3219	E	I-Disease
3219	.	I-Disease
3219	C	I-Disease
3219	.	I-Disease
3219	1	I-Disease
3219	.	I-Disease
3219	1	I-Disease
3219	.	I-Disease
3219	1	I-Disease
3219	.	I-Disease
3219	49	I-Disease
3219	)	I-Disease
3219	deficiency	I-Disease
3219	is	O
3219	the	O
3219	most	O
3219	common	O
3219	human	O
3219	enzymopathy	B-Disease
3219	;	O
3219	more	O
3219	than	O
3219	300	O
3219	different	O
3219	biochemical	O
3219	variants	O
3219	of	O
3219	the	O
3219	enzyme	O
3219	have	O
3219	been	O
3219	described	O
3219	.	O
3220	In	O
3220	many	O
3220	parts	O
3220	of	O
3220	the	O
3220	world	O
3220	the	O
3220	Mediterranean	O
3220	type	O
3220	of	O
3220	G6PD	B-Disease
3220	deficiency	I-Disease
3220	is	O
3220	prevalent	O
3220	.	O
3221	However	O
3221	,	O
3221	G6PD	O
3221	Mediterranean	O
3221	has	O
3221	come	O
3221	to	O
3221	be	O
3221	regarded	O
3221	as	O
3221	a	O
3221	generic	O
3221	term	O
3221	applied	O
3221	to	O
3221	similar	O
3221	G6PD	O
3221	mutations	O
3221	thought	O
3221	,	O
3221	however	O
3221	,	O
3221	to	O
3221	represent	O
3221	a	O
3221	somewhat	O
3221	heterogeneous	O
3221	group	O
3221	.	O
3222	A	O
3222	C	O
3222	-	O
3222	-	O
3222	-	O
3222	-	O
3222	T	O
3222	mutation	O
3222	at	O
3222	nucleotide	O
3222	563	O
3222	of	O
3222	G6PD	O
3222	Mediterranean	O
3222	has	O
3222	been	O
3222	identified	O
3222	by	O
3222	Vulliamy	O
3222	et	O
3222	al	O
3222	.	O
3222	,	O
3222	and	O
3222	the	O
3222	same	O
3222	mutation	O
3222	has	O
3222	been	O
3222	found	O
3222	by	O
3222	De	O
3222	Vita	O
3222	et	O
3222	al	O
3222	.	O
3222	in	O
3222	G6PD	O
3222	Mediterranean	O
3222	,	O
3222	G6PD	O
3222	Sassari	O
3222	,	O
3222	and	O
3222	G6PD	O
3222	Cagliari	O
3222	.	O
3223	The	O
3223	latter	O
3223	subjects	O
3223	had	O
3223	an	O
3223	additional	O
3223	mutation	O
3223	,	O
3223	at	O
3223	nucleotide	O
3223	1311	O
3223	,	O
3223	that	O
3223	did	O
3223	not	O
3223	produce	O
3223	a	O
3223	coding	O
3223	change	O
3223	.	O
3224	We	O
3224	have	O
3224	examined	O
3224	genomic	O
3224	DNA	O
3224	of	O
3224	five	O
3224	patients	O
3224	-	O
3224	-	O
3224	four	O
3224	of	O
3224	Spanish	O
3224	origin	O
3224	and	O
3224	one	O
3224	of	O
3224	Jewish	O
3224	origin	O
3224	-	O
3224	-	O
3224	having	O
3224	enzymatically	O
3224	documented	O
3224	G6PD	O
3224	Mediterranean	O
3224	.	O
3225	All	O
3225	had	O
3225	both	O
3225	the	O
3225	mutation	O
3225	at	O
3225	nucleotide	O
3225	563	O
3225	and	O
3225	that	O
3225	at	O
3225	nucleotide	O
3225	1311	O
3225	.	O
3226	A	O
3226	sixth	O
3226	sample	O
3226	,	O
3226	resembling	O
3226	G6PD	O
3226	Mediterranean	O
3226	kinetically	O
3226	but	O
3226	with	O
3226	a	O
3226	slightly	O
3226	rapid	O
3226	electrophoretic	O
3226	mobility	O
3226	,	O
3226	was	O
3226	designated	O
3226	G6PD	O
3226	Andalus	O
3226	and	O
3226	was	O
3226	found	O
3226	to	O
3226	have	O
3226	a	O
3226	different	O
3226	mutation	O
3226	,	O
3226	a	O
3226	G	O
3226	-	O
3226	-	O
3226	-	O
3226	-	O
3226	A	O
3226	transition	O
3226	at	O
3226	nucleotide	O
3226	1361	O
3226	,	O
3226	producing	O
3226	an	O
3226	arginine	O
3226	-	O
3226	to	O
3226	-	O
3226	histidine	O
3226	substitution	O
3226	.	O
3227	These	O
3227	studies	O
3227	suggest	O
3227	that	O
3227	G6PD	O
3227	Mediterranean	O
3227	is	O
3227	,	O
3227	after	O
3227	all	O
3227	,	O
3227	relatively	O
3227	homogeneous	O
3227	.	O
3228	A	O
3228	normal	O
3228	male	O
3228	with	O
3228	an	O
3228	inherited	O
3228	deletion	O
3228	of	O
3228	one	O
3228	exon	O
3228	within	O
3228	the	O
3228	DMD	B-Disease
3228	gene	O
3228	.	O
3229	We	O
3229	describe	O
3229	two	O
3229	brothers	O
3229	with	O
3229	identical	O
3229	inherited	O
3229	deletions	O
3229	of	O
3229	one	O
3229	single	O
3229	exon	O
3229	within	O
3229	the	O
3229	middle	O
3229	of	O
3229	the	O
3229	DMD	B-Disease
3229	gene	O
3229	;	O
3229	one	O
3229	brother	O
3229	has	O
3229	Becker	B-Disease
3229	muscular	I-Disease
3229	dystrophy	I-Disease
3229	diagnosed	O
3229	at	O
3229	11	O
3229	years	O
3229	of	O
3229	age	O
3229	,	O
3229	whereas	O
3229	the	O
3229	older	O
3229	brother	O
3229	is	O
3229	normal	O
3229	at	O
3229	18	O
3229	.	O
3230	These	O
3230	results	O
3230	have	O
3230	implications	O
3230	for	O
3230	genetic	O
3230	counselling	O
3230	and	O
3230	prenatal	O
3230	diagnosis	O
3230	in	O
3230	families	O
3230	with	O
3230	Becker	B-Disease
3230	muscular	I-Disease
3230	dystrophy	I-Disease
3230	.	O
3230	.	O
3231	Duchenne	B-Disease
3231	muscular	I-Disease
3231	dystrophy	I-Disease
3231	gene	O
3231	expression	O
3231	in	O
3231	normal	O
3231	and	O
3231	diseased	O
3231	human	O
3231	muscle	O
3231	.	O
3232	A	O
3232	probe	O
3232	for	O
3232	the	O
3232	5	O
3232	end	O
3232	of	O
3232	the	O
3232	Duchenne	B-Disease
3232	muscular	I-Disease
3232	dystrophy	I-Disease
3232	(	O
3232	DMD	B-Disease
3232	)	O
3232	gene	O
3232	was	O
3232	used	O
3232	to	O
3232	study	O
3232	expression	O
3232	of	O
3232	the	O
3232	gene	O
3232	in	O
3232	normal	O
3232	human	O
3232	muscle	O
3232	,	O
3232	myogenic	O
3232	cell	O
3232	cultures	O
3232	,	O
3232	and	O
3232	muscle	O
3232	from	O
3232	patients	O
3232	with	O
3232	DMD	B-Disease
3232	.	O
3233	Expression	O
3233	was	O
3233	found	O
3233	in	O
3233	RNA	O
3233	from	O
3233	normal	O
3233	fetal	O
3233	muscle	O
3233	,	O
3233	adult	O
3233	cardiac	O
3233	and	O
3233	skeletal	O
3233	muscle	O
3233	,	O
3233	and	O
3233	cultured	O
3233	muscle	O
3233	after	O
3233	myoblast	O
3233	fusion	O
3233	.	O
3234	In	O
3234	DMD	B-Disease
3234	muscle	O
3234	,	O
3234	expression	O
3234	of	O
3234	this	O
3234	portion	O
3234	of	O
3234	the	O
3234	gene	O
3234	was	O
3234	also	O
3234	revealed	O
3234	by	O
3234	in	O
3234	situ	O
3234	RNA	O
3234	hybridization	O
3234	,	O
3234	particularly	O
3234	in	O
3234	regenerating	O
3234	muscle	O
3234	fibers	O
3234	.	O
3234	.	O
3235	Molecular	O
3235	and	O
3235	phenotypic	O
3235	analysis	O
3235	of	O
3235	patients	O
3235	with	O
3235	deletions	O
3235	within	O
3235	the	O
3235	deletion	O
3235	-	O
3235	rich	O
3235	region	O
3235	of	O
3235	the	O
3235	Duchenne	B-Disease
3235	muscular	I-Disease
3235	dystrophy	I-Disease
3235	(	O
3235	DMD	B-Disease
3235	)	O
3235	gene	O
3235	.	O
3236	Eighty	O
3236	unrelated	O
3236	individuals	O
3236	with	O
3236	Duchenne	B-Disease
3236	muscular	I-Disease
3236	dystrophy	I-Disease
3236	(	O
3236	DMD	B-Disease
3236	)	O
3236	or	O
3236	Becker	B-Disease
3236	muscular	I-Disease
3236	dystrophy	I-Disease
3236	(	O
3236	BMD	B-Disease
3236	)	O
3236	were	O
3236	found	O
3236	to	O
3236	have	O
3236	deletions	O
3236	in	O
3236	the	O
3236	major	O
3236	deletion	O
3236	-	O
3236	rich	O
3236	region	O
3236	of	O
3236	the	O
3236	DMD	B-Disease
3236	locus	O
3236	.	O
3237	This	O
3237	region	O
3237	includes	O
3237	the	O
3237	last	O
3237	five	O
3237	exons	O
3237	detected	O
3237	by	O
3237	cDNA5b	O
3237	-	O
3237	7	O
3237	,	O
3237	all	O
3237	exons	O
3237	detected	O
3237	by	O
3237	cDNA8	O
3237	,	O
3237	and	O
3237	the	O
3237	first	O
3237	two	O
3237	exons	O
3237	detected	O
3237	by	O
3237	cDNA9	O
3237	.	O
3238	These	O
3238	80	O
3238	individuals	O
3238	account	O
3238	for	O
3238	approximately	O
3238	75	O
3238	%	O
3238	of	O
3238	109	O
3238	deletions	O
3238	of	O
3238	the	O
3238	gene	O
3238	,	O
3238	detected	O
3238	among	O
3238	181	O
3238	patients	O
3238	analyzed	O
3238	with	O
3238	the	O
3238	entire	O
3238	dystrophin	O
3238	cDNA	O
3238	.	O
3239	Endpoints	O
3239	for	O
3239	many	O
3239	of	O
3239	these	O
3239	deletions	O
3239	were	O
3239	further	O
3239	characterized	O
3239	using	O
3239	two	O
3239	genomic	O
3239	probes	O
3239	,	O
3239	p20	O
3239	(	O
3239	DXS269	O
3239	;	O
3239	Wapenaar	O
3239	et	O
3239	al	O
3239	.	O
3239	)	O
3239	and	O
3239	GMGX11	O
3239	(	O
3239	DXS239	O
3239	;	O
3239	present	O
3239	paper	O
3239	)	O
3239	.	O
3240	Clinical	O
3240	findings	O
3240	are	O
3240	presented	O
3240	for	O
3240	all	O
3240	80	O
3240	patients	O
3240	allowing	O
3240	a	O
3240	correlation	O
3240	of	O
3240	phenotypic	O
3240	severity	O
3240	with	O
3240	the	O
3240	genotype	O
3240	.	O
3241	Thirty	O
3241	-	O
3241	eight	O
3241	independent	O
3241	patients	O
3241	were	O
3241	old	O
3241	enough	O
3241	to	O
3241	be	O
3241	classified	O
3241	as	O
3241	DMD	B-Disease
3241	,	O
3241	BMD	B-Disease
3241	,	O
3241	or	O
3241	intermediate	O
3241	phenotype	O
3241	and	O
3241	had	O
3241	deletions	O
3241	of	O
3241	exons	O
3241	with	O
3241	sequenced	O
3241	intron	O
3241	/	O
3241	exon	O
3241	boundaries	O
3241	.	O
3242	Of	O
3242	these	O
3242	,	O
3242	eight	O
3242	BMD	B-Disease
3242	patients	O
3242	and	O
3242	one	O
3242	intermediate	O
3242	patient	O
3242	had	O
3242	gene	O
3242	deletions	O
3242	predicted	O
3242	to	O
3242	leave	O
3242	the	O
3242	reading	O
3242	frame	O
3242	intact	O
3242	,	O
3242	while	O
3242	21	O
3242	DMD	B-Disease
3242	patients	O
3242	,	O
3242	7	O
3242	intermediate	O
3242	patients	O
3242	,	O
3242	and	O
3242	1	O
3242	BMD	B-Disease
3242	patient	O
3242	had	O
3242	gene	O
3242	deletions	O
3242	predicted	O
3242	to	O
3242	disrupt	O
3242	the	O
3242	reading	O
3242	frame	O
3242	.	O
3243	Thus	O
3243	,	O
3243	with	O
3243	two	O
3243	exceptions	O
3243	,	O
3243	frameshift	O
3243	deletions	O
3243	of	O
3243	the	O
3243	gene	O
3243	resulted	O
3243	in	O
3243	more	O
3243	severe	O
3243	phenotype	O
3243	than	O
3243	did	O
3243	in	O
3243	-	O
3243	frame	O
3243	deletions	O
3243	.	O
3244	This	O
3244	is	O
3244	in	O
3244	agreement	O
3244	with	O
3244	recent	O
3244	findings	O
3244	by	O
3244	Baumbach	O
3244	et	O
3244	al	O
3244	.	O
3244	and	O
3244	Koenig	O
3244	et	O
3244	al	O
3244	.	O
3244	but	O
3244	is	O
3244	in	O
3244	contrast	O
3244	to	O
3244	findings	O
3244	,	O
3244	by	O
3244	Malhotra	O
3244	et	O
3244	al	O
3244	.	O
3244	at	O
3244	the	O
3244	5	O
3244	'	O
3244	end	O
3244	of	O
3244	the	O
3244	gene	O
3244	.	O
3245	Cloning	O
3245	of	O
3245	breakpoints	O
3245	of	O
3245	a	O
3245	chromosome	O
3245	translocation	O
3245	identifies	O
3245	the	O
3245	AN2	O
3245	locus	O
3245	.	O
3246	Chromosome	O
3246	translocations	O
3246	involving	O
3246	11p13	O
3246	have	O
3246	been	O
3246	associated	O
3246	with	O
3246	familial	B-Disease
3246	aniridia	I-Disease
3246	in	O
3246	two	O
3246	kindreds	O
3246	highlighting	O
3246	the	O
3246	chromosomal	O
3246	localization	O
3246	of	O
3246	the	O
3246	AN2	O
3246	locus	O
3246	.	O
3247	This	O
3247	locus	O
3247	is	O
3247	also	O
3247	part	O
3247	of	O
3247	the	O
3247	WAGR	B-Disease
3247	complex	O
3247	(	O
3247	Wilms	B-Disease
3247	tumor	I-Disease
3247	,	O
3247	aniridia	B-Disease
3247	,	O
3247	genitourinary	B-Disease
3247	abnormalities	I-Disease
3247	,	O
3247	and	O
3247	mental	B-Disease
3247	retardation	I-Disease
3247	)	O
3247	.	O
3248	In	O
3248	one	O
3248	kindred	O
3248	,	O
3248	the	O
3248	translocation	O
3248	is	O
3248	associated	O
3248	with	O
3248	a	O
3248	deletion	O
3248	,	O
3248	and	O
3248	probes	O
3248	for	O
3248	this	O
3248	region	O
3248	were	O
3248	used	O
3248	to	O
3248	identify	O
3248	and	O
3248	clone	O
3248	the	O
3248	breakpoints	O
3248	of	O
3248	the	O
3248	translocation	O
3248	in	O
3248	the	O
3248	second	O
3248	kindred	O
3248	.	O
3249	Comparison	O
3249	of	O
3249	phage	O
3249	restriction	O
3249	maps	O
3249	exclude	O
3249	the	O
3249	presence	O
3249	of	O
3249	any	O
3249	sizable	O
3249	deletion	O
3249	in	O
3249	this	O
3249	case	O
3249	.	O
3250	Sequences	O
3250	at	O
3250	the	O
3250	chromosome	O
3250	11	O
3250	breakpoint	O
3250	are	O
3250	conserved	O
3250	in	O
3250	multiple	O
3250	species	O
3250	,	O
3250	suggesting	O
3250	that	O
3250	the	O
3250	translocation	O
3250	falls	O
3250	within	O
3250	the	O
3250	AN2	O
3250	gene	O
3250	.	O
3250	.	O
3251	Linkage	O
3251	analysis	O
3251	of	O
3251	the	O
3251	apolipoprotein	O
3251	C2	O
3251	gene	O
3251	and	O
3251	myotonic	B-Disease
3251	dystrophy	I-Disease
3251	on	O
3251	human	O
3251	chromosome	O
3251	19	O
3251	reveals	O
3251	linkage	O
3251	disequilibrium	O
3251	in	O
3251	a	O
3251	French	O
3251	-	O
3251	Canadian	O
3251	population	O
3251	.	O
3252	The	O
3252	gene	O
3252	for	O
3252	human	O
3252	apolipoprotein	O
3252	C2	O
3252	(	O
3252	APOC2	O
3252	)	O
3252	,	O
3252	situated	O
3252	on	O
3252	the	O
3252	proximal	O
3252	long	O
3252	arm	O
3252	of	O
3252	chromosome	O
3252	19	O
3252	,	O
3252	is	O
3252	closely	O
3252	linked	O
3252	to	O
3252	the	O
3252	gene	O
3252	for	O
3252	the	O
3252	most	O
3252	common	O
3252	form	O
3252	of	O
3252	adult	O
3252	muscular	B-Disease
3252	dystrophy	I-Disease
3252	,	O
3252	myotonic	B-Disease
3252	dystrophy	I-Disease
3252	(	O
3252	DM	B-Disease
3252	)	O
3252	.	O
3253	Six	O
3253	APOC2	O
3253	RFLPs	O
3253	(	O
3253	TaqI	O
3253	,	O
3253	BglI	O
3253	,	O
3253	BanI	O
3253	,	O
3253	BamHI	O
3253	,	O
3253	NcoI	O
3253	,	O
3253	and	O
3253	AvaII	O
3253	)	O
3253	have	O
3253	been	O
3253	identified	O
3253	to	O
3253	date	O
3253	.	O
3254	We	O
3254	have	O
3254	conducted	O
3254	a	O
3254	comprehensive	O
3254	DM	B-Disease
3254	linkage	O
3254	study	O
3254	utilizing	O
3254	all	O
3254	six	O
3254	RFLPs	O
3254	and	O
3254	involving	O
3254	50	O
3254	families	O
3254	and	O
3254	372	O
3254	individuals	O
3254	.	O
3255	The	O
3255	most	O
3255	informative	O
3255	RFLPs	O
3255	are	O
3255	,	O
3255	in	O
3255	descending	O
3255	order	O
3255	,	O
3255	NcoI	O
3255	(	O
3255	lod	O
3255	=	O
3255	6	O
3255	.	O
3255	64	O
3255	,	O
3255	theta	O
3255	=	O
3255	0	O
3255	.	O
3255	05	O
3255	)	O
3255	,	O
3255	BglI	O
3255	(	O
3255	lod	O
3255	=	O
3255	6	O
3255	.	O
3255	12	O
3255	,	O
3255	theta	O
3255	=	O
3255	0	O
3255	.	O
3255	05	O
3255	)	O
3255	,	O
3255	AvaII	O
3255	(	O
3255	lod	O
3255	=	O
3255	6	O
3255	.	O
3255	02	O
3255	,	O
3255	theta	O
3255	=	O
3255	0	O
3255	.	O
3255	03	O
3255	)	O
3255	,	O
3255	BanI	O
3255	(	O
3255	lod	O
3255	=	O
3255	5	O
3255	.	O
3255	76	O
3255	,	O
3255	theta	O
3255	=	O
3255	0	O
3255	.	O
3255	04	O
3255	)	O
3255	,	O
3255	TaqI	O
3255	(	O
3255	lod	O
3255	=	O
3255	4	O
3255	.	O
3255	29	O
3255	,	O
3255	theta	O
3255	=	O
3255	0	O
3255	.	O
3255	06	O
3255	)	O
3255	,	O
3255	and	O
3255	BamHI	O
3255	(	O
3255	lod	O
3255	=	O
3255	1	O
3255	.	O
3255	75	O
3255	,	O
3255	theta	O
3255	=	O
3255	0	O
3255	.	O
3255	01	O
3255	)	O
3255	.	O
3256	A	O
3256	substantial	O
3256	increase	O
3256	in	O
3256	the	O
3256	lod	O
3256	scores	O
3256	over	O
3256	those	O
3256	seen	O
3256	with	O
3256	the	O
3256	individual	O
3256	RFLPs	O
3256	was	O
3256	obtained	O
3256	when	O
3256	the	O
3256	linkage	O
3256	of	O
3256	the	O
3256	entire	O
3256	APOC2	O
3256	haplotype	O
3256	(	O
3256	composed	O
3256	of	O
3256	the	O
3256	six	O
3256	RFLPs	O
3256	)	O
3256	was	O
3256	studied	O
3256	(	O
3256	lod	O
3256	=	O
3256	17	O
3256	.	O
3256	87	O
3256	,	O
3256	theta	O
3256	=	O
3256	0	O
3256	.	O
3256	04	O
3256	)	O
3256	.	O
3257	We	O
3257	have	O
3257	observed	O
3257	significant	O
3257	inter	O
3257	-	O
3257	APOC2	O
3257	RFLP	O
3257	linkage	O
3257	disequilibrium	O
3257	.	O
3258	Consequently	O
3258	,	O
3258	the	O
3258	three	O
3258	most	O
3258	informative	O
3258	RFLPs	O
3258	have	O
3258	been	O
3258	found	O
3258	to	O
3258	be	O
3258	BanI	O
3258	,	O
3258	TaqI	O
3258	,	O
3258	and	O
3258	either	O
3258	BglI	O
3258	,	O
3258	AvaII	O
3258	,	O
3258	or	O
3258	NcoI	O
3258	polymorphisms	O
3258	.	O
3259	We	O
3259	also	O
3259	demonstrate	O
3259	linkage	O
3259	disequilibrium	O
3259	between	O
3259	DM	O
3259	and	O
3259	APOC2	O
3259	in	O
3259	our	O
3259	French	O
3259	-	O
3259	Canadian	O
3259	population	O
3259	(	O
3259	standardized	O
3259	disequilibrium	O
3259	constant	O
3259	phi	O
3259	=	O
3259	.	O
3259	22	O
3259	,	O
3259	chi	O
3259	2	O
3259	=	O
3259	5	O
3259	.	O
3259	12	O
3259	,	O
3259	df	O
3259	=	O
3259	1	O
3259	,	O
3259	P	O
3259	less	O
3259	than	O
3259	0	O
3259	.	O
3259	04	O
3259	)	O
3259	.	O
3260	This	O
3260	represents	O
3260	the	O
3260	first	O
3260	evidence	O
3260	of	O
3260	linkage	O
3260	disequilibrium	O
3260	between	O
3260	APOC2	O
3260	and	O
3260	the	O
3260	DM	B-Disease
3260	locus	O
3260	.	O
3261	Phenylalanine	O
3261	hydroxylase	O
3261	gene	O
3261	haplotypes	O
3261	in	O
3261	Polynesians	O
3261	:	O
3261	evolutionary	O
3261	origins	O
3261	and	O
3261	absence	O
3261	of	O
3261	alleles	O
3261	associated	O
3261	with	O
3261	severe	O
3261	phenylketonuria	B-Disease
3261	.	O
3262	A	O
3262	total	O
3262	of	O
3262	630	O
3262	haplotypes	O
3262	for	O
3262	the	O
3262	phenylalanine	O
3262	hydroxylase	O
3262	(	O
3262	PAH	O
3262	)	O
3262	gene	O
3262	locus	O
3262	were	O
3262	established	O
3262	in	O
3262	five	O
3262	groups	O
3262	of	O
3262	Polynesians	O
3262	comprising	O
3262	Samoans	O
3262	,	O
3262	Tongans	O
3262	,	O
3262	Cook	O
3262	Islanders	O
3262	,	O
3262	Maori	O
3262	,	O
3262	and	O
3262	Niueans	O
3262	.	O
3263	Considerable	O
3263	genetic	O
3263	continuity	O
3263	was	O
3263	demonstrated	O
3263	between	O
3263	these	O
3263	widely	O
3263	dispersed	O
3263	populations	O
3263	,	O
3263	since	O
3263	three	O
3263	common	O
3263	haplotypes	O
3263	(	O
3263	4	O
3263	,	O
3263	1	O
3263	,	O
3263	and	O
3263	7	O
3263	)	O
3263	constituted	O
3263	over	O
3263	95	O
3263	%	O
3263	of	O
3263	alleles	O
3263	.	O
3264	A	O
3264	control	O
3264	group	O
3264	of	O
3264	individuals	O
3264	from	O
3264	Southeast	O
3264	Asia	O
3264	shared	O
3264	the	O
3264	same	O
3264	major	O
3264	haplotypes	O
3264	,	O
3264	4	O
3264	,	O
3264	1	O
3264	,	O
3264	and	O
3264	7	O
3264	,	O
3264	with	O
3264	Polynesians	O
3264	.	O
3265	These	O
3265	data	O
3265	provide	O
3265	further	O
3265	support	O
3265	for	O
3265	the	O
3265	theories	O
3265	of	O
3265	genetic	O
3265	homogeneity	O
3265	and	O
3265	of	O
3265	Asian	O
3265	affinities	O
3265	of	O
3265	the	O
3265	Polynesian	O
3265	precursor	O
3265	populations	O
3265	.	O
3266	The	O
3266	absence	O
3266	of	O
3266	severe	O
3266	phenylketonuria	B-Disease
3266	(	O
3266	PKU	B-Disease
